PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12N 1/21, A61K 38/16, A61K 38/17, C07K 14/00, C07K 14/435, C07K 16/00, C12N 5/10, C12N 15/11, C12N 15/12, C12N 15/63, G01N 33/50

A1

(11) International Publication Number: WO 00/06698

(43) International Publication Date: 10 February 2000 (10.02.2000)

(21) International Application Number: PCT/US99/17130

(22) International Filing Date: 29 July 1999 (29.07.1999)

(30) Priority Data:

60/094,657	30 July 1998 (30.07.1998)	US
60/095,454	06 August 1998 (06.08.1998)	US
60/095,455	06 August 1998 (06.08.1998)	US
60/095,486	05 August 1998 (05.08.1998)	US
60/096,319	12 August 1998 (12.08.1998)	US

Published

(60) Parent Application or Grant
HUMAN GENOME SCIENCES, INC. [/];
(). KOMATSOULIS, George, A. [/]; (). ROSEN, Craig, A. [/];
(). RUBEN, Steven, M. [/]; (). DUAN, Roxanne [/];
(). MOORE, Paul, A. [/]; (). SHI, Yanggu [/]; (). LAFLEUR, David [/]; (). WEI, Ying-Fei [/]; (). NI, Jian [/];
(). FLORENCE, Kimberly, A. [/]; (). YOUNG, Paul, E. [/];
(). BREWER, Laurie, A. [/]; (). SOPPET, Daniel, R. [/];
(). ENDRESS, Gregory, A. [/]; (). EBNER, Reinhard [/];
(). OLSEN, Henrik, S. [/]; (). MUCENSKI, Michael [/];
(). KOMATSOULIS, George, A. [/]; (). ROSEN, Craig, A. [/];
(). RUBEN, Steven, M. [/]; (). DUAN, Roxanne [/];
(). MOORE, Paul, A. [/]; (). SHI, Yanggu [/]; (). LAFLEUR, David [/]; (). WEI, Ying-Fei [/]; (). NI, Jian [/];
(). FLORENCE, Kimberly, A. [/]; (). YOUNG, Paul, E. [/];
(). BREWER, Laurie, A. [/]; (). SOPPET, Daniel, R. [/];
(). ENDRESS, Gregory, A. [/]; (). EBNER, Reinhard [/];
(). OLSEN, Henrik, S. [/]; (). MUCENSKI, Michael [/];
(). HOOVER, Kenley, K. ; ().

(54) Title: 98 HUMAN SECRETED PROTEINS

(54) Titre: 98 PROTEINES HUMAINES SECRETEES

(57) Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

(57) Abrégé

La présente invention concerne de nouvelles protéines humaines sécrétées, ainsi que des acides nucléiques isolés contenant les régions codantes des gènes codant pour ces protéines. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps, et des méthodes de recombinaison permettant de produire les protéines humaines sécrétées. L'invention concerne enfin des méthodes diagnostiques et thérapeutiques utilisées dans le traitement de troubles associés à ces nouvelles protéines humaines sécrétées.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 1/21, 5/10, 15/11, 15/12, 15/63, A61K 38/16, 38/17, C07K 14/00, 14/435, 16/00, G01N 33/50

A1

(11) International Publication Number: WO 00/06698

(43) International Publication Date: 10 February 2000 (10.02.00)

(21) International Application Number: PCT/US99/17130

(22) International Filing Date: 29 July 1999 (29.07.99)

(30) Priority Data:

60/094,557	30 July 1998 (30.07.98)	US
60/095,486	5 August 1998 (05.08.98)	US
60/095,455	6 August 1998 (06.08.98)	US
60/095,454	6 August 1998 (06.08.98)	US
60/096,319	12 August 1998 (12.08.98)	US

(71) Applicant (*for all designated States except US*): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): KOMATSOULIS, George, A. [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US). DUAN, Roxanne [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). MOORE, Paul, A. [GB/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US). SHI, Yanggu [CN/US]; Apartment 102, 437 West Side Drive, Gaithersburg, MD 20878 (US). LAFLEUR, David [US/US]; 3142 Quesada Street, N.W., Washington, DC 20015 (US). WEI, Ying-Fei [CN/US]; 242 Gravatt Drive, Berkeley, CA 94705 (US). NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). FLORENCE, Kimberly, A. [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). BREWER, Laurie, A. [US/US]; Apartment 115, 410 Van Dyke Street, St. Paul, MN 55119-4321 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). MUCENSKI, Michael [US/US]; 3265 Mandale Drive, Cincinnati, OH 45239 (US).

(74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.

(54) Title: 98 HUMAN SECRETED PROTEINS

(57) Abstract

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Description

98 Human Secreted Proteins

Field of the Invention

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

Background of the Invention

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoeitin. Thus, in light of

the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

Summary of the Invention

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

Detailed Description

Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are less than 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, or 7.5 kb in length. In a further embodiment, polynucleotides of the invention comprise at least 15 contiguous nucleotides of the coding sequence, but do not comprise all or a portion of any intron. In another embodiment, the nucleic acid comprising the coding sequence does not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene in the genome).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42° C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's

solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M NaH_2PO_4; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA

that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched , for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

(See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

__**Polynucleotides and Polypeptides of the Invention**__

FEATURES OF PROTEIN ENCODED BY GENE NO: 1

The translation product of this gene is a human glycoprotein-associated amino acid transporter (See, e.g., Genbank Accession No. emb|CAA10198.1| (AJ130718); all references available through this accession are hereby incorporated by reference herein). Amino acid transport across cellular membranes is mediated by multiple transporters with overlapping specificities. The transport system L, which mediates Na+-independent exchange of large neutral amino acids, consists of a novel amino acid permease-related protein (LAT1 or AmAT-L-lc) which for surface expression and function requires formation of disulfide-linked heterodimers with the glycosylated heavy chain of the h4F2/CD98 surface antigen. h4F2hc also associates with other mammalian light chains, e.g. y+LAT1 from mouse and human which are

approximately 48% identical with LAT1 and thus belong to the same family of glycoprotein-associated amino acid transporters.

The novel heterodimers form exchangers which mediate the cellular efflux of cationic amino acids and the Na+-dependent uptake of large neutral amino acids. These transport characteristics and kinetic and pharmacological fingerprints identify them as y+L-type transport systems. mRNA encoding my+LAT1 is detectable in most adult tissues and expressed at high levels in kidney cortex and intestine. This indicates that the y+LAT1-4F2hc heterodimer, besides participating in amino acid uptake/secretion in many cell types, is the basolateral amino acid exchanger involved in transepithelial reabsorption of cationic amino acids; hence, its defect might be the cause of the human genetic disease lysinuric protein intolerance.

The gene encoding the disclosed cDNA is believed to reside on chromosome 14. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 14.

Preferred polypeptides comprise the following amino acid sequence: LALYSALFSYSGWDTLN (SEQ ID NO: 237), VTEEIKNPERNLPL (SEQ ID NO: 238), IGISMPIVT (SEQ ID NO: 239), IYILTNVAYYTVL (SEQ ID NO: 240), SDA VAVTFADQ (SEQ ID NO: 241), VALSCFGGLNASI (SEQ ID NO: 242), SRLFFV GSREGHLPD (SEQ ID NO: 243), SFSYWFFVGLS (SEQ ID NO: 244), VGQLYLR WKEP (SEQ ID NO: 245), RPRPLKLSVFFPIVFC (SEQ ID NO: 246), DTINSLIGI (SEQ ID NO: 247), LLAAACICLLTFINCAYVKWGTLVQDIFTYAKVLALIAVI VAGIVRLGQGASTHFENSFEGSSFAVGDIALALYSALFSYSGWDTLNYVTEEI KNPERNLPLSIGISMPIVTIIYILTNVAYYTVLDMRDILASDAVAVTFADQIFGIF NWIIPLSVALSCFGGLNASIVAASRLFFVGSREGHLPDAICMIHVERFTPVPSLL FNGIMALIYLCVEDIFQLINYYSFSYWFFVGLSIVGQLYLRWKEPDRPRPLKLS VFFPIVFCLCTIFLVAVPLYSDTINSLIGIAIALSGLPFYFLIIRVPEHKRPLYLRRI VGSATRYLQVLCMSVAAEMDLEDGGEMPKQRDPKSN (SEQ ID NO: 249) and/or ATALPPKIVGSATRYLQVLCMSVAAEMDLEDGGEMPKQRDPKSN (SEQ ID NO: 248). Polynucleotides encoding these polypeptides are also provided.

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of THP-1 monocyte cells to calcium. Thus, it is likely that the product of this gene is involved in a signal

transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both THP-1 monocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocytes.

This gene is expressed primarily in endothelial cells and brain, and, to a lesser extent, in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the neural or gastrointesinal systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulation system or central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 124 as residues: Glu-102 to Asn-110, Arg-256 to Leu-266, Pro-316 to Trp-328, Pro-331 to Arg-336, Met-350 to Gly-358. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain combined with its homology to a amino acid transporter and biological activity of increasing ion flux in monocytes indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,

Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1550 of SEQ ID NO:11, b is an integer of 15 to 1564, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 2

The gene encoding the disclosed cDNA is believed to reside on the X chromosome. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for the X chromosome.

Preferred polypeptides of the invention comprise the following amino acid sequence:

AARGSGVRDPLEEAVCPFSDLQLHAGRTTALFKAVRQGHLSLQRLLLSFVCLCPAPRGGAYRGRQASLSCGGLHPVRASRLLCLPKQAWAMAGAPPPVSLPPCSLISDCCASNQRDSVG (SEQ ID NO: 250). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in cord blood cells, and, to a lesser extent, in frontal lobe of the brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, reproductive, hematopoietic or neural disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and central nervous systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, developmental, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 125 as residues: His-56 to Gln-65, Leu-80 to Ile-85. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in cord blood cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1743 of SEQ ID NO:12, b is an integer of 15 to 1757, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 3

This gene is expressed primarily in human T cell lymphomas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, T cell lymphoma, immunodeficiencies, in addition to other immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 126 as residues: Met-1 to Phe-10. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in human T cell lymphomas indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1359 of SEQ ID NO:13, b is an integer of 15 to 1373, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 4

The protein product of this clone shares sequence homology with the C-teminus of a human N-acetylglucosamine-phosphate mutase (See, e.g., Genbank Accession No. gb|AAC72409.1| (AF102265); all references available through this accession are hereby incorporated by reference herein.) Hofmann, et al. (Eur. J. Biochem. 221:741-747 (1994)) studied the N-acetylglucosamine-phosphate mutase of Saccharomyces cerevisiae and showed it to be essential for viability. A S. cerevisiae agm1 deletion mutant progressed through only approximately five cell cycles to form a 'string' of undivided cells with an abnormal cell morphology resembling

glucosamine auxotrophic mutants. Expression of the AGM1 gene on a multi-copy plasmid led to a significantly increased N-acetylglucosamine-phosphate mutase activity. Unlike over-expression of the S. cerevisiae AGM1 gene in a phosphoglucomutase (pgm1 delta/pgm2 delta) double deletion mutant which could restore phosphoglucomutase activity, over-expression of the PGM2 gene encoding the major isoenzyme of phosphoglucomutase did not increase N-acetylglucosamine-phosphate-mutase activity and did not restore growth of agm1 deletion mutant cells. These observations indicate that the different hexosephosphate mutases of S. cerevisiae have partially overlapping substrate specificities but, nevertheless, distinct physiological functions. The human N-acetylglucosamine-phosphate-mutase is expected to share at least some biological activities with the Agm1 protein.

Preferred polypeptide fragments of the invention comprise the following amino acid sequences: LSKAFLDSPNRLLAVEMNTDHLRLTVPNGIGALKLRXMEHYFSQGLSVQLFNDGSKGKLNHLCGADFVKSHQKPPQGMEIKSNERCCSFDGDADRIVYYYHDADGHFHLIDGDKIATLISSFLKELLVEIGESLNIGVVQTAYANGSSTRYLEEVMKVPVYCTKTGVKHLHHKAQEFDIGVYFEANGHGTALFSTAVEMKIKQSAEQLEDKKRKAAKMLENIIDLFNQAAGDAISDMLVIEAILALKGLTVQQWDALYTDLPNRQLKVQVADRRVISTTXAERQAVTPPGLQEAINDLVKKYKLSRAFVRPSGTEDVVRVYAEADSQESADHLAHEVSLAVFQLAGGIGERPQPGF (SEQ ID NO: 251), LSKAFLDSPNRLLAVEMNTDHLRLTV (SEQ ID NO: 252), PNGIGALKLRXMEHYFSQGLSVQLFNDG (SEQ ID NO: 253), SKGKLNHLCGADFVKSHQKPPQGMEIKS (SEQ ID NO: 254), NERCCSFDGDADRIVYYYHDADGHFHLI (SEQ ID NO: 255), DGDKIATLISSFLKELLVEIGESLNIGV (SEQ ID NO: 256), VQTAYANGSSTRYLEEVMKVPVYCTKTG (SEQ ID NO: 257), VKHLHHKAQEFDIGVYFEANGHGTALFS (SEQ ID NO: 258), TAVEMKIKQSAEQLEDKKRKAAKMLENI (SEQ ID NO: 259), IDLFNQAAGDAISDMLVIEAILALKGLT (SEQ ID NO: 260), VQQWDALYTDLPNRQLKVQVADRRVIST (SEQ ID NO: 261), TXAERQAVTPPGLQEAINDLVKKYKLSR (SEQ ID NO: 262), AFVRPSGTEDVVRVYAEADSQESA (SEQ ID NO: 263), and/or DHLAHEVSLAVFQLAGGIGERPQPGF (SEQ ID NO: 264). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in fetal brain, and, to a lesser extent, in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental disorders, particularly of the central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central and peripheral nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 127 as residues: Asn-36 to Lys-42, Lys-53 to Gln-60, Ile-64 to Ala-77, Ala-128 to Tyr-135, Lys-184 to Ala-199, Leu-245 to Leu-250. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution of N-acetylglucosamine-phosphate mutase in fetal brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital

malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3726 of SEQ ID NO:14, b is an integer of 15 to 3740, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 5

This gene is expressed primarily in human stomach and stomach tumor cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the gastrointestinal system, particularly cancer or ulcers of stomach tissue. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the

tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., gastrointestinal, or cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tumors of the stomach indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis, treatment and intervention of these tumors, in addition to other tumors where expression has been indicated. Additionally, the protein product of this gene may play a role in the normal function of the stomach and/or digestive system. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1182 of SEQ ID NO:15, b is an integer of 15 to 1196, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 6

Preferred polypeptides of the invention comprise the following amino acid sequences:

FEIALPRESNITVLIKLGTPTLLAKPCYIVISKRHITMLSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMSGPCPFGEVQLQPSTSLLPTLNRTFIWDVKAHKSIGLELQFSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCSNGTVSRIKM (SEQ ID NO: 266). and/or GTRAAPGLGAWGRRSPPSFSPPRPRRPGVMAGLNCGVSIALLGVLLLGAARLPRGAEAFEIALPRESNITVLIKLGTPTLLAKPCYIVISKRHITMLSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMSGPCPFGEVQLQPSTSLLPTLNRTFIWDVKAHKSIGLELQFSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCSNGTVSRIKMQFGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGSATLMSANYPEGFPEDELMTWQFVVPAHLRASVSFLNFNLSNCERKEERVEYYIPGSTTNPEVFKLEDKQPGNMAGNFNLSLQGCDQDAQSPGILRLQFQVLVQHPQNESNKIYVVDLSNERAMSLTIEPRPVKQSRKFVPGCFVCLESRTCSSNLTLTSGSKHKISFLCDDLTRLWMNVEKP (SEQ ID NO: 265). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in placenta, and to a lesser extent in, prostate and ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, male and female infertility, and associated disorders of the reproductive system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene in the prostate, placenta and ovary indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment, prevention, and/or diagnosis of male or female infertility, endocrine

disorders, fetal deficiencies, ovarian failure, amenorrhea, ovarian cancer, benign prostate hyperplasia and prostate cancer. Similarly, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within placental tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2195 of SEQ ID NO:16, b is an integer of 15 to 2209, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 7

The translation product of this gene shares homology with the human and rat HNK-1 sulfotransferase protein (See, e.g., Genbank Accession Nos. gb|AAB88123.1| (AF022729) and gi|2921306|gb|AAC04707.1| (AF033827); all references available through these accessions are hereby incorporated herein by reference.) Ong E, et al., (J Biol Chem. 273(9):5190-5 (1998)) have characterized the human HNK-1 sulfotransferase, and show that it is involved in the synthesis of the HNK-1

carbohydrate epitope which is expressed on various adhesion molecules in the nervous system and on immune cells (e.g., natural killer cells) and is suggested to play a role in cell-cell and cell-substratum interactions. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with HNK-1 sulfotransferase proteins. Such activities are known in the art, some of which are described elsewhere herein, or in, for example, Bakker, et al., J Biol Chem. 272:29942-6 (1997), incorporated herein by reference. Based on sequence similarity between sulfotransferases, a consensus sequence for the active site was developed (Ong, et al., supra). The consensus pattern is as follows: xxRPDzzzz, where x represents hydrophobic amino acid residues and z represents any amino acid residue. Therefore,

Preferred polypeptides of the invention comprise the following amino acid sequences: FVRDPFVRL (SEQ ID NO: 267), FLFVRDPFVRLIS (SEQ ID NO: 268), FLFVRDPFVRLISAF (SEQ ID NO: 269), and/or YLHTSFSRPHTGPPLPTPG PDRDRELTADSDVDEFLDKFLSAGVKQSDLPRKETEQPPAPGSMEENVRGY DWSPRDARRSPDQGRQQAERRSVLRGFCANSSLAFPTKERAFDDIPNSELSHL IVDDRHGAIYCYVPKVACTNWKRVMIVLSGSLLHRGAPYRDPLRIPREHVH NASAHLTFNKFWRRYGKLSRHLMKVKLKKYTKFLFVRDPFVRLISAFRSK FELENEEFYRKFAVPMLRLYANHTSLPASAREAFRAGLKVSFANFIQYLLDPH TEKLAPFNEHWRQVYRLCHPCQIDYDFVGKLETLDEDAAQLLQLLQVDRQ LRFPPSYRNRTASSWEEDWFAKIPLAWRQQLYKLYEADFVLFGYPKPENLL RD (SEQ ID NO: 270). Polynucleotides encoding these polypeptides are also provided.

Further preferred are the sulfotransferase active site polypeptides listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence referenced in Table I for this gene. The additional contiguous amino acid residues is N-terminal or C- terminal to the sulfotransferase active site polypeptides. Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the sulfotransferase active site polypeptides, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domains are characteristic of a signature specific to sulfotransferase proteins. The nucleotides sequence of this gene was found to be

homologous to the human hypoxanthine guanine phosphoribosyl transferase 2 cDNA which is know to be involved in the purine salvage pathway resulting in the maintainance of homeostatic levels of uric acid (See Genbank Accession No.T30127).

The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed to a very high level in HL-60 myelogenous leukemia cell lines, and to a lesser extent, in most cell types of the immune system.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, myelopoiesis, and metabolic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, metabolic, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 130 as residues: Ser-39 to Gly-46, Leu-49 to Ala-62, Lys-79 to Ala-93, Gly-95 to Asp-105, Ser-107 to Val-127, Gly-193 to Leu-200, Lys-218 to Ser-227, Lys-234 to Thr-239, Pro-366 to Asp-379, Pro-406 to Asp-414. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in HL-60 myelogenous leukemia cell lines and homology to HNK-1 sulfotransferase proteins indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention and/or treatment of a variety of immune system disorders, including but not limited to, those involving the HNK-1 carbohydrate epitope. (e.g. HNK-1 as an auto-antigen

in peripheral demyelinative neuropathy). Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, expression of this gene product in tonsils indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the homology to a conserved purine metabolism protein may suggest that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of various metabolic disorders such as Tay-Sach's Disease, phenylkenonuria, galactosemia, porphyrias, Hurler's syndrome, and various urogenital disorders related to metabolic conditions, particularly Lesch-Nyhan syndrome. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1760 of SEQ ID NO:17, b is an integer of 15 to 1774, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 8

When tested against Jurkat T-cell lines, supernatants removed from cells containing this gene activated the gamma activating sequence (GAS) promoter element. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway, a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Thus, it is likely that this gene activates T-cells through the Jak-STAT signal transduction pathway.

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: KLVRLQVPVRNSRVDPRVRSKIGSRRWMLQLI MQLGSVLLTRCPFWGCFSQLMLYAERAEARRKPDIPVPYLYFDMGAAVLCA SFMSFGVKRRWFALGAALQLAISTYAAYIGGYVHYGDWLKVRMYSRTVAII GGFLVLASGAGELYRRKPRSRSLQSTGQVFLGIYLICVAYSLQHSKEDRLA YLNHLPGGELMIQLFFVLYGILALAFLSGYYVTLAAQILAVLLPPVMLLIDG NVAYWHNTRRVEFWNQMKLLGESVGIFGTAVILATDG (SEQ ID NO: 271).

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MQLGSVLLTRCPFWGCFSQLMLYAERAEARRKPDIPVP YLYFDMGAAVLCASFMSFGVKRRWFALGAALQLAISTYAAYIGGYVHYGD

WLKVRMYSRTVAIIGGFLVLASGAGELYRRKPRSRSLQSTGQVFLGIYLICVAYSLQHSKEDRLAYLNHLPGGELMIQLFFVLYGILAPGLSVRLLRDPRCPDPGCTAAPCHAAH (SEQ ID NO: 272). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

This gene is expressed primarily in endometrial tumors, and to a lesser extent, in T-cells, pituitary and to a certain extent in most cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, female reproductive, immune, or endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and/or immune systems expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 131 as residues: Ala-27 to Asp-34, Tyr-116 to Leu-125. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution predominantly in the endometrium indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of a range of immune and/or reproductive disorders including endometriosis, endometritis, and endometrioma. Similarly, the tissue distribution in T-cells and the ability of supernatants expressing this gene to stimulate the GAS promoter element in T-cells indicates polynucleotides and

polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the tissue distribution in pituitary indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of the Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-,

hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-,hypoparathyroidism), hypothallamus, and testes.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1660 of SEQ ID NO:18, b is an integer of 15 to 1674, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 9

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of the myeloid leukemia cell line AML-193 to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of myeloid leukemia cells, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating myeloid leukemia cells.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: SNEILLSFPQNYYIQWLNGSLIHGLWNLASLFS NLCLFVLMPFAFFFLESEGFAGLKKGIRARILETLVMLLLLALLILGIVWVAS ALIDNDAASMESLYDLWEFYLPYLYSCISLMGCLLLLLCTPVGLSRMFTVMG HLLVKPTILEDLDEQIYIITLEEEALQRRLNGLSSSVEYNIMELEQELENVKTL KTKLERRKKASAWERNLVYPAVMVLLLIETSISVLLVACNILCLLVDETAM PKGTRGPGIGNASLSTFGFVGAALEIILIFYLMVSSVVGFYSLRFFGNFTPKKD DTTMTKIIGNCVSILVLSSALPVMSRTLGITRFDLLGDFGRFNWLGNFYIVLS YNLLFAIVTTLCLVRKFTSAVREELFKALGLHKLHLPNTSRDSETAKPSVNGH

QKAL (SEQ ID NO: 273). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in fetal heart, and to a lesser extent, in colon and the adult pulmonary system.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, heart, lung and digestive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular, pulmonary and digestive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, cardiovascular, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 132 as residues: Glu-67 to Asn-74, Glu-88 to Asn-93, Lys-95 to Ala-107, Ala-147 to Arg-153, Phe-197 to Thr-205, Pro-292 to His-308. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in fetal heart, colon and pulmonary tissues and the biological activity in increasing the permeability of the plasma membrane of the myeloid leukemia cell line AML-193 to calcium, likely indicating that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of myeloid leukemia cells, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, prevention, and/or detection of a range of disorders including a variety of vascular disorders and conditions, which include, but are not limited to miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, myocardial infarction, myocarditis, ischemia, thrombosis, coronary artery disease,

arteriosclerosis, and/or atherosclerosis; pulmonary edema and embolism, bronchitis and/or cystic fibrosis; Crohn's Disease and/or colon cancer. Similarly, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2004 of SEQ ID NO:19, b is an integer of 15 to 2018, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 10

The protein product of this clone shares sequence homology with the human MaxiK channel beta 2 subunit (See, Genbank Accession No. gb|AAD23380.1|AF099137_1 (AF099137); all references available through this accession are hereby incorporated herein by reference), which is believed to be a modulatory subunit of the voltage and Ca2+ activated K+ (MaxiK) channel. Additionally, this protein shares homology to the human calcium-activated potassium

channel beta subunit, which, when combined with its corresponding alpha subunit and modulating peptide, are believed to be useful in treating asthma, angina, hypertension, incontinence, migraine, irritable bowel syndrome (IBS). The subsequent heteromultimer that forms upon combining the alpha, beta, and modulator subunits are also thought to be useful in preventing premature labour, preventing and treating cerebral ischemia, inducing pain modulation and decreasing neurogenic inflammation in a patient (See GeneSeq Accession No. R85306).

Preferred polypeptides comprise the soluble domain which consists of the following amino acid sequence: RSYMQSVWTEESQCTLLNASITETFNCSFSCGP DCWKLSQYPCLQVYVNLTSSGEKLLLYHTEETIKINQKCSYIPKCGKNFEESM SLVNVVMENFRKYQHFSCYSDPEGNQKSVILTKLYSSNVLFHSLFWPTCMMA GGVAIVAMVKLTQYLSLLCERIQRINR (SEQ ID NO: 274). Polynucleotides encoding these polypeptides are also provided. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with modulatory subunits of voltage and Ca2+ activated K+ channel proteins. Such activities are known in the art, some of which are described in Wallner, et al., PNAS 96:4137-4142 (1999), incorporated herein by reference.

This gene is expressed primarily in adrenal gland tumor, and to a lesser extent, in Hodgkin's lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine and immune disorders, particularly Hodgkin's Lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and/or endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression

level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 133 as residues: Trp-25 to Gln-30, Pro-50 to Gln-57, Pro-93 to Glu-101, Arg-114 to Cys-121, Ser-123 to Gln-129, Ile-177 to Arg-182. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in adrenal gland tumor and it's identification as the modulatory subunit of the voltage and Ca2+ activated K+ (MaxiK) channel indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-,hypoparathyroidism), hypothallamus, and testes. Alternatively, expression in proliferative immune tissues combined with its homology to a novel human K channel indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in Hodgkin's lymphoma indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2084 of SEQ ID NO:20, b is an integer of 15 to 2098, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 11

The translation product of this gene shares homology with collagen and collagen like proteins (See, e.g., Genbank Accession Nos. gi|2920535|gb|AAC39658.1| (AF018081) and gi|2384942|gb|AAB69961.1| (AF022985); all references available through these accession numbers are hereby incorporated by reference herein). Additionally, it has been determined that this gene has homology to the human Kruppel related zinc finger protein (HTF10) which is known to be important as a transcription factor, particularly in development (See Genebank Accession No.L11672).

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: AFAHLQLGPMWKLWRAEEGAAALGGALFLLL FALGVRQLLKQRRPMGFPPGPPGLPFIGNIYSLAASSELPHVYMRKQSQVYG EVQPRRAPGREGRQAGPGWPGPSWLDLWPPLGRLVGTSPCAGCPLRDTRFPG LEGRS PRRRAPLQGEPRPCR (SEQ ID NO: 275). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in human erythroleukemia cell line (HEL), serum induced smooth muscle, and to a lesser extent in human 8 week whole embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, leukemia, musculoskeletal, or developmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system and muscular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, musculoskeletal, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 134 as residues: Leu-30 to Gly-38, Arg-67 to Val-72, Val-76 to Ala-89, Pro-118 to Arg-123, Gly-129 to Ala-136, Leu-138 to Arg-146. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in human erythroleukemia cell line (HEL), and serum induced smooth muscle, and the shared homology with collagen and collagen like proteins indicates that polynucleotides and polypeptides corresponding to this gene are useful for disorders of hematopoietic or muscular systems, such as leukemia and

muscular dystrophy. Additionally, the shared homology with collagen proteins would suggest that this protein may also be important in the diagnosis or treatment of various autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid, etc.).

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g., for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g., for treating infections, tumours); haemostatic or thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1732 of SEQ ID NO:21, b is an integer of 15 to 1746, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 12

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MRVRIGLTLLLCAVLLSLASASSDEEGSQD ESLGFQDYFDIR (SEQ ID NO: 276). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8.

This gene is expressed primarily in dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 135 as residues: Ser-22 to Ser-41, Glu-43 to Thr-50,

Ser-63 to Leu-68, Ser-71 to Gly-84, Ser-96 to Gly-114. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation

modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g., for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g., for treating infections, tumours); haemostatic or thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2862 of SEQ ID NO:22, b is an integer of 15 to 2876, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 13

A preferred polypeptide variant of the invention comprises the following amino acid sequence: MARGSLRRLLRLLVLGLWLALLRSVAGEQAPGTAPC SRGSSWSADLDKCMDCSTSCPLPA ALAHPWGRSEPDLRAGAAFWLFGLE

TMPQE REVHHPHRGDRRRGLPSCGADPVTMCPLPAGARPLIIHSSILEPVSAS QTRREPSSSNHK GGGGR (SEQ ID NO: 277). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 16. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 16.

This gene is expressed primarily in tumor growth factor or lipopolysaccharide treated bone marrow stroma, epithelioid sarcoma, umbilical vein endothelial cells, and to a lesser extent, in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoiesis or immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic, integumentary, or immune systems expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic, immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 136 as residues: Pro-35 to Trp-42, Pro-65 to Asp-72, Thr-86 to Phe-93, Ile-97 to Glu-103. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in tumor growth factor or lipopolysaccharide treated bone marrow stroma, epithelioid sarcoma, and umbilical vein endothelial cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious

disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g., for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for

control of fertility); chemotactic and chemokinetic activities (e.g., for treating infections, tumours); haemostatic or thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1038 of SEQ ID NO:23, b is an integer of 15 to 1052, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 14

The translation product of this gene shares sequence homology with chromaffin granule amine transporter protein which is thought to be important in vesicle membrane amine transport, particularly in the neural and endocrine tissue, and the human vesicular monoamine transporter hVMAT1 which is involved in the regulation of amine storage in cardiovascular, endocrine, and central nervous system function (See, Genbank Accession Nos. gi|1314290 and gb|AAC50472.1|; all references available through these accession numbers are hereby incorporated by reference herein). Based on these sequence similarities, The translation product of this gene is expected to share at least some biological activities with amine transporter proteins. Such activities are known in the art, some of which are described in Erickson, et al., PNAS 93:5166-5171 (1996), and/or Liu, et al., Cell 70:539-551 (1992), which are both incorporated herein by reference.

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GTSFLDPTLSLFVLEKFNLPAGYVGLVFLGMAL SYAISSPLFGLLSDKRPPLRKWLLVFGNLITAGCYMLLGPVPILHIKSQLWLL VLILVVSGLSAGMSIIPTFPEILSCAHENGFEEGLSTLGLVSGLFSAMWSIGAF MGPTLGGFLYEKIGFEWAAAIQGLWALISGLAMGLFYLLEYSRRKRSKSQNIL STEEERTTLLPNET (SEQ ID NO: 278). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in colon cancer, osteoclastoma, and T-cell lymphoma, and to a lesser extent in many tumor or proliferative tissues such as endometrial tumor, chondrosarcoma, induced umbilical vein endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases resulting from disorders in small molecule transport (i.e., signalling molecules) in afflicted tissues and organs, particularly of the endocrine and central nervous systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculoskeletal, immune, and/or digestive systems and cancer expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 137 as residues: Ser-114 to Asn-123, Thr-127 to Thr-132. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in colon cancer, osteoclastoma, and T-cell lymphoma and homology to amine transporter family members indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders or diseases resulted from small molecule transport in afflicted tissues and organs, particularly that of colon, osteoclast or T-cells. The expression in cancer tissues, and shared homology with transporter proteins may also indicate its role in anti-cancer drug resistance. Additionaly, the protein can be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumours); haemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; or for identifying inhibitors or promoters of the transport of toxic molecules to vesicles, for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1527 of SEQ ID NO:24, b is an integer of 15 to 1541, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 15

The translation product of this gene shares sequence homology with the human prolyl 4-hydroxylase alpha (II) subunit which is important in catalyzing the formation of 4-hydroxyproline in collagens which is essential for the folding of newly synthesised collagen polypeptide chains into triple-helical molecules (See Genbank Accession No. gb|AAB71339.1|; all references available through this accession are hereby incorporated herein by reference). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with Prolyl 4-hydroxylase proteins. Such activities are known in the art, some of which are described in Annunen, et al., J. Biol. Chem. 272:17342-17348 (1997) which is incorporated herein by reference.

When tested against U937 myeloid and Jurkat T-cell cell lines, supernatants removed from cells containing this gene activated the gamma activating sequence (GAS), a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Thus, it is likely that this gene activates myeloid cells and T-cells through the Jak-STAT signal transduction pathway.

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:

GTREARLRDLTRFYDKVLSLHEDSTTPVANPLLAFTLIKRLQSDWRNVVHSL EASENIRALKDGYEKVEQDLPAFEDLEGAARALMRLQDVYMLNVKGLAR GVFQRVTGSAITDLYSPKRLFSLTGDDCFQVGKVAYDMGDYYHAIPWLEEA VSLFRGSYGEWKTEDEASLEDALDHLAFAYFRAGNVSCALSLSREFLLYSPD NKRMARNVLKYERLLAESPNHVVAEAVIQRPNIPHLQTRDTYEGLCQTL GSQPTLYQIPSLYCSYETNSNAYLLLQPIRKEVIHLEPYIALYHDFVSDSEAQ KIRELAEPWLQRSVVASGEKQLQVEYRISKSAWLKDTVDLKLVTLNHRIAA LTGLDVRPPYAEYLQVVNYGIGGHYEPHFDHATSPSSPLYRMKSGNRVATFM IYLSSVEAGGATAFIYANLSVPVVRNAALFWWNLHRSGEGDSDTLHAGCP VLVGDKWVANKWIHEYGQEFRRPCSSSPED (SEQ ID NO: 282). Additional,

Preferred polypeptides comprise the following amino acid sequence: GTREA RLRDLTRFYDKVLSLHEDSTTPVANPLLAFTLIKRLQSDWRNVVHSLEASENI RALKDGYEKVEQ DLPAFEDLEGAARAL (SEQ ID NO: 279), ALMRLQD (SEQ ID NO: 280), and/or VEAGGAT (SEQ ID NO: 281). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in lymph node breast cancer, colon carcinoma, and to a lesser extent in osteoblasts and adipocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of connective and immune tissues, particularly autoimmune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the connective tissues in breast, colon, bone, and fat, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, connective, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 138 as residues: Ser-74 to Ala-84, Gln-156 to Tyr-161, Tyr-184 to Asn-189, Ser-218 to Ile-223, Pro-299 to Ser-308, His-359 to Thr-368, Tyr-390 to Asp-404. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in lymph node breast cancer and colon carcinoma and homology to prolyl 4-hydroxylase alpha (II) subunit indicates that polynucleotides and polypeptides corresponding to this gene are useful for intervention of connective tissue disorders and diseases (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation), as well as, in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, andspecific joint abnormalities as well as chondrodysplasias ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid. Alternatively, the tissue distribution within various tissue carcinomas and tumor tissues, and biological activity reflected by the binding and activation of the GAS promoter element indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders.

Expression in cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2065 of SEQ ID NO:25, b is an

integer of 15 to 2079, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 16

In an additional embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: IQPSHAALLHCRSTFRKTECLDPW WVRRQLLGMAGIGGLQKMKAPHTGVLHLGSVWVFLGPFLLGVGYTLTFNPL SGCMSTVRWLNSNITANRTLSRSVCHVTPLHRSLSPHDGEYLRQMLLNSSSR AGEAGSWGY (SEQ ID NO: 283). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 20. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 20.

This gene is expressed primarily in fetal liver, and, to a lesser extent, in a variety of fetal and other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, liver disorders and cancers (e.g., hepatoblastoma, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hepatic, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 139 as residues: Ser-67 to Tyr-75. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and treatment of liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1933 of SEQ ID NO:26, b is an integer of 15 to 1947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 17

The translation product of this gene shares sequence homology with human laminin B1 which is thought to be an important structural extracellular matrix component involved in cell migration and signalling, paricularly in stimulating epithelial cell growth and differentiation (See, Genbank Accession No gi|186837).

Preferred polypeptides of the invention comprise the following amino acid sequences: CSSPPGRLPWCWTAPRTLGKHGSLISTLRLTAPLHLAWKMMLS RKALFVLLNTPVLFHALEGRLFSKLCHHHTIQRTLTVPKFRSS (SEQ ID NO: 284), RSPTSRVQLLKRQSCPCQRNDLNEEPQHFTHYAIYDFIVKGSCFCNG HADQCIPVHGFRPVKAPGTFHMVHGKCM (SEQ ID NO: 285), and/or HNTAG SHCQHCAPLYNDRPWEAADGKTGAPNECRTCKCNGHADTCHFDVNVWEAS GNRSGGVCDDCQHNTEGQYCQRCKPGFYRDLRRPFSAPDACKPCSCHPV GSAVLPANSVTFCDPSNGDCPCKPGVAGRRCDRCMVGYWGFGDYGCRP CDCAGSCDPITGDCISSHTDIDWYHEVPDFRPVHNKSEPAWEWEDAQGFSAL LHSGKCECKEQTLGNAKAFCGMKYSYVLKIKILSAHDKGTHVEVNVKIK-KVLKSTKLKIFRGKANIISRIMDGQ RMHLSNPQSWFGIPCSRT (SEQ ID NO: 286). Polynucleotides encoding these polypeptides are also provided.

Included in this invention as preferred domains are Laminin-type EGF-like (LE) domain signatures, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Laminins are the major noncollagenous components of basement membranes that mediate cell adhesion, growth migration, and differentiation. They are composed of distinct but related alpha, beta and gamma chains. The three chains form a cross-shaped molecule that consist of a long arm and three short globular arms. The long arm consists of a coiled coil structure contributed by all three chains and cross-linked by interchain disulfide bonds. Beside different types of globular domains each subunit contains, in its first half, consecutive repeats of about 60 amino acids in length that include eight conserved cysteines. The tertiary structure of this domain is remotely similar in its N-terminal to that of the EGF-like module. It is known as a 'LE' or 'laminin-type EGF-like' domain. The number of copies of the LE domain in the different forms of laminins is highly variable; from 3 up to 22 copies have been found. A schematic representation of the topology of the four disulfide bonds in the LE domain is shown below.

```
    +-------------------+
  +-|-----------+       |  +--------+  +-----------------+
  | |           |       |  |        |  |                 |
xxCxCxxxxxxxxxxxCxxxxxxxCxxCxxxxxGxxCxxCxxgaagxxxxxxxxxxxCxx
                        **********************************
  sssssssssssssssssssssssssssssssssss
```

```
'C': conserved cysteine involved in a disulfide bond
'a': conserved aromatic residue
'G': conserved glycine (lower case = less conserved)
's': region similar to the EGF-like domain
'*': position of the pattern
```

In mouse laminin gamma-1 chain, the seventh LE domain has been shown to be the only one that binds with a high affinity to nidogen. The binding-sites are located on the surface within the loops C1-C3 and C5-C6. Long consecutive arrays of LE domains in laminins form rod-like elements of limited flexibility, which determine the spacing in the formation of laminin networks of basement membranes. We derived a signature pattern for the LE domain which covers the C-terminal half of the repeat starting with the fourth conserved cysteine. The consensus pattern is as follows: C-x(1,2)-C-x(5)-G-x(2)-C-x(2)-C-x(3,4)-[FYW]-x(3,15)-C [All C's are involved in disulfide bonds]

Preferred polypeptides of the invention comprise the following amino acid sequence: CDDCQHINTEGQYCQRCKPGFYRDLRRPFSAPDACKPC (SEQ ID NO: 287) and/or CPCKPGVAGRRCDRCMVGYWGFGDYGCRPCDCAGSC (SEQ ID NO: 288). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the laminin-type EGF-like domains listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence encoded by this gene. The additional contiguous amino acid residues is N-terminal or C- terminal to the laminin-type EGF-

like domain. Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the laminin-type EGF-like domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domain is characteristic of a signature specific to Laminin proteins. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with Laminin proteins. Such activities are known in the art, some of which are described elsewhere herein.

This gene is expressed primarily in osteoblastic tissues and cell types, including osteoblasts, osteoblastomas and osteoclastomas. Expression is also abundant in vascular-pulmonary tissues such as lung, micro-vasculature, pulmonary, endothelial and smooth muscle cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and malignancies (particularly of osteoblastic tissues and rhabdomyosarcoma), as well as cardiovascular and respiratory or pulmonary disorders such as athsma, pulmonary edema, pneumonia, atherosclerosis, restenosis, stoke, thrombosis hypertension, inflammation and wound healing. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardio-respiratory system, and skeletal system expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., skeletal, osteoblast, cardio-respiratory, vascular, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, pulmonary surfactant, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 140 as residues: Ser-28 to Cys-34, Thr-51 to Thr-58, Tyr-64 to Asn-81, Asp-111 to Lys-116, Asp-145 to Phe-160, Pro-203 to Glu-217. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in osteoblastic tissues and cell types and homology to laminin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, prevention and diagnosis of cardiovasular and respiratory or pulmonary disorders such as asthma, pulmonary edema, pneumonia, atherosclerosis, restenosis, stoke, angina, thrombosis hypertension, inflammation and wound healing. As a homolog of laminin, this gene product quite possibly has a role in cell adhesion, migration, proliferation, angiogenesis, chondrogenesis, wound healing and oncogenesis. An EST (Int J Cancer 1996 May 16;66(4):571-577) with an identical sequence to part of this contig was shown to be differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma and therefore might have an important role in the determination or maintenance of the normal phenotype, and thus its loss is possibly involved in the progression of malignancies, particularly of skeletal muscle. Similarly, the homology to a laminin would suggest a role in the detection and treatment of disorders and conditions afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation) in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 3365 of SEQ ID NO:27, b is an integer of 15 to 3379, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 18

The gene encoding the disclosed cDNA is believed to reside on chromosome 10. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 10.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: NISSQYCILKSLEMMISGLKLLVLFLKFAPENY CLSTETLQMPNRHLRLSKATCYLMKCLLPSYFE (SEQ ID NO: 289). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in placenta, brain, and to a lesser extent, in a variety of other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, behavioral, or nervous system disorders, such as: depression, schizophrenia, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, dementia, paranoia, addictive behavior, epilepsy, transmissible spongiform encephalopathy (TSE), Creutzfeldt-Jakob disease (CJD). Other diseases and conditions related to expression in the placenta might include developmental anomalies and fetal deficiencies, ovarian and endometrial cancers, reproductive disfunction and pre-natal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and reproductive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial

fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 141 as residues: Ala-16 to Leu-22. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, expression in placenta would suggest a possible role in the treatment and diagnosis of developmental anomalies and fetal deficiencies, ovarian and endometrial cancers, reproductive disfunction and pre-natal disorders.

Similarly, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may

show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1992 of SEQ ID NO:28, b is an integer of 15 to 2006, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 19

The translation product of this gene shares sequence homology with the murine transforming protein (See, e.g., Genbank Accession No. gi|53529|emb|CAA36859.1|; all references available through this accession are hereby incorporated by reference herein).

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PIEGTPAGTGPEFPGRPTRPQRMRSLISSHPCQ HLLLLLLLLFLILAILVDVKWYLVLFICISLMTSDVEHLFMCLLAIRISSWR NVY (SEQ ID NO: 290). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in activated and basal T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, metastasis, wound healing, inflammation, anemias (leukemia) and other hematopoietic disorders. Similarly, polypeptides and antibodies directed to these

polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in activated T-cells and the homology to a murine transforming protein indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of

various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate igands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumours); haemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3056 of SEQ ID NO:29, b is an

integer of 15 to 3070, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 20

The translation product of this gene was shown to have homology to the Mus musculus ALG-2 protein, which is known to code for a Ca(2+)-binding protein required for T cell receptor-, Fas-, and glucocorticoid-induced cell death. ALG-2 mediate Ca(2+)-regulated signals along the death pathway and may play a role in the onset of Alzheimer's Disease (See e.g., Genbank Accession No.gil1213520; all references available through this accession are hereby incorporated by reference herein).

Preferred polypeptides comprise the following amino acid sequence: NWVPT CLCPSAPCSFHLLSRFKCLFSPQRLTDIFRRYDTDQDGWIQVSYEQYLSMVFS IV (SEQ ID NO: 291), and/or QRLTDIFRRYDTDQDGWIQVSYEQYLSMVFSIV (SEQ ID NO: 292). Polynucleotides encoding these polypeptides are also provided.

When tested against K562 cell lines, supernatants removed from cells containing this gene activated the ISRE (interferon-sensitive responsive element). Thus, it is likely that this gene activates immune or leukemia cells through the Jaks-STAT signal transduction pathway. ISRE is a promoter element found upstream in many genes which are involved in the Jaks-STAT pathway. The Jaks-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MFYKLTLILCELSVAGVTQAASQRPLQRLPRHICSQR XPPGRCLLKAXLQTTWXXPDKPI PRLSPPLXSDPKR (SEQ ID NO: 293). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

This gene is expressed primarily in placenta, and to a lesser extent, in a variety of other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental anomalies, fetal deficiencies ovarian and endometrial cancers, reproductive dysfunction and pre-natal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, developmental, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 143 as residues: Arg-24 to Arg-31, Ile-33 to Gly-41. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in placenta indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, prevention and/or diagnosis of developmental anomalies, fetal deficiencies, ovarian and endometrial cancers, reproductive dysfunction and pre-natal disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells combined with the observed ISRE activity, and homology to the apoptosis linked, ALG-2 indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2213 of SEQ ID NO:30, b is an integer of 15 to 2227, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 21

The translation product of this gene was shown to have homology to the human histo-blood group A transferase (See, e.g., Genbank Accession No. gb|AAD26573.1|AF134413_1 (AF134413); all references available through this accession are hereby incorporated by reference herein) which is known to represent one of the major allogeneic antigens in both erythrocytes and tissues of humans. Its been proposed that the A phenotype is associated with the glycosyltransferas that converts the H substance associated with the O phenotype to A through the addition of alpha1-3-N-acetylgalactosamine or alpha1-3-galactosyl residues to the H antigen Fuc-alpha1-2Gal- beta1-R. Therefore, the primary product of the histo-blood group A is its respective glycosyltransferase. Preferred polypeptides of the invention comprise the following amino acid sequence: TSSPVFSFCSMAVREPDHLQ RVSLPRYNVSASLQWLPCHRIVLQPWHMCAMWELGQVLFHPVAPREGAAPS PVSTLTWPSSCSHSESTMELELQF (SEQ ID NO: 294), LPCHRIV (SEQ ID NO: 296), SLQWLPCHRIVLQPW (SEQ ID NO: 297), and/or MAVREPDHLQRVSLPR (SEQ ID NO: 295). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in 12-week-old human embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental anomalies, fetal deficiencies, pre-natal disorders, hematopoietic disorders, or cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing fetus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic, lymph, developing, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in 12 week old embryo indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental anomalies, fetal deficiencies, pre-natal disorders and cancer. Similarly, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Alternatively, the tissue distribution and homology to human blood group A and B glycosyltransferase enzymes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1274 of SEQ ID NO:31, b is an integer of 15 to 1288, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 22

The translation product of this gene shares sequence homology with CD97 (EMR1), which is thought to be important in both adhesion and signaling processes early after leukocyte activation (See, e.g., Genbank Accession No. gil784994; all references available through this accession are hereby incorporated by reference herein). EMR1 belongs to a novel family of G-protein receptors that has recently been recognized on the basis of homologous primary amino acid sequences, comprises receptors to hormones of the secretin/vasoactive intestinal peptide/glucagon family, parathyroid hormone and parathyroid hormone-related peptides, growth hormone-releasing factor, corticotropin-releasing factor, and calcitonin. Proteins with seven transmembrane segments (7TM) define a superfamily of receptors (7TMreceptors) sharing the same topology: an extracellular N-terminus, three extramembranous loops on either side of the plasma membrane, and a cytoplasmic C-terminal tail. Upon ligand binding, cytoplasmic portions of the activated receptor interact with heterotrimeric G-coupled proteins to induce various second messengers, which subsequently activate various signal transduction pathways depending upon the specific G-coupled protein associated with the receptor. Preferred polypeptides of the invention comprise the following amino acid sequence: CFKRKPKREHCSCP
ITYQSLGDILNASFFSKRKGMQEVKLNSYVVSGTIGLKEKISLSEPVFLTFRHN
QPGDKRTKHICVYWEGSEGGRWSTEGCSHVHSNGSYTKCKCFHLSSFAVLV
ALAPKEDPVLTVITQVGLTISLLCLFLAILTFLLCRPIQNTSTSLHLELSLCLFLA
HLLFLTGINRTEPEVLCSIIAGLLHFLYLACFTWMLLEGLHLFLTVRNLKVAN
YTSTGRFKKRFMYPVGYGIPAVIIAVSAIVGPQNYGTFTHCWLKLDKGFIWSF
MGPVAVIILINLVFYFQVLWILRSKLSSLNKEVSTIQDTRVMTFKAISQLFILGC
SWGLGFFMVEEVGKTIGSIIAYSFTIINTLQGVLLFVVHCLLNRQVRMEYKKW

FSGMRKGVETESTEMSRSTTQTKTEEVGKSSEIFIIKGGTASSSAESTKQPQPQVHLVSAAWLKMN (SEQ ID NO: 298), and/or FFWKENLRRNGSREDFARRATQLIQSVELSIWNASFASPGKGQISEFDIVYETKRCNETRENAFLEAGNNTMDINCADALKGNLRESTAVALSLINLLGIF SEQ ID NO: 299. Polynucleotides encoding these polypeptides are also provided.

Included in this invention as preferred domains are two EGF-like protein domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). First, a sequence of about forty amino-acid residues long found in the sequence of epidermal growth factor (EGF) has been shown to be present in a large number of membrane-bound and extracellular, mostly animal proteins. Many of these proteins require calcium for their biological function and a calcium-binding site has been found to be located at the N-terminus of some EGF-like domains. Calcium-binding is crucial for numerous protein-protein interactions. We have used the N-terminal part of the EGF domain as a consensus pattern. It includes the negative N-terminus and the possible hydroxylation site. The consensus pattern is as follows: [DEQN].[DEQN]{2}C.{3,14}C.{3,7}C.[DN].{4}[FY].C [The four C's are involved in disulfide bonds].

Preferred polypeptides of the invention comprise the following amino acid sequence: DINECETGLAKCKYKAYCRNKVGGYIC (SEQ ID NO: 300). Polynucleotides encoding these polypeptides are also provided. Secondly, post-translational hydroxylation of aspartic acid or asparagine to form erythro-beta-hydroxyaspartic acid or erythro-beta-hydroxyasparagine has been identified in a number of proteins with domains homologous to (EGF). Based on sequence comparisons of the EGF-homology region that contains hydroxylated Asp or Asn, a consensus sequence located in the N-terminal of EGF-like domains has been identified that seems to be required by the hydroxylase(s). The consensus sequence is as follows: C.[DN].{4}[FY].C.C.

Preferred polypeptides of the invention comprise the following amino acid sequence: CRNKVGGYICSC (SEQ ID NO: 301). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the calcium-binding EGF-like domain and aspartic acid and asparagine hydroxylation site listed above, and at least

5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence referenced in Table I for this gene and the embodiments listed herein. The additional contiguous amino acid residues is N-terminal or C- terminal to one or both of the listed domains. Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to one or both of the listed domains, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domains are characteristic of a signature specific to EGF like proteins. Based on the sequence similarity and conserved domains, The translation product of this gene is expected to share at least some biological activities with EGF-like proteins. Such activities are known in the art, some of which are described elsewhere herein.

This gene is expressed primarily in eosinophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders or anemias and leukemias, immunodeficiencies; infection, lymphomas, auto-immunities and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 145 as residues: Ser-22 to Ser-30, Pro-33 to Cys-48, Asp-50 to Lys-67, Pro-117 to Ser-130. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in eosinophils combined with its homology to a known human seven transmembrane domain protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders, particularly considering the fact that the majority of 7 transmembrane receptors are tightly associated with signal transduction pathways which are integral to the modulation of the cell cycle. As such, the protein product of this gene may play a role in the regulation of cellular division, where loss of regulation may result in proliferating cells and the onset of tumors or cancer. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Similarly, the tissue distribution and homology to CD97 indicates that the protein product of this gene might be a marker for differentiation and activation of eosinophils, and therefore is useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, auto-immunities, immunodeficiencies (e.g., AIDS), immuno-supressive conditions (transplantation) and hematopoietic disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. In addition this gene product is applicable in conditions of general microbial infection, inflammation or cancer. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3266 of SEQ ID NO:32, b is an integer of 15 to 3280, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 23

The translation product of this gene has been found to have homology to the rat neural F box protein NFB42, in addition to a conserved Caenorhabditis elegans C14B1.3 protein (See, e.g., Genbank Accession Nos. gi|3851648|gb|AAC97505.1| (AF098301) and gi|558270; all references available through these accessions are hereby incorporated by reference herein). Preferred polypeptides of the invention comprise the following amino acid sequence: ALCPHPHLILNVTVSPAPSCRHVK KVVASPSPSTTMIAMDAPHSKAALDSINELPENILLELFTHVPARQLLLNCRL VCSLWRDLIDLMTLWKRKCLREGFITKDWDQPVADWKIFYFLRSLHRNLLR NPCAEEDMFAWQIDFNGGDRWKVESLPGAHGTDFPDPKVKKYFVTSYEMCL KSQLVDLVAEGYWEELLDTFRPDIVVKDWFAARADCGCTYQLKVQLASA DYFVLASFEPPPVTIQQWNNATWTEVSYTFSDYPRGVRYILFQHGGRDTQY WAGWYGPRVTNSSIVVSPKMTRNQASSEAQPGQKHGQEEAAQSPYRAVV QIF (SEQ ID NO: 302). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in immune cells, especially primary dendritic cells, and T cells, and to a lesser extent in a variety of other tissues including breast, keratinocytes, epididiymus (cauda), lung, multiple sclerosis, endometrial stromal cells, IL4 induced umbilical vein endothelial cells, fetal kidney, fetal dura mater, rejected kidney, and osteoblasts.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders, particularly of the immune system or endothelial cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 146 as residues: Pro-41 to Cys-47, Phe-52 to Gly-59, Pro-62 to His-70. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in T-cells indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,

such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate igands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g., for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumours); haemostatic or thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1283 of SEQ ID NO:33, b is an integer of 15 to 1297, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 24

The translation product of this gene shares sequence homology with the human, mouse, and bovine dopamine hydroxylase which is thought to be important in the modification of dopamine, a neurotransmitter (See Genbank Accession Nos. gi|30474, gi|162965, and/or gi|2358082; all references available through these accessions are hereby incorporated by reference herein). Preferred polypeptides of the invention comprise the following amino acid sequence: RQRSWNPGT NCYHPNMPDAFLTCETVIFAWAIGGEGFSYPPHVGLSLGTPLDPHYVLLEVH YDNPTYEEGLIDNSGLRLFYTMDIRKYDAGVIEAGLWVSLFHTIPPGMPEF QSEGHCTLECLEEALEAEKPSGIHVFAVLLHAHLAGRGIRLRHFRKGKEMKL LAYDDDFDFNFQEFQYLKEEQTILPGDNLITECRYNTKDRAEMTWGGLSTR SEMCLSYLLYYPRINLTRCASIPDIMEQLQFIGVKEIYRPVTTWPFIIKSPKQYK NLSFMDAMNKFKWTKKEGLSFNKLVLSLPVNVRCSKTDNAEWSIPRNDSIT SRYRKTL (SEQ ID NO: 303). Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MCCWPLLLLWGLLPGTAAGGSGRTYPHRTLLDSEGK YWLGWSQRGSQIAFRLQVRTAGYVGFGFSPTGAMASADIVVGGVAHGR PYLQDY FTNANRELKKDAQQDYHLEYAMENSTHTIIEFTRELHTCDINDKS ITDSTVRVIWAYHHE DAGEAGPKYHDSNRGTKSLRLLNPEKTSVLSTALPYF DLVNQDVPIPNKDTTYWCQMFKIPVFQEKHHVIKVEPVIQRGHESLVHHILL YQCSNNFNDSVPGIRARIAITPTCPMHSSPV KL (SEQ ID NO: 304). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in brain, the pulmonary system, and to a lesser extent in kidney.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and behavioral disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., sputum, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 147 as residues: Ser-33 to Trp-38, Gly-40 to Gly-45, Asn-93 to Asp-105, Thr-128 to Thr-137, Glu-150 to Lys-167, Pro-197 to Tyr-203, Cys-242 to Asn-247, Ser-253 to Tyr-258, His-307 to Glu-314, Glu-357 to Gly-362, Trp-373 to Gln-378, Ser-402 to Glu-408. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain and homology to a protein involved in the modification of dopamine indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive

compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, the homology to dopamine hydroxylase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-,hypoparathyroidism), hypothallamus, and testes. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2170 of SEQ ID NO:34, b is an integer of 15 to 2184, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 25

When tested against Jurkat T-cell lines, supernatants removed from cells containing this gene activated the gamma activating sequence (GAS), a promoter element found upstream of many genes which are involved in the Jak-STAT pathway.

The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Thus, it is likely that this gene activates T-cells through the JakStat signal transduction pathway.

This gene is expressed in a variety of human normal and diseased tissues including breast, infant adrenal gland, skin tumor, colon, pituitary, Wilm's tumor, and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer and other proliferative disorders, afflicting endocrine or endothelial tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system or of breast and/or breast lymph nodes, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in breast, infant adrenal gland, skin tumor, colon, pituitary, and Wilm's tumor, and biological activity in activating the GAS promoter element indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-,hypoparathyroidism), hypothallamus, and testes. Alternatively, the tissue distribution and biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the

diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells. (i.e., breast, skin and Wilm's tumors) indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy.Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 935 of SEQ ID NO:35, b is an integer of 15 to 949, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 26

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: TGTFWSPRSQRRGCCGRRAPRPEAMENGAVYS PTTEEDPGPARGPRSGLAAYFFMGRLPLLRRVLKGLQLLLSLLAFICEEVVSQ CTLCGGLYFFEFVSCSAFLLSLLILIVYCTPFYERVDTTKVKSSDFYITLGTGCV FLLASIIFVSTHDRTSAEIAAIVFGFIASFMFLLDFITMLYEKRQESQLRKPENTT RAEALTEPLNA (SEQ ID NO: 305). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in dendritic cells, and to a lesser extent in melanocytes, fetal liver and spleen and several other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation, and disorders of the hepatic and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic, hepatic, immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 149 as residues: Phe-63 to Ser-75, Thr-97 to Ser-102, Glu-128 to Arg-143. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in dendritic cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the tissue distribution in fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various would-healing models and/or tissue trauma. Furthermore, the protein may also be used to determine biological activity, raise

antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3324 of SEQ ID NO:36, b is an integer of 15 to 3338, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 27

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ASAPRVMRGHLAGFPALSGLASVCLWATFSA QLPGPVAATSWTPAPLGCSAARSGPEKRLGTAAPGSAASLAQAGPGAPCRV LPVDPAPAALNVREPGWLGGLFDGALLQVLLNFLRKSTDVLMDTREAESLEV E (SEQ ID NO: 306).

In another embodiment polypeptides of the invention comprise the following amino acid sequence: NKLHSFPVFLSQLLLDRQLLHAPQTLPTPHCGGSSRPGP SHPPWLLIQLPCVHVALWQMLRDFSDSRITPSTLTTQPAAQTAAPAKDQES DIVGGEGILCDIAFLQEDHPLGVGGASAPSSRRELSRRGVHTQTLPEDGTLHG TPSSSFDCGIKYIISWPLAPGCDLPSLELSLVCKGVSSCMGFAAG (SEQ ID NO: 307). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in endothelial cells, lung, and fetal kidney, and to a lesser extent in epididymis, keratinocytes and cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cardiovascular diseases involving endothelial cell disturbances such as atheroschlerosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cardiovascular, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 150 as residues: Arg-47 to Leu-54. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in endothelial cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating disorders of endothelial cells such as atheroschlerosis, vasculitis, cardiovascular disease, and emphysema. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. The polypeptide may possess a wide range of undetected biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction ofother cytokines; immunostimulating/immunosuppressant activities (e.g., for treating human immunodeficiency virus infection, cancer, autoimmunediseases and allergy); regulation of haematopoiesis (e.g., for treatinganaemia or as adjunct to chemotherapy); stimulation of growth of bone,cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds,stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g., for treating infections, tumours); haemostatic or

thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1549 of SEQ ID NO:37, b is an integer of 15 to 1563, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 28

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PGRPTRPTKNKVCVCLGMLFWAYPICVFIDSL SCQPCLWSTGATSHFNSPTTSPLFTLFMPCALAPNPFT QLGKLDDR (SEQ ID NO: 308). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in meningima.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, tumors or disorders of the central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For

a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 151 as residues: His-29 to Thr-34. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in meningima indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception, as well as disorders of the meninges such as meningioma and meningitis. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1034 of SEQ ID NO:38, b is an integer of 15 to 1048, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 29

The translation product of this gene has been shown to encode a human brain specific mitochondrial carrier (Genbank Accession No. gi|3851540|gb|AAD04346.1| (AF078544); all references available through this accession are hereby incorporated herein by reference) which shares sequence homology with the human body weight disorder associated gene C5 product which is known to be differentially expressed in obese compared to lean mice (See GeneSeq Accession No. R91281). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with mitochondrial carriers proteins. Such activities are known in the art, some of which are described in Sanchis et al, J. Biol. Chem. 273:34611-34615 (1998), incorporated herein by reference.

Included in this invention as preferred domains are mitochondrial energy transfer protein (METP) domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Structurally, members of the family of mitochondrial energy transfer proteins consist of three tandem repeats of a domain of approximately one hundred residues. Each of these domains contains two transmembrane regions. As a signature pattern, we selected one of the most conserved regions in the repeated domain, located just after the first transmembrane region. To detect this widespread family of proteins, a consensus sequence was developed that contains the most conserved regions in the repeated domain. The consensus pattern is as follows: P.[DE].[LIVAT][RK].[LRH][LIVMFY][QMAIGV].

Preferred polypeptides of the invention comprise the following amino acid sequences: PVDLTKTRLQ (SEQ ID NO: 309) and PTDVLKIRMQ (SEQ ID NO: 310). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the METP domains of the sequence listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence referenced in Table I for this gene. The additional contiguous amino acid residues is N-terminal or C- terminal to the METP domain. Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the METP domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domain is characteristic of a signature specific to mitochondrial energy transfer proteins.

The gene encoding the disclosed cDNA is believed to reside on chromosome X. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome X.

This gene is expressed primarily in brain, and to a lesser extent, in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and behavioral disorders and immune disorders and/or obesity. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the disgestive, immune, and nervous systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, neural, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 152 as residues: Gln-189 to Gly-195. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain and homology to mitochondrial carrier proteins indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1416 of SEQ ID NO:39, b is an integer of 15 to 1430, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 30

Preferred polypeptides of the invention comprise the following amino acid sequence: MTFGSTISPTSTHASPSLGFCCSWLLEDLEEQLYCSAFEEAALTR RICNPTSCWLPLDMELLHRQVLALQTQRVLLGMWLRRAWDTWVSPRRVAP GSRCLLTASHPCTEKRRKASAXQRNLGYPLAMLCLLVLTGLSVLIVAIHILEL LIDEAAMPRGMQGTSLGQVSFSKLGSFGAVIQVVLIFYLMVSSVVGFYSSPLF RSLRPRWHDTAMTQIIGNCVCLLVLSSALPVFSRTLGLTRFDLLGDFGRFNWL GNFYIVFLYNAAFAGLTTLCLVKTFTAAVRAELIRAFGLDRLPLPVSGFPQAS RKTQHQ (SEQ ID NO: 311): Polynucleotides encoding such polypeptides are also provided.

This gene is expressed primarily in immune system tissues (e.g. resting T-cells, primary dendritic cells, and neutrophils, apoptotic T-cells) and umbilical vein. This gene is expressed to a lesser extent in the gastrointestinal tissue (e.g. small intestine, colon), brain (e.g. cerebellum, frontal cortex), aorta endothelial cells, skin tumor, embryonic tissue, thymus, and cancers (e.g. cheek, breast, synovial).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and gastrointestinal tract expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 153 as residues: Asp-21 to Ser-29. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells (e.g. T-cells, dendritic cells, neutrophils) indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility; lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in skin tumors and cancerous tissue (e.g. cheek, breast, synovial sarcoma) indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression in cellular sources such as embryonic tissue marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the

expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The tissue distribution in cerebellum and frontal cortex indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2089 of SEQ ID NO:40, b is an integer of 15 to 2103, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 31

The polypeptide of this gene has been determined to have a zinc finger (Zinc finger, C2H2 type) domain at about amino acid position 16-50 of the amino acid sequence referenced in Table 1 for this gene. Therefore,

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: LCVCLVYLCMYGVCLCVIVCVSGVSLCLYVWGVSVCDCVSVFMCVCLCVIFCVYGKPRTEHYHSPHLAKQKAFREMCGRHDVSAAGIFQSYV (SEQ ID NO: 312). Polynucleotides encoding these polypeptides are also provided. 'Zinc finger' domains are nucleic acid-binding protein structures first identified in the Xenopus transcription factor TFIIIA. These domains have since been found in numerous nucleic acid-binding proteins. A zinc finger domain is composed of 25 to 30 amino-acid residues. There are two cysteine or histidine residues at both extremities of the domain, which are involved in the tetrahedral coordination of a zinc atom. It has been proposed that such a domain interacts with about five nucleotides. A schematic representation of a zinc finger domain is shown below:

```
        x  x
      x      x
     x        x
     x        x
     x        x
     x        x
      C      H
    x  \    /  x
   x     Zn     x
    x  /    \  x
      C      H
x x x x x        x x x x x
```

Many classes of zinc fingers are characterized according to the number and positions of the histidine and cysteine residues involved in the zinc atom coordination. In the first class to be characterized, called C2H2, the first pair of zinc coordinating residues are cysteines, while the second pair are histidines. A number of experimental reports have demonstrated the zinc- dependent DNA or RNA binding property of some members of this class. Some of the proteins known to include C2H2-type zinc fingers are listed below. We have indicated, between brackets, the number of zinc finger regions found in each of these proteins; a '+' symbol indicates that only partial sequence data is available and that additional finger domains is present.

This gene is expressed primarily in salivary gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, salivary gland related diseases, diseases of the mouth, and other digestive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., saliva, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 154 as residues: Gly-46 to His-54. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of salivary gland related diseases (mumps, calculi formation in ducts, sarcoidosis, facial palsy, tumors, Sjogrens Syndrome) and other digestive system disorders. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2335 of SEQ ID NO:41, b is an integer of 15 to 2349, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 32

This gene is expressed primarily in fetal tissue (e.g. spleen, liver, brain), cancerous tissues (e.g. ovarian, colon, stomach, parathyroid) and to a lesser extent in immune cells and tissue (e.g. B-cells, T-cells, bone marrow), and reproductive organs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, particularly of the colon and ovaries, disorders of the developing fetus, neurodegenerative conditions, and immune system disorders.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, reproductive, neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 155 as residues: Lys-35 to Lys-47. Polynucleotides encoding said polypeptides are also provided.

The expression of this gene within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in

modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution in immune cells (such as T-cells and B-cells) and immune tissues (bone marrow) indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in parathyroid indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for

the detection, treatment, and/or prevention of Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-,hypoparathyroidism) , hypothallamus, and testes. Additionally, the tissue distribution in brain tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1545 of SEQ ID NO:42, b is an integer of 15 to 1559, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 33

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in skin tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin disorders, particulary skin cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skin, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 156 as residues: Pro-38 to Gly-44, Phe-56 to Thr-64. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in skin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e.wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. Moreover, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm). Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1752 of SEQ ID NO:43, b is an integer of 15 to 1766, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 34

The translation product of this gene shares sequence homology with mitogen-induced prostate carcinoma (mouse) which is thought to be important in the etiology of cancer. In this respect, this gene is mitogen-induced and/or involved in cell proliferation.

Preferred polypeptides of the invention comprise the following amino acid sequence: GHMPYGWLTEIRAVYPAFDKNNPSNKLVSTSNTVTAAHIKKF TFVCMALSLTLCFVMFWTPNVSEKILIDIIGVDFAFAELCVVPLRIFSFFPVPVT VRAHLTGWLMTLKKTFVLAPSSVLRIIVLIASLVVLPYLGVHGATLGVGSLLA GFVGESTMVAIAACYVYRKQKKKMENESATEGEDSAMTDMPPTEEVTDIVE MREENE (SEQ ID NO: 313) and/or QVVFVAILLHSHLECREPLLIPILSLYMGA LVRCTTLCLGYYKNIHDIIPDRSGPELGGDATIRKMLSFWWPLALILATQRISR PIVNLFVSRDLGGSSAATEAVAILTATYPV (SEQ ID NO: 314). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome. 5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

This gene is expressed primarily in early infant and adult brain, retina, fetal tissue (e.g., liver, speen, whole embryo) and to a lesser extent in immune cells (e.g., monocytes and T-cells), colon, and parathyroid tumor tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancers, disorders of the immune system and nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system (cancers), expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 157 as residues: Arg-122 to Ser-139, Met-144 to Glu-149. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution and homology to mitogen induced prostate carcinoma (mouse) indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of cancers, including but not limited to the colon, parathyroid, and adrenal glands. Moreover, the expression within fetal tissue, and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution in immune cells (T-cells, monocytes) indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or

activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2558 of SEQ ID NO:44, b is an integer of 15 to 2572, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 35

This gene is expressed primarily in adult pulmonary tissue, umbilical vein, prostate, and fetal tissue (e.g.,heart).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases of the pulmonary system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pulmonary, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the

standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 158 as residues: Arg-45 to Gly-51, Glu-75 to Asn-81. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in pulmonary tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of disorders associated with developing lungs, particularly in premature infants where the lungs are the last tissues to develop. Additionally, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of lung tumors, since the gene is involved in the regulation of cell division, particularly since it is expressed in fetal tissue. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in

proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 512 of SEQ ID NO:45, b is an integer of 15 to 526, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 36

This gene is expressed primarily in adipose tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, fat metabolism. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,

the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 159 as residues: Pro-96 to Ser-106. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in adipose tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of obesity and other metabolic and endocrine conditions or disorders. Furthermore, the protein product of this gene may show utility in ameliorating conditions which occur secondary to aberrant fatty-acid metabolism (e.g. aberrant myelin sheath development), either directly or indirectly. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1018 of SEQ ID NO:46, b is an integer of 15 to 1032, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 37

This gene is expressed primarily in adult brain tissue, testes, placenta, kidney, infant and fetal tissue (e.g.,liver, spleen, lung) and to a lesser extent in immune cells (e.g.,T-cells and neutrophils) and in cancerous tissues (e.g.,ovarian tumor, Hodgekins lymphoma, pancreas, T-cell).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, CNS disorders, disorders of the testicles, cancer, particularly ovarian, pancreatic, T-cell, and Hodgekin's lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain,CNS, and testes expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, urogenital, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders"

and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,

such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, the tissue distribution in testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2666 of SEQ ID NO:47, b is an integer of 15 to 2680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 38

When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates fibroblast cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed primarily in endometrial stromal cells; endometrial tumors, keratinocytes, fetal tissue (e.g. liver, spleen) and to a lesser extent in endothelial cells and immune cells (e.g., T-cells).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endometrial carcinoma and immune cells disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in the endometrium indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility. The protein product is likely involved in preparation of the endometrium of implantation and could be administered either topically or orally. Alternatively, this gene could be

transfected in gene-replacement treatments into the cells of the endometrium and the protein products could be produced. Similarly, these treatments could be performed during artificial insemination for the purpose of increasing the likelyhood of implantation and development of a healthy embryo. In both cases this gene or its gene product could be administered at later stages of pregnancy to promote heathy development of the endometrium. Additionally, polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of endometrial carcinoma. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. The tissue distribution in immune cells such as helper T-cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such

as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in keratinocytes indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e.wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chrondomalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, amd

chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1716 of SEQ ID NO:48, b is an integer of 15 to 1730, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 39

This gene is expressed primarily in LNCAP cells (prostate cell line) and retina derived N2b5HR cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, prostate cancer and eye disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male urogenital and reproductive system expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative

to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 162 as residues: Asn-50 to Ser-57. Polynucleotides encoding said polypeptides are also provided.

The expression in prostate may indicate the gene or its products can be used in the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell carcinomas, ductal carcinomas, squamous cell carcinomas, or as hormones or factors with systemic or reproductive functions. The tissue distribution in retina indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of eye disorders including blindness, color blindness, impaired vision, short and long sightedness, retinitis pigmentosa, retinitis proliferans, and retinoblastoma, retinochoroiditis, retinopathy and retinoschisis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1261 of SEQ ID NO:49, b is an integer of 15 to 1275, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 40

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: RCCCRGCSCRARLCPPARSTAVAPECRGAHPSR AMRPGTALQAVLLAVLLVGLRAATGRLLSGQPVCRGGTQRPCYKVIYFHD TSRRLNFEEAKEACRRGWRPASQHRVLKMNRN (SEQ ID NO: 315). Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MRPGTALQAVLLAVLLVGLRAATGRLLSGQPVCRGG TQRPCYKVIYFHDTSRRLNFEEAKEACRRGWRPASQHRVLKMNRN (SEQ ID NO: 316). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle and human thyroid and to a lesser extent in amniotic cells and human endometrial stromal cells-treated with progesterone.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, thyroid disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 163 as residues: Ser-75 to Leu-81. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of endocrine disorders of the thyroid.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1748 of SEQ ID NO:50, b is an integer of 15 to 1762, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 41

This gene is expressed primarily in human testes tumor and bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the testicles including but not limited to testicular cancerand immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system and immune system expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 164 as residues: His-31 to Gly-41. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in testes, particularly testicular tumors, indicates that polynucleotices and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. The tissue distribution in bone marrow indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2045 of SEQ ID NO:51, b is an integer of 15 to 2059, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 42

The translation product of this gene shares sequence homology with protocadherins, which are related to cadherin, and possess cell adhesive ability. Cadherins are glycosylated integral membrane proteins that are involved in cell-cell adhesion.

This gene is expressed primarily in brain (infant, adult frontal lobe, manic depression tissue) and to a lesser extent in epididymus, healing groin wounds, ovary, adipocytes, and fetal tissue (e.g., kidney and retina).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders, impaired male and female fertility, developmental disorders, fibrosis, and manic depression . Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system and reproductive system expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 165 as residues: Val-35 to Lys-41, Ser-68 to Gln-73, Glu-88 to Glu-93, Arg-156 to Gly-163, Ala-199 to Gly-206, Asp-216 to Ser-226, Thr-249 to Asn-254, Asp-339 to Pro-345, Ile-370 to Gly-379, Pro-429 to Glu-434, Arg-461 to Pro-466, Ala-475 to Thr-482, Pro-585 to Gly-593, Glu-631 to Gln-639, Pro-674 to Pro-682, Gln-715 to Gly-720, Ser-736 to Arg-742. Polynucleotides encoding said polypeptides are also provided.

BLAST analysis reveals high homology to protocadherin sequences. These sequences are related to cadherin, and possess cell adhesive ability. Such proteins may have regulatory functions in the cell, as well as the cell-cell adhesive properties. Antibodies produced against these sequences are useful for modulating the binding activity of these protocadherins, and can be used therapeutically. The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease,

Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in epididymus indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Moreover, the expression within fetal tissue (e.g., kidney and retina) and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including blindness, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent

of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3268 of SEQ ID NO:52, b is an integer of 15 to 3282, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 43

Preferred polypeptides of the invention comprise the following amino acid sequence:

IRHEQQGEEDDEHARPLAESLLLAIADLLFCPDFTVQSHRRSTVDSAEDVHSL DSCEYTWEAGVGFAHSPQPNYIHDMNRMELLKLLLTCFSEAMYLPPAPESGS TNPWVQFFCSTENRHALPLFTSLLNTVCAYDPVGYGIPYNHLLFSDYREPLVE EAAQVLIVTLDHDSASSASPTVDGTTTGTAMDDADPPGPENLFVNYLSRIHRE EDFQFILKGIARLLSNPLLQTYLPNSTKKDPVPPGAASSLLEALRLQQEIPLLRA EEQRRPRIIPCPHPLLPQRCPGRSV (SEQ ID NO: 317). Polynucleotides encoding such polypeptides are also provided.

This gene is expressed primarily in brain, breast, breast cancer tissue and to a lesser extent in epididymus, amniotic cells, and embryo tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders, impaired CNS function, male sterility, and breast cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous and reproductive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, male reproductive, cancerous and wounded tissues) or bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 166 as residues: Pro-22 to Pro-31, Ser-38 to His-43, Asp-74 to Leu-79, Asp-113 to Glu-121, Leu-157 to Val-166, Ala-189 to Arg-196, Gln-206 to Arg-211. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain, particulary in the cerebellum, indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11,

15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in epididymus indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. The expression in the breast tissue may indicate its uses in the diagnosis and/or treatment of breast neoplasia and breast cancers, such as fibroadenoma, pipillary carcinoma, ductal carcinoma, Paget's Disease, medullary carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and abscess, duct ectasia, fat necrosis and fibrocystic diseases. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may

show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1846 of SEQ ID NO:53, b is an integer of 15 to 1860, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 44

Contact of cells with supernatant expressing the product of this gene increases the permeability of monocytes to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product of this gene binds a receptor on the surface of the monocyte cell. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocyte cells.

This gene is expressed primarily in CD34 positive cells derived from human cord blood.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders; immune dysfunction; defects in hematopoietic stem and progenitor cells; susceptibility to chemotherapy and irradiation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 167 as residues: Ala-38 to Leu-59, Ala-63 to Thr-71, Lys-82 to Leu-91, Glu-97 to Ser-107, Gln-143 to Ala-149, Ile-153 to Leu-158, Ser-169 to Arg-182. Polynucleotides encoding said polypeptides are also provided.

Elevated expression of this gene product in CD34 positive hematopoietic cells indicates that it is expressed by early stem and progenitor cells of the hematopoietic lineages. Therefore, this may represent a soluble factor that is able to control the survival, proliferation, differentiation, or activation of all hematopoietic lineages, including stem and progenitor cells. Thus, it could be quite useful, for example, in ex vivo expansion of stem cell numbers for hematopoietic disorders or for cancer patients. Alternately, it may represent a factor that influences the hematopoietic microenvironment by affecting stromal cells that release other factors required for hematopoietic development. Additionally, the tissue distribution in CD34 positive cells also indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis; therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 756 of SEQ ID NO:54, b is an integer of 15 to 770, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 45

This gene is expressed primarily in breast and 12-week old human embryos and to a lesser extent in stomach cancer and liver.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer; stomach cancer; embryonic defects; hepatic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for the diagnosis and/or treatment of a variety of disorders. Elevated expression of this gene product in stomach cancer indicates it is useful as a marker or therapeutic target for stomach cancer. Alternately, expression in breast tissue is influenced by the presence or absence of breast cancer tissue, and may thus also serve as a diagnostic marker for this cancer as well. Expression in the developing embryo may correlate with the normal development of human embryhos, and expression in the liver is involved in the regulation of normal liver function and/or liver regeneration.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1079 of SEQ ID NO:55, b is an integer of 15 to 1093, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 46

This gene is expressed primarily in human hypothalamus derived from a patient with schizophrenia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, schizophrenia; neurological disorders; impaired nervous system function. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 169 as residues: Glu-34 to Trp-39. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain, particularly in the hypothalamus, indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal

cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 618 of SEQ ID NO:56, b is an integer of 15 to 632, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 47

The translation product of this gene shares sequence homology with human lecithin-cholesterol acyltransferase (LCAT), which catalyses the transfer of fatty acid from the sn-2 position of lecithin to the free hydroxyl group of cholesterol. Preferred polypeptides of the invention comprise the following amino acid sequence: RLVYN KTSRATQFPDGVDVRVPGFGKTFSLEFLDPSKSSVGSYFHTMVESLVGWGYT RGEDVRGAPYDWRRAPNENGPYFLALREMIEEMYQLYGGPVVLVAHSMGN MYTLYFLQRQPQAWKDKYIRAFVSLGAPWGGVAKTLRVLASGDNNRIPVIG

PLKIREQQRSAVSTSWLLPYNYTWSPEKVFVQTPTINYTLRDYRKFFQDIGFE DGWLMRQDTEGLVEATMPPGVQLHCLYGTGVPTPDSFYYESFPDRDPKICFG DGDGTVNLKSALQCQAWQSRQEHQVLLQELPGSEHIEMLANATTLAYLKRV LLGP (SEQ ID NO: 318). Polynucleotides encoding such polypeptides are also provided.

This gene is expressed primarily in osteoblasts & dendritic cells and to a lesser extent in muscle and other hematopoietic cell lineages.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders; immune dysfunction; osteoporosis; osteopetrosis; muscle degeneration. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 170 as residues: Cys-65 to Ser-71. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution and homology to lecithin-cholesterol acyltransferase (LCAT) indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of disorders. For example, artheroscelerosis is a pathological condition of mammals characterised by the accumulation of cholesterol in the arteries, which leads to heart disease, strokes, heart attacks and peripheral vascular disease. The enzyme could be used in a novel method of treating atherosclerosis, which involves increasing the level of LCAT activity, which then causes a decrease in the accumulation of cholesterol. The method and the

products can be used for the prophylaxis and treatment of atherosclerosis, and associated heart disease, myocardial infarction, stroke and peripheral vascular disease, as well as individuals suffering from Fish Eye Syndrome (caused by LCAT deficiency) or Classic LCAT Deficiency Syndrome. Alternately, elevated expression of this gene product in osteoblasts and hematopoietic cell lineages indicates that it may play additional roles in bone turnover, regulation of immune system function, and muscular function.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2673 of SEQ ID NO:57, b is an integer of 15 to 2687, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 48

When tested against HELA epithelial cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates epithelial cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in adult brain, infant brain, fibroblasts, embryonic and fetal tissue (e.g., spleen, liver), placenta and to a lesser extent in endocrine organs, cancerous colon and breast.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, dementia, epilepsy, schizophrenia, and developmental abnormalities. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, endocrine system, and during development, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. In addition, the expression of this gene product in synovium (synovial sarcoma) would suggest a role in the detection and treatment of disorders and

conditions afflicting the skeletal system, in particular osteoporosis, bone cancer, connective tissue disorders (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation). The protein is also useful in the diagnosis or treatment of various autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, and dermatomyositis), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid, etc.). The tissue distribution in endocrine tissues indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-,hypoparathyroidism), hypothallamus, and testes. Additionally, the expression within fetal tissue, cancerous colon and breast, and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the

polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 605 of SEQ ID NO:58, b is an integer of 15 to 619, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 49

Preferred polypeptides of the invention comprise the following amino acid sequence or a subfragment thereof: MNKEDKVWNDCKGVNKLTNLEEQYIILIFQ NGLDPPANMVFESIINEIGIKNNISNFFAKIPFEEANGRLVACTRTYEESIKGSC GQKENKIKTVSFESKIQLRSKQEFQFFDEEEETGENHTIFIGPVEKLIVYPPPPA KGGISVTNEDLHCLNEGEFLNDVIIDFYLKYLVLEKLKKEDADRIHIFSSFFYK RLNQRERRNHETTNLSIQQKRHGRVKTWTRHVDIFEKDFIFVPLNEAAHWFL AVVCFPGLEKPKYEPNPHYHENAVIQKCSTVEDSCISSSASEMESCSQNSSAK

PVIKKMLNKKHCIAVIDSNPGQEESDPRYKRNICSVKYSVKKINHTASENEEF NKGESTSQKS (SEQ ID NO: 319). Polynucleotides encoding such polypeptides are also provided.

This gene is expressed primarily in fetal tissue, stomach, brain, endometrial cells, and bone and to a lesser extent in prostate, retina, adipocytes, smooth muscle, and tumors of the endometrium, ovaries, and parathyroid.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of the endocrine system, ulcers, stomach cancer, epilepsy, schizophrenia, dementia, bone growth, developmental disorders and resorption. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system and neural systems expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, endocrine system, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS,

psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Expression of this gene product in stomach tissue indicates involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of stomach cancer, and cancer in general. The expression within embryonic, fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution in parathyroid tumor indicates polynucleotides and polypeptides corresponding to this

gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-,hypoparathyroidism) , hypothallamus, and testes. The tissue distribution in testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1364 of SEQ ID NO:59, b is an integer of 15 to 1378, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 50

The translation product of this gene shares good protein homology with Xenopus NaDC-2 gene and a rabbit renal sodium/dicarboxylate cotransporter. The translation product of this gene also shares good homology with a rat placental protein which is a sodium-coupled high affinity dicarboxylate transporter. Therefore, it is likely that that the translated product encoded by this gene shares similar biological activity.

This gene is expressed primarily in the placenta and colon adenocarcinoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental abnormalities as well as failure to thrive anomalies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system and colon, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 173 as residues: Lys-166 to Gly-181. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in human placenta and the shared homology of this translation product to a rat placental protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product is produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or

survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product is produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. The tissue distribution in colon tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders involving the colon. Expression of this gene product in colon tissue indicates involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of colon cancer, and cancer in general.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:60 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1112 of SEQ ID NO:60, b is an integer of 15 to 1126, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 51

This gene is expressed primarily in the spinal cord.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, paralysis, neurologic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of

the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spinal cord indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:61 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2064 of SEQ ID NO:61, b is an integer of 15 to 2078, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 52

This gene is expressed primarily in keratinocytes, brain, fetal tissues, pericardium, stomach, and cancerous tissues (e.g., stomach, adrenals, parathyroid, germ cell, colon, breast).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin disorders, neurodegenerative and developmental disorders, heart disease, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular and gastrointestinal systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of

Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in keratinocytes indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e.wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chrondomalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, amd chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita,

familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). The expression within fetal tissue (e.g., spleen and liver) and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Additionally, the tissue distribution in the pericardium of the heart indicates that the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the

protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 748 of SEQ ID NO:62, b is an integer of 15 to 762, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 53

This gene is expressed primarily in the brain and in cartilage and to a lesser extent in the retina, activated T-cells, pineal gland, the lungs, and in synovial sarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological diseases, such as epilepsy and dementia, osteoarthritis, retinopathies, hematopoietic diseases, emphysema, and lung cancer . Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neurologic system, cartilage and musculature, vision, the hematopoietic system, and the pulmonary system expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 176 as residues: Arg-34 to Cys-44. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in T-cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such

as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions afflicting the skeletal system, in particular osteoporosis, bone cancer, connective tissue disorders (e.g. arthritis, trauma, tendonitis, chrondomalacia and inflammation). The protein is also useful in the diagnosis or treatment of various autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, and dermatomyositis), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid, etc.). Additionally, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have

applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:63 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1080 of SEQ ID NO:63, b is an integer of 15 to 1094, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 54

This gene is expressed primarily in umbilical vein endothelial cells induced by IL-4.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, angiogenesis, inflammatory disorders, hematopoietic disease. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the angiogenic and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in endothelial cells indicates polynucleotides and polypeptides corresponding to this gene are useful in the detection, treatment, and/or prevention of vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or embolism. For example, this gene product may represent a soluble factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons. Likewise, it is involved in controlling the digestive process, and such actions as peristalsis. Similarly, it is involved in controlling the vasculature in areas where smooth muscle surrounds the endothelium of blood vessels. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human

immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:64 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1347 of SEQ ID NO:64, b is an integer of 15 to 1361, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 55

This gene is expressed primarily in both normal and cancerous pancreas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diabetes, gastrointestinal disorders, and pancreatic cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and blood systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded

tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in pancreas indicates that the protein products of this gene are useful as a therapeutic and/or diagnostic agent for pancreatic disorders and disorders of the endocrine and exocrine system, including but not limited to diabetes, blood disorders, pancreatic cancer, gastrointestinal diseases, hormomal imbalance, autoimmune disorders, cystic fibrosis, pancreatitis, and gallstones. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:65 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 933 of SEQ ID NO:65, b is an integer of 15 to 947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:65, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 56

The translation product of this gene shares sequence homology with oxidoreductase. Preferred polypeptides of the invention comprise the following amino acid sequence: MSPLSAARAALRVYAVGAAVILAQLLRRCRGGFLEPVXPPRP DRVAIVTGGTDGIGYSTANIWRDLGMHVIIAGNNDSKAKQVVSKIKEETLND KVEFLYCDLASMTSIRQFVQKFKMKKIPLHVLINNAGVMMVPQRKTRDGFEE HFGLNYLGHFLLTNLLLDTLKESGSPGHSARVVTVSSATHYVAELNMDDLQS

SACYSPHAAYAQSKLALVLFTYHLQRLLAAEGSHVTANVVDPGVVNTDXYK HVFWATRLAKKLLGWLLFKTPDEGAWTSIYAAVTPELEGVGGRYLYNEKET KSLHVTYNQKLQQQLWSKSCEMTGVLDVTL (SEQ ID NO: 320). The mature form of this protein begins at residue 32. Thus, polypeptides comprising residues 2-330 and 32-330 of the sequence shown above are also provided. Polynucleotides encoding such polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MSPLSAARAALRVYAVGAAVILAQLLRRCRGGFLEP VXPPRPDRVAIVTGGTDGIG YSTANIWRDLACMLS (SEQ ID NO: 321). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in breast cancer cells, osteoclastoma, wilm's tumor, thymus stromal cells, and T cell helper I.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, e.g., breast cancer, osteoclastoma, and wilm's tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, kidney, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, breast milk, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in breast cancer tissue, combined with the homology to oxidoreductase indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of cancer, particularly, breast cancer, osteoclastoma, and wilm's tumor. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative

conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:66 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1362 of SEQ ID NO:66, b is an

integer of 15 to 1376, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:66, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 57

This gene is expressed primarily in monocytes, T cell helper II and B cell lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly B-cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 180 as residues: Asp-30 to Val-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in monocytes, T cell helper, and B cell lymphoma cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of B cell lymphoma. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or

other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:67 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2420 of SEQ ID NO:67, b is an integer of 15 to 2434, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 58

This gene is expressed primarily in human lung cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pulmonary diseases and/or disorders, particularly cancers of the lung. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, pulmonary lavage, pulmonary surfactant, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 181 as residues: Phe-39 to Asp-45. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in lung cancer tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders such as ARDS, cystic fibrosis, and cancer, particularly lung cancer. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:68 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1072 of SEQ ID NO:68, b is an integer of 15 to 1086, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 59

This gene is expressed primarily in larynx carcinoma and early stage human lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, gastrointestinal, and pulmonary diseases and/or disorders, particularly larynx carcinoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, gastrointestinal, pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, pulmonary lavage, sputum, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 182 as residues: His-42 to Lys-49. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in larynx carcinoma and early stage human lung indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating immune system disorders such as cancer, particularly larynx carcinoma. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the

polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:69 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1248 of SEQ ID NO:69, b is an integer of 15 to 1262, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 60

Preferred polypeptides of the invention comprise the following amino acid sequence: MEVTTEDTSRTDVSEPATSGGAADGVTSIAPTAVASSTTAASITTA ASSMTVASSAPTTAASSTTVASIAPTTTASSMTAASSTPMTLALPAPTSTXTGR TPSTTATGHPSLSTALAQVPKSSALPRTATLATLATRAQTVATTANTSSPMST RPSPSKHMPSDTAASPVPPMXPQAQGPISQVSVDQPVVNTTXKSTXMPSNTT XEPLTQAVVDKTLLLVVLLLGVTLFITVLVLFALQAYESYKKKDYTQVDYLI

NGMYADSEM (SEQ ID NO: 322). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ARCPELPGLRCRPRPRAGPQAPSYCPRATRPPG ACCARMRLLLEWRVYLRLTCATKDGMARECPTTWLSPPAKPDFAQRHSVK PTALQGGRWSRLGASP (SEQ ID NO: 323). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in adipocytes, osteoblasts, cerebellum, hypothalamus and Hodgkin's lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic, skeletal, neural, and immune diseases and/or disorders, particularly Hodgkin's lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., metabolic, skeletal, neural, immune, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 183 as residues: Pro-33 to Gln-40, Gly-51 to Arg-56. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in Hodgkin's lymphoma cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders such as cancer, particularly Hodgkin's lymphoma. The secreted protein can also be used to determine biological activity, to

raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:70 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1628 of SEQ ID NO:70, b is an integer of 15 to 1642, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 61

The translation product of this gene shares sequence homology with polypeptide in the cystatin family. Cystatin polypeptides are cysteine protease inhibitors. For an analysis of the composition of several members of the cystatin family, see Gene (1987) 61(3):329-338, incorporated herein by reference. The cystatin activity of polypeptides encoded by this gene is measured by several assays known in the art including assays described in coowned, copending US Patent Application Serial No. 08/744,138, incorporated herein by reference. Preferred polypeptides of the invention comprise the following amino acid sequence: LPATVEFAVHTFNQQSKD YYAYRLGHILNSWKEQVESKTVFSMELLLGRTRCGKFEDDIDNCHFQESTEL NNTFTCFFTISTRPWMTQFSLLNKTC (SEQ ID NO: 324). Fragments of such polypeptides having cystatin activity (cysteine protease inhibitory activity are particularly preferred). Polynucleotides encoding such polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: LLWARGLGRAKSAVPTVST MLGLPWKGGLS WALLLLLLGSQILLIYAWHFHEQRDCDEHNVMARYLPATVEFAVHTFNQQS KDYYAYRLGHILNSWKEQVESKTVFSMELLLGRTRCGKFEDDIDNCHFQE STELNNTFTCFFTISTRPWMTQFSLLNK TCLEGFH (SEQ ID NO: 325). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in testes and epididiymus. For a review of a cystatin showing testes- specific expression see Mol. Endocrinol. (1992 Oct.) 6(10):1653-1664, incorporated herein by reference.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, They should therefore serve a protective function to regulate the activities of such endogenous proteinases, which otherwise may cause uncontrolled proteolysis and tissue damage. Cysteine proteinase activity can normally not be measured in body fluids, but can been detected extracellularly in conditions like endotoxin-induced sepsis, metastasizing cancer, and at local inflammatory processes

in rheumatoid arthritis , purulent bronchiectasis and periodontitis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, testicular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, seminal fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 184 as residues: Phe-31 to Asp-38, Asn-59 to Tyr-65, Ser-76 to Glu-82, Thr-96 to Cys-108, Gln-111 to Asn-118. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in testes and epididymus, combined with the homology to cystatins indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent

of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Cysteine proteinase inhibitors of the cystatin superfamily are ubiquitous in the body and are generally tight-binding inhibitors of papain-like cysteine proteinases, such as cathepsins B, H, L, S, and K. They should therefore serve a protective function to regulate the activities of such endogenous proteinases, which otherwise may cause uncontrolled proteolysis and tissue damage. Cysteine proteinase activity can normally not be measured in body fluids, but can been detected extracellularly in conditions like endotoxin-induced sepsis, metastasizing cancer, and at local inflammatory processes in rheumatoid arthritis, purulent bronchiectasis and periodontitis, which indicates that a tight cystatin regulation is a necessity in the normal state. A deficiency state in which the levels of the intracellular cystatin, cystatin B, are lowered due to mutations has recently been shown to segregate with a form of progressive myoclonus epilepsy, which points to additional specialized functions of cystatins. Moreover, results showing that chicken cystatin inhibits polio virus replication, human cystatin C inhibits corona- and herpes simplex virus

replication, and human cystatin A inhibits rhabdovirus-induced apoptosis in cell cultures indicates that cystatins play additional roles in the human defense system. The cystatins constitute a superfamily of evolutionarily related proteins, all composed of at least one 100-120 residue domain with conserved sequence motifs.

The previously well characterized single-domain human members of this superfamily could be grouped in two protein families. The Family 1 members, cystatins (or stefins) A and B, contain approximately 100 amino acid residues, lack disulfide bridges, and are not synthesized as preproteins with signal peptides. The Family 2 cystatins (cystatins C, D, S, SN, and SA) are secreted proteins of approx. 120 amino acid residues (Mr 13,000-14,000) and have two characteristic intrachain disulfide bonds. Recently, we identified an additional human cystatin superfamily member by EST1 sequencing in epithelial cell derived cDNA libraries which we named cystatin E. The same cystatin was independently discovered by differential display experiments as a mRNA species down-regulated in breast tumor tissue, but present in the surrounding epithelium and reported under the name cystatin M . Cystatin E/M is an atypical, secreted low-Mr cystatin in that it is a glycoprotein and just shows 30-35% sequence identity in alignments with the human Family 2 cystatins, which shows that additional cystatin families are yet to be identified. The cystatin E/M gene has been localized to chromosome 2 , whereas all human Family 2 cystatin genes are clustered on the short arm of chromosome 20, which further stresses that cystatin E/M is just distantly related to the other secreted human low-Mr cystatins. It is believed therefore, that polypeptides encoded by this gene are useful in diagnosing and treating disease consistent with the aforementioned conditions in which cystatins are implicated.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:71 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 907 of SEQ ID NO:71, b is an

integer of 15 to 921, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 62

The translation product of this gene shares sequence homology with Neutrophil Gelatinase-Associated Lipocalin which is thought to be important in immune regulation (See Genbank and Geneseq Accession Nos. emb|CAA58127.1, and US5627034, respectively; all references and information available through these accessions are hereby incorporated herein by reference; for example, Biochem. Biophys. Res. Commun. 202 (3), 1468-1475 (1994), and FEBS Lett. 314 (3), 386-388 (1992)).

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: LEQKLELHRGGGRSRTSGSPGLQEFGTREERGE GEQRTGREFSGNGGRAVEAARMRLLCGLWLWLSLLKVLQAQTPTPLPLPP PMQSFQGNQFQGEWFVLGLAGNSFRPEHRALLNAFTATFELSDDGRFEVWN AMTRGQHCDTWSYVLIPAAQPGQFTVDHGVGRSWLLPPGTLDQFICLGRAQ GLSDDNIVFPDVTGXALDL XSLPWVAAPA (SEQ ID NO: 326). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in epididiymus and osteoclastoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive and skeletal diseases and/or disorders, particularly cancers such as osteoclastoma testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, testicular, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, seminal fluid, urine, synovial fluid and spinal fluid)

or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 185 as residues: Met-82 to Thr-90. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in epididiymus and homology to neutrophil gelatinase-associated lipocalin indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of skin diseases and immune system disorders such as cancer, particularly osteoclastoma. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:72 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 892 of SEQ ID NO:72, b is an integer of 15 to 906, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 63

The translation product of this gene was shown to have homology to colipase which plays an essential role in the intestinal fat digestion by anchoring lipase on lipid/water interfaces in the presence of bile salts (See Genbank Accession No. gb|AAA03513.1; all references and information available through this accession are hereby incorporated by reference herein).

This gene is expressed primarily in epididiymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive diseases and/or disorders, particularly epididiymus-related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, seminal fluid, bile, chyme, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 186 as residues: Ile-40 to Cys-49, Arg-52 to Cys-57,

Ser-94 to Trp-99, Gly-105 to Gly-111. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in epididiymus indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system diseases and disorders of the epididiymus. Polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:73 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 666 of SEQ ID NO:73, b is an integer of 15 to 680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 64

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: MCVCERKRGREKEGGVTPTMTSNFPFCTLILGI AQAQACPGCPGDWPGLGSGVGEGLHHIRTCRTPIPCSPPAPAAACLGSGH ARLPCVLRLWPVPANLSSPFRLEALHCSFWSSPLLPAPIILAFFGFRDLLTDFL LAACLLTFQKTPLELPMAVVHLLVATPCYQMLDNLPLPSAAAN WC (SEQ ID NO: 327). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in melanocytes and placenta and to a lesser extent in bone marrow and many cells of the immune system, including B-cells, dendritic cells, and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin cancer and disorders of the reproductive and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., reproductive tissue, hematopoietic tissue, melanocytes and cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in melanocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the skin, the reproductive system, and the immune system, particularly cancers. Representative uses are described in the "Biological Activity",

"Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e.wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chrondomalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, amd chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:74 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1619 of SEQ ID NO:74, b is an integer of 15 to 1633, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:74, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 65

Preferred polypeptides of the invention comprise the following amino acid sequence: YLWGRPRLRMRAGTSPSAPWGEKREKLGHKLPVALQGYHPWIL LECTVFWARVVLACFSLYLIRGPNCINRQPEPTYQKACNLDCSSDFGQER APAWELLGPESEQRLREYTAQGLQSLASSHRWRQFKTEGKMRGGASPLPWLI CFW LCSYKGSDNSLKPVVPGPTLCPQSLVSPSVHPSTRSASLGRHRAEAA (SEQ ID NO: 328). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: MPGILAGIPVKDLCLSLLQGFRLLLLCVCPGWL SGWMGGQKGSPRIVDIG (SEQ ID NO: 329). Polynucleotides encoding these polypeptides are also provided. This gene maps to chromosome 15, accordingly, polynucleotides of the invention is used in linkage analysis as a marker for chromosome 15.

This gene is expressed primarily in brain and breast and to a lesser extent in the liver, pancreas, and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the brain and CNS, the reproductive system, or the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, the reproductive system, and the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., brain and other tissue of the nervous system, mammary tissue, eendocrine tissue, hepatic tissue, reproductive tissue, cells

and tissue of the immune system, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 188 as residues: Met-37 to Ser-43. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the central nervous system, the reproductive system, and the immune system, including cancers. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:75 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1008 of SEQ ID NO:75, b is an integer of 15 to 1022, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 66

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: AKGEERKEAFSLKMVQLSSEPISFGLMYLYLGV FFHLIYPGALSITTLGKHSHPFFTAEQNSTVWMEHTLFHQSPVASHLVCFQSF AFSE (SEQ ID NO: 330). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in the brain and the immune system, in particular T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the brain, such as Alzheimer's or disorders affecting the immune system, such as AIDS. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and CNS and the immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the brain and CNS or disorders affecting the immune system. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:76 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1170 of SEQ ID NO:76, b is an

integer of 15 to 1184, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 67

The translation product of this gene shares sequence homology with penaeidin-2 which is thought to be a members of a new family of antimicrobial peptides from the hemolymph of shrimps Penaeus vannamei. The molecules display antimicrobial activity against fungi and bacteria with a predominant activity against Gram-positive bacteria.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GPAHPASPPLMTLSLQLAELVHFVCAFQSQWT GVYPMMPPLKPTEPLCFA CVPCRV (SEQ ID NO: 331). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in spleen.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly disorders affecting the spleen, including bacterial and fungal infections. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoetic and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., immune, hematopoietic, and cells and tissue of the immune system, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spleen and homology to the penaeidin family of antibiotics indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the spleen, especially fungal and bacterial infections. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:77 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 298 of SEQ ID NO:77, b is an integer of 15 to 312, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 68

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of THP-1 cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both monocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating immune and hematopoietic cells and tissue cell types. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell.

Moreover, when tested in TF-1 cell lines, the protein product of this gene has been shown to alter the steady-state messenger RNA levels of the following genes: c-fos, c-jun, egr-1, b561, bcl-2, CD40, cyclin D2, GADPH, ICER, MAD3, p21, STAT3, ID3, and STAT-1. When tested in U937 cell lines, the protein product of this gene has been shown to alter the steady-state messenger RNA levels of the following genes: egr2, MKP1, ATF3, B562, cyclin D, cyclin D2, GATA3, MAD3, p21, TGF, DHFR, and JAK3. Based upon these results, it is anticipated that polynucleotides and polypeptides corresponding to this gene are useful as agonists or antagonists of the above referenced genes. Such activity is useful in therapeutic and/or diagnostic applications as referenced and more specifically discussed elsewere herein.

In specific embodiments, polpeptides of the invention comprise the sequence:MLLEVYGDSISVTVAIPL (SEQ ID NO:332), MHSPCQSKAADGLGKSETE (SEQ ID NO: 333), and/or MLKSLGLSTN (SEQ ID NO: 334). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: AQRLAEECFYMLLEVYGDSISVTVAIPLMHSP CQSKAADGLGKSETEMLKSLGLSTNMSPFHLLGLKVFLTWALTLAQICLY FFEVQPLGLLALNFFCTATAGLKELCMHPPSLAFTPEFHTSLSPLAIPSFCGTS VSLSNSHTIPLSLYLPFPSKSRMPDTLHLLVHSLPLVHSQVLPVKDVTIEWPLC QRCLGSTCH Q (SEQ ID NO: 335). Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 11 - 27 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 28 to 143 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in neutrophils and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders and/or diseases affecting the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., immune, hematopoietic, cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 191 as residues: Pro-97 to Asp-104. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in neutrophils and T-cells, combined with the detected calcium flux biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the immune system. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their

interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:78 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1356 of SEQ ID NO:78, b is an integer of 15 to 1370, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 69

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: WIPRAAGIRHEVQVSLFQMFCFSSIFCSH EHTHLPGTFWLFLFLFLILPPSCPCFLPFSLAIETVRWPCWHHPTSFELCY PGTSIYYASRGGPXPNSEX (SEQ ID NO: 336). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders affecting the immune system, and neutrophils in particular. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., blood cells,

and cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the immune system and neutrophils in particular. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:79 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 354 of SEQ ID NO:79, b is an integer of 15 to 368, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 70

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: XNXKSPLTIGNKSWSSTAVAAALELVDPPGCR NSARDSPELVHLGKGRPRKLMTYLFCSSISLLLLKVHSSGHQDIRKAKSKVP RLLIIQCPQQRE (SEQ ID NO: 337). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting smooth muscle tissue, particularly vascular conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of smooth muscle tissue expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial

fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 193 as residues: Ser-18 to Val-31. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution primarily in smooth muscle indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting smooth muscle tissue. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:80 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1074 of SEQ ID NO:80, b is an integer of 15 to 1088, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:80, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 71

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by

the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GPEENLSPSTPSQMPTIWVKLCLLQVCHGLFP LLKHWSQPMPLCVTLAPVSYWL (SEQ ID NO: 338). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in fetal heart, smooth muscle, and frontal cortex.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, muscular, vascular, or neural diseases and/or disorders, particularly defects or injury to cardiac muscle. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., muscular, vascular, neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal heart indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating defects to the heart either due to injury or congenital defects. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection,

treatment; and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:81 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1848 of SEQ ID NO:81, b is an integer of 15 to 1862, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:81, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 72

The translation product of this gene shares sequence homology with adipose complement related protein which is thought to be important in regulating energy metabolism, insulin levels and fat stores. Moreover, the protein product of this gene has also been shown to have homology to the complement subcomponent C1Q A-chain precursor and HP-25 protein (See Genbank and Geneseq Accession Nos. emb|CAA41664.1, dbj|BAA02352.1, and W98013; all references and information

available through this accession are hereby incorporated by reference herein). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with complement proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PRVRKEPEAMQWLRVRESPGEATGHRVTMG TAALGPVWAALLLFLLMCEIPMVELTFDRAVASDCQRCCDSEDPLDPAHVSS ASSSGRPHALPEIRPYINITILKGDKGDPGPMGLPGYMGREGPQGEPGPQGSK GDKGEMGSPGAPCQKRFFAFSVGRKTALHSGEDFQTLLFERVFVNLDGC FDMATGQFAAPLRGIYFFSLNVHSWNYKETYVHIMHNQKEAVILYAQPS ERSIMQSQSVMLDLAYGDRVWVRLFKRQRENAIYSNDFDTYITFSGHLIKA EDD (SEQ ID NO: 339). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in placenta and, fetal kidney, and umbilical vein and to a lesser extent in fetal heart, fetal liver/spleen, microvascular endothelial cells and cancers of the lung and pharynx.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, vascular, renal, and reproductive diseases and/or disorders, particularly cancers of the lung and pharynx. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., vascular, renal, reproductive, immune, hematpoietic, pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 195 as residues: Asp-36 to Asp-48, Ser-57 to His-62, Lys-77 to Gly-84, Met-92 to Gly-114, Gln-203 to Ile-209, Lys-231 to Tyr-239. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in pharynx or lung, combined with the homology to adipose complement related proteins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating cancers of the pharynx or lung by modifying the metabolic balance in such tissues. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:82 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1604 of SEQ ID NO:82, b is an integer of 15 to 1618, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:82, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 73

The translation product of this gene shares sequence homology with a hypothetical 54.7 kD protein (F37A4.1) from Caenorhabditis elegans (SwissProt locus YPT1_CAEEL, accession P41879). The protein product of this gene also has homology to the human NG26 which is thought to contain a human major histocompatibility complex class III and is involved in T-cell maturation (See Genbank Accession No. gb|AAD18079.1|(AF129756); all references and information available through this accession are hereby incorporated by reference herein; for example, J. Neurochem. 69 (6), 2516-2528 (1997)). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with nitric oxide synthase proteins.

Preferred polypeptides of the invention comprise the following amino acid sequence: MLYPGSVYLLQKALMPVLLQGQARLVEECNGRRAKLLACDGNE IDTMFVDRRGTAEPQGQKLVICCEGNAGFYEVGCVSTPLEAGYSVLGWNHP GFAGSTGVPFPQNEANAMDVVVQFAIHRLGFQPQDIIIYAWSIGGFTATWAA MSYPDVSAMILDASFDDLVPLALKVMPDSWRGLVTRTVRQHLNLNNAEQLC RYQGPVLLIRRTKDEIITTTVPEDIMSNRGNDLLLKLLQHRYPRVMAEEGLRV VRQWLEASSQLEEASIYSRWEVEEDWCLSVLRSYQAEHGPDFPWSVGEDMS ADGRRQLALFLARKHLHNFEATHCTPLPAQNFQMPWHL (SEQ ID NO: 340). Polynucleotides encoding such polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: VCPKWCRFLTMLGHCCYFWQVWPASEALAA GPTPSTGSSSPSWKQHIGTSLQKTRGSLPTTTLTSGAGQSTSTGKNPAAGR SLEGALPAGVWPCFAQSPCTGGQQTP SSTGLRSCLVRSPATWWRTP (SEQ ID NO: 341). Polynucleotides encoding these polypeptides are also provided.

Preferred polypeptides of the invention comprise the following amino acid sequence: WIPRAAGIRHEIYREXDSERAPASVPETPTAVTAPHSSSWDTYYQ PRALEKHADSILALASVFWSISYYSSPFAFFYLYRKGYLSLSKVVPFSHYAG TLLLLLAGVACXRGIGRWTNPQYRQFITILEATHRNQSSENKRQLANYNFD FRSWPVDFHWEEPSSRKESRGGPSRRGVALLRPEPLHRGTADTLLNRVKKL

PCQITSYLVAHTLGRRMLYPGSVYLLQKALMPVLLQGQARLVEECNGRRAK LLACDGNEIDTMFVDRRGTAEPQGQKLVICCEGNAGFYEVGCVSTPLEAGYS VLGWNHPGFAGSTGVPFPQNEANAMDVVVQFAIHRLGFQPQDIIIYAWSI GGFTATWAAMSYPDVSAMILDASFDDLVPLALKVMPDSWRGLVTRTVRQ HLNLNNAEQLCRYQGPVLLIRRTKDEIITTTVPEDIMSNRGNDLLLKLLQHRY PRVMAEEGLRVVRQWLEASSQLEEASIYSRWEVEEDWCLSVLRSYQAEHGP DFPWSVGEDMSADGRRQLALFLARKHLHNFEATHCT PLPAQNFQMPWHL (SEQ ID NO: 342). Polynucleotides encoding these polypeptides are also provided. A preferred polypeptide variant of the invention comprises the following amino acid sequence: HERAXGPSRGHGELLSCVLGPRLYKIYRERDSERAPASVPETPTA VTAPHSSSWDTYYQP RALEKHADSILALASVFWSISYYSSPFAFFYLYRKGY LSLSKVVPFSHYAGTLLLLLAGV ACSEALAAGPTPSTGSSSPSWKQHIGTSLQ KTRGSLPTTTLTSGAGQSTSTGKNPAAGRSLEGALPAGVWPCFAQSPCTGG QQTPSSTGL RSCLVRSPATWWRTP (SEQ ID NO: 343). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in cerebellum, pituitary, fetal liver, and primary dendritic cells and to a lesser extent in in a wide range of tissues and developmental stages (i.e. fetal and adult tissue, etc.).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural, developmental, and immune diseases and/or disorders. particularly those involving self recognition and T- anc B-cell maturation, and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural or hormonal system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, developmental, immune, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g., serum,

plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 196 as residues: Thr-23 to Lys-34, Leu-41 to Ser-47, Ala-57 to Ala-68, Pro-89 to Gly-101, Pro-110 to Pro-117. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in developmental and immune cells, combined with the homology to the human major histocompatibility complex class III region, indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of cancer and other proliferative disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and

in the differentiation and/or proliferation of various cell types. Potentially. this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:83 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2020 of SEQ ID NO:83, b is an integer of 15 to 2034, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:83, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 74

The translation product of this gene shares sequence homology with the br-1 protein from the snail nervous system (EMBL HPBR1GENE) which codes for nitric oxide synthetase and which is thought to be important in mediating a variety of cellular responses, including vasodilation. Preferred polypeptides of the invention comprise the following amino acid sequence: MFKRHQRLKKDSTQAEEDLSEQ EQNQLNVLKKHGYVVGRVGRTFLYSEEQKDNIPFEFDADSLAFDMENDPVM GTHKSTKQVELTAQDVKDAHWFYDTPGITKENCILNLLTEKEVNIVLPTQSIV PRTFVLKPGMVLFLGAIGRIDFLQGNQSAWFTVVASNILPVHITSLDRADALY QKHAGHTLLQIPMGGKERMAGFPPLVAEDIMLKEGLGASEAVADIKFSSAG WVSVTPNFKDRLHLRGYTPEGTVLTVRPPLLPYIVNIKGQRIKKSVAYKTKKP PSLMYNVRKKKGKINV (SEQ ID NO: 344). Polynucleotides encoding such polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MLPARLPFRLLSLFLRGSAPTAARHGLREPLLERRCAA ASSFQHSSSLGRELPYDPVDTEGFGEGGDMQERFLFPEYILDPEPQPTREKQL QELQQQQEEEERQRQQRREERRQQNLRARSREHPVVGHPDPALPPSGVNCS GCGAXLHCQDAGVPGYLPREKFLRTAEADGGLARTVCQRCWLLSHHRRALR LQVSREQYLELVSAALRXPGPSLVLYMVDLLDLPDALLPDLPALVGPKQLIV LGNKVDLLPQDAPGYRQRLRERLWEDCARAGLLLAPGTKGHSAPSRTSHR TGRIRIRRTGPAQWSGTCG (SEQ ID NO: 345). Polynucleotides encoding these polypeptides are also provided.

When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in early stage human brain, smooth muscle, and endometrial tumor and to a lesser extent in a variety of tissues representing many organs and developmental states.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cardiovascular, vascular, and neural diseases and/or disorders, particularly congestive heart disease and neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory and neural systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cardiovascular, vascular, neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,

urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 197 as residues: Phe-42 to Leu-48, Pro-53 to Asp-58, Pro-81 to Glu-123, Asp-256 to Trp-269, Gly-282 to Ser-306, Arg-333 to Gly-339, Arg-403 to Gln-425, Ser-446 to Asn-452, His-475 to Gln-480, Gly-592 to Met-597, Pro-635 to His-642, Lys-667 to Lys-672, Lys-678 to Ser-684. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in smooth muscle and vascular tissues, combined with the homology to nitric oxide synthetase indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of congestive heart failure and neurological degenerative disorders. polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to

miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:84 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2226 of SEQ ID NO:84, b is an integer of 15 to 2240, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:84, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 75

The translation product of this gene shares sequence homology with the human KE04p, in addition to an unidentifed C.elegans gene.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 9 - 25 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 1 to 8 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PSFRRERVETGGGGPVTIIGTEGPFLPLPGGTRM NMTQARVLVAAVVGLVAVLLYASIHKIEEGHLAVYYRGGALLTSPSGPGYH

IMLPFITTFRSVQTTLQTDEVKNVPCGTSGGVMIYIDRIEVVNMLAPYAVFDIV RNYTADYDKTLIFNKIHHELNQFCSAHTLQEVYIELFDQIDENLKQALQKDL NLMAPGLTIQAVRVTKPKIPEAIRRNFELMEAEKTKLLIAAQKQKVVEKEA ETERKKAVIEAEKIAQVAKIRFQQKVMEKETEKRISEIEDAAFLAREKAKA DAEYYAAHKYATSNKHKLTPEYLELKKYQAIASNSKIYFGSNIPNMFVDSSC ALKYSD IRTGRESSLPSKEALEPSGENVIQNKESTG (SEQ ID NO: 346). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 10. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 10.

This gene is expressed primarily in fetal tissue, including 8 week whole embryo, fetal liver spleen, nine week old early stage human, fetal heart,fetal liver, fetal lung, and placenta and to a lesser extent in a variety of cancers, and other normal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and diseases of fetal development. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the fetal tissues, especially the liver, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, hepatic, immune, hematopoietic, pulmonary, cardiovascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 198 as residues: Leu-68 to Lys-74, Tyr-109 to Lys-115, Gln-200 to Val-205, Lys-207 to Lys-214, Glu-237 to Ile-244, Ala-271 to Thr-

279, Ser-317 to Ser-329, Gln-342 to Gly-348. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution of this gene (primarily fetal tissue and cancerous tissue, both of which are undergoing rapid growth) indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of cancer and disorders of fetal development. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:85 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1474 of SEQ ID NO:85, b is an integer of 15 to 1488, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:85, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 76

When tested against U937 and Jurkat cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid and T-cells, and to a lesser extent in other immune cells and tissue cell types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: WSTGNASWEKKDNFILSADFEMMGLGNGRR SMKSPPLVLAALVACIIVLGFNYWIASSRSVDLQTRIMELEGRVRRRAAERG AVELKKNEFQGELEKQRFQLDKIQSSHNFQLESVNKLYQDEKAVLVNNITTG ERLIRVLQDQLKTLQRNYGRLQQDVLQFQKNQTNLERKFSYDLSQCINQMKE VKEQCEERIEEVTKKGNEAVASRDLSENNDQRQQLQALSEPQPRLQAAGL

PHTEVPQGKGNVLGNSKSQTPAPSSEVVLDSKRQVEKEETNEIQVVNEE PQRDRLPQEPGREQVVEDRPVGGRGFGGAGELGQTPQVQAALXVSQENPE MEGPERDQLVIPDGQEEEQEAAGEGRNQQKLRGEDDYNMDENEAESETDKQ AALAGNDRNIDVFNVE DQKRDTINLLDQREKRNHTL (SEQ ID NO: 347). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 9. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9.

This gene is expressed primarily in human endometrial tumor and other tumors and to a lesser extent in a variety of other healthy adult and fetal tissues

Therefore. polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental diseases and/or disorders, particularly cancer and other proliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endometrial tissue, cervix and uterus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 199 as residues: Asn-6 to Lys-12, Leu-65 to Phe-70, Glu-73 to His-88, Gln-123 to Gln-135, Gln-142 to Leu-156, Arg-173 to Gly-181, Asp-189 to Gln-199, Ser-204 to Arg-209, Glu-219 to Gly-225, Gly-229 to Pro-238, Ser-246 to Asn-256, Glu-263 to Arg-276. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in endometrial tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of

endometrial, cervical and uterine cancer. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:86 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3160 of SEQ ID NO:86, b is an integer of 15 to 3174, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:86, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 77

The translation product of this gene shares sequence homology with protein disulfide isomerase from Acanthamoeba castellanii (See Genbank Locus ACADISPROA accession L28174, genpep locus 456013) which is thought to be important in converting proteins into their native conformations. The protein product of this gene was also shown to have homology to a phospholipase C homologue

derived from a mast cell cDNA library (See Geneseq Accession No. R99411). All references and information available through these accessions are hereby incorporated by reference herein - for example, Gene 150 (1), 175-179 (1994).

Included in this invention as preferred domains are endoplasmic reticulum targeting sequence domain and the thioredoxin family active site domain, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Proteins that permanently reside in the lumen of the endoplasmic reticulum (ER) seem to be distinguished from newly synthesized secretory proteins by the presence of the C-terminal sequence Lys-Asp-Glu-Leu (KDEL) [1,2]. While KDEL is the preferred signal in many species, variants of that signal are used by different species. This situation is described in the following table.

Signal	Species
KDEL	Vertebrates, Drosophila, Caenorhabditis elegans, plants
HDEL	Saccharomyces cerevisiae, Kluyveromyces lactis, plants
DDEL	Kluyveromyces lactis
ADEL	Schizosaccharomyces pombe (fission yeast)
SDEL	Plasmodium falciparum

The signal is usually very strictly conserved in major ER proteins but some minor ER proteins have divergent sequences (probably because efficient retention of these proteins is not crucial to the cell). Proteins bearing the KDEL-type signal are not simply held in the ER, but are selectively retrieved from a post-ER compartment by a receptor and returned to their normal location. The concensus pattern is as follows: [KRHQSA]-[DENQ]-E-L>. Thioredoxins are small proteins of approximately one hundred amino- acid residues which participate in various redox reactions via the reversible oxidation of an active center disulfide bond. They exist in either a reduced form or an oxidized form where the two cysteine residues are linked in an intramolecular disulfide bond. Thioredoxin is present in prokaryotes and eukaryotes and the sequence around the redox-active disulfide bond is well conserved. Bacteriophage T4 also encodes for a thioredoxin but its primary structure is not homologous to bacterial, plant and vertebrate thioredoxins. A number of eukaryotic

proteins contain domains evolutionary related to thioredoxin, all of them seem to be protein disulphide isomerases (PDI). PDI (EC 5.3.4.1) is an endoplasmic reticulum enzyme that catalyzes the rearrangement of disulfide bonds in various proteins. The various forms of PDI which are currently known are: - PDI major isozyme: a multifunctional protein that also function as the beta subunit of prolyl 4-hydroxylase (EC 1.14.11.2), as a component of oligosaccharyl transferase (EC 2.4.1.119), as thyroxine deiodinase (EC 3.8. 1.4), as glutathione-insulin transhydrogenase (EC 1.8.4.2) and as a thyroid hormone-binding protein - ERp60 (ER-60; 58 Kd microsomal protein). ERp60 was originally thought to be a phosphoinositide-specific phospholipase C isozyme and later to be a protease. - ERp72. - P5. All PDI contains two or three (ERp72) copies of the thioredoxin domain. The concensus pattern is as follows: [LIVMF]-[LIVMSTA]-x-[LIVMFYC]-[FYWSTHE]-x(2)-[FYWGTN]-C-[GATPLVE]-[PHYWSTA]-C-x(6)-[LIVMFYWT]. The two C's form the redox-active bond.

Preferred polypeptides of the invention comprise the following amino acid sequence: SLHRFVLSQAKDEL (SEQ ID NO: 348), FIKFFAPWCGHCKALAPTW (SEQ ID NO: 349), and/or FIKFYAPWCGHCKTLAPTW (SEQ ID NO: 350). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the endoplasmic reticulum targeting sequence domain and thioredoxin family active site domain of the sequence referenced in Table for this gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of this referenced sequence. The additional contiguous amino acid residues is N-terminal or C- terminal to the endoplasmic reticulum targeting sequence domain and thioredoxin family active site domain. Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the endoplasmic reticulum targeting sequence domain and thioredoxin family active site domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with thioredoxin proteins. Such activities are known in the art, some of which are described elsewhere herein.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: RRGRGVPGPRGRRRLWSAACGHCQRLQPTWN DLGDKYNSMEXAKVYVAKVDCTAHSDVCSAQGVRGYPTLKLFKPGQEAV KYQGPRDFQTLENWMLQTLNEEPVTPEPEVEPPSAPELKQGLYELSASNFELH VAQGDHFIKFFAPWCGHCKALAPTWEQLALGLEHSETVKIGKVDCTQHY FLCSGNQVRGYPTLLWFRDGKKVDQYKGKRDLESLREYVESQLQRTETGA TETVTPSEAPVLAAEPEADKGTVLALTENNFDDTIAEGITFIKFYAPWCGHC KTLAPTWEELSKKEFPGLAGVKIAEVDCTAERNICSKYSVRGYPTLLLFRGGK KVSEHSGGRDLDS LHRFVLSQAKDEL (SEQ ID NO: 351). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in human chondrosarcoma and endothelial cells and to a lesser extent in a wide range of normal and diseased adult and fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, chondrosarcoma and other cancers and proliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., vascular, skeletal, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in chondrosarcoma, combined with the homology to protein disulfide isomerase and phospholipase C indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of

chondrosarcoma and other cancers and proliferative disorders, and possibly as a reagent for in vitro production of proteins. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Moreover, the expression in endothelial cells indicates the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:87 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2766 of SEQ ID NO:87, b is an integer of 15 to 2780, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:87, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 78

This gene is expressed primarily in thyroid and thymus

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, thyroid diseases including thyroid cancer and diseases of function including Grave's Disease, hyper- and hypo- thyroidism as well a's Diseases of the thymus. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., endocrine, immune, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in thyroid cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the thyroid and thymus. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of

Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancrease (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-,hypoparathyroidism), hypothallamus, and testes. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:88 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1047 of SEQ ID NO:88, b is an integer of 15 to 1061, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:88, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 79

The translation product of this gene shares sequence homology with collagen which is thought to be important as a structural material in a variety of human tissues and products including hair, nails, muscle and bone.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MRPQGPAASPQRLRGLLLLLLLQLPAPSSASEIPKGKQK AHSGRGRWWTCIMECAYKGQQECLVETGALGPMAFRVHLGSQVGMDSKEK RGNV (SEQ ID NO: 352). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle and to a lesser extent in 12 week old early stage human, epdidymus, healing groin wound, synovial hypoxia,

stromal cells, ulcerative colitis, breast and 8 week old embryo, as well as a variety of other normal and diseased cell types from adult and fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders as well a's Diseases of smooth muscle. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., vascular, developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 202 as residues: Glu-32 to Glu-46, Pro-63 to Ala-71, Pro-81 to Lys-90, Ser-97 to Trp-111, Lys-130 to Ser-135, Leu-147 to Cys-154, Asp-179 to Asn-186, Ser-219 to Gly-229. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in smooth muscle and homology to collagen indicates that polynucleotides and polypeptides corresponding to this gene are useful for trearment and diagnosis of diseases of vascular diseases and/or disorders. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e.wounds, rashes, prickly heat disorder, psoriasis, dermatitis),

atherosclerosis, uticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, althletes foot, and ringworm).

Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chrondomalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, amd chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:89 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1328 of SEQ ID NO:89, b is an

integer of 15 to 1342, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:89, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 80

This gene is expressed primarily in immune cells and to a lesser extent in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, T cell or B cell leukemia and various immunodeficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 203 as residues: Gly-3 to Gln-9. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system diseases such as immunodeficiencies and T cell and/or B cell leukemia. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:90 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 756 of SEQ ID NO:90, b is an integer of 15 to 770, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:90, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 81

The translation product of this gene shares sequence homology with IgE receptor. See for example, Isolation and Characterization of cDNAs coding for the Beta Subunit of the High-affinity Receptor for Immunoglobulin E, Proc. Natl. Acad. Sci. U S A. (1988 Sep.) 85(17): 6483-6487. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with IgE receptor proteins. Such activities are known in the art, some of which are described elsewhere herein. IgE and its receptors are believed to have evolved as a mechanism to protect mammals against parasites. But other and intrinsically innocuous antigens can subvert this system to provoke an allergic response. For human populations in industrialized countries, allergy and asthma now represent a far greater threat than parasitic infection, and the main impetus for current studies of the IgE system is the hope of understanding and intervening in the aetiology of allergic diseases. The high-affinity receptor for immunoglobulin (Ig) E (Fc epsilon RI) on mast cells and basophils plays a key role in IgE-mediated allergies. Fc epsilon RI is composed of one alpha, one beta, and two gamma chains, which are all required for cell surface expression of Fc epsilon RI, but only the alpha chain is involved in the binding to IgE. Fc epsilon RI-IgE interaction is highly species specific, and rodent Fc epsilon RI does not bind human IgE. New homolog can be used to develop ant-allergic agents. FcR deliver signals when they are aggregated at the cell surface. The aggregation of FcR having immunoreceptor tyrosine-based activation motifs (ITAMs) activates sequentially src family tyrosine kinases and syk family tyrosine kinases that connect transduced signals to common activation pathways shared with other receptors. FcR with ITAMs elicit cell activation, endocytosis, and phagocytosis. The nature of responses depends primarily on the cell type. The aggregation of FcR without ITAM does not trigger cell activation. Most of these FcR internalize their ligands, which can be endocytosed, phagocytosed, or transcytosed. The fate of internalized receptor-ligand complexes depends on defined sequences in the intracytoplasmic domain of the receptors. The coaggregation of different FcR results in positive or negative cooperation. Some FcR without ITAM use FcR with ITAM as signal transduction subunits. The coaggregation of antigen receptors or of FcR having ITAMs with FcR having immunoreceptor tyrosine-based inhibition motifs (ITIMs)

negatively regulates cell activation. FcR therefore appear as the subunits of multichain receptors whose constitution is not predetermined and which deliver adaptative messages as a function of the environment.

The polypeptide of this gene has been determined to have four transmembrane domains at about amino acid position 51 - 67, 89 - 105, 119 - 135, and 190 - 206 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ETRVKTSLELLRTQLEPTGTVGNTIMTSQPVPN ETIIVLPSNVINFSQAEKPEPTNQGQDSLKKHLHAEIKVIGTIQILCGMMVLSL GIILASASFSPNFTQVTSTLLNSAYPFIGPFFFIISGSLSIATEKRLTKLLVHSSLV GSILSALSALVGFIILSVKQATLNPASLQCELDKNNIPTRSYVSYFYHDSLYTT DCYTAKASLAGXLSLMLICTLLEFCLAVLTAVLRWKQAYSDFPGSVLFLPH SYIGNSGMSSKMTI IDCGYEELLTS (SEQ ID NO: 353). Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MMVLSLGIILASASFSPNFTQVTSTLLNSAYPFIGPFFFI ISGSLSIATEKRLTKLLVHSSLVGSILSALSALVGFIILSVKQATLNPASLQC ELDKNNIPTRSYVSYFYHDSLYTTDCYTAKASLAGXLSLMLICTLLEFCL AVLTAVLRWKQAYSDFPGSVLFLPHSYIGNSGMSSKMTHDCGYEELLTS (SEQ ID NO: 354). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in immune system tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system diseases and/or disorders such as cancer. Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 204 as residues: Gln-23 to Lys-39, Glu-150 to Thr-158. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells and tissues combined with the homology to IgE receptor indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that

influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:91 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1556 of SEQ ID NO:91, b is an integer of 15 to 1570, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:91, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 82

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GASCEGGGAAARAALGVHRSQKALLVFRRTL SNLLYMPLLRGLLWLQVLCAGPLHTEAVVLLVPSDDGRAFLLRSRLLHPEAH VPPAADRGASLQCVLHQAAPKSRPRSPAAGAALLHXPRRTGDEPCREFHGN GFPGPTQLTPGECGLPAPSSLLQHASAPVRTGSEGQVVGCPRARGETGEGLSL

AFLSSLMFTSRNGLVGC GASCEGGGAAARAALGVHRSQKALLVFRRTLSNL LYMPLLRGLLWLQVLCAGPLHTEAVVLLVPSDDGRAFLLRSRLLHPEAHVPP AAD RGASLQCVLHQAAPKSRPRSPAAGAALLHXPRRTGDEPCREFHGNGFP GPTQLTPGECGLPAPSSLLQHASAPVRTGSEGQVVGCPRARGETGEGLSLA FLSSLMFTSRNGLVGC (SEQ ID NO: 355). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed primarily in activated T cells, and to a lesser extent in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly immunodeficeincies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 205 as residues: Pro-67 to Ser-73. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in activated T cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immunodeficiencies. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and

elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:92 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 2936 of SEQ ID NO:92, b is an integer of 15 to 2950, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:92, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 83

The translation product of this gene was shown to have homology to the human transmembrane protein (See Genbank Accession No. gb|AAC51364.1| (AF000959); all references and information available through this accession are hereby incorporated by reference herein; for example, Genomics 42 (2), 245-251 (1997)) which is thought to be implicated in velo-cardio-facial syndrome.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MGSAALEILGLVLCLVGWGGLILACGLPMWQVTAFLD HNIVTAQTTWKGLWMSCVVQSTGTCSAKCTTRCWL (SEQ ID NO: 356). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 22. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 22.

This gene is expressed primarily in dementia brain tissue, and to a lesser extent in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural diseases and/or disorders, particularly dementia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 206 as residues: Ser-201 to Tyr-217. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dementia brain tissue, combined with the homology to the transmembrane protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of dementia, and potentially for velo-cardio-facial syndrome. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:93 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1708 of SEQ ID NO:93, b is an integer of 15 to 1722, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:93, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 84

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: LKRAPPGPALAKGLLQPSSTFQALETNIGDQVR RHSTAVVIREMTSYILISFVLLIGVGCIEKDQSCPVFGGRKRLHLLFVGGQLRQ VRMLRGELSCACYRPHVQALQLGGCTCF (SEQ ID NO: 357). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in the adult pulmonary system.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cystic fibrosis, bronchitis and any pulmonary disorders in general. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pulmonary, cardiovascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, pulmonary surfactant, pulmonary lavage/sputum, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene only in the pulmonary system indicates that it plays a key role in the functioning of the pulmonary system. This would suggest that misregulation of the expression of this protein product in the adult could lead to lymphoma or sarcoma formation, particularly in the lung and the protein product could be used either in the treatment and/or detection of these disease states. The gene

or gene product may also useful in the treatment and/or detection of pulmonary defects such as pulmonary edema and embolism, bronchitis and cystic fibrosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:94 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 621 of SEQ ID NO:94, b is an integer of 15 to 635, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:94, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 85

The translation product of this gene was found to be homologous to CAM proteins. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with CAM proteins. Such activities are known in the art, some of which are described elsewhere herein.

A preferred polypeptide varient of the invention comprises the following amino acid sequence: MLCPWRTANLGLLLILTIFLVAEAEGAAQPNNSLM
LQTSKENHALASSSLCMDEKQITQNYSKVLAEVNTSWPVKMATNAVLC
CPPIALRNLIIITWEIILRGQPSCTKAYKKETNETKETNCTDERITWVSRPDQ
NSDLQIRTVAITHDGYYRCIMVTPDGNFHRGYHLQVLVTPEVTLFQNRNRTA
VCKAVAGKPAAHISWIPEGDCATKQEYWSNGTVTVKSTCHWEVHNVSTV
NCHVSHLTGNKSLYIELLPVPGAKKSSKLYIPYIILTIIILTIVGXIWLLKVNG
CXKYKLNKPESTPVVEEDEMQPYAFYTEKNNPLXXTTNKVKASEALQSEV

DTDLHTL (SEQ ID NO:208). Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 271 - 287 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 288 to 348 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, metastasis, wound healing, inflammation, anemias (leukemia) and other hematopoeitic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 208 as residues: Asp-53 to Tyr-61, Pro-105 to Ile-128, Arg-133 to Leu-140, Gln-182 to Ala-188, Pro-205 to Asn-218, Gly-259 to Ala-264, Asn-290 to Ser-302, Glu-307 to Tyr-314, Tyr-317 to Lys-332. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, auto-immunities,

immunodeficiencies (e.g. AIDS), immuno-supressive conditions (transplantation) and hematopoeitic disorders. In addition this gene product is applicable in conditions of general microbial infection, inflammation or cancer. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:95 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3784 of SEQ ID NO:95, b is an integer of 15 to 3798, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:95, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 86

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: VIKLICPAAFPVYFQDMARGCVCSLCASVCIFLS SLFPLLPSVHSVNIISCLLLSKCFEGLELMCEHL YQLSQLHVLHHIFSYLLCTP (SEQ ID NO: 358). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in embryonic tissue and to a lesser extent in in a variety of other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental anomalies, fetal deficiencies, cancer and neoplastic states. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing fetus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, differentiating, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in embryonic tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of developmental anomalies, fetal deficiencies and pre-natal disorders, as well as abnormal cell proliferation and/or differentiation, neoplastic states and cancer. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:96 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2669 of SEQ ID NO:96, b is an integer of 15 to 2683, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:96, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 87

The translation product of this gene shares sequence homology with inter-alpha-trypsin inhibitor which is thought to be important in inhibition of trypsin and other serine proteases (See Genbank Accession No. pir|S30350|S30350; all references and information available through this accession are hereby incorporated herein by reference; for example, Eur. J. Biochem. 179 (1), 147-154 (1989), J. Biol. Chem. 264 (27), 15975-15981 (1989), and J. Biol. Chem. 266 (2), 747-751 (1991)).

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of THP-1 cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both monocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocytes, and to a lesser extent, other immune and/or hematopoietic cells. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the

following amino acid sequence: YXIPGSTHASGRQRGSGRGEDDSGPPPSTVINQ NETFANIIFKPTVVQQARIAQNGILGDFIIRYDVNREQSIGDIQVLNGYFVHYF APKDLPPLPKNVVFVLDSSASMVGTKLRQTKDALFTILHDLRPQDRFSIIGFS NRIKVWKDHLISVTPDSIRDGKVYIHHMSPTGGTDINGVLQRAIRLLNKYVAH SGIGDRSVSLIVFLTDG KPTVGETHTLKILNNTREAARGQVCIFTIGIGNDVD FRLLEKLSLENCGLTRRVHEEEDAGSQLIGFYDEIRTPLLSDIRIDYPPSSVVQ ATKTLFPNYFNGSEIIIAGKLVDRKLDHLHVEVTASNSKKFIILKTDVPVRPQK AGKDVTGSPRPGGDGEGDXNHIERLWSYLTTKELLSSWLQSDDEPEKERLRQ RAQALAVSYRFLTPFTSMKLRGPVPRMDGLEEAHGMSAAMGPEPVVQSVR GAGTQPGPLLKKPYQPRIKISKTSVDGDPHFVVDFPLSRLTVCFNIDGQPGDIL RLVSDHRDSGVTVNGELIGAPAPPNGHKKQRTYLRTITILINKPERSYLEITPS RVILDGGDRLVLPCNQSVVVGSWGLEVSVSANANVTVTIQGSIAFVILIHLYK KPAPFQRHHLGFYIANSEGLSSNCHGLLGQFLNQDARLTEDPAGPSQNLTHP LLLQVGEGPEAVLTVKGHQVPVVWKQRKIYN GEEQXDCWFARNMPPN (SEQ ID NO: 359). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in placenta and adipose tissue and to a lesser extent in several other organs and tissues including cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of developing organs and metabolic diseases, in addition to vascular diseases and conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing systems and metabolic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 210 as residues: Lys-5 to Lys-10, Asn-33 to Lys-39, Asp-48 to Lys-54, Pro-62 to Asp-67, Asn-116 to Arg-123, His-157 to Ala-162, Val-242 to Lys-249, Val-251 to Asp-264. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in placenta, combined with the homology to inter-alpha-trypsin inhibitor and the detected calcium flux biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of developing and metabolic systems. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to miscrovascular disease,

vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Polynucleotides and polypeptides of the invention are also useful for the treatment, detection, and/or prevention of inflammation, tumor invasion and metastasis, wound healing, liver disease, disseminated intravascular coagulation, alzheimer's Disease, ophthalmic disease, apoptosis, tissue remodeling, intrauterine growth retardation, preeclampsia, angiogenesis, cell migration, fetal development, trophoblast implantation, ovulation, pemphigus and psoriasis, and antiviral therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:97 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2167 of SEQ ID NO:97, b is an integer of 15 to 2181, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:97, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 88

The translation product of this gene was shown to have homology to the human colon carcinoma antigen NY-CO-7 (See Genbank and Geneseq Accession Nos. gb|AAC18038.1| (AF039689) and WO9904265; all references available through this accession are hereby incorporated herein by reference; for example, Int. J. Cancer 76 (5), 652-658 (1998)).

This gene is expressed primarily in breast and breast cancer and to a lesser extent in several other organs and tissues including cancers.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of reproductive organs and the gastrointestinal system, including cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., gastrointestinal, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, breast milk, chyme, bile, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 211 as residues: Gly-22 to Gly-28, Leu-71 to Phe-77, Asn-101 to Val-108, Pro-122 to Ser-127, Arg-149 to Pro-154, Gly-191 to Phe-196, Pro-199 to Thr-211. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in breast and breast cancer tissue, combined with the homology to a colon cancer antigen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the reproductive systems and cancers. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:98 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1943 of SEQ ID NO:98, b is an integer of 15 to 1957, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:98, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 89

The translation product of this gene shares sequence homology with the amino acid and protein sequence of a Xenopus transmembrane protein of unknown function. The very 5'-end of the contig is identical to the mRNA for the human LGN mosaic protein. Based on the sequence similarity, the translation product of this gene is

expected to share at least some biological activities with LGN mosaic proteins. Such activities are known in the art, some of which are described elsewhere herein. Preferred polypeptides of the invention comprise the following amino acid sequence: PRVRPPTKALAVTFTTFVTEPLKHIGKGTGEFIKALMKEIPALLHLPVLIIMALAILSFCYGAGKSVHVLRHIGGPEREPPQALRPRDRRRQEEIDYRPDGGAGDADFHYRGQMGPTEQGPYAKTYEGRREILRERDVDLRFQTGNKSPEVLRAFDVPDAEAREHPTVVPSHKSPVLDTKPKETGGILGEGTPKESSTESSQSAKPVSGQDTSGNTEGSPAAEKAQLKSEAAGSPDQGSTYSPARGVAGPRGQDPVSSPCG (SEQ ID NO:339). Polynucleotides encoding such polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in small intestine and adipocytes and to a lesser extent in various other normal and transformed cell types, mostly of endocrine origin.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, conditions of growth and metabolism. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., metabolic, gastrointestinal, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, bile, chyme, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 212 as residues: Pro-40 to Gly-68, Gly-79 to Arg-93, Phe-106 to Glu-114, Pro-122 to His-129, Thr-143 to Gly-149, Gly-155 to Ala-168,

Val-171 to Gly-182, Ala-195 to Pro-207, Pro-214 to Val-220. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in small intestine indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of disorders of growth and metabolism as well as endocrine abnormalities. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:99 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1098 of SEQ ID NO:99, b is an integer of 15 to 1112, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:99, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 90

The translation product of this gene shares sequence homology with IgE receptor beta chain which is thought to be important in immune function.

This gene is expressed primarily in kidney medulla tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and renal diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and renal systems,

expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, renal, urogenital, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in kidney renal medulla tissue, combined with the homology to the IgE receptor beta chain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of immune and renal disorders. The protein product of this gene could be used in the treatment and/or detection of kidney diseases including renal failure, nephritus, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe kidney, polycystic kidney, and Falconi's syndrome. Alternatively, this gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the

protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:100 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 873 of SEQ ID NO:100, b is an integer of 15 to 887, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:100, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 91

The translation product of this gene shares sequence homology with Diff 40 gene product (See Genbank Accession No. gb|AAC51134.1; all references and information available through this reference are hereby incorporated herein).

Preferred polypeptides of the invention comprise the following amino acid sequence: PRVRSIKVTELKGLANHVVVGSVSCETKDLFAALPQVVAVDIN DLGTIKLSLEVTWSPFDKDDQPSAASSVNKASTVTKRFSTYSQSPPDTPS LREQAFYNMLRRQEELENGTAWSLSSESSDDSSSPQLSGTARHSPAPRPLV QQPEPLPIQVAFRRPETPSSGPLDEEGAVAPVLANGHAPYSRTLSHISEASVNA ALAEASVEAVGPKSLSWGPSPPTHPAPTHGKHPSPVPPALDPGHSATSST LGTTGSVPTSTDPAPSAHLDSVHKSTDSGPSELPGPTHTTTGSTYSAITTTHS APSPLTHTTTGSTHKPIISTLTTTGPTLNIIGPVQTTTSPTHTMPSPSSHSNSPQ YVDFCSSVCDNIFVHYVIGIFFHTLYSSKTL (SEQ ID NO:360), and/or PRVRS IKVTELKGLANHVVVGSVSCETKDLFAALPQVVAVDINDLGTIKLSLEVTWSP FDKDDQPSAASSVNKASTVTKRFSTYSQSPPDTPSLREQAFYNMLRRQEELE NGTAWSLSSESSDDSSSPQLSGTARHSPAP RPLVQQPEPLPIQVAFRRPET

PSSGPLDEEGAVAPVLANGHAPYSRTLSHISEASVNAALAEASVEAVGPKSL SWGPSPPTHPAPTHGKHPSPVPPALDPGHSATSSTLGTTGSVPTSTD (SEQ ID NO: 361). Polynucleotides encoding these polypeptides are also provided. Polypeptides of the invention do not consist of the primary amino acid sequence shown as Geneseq Accession No:W69430, which is hereby incorporated herein by reference.

This gene is expressed primarily in liver and to a lesser extent in gall bladder tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic and endocrine diseases and/or disorders, particularly hepatic and gall bladder disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic and endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hepatic, metabolic, gall bladder, gastrointestinal, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, bile, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 214 as residues: Val-9 to Cys-14, Pro-42 to Thr-47, Thr-56 to Ala-64, Asp-88 to His-98, Cys-128 to Ser-136, Arg-153 to Trp-161. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in liver and gall bladder, combined with the homology to the diff 40 gene product indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of endocrine and metabolic disorders. polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers. Representative uses are described in the "Hyperproliferative Disorders", "infectious disease", and

"Binding Activity" sections below, in Example 11, and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:101 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1234 of SEQ ID NO:101, b is an integer of 15 to 1248, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:101, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 92

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 3 - 19 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

This gene is expressed primarily in fetal brain and to a lesser extent in pancreas tumor, melanocyte and infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural diseases and/or disorders, particularly neurodevelopmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are

useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of developmental disorders of the central nervous system. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyclinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:102 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1827 of SEQ ID NO:102, b is an integer of 15 to 1841, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:102, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 93

The translation product of this gene shares sequence homology with a probable membrane protein YGL054c -yeast (Saccharomyces cerevisiae). Moreover, The translation product of this gene also have homology to the human and mouse cornichon protein which is known to be necessary for both anterior-posterior and dorsal-ventral pattern formation in conjunction with the EGF receptor signaling process (See Genbank Accession Nos. gb|AAC98388.1| (AF104398), and sp|P52159; all references and information available through these accessions are hereby incorporated herein by reference: for example, Cell 81 (6), 967-978 (1995)).

The polypeptide of this gene has been determined to have two transmembrane domains at about amino acid position 57 - 73, and 121 - 137 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 1 - 14 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: YGCEKTTEGGRRRRRRMEAVVFVFSLLDCCAL IFLSVYYFIITLSDLECDYINARSCCSKLNKWVIPELIGHTIVTVLLLMSLHWF IFLLNLPVATWNIYRYIMVPSGNMGVFDPTEIHNRGQLKSHMKEAMIKLGFH LLC FFMYLYSMILALIND (SEQ ID NO:362). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in activated T-cells and to a lesser extent in endometrial tumor, T cell helper II cells, microvascular endothelial cells, Raji cells treated with cyclohexamide and umbilical vein endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, and vascular diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 216 as residues: Ser-39 to Asn-45, Asn-103 to Ser-109. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in activated T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders involving activated T-cells. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or

other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:103 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 671 of SEQ ID NO:103, b is an integer of 15 to 685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:103, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 94

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ARAPAPSLPPLPSPAPALAPAHSLLGLLLGRMS GSSLPSALALSLLLVSGSLLPGPGAAQNVRVQSGQDQ (SEQ ID NO: 363). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in dendritic cells and to a lesser extent in healing abdomen wound, and pancreas islet cell tumor cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly wound healing disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 217 as residues: Gln-34 to Lys-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dendritic cells and early healing wound indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating

wounds to enhance the healing process. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27; and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosis, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:104 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is

cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1154 of SEQ ID NO:104, b is an integer of 15 to 1168, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:104, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 95

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of aortic smooth muscle cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both smooth muscle cells, and in other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating smooth muscle cells. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell.

This gene is expressed primarily in pancreatic carcinoma, gall bladder and primary dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic and immune diseases and/or disorders, particularly cancers, such as pancreatic carcinoma and gall bladder tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., metabolic, immune, hematpoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such

a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 218 as residues: Lys-34 to Ile-41. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in pancreatic carcinoma and gall bladder indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating cancer, such as pancreatic carcinoma and gall bladder tumors. Representative uses are described here and elsewhere herein. Alternatively, the detected calcium flux biological activity indicates the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to miscrovascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:105 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1161 of SEQ ID NO:105, b is an integer of 15 to 1175, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:105, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 96

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 10 - 26 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 27 to 48 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

This gene is expressed primarily in osteosarcoma, wilm's tumor, ovarian cancer and in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammatory diseases and cancers, such as osteosarcoma, wilm's tumor and ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., skeletal, renal, reproductive, immune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 219 as residues: Ser-30 to Pro-35. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of inflammatory conditions and cancer, such as osteosarcoma, wilm's tumor and ovarian cancer. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases

and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:106 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1007 of SEQ ID NO:106, b is an

integer of 15 to 1021, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:106, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 97

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GTSKDCVLYAFLDPGMAVPLFLYIFTLLPLLPF LLSLCFSPLTVKRSSSSESKSSL (SEQ ID NO: 364). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in ovarian cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, ovarian, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial amniotic fluid, fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level; i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 220 as residues: Thr-28 to Ser-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in ovarian tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating and diagnosing cancer, e.g., ovarian cancer. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of

developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:107 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 816 of SEQ ID NO:107, b is an integer of 15 to 830, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:107, and where b is greater than or equal to a + 14.

FEATURES OF PROTEIN ENCODED BY GENE NO: 98

This gene is expressed primarily in macrophages and breast cancer tissue and to a lesser extent in osteoblasts and smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system dysfunction; inflammation; breast cancer; cancer; osteoporosis; osteopetrosis; peristaltic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and skeletal systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 221 as residues: Glu-16 to Ala-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of disorders. Expression in macrophages and other hematopoietic cell types indicates that this gene product is involved in the regulation of hematopoietic cell survival, proliferation, differentiation, or activation. It is involved in the control of such processes as immune surveillance, antigen presentation, T cell activation, cytokine release, and inflammation. Expression in breast cancer tissue may possibly correlate with the diagnosis and differentiation of cancerous tissue from normal breast tissue.

Expression in osteoblasts and osteoclasts may implicate this gene product in the process of bone turnover, and target it as a likely candidate for the treatment of osteoporosis and/or osteopetrosis. Finally, expressio in smooth muscle may indicate an involvement in the normal function of numerous internal organs and in the function of the digestive system.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:108 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1287 of SEQ ID NO:108, b is an integer of 15 to 1301, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:108, and where b is greater than or equal to a + 14.

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HDPTK41	209965 06/11/98	pCMVSport 3.0	11	1564	1	1564	39	39	124	1	26	27	369
2	HFXGT26	209965 06/11/98	Lambda ZAP II	12	1757	1	1757	13	13	125	1	22	23	85
3	HLTGX30	209965 06/11/98	Uni-ZAP XR	13	1373	1	1373	13	13	126	1	41	42	43
4	HLTHG37	209965 06/11/98	Uni-ZAP XR	14	3740	1908	3740	50	50	127	1	1	2	319
4	HLTHG37	209965 06/11/98	Uni-ZAP XR	109	1932	98	1932	313	313	222	1	35	36	42
5	HNTMZ90	209965 06/11/98	pSport1	15	1196	1	1196	282	282	128	1	21	22	45

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
6	HPIBX03	209965 06/11/98	Uni-ZAP XR	16	2209	1	2178	81	81	129	1	29	30	709
7	H6EDY30	209965 06/11/98	Uni-ZAP XR	17	1774	1	1774	321	321	130	1	29	30	414
8	HAMGR28	209965 06/11/98	pCMVSport 3.0	18	1674	47	1674	98	98	131	1	18	19	242
8	HAMGR28	209965 06/11/98	pCMVSport 3.0	110	1534	1	1534	40	40	223	1	18	19	203
9	HAPNZ94	209965 06/11/98	Uni-ZAP XR	19	2018	255	2018	287	287	132	1	36	37	312
10	HATCP77	209965 06/11/98	Uni-ZAP XR	20	2098	1	2098	37	37	133	1	21	22	182

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
11	HDABR72	209965 06/11/98	pSport1	21	1746	1	1746	28	28	134	1	29	30	146
12	HDPKB18	209965 06/11/98	pCMVSport 3.0	22	2876	1	2876	98	98	135	1	21	22	122
12	HDPKB18	209965 06/11/98	pCMVSport 3.0	111	2871	1	2871	87	87	224	1	21	22	42
13	HEQCC55	209965 06/11/98	pCMVSport 3.0	23	1052	30	1052	62	62	136	1	27	28	112
13	HEQCC55	209965 06/11/98	pCMVSport 3.0	112	1037	1	1037	57	57	225	1	27	28	155
14	HETDE26	209965 06/11/98	Uni-ZAP XR	24	1541	1	1541	205	205	137	1	29	30	139

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
15	HOEDH84	209965 06/11/98	Uni-ZAP XR	25	2079	1	2079	256	256	138	1	20	21	404
16	HPIBT55	209965 06/11/98	Uni-ZAP XR	26	1947	129	1947	253	253	139	1	30	31	95
17	HSLCS05	209965 06/11/98	Uni-ZAP XR	27	3379	1	3354	168	168	140	1	23	24	239
18	HDPDD03	209965 06/11/98	pCMVSport 3.0	28	2006	1	2006	233	233	141	1	21	22	53
19	HDPDI66	209965 06/11/98	pCMVSport 3.0	29	3070	1	3070	93	93	142	1	45	46	66
20	HDTDQ23	209965 06/11/98	pCMVSport 2.0	30	2227	1	2206	148	148	143	1	20	21	108

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
20	HDTDQ23	209965 06/11/98	pCMVSport 2.0	113	2214	1	2206	148	148	226	1	20	21	73
21	HE2PY40	209965 06/11/98	Uni-ZAP XR	31	1288	1	1288	147	147	144	1	22	23	83
22	HEONM66	209965 06/11/98	pSport1	32	3280	1	3280	89	89	145	1	24	25	166
22	HEONM66	209965 06/11/98	pSport1	114	3300	1	3300	98	98	227	1	20	21	166
23	HKAEG43	209965 06/11/98	pCMVSport 2.0	33	1297	1	1297	32	32	146	1	29	30	70
23	HKAEG43	209965 06/11/98	pCMVSport 2.0	115	1286	1	1286	21	21	228	1	29	30	70

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
24	HLHDP65	209965 06/11/98	Uni-ZAP XR	34	2184	1	2184	19	19	147	1	19	20	412
24	HLHDP65	209965 06/11/98	Uni-ZAP XR	116	2189	1	2189	26	26	229	1	21	22	272
25	HLMDO03	209965 06/11/98	Uni-ZAP XR	35	949	1	949	72	72	148	1	45	46	84
26	HMAGK93	209965 06/11/98	Uni-ZAP XR	36	3338	162	1884	164	164	149	1	30	31	153
27	HMEAL02	209965 06/11/98	Lambda ZAP II	37	1563	1	1563	237	237	150	1	33	34	129
28	HMKCH52	209965 06/11/98	pSport1	38	1048	1	1048	53	53	151	1	17	18	61

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
29	HCEFB69	209965 06/11/98	Uni-ZAP XR	39	1430	1	1430	188	188	152	1	24	25	224
30	HNFFC43	203027 06/26/98	Uni-ZAP XR	40	2103	209	2058	488	488	153	1	15	16	68
31	HSPMG77	203027 06/26/98	pSport1	41	2349	1	2349	130	130	154	1	46	47	83
32	HSQAC69	203027 06/26/98	Uni-ZAP XR	42	1559	1	1559	146	146	155	1	21	22	60
33	HSTBJ86	203027 06/26/98	Uni-ZAP XR	43	1766	1	1766	120	120	156	1	24	25	83
34	HLDQR62	203027 06/26/98	pCMVSport 3.0	44	2572	427	2572	520	520	157	1	18	19	161

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
35	HUVDJ43	203027 06/26/98	Uni-ZAP XR	45	526	69	526	89	89	158	1	31	32	146
36	HADCP14	203027 06/26/98	pSport1	46	1032	1	1032	35	35	159	1	20	21	142
37	HBXCF95	203027 06/26/98	ZAP Express	47	2680	1	2680	118	118	160	1	22	23	50
38	HEQBU15	203027 06/26/98	pCMVSport 3.0	48	1730	1	1730	56	56	161	1	26	27	64
39	HL1BD22	203027 06/26/98	Uni-ZAP XR	49	1275	1	1275	53	53	162	1	39	40	58
40	HOEEU24	203027 06/26/98	Uni-ZAP XR	50	1762	1	1762	113	113	163	1	21	22	374

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
40	HOEEU24	203027 06/26/98	Uni-ZAP XR	117	1763	1	1763	113	113	230	1	21	22	81
41	HTTBR96	203027 06/26/98	Uni-ZAP XR	51	2059	1	2059	96	96	164	1	26	27	63
42	HWHQS55	203027 06/26/98	pCMVSport 3.0	52	3282	1	3282	169	169	165	1	26	27	742
43	HCEEK50	203027 06/26/98	Uni-ZAP XR	53	1860	1	1860	233	233	166	1	17	18	213
44	HCWBU94	203027 06/26/98	ZAP Express	54	770	1	770	109	109	167	1	26	27	212
45	HE2NR62	203027 06/26/98	Uni-ZAP XR	55	1093	1	1093	145	145	168	1	38	39	74

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
46	HHSGH19	203027 06/26/98	Uni-ZAP XR	56	632	1	632	291	291	169	1	15	16	47
47	HDPGT01	203027 06/26/98	pCMVSport 3.0	57	2687	138	2687	8	8	170	1	28	29	87
48	HOBAF11	203027 06/26/98	pBluescript	58	619	153	579	166	166	171	1	30	31	41
49	HOHCA35	203027 06/26/98	pCMVSport 2.0	59	1378	1	1378	153	153	172	1	15	16	47
50	HPMGP24	203027 06/26/98	Uni-ZAP XR	60	1126	1	1126	215	215	173	1	33	34	232
51	HSDIE16	203027 06/26/98	Uni-ZAP XR	61	2078	1	2078	182	182	174	1	29	30	44

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
52	HSOBK48	203027 06/26/98	Uni-ZAP XR	62	762	1	762	433	433	175	1	16	17	84
53	HTADH39	203027 06/26/98	Uni-ZAP XR	63	1094	1	1094	173	173	176	1	24	25	65
54	HUSGT36	203027 06/26/98	pSport1	64	1361	1	1361	112	112	177	1	16	17	54
55	HVAAE95	203027 06/26/98	pSport1	65	947	1	947	325	325	178	1	14	15	82
56	HIIEAH25	203071 07/27/98	pCMVSport 3.0	66	1376	1	1376	43	43	179	1	31	32	330
56	HHEAI25	203071 07/27/98	pCMVSport 3.0	118	1375	1	1375	43	43	231	1	31	32	71

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
57	HBJIY92	203071 07/27/98	Uni-ZAP XR	67	2434	487	2366	548	548	180	1	29	30	40
58	HCLCW50	203071 07/27/98	Lambda ZAP II	68	1086	1	1086	255	255	181	1	17	18	51
59	HDRMF68	203071 07/27/98	pSport1	69	1262	1	1262	309	309	182	1	22	23	54
60	HOUGG12	203071 07/27/98	Uni-ZAP XR	70	1642	35	1642	116	116	183	1	22	23	61
61	HEEAQ11	203071 07/27/98	Uni-ZAP XR	71	921	1	921	213	213	184	1	28	29	147
62	HEEAZ65	203071 07/27/98	Uni-ZAP XR	72	906	1	906	182	182	185	1	19	20	160

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
63	HEGAN94	203071 07/27/98	Uni-ZAP XR	73	680	1	680	133	133	186	1	23	24	121
64	HFXBL33	203071 07/27/98	Lambda ZAP II	74	1633	1	1633	152	152	187	1	24	25	162
65	HLIBD68	203071 07/27/98	pCMVSport 1	75	1022	1	1022	186	186	188	1	35	36	50
66	HLTCO33	203071 07/27/98	Uni-ZAP XR	76	1184	1	1184	80	80	189	1	18	19	64
67	HLYAC95	203071 07/27/98	pSport1	77	312	1	312	92	92	190	1	16	17	46
68	HNFGF20	203071 07/27/98	Uni-ZAP XR	78	1370	38	1370	206	206	191	1	45	46	143

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
69	HNHKS18	203071 07/27/98	Uni-ZAP XR	79	368	1	368	125	125	192	1	36	37	81
70	HSLJW78	203071 07/27/98	Uni-ZAP XR	80	1088	1	1088	159	159	193	1	20	21	44
71	HHFHD01	203071 07/27/98	Uni-ZAP XR	81	1862	1	1862	177	177	194	1	16	17	41
72	HLWAE11	203071 07/27/98	pCMVSport 3.0	82	1618	1	1618	85	85	195	1	27	28	259
73	HCYBN55	203071 07/27/98	pBluescript SK-	83	2034	1	1984	341	341	196	1	19	20	117
73	HCYBN55	203071 07/27/98	pBluescript SK-	119	1022	78	1022		3	232	1	1	2	225

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
74	HEONX38	203071 07/27/98	pSport1	84	2240	5	2240	23	23	197	1	23	24	698
74	HEONX38	203071 07/27/98	pSport1	120	2311	1	2311	24	24	233	1	23	24	314
75	HLDQU79	203071 07/27/98	pCMVSport 3.0	85	1488	1	1488	99	99	198	1	23	24	348
76	HSYBK21	203071 07/27/98	pCMVSport 3.0	86	3174	1	1466	119	119	199	1	29	30	401
77	HELBC12	203071 07/27/98	Uni-ZAP XR	87	2780	2110	2738	120	120	200	1	30	31	324
78	HTHDS25	203071 07/27/98	Uni-ZAP XR	88	1061	1	1061	70	70	201	1	15	16	90

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
79	HFIHO70	203071 07/27/98	pSport1	89	1342	1	1271	141	141	202	1	30	31	243
79	HFIHO70	203071 07/27/98	pSport1	121	1286	1	1279	131	131	234	1	30	31	93
80	HPMEI86	203071 07/27/98	Uni-ZAP XR	90	770	40	770	50	50	203	1	30	31	75
81	HSOBV29	203071 07/27/98	Uni-ZAP XR	91	1570	207	1570	244	244	204	1	24	25	248
82	HWABY10	203071 07/27/98	pCMVSport 3.0	92	2950	78	2914	263	263	205	1	22	23	168
83	HACCI17	203071 07/27/98	Uni-ZAP XR	93	1722	336	1714	461	461	206	1	24	25	218

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
83	HACCI17	203071 07/27/98	Uni-ZAP XR	122	1380	12	1380	135	135	235	1	24	25	72
84	HAPQT22	203070 07/27/98	Uni-ZAP XR	94	635	1	635	132	132	207	1	17	18	72
85	HDPBO81	203070 07/27/98	pCMVSport 3.0	95	3798	1	3798	265	265	208	1	26	27	348
85	HDPBO81	203070 07/27/98	pCMVSport 3.0	123	3793	1	3793	255	255	236	1	26	27	348
86	HDPGI49	203070 07/27/98	pCMVSport 3.0	96	2683	1	2640	266	266	209	1	29	30	72
87	HDTBV77	203070 07/27/98	pCMVSport 2.0	97	2181	1	2181	326	326	210	1	22	23	608

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
88	HFIUE82	203070 07/27/98	pSport1	98	1957	1	1957	24	24	211	1	23	24	251
89	HHEND31	203070 07/27/98	pCMVSport 3.0	99	1112	1	1112	109	109	212	1	25	26	225
90	HKMND01	203069 07/27/98	pBluescript	100	887	1	887	23	23	213	1	26	27	50
91	HLDBI84	203069 07/27/98	pCMVSport 3.0	101	1248	1	1248	50	50	214	1	35	36	171
92	HLTEK17	203069 07/27/98	Uni-ZAP XR	102	1841	1	1841	112	112	215	1	13	14	47
93	HEBEJ18	203069 07/27/98	Uni-ZAP XR	103	685	7	649	51	51	216	1	15	16	139

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
94	HMEAI48	203069 07/27/98	Lambda ZAP II	104	1168	1	1168	95	95	217	1	29	30	40
95	HNHGN91	203069 07/27/98	Uni-ZAP XR	105	1175	161	1175	184	184	218	1	24	25	51
96	HODAE92	203069 07/27/98	Uni-ZAP XR	106	1021	1	1021	123	123	219	1	29	30	48
97	HODDF13	203069 07/27/98	Uni-ZAP XR	107	830	1	830	46	46	220	1	27	28	41
98	HCDCF30	203027 06/26/98	Uni-ZAP XR	108	1301	102	1301	151	151	221	1	14	15	40

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly , the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization

probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

Signal Sequences

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of

these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Polynucleotide and Polypeptide Variants

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

By a polynucleotide having a nucleotide sequence at least, for example, 95%

"identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown inTable 1, the ORF (open reading frame), or any fragement specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the presence invention can be determined conventionally using known computer programs. A preferred method for determing the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identiy are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the lenght of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence

that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignement of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequnce are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid.

These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using known computer programs. A preferred method for determing the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is becuase the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and

C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequnce are manually corrected for. No other manual corrections are to made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E. coli).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an

organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic

activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of

the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is

1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

Polynucleotide and Polypeptide Fragments

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the

invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Epitopes & Antibodies

In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983).)

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')2 fragments) which are capable of specifically binding to protein. Fab and F(ab')2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these

fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

Fusion Proteins

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the

IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

Vectors, Host Cells, and Protein Production

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral

vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1

and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids

containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or

translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991)) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example. is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the

present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99mTc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as

deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example, 131I, 112In, 99mTc), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

Biological Activities

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

Immune Activity

A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic

anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies. Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitis, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

Hyperproliferative Disorders

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenstron's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

Infectious Disease

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response.

Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox , hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Norcardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Menigococcal), Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus, Pasteurella), Pseudomonas, Rickettsiaceae,

Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteocarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stoke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

Chemotaxis

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotaxic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotaxic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotaxic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors),or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable

of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a

candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity , and (b) determining if a biological activity of the polypeptide has been altered.

Other Activities

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, caricadic rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

Other Preferred Embodiments

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X

wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group.. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a

biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1

and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is

defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

Examples

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

Vector Used to Construct Library	Corresponding Deposited Plasmid
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lafmid BA	plafmid BA
pSport1	pSport1
pCMVSport 2.0	pCMVSport 2.0

pCMVSport 3.0	pCMVSport 3.0
pCR®2.1	pCR®2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional

plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P-γ-ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).). The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 µl of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM $MgCl_2$, 0.01% (w/v) gelatin, 20 µM each of dATP, dCTP, dGTP, dTTP, 25

pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., Nucleic Acids Res. 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of

the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P^{32} using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing

individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^r), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 ($O.D.^{600}$) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1

mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM immidazole. Immidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The

origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

The following alternative method can be used to purify a polypeptide expressed in *E coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfuidics. Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A_{280} monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five µg of a plasmid containing the polynucleotide is co-transfected with 1.0 µg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One µg of BaculoGold™ virus DNA and 5 µg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 µl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then

resuspended in a microcentrifuge tube containing 200 µl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 µCi of ^{35}S-methionine and 5 µCi ^{35}S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109),

pCMVSport 2.0, and pCMVSport 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No.209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five µg of the expression plasmid pC6 is cotransfected with 0.5 µg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of metothrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 µM, 2 µM, 5 µM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 µM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGC CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCCAAAA CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCT CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

__Example 10: Production of an Antibody from a Polypeptide__

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in

any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 μg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

It will be appreciated that Fab and F(ab')2 and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')2 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced

using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

Example 11: Production Of Secreted Protein For High-Throughput Screening Assays

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at 2 x 10^5 cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45

minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl2 (anhyd); 0.00130 mg/L $CuSO_4$-$5H_2O$; 0.050 mg/L of $Fe(NO_3)_3$-$9H_2O$; 0.417 mg/L of $FeSO_4$-$7H_2O$; 311.80 mg/L of Kcl; 28.64 mg/L of $MgCl_2$; 48.84 mg/L of $MgSO_4$; 6995.50 mg/L of NaCl; 2400.0 mg/L of $NaHCO_3$; 62.50 mg/L of NaH_2PO_4-H_20; 71.02 mg/L of Na_2HPO4; .4320 mg/L of $ZnSO_4$-$7H_2O$; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H_20; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H_20; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H_20; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalainine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tryrosine-2Na-$2H_20$; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319

mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B_{12}; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

Example 12: Construction of GAS Reporter Construct

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six

members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

		JAKs			STATS	GAS(elements) or ISRE
Ligand	tyk2	Jak1	Jak2	Jak3		
IFN family						
IFN-a/B	+	+	-	-	1,2,3	ISRE
IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
Il-10	+	?	?	-	1,3	
gp130 family						
IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
Il-11(Pleiotrophic)	?	+	?	?	1,3	
OnM(Pleiotrophic)	?	+	+	?	1,3	
LIF(Pleiotrophic)	?	+	+	?	1,3	
CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
G-CSF(Pleiotrophic)	?	+	?	?	1,3	
IL-12(Pleiotrophic)	+	-	+	+	1,3	
g-C family						
IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
IL-7 (lymphocytes)	-	+	-	+	5	GAS
IL-9 (lymphocytes)	-	+	-	+	5	GAS
IL-13 (lymphocyte)	-	+	?	?	6	GAS
IL-15	?	+	?	+	5	GAS
gp140 family						
IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
IL-5 (myeloid)	-	-	+	-	5	GAS
GM-CSF (myeloid)	-	-	+	-	5	GAS
Growth hormone family						
GH	?	-	+	-	5	

PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
Receptor Tyrosine Kinases						
EGF	?	+	+	-	1,3	GAS (IRF1)
PDGF	?	+	+	-	1,3	
CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCC
GAAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

5':<u>CTCGAG</u>ATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAA
TGATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCG
CCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCT
CCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCT
AGGCTTTTGCAAA<u>AAGCTT</u>:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, Il-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

Example 13: High-Throughput Screening Assay for T-cell Activity.

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml genticin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells (10^7 per transfection), and resuspend in OPTI-MEM to a final concentration of 10^7 cells/ml. Then add 1ml of 1 x 10^7 cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20^oC until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4^oC and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

Example 14: High-Throughput Screening Assay Identifying Myeloid Activity

The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest 2x10e^7 U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing

10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM KCl, 375 uM $Na_2HPO_4.7H_2O$, 1 mM $MgCl_2$, and 675 uM $CaCl_2$. Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting $1x10^8$ cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of $5x10^5$ cells/ml. Plate 200 ul cells per well in the 96-well plate (or $1x10^5$ cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS

(Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as $5x10^5$ cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to $1x10^5$ cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

Example 16: High-Throughput Screening Assay for T-cell Activity

NF-κB (Nuclear Factor κB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-κB regulates the expression of genes involved in immune cell activation, control of apoptosis (NF- κB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- κB is retained in the cytoplasm with I-κB (Inhibitor κB). However, upon stimulation, I- κB is phosphorylated and degraded, causing NF- κB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- κB include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-κB promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF-kB would be useful in treating diseases. For example, inhibitors of NF-κB could be used to treat those

diseases related to the acute or chronic activation of NF-kB, such as rheumatoid arthritis.

To construct a vector containing the NF-κB promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF-κB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:
5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:
5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene) Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA GCTT:3' (SEQ ID NO:10)

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-κB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-κB/SV40/SEAP cassette is removed from the above NF-κB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly,

the NF-κB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF-κB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1,1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 µl of 2.5x dilution buffer into Optiplates containing 35 µl of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 µl Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 µl Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

Reaction Buffer Formulation:

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5

13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO_2 incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37°C in a CO_2 incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10^6 cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10^6 cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4 . The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular Ca^{++} concentration.

Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford,MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford,MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na3VO4, 2 mM Na4P2O7 and a cocktail of protease inhibitors (# 1836170) obtained from Boeheringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order: First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg_{2+} (5mM ATP/50mM $MgCl_2$), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM $MgCl_2$, 5 mM $MnCl_2$, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30°C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mm EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavadin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phospotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive

incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Manheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for

precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard curve.

Example 23: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 μg/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1 μg/kg/hour to about 50 μg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), bucally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to

modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and R. Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. USA 82:3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324.. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's

solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in

the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

Example 24: Method of Treating Decreased Levels of the Polypeptide

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

Example 25: Method of Treating Increased Levels of the Polypeptide

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

Example 26: Method of Treatment Using Gene Therapy

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 27: Method of Treatment Using Gene Therapy - In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata H. et al. (1997) Cardiovasc. Res. 35(3):470-479, Chao J et al. (1997) Pharmacol. Res. 35(6):517-522, Wolff J.A. (1997) Neuromuscul. Disord. 7(5):314-318, Schwartz B. et al. (1996) Gene Ther. 3(5):405-411, Tsurumi Y. et al. (1996) Circulation 94(12):3281-3290 (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The

polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) Ann. NY Acad. Sci. 772:126-139 and Abdallah B. et al. (1995) Biol. Cell 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely

differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A

time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

Example 28: Transgenic Animals.

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i.e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e.g., Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pleuripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse

transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Example 29: Knock-Out Animals.

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in

the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and

Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 259, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
July 27, 1998	203070

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer Yvette E. Simms PCT International Division	Authorized officer

Form PCT/RO/134 (July 1992)

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 260, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
July 27, 1998	203069

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer: Yvette E. Simms, PCT International Division	Authorized officer

Form PCT/RO/134 (July 1992)

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 253, line N/A

B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ☐

Name of depository institution American Type Culture Collection

Address of depository institution *(including postal code and country)*

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
July 27, 1998	203071

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer Yvette E. Simms PCT International Division	Authorized officer

Form PCT/RO/134 (July 1992)

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 249, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
June 26, 1998	203027

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer Yvette E. Simms PCT International Division	Authorized officer

Form PCT/RO/134 (July 1992)

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 243, line N/A

B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet ☐

Name of depositary institution American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
June 11, 1998	209965

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer Yvette E. Simms PCT International Division	Authorized officer

Form PCT/RO/134 (July 1992)

Claims

What Is Claimed Is:

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:
(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

(c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 98 Human Secreted Proteins

<130> PZ031.PCT

<140> Unassigned
<141> 1999-07-28

<150> 60/094,657
<151> 1998-07-30

<150> 60/095,486
<151> 1998-08-05

<150> 60/095,455
<151> 1998-08-06

<150> 60/095,454
<151> 1998-08-06

<150> 60/096,319
<151> 1998-08-12

<160> 364

<170> PatentIn Ver. 2.0

<210> 1
<211> 733
<212> DNA
<213> Homo sapiens

<400> 1
```
gggatccgga gcccaaatct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg      60
aattcgaggg tgcaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga     120
tctcccggac tcctgaggtc acatgcgtgg tggtggacgt aagccacgaa gaccctgagg     180
tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg     240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact     300
ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca acccccatcg     360
agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc     420
catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct     480
atccaagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga     540
ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag ctcaccgtgg     600
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggctctgc     660
acaaccacta cacgcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc     720
gactctagag gat                                                        733
```

<210> 2
<211> 5
<212> PRT
<213> Homo sapiens

<220>
<221> Site
<222> (3)

<223> Xaa equals any of the twenty naturally ocurring L-amino acids

<400> 2
Trp Ser Xaa Trp Ser
1 5

<210> 3
<211> 86
<212> DNA
<213> Homo sapiens

<400> 3
gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60
cccgaaatat ctgccatctc aattag 86

<210> 4
<211> 27
<212> DNA
<213> Homo sapiens

<400> 4
gcggcaagct ttttgcaaag cctaggc 27

<210> 5
<211> 271
<212> DNA
<213> Homo sapiens

<400> 5
ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60
aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc 120
gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6
<211> 32
<212> DNA
<213> Homo sapiens

<400> 6
gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7
<211> 31
<212> DNA
<213> Homo sapiens

<400> 7
gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8
<211> 12
<212> DNA

<213> Homo sapiens

<400> 8
ggggactttc cc 12

<210> 9
<211> 73
<212> DNA
<213> Homo sapiens

<400> 9
gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60
ccatctcaat tag 73

<210> 10
<211> 256
<212> DNA
<213> Homo sapiens

<400> 10
ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60
caattagtca gcaaccatag tcccgcccct aactccgccc atcccgcccc taactccgcc 120
cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240
cttttgcaaa aagctt 256

<210> 11
<211> 1564
<212> DNA
<213> Homo sapiens

<400> 11
gcggacggtg ggctgtgcaa ccttcctccc tttcttaaat gcttggggca tttgtctggc 60
cttccctttt actgctggct gctgcctgca tctgtctctt aaccttcatt aactgtgcct 120
atgtcaaatg ggaaccctg gtacaagata ttttcaccta tgctaaagta ttggcactga 180
tcgcggtcat cgttgcaggc attgttagac ttggccaggg agcctctact cattttgaga 240
attcctttga gggttcatca tttgcagtgg gtgacattgc cctggcactg tactcagctc 300
tgttctccta ctcaggctgg gacaccctca actatgtcac tgaagagatc aagaatcctg 360
agaggaacct gcccctctcc attggcatct ccatgcccat tgtcaccatc atctatatct 420
tgaccaatgt ggcctattat actgtgctag acatgagaga catcttggcc agtgatgctg 480
ttgctgtgac ttttgcagat cagatatttg gaatatttaa ctggataatt ccactgtcag 540
ttgcattatc ctgttttggt ggcctcaatg cctccattgt ggctgcttct aggcttttct 600
ttgtgggctc aagagaaggc catctccctg atgccatctg catgatccat gttgagcggt 660
tcacaccagt gccttctctg ctcttcaatg gtatcatggc attgatctac ttgtgcgtgg 720
aagacatctt ccagctcatt aactactaca gcttcagcta ctggttcttt gtggggcttt 780
ctattgtggg tcagctttat ctgcgctgga aggagcctga tcgacctcgt cccctcaagc 840
tcagcgtttt cttcccgatt gtcttctgcc tctgcaccat cttcctggtg gctgttccac 900
tttacagtga tactatcaac tccctcatcg gcattgccat tgccctctca ggcctgccct 960
tttacttcct catcatcaga gtgccagaac ataagcgacc gctttacctc cgaagatcgt 1020
ggggtctgcc acaaggtacc tccaggtcct gtgtatgtca gttgctgcag aaatggattt 1080
ggaagatgga ggagagatgc ccaagcaacg ggatcccaag tctaactaaa caccatctgg 1140
aatcctgatg tggaaagcag ggtttctgg tctactggct agagctaagg aagttgaaaa 1200
ggaaagctca cttctttgga ggcacctgtc cagaagcctg gcctaggcag cttcaacctt 1260
tgaacttact ttttgaaatg aaaagtaatt tatttgtttt gctacatact gttccagact 1320
tttaaagggg acaatgaagg tgactgtggg gaggagcatg tcaggtttgg gcttggttgt 1380
tttagaagca cctgggtgtg cctacctact cctcttttct tttaaagggg cccacaatgc 1440

tccaatttcc tgtctccttt agagagacat gaaactatca caggtgctgg atgacaataa 1500
aagtttatgt tcctaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaagggcggc 1560
cccg 1564

<210> 12
<211> 1757
<212> DNA
<213> Homo sapiens

<400> 12
ggcacgaggt agatgggttt ttggtgtgga tgtcctttct gtttgttagt tgtccttcta 60
acagacagga ccctcagctg caggtctgtt ggagtacccct gcaatgtgag gtgtcagtgt 120
gcccctgctg gagggtgcct cccagttagg ctgctcgcgg gtcaggggtc agggacccac 180
ttgaggaggc agtctgcccg ttctcagatc tccagctgca tgctgggaga accactgctc 240
tcttcaaagc tgtcagacag ggacatttaa gtctgcagag gttactgctg tctttttgtt 300
tgtctgtgcc ctgcccccag aggtggagcc tacagaggca ggcaggcctc cttgagctgt 360
ggtgggctcc acccagttcg agcttcccgg ctgctttgtt tacctaagca agcctgggca 420
atggcgggcg cccctccccc agtctcgctg ccgccttgca gtttgatctc agactgctgt 480
gctagcaatc agcgagactc cctggggtag gaccctctga gccaggtggg ggatataatc 540
ttgtggtgcg ccatttttta agcccgtcgg aaaagcgcag tattcaggtg ggagtgaccc 600
gattttcccg attttccagg tgccgtccgt catccctttc tttgattagg aaagggaact 660
ccctgacccc ttgcgcttcc cgagtgaggc aatgccttgc gctgctttgg ctcgtgcatg 720
gtgcgtgcac ccactgacct gcgcccactg tctggcactc cctagtgaga tgaacccggt 780
acctcagatg gaaatgcaga aatcacccgt cttctgcgtt gctcaggctg ggagctgtag 840
accagagctg ttcctattcc gccatcttgg ctcctccccc acccccgcc caatcctaag 900
tttatctctt aacaaagtaa atactgcaca cgtatttaca tgttttaaaa tattgtttat 960
ggagcactta ctatgtgttt tacggtccaa gtactttata ttattcactg actctttata 1020
gcaactctat aacatattaa tagattgtct caatttcact gatgacaaaa ctggcagctt 1080
agtaactaat gagtaacaat accagcccct aaaacctagg gtctttccac tacagcacac 1140
tctgactgac attgctcttg ttcagacaca gcactcttca cctagaaaag gatggagagc 1200
tagaaagtgg ttttcttttt caagttgttc ccattcatca atattctatc aagatatatg 1260
gaagagttat tttctaggtc ttccagaagg ggctgctgac acttgggaat tcaaaataat 1320
tactccagag ggaaatgtgg gcatagaaac tttttaaaaa ctgaattttc ccgatctaat 1380
atcggcttcc acatacagta tattatttct taaaaatcag ccagaaatgc acctgcagtt 1440
ttatctactg gattttcctt tcccagcccc attcttcttt aagtagtttt ttttccccat 1500
tttataaaag aaaagcatac ctcccaccta tagcttccct ccttatggta tattatctca 1560
ggggataatt tgaaatattg cttgagacac aattctcatt aagaaataaa ctttcaggct 1620
gggtgcagtg gctcacactt gtaatcccag aactttggga ggccaaggcg gggg aggatc 1680
cctgaaggcc aagagttcaa gaccagcctg gaatatatac caagatcccc tctccacaaa 1740
aaaaaaaaaa aaaaaaa 1757

<210> 13
<211> 1373
<212> DNA
<213> Homo sapiens

<400> 13
gtgaaatgaa atatgtatac caaaacacat aaatttaagt tttataattt tcttttcttg 60
tggatctgga aaattttctt tctgctgttt ttcattctga tagttgcttt ggctttccct 120
attcccctgcc tttccatatt ttgaaatgtt ttggtcaaat tttttcctgt tgagtgtgca 180
gtatgttttg attgttaatt ttattgacca tcatctcagt ggattattta tttgaaactt 240
ttctgtttcc tgttctggaa tgtttcctgc tctggaagcc atattttaac tgtatactga 300
tccagcttta tttatcttaa gtatttttac aattatttta ctgataatat ataactaggt 360
ataatcactc tagtcagtga aatcaaactg ataacacaaa atgatgctgc tagtaaattt 420
agcctgaaaa ggatcagagg aagcactttt tagtctaagt agtcaagatc aataaactta 480
gaatgagagt tttgtattat ttagccttgt gatagaagga aaaagtacag ttattgaatc 540
tgtatattaa tttatgcaaa atacacacat tatctttcca ttaacacagt agtatgacat 600

acagtttat caccactgga ttcatgtatg cttaaaatga aaatgaaagg aacacacagg 660
aaagtagctt cttatcttcc cagatacagc ctccaagagt gcctctgctg tgtactggag 720
tgagtttgaa gaagttcagg taatcctctc ctaaccagca gcttaactta aagtgcatct 780
tcatttttgt cctaccacta aaagcttgct tattgacctc cttctttcct gtctcctaaa 840
ttgtgactgg ctctcagtta gacttgcatc tgttgctatt tgtagcagca attgcaggat 900
tcatttgctt tttctcttgc agtgtatttc tgaatgtttt ataactctgg gtatgcataa 960
tgtacgtata tgcatatcca tatggtcaag agttttcaga attctttgtt tgaataatga 1020
atgtgtgtat tccctacccc ttgtttgctt ctgtcttaac atttaagctt tgcttattaa 1080
aatgtatttg ttttaatgct ttctctttag attgtaagct cttcatgggc agtggtcaga 1140
tattctgtat ttgtaacttc ccgagaatct agtattttat catgtacata atgaacatag 1200
aatagtattg attggaagga cagtgaagta caaaatgaga ttctaaaatg acatttttcat 1260
tagggctcac aagtgtataa gaagtatccc tttcctattt ttttgtttaa tactttagaa 1320
gctattacat taaaaaagct attctcatta aaaaaaaaaa aaaaaaaaaa aaa 1373

<210> 14
<211> 3740
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (957)
<223> n equals a,t,g, or c

<400> 14
actctctaag gctttttgg actcaccaaa caggcttctt gcagtggaga tgaatacaga 60
tcacttaagg ttgactgtgc caaatggcat aggggccctg aagctaaggg aaatggaaca 120
ctacttctca cagggcctgt cagttcagct gtttaatgat gggtccaagg gcaaactcaa 180
tcatttatgt ggagctgact ttgtgaaaag tcatcagaaa cctccacagg gaatggaaat 240
taagtccaat gaaagatgct gttcttttga tggagatgca gacagaattg tttattacta 300
ccatgatgca gatggccact ttcatctcat agatggagac aagatagcaa cgttaattag 360
cagtttcctt aaagagctcc tggtggagat tggagaaagt ttgaatattg gtgttgtaca 420
aactgcatat gcaaatggaa gttcaacacg gtatcttgaa gaagttatga aggtacctgt 480
ctattgcact aagactggtg taaaacattt gcaccacaag gctcaagagt ttgacattgg 540
agtttatttt gaagcaaatg ggcatggcac tgcactgttt agtacagctg ttgaaatgaa 600
gataaaacaa tcagcagaac aactggaaga taagaaaaga aaagctgcta agatgcttga 660
aaacattatt gacttgttta accaggcagc tggtgatgct atttctgaca tgctggtgat 720
tgaagcaatc ttggctctga agggcttgac tgtacaacag tgggatgctc tctatacaga 780
tcttccaaac agacaactta aagttcaggt tgcagacagg agagttatta gcactaccra 840
tgctgaaaga caagcagtta cacccccagg attacaggag gcaatcaatg acctggtgaa 900
gaagtacaag ctttctcgag cttttgtccg gccctctggt acagaagatg tcgtccngag 960
tatatgcaga agcagactca caagaaagtg cagatcacct tgcacatgaa gtgagcttgg 1020
cagtatttca gctggctgga ggaattggag aaaggcccca accaggtttc tgaagataat 1080
tttcatattc ctgagaaact ggacttttta caagtcttta caaaactgtc aataataatg 1140
gcagtactaa gagatttata atcataatgt ttacaatgca gcctactgga ttgtctctag 1200
atctgttttt cttaaacact aacagaataa ttctttataa ataggtaagc cttacacttg 1260
ttaaagaaat ttacctctaa tttcagtctc actaatgtaa aatactggga cttaagtata 1320
caattcagtc actaactgta cagttttatg tggggaacaa ttcatgcagg ctactggaaa 1380
attaaatctt attaccaact ccttgtgata tctttgccat caccatcaca tgagcaagat 1440
gatgttttgc agcattcccc attgctgata caaatggaga gggcagagaa gactttatac 1500
aaccagtttt tccattgcag agtcttaaga aagattatta gatgacttac ctatatgact 1560
aatgccatca ggaactcaga ggtatgaata gggggttgtc catccctctt ccatactgag 1620
gtggagatgc tcatgcaata cttttaagga tgcatggtcc agccttcagt tattcttcac 1680
tgctcttggt gaaggtatgt gggagaaaaa ctaattataa tacgtttccc agcctctgat 1740
ggagaaggaa caccattctg ataccagaac atggttaata aggaaaagag aaaaatcccc 1800
aaccaatctt aattgaacca agtctgaaac caatggaaaa aaaaaatggg tagtgtatat 1860
tttgcaggtt taagacaact caggacaata aaaacaatgg actttacatg tgtatatata 1920
tagctctctt aggcaccata atcagtatga gccaacaata tttaaacttg attcaggcca 1980

```
cattcagaca tttgctctta tatacaaata tttaaattaa atacaatctg aaatgtgttc   2040
tgttacatac aaaaaaggaa aaactataca acgcagagca gtgtgtgtgt tttaaataat   2100
tacatttaca tgtaagctaa atggaaccag caatggtgct caagttttta tcatcccttc   2160
cagaaaatct ttttctacca tctcttctat tttttgcctg gctttgctgg aacatggttt   2220
gtggttctcc agtttcatgt ccttattagg gaaggcattt gagtagagga taggactccc   2280
tgagtgtcct ccacatcggc ttgtgacttt gctgttgaag acttgactga gcacattgaa   2340
gaacggcagg agctgctcca tactgcgcac ggtgcagatg gtgagcagca agtgccctgg   2400
ctcccaaccc aatgttctcc ctgagttgtc ttcccctgga tttttctgca gaaaacaaaa   2460
agtgaactgg tattaataca acagacaatg tggtatgtta gaaaaattaa aaatatataa   2520
actttggcaa ttggtcaaga aatgaataca aatgacatta agtttctaac tcctgacctg   2580
atcaaaaccc ttggtgcttc tgagaccttt tactgccatt tattagtttt acatggagca   2640
gtctaacatt gtagtaatag ttcccaacta gaatgcgcag ataagcttag ttaacagaaa   2700
tagctttgaa caggaataga gtcaaacata aaagttttat gttgtgcttt gtatttactc   2760
aaaaagctcc caggtttctg aaccctcact actgtaacca aggactaggt cacaaaatta   2820
ctacagaaaa aaggaacaaa gtgctttata catttcataa tatatcccct tttattataa   2880
ttagttaatt cccttttatc taaatggcct aaatttgcca tgatggtagc agtgtccaaa   2940
gtgaataatt actgtcagta ctgcatcaca gagaaaggaa gggatccctc aggagacact   3000
gctgtctcct tctgggttgt gctaaacaac atagggagga aagctggacc tggagtcaaa   3060
ggaattgagt tagtgtgctg gctctgccat acttacggca cccttgggca ggatatacaa   3120
aggttcctca cttataaaat gggacagtct aaaactacct tttagtagag aagtcaaatg   3180
agaaggtatg tgaaaactct gtcaactaaa tataaagact aataatttgg gtattaagag   3240
gctagtttga gaagccacct gaattacaca aacacagcta cagacatcat tctgtctaga   3300
gaaagataag agagaacagg ttggttgaac ttgggcagaa tcacagatac aattccacac   3360
taaagaatga aaataagcaa tgaactagac agaaggaaga aatcatgaag acttaggaag   3420
cagaattaca atctgtcata ttaacaaatg gagtttgcct tctaagatca gatgttgctc   3480
agaaactttc attgtttacc taataattta atatcactag tttcctagtg ggtcaagcag   3540
atgcaaaatc cagcttattt tcttctatgt gctctcaagc ttattgctta ttttaaagta   3600
aaatcctgaa aaaggaaaat attaggttgg tgcaaacgta attgcggttt ttgcattgtt   3660
gaaatttgcc gttttatatt ggagtacatt cttaaataaa tgtggttatg ttatacaaaa   3720
aaaaaaaaaa aaaactcgag                                               3740
```

<210> 15
<211> 1196
<212> DNA
<213> Homo sapiens

<400> 15

```
ccacgcgtcc ggtgaatctg gatgatctat ttatgtcatt tatctatgtg tctcttctta     60
tgccagtacc ccactgtctt gattattgtg gctttatggt gtcttgaaat taagtattgt    120
taagctttgc aatcttttcc aagattgttt tggctatagg tcctttcttt ataaagttta    180
tattaagctt ctccattttt ctttaagaaa aaatctgctg gaatggcact gaatttttag    240
gtcgatttgg gaagaattga caatattgaa cctttcaatc gatggacatg gtatgtttct    300
gcatttattt gggcctttta aaatttatct cagcaatatt ttgtagtttt agtgaagaag    360
tcttgtatat atcttttgtt aaatgtattc ctaaatattt tgtggaaatg ttactgtaaa    420
tagtacttta atttcatttt taagtttatt gctggtatac agaaatatgt tttatttttg    480
taatattgac ttttatattc tgtaatctta tttaaattca cttagttcag tagtagttct    540
tatttttatt ttattgcaag tgccttaggg ataccttgtg tacacaatcc atgtcatata    600
tgaataacca acaggtttac cttttgtttc ttcttgcttt gtcgtaatgg ctaggacctt    660
ccaacctaaa tggttgaata gaagcggtgt gtgagtttat tactcttgtc ttattctcaa    720
cagcagagga tagcgtctag tttttcacta ttaaaatatg ttagctatag gttttttccg    780
tttcatgttt ttatcagatt gaagatccct tttattccta ttttgccaag agtgtcatga    840
atgcatgttg aatttcacca agtacttttt cctgcatctg ttgagagaat cttgactttt    900
ctcttttatt ttgttaatgt agattcttta atgttaaact gatcttgcat tcctgatata    960
aaccatactt agtcatgata tgttatcccc tttatataat gctggattcg gtttgcaaat   1020
attttgtttg atttttgcat ctatgctcat gagacagatt ggtctgtgat tttcctttct   1080
tgtaagtctt gtcaggtgtc agggcttggt taattttgac acatttacaa acatatattt   1140
ttaagataaa aataaacttc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa       1196
```

<210> 16
<211> 2209
<212> DNA
<213> Homo sapiens

<400> 16
```
gagctgcgcc gggcttgggc gcctggggcc gccgctcccc accgtcgttt tccccaccga 60
ggccgaggcg tccccggagtc atggccggcc tgaactgcgg ggtctctatc gcactgctag 120
gggttctgct gctgggtgcg gcgcgcctgc cgcgcggggc agaagctttt gagattgctc 180
tgccacgaga aagcaacatt acagttctca taaagctggg gaccccgact ctgctggcaa 240
aaccctgtta catcgtcatt tctaaaagac atataaccat gttgtccatc aagtctggag 300
aaagaatagt ctttaccttt agctgccaga gtcctgagaa tcactttgtc atagagatcc 360
agaaaaatat tgactgtatg tcaggcccat gtcctttggg ggaggttcag cttcagccct 420
cgacatcgtt gttgcctacc ctcaacagaa ctttcatctg ggatgtcaaa gctcataaga 480
gcatcggttt agagctgcag ttttccatcc ctcgcctgag gcagatcggt ccgggtgaga 540
gctgcccaga cggagtcact cactccatca gcggccgaat cgatgccacc gtggtcagga 600
ttggaacctt ctgcagcaat ggcactgtgt cccggatcaa gatgcawgaa ggagtgaaaa 660
tggccttaca cctcccatgg ttccacccca gaaatgtctc cggcttcagc attgcaaacc 720
gctcatctat aaaacgtctg tgcatcatcg agtctgtgtt tgagggtgaa ggctcagcaa 780
ccctgatgtc tgccaactac ccagaaggct tccctgagga tgagctcatg acgtggcagt 840
ttgtcgttcc tgcacacctg cgggccagcg tctccttcct caacttcaac ctctccaact 900
gtragaggaa ggaggagcgg gttgaatact acatcccggg ctccaccacc aaccccgagg 960
tgttcaagct ggaggacaag cagcctggga acatggcggg gaacttcaac ctctctctgc 1020
aaggctgtga ccaagatgcc caaagtccag ggatcctccg gctgcagttc caagttttgg 1080
tccaacatcc acaaaatgaa agcaataaaa tctacgtggt tgacttgagt aatgagcgag 1140
ccatgtcact caccatcgag ccacggcccg tcaaacagag ccgcaagttt gtccctggct 1200
gtttcgtgtg tctagaatct cggacctgca gtagcaacct caccctgaca tctggctcca 1260
aacacaaaat ctccttcctt tgtgatgatc tgacacgtct gtggatgaat gtggaaaaam 1320
ccataagytg cacagaccac cggtactgcc aaaggaaatc ctactcacty caggtgccca 1380
gtgacatcct ycamctgcct gtggagctgc atgacttctc ctggaagctg ctggtgccca 1440
aggacaggct cagcctggtg ctggtgccag cccagaagct gcagcagcat acacacgaga 1500
agccctgcaa caccagcttc agctacctcg tggccagtgc catacccagc caggacctgt 1560
acttcggctc cttctgcccg ggaggctcta tcaagcagat ccaggtgaag cagaacatct 1620
cggtgaccct tcgcaccttt gcccccagct tccgacaaga ggcctccagg cagggtctga 1680
cggtgtcctt tataccttat ttcaaagagg aaggcgtttt cacggtgacc cctgacacaa 1740
aaagcaaggt ctacctgagg acccccaact gggaccgggg cctgccatcc ctcacctctg 1800
tgtcctggaa catcagcgtg cccagagacc aggtggcctg cctgactttc tttaaggagc 1860
ggagcggcgt ggtctgccag acagggcgcg cattcatgat catccaggag cagcggaccc 1920
gggctgagga gatcttcagc ctggacgagg atgtgctccc caagccaagc ttccaccatc 1980
acagcttctg ggtcaacatc tytaaytgma gccccacgag cggcaagcag ctagacctgc 2040
tcttctcggt gacacttacc ccaaggactg tggacttgac tgtcatcctc atcgcagcgg 2100
tgggaggtgg agtcttactg ctgtctgccc tcgggctcat catttgctgt gtgaaaaaaa 2160
aaaaaarama aacaaggggc cccgctgtgg gtatctacaa tggcaacat 2209
```

<210> 17
<211> 1774
<212> DNA
<213> Homo sapiens

<400> 17
```
taggcacccc aggcttttac actttatgtt ccggttcgta tgttgtgtga attgtaaccg 60
gataccaatt tcacacaagg aaccagctta tgaccatgat tacgccaagc tcgaaattaa 120
ccctcactaa agggaacaaa agctggagct ccaccgcggt ggcggccgct ctagaactag 180
tggatccccc gggctgcagg aattcggcac gagcggctgc gggcgcgagg tgaggggcgc 240
gaggttccca gcaggatgcc ccggctctgc aggaagctga agtgagaggc ccggagaggg 300
cccagcccgc ccggggcagg atgaccaagg cccggctgtt ccggctgtgg ctggtgctgg 360
ggtcggtgtt catgatcctg ctgatcatcg tgtactggga cagcgcaggc gccgcgcact 420
```

```
tctacttgca cacgtccttc tctaggccgc acacgggcc gccgctgccc acgcccgggc 480
cggacaggga cagggagctc acggccgact ccgatgtcga cgagtttctg gacaagtttc 540
tcagtgctgg cgtgaagcag agtgaccttc ccagaaagga gacggagcag ccgcctgcgc 600
cggggagcat ggaggagaac gtgagaggct acgactggtc cccgcgcgac gcccggcgca 660
gcccagacca gggccggcag caggcggagc ggaggagcgt gctgcggggc ttctgcgcca 720
actccagcct ggccttcccc accaaggagc gcgcattcga cgacatcccc aactcggagc 780
tgagccacct gatcgtggac gaccggcacg gggccatcta ctgctacgtg cccaaggtgg 840
cctgcaccaa ctggaagcgc gtgatgatcg tgctgagcgg aagcctgctg caccgcggtg 900
cgccctaccg cgacccgctg cgcatcccgc gcgagcacgt gcacaacgcc agcgcgcacc 960
tgaccttcaa caagttctgg cgccgctacg ggaagctctc ccgccacctc atgaaggtca 1020
agctcaagaa gtacaccaag ttcctcttcg tgcgcgaccc cttcgtgcgc ctgatctccg 1080
ccttccgcag caagttcgag ctggagaacg aggagttcta ccgcaagttc gccgtgccca 1140
tgctgcggct gtacgccaac cacaccagcc tgcccgcctc ggcgcgcgag gccttccgcg 1200
ctggcctcaa ggtgtccttc gccaacttca tccagtacct gctggacccg cacacggaga 1260
agctggcgcc cttcaacgag cactggcggc aggtgtaccg cctctgccac ccgtgccaga 1320
tcgactacga cttcgtgggg aagctggaga ctctggacga ggacgccgcg cagctgctgc 1380
agctactcca ggtggaccgg cagctccgct tccccccgag ctaccggaac aggaccgcca 1440
gcagctggga ggaggactgg ttcgccaaga tccccctggc ctggaggcag cagctgtata 1500
aactctacga ggccgacttt gttctcttcg gctaccccaa gcccgaaaac ctcctccgag 1560
actgaaagct ttcgcgttgc tttttctcgc gtgcctggaa cctgacgcac gcgcactcca 1620
gtttttttat gacctacgat tttgcaatct gggcttcttg ttcactccac tgcctctatc 1680
cattgagtac tgtatcgata ttgtttttta agattaatat atttcaggta tttaatacga 1740
aaaaaaaaaa aaaaaaactc gaggggggc ccgg 1774
```

<210> 18
<211> 1674
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1649)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1663)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1665)
<223> n equals a,t,g, or c

<400> 18

```
caagttggta cgcctgcagg taccggtccg gaattcccgg gtcgacccac gcgtccggtc 60
gaagataggt tcgagacggt ggatgttgca gctgatcatg cagttgggtt cggtgctgct 120
cacacgctgc ccctttggg gctgcttcag ccagctcatg ctgtacgctg agagggctga 180
ggcacgccgg aagcccgaca tcccagtgcc ttacctgtat ttcgacatgg gggcagccgt 240
gctgtgcgct agtttcatgt cctttggcgt gaagcggcgc tggttcgcgc tgggggccgc 300
actccaattg gccattagca cctacgccgc ctacatcggg ggctacgtcc actacgggga 360
ctggctgaag gtccgtatgt actcgcgcac agttgccatc atcggcggct ttcttgtgtt 420
ggccagcggt gctggggagc tgtaccgccg gaaacctcgc agccgctccc tgcagtccac 480
cggccaggtg ttcctgggta tctacctcat ctgtgtggcc tactcactgc agcacagcaa 540
ggaggaccgg ctggcgtatc tgaaccatct cccaggaggg gagctgatga tccagctgtt 600
cttcgtgctg tatggcatcc tggccctggc ctttctgtca ggctactacg tgaccctcgc 660
tgcccagatc ctggctgtac tgctgccccc tgtcatgctg ctcattgatg gcaatgttgc 720
ttactggcac aacacgcggc gtgttgagtt ctggaaccag atgaagctcc ttggagagag 780
```

tgtgggcatc ttcggaactg ctgtcatcct ggccactgat ggctgagttt tatggcaaga 840
ggctgagatg ggcacaggga gccactgagg gtcaccctgc cttcctcctt gctggcccag 900
ctgctgttta tttatgcttt ttggtctgtt tgtttgatct tttgcttttt taaaattgtt 960
ttttgcagtt aagaggcagc tcatttgtcc aaatttctgg gctcagcgct tgggagggca 1020
ggagccctgg cactaatgct gtacaggttt ttttcctgtt aggagagctg aggccagctg 1080
cccactgagt ctcctgtccc tgagaaggga gtatggcagg gctgggatgc ggctacagag 1140
agtgggagag tgggagacag aggaaggaag atggagattg gaagtgagca aatgtgaaaa 1200
attcctcttt gaacctggca gatgcagcta ggctctgcag tgctgtttgg agactgtgag 1260
agggagtgtg tgtgttgaca catgtggatc aggcccagga agggcacagg ggctgagcac 1320
tacagaagtc acatgggttc tcagggtatg ccaggggcag aaacagtacc ggctctctgt 1380
cactcacctt gagagtagag cagaccctgt tctgctctgg gctgtgaagg gctggagcag 1440
gcagtggcca gctttgccct tcctgctgtc tctgtttcta gctccatggt tggcctggtg 1500
ggggtggagt tccctcccaa acaccagacc acacagtcct ccaaaaataa acattttata 1560
tagamaaaaa aaaaaaaaaa aagggcggcc gctctagagg atccctcgag ggcccaagc 1620
ttacgcgtgc atgcgacgtc atagctctnt ccctatagaa gtngnaaagg gttc 1674

<210> 19
<211> 2018
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (2010)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2012)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2014)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2016)
<223> n equals a,t,g, or c

<400> 19
cagcaatgaa atcctgcttt cttttcctca gaactactat attcagtggc taaatggctc 60
cctgattcat ggtttgtgga atcttgcttc cctttttccc aacctttgyt tatttgtatt 120
gatgcccttt gccttttcct ttctggaatc agaaggcttt gctggcctga aaaagggaat 180
ccgagcccgc atttagagaa cttggtcat gcttcttctt cttgcgttac tcattcttgg 240
gatagtgtgg gtagcttcag cactcattga caacgatgcc gcaagcatgg aatctttata 300
tgatctctgg gagttctatc taccctattt atattcctgt atatcattga tgggatgttt 360
gttacttctc ttgtgtacac cagttggcct ttctcgtatg ttcacagtga tgggtcactt 420
gctagtgaag ccaacaattc ttgaagacct ggatgaacaa atttatatca ttaccttaga 480
ggaagaagca ctccagagac gactaaatgg gctgtcttca tcggtggaat acaacataat 540
ggagttggaa caagaacttg aaaatgtaaa gactcttaac acaaaaattag agaggcgaaa 600
aaaggcttca gcatgggaaa gaaatttggt gtatcccgct gttatggttc tccttcttat 660
tgagacatcc atctcggtcc tcttggtggc ttgtaatatt ctttgcctat tggttgatga 720
aacagcaatg ccaaaaggaa caagggggcc tggaatagga aatgcctctc tttctacgtt 780
tggttttgtg ggagctgcgc ttgaaatcat tttgatttc tatcttatgg tgtcctctgt 840
tgtcggcttc tatagccttc gatttttggg aaactttact cccaagaaag atgacacaac 900
tatgacaaag atcattggaa attgtgtgtc catcttggtt ttgagctctg ctctgcctgt 960

gatgtcgaga acactgggaa tcactagatt tgatctactt ggcgactttg gaagctttaa 1020
ttggctggga aatttctata ttgtattatc ctacaatttg ctttttgcta ttgtgacaac 1080
attgtgtctg gtccgaaaat tcacctctgc agttcgagaa gaacttttca aggccctagg 1140
gcttcataaa cttcacttac caaatacttc aagggattca gaaacagcca agccttctgt 1200
aaatgggcat cagaaagcac tgtgagacgc acagacggcg tcttctgcca ccaagagacc 1260
cgagaactcc agattcacga cattcctgtc ccatgtagaa gcatttccat tcaaccgtgg 1320
cccctcttca gaacctagac ctatcagtgc catttttttt tcataatcta cgaagaactt 1380
ggctatggct gatctttttt aaatttaact ttctgatgga ccctgtagtt tccagttaag 1440
tgcagattcc ttacagacat atagaacagc gcattcttct gtagacattt gctcatgttg 1500
gtaaatacaa tcacccatat gaaaaaattg ttttcacctg atatgaaaat gttagaaaag 1560
gcaaactccg ggacttctaa agatttactt aaatcccatt atgtacttta ttcagaatgt 1620
agaagctgac ttgaaaggca tccttggtac taagtgaagc ttattcagaa aatgcatttt 1680
tcaaatgcaa tggcaactgc ttgtagatat catttttgca gtgtatgttg gagctgtaat 1740
ggttgcaatt atgtttctta tttccttaaa agcaaaaagc gtagtttctg atttatgtta 1800
tagaatgata ctgattagac tttgagccaa ggggaaaata ctaaattctt ttaaacctgg 1860
agccttagag agccacagga atatcttctg ttgtacagtc taataagctg tggtaggaag 1920
tatcatgtaa tcacagttta atgacagttt atgtatatat ataattcagt attccctcga 1980
gggggggccc ggtacccaat tcgcccaagn tnancnag 2018

<210> 20
<211> 2098
<212> DNA
<213> Homo sapiens

<400> 20
ggcacgaggg accgagctat tctcctggga ctggctatga tggtgtgctc catcatgatg 60
tattttctgc tgggaatcac actcctgcgc tcatacatgc agagcgtgtg gaccgaagag 120
tctcaatgca ccttgctgaa tgcgtccatc acggaaacat ttaattgctc cttcagctgt 180
ggtccagact gctggaaact ttctcagtac ccctgcctcc aggtgtacgt taacctgact 240
tcttccgggg aaaagctcct cctctaccac acagaagaga caataaaaat caatcagaag 300
tgctcctata tacctaaatg tggaaaaaat tttgaagaat ccatgtccct ggtgaatgtt 360
gtcatggaaa acttcaggaa gtatcaacac ttctcctgct attctgaccc agaaggaaac 420
cagaagagtg ttatcctaac aaaactctac agttccaacg tgctgttcca ttcactcttc 480
tggccaacct gtatgatggc tgggggtgtg gcaattgttg ccatggtgaa acttacacag 540
tacctctccc tactatgtga gaggatccaa cggatcaata gataaatgca aaaatggata 600
aaataatttt tgttaaagct caaatactgt ttctttcat tcttcaccaa agaaccttaa 660
gtttgtaacg tgcagtctgt tatgagttcc ctaatatatt cttatatgta gagcaataat 720
gcaaaagctg ttctatatgc aaacatgatg tctttattat tcaggagaat aaataactgt 780
tttgtgttgg ttggtggttt tcataatctt atttctgtac tggaactagt actttcttct 840
ctcattccgc caaaacaggg ctcagttatt catttgccaa gcttcgtgga ggaatgtagg 900
tgacatcaat gtgataaagt ctgtgttctg agttgtcaga tctcttgaag acaatatttt 960
tcatcactta ttgtttacta aagctacagc caaaaatatt ttttttcttt attctaaact 1020
gagccctata gcaagtgaag ggaccagatt tcctaattaa aggaagttag gtacttttct 1080
tgtatttttt accatatcac tgtaaagaag aggggaaacc cagccagcta cttttttca 1140
tcacttttta ttcataactt cagatttgta aaactaattt ccaaaatata agctgttttc 1200
attagccagt tctataatat cttcctgtga tttatgtaga aaatgaacac accccttttc 1260
catttaagac cctgctactg tgtgaagaga tgatacttac aaggagtgtc attacctgtg 1320
agctgactga atgttggtag gtgctccatt acaatccagg aaagtctgtg ttactgatat 1380
ttgtgtggaa atctttattt cacttcaatt taaccattag atggtaaaat taagatgcta 1440
cttgttggta aaaattggtg gactggtttc aatgggtaaa tgtgttgtgg caaattaatg 1500
tgttggaata ttgctctttg tgaatttgtg cttaagtcaa tgaatgtgta gtatctctt 1560
ctgacaagca ttccctattg ggattttaaa gctatgtgca cagaatatta gtctcttcta 1620
catgttttat ttttctattt ataattccct tttttgttgt tatattttat acacagaata 1680
gatctttttt ctaacacata tttgaactga ataacagact taaagaaagc ctttgttcac 1740
attgctattt acttttgtgt ttgggggaaa atacgaggga ttgattttaa ataaaaaaca 1800
ttccatcttt catttaatat caatatcaaa agaagaagac aaacatctat ctttctcatc 1860
tatatttaag taccttttg taatgtagta tcaaagtttt ttaggtaatg caaaatttta 1920
caaatcattt gtggaatgaa tggtaaaact aatctgatga aatggaaaat tatttctgcaa 1980

```
tattgtaatt catagtttga cttttcataa gcaaataaat ccctaggatg taatcaggac      2040
ttcaaatgtg taattaaatt tttttaaaaa aaatctaaaa aaaaaaaaaa aaaaaaa         2098
```

<210> 21
<211> 1746
<212> DNA
<213> Homo sapiens

<400> 21

```
gcgttcgcgc acctccagct cgggccgatg tggaagcttt ggagagctga agagggcgcg        60
gcggcgctcg gcggcgcgct cttcctgctg ctcttcgcgc taggggtccg ccagctgctg       120
aagcagaggc ggccgatggg cttccccccg gggccgccgg ggctgccatt tatcggcaac       180
atctattccc tggcagcctc atccgagctt ccccatgtct acatgagaaa gcagagccag       240
gtgtacggag aggtacagcc ccgacgggcc ccgggcaggg agggccgcca ggctggcccg       300
ggctggccag ggccttcctg gttggactta tggccgcccc tgggccgact agtcgggacc       360
tctccgtgtg ccggctgccc tttgagggac acccgcttcc cgggtctgga agggagaagt       420
cctcgacgcc gtgcccccct gcagggggag ccccgcccct gccggtgacc cactccgggc       480
cgaggctccg aggcgatcca gtcctgattt tcccgctacc gctcgagctc ttgctcctgc       540
gcctgcgccg tttggctcgc cagccgcgcc gccacttcag gtccagggtg gacgcatgcc       600
ctcaggtgcg ggcgtcttgc gagtcggcct cgcagctctg tggaagctgc acgcggcttg       660
tcggaaaatc aaggcgttct gagttctaga tggttaatag caggttcttc ggtgtctgca       720
gtcgacgaac gactggtgta ggcgtttgct gtgagaatgg agaatgcagg ggaacgcccc       780
tgactgagaa gcgggccctg ggaaacgatt gtgaacgcgt gaatgaattg atgactaaaa       840
tccgctgcgg gggtcctaca gcgcagatgg taatgccgtt ctgactggct gggaacggca       900
ccttagcaga tacttaaaag gcgccttctg tgtgccactg tcactgccaa cttggtgact       960
catttaaaac tcataaccag ccggtgaggt cggtacttcg ctcctcctca ttctgcggag      1020
gggaaagcag cacggaaatg ccctgtgact ggcagcggaa aaggcgacca ccgcttgtgt      1080
gtgggtgtcc cgacgtccgg agggggcagg agtttccacg ggtcctggga cagagctcac      1140
ctgttttgtt ttgaattaca cttatttata tgcaactaca ggcctgacgc tagcggtgaa      1200
gaaggcagat acagcctttt aaggagttgg cagatgagtg ggagagagaa aactaatctc      1260
attatcggcc acaggctgtg gtcagtgttt tgaaggaaaa gtacagggat gtttggcaac      1320
tgtggtattt caggtttgac cttaaatcct tacttaaacc agtttttaca aggattggtc      1380
taggtgcccg ggcgcggtgc tcacgcctat aatcccagca ctttgggagg ccgaggcggg      1440
cggatcacga aatcaggaga tcgagaccgt cgtggctaac acggtgaaac cccatctcta      1500
ctaaaagaat acaaaaaatt ggccgggcgt ggtggcgggc acctgtggtc ccagctattc      1560
gggaggctgg ggcaggagag tggcgtgaac ccgggaggcg gagctttcag tgagccgaga      1620
tcgcgccact gcactccagc ctgggcaaca gagccagact ccgtctcaaa aaaaaaaaaa      1680
aaaaagggcg gccgctctag aggatccaag cttacgtacc cgtgcatgcg acgtcaatag      1740
ctcttc                                                                 1746
```

<210> 22
<211> 2876
<212> DNA
<213> Homo sapiens

<400> 22

```
ccacgcgtcc ggcggcgagg cggcggtggt ggctgagtcc gtggtggcag aggcgaaggc        60
gacagctcta ggggttggca ccggccccga gaggaggatg cgggtccgga tagggctgac       120
gctgctgctg tgtgcggtgc tgctgagctt ggcctcggcg tcctcggatg aagaaggcag       180
ccaggatgaa tccttagatt ccaagactac tttgacatca gatgagtcag taaaggacca       240
tactactgca ggcagagtag ttgctggtca aatatttctt gattcagaag aatctgaatt       300
agaatcctct attcaagaag aggaagacag cctcaagagc caagaggggg aaagtgtcac       360
agaagatatc agctttctag agtctccaaa tccagaaaac aaggactatg aagagccaaa       420
gaaagtacgg aaaccaggta gtctggacat ttttccttgct ttttgattta tttaggggac       480
aactgaaaat tttaagctaa tgaataaaga ggctgaagaa gactggcttc actgattatt       540
acccacaaat aatatatgga gtgtagtttg gagagaattt ctagatttta atataccaaa       600
gttattcact taacagattt gacccaagtt acataagctg aattccatag atgagattgc       660
```

```
atttatcttt ttattaatat cctgacgttt ctttttggaa tcaagtatgt aaataccttt      720
ctcactgaga aatttaaaaa aataatatgt cagggtagca tacaaaacag aaacttagga      780
agaactgtct aacatgccac tatggttatt ttcaggattg tggtaggatt attactacaa      840
taaccttgtc gatcatccta ggtaatttga tttaggtgtt tatccctcag ctgacgcttg      900
tgtgtacttc catcctattc taactttcac aatcttgaaa cctctacttt tcaatttaaa      960
acttgacctt tttcacaata gtcttctaaa tattaatcct tttaaaaatt attaatgtat     1020
gcattctacc atgtcttgtt gcccttctgt catttattat ttcaatgatc actgccttat     1080
ctgtttatta ttccattact aaccactctc aggaactgat ccaaattgga actttttaaa     1140
aaaatagaat ttttttttac tacaaatata ccattctcat gaatagaaaa ctatttttaa     1200
aaaattaaaa gtacatgaat cccatcaact agaaataaca gctgctcaca tcatggagaa     1260
tattctctca ggattttttt aggtgtatca gtagttttaa gaaaagtaaa ttgggtcaaa     1320
atgtgtattc tatgttgcag cctgcatttt gcacttaaca gtttaccatg aatgtttttc     1380
catgtcattt agcttatttt caatttgata gttaatggct ataaaaaatt ttatttgtaa     1440
atatatggta ccataaacca aaacgtttat gttttcctgg gagatcattt tagatgtatc     1500
tttgtgccta tctgtgaaaa tttccttaga attcttaaag taaatttgct gaattggatg     1560
taaaagttta aaagacagta gatacacatt gttaaattgt tcttcagaaa agtgattctg     1620
tttacttcct ctgaaaatac ctctttccct gtacctcacc caagtgtgta ttaccatttt     1680
aaaattttta ctaaatataa tttaattcat tcttcatttt ttaattaggg attttttttt     1740
ttttttttta gtttttatat ttttagagac atggtctcac tctgtcactc aggctggagt     1800
gcagtggcac gatcatagtt cactgcagcc ttgaactcag gtgatctccc tctttggcct     1860
cccaaagtgc tgggattaca ggcatgagac actacatcaa gcctgggaaa tttttaaaca     1920
tgcataaaag tagagggtaa aatgacaccc cttaccaacc ctcactcagc ttcaataaac     1980
atcaacattc tgctggtctt ttcatcttta ctaccctaca cacatttgcc ctttttttct     2040
ttcctagaat attttaaggc aaattccgca tgtgctttta catctctgtg tctctctcta     2100
gtaagaatgt tcttttcagc aaaatcacag aattagccat tactccttta ttacctaata     2160
cccagactgt ttaatttttc tagttgcttc aagtgtctgt ttacaattta tttgtttgaa     2220
ttcatttcta agctactcag gaggctgagt caggagaatt gcttgaaccc aagaggcaga     2280
ggttgcagtg agctgagatc gtgccactgt actccagcct gggtgacaaa gtgagactcc     2340
atgtcaaaac aaaacaaaac aaaacaaaac aaaacaaaac aaacaacaca attgaataat     2400
atccctcagt tattatttag agaagagatg actcaatata aatgtaatat gtgatcattt     2460
ggtcacagaa tgaatttcag tcattgctta ggtaagcctg gtaaaaaaaa aaaaaaacgg     2520
gattccatga ttagtgtgtt gaaaaggggc ttgccaaagt gtaacagaca gagccgggtg     2580
cagtggctca cgcctgtaat cccagaactt tgggaggcca aggcaggcgg atcacgaggt     2640
caagagattg agacaatcct ggccaacatg gtgaagcccc gtatcaacta aaaatacaaa     2700
aacaattagc tgggcgtggt gacatgtgcc tgtagtccca gctactcagg aggctgaggc     2760
aggagaattg cttgaacctg ggaggcggag gctgcagtga gctgagattg ctccactgca     2820
ctccagcctg gccacagagt gagattccat ctcaaaaaaa aaaaaaaaaa aaaaaa         2876
```

<210> 23
<211> 1052
<212> DNA
<213> Homo sapiens

<400> 23

```
tcgacccacg cgtccgccca cgcgtccgcc cacgcgtccg ggcgggcgca ggacgtgcac       60
tatggctcgg ggctcgctgc gccggttgct gcggctcctc gtgctggggc tctggctggc      120
gttgctgcgc tccgtggccg gggagcaagc gccaggcacc gccccctgct cccgcggcag      180
ctcctggagc gcggacctgg acaagtgcat ggactgcagc acctcctgcc cccttccggc      240
tgctttggcc catccttggg ggcgctctga gcctgacctt cgtgctgggg ctgctttctg      300
gctttttggt ctggagacga tgccgcagag agagaagttc accaccccca tagaggagac      360
cggcggagag ggctgcccag ctctggcgct gatccagtga caatgtgccc cctgccagcc      420
ggggctcgcc cactcatcat tcattcatcc attctagagc cagtctctgc ctcccagacg      480
cggcgggagc caagctcctc caaccacaag gggggtgggg ggcggtgaat cacctctgag      540
gcctgggccc agggttcagg ggaaccttcc aaggtgtctg gttgccctgc ctctggctcc      600
agaacagaaa gggagcctca cgctggctca cacaaaacag ctgacactga ctaaggaact      660
gcagcatttg cacaggggag gggtgccct ccttcctaga ggccctgggg gccaggctga       720
cttggggggc agacttgaca ctaggcccca ctcactcaga tgtcctgaaa ttccaccacg      780
gcggtcaccc tgggggtta gggacctatt tttaacacta gggggctggc ccactaggag       840
```

ggctggccct aagatacaga cccccccaac tccccaaagc ggggaggaga tatttatttt 900
ggggagagtt tggaggggag ggtggggggg gggaaaaaaa aataaaaaaa aaaattttta 960
atttttaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1020
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1052

<210> 24
<211> 1541
<212> DNA
<213> Homo sapiens

<400> 24
ggcacgagct tcctcgatcc tactctgtct ctctttgttt tggagaagtt caatttacca 60
gctggatatg tgggactagt attcctgggt atggcactgt cctatgccat ctcttcacca 120
ctatttggtc tcctaagtga taaaaggcca cctctaagga aatggcttct ggtgtttggc 180
aacttaatca cagccgggtg ctacatgctc ttagggcctg tcccaatctt gcatattaaa 240
agtcagctct ggctgctggt gctgatatta gttgtaagtg gcctctctgc tggaatgagt 300
ataattccaa ctttcccgga aattctcagt tgtgcacatg aaaatgggtt tgaagaggga 360
ttaagtacat tgggacttgt atcaggtctt tttagtgcaa tgtggtcaat tggtgctttt 420
atgggaccaa cgctgggtgg atttctgtat gagaaaattg gttttgaatg ggcagcagct 480
atacaaggtc tatgggctct gataagtgga ttagccatgg gcttgtttta tctactggag 540
tattcaagga gaaaaaggtc taaatctcaa aacatcctca gcacagagga ggaacgaact 600
actctcttgc ctaatgaaac ctagtccgat ggatcctgga ttgatacaag gttgagaaat 660
gaatgctcct ggccttaaac atcaccgtag gaagggtttt taaaatttta cgcgcaaaac 720
tccgtggacc ccgtgccagt gtcttggaag tgtcaacgtg tttttggatg atcctgtatt 780
gggctgtact tactgtgata ctgaaaagct gtcctgctga agcagctata tttgaaatat 840
taagtatgaa aggagtaatt aaaaacaagc aaaacaaaac aagacttagt ttttaaatga 900
ccaaacttgt ccttaaagat gttgttatta actcgagtta gttcttattt cctctgttta 960
tttttattc taagtacact gattctgtga atgtaccttt tttattacac agggaaagaa 1020
atgaattaat ttgatatgct ctaaatacat aaaggtgctt caaaatatgt agaaacatta 1080
ctatgaaatc agtttttaaa agatatactt tctctttgtc ctgaggtttt tcggtcttgt 1140
tcaaaaggaa gaattcttgc ctgccataca gaaactctct agcactccct gaccttaagc 1200
ttttctaaaa attctgtttg tgtgaaaagt acaagaataa caatacttac aacttccatt 1260
tttgtaacct acgttcactt atgatctgga tttataaaca ttacttggta taacgttttt 1320
catttccttt aatgtctctg tttttttggct ctaccatctg ttttgttttt gtttttatct 1380
atatcttggt agatgtattt catccctaga gcaggtcagc ctccttcccc taatgcgaat 1440
gcttgttttg ttagggaagg gcttcctcca acttcgtgtg aaattgtgat gttgaagtga 1500
ataaatgtct attgtgtaac aaaaaaaaaa aaaaaaaaaa a 1541

<210> 25
<211> 2079
<212> DNA
<213> Homo sapiens

<400> 25
ggcacgaggg aggcgcggct gcgggacctg actagattct acgacaaggt actttctttg 60
catgaggatt caacaacccc tgtggctaac cctctgcttg catttactct catcaaacgc 120
ctgcagtctg actggaggaa tgtggtacat agtctggagg ccagtgagaa catccgagct 180
ctgaaggatg gctatgagaa ggtggagcaa gaccttccag cctttgagga ccttgaggga 240
gcagcaaggg ccctgatgcg gctgcaggac gtgtacatgc tcaatgtgaa aggcctggcc 300
cgaggtgtct ttcagagagt cactggctct gccatcactg acctgtacag ccccaaacgg 360
ctcttttctc tcacagggga tgactgcttc caagttggca aggtggccta tgacatgggg 420
gattattacc atgccattcc atggctggag gaggctgtca gtctcttccg aggatcttac 480
ggagagtgga agacagagga tgaggcaagt ctagaagatg ccttggatca cttggccttt 540
gcttatttcc gggcaggaaa tgtttcgtgt gccctcagcc tctctcggga gtttcttctc 600
tacagcccag ataataagag gatggccagg aatgtcttga aatatgaaag gctcttggca 660
gagagcccca accacgtggt agctgaggct gtcatccaga ggcccaatat accccacctg 720
cagaccagag acacctacga ggggctatgt cagaccctgg gttcccagcc cactctctac 780

```
cagatcccta gcctctactg ttcctatgag accaattcca acgcctacct gctgctccag      840
cccatccgga aggaggtcat ccacctggag ccctacattg ctctctacca tgacttcgtc      900
agtgactcag aggctcagaa aattagagaa cttgcagaac catggctaca gaggtcagtg      960
gtggcatcag gggagaagca gttacaagtg gagtaccgca tcagcaaaag tgcctggctg     1020
aaggacactg ttgacctaaa actggtgacc ctcaaccacc gcattgctgc cctcacaggc     1080
cttgatgtcc ggcctcccta tgcagagtat ctgcacgtcg tgaactatgg catcggagga     1140
cactatgagc ctcactttga ccatgctacg tcaccaagca gccccctcta cagaatgaag     1200
tcaggaaacc gagttgcaac atttatgatc tatctgagct cggtggaagc tggaggagcc     1260
acagccttca tctatgccaa cctcagcgtg cctgtggtta ggaatgcagc actgttttgg     1320
tggaacctgc acaggagtgg tgaaggggac agtgacacac ttcatgctgg ctgtcctgtc     1380
ctggtgggag ataagtgggt ggccaacaag tggatacatg agtatggaca ggaattccgc     1440
agaccctgca gctccagccc tgaagactga actgttggca gagagaagct ggtggagtcc     1500
tgtggctttc cagagaagcc aggagccaaa agctggggta ggagaggaga aagcagagca     1560
gcctcctgga agaaggcctt gtcagctttg tctgtgcctc gcaaatcaga ggcaagggag     1620
aggttgttac caggggacac tgagaatgta catttgatct gccccagcca cggaagtcag     1680
agtaggatgc acagtacaaa ggagggggga gtggaggcct gagagggaag tttctggagt     1740
tcagatactc tctgttggga acaggacatc tcaacagtct caggttcgat cagtggtct      1800
tttggcactt tgaaccttga ccacagggac caagaagtgg caatgaggac acctgcagga     1860
ggggctagcc tgactcccag aactttaaga ctttctcccc actgccttct gctgcagccc     1920
aagcagggag tgtccccctc ccagaagcat atcccagatg agtggtacat tatataagga     1980
ttttttttaa gttgaaaaca actttctttt cttttgtat gatggttttt taacacagtc      2040
attaaaaatg tttataaatc aaaaaaaaaa aaaaaaaaa                            2079
```

<210> 26
<211> 1947
<212> DNA
<213> Homo sapiens

<400> 26

```
tgtaaacaga ttggagaatc tagcaataag attcaaagct aatctggagc ataaaggcac       60
agttcagaga cagaataaca gggatcacaa gcatgaatta aaaggaattt atttgcttca      120
agttcctaga tacaaccttc ccatgctgca cttctccact gtcggagcac gttccgaaaa      180
acagaatgcc ttgatccctg gtgggtgcga aggcagttgt tagggatggc aggcattggt      240
gggctccaaa agatgaaggc cccacacaca ggtgtgctgc atttgggatc tgtgtgggtg      300
tttcttggac cctttcttct gggagtaggg tacacactaa cgtttaatcc gctgtctggg      360
tgcatgtcca cagtacggtg gctaaactcg aacatcactg caaataggac gctgagcagg      420
tccgtctgtc atgtcacgcc actgcacagg tccttgtccc cacacgacgg ggagtacttg      480
cgtcagatgt tattgaatag ctcgtctcgg gcaggggaag cggggagttg ggatattaa       540
ttgggggttt taattctatt atcatgtcag ctgacattat gactatataa tgtagttaga      600
gacaattttt atcttgctta tagtaaaggt tcagcctgcc aattgtaaat cattctaatt      660
tggcaggctt atttttgaca ttggaaaggg cagaaagcga tttgccccag tagtgtaata      720
ggagttatag accagaggct gaaacccaaa ctatataaaa aggaattcag tggagggggc      780
tttgtaatct ccattaattt gtgttgctac ttccaggatc accaaaaatt acatgtaatt      840
ttacatgtta aacacattga aacataacct atgtttataa agcataacgg gcttcccttc      900
cagaagctct cctgcttgtc atgaagtgag aacaatgaaa agtcatagca gatactcagt      960
ttaactctgt gtagaaccta gtagtgtttg agctgttatt cagatttgaa ttcagactgt     1020
gtgttgtttg cttatggaca ctgcctgtcg ttctgtcact gttaaattaa tgagtctata     1080
aggtttttct tccagaggcc ataggtgaca tcactaaaat tgcaagataa attgtaatct     1140
ttgctgctgc tgcactcccc aacctctccc ccaccccccg tggtgtgctg ctttctagat     1200
gagcgtgttt tggagcaggc ccatctggga cactctatgc tttcaccaag gaagtgcgat     1260
ctgagcagcc acaatccagc caaaagagga tcgtagatat ttgctctgat caactagatg     1320
aaaatatagc agaatggatt tagcccactg ctctgtttta tccaactgag tctctgacca     1380
gcaattggtg cataattatt acagcaaaag ttaagaaatg aaactgtagc aattatgtaa     1440
atgaatgtgt tggcctctta atacctgtta ctagtggact tcctgtgagg aagttagttt     1500
tttgttttga tgaaatgctt tcgtttttta aatcttaatt ctgctgtcca catcctccca     1560
aagtgtgctt acttcatttg tttaatttaa atgaactttc ctccttgtat gtatgaggtg     1620
acttggtggg tggggtgggt ggtttttgtt tttgtgtttt ttctttctta gggcatctgt     1680
aggcctcaaa ggacctttcc tttaggtcat attcctcaga aagtcttcaa tcttcccttg     1740
```

```
tttttgtttg tttgtttttc ttaaagaata ttttcaaagc ttaaatttgt atattaattt    1800
aggactattt agaagtatag gctgtcgttg gcggcagcag tatattctga aatgtctcat    1860
agatatatat ttttgaataa agatggtgtt gttgaacaaa aaaaaaaaaa aaaaaaaaac    1920
tcgagggggg gcccggtacc caattcg                                         1947


<210> 27
<211> 3379
<212> DNA
<213> Homo sapiens

<400> 27
atgatattca agtcgaattc ccctcactaa agggaaaaaa gctggagctc caccgcggtg      60
gcggccgctc taaacctact ggatcccccg ggatgcagga attcggcacg aggtctcggc     120
tccctccggc acccgcccgg cccggctgct cccggctcct cccggccatg gggagctgcg     180
cgcggctgct gctgctctgg ggctgcacgg tggtggccgc aggactgagt ggagtagctg     240
gagtgagttc ccgctgtgaa aaagcctgca accctcggat gggaaatttg gctttggggc     300
gaaaactctg ggcagacacc acctgcggtc agaatgctac cgaactgtac tgcttctaca     360
gtgagaacac ggatctgact tgtcggcagc ccaaatgtga caagtgcaat gctgcctatc     420
ctcacctggc tcacctgcca tctgccatgg cagactcatc cttccggttt cctcgcacat     480
ggtggcagtc tgcggaggat gtgcacagag aaaagatcca gttagacctg gaagctgaat     540
tctacttcac tcacctaatt gtgatgttca agtcccccag gccggctgcc atggtgctgg     600
accgctccca ggactttggg aaaacatgga agccttataa gtactttgcg actaactgct     660
ccgctacatt tggcctggaa gatgatgttg tcaagaaagg cgctatttgt acttctaaat     720
actccagtcc ttttccatgc actggaagga aggttatttt caaagctttg tcaccaccat     780
acgatacaga gaacccttac agtgccaaag ttcaggagca gctgaagatc accaacctcc     840
cgcgtgcagc tgctgaaacg acagtcttgt ccctgtcaga gaaatgacct gaacgaagag     900
cctcaacatt ttacacacta tgccatctat gatttcattg tcaagggcag ctgcttctgc     960
aatggccacg ctgatcaatg catacctgtt catggcttca gacctgtcaa ggccccagga    1020
acattccaca tggtccatgg gaagtgtatg tgttagcaca acacagcagg cagccactgc    1080
cagcactgtg ccccgttata caatgaccgg ccatggcagg cagctgatgg caaaacgggg    1140
gctcccaacg agtgcagaac ctgcaagtgt aatgggcatg ctgatacctg tcacttcgac    1200
gttaatgtgt gggaggcatc agggaatcgt agtggtggtg tctgtgatga ctgtcagcac    1260
aacacagaag gacagtattg ccagaggtgc aagccaggct tctatcgtga cctgcggaga    1320
cccttctcag ctccagatgc ttgcaaaccg tgttcctgcc atccagtagg atcagctgtc    1380
cttcctgcca actcagtgac cttctgcgac cccagcaatg gtgactgccc ttgcaagcct    1440
ggggtggcag ggcgacgttg tgacaggtgc atggtgggat actggggctt cggagactat    1500
ggctgtcgac catgtgactg tgcagggagc tgtgacccta tcaccggaga ctgcatcagc    1560
agccacacag acatagactg gtatcatgaa gttcctgact tccgtcccgt gcacaataag    1620
agcgaaccag cctgggagtg ggaggatgcg caggggtttt ctgcacttct acactcaggt    1680
aaatgcgaat gtaaggaaca gacattagga aatgccaagg cattctgtgg aatgaaatat    1740
tcatatgtgc taaaaataaa gattttatca gctcatgata aaggtactca tgttgaggtc    1800
aatgtgaaga ttaaaaaggt cttaaaatct accaaactga agattttccg agggaaagcg    1860
aacattatat ccagaatcat ggacggacag aggatgcact tgtccaatcc tcaatcctgg    1920
tttggaatac cttgtagcag gacatgagga tataagaaca ggcaaactaa ttgtgaatat    1980
gaaaagcttt gtccagcact ggaaaccttc tcttggaaga aaagtcatgg atattttaaa    2040
aagagagtgc aagtagcatt aagatggata gcacataatg gcacttggct atgtccaaaa    2100
cacaaacttt agagcaagaa gacctcagac aggaaactgg aattttttaa agtgccaaaa    2160
catatagaaa tgtttgaatg catgggtctt tatctaattt atctcttctg gacccatgtt    2220
taaatacagt tttatttcat gaagagaaat gaaaacccct acactgatat ctgttttcta    2280
tgggactgat tctgaaattc ttaactatta agaatatttt aatagcagca tgacatttag    2340
cagtaatcca ttaagggcag tacctctaac aaggacgcct tccagcttca gctatgttac    2400
ttacgtttga tgctacttaa agtaatgaat gacgttttaa ggaatcccta accctactat    2460
cagaaaaggt gtttgttaaa gagccttctc ttgtgtgtta cgcatgaact ttgctctgta    2520
ggtgttaaat ggaccctctc catgtgtata tagtatttcc ttgtataaag cactttacta    2580
cctaccactt gtgttgtgaa cgtttggtga ctgctgttga aagaaggaaa agggtgtgtg    2640
agaaagccta ctgaagcagc agcactgcca ctacatgtgg acaaaagtga acatataaaa    2700
gaagttgtgc tatttaactc tgaatacttg gagaaactag gtgaagatgc aaccagaaag    2760
gagaatatgt atgcgtgaag tctcagcttt gagctggagg ctagattcca agatgacagc    2820
```

catgatgaaa cttttaaaa aactaaacca gaagagactt taaaataaga gaaagaaatc 2880
ataaatgtag acatatgctt ggctaaaggg gaaatggact ttaaatttta aagagctcat 2940
ttgcaatgca cttgtataca cttcaaaaat tattgtagac acagaatttg ttatattttt 3000
gtgcttagta tttaaacctg aacattgaaa cagttttcct ccttgtcttt cttaacagta 3060
atagtcatta tatttacctg tttttaaca caatgtatgt gatagtcaaa aaatcacagt 3120
ttttcattat tattcatctt ctgtacccac gcataaccac tatacatagt ttcttttgta 3180
cttgaatata caaaacatga acacagtgcc atatgaataa tttcacatac agaacctttt 3240
tttctctgaa gtcctgtgga cttgcaaata tatatatata ttgctttgtt aatttgtttt 3300
tatatttcat atatgtaata aaggaatatg atctgaaaaa aaaaaaaaaa aaaaactcga 3360
gggggggccc gtacccaaa 3379

<210> 28
<211> 2006
<212> DNA
<213> Homo sapiens

<400> 28
cccacgcgtc cgcggacgcg tgggattttc tcttaagaaa aaaaaaggaa gacgttttaa 60
taggaaaaga aaaacaagaa gcagtagcag ctaggtaatt taaacgtctt cctttttttt 120
tcttaagaga aaatggaaca tttaggttaa atgtctttaa attttaccac ttaacaacac 180
tacatgccca taaaatatat ccagtcagta ctgtatttta aaatcccttg aaatgatgat 240
atcagggtta aaattacttg tattgtttct gaagtttgct cctgaaaact actgtttgag 300
cactgaaacg ttacaaatgc ctaataggca tttgagactg agcaaggcta cttgttatct 360
catgaaatgc ctgttgccga gttattttga atagaaatat tttaaagtat caaaagcaga 420
tcttagttta agggagtttg gaaaaggaat tatatttctc tttttcctga ttctgtactc 480
aacaagtctt gatggaatta aaatactctg ctttattctg gtgagcctgc tagctaatat 540
aagtattgga caggtaataa tttgtcatct ttaatattag taaaatgaat taagatatta 600
taggattaaa cataatttta tacggttagt actttattgg ccgacctaaa tttatagcgt 660
gtggaaattg agaaaaatga agaaacagga cagatatatg atgaattaaa aatatatata 720
ggtcaatttt ggtctgaaat ccctgaggtg tttttaacct gctacactaa tttgtacact 780
aatttatttc tttagtctag aaatagtaaa ttgtttgcaa gtcactaata atcattagat 840
aaattatttt cttggccata gccgataatt ttgtaatcag tactaagtgt atacgtattt 900
ttgccacttt ttcctcagat gattaaagta agtcaacagc ttattttagg aaactggaaa 960
agtaataggg aaagagattt cactatttgc ttcatcagtg gtagggggc ggtgactgca 1020
actgtgttag cagaaattca cagagaatgg ggatttaagg ttagcagaga aacttggaaa 1080
gttctgtgtt aggatcttgc tggcagaatt aactttttgc aaaagtttta tacacagata 1140
tttgtattaa atttggagcc atagtcagaa gactcagatc ataattggct tatttttcta 1200
tttccgtaac tattgtaatt tccacttttg taataatttt gatttaaaat ataaatttat 1260
ttatttattt ttttaatagt caaaaatctt tgctgttgta gtctgcaacc tctaaaatga 1320
ttgtgttgct tttaggattg atcagaagaa acactccaaa aattgagatg aaatgttggt 1380
gcagccagtt ataagtaata tagttaacaa gcaaaaaaag tgctgccacc ttttatgatg 1440
attttctaaa tggagaaaca tttggctgca tccacataga cctttatgtt ttgttttcag 1500
ttgaaaactt gcctcctttg gcaacattcg taaatgaagc agaatttttt tttctctttt 1560
ttccaaatat gttagttttg ttcttgtaag atgtatcatg ggtattggtg ctgtgtaatg 1620
aacaacgaat tttaattagc atgtggttca gaatatacaa tgttaggttt ttaaaaagta 1680
tcttgatggt tcttttctat ttataatttc agactttcat aaagtgtacc aagaatttca 1740
taaatttgtt ttcagtgaac tgctttttgc tatggtaggt cattaaacac agcacttact 1800
cttaaaaatg aaaatttctg atcatctagg atattgacac atttcaattt gcagtgtctt 1860
tttgactgga tatattaacg ttcctctgaa tggcattgat agatggttca gaagagaaac 1920
tcaatgaaat aaagagaata tttattcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980
aaagggcggc cgctctagag gatccc 2006

<210> 29
<211> 3070
<212> DNA
<213> Homo sapiens

<400> 29
gttggagcct tagaccttcg aagtgaccta tagaaggtac gcctgcaggt accggtccgg 60
aattcccggg tcgacccacg cgtccgcaac gtatgaggag tctgatttct tcacatcctt 120
gtcaacattt gttgttgttg ttgttgttgt tgtttttaat tttagctatc ctagtagatg 180
tgaagtggta tctcgtgctt tttatttgca tttctctaat gactagtgat gttgaacatc 240
ttttcatgtg cttgttggcc attcgtatat cttcttggag aaatgtctat taagtccttt 300
gcccaatttc aaattggctt gtctttttgt tgagttataa ccattgaatt ttaattgctg 360
taaaacactc catgagtaca tgtagcatgc actcaataac tattagctaa tactatagtt 420
gtaattattt ttgccacatg tggcctgaat tggaaggaaa ttgcctagtt tttccaagta 480
ggagtggaga tgtaacaaaa cctgtattta aggccaataa agatttgact ctgtcagtgt 540
tgatactttg cttttaattg atgctcccaa atcaagaaat tagaaacgtg tatacataag 600
aatcagttta tctttggcag aaatcagtat attatcaatg tttaattaat tcctaagaat 660
taatggcaat agtgcctcta gttttagctg agatttagat catctttctt cattctgccc 720
tgttatgcga catttgctat aaatgccaca atgagaattt tttgaaacct gggtcagaga 780
agcctacttt ttatatttaa taagtatgtg attgatgtat tatcattggt ttatgcttat 840
tgcatcttgg ttttatgggg tgttcaaaag aagatagatg agaataggtg atccaaagta 900
atttagaatt ttatcctcca gttgggactg aaccatcttg aactgatgaa tatattctac 960
caggtttata ggtagatatg ccgtttcatt atatcggtga tttggagtga gacagtagct 1020
tttaagcaga acaacagcca tatgtaagtc taaatttggt tattttcttt gaataagcaa 1080
tggaaactgt atgcattcag gaactggtga ttcagatatc ttctgaaggc cctctctccc 1140
ctgtgctccc acagcttttg tcctgaactc tcctgtctcc ttgcgatgcc tctgtgccta 1200
tacctatttt gtgaactctg cctgcaatgc cgtcccaagt cagttggtga ctcctcaaac 1260
ctcactgaag tctttcgggg tggattcaaa tgctgctttt agccattaaa atctgttaca 1320
tctgttacat actttcacaa tagcacttat cctagtgtag ttttaaaaat gcacttaaaa 1380
atttttaaag cagtgcatgc atgcagtaaa caaaattgga cagtacagaa ataaatggtg 1440
aagacagtct cccagttttc ttccccatgg atagcacttt ctctttttta tccttccaaa 1500
gatattttgt gctgatacaa gaatttttat accgtatgaa gtgcttattc atcttatctt 1560
ttacttcagg gtaatttatg agtaatgaaa aaattcaagc attacaaaaa tgtagagtgt 1620
gtgaagcaaa aggtcccctt tactttgatc cctaacacta gccctttcca aataacactg 1680
tcctaattaa cattcctctc tccagaagta acctctgtta taagccttgt ctgtgccttc 1740
agattgttct gcttacactt atatgcctat ttaaaagtgt atatttttgt attttgtttg 1800
tttgtttgtt tgagacagag tttcgctctt gttgcccagg ctgaagtgca atggcactat 1860
ctctgctcac tacaacctgt gtctccctgg ttcaagtgat tctcctggct cagcctcctg 1920
agtagctagg attacaggtg cacgccacca tgcccggcta atttttgtat ttttagtaga 1980
gatggagttt caccatgttg gccaggctgg tcacgaactc ctgacctcag gttatccacc 2040
caccttggcc tttcaaactg ctgggattac aaggcatgag ccactgtgcc cggccaagaa 2100
tttttttatc gataccatag tgagctctct gcctcttcgg aacgatgtcc actttgctta 2160
tgatcaaccc aagcaggact cttctctccc tggacgcctc tcccctggtc tggaatcttc 2220
cagttctgcc agaattggcc tttcccagat gctgcaaact tccagttgaa cccctttttc 2280
tgtgtggccc ctggggctgc gagaccaaaa tccatgagtt ctgtgtaccc tagacctttg 2340
gaaggtgaga gcagggccct gagaaaaggc aaaacgcctc ctctccctga tgatacccct 2400
acccgcccta ctcctcacca gaattgtcag tggcctttca ccacagtggt ccttcctgcc 2460
tgagccctgc actgtcccag accacacaga agtctggtca cctctgggcg cctgggatgg 2520
tcaccgaaga gaagcacgct gtccccgtct tctcctggct tctgccagaa aatcgaacaa 2580
gtgcaattaa cacactgtta ctgccgaagc ctgaaactcc caggacttgt ccttgatcct 2640
tccagaaacc accaggtccg gcacttggag ccccccggac agggacctcc cagccgagcc 2700
ctcaaagaac tccatgaaat caggaactgc ttgatgaaat gtatctcctt gtacctggaa 2760
gatgaagccc aaacacccac acctctgtct cccccagggc tcgggatgtc tccagcagcc 2820
cggccacgca gcttcccagg tgggctcggg gaggtgggag cagggaccat ctctgtcccc 2880
tccaccctca ctccatccac ctcggagacc accctccccc agccagatac ggaataaaac 2940
tacagacgca gaaaaaaaaa aaaaaaaaaa gggcggccgc tctagaggat ccctcgaggg 3000
gccccagctt acgcgtgcat gcgacgtcat agctctctcc ctatagtgag tcgtattata 3060
agggagcaaa 3070

<210> 30
<211> 2227
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (289)
<223> n equals a,t,g, or c

<400> 30
```
cggacgcgtg ggtcgaccca cgcgtccggg aaaaarggaa aaratgccgt gtaaaatctc     60
gttctgtgtc tgaattgccg taggctcaga tcttcatttg aggttctgtg tctgaattgc    120
cgtaggctca gatcttcatt tgaggttatg ttctataagt taacgttgat cttgtgtgag    180
ctttcggtag ctggagtaac acaggcggcc tcacagcgac ctctccagcg ccttccaagg    240
cacatctgca gccagcgtaa tcctcctggg agatgcctcc tcaaggccnt gctccagacc    300
acgtggggar ggcctgacar ccaattccca ggctgtcccc acccttgrag agtgacccta    360
aacgctagac agatggggaa tgggaaagaa aagaaagctg cagacctcaa gttaaaattc    420
cctcaaaaac gttttttattt atctgctttt tctgaaagga taaaggcttt ttgaaaatta    480
ttttctaaca aataacatga acacttctag aaaccctaga aaaacacaaa gtattcaaaa    540
tagaaagaaa aattacccat tactctttaa gccagcatta tccattgcgg tgcttttgga    600
gttgggtgag gccgtagcct ctgccaagtc aaggagcccg gtggtggctg tggcattcct    660
gcagggttgt ttttttttct ttgagatgga gtctcactct tgtcacccca gctggaatgt    720
ggtggtgtaa acagctcact gcagccttga ccctgaggct caagcgatcc ttctgccttg    780
gcctcctgag tagctgggat cccaggcgag agtcaccaca ccctgtccat gttcctgcag    840
gtcttgatat gcgaggacgc tgtgtcttcc ctgccacatt ttcttcttct ttcttgagac    900
agacccttgc tccatcaccc aggccagagt gtggtsgtgc gaacacggct cactgcagcc    960
tcgaccctca ggctcaagcg atcctcacgc ctcggacccc caaagtgctg ggatcacagg   1020
cgagagtcac catgctggcc tgaatcttca gggtatttta cggttgaagt gtcacttact   1080
tarccatscc tgtttcaaga gtgtaggtgg tcaccctgtc tctgycgctg acctggcctg   1140
gaccctcggc tgtgagaggg aggggtgggc tgggctggag gaacctraag ccctcgtgat   1200
gtcacaagcc catctggctg ggcatccccct gctgtgtcct gagctgcaca tgccccaggt   1260
ggccccccaca gcagaggcga gccactgrag ggtgragggc ttccacggac ggtcttcagg   1320
ggragaagaa gggcccaggc ccccaggaga ctcaggagac cagagcctgg ggtcaggggc   1380
tyagcagggg ctyarccagg gctggatgtc cggagccagc cccgmagccc tgkgktcttt   1440
gttcttcgca ctcccaccgt ccgtgtgaac agctccagcc ccacctgcgc ctccctgtgc   1500
tgggctccat cagggagccc agaagacgtg tgtgcttctg aaattgggtc cctacatgcc   1560
tttgtcccag tgcaccttgc tccttccatt tactatcgag atttaaatgc ctgttttctc   1620
cccagaggtt gacggatata ttcagacgtt acgacacgga tcaggacggc tggattcagg   1680
tgtcgtacga acagtacctg tccatggtct tcagtatcgt atgaccctgg cctctcgtga   1740
agagcagcac aacatggaaa gagccaaaat gtcacagttc ctatctgtga gggaatggag   1800
cacaggtgca gttagatgct gttcttcctt tagatttgt cacgtgggga cccagctgta    1860
catatgtgga taagctgatt aatggttttg caactgtaat agtagctgta tcgttctaat   1920
gcagacattg gatttggtga ctgtctcatt gtgccatgag gtaaatgtaa tgtttcaggc   1980
attctgcttg caaaaaaatc tatcatgtgc ttttctagat gtctctggyt ctatagtgca   2040
aatgctttta ttagccaata ggaattttaa aataacatgg aacttacaca aaaggctttt   2100
catgtgcctt actttttaa aaaggagttt attgtattca ttggaatatg tgacgtaagc    2160
aataaaggga atgttagacg tgtaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa   2220
aaaaaaa                                                             2227
```

<210> 31
<211> 1288
<212> DNA
<213> Homo sapiens

<400> 31
```
cccccgggct gcaggaattc ggcacgagcc tgacctcccc agcctcatct ctccctcctc     60
tgctctcgcc ctctgtgctc cagccaacgt ggcctgtcac tcgtccacct gccatactgt    120
cctgactcca ggcctttgcc tgtgctatgg cctctgttgg gaccactctt gtctctcccc    180
tgctgtgtct gctaattccc actcgtgtca gtgatccatg gctgcagaac acaccactcc    240
atccatggaa aacaatcaca atcattgatt actatctctc cctgggcttc ctggggtgga    300
ctgggctcag ctgggtggtt cactttgggg cctcagcagt catgggcaga cagtggctgg    360
```

ggtcactgca aagacttccc tgcatctctg gcagttgatg ctggctgtca tctgagacac 420
ctacccaggg cctctccctg gggcctgggc tcctgcttag cttggttggg aggctccaag 480
accaacatcc caagaaagat gagacagaag ccagatcacc tttttgggcc tggcttcaga 540
agtcacccag catcacttct gctgcattta tttcttaaaa cacaaatatc aaaccccatc 600
tcttgatggg agggggcctc atggtttgta aacatgttct aaactccact ctgcccggcc 660
ttggctcaac gtgtctggta atgtgtgggc tgtgaggctc cccgaacgta gacctcagac 720
tgcaacgctg gccgttacag gctctggcac acgggcccac gtcaggccca tcgccacagt 780
gatggttgtt ctgtgactgt ttctggtggc ctctgctcca cactccaggc tgacgctgtg 840
ccccttccac tgggaccctc gggtggcttc catgcacttg tgccctaaat cctgctccta 900
gactaaactt catctcctgt gttctcattc tgcagcatgg ctgttaggga acctgaccat 960
ctgcagcgcg tctcgttgcc aaggtataat gtcagtgcct cccttcagtg gctcccatgt 1020
cacagaattg tcctgcagcc ctggcacatg tgtgccatgt gggagctggg gcaggtcctc 1080
tttcatcctg tggctccgag ggaggggcc gctccttccc cagtctctac cctgacttgg 1140
ccctcgtcct gcagccactc agagagcacg atggagctgg agcttcagtt ttgaccaaat 1200
gcgtgtcgcc ggcttttgtg tgtgtgtgtg tgtgacagag ccagaccctg tctttaaaaa 1260
aaaaaaaaaa aaactcgagg gggggccc 1288

<210> 32
<211> 3280
<212> DNA
<213> Homo sapiens

<400> 32
gcgtccggtg agaggcaagg acttttcatc tttagggcat tctgaccacg tcctgcttca 60
gagagattgt tcccggcgtc tcagtgctat ggggagcagg ttcctcctgg tcctgctctc 120
aggtctcact gtcttactgg ctctgccagg atcagaagcc aagaattctg gagcttcctg 180
tcctccatgc cctaaatatg ccagctgcca caacagcacc cactgtactt gtgaagatgg 240
ctttcgggcc aggtctggca ggacatactt tcatgattcc tctgagaagt gtgaagatat 300
taatgaatgt gaaaccgggc tggcaaagtg caagtataaa gcatattgta ggaataaagt 360
tggaggttac atctgtagct gtttggtaaa atatacttta ttcaactttc tggctggtat 420
tatagattat gatcatccgg attgttatga gaacaatagt caagggacga cacagtcaaa 480
cgtggatatt tgggtgagtg gggtgaagcc tggatttggg aaacagctgg tacgtataac 540
tatgccattt tcctacccaa acattaacat gtcttcctgt gatttttagg gtagggtagt 600
tctatccagg ggtaattttg tcctctgtcc caaggtcatc tgtcaatgac tggggacact 660
tttggttgtc ataccttggg ggtgatgtgt gtgactggca tctggtggat ggagaccagg 720
gatacagctc aacatcctac agtgcccagg acagcctccc acaatcaaga agtgcctagt 780
gccatatgtc catagagata gagaaataca agtgtagggg gaaagtgcct cagctggcat 840
tcaaagacct acatcaagca cctagattct caatgccaca cgcaccttgt agcaccttaa 900
taaatatcgt tgccttctgg gctccccact ccaacacttg tgcatattcc ctatttctta 960
catttcagta agagtcaatc taattagctt aatttttttg gaaggaaaat ctgagaagaa 1020
atggaagcag agaggacttt gcaagaaggg ctactcaact aattcaaagc gtggagttga 1080
gcatctggaa tgcgagtttt gcttctccag gaaagggtca aatttctgaa tttgatatag 1140
tctatgaaac caagaggtgc aatgagacaa gggagaatgc ttttctggaa gctggaaata 1200
acaccatgga tatcaactgt gctgatgctt taaaaggaaa cctaagagag agcactgcag 1260
ttgccctatc acttatcaat ctcttgggga tattctgaat gcatcctttt ttagtaaacg 1320
aaaagggatg caggaagtaa aactgaactc ttacgttgtg agcggcacca tcggtttgaa 1380
ggaaaaaatt tccctctctg aacctgtgtt cctgactttt cgccataatc agcctggtga 1440
caagagaaca aaacatatct gtgtctactg ggagggatca gagggaggcc gctggtccac 1500
ggagggctgc tctcatgtgc acagcaacgg ttcttacacc aaatgcaagt gcttccatct 1560
gtccagcttt gccgtcctcg tggctcttgc ccccaaggag gaccctgtgc tgaccgtgat 1620
cacccaggtg gggctgacca tctctctgct gtgcctcttc ctggccatcc tcaccttcct 1680
cctgtgccgg cccatccaga acaccagcac ctccctccat ctagagctct ccctctgcct 1740
cttcctggcc cacctcctgt tcctgacggg catcaacaga actgagcctg aggtgctgtg 1800
ctccatcatt gcagggctgc tgcacttcct ctacctggct tgcttcacct ggatgctcct 1860
ggaagggctg cacctcttcc tcaccgtcag gaacctcaag gtggccaact acaccagcac 1920
gggcagattc aagaagaggt tcatgtaccc tgtaggctac gggatcccag ctgtgattat 1980
tgctgtgtca gcaatagttg gaccccagaa ttatggaaca tttactcact gttggctcaa 2040
gcttgataaa ggattcatct ggagcttcat ggggccagta gcagtcatta tcttgataaa 2100

cctggtgttc tacttccaag ttctgtggat tttgagaagc aaactttcct ccctcaataa 2160
agaagtttcc accattcagg acaccagagt catgacattt aaagccattt ctcagctatt 2220
tatcctgggc tgttcttggg gccttggttt ttttatggtt gaagaagtag ggaagacgat 2280
tggatcaatc actgcatact cattcaccat catcaacacc cttcagggag tgttgctctt 2340
tgtggtacac tgtctcctta atcgccaggt tcgaatggaa tataaaaagt ggtttagtgg 2400
gatgcggaaa ggggtagaaa ctgaaagcac tgagatgtct cgctctacta cccaaaccaa 2460
aacggaagaa gtggggaagt cctcagaaat ctttcataaa ggaggcactg catcatcatc 2520
tgcagagtca accaagcaac cgcagccaca ggttcatctc gtctctgctg cttggctaaa 2580
gatgaactga cctggcaagt gccatggcaa tgacccggaa gttacccctc ctttccgttt 2640
gtctacagcg cccctgtggt cacacataga ttggacaaat gccactattt ctagctttcc 2700
tgtgaaaagt ctaggctcat tcacctattt tggcttttta tgttcataga aagaacaaga 2760
catttgggag aattcttaga tccagagtcc agtagtgtgg cacgtgcaat gaagtgtcgg 2820
aaggatgcat tttaaagatg gcgggcggga gaagtggatt ttcttcttgc agctactgcc 2880
accttgccag aaactcacta actggcatct ggattcagct catagttccc tttctggcct 2940
ctctgctgta ttttatgctc ccaaagatct tacattaaca ctccacattc acataattca 3000
acaattttca tatggatcag tattaaagag ggtgttgcat tttgcaatac aaaaatgcat 3060
tatcaggtgc tggagaggat gtggagaaat aggaacactt ttacactgtt ggtgggactg 3120
taaactagtt caaccattgt ggaagtcagt gtggcgattc ctcagggatc taggactagg 3180
aataccattt gacacagcta tcccattact gggtatatac cccaagggct ataaatcatg 3240
ctgctataaa gacacatgca cacgtaaaaa aaaaaaaaaa 3280

<210> 33
<211> 1297
<212> DNA
<213> Homo sapiens

<400> 33
ccacgcgtcc ggactgcttt acggacattg gatgaagccg aagcatttag aatggtgcct 60
ggcacacagt tggtgcgtga tatggttaag ctttgtgtcc ccacccacat ctcatcttga 120
atgtgacggt ttccccggct ccctcctgcc gccatgtgaa gaaggtcgtt gcttcccctt 180
caccttccac caccatgatt gccatggatg ctccccactc caaagcagcc ctggacagca 240
ttaacgagct gcccgagaac atcctgctgg agctgttcac gcacgtgccc gcccgccagc 300
tgctgctgaa ctgccgcctg gtctgcagcc tctggcggga cctcatcgac ctcatgaccc 360
tctggaaacg caagtgcctg cgagagggct tcatcaccaa ggactgggac cagcccgtgg 420
ccgactggaa aatcttctat ttcctacgga gcctgcatag gaacctcctg cgcaacccgt 480
gtgctgaaga ggatatgttt gcatggcaaa ttgatttcaa tggtggggac cgctggaagg 540
tggagagcct ccctggagcc cacgggacag attttcctga ccccaaagtc aagaagtatt 600
ttgtcacatc ctacgaaatg tgcctcaagt cccagctggt ggaccttgta gccgagggct 660
actgggagga gctactagac acattccggc cggacatcgt ggttaaggac tggtttgctg 720
ccagagccga ctgtggctgc acctaccaac tcaaagtgca gctggcctcg gctgactact 780
tcgtgttggc ctccttcgag cccccacctg tgaccatcca acagtggaac aatgccacat 840
ggacagaggt ctcctacacc ttctcagact acccccgggg tgtccgctac atcctcttcc 900
agcatggggg cagggacacc cagtactggg caggctggta tgggccccga gtcaccaaca 960
gcagcattgt cgtcagcccc aagatgacca ggaaccaggc ctcctccgag gctcagcctg 1020
ggcagaagca tggacaggag gaggctgccc aatcgcccta ccgagctgtt gtccagattt 1080
tctgacagct gtccatcctg tgtctgggtc agccagaggt tcctccaggc aggagctgag 1140
catggggtgg gcagtgaggt ccctgtacca gcgactcctg ccccggttca accctaccag 1200
cttgtggtaa cttactgtca catagctctg acgttttgtt gtaataaatg ttttcaggcc 1260
gggcaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 1297

<210> 34
<211> 2184
<212> DNA
<213> Homo sapiens

<400> 34
ggcacgaggc gcccgaggat gtgctgctgg ccgctgctcc tgctgtgggg gctgctcccc 60

```
gggacggcgg cggggggctc gggccgaacc tatccgcacc ggaccctcct ggactcggag    120
ggcaagtact ggctgggctg gagccagcgg ggcagccaga tcgccttccg cctccaggtg    180
cgcactgcag gctacgtggg cttcggcttc tcgcccaccg gggccatggc gttcgccgac    240
atcgtcgtgg gcggggtggc ccacgggcgg ccctacctcc aggattattt tacaaatgca    300
aatagagagt tgaaaaaaga tgctcagcaa gattaccatc tagaatatgc catggaaaat    360
agcacacaca caataattga atttaccaga gagctgcata catgtgacat aaatgacaag    420
agtataacgg atagcactgt gagagtgatc tgggcctacc accatgaaga tgcaggagaa    480
gctggtccca agtaccatga ctccaatagg ggcaccaaga gtttgcggtt attgaatcct    540
gagaaaacta gtgtgctatc tacagcctta ccatactttg atctggtaaa tcaggacgtc    600
cccatcccaa acaaagatac aacatattgg tgccaaatgt ttaagattcc tgtgttccaa    660
gaaaagcatc atgtaataaa gcttgagcca gtgatacaga gaggccatga gagtctggtg    720
caccacatcc tgctctatca gtgcagcaac aactttaacg acagcgttct ggagtccggc    780
cacgagtgct atcaccccaa catgcccgat gcattcctca cctgtgaaac tgtgattttt    840
gcctgggcta ttggtggaga gggcttttct tatccacctc atgttggatt atcccttggc    900
actccattag atccgcatta tgtgctccta gaagtccatt atgataatcc cacttatgag    960
gaaggcttaa tagataattc tggactgagg ttattttaca caatggatat aaggaaatat   1020
gatgctgggg tgattgaggc tggcctctgg gtgagcctct tccataccat ccctccaggg   1080
atgcctgagt tccagtctga gggtcactgc actttggagt gcctggaaga gctctggaag   1140
ccgaaaagcc aagtggaatt catgtgtttg ctgttcttct ccatgctcac ctggctggca   1200
gagcatcagg ctgcgtcatt ttcgaaaagc gaaggaaatg aaattacttg cctatgatga   1260
tgattttgac ttcaatttcc aggagtttca gtatctaaag gaagaacaaa caatcttacc   1320
aggagataac ctaattactg agtgtcgcta caacacgaaa gatagagctg agatgacttg   1380
gggaggacta agcaccagga gtgaaatgtg tctctcatac cttctttatt acccaagaat   1440
taatcttact cgatgtgcaa gtattccaga cattatggaa caacttcagt tcattggggt   1500
taaggagatc tacagaccag tcacgacctg gcctttcatt atcaaaagtc ccaagcaata   1560
taaaaacctt tctttcatgg atgctatgaa taagtttaaa tggactaaaa aggaaggtcc   1620
ctccttcaac aagctggtcc tcagcctgcc agtgaatgtg agatgttcca agacagacaa   1680
tgctgagtgg tcgattccaa ggaatgacag cattacctcc agatatagaa agaccctata   1740
aagccagaac cctttggtgt gtggcacgtc ttcttccctc ttcccctgcc acagagattt   1800
ctcccatcca acttgcttgt ttgccttctg ctaactcagc tgcacgctga gcaccaagag   1860
cttgtgatca aaattctgtt ggacttgaca atgttttcta tgatctgaac ctgtcatttg   1920
aagtacaggt taaagactgt gtccactttg ggcatgaaga gtgtggagac ttttcttccc   1980
cattttccct ccctcctttt tcctttccat gttacatgag agacatcaat caggttctct   2040
tctctttctt agaaatatct gatgttatat atacatggtc aataaaataa aactggcctg   2100
acttaagata accattttaa aaaattgggc tgtcatgtgg gaataaaaga attctttctt   2160
tcctaaaaaa aaaaaaaaaa aaaa                                          2184
```

<210> 35
<211> 949
<212> DNA
<213> Homo sapiens

<400> 35

```
ggcacgagct cccattgacc ttattgctca gagtgcagta ttagggcaag gtttcgccac     60
tgcctccctc catgaatgta tttctccctc ctgccctggg gacatgggga gtggcccgtt    120
tctttcccca tctagtccca gaaagatggt gtttggtttt ctgttgttgg attttttttt    180
tttttttttt tttttgcacc aaagtggcaa ctaggtcagt gttgggggat caagctggcc    240
tcggggtggg gggcccccac ctgcctctcc ctggttccca cagtgttagc gtccctgaaa    300
agacaatatt ctctctaaag caataagggg tgacgggccg gggggagtgt ttgctgctgc    360
tggcccccag ctccccttcc ctgccaggtg tgggggagac tcctgttgtg actgaatgta    420
acccccccac ccctgccgca gccaatgcag gggaaggggg acactcttcc tgtctcttct    480
ccccagctaa agagactttg gacttagggg gcccatgagc ctggagaggc cttaaccctg    540
tgaggaagta tagggggagc cctctcccac ccccatcccc ttctgagagt ggtcaatgtt    600
tacaagcccc tgagcccccc tgcccaggga ctcagacccc gttgctgtcc ttccccggcc    660
ccggtcttcc tgggccctcg ctgctcctct gccctttctg gggttggggt gggtgcaggg    720
gtcaccgtgt tccctgtctg ccttgtaccc acagtctccc cgccccctct ccaccctgtg    780
tgacttccct ctcttttacc tgctcctgta aatactccct tctcccaata aaacttggtg    840
tgtgttctcc aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa    900
```

```
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa                949

<210> 36
<211> 3338
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (2861)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (3328)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (3330)
<223> n equals a,t,g, or c

<400> 36
taccgggaca ttctggagtc cgagaagtca acggcgcggt tgctgcggcc gccgcgctcc      60
ccggcccgag gcgatggaga acggagcggt gtacagcccc actacggagg aggacccggg     120
ccccgccaga ggcccccgga gcggcctcgc tgcctacttt ttcatgggcc ggctcccatt     180
gctccggcgc gttctcaagg gcttgcagct gttgctgtct ctgctggcct tcatctgtga     240
agaagttgta tcacaatgta ctttatgtgg aggactttat tttttgagtt ttgtaagctg     300
cagtgccttt cttctgagtc tccttatact gattgtgtat tgcactccat tttatgagag     360
agttgatacc acaaaagtaa aatcatcgga tttttatatt actttgggaa caggatgtgt     420
gtttttgttg gcatccatca tttttgtttc cacacatgac aggacttcag ctgagattgc     480
tgcaattgtg tttggattta tagcaagttt tatgttccta cttgacttta tcactatgct     540
gtatgaaaaa cgacaggagt cccagctgag aaaacctgaa aataccacta gggctgaagc     600
cctcactgag ccacttaatg cctaaagact ctggggagca gatgttacct aaggtagtga     660
ccctgcattg tggtgcctga gccctggcag aagctcttgt aaaatttgtt aattgtttaa     720
accacttctt ttggagagca aggggaaggt caagaaggca gttttatcaa tattgtgtca     780
gtcaccacaa agtaggccag ataagttaaa aaaaattttt ttttaaataa taattgaaac     840
ttatctcaaa tggagatttt ggtgggagga ggagaaaaca attgttttta aatcacacag     900
ctcaacggtt gataaatgat tctgtcattc tgttacaggt cattctttta ctaggcttag     960
cttccaaatt atgctttata gctgtataaa catcgtgatt atattcatct acttagaaat    1020
tgttttattt ttaaattaat ttgcttagct gtttgttttg atgcttagat tatgttctgt    1080
taatgggaat ttaacatatt taagaaacca atatttaaaa tgttggtcta ggtttttttc    1140
cttaacatat attaccaggc tttactgtat ttcactcagc cttaaatgtt ataatatttt    1200
tggataacgg ttattaattc tttgagacct tcgtatagcc tataaaatgt atgggagatg    1260
ttggtatttt atgtgtataa aagcaacaat atcagcaact tcgtgtttat actgcacctt    1320
ggttgttgat gtcaagtaaa aaaaagattg ttttgtaaca cataaaaaaa tggaagaaac    1380
tgataccaca cctaaggacc aaagataaga aagacttttt gcccaagaca gtgaaagtaa    1440
ttataaaaac aagctttgac cacttaccaa gtatctgaag agatgagttc atactatgat    1500
ttagaaagtg gttcaattcc cctgttggca tatgattatt tttactaaaa ttaatacagc    1560
tctgtgggtc ttccttagtg tttttctttga agccaatctg ttttttttag gacaccagcc    1620
tttggttttt catctgttcg agatgcctct tctctgtctc cttatcagat agaaatggag    1680
tcatgtgctg ctgcttcatc tagcagaggt tggcctctgg ctctgacact ttttgtcagt    1740
tgtctttagg tggtcctgaa tcttgggccc ttttgattgt gaatactgtg tagcaggatc    1800
ttgagagtcc ttgttcttac ataggcattg ctctagtttg tctttggcaa aaaaaaaaaa    1860
aaaaaaaagt aaatatccag ggaaccctgc ccagactaat actgttggtg gcataagaga    1920
atcaagccat tctcaagaga taacttcata accagaattg tctgttggct agcagctgtc    1980
acagataggc agggcacttg ggatatgacc tttctgtcca ggtgattcac agactagacc    2040
tttcttatcc tcctcctaga gttttgactt gggactctag tgttaagatg atgagcccgt    2100
```

```
gcatcaggtc cttctgcact ttggtggaag tctcccaggg taggtttcct atttgaaaca 2160
gtggaatcat gtttccagtg ataaagttta atgacctcat cctttttttt ttttctcatc 2220
tgccatttgt gtgtcttaga tgggttttaa ttgcatgaat gtggctaatg tggttctcag 2280
aaattggtca gtatggcccr acatagcttc tgctctgtct tactgactca atacctttag 2340
gatttgtatc agagtttgga tactagtgtt agtggtggtg tcaccactac ttaattggga 2400
gataatgaaa ccaatcatgg atgctgtttt tattgggcat gtcatctaag agaggagaaa 2460
tagctgggtt ttgggtctaa ttatgaataa ggactgattc agaaaacgag tttatggtag 2520
gtagactaaa gtttcacatc agactgtacc attgtgattt agacctatct aaaattcaga 2580
gcatatcatc tgggctacct cagggtcacc acccatgtat tgggcttagt caggattgac 2640
agatacattc tcagctggcc tgtcatataa aacatactgt cattgagctt aagctccgct 2700
tgttctgagg tttcacctcc atgtgtttca ttggtgcaaa agtggatctc ttagttggtc 2760
acttaattct ttctttttca gaaagatagt atgttcactg gtatatttgg tcactcttag 2820
aaccttcctt cacattgttt tttatgggac ccatgaatgg nttagccttt cttttctatt 2880
gtagaaggaa ataaatagga gtaaaaagac cattgtagta aataagttca aggggaactt 2940
gggaccagaa accactgtta tgtacaaaaa aatggcaaat tcaataaact caaatttaaa 3000
ataattttta aattaacagt tatgataaat tttatatttt atacaaatag attgcttaga 3060
atggttctca agaattataa gagaaatgaa ctcacagtac aaaaatttta taattactat 3120
acttgtgttt tgtttggggg ctgggaaatg tatttttaca ttgtagccaa tcatttttata 3180
tttgtcaatt taaatcttat gggtcttttt tttttatcct ctcttgatgt cagattttat 3240
agtcttttta aataaatcca tttaattaaa acgttaaaaa aaaaaaaaaa aaaaaaaaaa 3300
gggcggccgc tcgcgaatct agaactangn cccacgcg 3338
```

<210> 37
<211> 1563
<212> DNA
<213> Homo sapiens

<400> 37

```
cggcacgagg agaaaaggac tcagaccttc cagattggct ccagaaggca gctgctgtca 60
gtgattttcc ttacagacca ttgcagccac ctaccttgcg ccatggtccc gagacagcat 120
ggcgtcttcc cccacacgga cctgcaggtg gcctcttagg agctttctcg ctgaaggagg 180
tcatccctct tagtcacatc tgagcagcac tcacttaggc ctcggccccg agggtcatgc 240
gggggcacct ggccgggttc ccggctctgt ctggtctggc atctgtctgc ctttgggcta 300
ccttttcggc acagctccct gggcctgtgg ctgctacaag ctggactcca gctcccctgg 360
gctgcagtgc tgctcgcagt ggtccagaaa agaggctggg cacagcggct cctggctcag 420
cagcatcctt ggcgcaggct ggcccaggag ctccgtgcag ggtgctgcca gttgacccag 480
ccccggctgc actcaatgtc cgagaaccgg gctggctggg gggcctcttt gacggagctt 540
tactccaagt cttgctgaat ttcctgagga aaagcactga tgttctcatg gacacaaggg 600
aggcagaatc tcttgaagta gaataaactg cactcctttc cagtcttcct ttctcagctt 660
ctcctggacc gccagctcct ccatgcgcct cagacactcc caacgccgca ctgcgggggt 720
tcctcccgcc ctggcccatc tcatccccct tggctgttga tacagctccc ctgtgtgcat 780
gtcgccctgt ggcagatgct cagggacttc tcagactcca ggatcactcc gagtacactg 840
accacacagc ctgctgcaca aactgcagcg ccagctaagg accaggaatc tgacattgtc 900
ggaggtgaag ggatcctttg tgacatagct ttcctccagg aggaccatcc actgggtgtc 960
gggggagctt ctgccccaag tagcaggagg gagctgtcaa ggcgtggagt tcacactcaa 1020
acactcccag aggacggcac tctgcatggg acgccatcca gctcctttga ctgtggaatc 1080
aagtacatta tcagctggcc cctggctcct ggctgtgacc tcccttcgct tgaactgagc 1140
cttgtgtgta agggcgtatc aagttgtatg ggcttcgccg ctgggtgacc ccaaatgcaa 1200
ctccaggaag catgggttac caatgactaa ggttaacgat cagctgggcg cggtgctgac 1260
gcctgtaatc ccagcacttt gggaggtcga ggcgaatgga tcacgaggtc aggagttcaa 1320
gaccagcctg gccaacatgg tgaaaccccc atctctacta aaaatacaaa aattagccgg 1380
gcgtggtggc gggcgcctgt agtcccagct actcaagagg ctgaggcagg agaatcgcgt 1440
gaactcggga ggcgcagctt gcagtgagct gagatctcgc ccgctgcact ccagcctggg 1500
cggcagagcg agactccgtc tcaaaaaaaa aaaaaaaaaa aaaaaaaact cgaggggggg 1560
ccc 1563
```

<210> 38

```
<211> 1048
<212> DNA
<213> Homo sapiens

<400> 38
cccgggtcga cccacgcgtc cgacaaaaaa caaggtatgt gtgtgccttg ggatgctttt      60
ctgggcttac cccatctgtg tcttcataga ttctctgtcc tgccagccat gtctttggtc     120
cacaggagcc acttcccact tcaactctcc cacaacctcc ccactgttta ctctcttcat     180
gccctgtgct cttgccccaa atcccttcac ccaattggga aaactggatg atagataagt     240
agtttcttat ttacatgcat ttctctggaa attaaagttg ctttccagct agtatttcct     300
cacgtcggaa gcatgtgtaa aataacacat ggaaactatt tccacctggc acataagaaa     360
aaaagggtct gcctatattg taactgactt ctacactttg catgttttag tctgacccac     420
aatttttttt tttggatagt tgaagtaaaa aacgtggtta caagatgact aaagtttggc     480
ctacaatttc ctgtttggac aacaggaaga attgtgcagt gttttgcaac aggactaatt     540
ctagattctc actgccctta aagataacta gagggaaagg gtcttctctt tctttttcat     600
ttattaaaga tacttacagg ttcttcagaa gaagtgatgg gtccttttagg taatgaaata     660
ggtgttgatg gtgttatggg tgatgatgta actggtggcg gctgtataaa gtcttcatcc     720
ttaaacatca gaactgagag ttgggttact gatttaaaag aaaatgtgta ttaatctaca     780
gtccactacc ttgactacca ggaacttgtc acaactacct catatcctgg cacaggattc     840
aaaaggcaaa atctggaacc taattacgtg tagccaaata ttaagcttcc tcttagatca     900
aacagtacaa taaatattcc ttattaagga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa     960
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa    1020
aaaaaaaaaa aaaaaaaagg gcggccgc                                       1048


<210> 39
<211> 1430
<212> DNA
<213> Homo sapiens

<400> 39
cggcacgagg agcagctgag tcccttccct gtctttcact cttctggcat cggtggtttt      60
acttcttcga ttgaaccctg cttcctcgac cccccctgga ggccgccttc ttcaggcgcc     120
tcccttctct ccacgagctc gctctgacag ctgaggaact ggcaagatcc tgctacccag     180
agggtgaatg ggtatctttc ccggaataat cctaattttt ctaagggtga agtttgcaac     240
ggcggccgtg attgtaagcg gacaccagaa aagtaccact gtaagtcatg agatgtctgg     300
tctgaattgg aaaccctttg tatatggcgg ccttgcctct atcgtggctg agtttgggac     360
tttccctgtg gaccttacca aaacacgact tcaggttcaa ggccaaagca ttgatgcccg     420
tttcaaagag ataaaatata gagggatgtt ccatgcgctg tttcgcatct gtaaagagga     480
aggtgtattg gctctctatt caggaattgc tcctgcgttg ctaagacaag catcatatgg     540
caccattaaa attgggattt accaaagctt gaagcgctta ttcgtagaac gtttagaaga     600
tgaaactctt ttaattaata tgatctgtgg ggtagtgtca ggagtgatat cttccactat     660
agccaatccc accgatgttc taaagattcg aatgcaggct caaggaagct tgttccaagg     720
gagcatgatt ggaagcttta tcgatatata ccaacaagaa ggcaccaggg gtctgtggag     780
ggtaagtact cttttcctgc tattatccta cactctcagt tcctacaatt tgcagagaat     840
ttttttttat ataaagacat aaaatcgtga attataatcc aaaaactaag gtaagaaact     900
cctcatctcc cttgaaaggc ccaaaactta tcattggcct tttatttctg cataatgttt     960
ggggattata taggtgggga aagttattac attatttgag atggctgttt cgatcatatt    1020
cacagtgaat gtagttgttc agtgtatttt tttgcaagtt ctgtactaac acgatgatgt    1080
atgtctttgt agtgcttatg ttcaaaagct gttaccggct gtgtgctgtg gctcatgcct    1140
gtagtcccag cactttggga ggccaacgcg ggtggatcac ttgaggtcag aagttcaaga    1200
ccagcctggc caacctggtg aaaccccatc tcaactagaa atacaaaaat tagccaggca    1260
tggtggtgca tggctgtggt cacagctact caggaggctg aggcgggaga attgtttgag    1320
ccctggaggt ggaggttgca gtgagccaag atcatgccac tgcactccag cctgggtgac    1380
ggggcgagac tctgtctcaa aaaaaaaaaa aaaaaaaaaa aaaactcgag               1430


<210> 40
<211> 2103
```

<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (2101)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2102)
<223> n equals a,t,g, or c

<400> 40
ttcctcgtag cgagcctagt ggcgggtgtt tgcattgaaa cgtgagcgcg acccgacctt 60
aaagagtggg gagcaaaggg aggacagagc cctttaaaac gaggcgggtg gtgcctgccc 120
ctttaagggc ggggcgtccg gacgactgta tctgagcccc agactgcccc gagtttctgt 180
cgcaggctgc gaggaaaggc ccctaggctg ggtctgggtg cttggcggcg gcggcttcct 240
ccccgctcgt cctccccggg cccagaggca cctcggcttc agtcatgctg agcagagtat 300
ggaagcacct gactacgaat gctatccgtg cgagaacagc tattccacga gaggatccgc 360
gagtgtatta tatcaacact tctgtttgca acactgtaca tcctctgcca catcttcctg 420
acccgcttca agaagcctgc tgagttcacc acagggtgtc ctgggccggg tctmtgagac 480
agtggtgatg ttgatgctcc tcactctgct ggtgctaggt atggtgtggg tggcatcagc 540
cattgtggac aagaacaagg ccaacagaga gtcactctat gactttggg agtactatct 600
cccctacctc tactcatgca tctccttcct tggggttctg ctgctcctgg ctgctggaag 660
acctggagga gcagctgtac tgctcagcct ctgaggaggc agccctgacc cgcaggatct 720
gtaatcctac ttcctgctgg ctgcctttag acatggagct gctacacaga caggtcctgg 780
ctctgcagac acagagggtc ctgctgggta tgtggcttcg tagggcttgg gatacctggg 840
tttccccaag gagagtagcc cctggttcca ggtgcttgct gacagcctcc catccctgca 900
cagagaagag gcggaaggct tcagcctgkc aacggaacct gggctacccc ctggctatgc 960
tgtgcttgct ggtgctgacg ggcctgtctg tgctcattgt ggccatccac atcctggagc 1020
tgctcatcga tgaggctgcc atgccccgag gcatgcaggg tacctcctta ggccaggtct 1080
ccttctccaa gctgggctcc tttggtgccg tcattcaggt tgtactcatc ttttacctaa 1140
tggtgtcctc agttgtgggc ttctatagct ctccactctt ccggagcctg cggcccagat 1200
ggcacgacac tgccatgacg cagataattg ggaactgtgt ctgtctcctg gtcctaagct 1260
cagcacttcc tgtcttctct cgaaccctgg ggctcactcg ctttgacctg ctgggtgact 1320
ttggacgctt caactggctg ggcaatttct acattgtgtt cctctacaac gcagcctttg 1380
caggcctcac cacactctgt ctggtgaaga ccttcactgc agctgtgcgg gcagagctga 1440
tccgggcctt tgggctggac agactgccgc tgcccgtctc cggtttcccc caggcatcta 1500
ggaagaccca gcaccagtga cctccagctg gggtgggaa ggaaaaaact ggacactgcc 1560
atctgctgcc taggcctgga gggaagccca aggctacttg gacctcagga cctggaatct 1620
gagagggtgg gtggcagagg ggagcagagc catctgcact attgcataat ctgagccaga 1680
gtttgggacc aggacctcct gcttttccat acttaactgt ggcctcagca tggggtaggg 1740
ctgggtgact gggtctagcc cctgatccca aatctgttta cacatcaatc tgcctcactg 1800
ctgttctggg ccatccccat agccatgttt acatgatttg atgtgcaata gggtggggta 1860
ggggcaggga aaggactggg ccagggcagc ctcgggagat agattgtctc ccttgcctct 1920
ggcccagcag agcctaagca ctgtgctatc ctggaggggc tttggaccac ctgaaagacc 1980
aaggggatag ggaggaggag gcttcagcca tcagcaataa agttgatccc agggtttgct 2040
ttgttttttt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2100
nna 2103

<210> 41
<211> 2349
<212> DNA
<213> Homo sapiens

<400> 41
tcgacctacg cgtccgtcta tttctgtgtc tgtatgtatg ggatgtgtct gattgtgtgt 60

```
ctgtggtgta tttctgtgtc tgtatgtatg gggtgtgtgt gattgtgtgt gtgtctggtg    120
tatctctgta tgtatggggt gtgtctgtgt gtgattgtgt gtgtgtctgg tgtatctctg    180
tgtctgtatg tatggggtgt gtctgtgtgt gattgtgtgt ctgtgtttat gtgtgtgtgt    240
ctttgtgtga tttttgtgt atatggcaaa cccagaacag aacattatca ctcacctcac     300
ctggcaaaac aaaaagcttt cagagagatg tgtggccgtc atgatgtctc agctgcaggc    360
atttttcaaa gttatgtttg atgcagctgg cacctttctt ctcggggaca aatgtgatct    420
ttgatcattg agttgagaat gagtttactc aataatttta aaatgcctcg gtgtgagagg    480
atgggctgct agtaaacatt tgtggcaaat atgcgttgcc ttttcctcct tcaagtgcat    540
ggggcaggct gcttctctgc acgtccatct gtgggtcagt ctgtcctgcc acctcccttg    600
ccccagggct tagtgccctg tgtggatcac ggctgcccca gggatgctgg ggaaggattc    660
agcccaacaa atagattcgt tgacgtcctc tcaacgaatg tgtgctttta aaaatgtctt    720
taattttgca ctccatttca tacaacaggt gcacatttaa aacatttatt tttaaacagc    780
tctgtcttct cagcactgca gactatttct cgctcacttg acaggcagac gttgggacta    840
tgttcttttc ctgccaagaa tccatcagcc ccccaatgcc tgcacctcga gtccagactc    900
cttagcgttg cgttgggacg taattccccg ttagcatccc cagccccttc tccccctgtg    960
agccagcctg ggttcttttc tttttccttt cttccctgtt ttccttcttt ctttttttggg   1020
tttgtaataa gtaatataca gtcttgtggt taagaaatca aaataataaa gaagatacgg   1080
cttgaggatt cttgctctgc actggtcctt ccgccaggac ctggtgcgtc ccccaagagg   1140
gccttgccat gtgcgagctg agacacatgt tcacactttc ctcctttttt gtacaaaagg   1200
tagcacatgg taaatagcgt ctgcacgctt ctcccctcgc tctgtcttcg ggactactcc   1260
acatccatga agaagcagca tccttattct cttgcacagt gggcagtggc tacactgtat   1320
tcactcgtct ctgctgatgg gcactattgt agtggtgcaa ttagtaacct agtatacatg   1380
cccttcagcg tgtgtactgg tgtatggatc tcacattccc agaggctgag tgaaagaata   1440
aaggcttttt gacagtattc ctcaggtact cacacactcg ctctgtgagc cacgtgatca   1500
tgggagcggc tccctgcaga ggtgtctgat gggagaggct gatgtccttg tctgatggtt   1560
gctccaacct gagaatggtg agctgctctc ccaatgcaga ctttcatcac ttgcatctca   1620
tgcgtgagat tgaactgctt ctcatttatg tttttatctt tgtttgccca tattttagct   1680
gggttgctaa tcttttaatg ttttctaggc gcttttcata aattagggag tttagctgta   1740
gtgatgtgag ttgaaagtat tttttcaaat cgtcattgtc ttgactttcc tttttttttt   1800
tcttttgcca cttaaaatat gtagttgaat ctcagtattt gggggcttct ggattttgag   1860
tcgtagttga aaaggtcttc ctattctgag gttatacagg aattcaccca tttttttcct   1920
aatattttat ttccatttaa acttttgacc cacttggatt gattttgttg tatggtgtca   1980
agtatgggtc caagtttgct tttctgacct ggggatccta acatcgttca tcaaaatctc   2040
catgttggcc gggcgtggtg gctcaagcct gtaatcccag cactttggga ggctgaggtc   2100
ggtggatcac aaggtcagga gatcgagacc accctggcta acacggtgaa atcctatctc   2160
tactaaaaat acaacaaatt agccgggtgt ggtggcaggc acctgtagtc ccagctactc   2220
aggaggctga ggcaggagaa tcgcttgaac ccgggaagcg gaggttgcag tgagctgaga   2280
ttgcgccact gcactccagc ttgggtgaca gagcaagact ctgtctcaca aaaaaaaaaa   2340
aaaaagggc                                                          2349
```

<210> 42
<211> 1559
<212> DNA
<213> Homo sapiens

<400> 42

```
attcatgcca aaacataggc tttcagtgcc tattacatat ggctttcagc tctctctact     60
gagggatgta ggagtttatt tctgaggtct gagcctcttt tcctttactt cctttactct    120
ttcctaagcc ttctttataa aaactatgca tgttctattg ttttcctttt tgattccctt    180
tcttttatta tccccagtag gagtgacttg taattctcat atgttagaaa ggcaggtctc    240
ctggttgaag aaaagatcca cccaagcaag tcagcagttt aataaatttt tgaggggat     300
ctcaaatgtg ggaaggattg ttatataaga caaccaaatg atgacatgag acaataaatg    360
ctataggaat tatggaggaa taattagcta tttattttct tggttaggga agagatatta    420
ttagttgtag aagtaattac taacttctac attttttatt gtggaaatca aaaatatata    480
tatgaaaata aaatgttata attgacttca gtgtcccata aaccagcttc caacaattac    540
caaattgtga ccaatccttt acacacatgc acaggtgtcc ctccagtatc tgtggggcat    600
tggttctagg accacttatg gataccaaca tctatggatg ctcaagtccc tgatataaaa    660
tggtggacta tatgcatata acccgtgtac gtcccgtatt aaccaaatcc tccctagatc    720
```

acttacaaca cgtaacacaa tctaaatgcc acgttaacaa ccgtcatact gtattaagcg 780
aataaccccg ccaaaaatgt acttctctca gtccagacgc cttttttttt tgtgtgtgga 840
atatcccagc ccccaagtcc ccttcaaccc cctggcacat aggaggctga ctgcgtgtgt 900
gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgcatac agacacacat atctctgaaa 960
tgtaaatatt ctctctttaa aaaaattatt atcacagcta aacaaattac cagtaattct 1020
cttatcctca tatacccggt gttcagattt tctagattgg ctcctaattt ttttacagat 1080
tatttgaatc tgattcaatt catgtactgt aatgtttgat aacttaagta ccctttatag 1140
gttcccttta ccacttcttt attaaattcc ttgtaatttg ttgtactaaa tggattgtct 1200
tcctagaatt tcctgtagtc tgaattatgt ggtaattgtt cacatgttcc agtgtcctct 1260
tatttcctgt gagttggtag ttagatctag aagcttgatt aaattcagat tttctctctt 1320
tagatcatca actttagatc atcaacttgg atcatttgtt tcattttgct tttgatatgt 1380
tgttttttag aattacctct taaaatttg atttaatttt ataatcatgt aaaatgttta 1440
taaatttcca aattcagatc agcaaaacac aataaaatct attcagagaa ggcaaaaaaa 1500
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 1559

<210> 43
<211> 1766
<212> DNA
<213> Homo sapiens

<400> 43
cggcacgagg agcactgaag tattcactac atgaagtata ttttgcactg tggacacaaa 60
ttagaaaaat tgcaagtagt ggtatattgt aattggcatg cactatatga gcagagtcaa 120
tgtgtctcct tgtagaatat tctctgatga tactcactat tatcccctct ctgctaagct 180
ttgttctgtg tctgaagggc ataaagcatg gaaactacat ttttcagact ccattaccag 240
aaggatatgg ttggatttca gcaatgagtg ggctttgcat aaaatttgga agacgaaaga 300
gaagaaaaac ctggctgctg caggttggaa cactggcaac aatagatacg gagtttgcaa 360
gaagctgcta agcttcctca ggaaaattat ttgtttcaat atttctggca tatgggatca 420
tcaattattg ttttcagtgg ttctggctga aaattggttc aattcttcta tctgagaatt 480
gttcatttct gtgcttcagg aaactaagac catcactggc agtttttgtt gagggatcct 540
tgtgcattca tttttcctta aaacagcctt cctaactttt actcccccag cctctatggt 600
tgtgtaagtc tttaattctt agagttacat ttctcttact cagtatatcc tagtgcggct 660
tctgttttcc agacccaacc ctgactgata tagtctccat gtgtttcaga tggtgggata 720
gtttggatat ttgtccctgc ccaaatttca tgttgaactc taatccccag tgctgtaggt 780
ggggcccaat gggaggtgtt cggatcatgg gggcagatcc ctcacggctt ggtgctgtct 840
tcgtgatagt gagttcttgt aagatctggt cattttaaag tgtttggcac ttgtaccatt 900
tcactgtgtc ttgctcctgc tttcaccatg tgaagtgcct gctccagctt cacttttcac 960
catgattgta aacttcctga ggcctcccta gaagccaagc agatgccatc accagggttc 1020
ctgtaaagca tgcagaactg ttagccaatt atacctcttt tctttacaaa ttaaaaacct 1080
ctttctttta caaaatggaa agaataaagg tatttcttta tagcaatgca agaacggcct 1140
aatacagatg gctctgccat tagtgagaaa attgagacgc tttctctaga tggcaaaaaa 1200
gttgtaaaaa taaaaggaaa ttattaatat accgtctatt gtgatcattt actaagttaa 1260
gcatattatt aagaagacaa gcataagttt aacacaattt ggcaatgaat aaaattgaag 1320
gagagagagc atatgttggc tttgctctgt gaaactcaaa tgaaatggtc acctgttcta 1380
gcagctcatg aaaaattctg cattgtttat tatgtgtcag gatcaacctt aaattcagtt 1440
ataaaaagtt tgatgattac aaaaaaaagg gaagcactaa gtaatatagg tacagagagg 1500
gaagagtgtc aaatagaatt ttcaatctgt gtataaggat acttaagcat ttttaagga 1560
aagcagaaag aagcatgaga aagtctacaa tgacatctat gtcaatataa caagctggat 1620
atttagagaa gaaactcttg attaaatact ttttatgata tgaacacaca catataatat 1680
gacatgactg tgttcatgga acataaagaa attcctctga ccaaagagaa ctggaaaaaa 1740
aaaaaaaaaa actcgagggg gggccc 1766

<210> 44
<211> 2572
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (2527)
<223> n equals a,t,g, or c

<400> 44
aattcggcac gagtctggac cttcttagmt tgcttgatat caggttgttt ttgtagccat 60
tttgcttcac agtcacctgg aatgccggga gcccctgctc atcccgatcc tctccttgta 120
catgggcgca cttgtgcgct gcaccaccct gtgcctgggc tactacaaga acattcacga 180
catcatccct gacagaagtg gcccggagct gggggagat gcaacaataa gaaagatgct 240
gagcttctgg tggcctttgg ctctaattct ggccacacag agaatcagtc ggcctattgt 300
caacctcttt gtttcccggg accttggtgg cagttctgca gccacagagg cagtggcgat 360
tttgacagcc acataccctg tggtcacatg ccatacggct ggttgacgga aatccgtgct 420
gtgtatcctg ctttcgacaa gaataacccc agcaacaaac tggtgagcac gagcaacaca 480
gtcacggcag cccacatcaa gaagttcacc ttcgtctgca tggctctgtc actcacgctc 540
tgtttcgtga tgttttggac acccaacgtg tctgagaaaa tcttgataga catcatcgga 600
gtggactttg cctttgcaga actctgtgtt gttcctttgc ggatcttctc cttcttccca 660
gttccagtca cagtgagggc gcatctcacc gggtggctga tgacactgaa gaaaaccttc 720
gtccttgccc ccagctctgt gctgcggatc atcgtcctca tcgccagcct cgtggtccta 780
ccctacctgg gggtgcacgg tgcgaccctg ggcgtgggct ccctcctggc gggctttgtg 840
ggagaatcca ccatggtcgc catcgctgcg tgctatgtct accggaagca gaaaaagaag 900
atggagaatg agtcggccac ggagggggaa gactctgcca tgacagacat gcctccgaca 960
gaggaggtga cagacatcgt ggaaatgaga gaggagaatg aataaggcac gggacgccat 1020
gggcactgca gggacagtca gtcaggatga cacttcggca tcatctcttc cctctcccat 1080
cgtattttgt tccctttttt ttgtttgtt ttggtaatga aagaggcctt gatttaaagg 1140
tttcgtgtca attctctagc atactgggta tgctcacact gacgggggga cctagtgaat 1200
ggtctttact gttgctatgt aaaaacaaac gaaacaactg acttcatacc cctgcctcac 1260
gaaaacccaa aagacacagc tgcctcacgg ttgacgttgt gtcctcctcc cctggacaat 1320
ctcctcttgg aaccaaagga ctgcagctgt gccatcgcgc ctcggtcacc ctgcacagca 1380
ggccacagac tctcctgtcc cccttcatcg ctcttaagaa tcaacaggtt aaaactcggc 1440
ttcctttgat ttgcttccca gtcacatggc cgtacaaaga gatggagccc cggtggcctc 1500
ttaaatttcc cttccgccac ggagttcgaa accatctact ccacacatgc aggaggcggg 1560
tggcacgctg cagcccggag tccccgttca cactgaggaa cggagacctg tgaccacagc 1620
aggctgacag atggacagaa tctcccgtag aaaggtttgg tttgaaatgc cccgggggca 1680
gcaaactgac atggttgaat gatagcattt cactctgcgt tctcctagat ctgagcaagc 1740
tgtcagttct cacccccacc gtgtatatac atgagctaac tttttaaat tgtcacaaaa 1800
gcgcatctcc agattccaga ccctgccgca tgacttttcc tgaaggcttg cttttccctc 1860
gcctttcctg aaggtcgcat tagagcgagt cacatggagc atcctaactt tgcattttag 1920
tttttacagt gaactgaagc tttaagtctc atccagcatt ctaatgccag gttgctgtag 1980
ggtaactttt gaagtagata tattacctgg ttctgctatc cttagtcata actctgcggt 2040
acaggtaatt gagaatgtac tacggtactt ccctcccaca ccatacgata aagcaagaca 2100
ttttataacg ataccagagt cactatgtgg tcctccctga aataacgcat tcgaaatcca 2160
tgcagtgcag tatatttttc taagttttgg aaagcaggtt ttttccttta aaaaaattat 2220
agacacggtt cactaaattg atttagtcag aattcctaga ctgaaagaac ctaaacaaaa 2280
aaatatttta aagatataaa tatatgctgt atatgttatg taatttattt taggctataa 2340
tacatttcct attttcgcat tttcaataaa atgtctctaa tacaatacgg tgattgcttg 2400
tgtgctcaac atacctgcag ttgaaacgta ttgtatcaat gaacattgta ccttattggc 2460
agcagtttta taaagtccgt catttgcatt tgaatgtaag gctcagtaaa tgacagaact 2520
attttncat tatgggtaac tggggaata aatggggtca ctgggagtag gg 2572

<210> 45
<211> 526
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (66)

<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (106)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (484)
<223> n equals a,t,g, or c

<400> 45
ctctgacagc ttcctctttg gccaagccct gcctctgtac agcctcgagt ggacagccag 60
aggtcnagac tggagcccag agcccaagat ggagccccag ctgggncctg aggctgccgc 120
cctccgccct ggctggctgg ccctgctgct gtgggtctca gccctgagct gttctttctc 180
cttgccagct tcttcccttt cttctctggt gccccaagtc agaaccagct acaattttgg 240
aaggactttc ctcggtcttg ataaatgcaa tgcctgcatc gggacatcta tttgcaagaa 300
gttctttaaa gaagaaataa gatctgacaa ctggctggct tcccaccttg ggactgcctc 360
ccgattccct ttgstttctt atccttgcaa attactccar atgattycca aaatctggsg 420
sccttgtgga ratcttttaa ctggtcagca awtwtcaaac gaaatctcca aacaggaaat 480
cttntgcctc ctgcatccac ccccaaagaa cttgcacatt gacgtt 526

<210> 46
<211> 1032
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (974)
<223> n equals a,t,g, or c

<400> 46
gtaaaattgt caaacattta tttttaaaaa taaaatgtgg tgggcggtta tgggtggagt 60
tattgggtcc tggctgtcgc cactgagcat tgctgaatgt tgtcatgact tgtggacttc 120
tcagagctgc gagcatgcgg gtgctctttg tggagatttg ctctgtgcct gtaggaaggt 180
gggtgtgtgg tgtgcattgc agcaacattg gtggaacaga tgtgtgtgcc cccatgctgt 240
catcagggtt cattgcacag gagcctcata cacactacag aaaatatgct cttgtaaccc 300
caagttcatg cggaggcatc cacacagatg gcagcagatc aggaaatgct ctcagccagt 360
cctcaggggc agtagggcag ccttcatctg ggtgcgcttg gcagccctga actttatctc 420
ttcttttcgt tgtatttctt taatatctta ttcagcattt tagtttcttt agttggatga 480
gttgttcagt gtctttgtac tgtacagttc tcctgtgctg ttggaatgga cgtcatgggc 540
tatgttactc ttttgaaata caaatttctc tttagaagtt ttggaaaatc tgttagagga 600
ggagttctga gaatatgaga agacttcttc ccacatagtt gtgcctgccc gatgtatttt 660
tccaaaaaaa ttgaaggtga acctgttgga agctcagttc tgagtttaat tgactacttt 720
gcagagacac aacactctct ttstagcatg tcccttggaa gaaaataggc tggtgcttgg 780
gtggtgatca gaactggcag ttattctagg cctaaaacag tttggcaata aaataagaaa 840
aaggggccac atgtggtggc tcatgcttta atccccacac tttgagaggc tgaggcaggg 900
ggattgcgtg aagccagcct gggcaacata aaatttaaaa attagccaga catggtggca 960
tgtgcctgtg ggtncagcaa cctgggtggc taagaccgaa ggatcacttg agcccaggaa 1020
gtcaaggctg ta 1032

<210> 47
<211> 2680
<212> DNA
<213> Homo sapiens

<400> 47
ggcacgagtc ttacagcaag tacttaacaa acttagattt ccataatcag atttatctca 60
aaccgcaaaa aaaagctgat tttattatgt taaactgata ggagattttt atgagagatg 120
aaagtaagcg atttaactt tttaatttt ttaattttg ctctgtttct cacacttgag 180
gcttttctga aattcaccaa aagagttttg gcagttgtgg ggaatttacc agaacccccc 240
attattaaaa caattggttt cttatattaa aatcatcaca caggttttgt gtacacagac 300
atttatgtta agccactgga tagaactaaa ctgtgtgtag gaacctgttt tctctaagaa 360
aggactcctt tgagttctgt aggatatgtg cttaaaggtt ttctgtgtca agctatttta 420
tgaaataaaa ttttacaaac aatgaagctt catttcaca cgttgtattt gtttaatgca 480
gacttggcct atacgagttt ttgaaattaa gggtttttc cgtaaaacta gcttaggagt 540
ttaatgagtc actgtgtctc tcacctctgt aggatgagca cagagatcac atttgagaag 600
caggtgtggg tgtttctgc tggtcacgtc tcctctgcct ctcctctggc tcagcagtta 660
cttttcctca gtcatggggg ctgcattcag ctgcgatgcc agcattaggg ccaagctctc 720
ccgcttctgt gacgttttat tacacgtact ctttatcagt agtagctgcc attccctgag 780
tgttccttcc accgtgcact gagaagggct gaggatttcc gaacatcaac ctcctctaac 840
cctctgtatg ggaattagat ttttatcatc ctgactgttg ggctttcta gagctcaggc 900
aacttgcccc tgggcgggat ggagcctgcc tgggggagt gtgaatgagg cttctgttgt 960
ctgtggcttg gctctctgtg gttggaaact tcagaagcag tagattccag gtgcaacatt 1020
tggtgcccgg acaagttgta aaacctgacc ttggggaggg ccttcactgg cagccagtgt 1080
ccacccgtga gcccggtgag cacagacgtt agagccaggg ccggcgggct cagaggttgg 1140
agccggggac cagtgggctc agaggtcgga gccggggacc agtgggctca gaggtcggag 1200
ccatgtccct gccgtgaagc tctgagggtt ggtggtgaca tcggggcgat tgtggcatcg 1260
cgattgtggt gtcttggctg cctttggccg gcgctgccac tgccctggtt tcatgacgta 1320
ggcaccacat ggtcctgtgt tgtctcactt acggctccac ttctggcttt tttctacttg 1380
ctcacccttg agataaactt ctatttcatt ttcatttcgg tttatatgtg ggtttcttc 1440
caggtctgat gttaagccta taatattgca atgtgatgtt ttgaagttaa ggtgtaatag 1500
agccagtgaa ccaagggttc acaccccagt gaaatacaaa tattcagaat tgagccactg 1560
tgttgccata ctgattatgt aatgtgtgat taacaagtat aatgtgtcac tttcaacatc 1620
agtttcatgc caaagttgca ttttattaga ttatttggga gttcactttg ggcccaaagg 1680
ctcgtgtcta cataataata acttatgatt tttcttttg tctttgtttt atttttgtt 1740
ttgtgttttt tgctttctag accatgccag agtaatctca gctttcttta gttactggat 1800
cacacatatc cttcctgaga agagcagtga ctaaaatgga atatctcttt aagaacagct 1860
cctctttaac aaaaaaactt aaaagacaaa tgtgagatgg gcttagagtt agttctctgg 1920
gaacttgaaa gacatttatg ccatattatt tattcacgtg tttgttcctg gtgggcaaga 1980
tgccatctga ggcttcagat gagaaattgg ggtaaaatgg aaatttttca cttatttgca 2040
attatatata tcttgaatta ctacataaaa cttgattctg tttctctact tattgtaaaa 2100
attgaaaatg gacattctgt taagttaaat gtatagtttg aagctcatat atttttatga 2160
agttttgaat caccttgtat ctgaaagtct ctgctttaag aatgctttct gggtattaaa 2220
atgttctagt ttaagtagtt tgaatatagt tgagtttttt ttctcttctc tactttgtga 2280
atcatatcag gtacctgttt ttcctgtttc gatttctttt tctgtgatag aagcagtcgt 2340
cagttcttgg tattactaag tgttaaaagc atcagtcagg ccgggtgcgg tggctcacgc 2400
ctgtaatcct ggcactttgg gagaccgagg caggcggatc acaacgtcag gagatcgaga 2460
gcatcctggc taacacggtg aaaccccatc tctattaaaa atacaaaaaa ttagccgggc 2520
gtggtggcgg gcgcctgtag tcccagctac tctggaggct gaggcaagag aatggcatga 2580
acctgggagg cagagcttgc agtgagctga gatcgcacca ctgcactgca gcctgggcga 2640
cagagcgaga ctccagctca aaataaaaaa aaaaaaaaaa 2680

<210> 48
<211> 1730
<212> DNA
<213> Homo sapiens

<400> 48
cccacgcgtc cgggggcctg tggcggagtc caagaggaac taggccgcct tcgggatggt 60
gtggagcgct gctcctgccc cctgttgcct cctcggggtc ctggggctgg tccaggtgtt 120
gggggcccaa gccgtgggcc cctggacggc ttcagcgtgt ttgggggcag ctcaggctca 180
gccctgcagg ccctgcaagg agagctctct gaggttattc tcagcttcag ctccctcaat 240

```
gactcactga atgagctcca gaccactgtg gagggccagg gcgctgatct ggctgacctg    300
ggggcaacca aggaccgtat catttctgag attaacaggc tgcagcagga ggccacagag    360
catgctacag agagtgaaga gcgcttccga ggcctagagg agggacaagc acagcccggc    420
cagtgcccca gcttagaggg gcgattgggc cgtcttgagg gtgtctgtga acggttggac    480
actgtggctg ggggactgca gggcctgcgc gagggccttt ccagacacgt ggctgggctc    540
tgggctgggc tccgggaaac caacaccacc agccagatgc aggcagccct gctggagaag    600
ctggtcgggg gacaggcggg cctgggcagg cggctgggtg cccttaacag ctccctgcag    660
ctcctggagg accgtctgca ccagctcagc ctgaaggacc tcactgggcc tgcaggagag    720
gctgggcccc cagggcctcc tgggctgcag ggacccccag gccctgctgg acctccagga    780
tcaccaggca aggacgggca agagggcccc atcgggccac caggtcctca aggtgaacag    840
ggagtggagg gggcaccagc agcccctgtg ccccaagtgg cattttcagc tgctctgagt    900
ttgccccggt ctgaaccagg cacggttccc ttcgacagag tcctgctcaa tgatggaggc    960
tattatgatc cagagacagg cgtgttcaca gtcgccactg gctggacgct acttgctgag   1020
cgcggtgctg actgggcacc ggcacgagaa agtggaggcc gtgctgtggc cgctccaacc   1080
agggcgtggc cggcgtagac tccgggtggc tacgagcctg agggcctgga gaataagccg   1140
gtggccgaga gccagcccag cccgggcacc ctgggcgtct tcagcctcat cctgccgctg   1200
caggccgggg acacggtctg cgtcgacctg gtcatggggc agctggcgca ctcggaggag   1260
ccgctcacca tcttcagcgg ggccctgctc tatggggacc cagagcttga acacgcgtag   1320
actggggtcc cgcccgacgt gtctacgtcg gctgaagaga cagcgggggc ggcgggctcc   1380
tggggtctcg cctgagacgg ggcacctagc cctgggcgag cgccgcaccc gggcccgcag   1440
cggcaccgcg cccagagcgg cctctcccca cgcccggggc gcgccggctc agggaggctc   1500
ggggccgccc atgcagactt ttggcctggc gcgatccccc aagaacccct ccagggccgg   1560
cctgcggagg agccgatcct cgcaccctcc gctccctcca ctggccctcc aggtcgattc   1620
cctgggctcc aggctccccc gcgcgggcgc cgcccaccgc catactaaac gatcgaggaa   1680
taaagacact tggtttttct aaaaaaaaaa aaaaaaaaaa aaggggccgg              1730
```

<210> 49
<211> 1275
<212> DNA
<213> Homo sapiens

<400> 49

```
ggcacgagcc agctcctctt ccaagatgtc ctccttaaac tttgccagtg aaatggagaa     60
gtactgtttg gggaataata tgctttcaag gttttgctta tttttgataa tgctcctgca    120
catccttctt tttttggtta tcttcattca acgtcacact gttgtctctc tctccaagca    180
ccaccccttt gttccaacta atggatcaaa gagttatagc agcttttaag gcctgattac    240
tacctgagga ggacctttgc ctaggctatt gctgcaaata agaaagatcc tttttaaaca    300
cactggtgca attctggaag gattacaaca tctatggcag catcaacaac cttggttaag    360
ttgggggtga agtcaccaag gagtgtgtaa atgctatctc ggaagagata ttgaagacat    420
ttgtccatga cttcaaaaca ttgctaagga tgaggatgtt gcaaaaaaaa aatattcaca    480
aggctttagt tgaaatggca aacaacttta agctggatgt ggaggaggat gatattgagg    540
aggtcacaga tgtggtcact gaggaattga ctaatgacga gttactggaa ccagaacaga    600
aatgcatagc aagaggaaag gaaactacag gagaaaaaaa gaaaagcccc caaggatatt    660
cacagtgatg ggtttaggca gaagcttttg cagacctcaa caaactcctt aaaacgtttg    720
aaaatgttga ctccaacatg aaatgatttt cattagtaga gaggaatgtt catcgtgcat    780
tatctattta caagcaaatc tatgatgaat aaaagaaaca aaccaaacaa accaccatga    840
acacatttct gaaaagagtg acatctcaag aagagcctca ggcaggtcct tcaggaggta    900
tcccagaaga agaaggcatt gttatcacag gacatgacag ctccctgggt gttattgccc    960
ttaaaggcct tccagtagga taaggtgtgg agatggaagg tgccgatttt tatgatcctg   1020
accctacata ggtctaggct aatgggtaat ggtgtgtttg tgtcttagtt tttaaagaaa   1080
aatgtaaaaa gtaaaaaata aaaataacat taatataggt aaaagtttat agaataagga   1140
tataaggaga gaaaaaaatt atcttcctct gtatttgtgt ttcaagctgt gttactacaa   1200
aagaataaaa aagttaagag aaattgtttt taaagtaaaa tagttacaat aatctaaaaa   1260
aaaaaaaaaa aaaaa                                                    1275
```

<210> 50
<211> 1762

<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (447)
<223> n equals a,t,g, or c

<400> 50
ggtggcctag agatgctgct gccgcggttg cagttgtcgc gcacgcctct gcccgccagc 60
ccgctccacc gccgtagcgc ccgagtgtcg gggggcgcac ccgagtcggg ccatgaggcc 120
gggaaccgcg ctacaggccg tgctgctggc cgtgctgctg gtggggctgc gggccgcgac 180
gggtcgcctg ctgagtgggc agccagtctg ccggggaggg acacagaggc cttgttataa 240
agtcatttac ttccatgata cttctcgaag actgaacttt gaggaagcca aagaagcctg 300
caggagggat ggaggccagc tagtcagcat cgagtctgaa gatgaacaga aactgataga 360
aaakttcatt gaaaacctct tgccatctga tggtgacttc tggattgggc tcaggaggcg 420
tgaggagaaa caaagcaata gcacagnctg ccaggacctt tatgcttgga ctgatggcag 480
catatcacaa tttaggaact ggtatgtgga tgagccgtcc tgcggcagcg aggtctgcgt 540
ggtcatgtac catcagccat cggcacccgc tggcatcgga ggcccctaca tgttccagtg 600
gaatgatgac cggtgcaaca tgaagaacaa tttcatttgc aaatattctg atgagaaacc 660
agcagttcct tctagagaag ctgaaggtga ggaaacagag ctgacaacac ctgtacttcc 720
agaagaaaca caggaagaag atgccaaaaa aacatttaaa gaaagtagag aagctgcctt 780
gaatctggcc tacatcctaa tccccagcat tccccttctc ctcctccttg tggtcaccac 840
agttgtatgt tgggtttgga tctgtagaaa aagaaaacgg gagcagccag accctagcac 900
aaagaagcaa cacaccatct ggccctctcc tcaccaggga aacagcccgg acctagaggt 960
ctacaatgtc ataagaaaac aaagcgaagc tgacttagct gagacccggc cagacctgaa 1020
gaatatttca ttccgagtgt gttcgggaga agccactccc gatgacatgt cttgtgacta 1080
tgacaacatg gctgtgaacc catcagaaag tgggtttgtg actctggtga gcgtggagag 1140
tggatttgtg accaatgaca tttatgagtt ctccccagac caaatgggga ggagtaagga 1200
gtctggatgg gtggaaaatg aaatatatgg ttattaggac atataaaaaa ctgaaactga 1260
caacaatgga aaagaaatga taagcaaaat cctcttattt tctataagga aaatacacag 1320
aaggtctatg aacaagctta gatcaggtcc tgtggatgag catgtggtcc ccacgacctc 1380
ctgttggacc cccacgtttt ggctgtatcc tttatcccag ccagtcatcc agctcgacct 1440
tatgagaagg taccttgccc aggtctggca catagtagag tctcaataaa tgtcacttgg 1500
ttggttgtat ctaactttta agggacagag ctttacctgg cagtgataaa gatgggctgt 1560
ggagcttgga aaaccacctc tgttttcctt gctctataca gcagcacata ttatcataca 1620
gacagaaaat ccagaatctt ttcaaagccc acatatggta gcacaggytg gcctgtgcat 1680
cggcaattct catatctgtt tttttcaaag aataaaatca aataaagagc aggaaaaaaa 1740
aaaaaaaaaa aaaaaactcg ag 1762

<210> 51
<211> 2059
<212> DNA
<213> Homo sapiens

<400> 51
cggcacgagg tttggtctaa gagtgagcag aactgtgttg ayatgggagc acatttggtt 60
gtgttcaaca cagaagcaga gcagtggaag gaggcatgca tccccagctg ataccttcgg 120
ttattgctgt agttttcatc ttacttctcg gtgtctgttt tattgcaagt tgtttggtga 180
ctcatcacaa cttttcacgc tgtaagagag gcacaggagt gcacaagtta gagcaccatg 240
caaagctcaa atgcatcaaa gagaaatcag aactgaaaag ttgctgaagg gagcacctgg 300
aactgttgtc ctattgactg gagaaccttc cagttccaac tgctattttc ctccttactg 360
acaacaagac gtgggctgag agttgaaagg aactgttcag ggatgggggc ccatctgatg 420
accatcagca cggaagctga gcagaacttt attattcagt ttctggatag acggctttcc 480
tatttcctg gacttagaga tgagaatgcc aaaggtcagt ggcgttgggt gggaccagac 540
gccatttaac ccacgccaga gtattctggc ataagaatga acccgacaac tytcagggag 600
aaaactgtgt tgttctggtc ttataaccaa gataaatggg cctggaatga tgttccttgt 660
aactttgaag caagtaggat ttgtaaaata cctggaacaa cattgaacta gaaactcaga 720

aagtggtcct tgtgatggaa agagaaaaga aaaaccaatt agaataaggc agaatgtacg 780
tgcgtcattg gaacacagaa aacatgctgg ttcatacagc gtttttagtc ataatggtct 840
tttttatttt gtttgattca ttcgagacaa catgtgtgta tgtgtgtgtg tgtgtgtgta 900
gataatgtgg tttttgtatg gtgtttgatg gaaggaataa tctttctttg ctttcttagt 960
agtatttcaa ggtgtttact tttcaattgg tgtgcactga atgcatgtat ggaagaatag 1020
cgtgaataat gcaatctctt tgtcattttt tccccttttct cagactctta gctcttaaaa 1080
ttcaaaagat gggatattct aactggtagt ggtgcatcat ttttaaccca aatattgcaa 1140
gcactttaaa gatttgaaac cacattttta ttgtttgatg tttcattttc agacttttta 1200
atgtcagtca ttacaattac attgcatgag gaaaattttt ccagaacaac agtgtggaat 1260
agttctgaat tatgctgttc tacagatgga aaaaagtcca aatgccttta aaaatttact 1320
tcttactcca cccaacacgt ttttgcaaag caagaagtct ttgtaagaca ccttaaacaa 1380
agtccttcaa ttctacagca gaggaaataa aatcccccag aagccaaagg gctcaccttc 1440
acattgttag ttcatgacag acccaggtgt gcttcattag agataacata cattcccttt 1500
ggtatcacag gaagttactg ggattactc gacctcatta cttagctaac gactggataa 1560
aatttcttaa ttgtttgaag taacattgta ttcgtgtttg cattattaat ttgaatagaa 1620
aataatcaca ttttcaaccc atttatacaa attgttaatg tttctttaga gctgtataac 1680
tatagtttga actagcaagg aagttattgt tttgacaacc agaaattatg cttttctggt 1740
gcatgaaaca ctaattgcaa agggcagtca catccaactt taataaaata tggtggtctt 1800
tcttaaaatt ttcaatttgc taatttttcc tggaaaccta actttcctac tactactttt 1860
aaaagcagta tttattttgt aaattagcta ctgatttttt gggtttgaaa tactggtgtt 1920
tgattgtgtg gtggtggtgg tggtgatgga tgcgtgtagc tgtgttaaaa gctgatactt 1980
ttagctgaaa tggtgctaaa taaatttgac tgtgtttgcc atattcacta aaaaaaaaaa 2040
aaaaaaacta gagggggg 2059

<210> 52
<211> 3282
<212> DNA
<213> Homo sapiens

<400> 52
cccacgcgtc cgacttaaaa gagaagcttt agctgccaaa gattgggaaa gggaaaggac 60
aaaaaagacc cctgggctac acggcgtagg tgcagggttt cctactgctg ttcttttatg 120
ctgggagctg tggctgtaac caactaggaa ataacgtatg cagcagctat ggctgtcaga 180
gagttgtgct tcccaagaca aaggcaagtc ctgtttcttt ttcttttttg gggagtgtcc 240
ttggcaggtt ctgggtttgg acgttattcg gtgactgagg aaacagagaa aggatccttt 300
gtggtcaatc tggcaaagga tctgggacta gcagaggggg agctggctgc aaggggaacc 360
agggtggttt ccgatgataa caaacaatac ctgctcctgg attcacatac cgggaatttg 420
ctcacaaatg agaaactgga ccgagagaag ctgtgtggcc ctaaagagcc ctgtatgctg 480
tatttccaaa ttttaatgga tgatcccttt cagatttacc gggctgagct gagagtcagg 540
gatataaatg atcacgcgcc agtatttcag gacaaagaaa cagtcttaaa aatatcagaa 600
aatacagctg aagggacagc atttagacta gaaagagcac aggatccaga tggaggactt 660
aacggtatcc aaaactacac gatcagcccc aactcttttt tccatattaa tattagtggc 720
ggtgatgaag gcatgatata tccagagcta gtgttggaca aagcactgga tcgggaggag 780
cagggagagc tcagcttaac cctcacagcg ctggatggtg ggtctccatc caggtctggg 840
acctctactg tacgcatcgt tgtcttggac gtcaatgaca atgccccaca gtttgcccag 900
gctctgtatg agacccaggc tccagaaaac agccccattg ggttccttat tgttaaggta 960
tgggcagaag atgtagactc tggagtcaac gcggaagtat cctattcatt ttttgatgcc 1020
tcagaaaata ttcgaacaac ctttcaaatc aatcctttt ctggggaaat ctttctcaga 1080
gaattgcttg attatgagtt agtaaattct tacaaaataa atatacaggc aatggacggt 1140
ggaggccttt ctgcaagatg tagggtttta gtggaagtat tggacaccaa tgacaatccc 1200
cctgaactga tcgtatcatc attttccaac tctgttgctg agaattctcc tgagacgccg 1260
ctggctgttt ttaagattaa tgacagagac tctggagaaa atggaaagat ggtttgctac 1320
attcaagaga atctgccatt cctactaaaa ccttctgtgg agaattttta catcctaatt 1380
acagaaggcg cgctggacag agagatcaga gccgagtaca acatcactat caccgtcact 1440
gacttgggga cacccaggct gaaaaccgag cacaacataa ccgtgctggt ctccgacgtc 1500
aataacaacg cccccgcctt cacccaaacc tcctacaccc tgttcgtccg cgagaacaac 1560
agccccgccc tgcacatcgg cagcgtcagc gccacagaca gagactcggg caccaacgcc 1620
caggtcacct actcgctgct gccgccccaa gacccgcacc tgcccctcgc ctccctggtc 1680

tccatcaacg cggacaacgg ccacctgttc gccctcaggt cgctggacta cgaggccctg 1740
caggctttcg agttccgcgt gggcgccaca gaccgcggct cccccgcgct gaacagcgag 1800
gcgctgggtg cgcgtgctgg tgctggacgc caacgacaac tcgcccttcg tgctgtaccc 1860
gctgcagaac ggctccgcgc cctgcaccga gctggtgccc cgggcggccg agccgggcta 1920
cctggtgacc aaggtggtgg cggtggacgg cgactcgggc cagaacgcct ggctgtcgta 1980
ccagctgctc aaggccacgg agcccgggct gttcggtgtg tgggcgcaca atggggaggt 2040
gcgcaccgcc aggctgctga gcgagcgcga cgcagccaag cacaggctgg tggtgcttgt 2100
caaggacaat ggcgagcctc ctcgctcggc caccgccacg ctgcacgtgc tcctggtgga 2160
cggcttctcc cagccctacc tgcctctccc ggaggcggcc ccggcccagg cccaggccga 2220
cttgctcacc gtctacctgg tggtggcgtt ggcctcggtg tcttcgctct tcctcctctc 2280
ggtgctcctg ttcgtggcgg tgcggctgtg caggaggagc agggcggcct cggtgggtcg 2340
ctgctcggtg cccgagggtc cttttccagg gcatctggtg gacgtgaggg gcgctgagac 2400
cctgtcccag agctaccagt atgaggtgtg tctgacggga ggccccggga ccagtgagtt 2460
caagttcttg aaaccagtta tttcggatat tcaggcacag ggccctggga ggaagggtga 2520
agaaaattcc accttccgaa atagctttgg atttaatatt cagtaaagtc tgtttttagt 2580
ttcatatact tttggtgtgt tacatagcca tgtttctatt agtttacttt taaatctcaa 2640
atttaagtta ttatgcaact tcaagcatta ttttcaagta gtatacccct gtggttttac 2700
aatgtttcat catttttttg cattaataac aactgggttt aatttaatga gtattttttt 2760
ctaaatgata gtgttaaggt tttaattctt tccaactgcc caaggaatta attactatta 2820
tatctcatta cagaaatctg aggttttgat tcatttcaga gcttgcatct catgattcta 2880
atcacttctg tctatagtgt acttgctcta tttaagaagg catatctaca tttccaaact 2940
cattctaaca ttctatatat tcgtgtttga aaaccatgtc atttatttct acatcatgta 3000
tttaaaaaga aatatttctc tactactatg ctcatgacaa aatgaaacaa agcatattgt 3060
gagcaatact gaacatcaat aataccctta gtttatatac ttattatttt atctttaagc 3120
atgctacttt tacttggcca atattttctt atgttaactt ttgctgatgt ataaaacaga 3180
ctatgcctta taattgaaat aaaattataa tctgcctgaa aatgaataaa aataaaacat 3240
tttgaaattt gtgaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 3282

<210> 53
<211> 1860
<212> DNA
<213> Homo sapiens

<400> 53
aattcggcac gagcagcagg gagaagagga tgatgagcat gccaggcccc tggccgagtc 60
cctgctcctg gccattgctg acctgctctt ctgcccggac ttcacggttc agagccaccg 120
gaggagcact gtggactcgg cagaggacgt ccactccctg gacagctgtg aatacatctg 180
ggaggctggt gtgggcttcg ctcactcccc ccagcctaac tacatccacg atatgaaccg 240
gatggagctg ctgaaactgc tgctgacatg cttctccgag gccatgtacc tgcccccagc 300
tccggaaagt ggcagcacca acccatgggt tcagttcttt tgttccacgg agaacagaca 360
tgccctgccc ctcttcacct ccctcctcaa caccgtgtgt gcctatgacc ctgtgggcta 420
cgggatcccc tacaaccacc tgctcttctc tgactaccgg gaacccctgg tggaggaggc 480
tgcccaggtg ctcattgtca ctttggacca cgacagtgcc agcagtgcca gccccactgt 540
ggacggcacc accactggca ccgccatgga tgatgccgat cctccaggcc ctgagaacct 600
gtttgtgaac tacctgtccc gcatccatcg tgaggaggac ttccagttca tcctcaaggg 660
tatagcccgg ctgctgtcca accccctgct ccagacctac ctgcctaact ccaccaagaa 720
agatccagtt ccaccaggag ctgctagttc tcttctggaa gctctgcgac ttcaacaaga 780
aattcctctt cttcgtgctg aagagcagcg acgtcctaga catccttgtc cccatcctct 840
tcttcctcaa cgatgcccgg gccgatcagt gtaagaccag ggtgggggtg ggatgctggg 900
ggctttcctg gcggcgaggt ggagggctgg ctatctgccc tgactcccag gagctcagcc 960
tggcactctg acctcctagg agggaggcct ccaaaatggt cactgcctgg gcccctcctt 1020
cccccctcca cccgagtgac ccctcccacg ccacctgccg cagctcgggt cggcctgatg 1080
cacattggtg tcttcatctt gctgcttctg agcggggagc ggaacttcgg ggtgcggctg 1140
aacaaaccct actcaatccg cgtgcccatg gacatcccag tcttcacagg gacccacgcc 1200
gacctgctca ttgtggtgtt ccacaagatc atcaccagcg ggcaccagcg gttgcagccc 1260
ctcttcgact gcctgctcac catcgtggtc aacggtaggg gcccggagct tgcactcccc 1320
gcgctcacca ccaggtggtg tcagccacag gccaacctgc cacttgctcc aggtttcaag 1380
cccctccagc ccacagaaag aacgcaagct tgtgtaccct tcatagtagc cacattaaaa 1440

aaaaagggtg acaacaattg aataatatgt tttatctatc atcatctcaa catgtagcca 1500
atatgaaaat tactaatgag atatttaata ttcccttctc acactcagtc ttgtcgccca 1560
ggctggagtg cagtggcacc atctcagctc actgcaacct ccgcccсttg ggttcaagca 1620
attctcatgc ctcagcctcc tgagtaggtg ggattacagg cgtgtgccac cacacctggc 1680
taatttttgt atctttagta gagacggggt tttgccatgt tgtccaggct ggtctcgaac 1740
tcctgacctc agatgatatg cccacctcag cctcccaaag tgctgggatt acaggcatga 1800
gccactgcat ctggcctttt taaaaaaaaa aaaaaaaaaa actcgagggg gggcccggta 1860

<210> 54
<211> 770
<212> DNA
<213> Homo sapiens

<400> 54
aattcggcac gagccgaggg gcgaatccat acatccgtcg tgtggactcg ccctgacatc 60
ccctcaacgc ttagactcgg cattcttttc attgcctgat gccgtttcat gccttctttg 120
cgtttcctcg ctctggccct cctgctggcc atccttcccg cacttcccaa cgcccatgcc 180
gcgccgggga ttggcggcct gatcggcggc ggctcccagg cctcagccaa ggaagagccc 240
cagagcaacg cgcaacccag cgccgatgag cgcaaacaac gactgctcag ccaggccgag 300
gaaacccggc agcgcctgac cgatctcaag gccgaactcg ccggcgcacc caaggagatc 360
agcgaggccc agcgtacgct ctccaaactg gtgagcgagg acaacagcga tctgcccgag 420
cgcctctcca agctttcggt gccggtactg gagcaacgcc tggcggcccg cgtggacgag 480
ctcgccctct ggcaacaagc gctcagcgcg gccaacagca tgctcatcag cgcgcagacc 540
cggcccgagc gcgcccaggc cgatatcagc aagaaccagt tgcgcatcga cgagatcaac 600
ggcctgctga aaagcggtcg ggagaacaac aagccgctga cggacgaacg tcgcgcgctg 660
ctcgagagta cttctagagc ggccgcgggc ccatcgattt tccacccggg tgggtacca 720
ggtaagtgta cccaattcgc cctatagtga gtcgtattac aattcactgg 770

<210> 55
<211> 1093
<212> DNA
<213> Homo sapiens

<400> 55
cagattcggc acgaggtttt tttaagatt tatttttaa aaattatttt tgtggacttg 60
ggtatcaatg atggcaccta cttttgggaa tctgtagctg tgctttgaga attgccatcg 120
gtcatgtgtt gcaccgttct ctgtatgttt acgtcctttg gactggcttc tcccaggatt 180
cttttctgtt tttgtttttt tgatttgggc tttatttttt tctgtgtact gtactatatt 240
gtaaaaggga ttttagcaga gactttagtc tttgggcaa gaggagaaca ggaatgctgg 300
gctgtttact ttaggtggag aacccatctt cagacctttg gactattttc tttcaactgc 360
agtgtataga aaaaccaaac tacgacctca gagcagagta ttaatgaaaa gcacaaaaaa 420
aggaactaag ttcagcgagg ggtgggggga gggggagat ttttcttttg aaaaataatg 480
actcttagga catttgtttt tcagttcaag tgctcttcag cactgtcttg tctcccaata 540
taccaaccca ctggcacatt tttctcttgt tttctctctc cgattttgct ctgtctcctc 600
agttaagtgt ttccttcctt tgtgcccccc gctggtgacc ctctgcttcc ctctctcttt 660
ccctttggca gctgcaatac acagtgttat tttggggaaa taaatctagc aaagcctcgc 720
cttccatgcc gagcgtcctc ttggctctga gagggaaagg tctgtccttg ggatgctctc 780
tggtcttttt tccccctaag tcttttctctt tcccatcata ccctccctg cccaccttgt 840
tttctgttct ccttttatta ggaattccca agtgaatttt attaatgtgg gagtggaaca 900
gatgctaaaa gctatccagg atttgtttc tgtttgtttt aaatttgtg gttccttccc 960
tttcctcccc ctcccatgcg taagacgttc tgtgtaacct ccattaaatt tggtacaaaa 1020
ccactcgcca gagctgtggt gtcagaaaaa taaaatatat tgtttcttam aaaaaaaaaa 1080
aaaaaaaact cga 1093

<210> 56
<211> 632

<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (29)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (46)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (94)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (162)
<223> n equals a,t,g, or c

<400> 56
```
cgcaattaat gtgagttagc tcactcatna ggcaccccag gctttncact ttatgctttc    60
cggctcgtat gttgtgtgga attgtgacgg atancaattt cacacaggaa acagctatgc   120
catgattacg ccaagctcga aattaaccct cactaaaggg ancaaaagct ggagctccac   180
cgcggtggcg gccgctctag aactagtgga tcccccgggc tgcaggaatt cggcacgaga   240
ctatgtatat atgtttaata tctgtctttt gaaatgcaga aatagtttaa atgtttcttt   300
gtctattttt cttttttttt aatgctaccc agggaaatat tttcatatca tttttaagtg   360
gcctgcctca atgtatattt atttcttttg aaacaaaaag gttctggaaa ctgtttttct   420
gtagctttaa atgaataggt gagcaaaatc tatatgggat gtaatttttt tgttcagtct   480
cttaaaaaat actttgtttt gctacatttg gttgtgcttg tggggaaaat aaaaacgcag   540
agatccttat atatttatgt caaagtaata ttttattatc tacataaaac agaaatgcac   600
aataaaaaaa aaaaaaaaaa gctcgagggg gg                                  632
```

<210> 57
<211> 2687
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1614)
<223> n equals a,t,g, or c

<400> 57
```
gtacaccatg ggcctccacc tccgccccta ccgtgtgggg ctgctcccgg atggcctcct    60
gttcctcttg ctgctgctaa tgctgctcgc ggacccagcg ctcccggccg gacgtcaccc   120
cccagtggtg ctggtccctg gtgatttggg taaccaactg gaagccaagc tggacaagcc   180
gacagtggtg cactacctct gctccaagaa gaccgaaagc tacttcacaa tctggctgaa   240
cctggaactg ctgctgcctg tgcatcattg actgctggat tgacaatatc aggctggttt   300
acaacaaaac atccagggcc acccagtttc ctgatggtgt ggatgtacgt gtccctggct   360
ttgggaagac cttctcactg gagttccctgg accccagcaa aagcagcgtg ggttcctatt   420
tccacaccat ggtggagagc cttgtgggct ggggctacac acggggtgag gatgtccgag   480
gggctcccta tgactggcgc cgagccccaa atgaaaacgg gccctacttc ctggccctcc   540
gcgagatgat cgaggagatg taccagctgt atgggggccc cgtggtgctg gttgccccaca   600
gtatgggcaa catgtacacg ctctactttc tgcagcggca gccgcaggcc tggaargaca   660
```

```
agtatatccg ggccttcgtg tcactgggtg cgccctgggg gggcgtggcc aagaccctgc     720
gcgtcctggc ttcaggagac aacaaccgga tcccagtcat cgggcccctg aagatccggg     780
agcagcagcg gtcagctgtc tccaccagct ggctgctgcc ctacaactac acatggtcac     840
ctgagaaggt gttcgtgcag acacccacaa tcaacaacac actgcgggac taccgcaagt     900
tcttccagga catcggcttt gaagatggct ggctcatgcg gcaggacaca gaagggctgg     960
tggaagccac gatgccacct ggcgtgcagc tgcactgcct ctatggtact ggcgtcccca    1020
caccagactc cttctactat gagagcttcc ctgaccgtga ccctaaaatc tgctttggtg    1080
acggcgatgg tactgtgaac ttgaagagtg ccctgcagtg ccaggcctgg cagagccgcc    1140
aggagcacca agtgttgctg caggagctgc caggcagcga gcacatcgag atgctggcca    1200
acgccaccac cctggcctat ctgaaacgtg tgctccttgg gccctgactc ctgtgccaca    1260
ggactcctgt ggctcggccg tggacctgct gttggcctct ggggctgtca tggcccacgc    1320
gttttgcaaa gtttgtgact caccattcaa ggccccgagt cttggactgt gaagcatctg    1380
ccatggggaa gtgctgtttg ttatcctttc tctgtggcag tgaagaagga agaaatgaga    1440
gtctagactc aagggacact ggatggcaag aatgctgctg atggtggaac tgctgtracc    1500
ttaggactgg ctccacaggg tggactggct gggccctggt cccagtccct gcctggggcc    1560
atgtgtcccc cctattcctg tgggcttttc atacttgcct actgggccct ggcncsgcag    1620
ccttcctatg agggatgtta ctgggctgtg gtcctgtacc cagaggtccc agggatcggc    1680
tcctggcccc tcgggtgacc cttcccacac accagccaca gataggcctg ccactggtca    1740
tgggtagcta gagctgctgg cttccctgtg gcttagctgg tggccagcct gactggcttc    1800
ctgggcgagc ctagtagctc ctgcaggcag gggcagtttg ttgcgttctt cgtggttccc    1860
aggccctggg acatctcact ccactcctac ctcccttacc accaggagca ttcaagctct    1920
ggattgggca gcagatgtgc ccccagtccc gcagctgtgt tccaggggcc ctgattcct     1980
cggatgtgct attggcccca ggactgaagc tgcctccctt caccctggga ctgtggttcc    2040
aaggatgaga gcaggggttg gagccatggc cttctgggaa cctatggaga aagggaatcc    2100
aaggaagcag ccaaggctgc tcgcagcttc cctgagctgc acctcttgct aaccccacca    2160
tcacactgcc accctgccct agggtctcac tagtaccaag tgggtcagca cagggctgag    2220
gatggggctc ctatccaccc tggccagcac ccagcttagt gctgggacta gcccagaaac    2280
ttgaatggga ccctgagaga gccaggggtc ccctgaggcc cccctagggg ccttctgtct    2340
gccccagggt gctccatgga tctccctgtg gcagcaggca tggagagtca gggctgcctt    2400
catggcagta ggctctaagt gggtgactgg ccacaggccg agaaaagggt acagcctcta    2460
ggtggggttc ccaaagacgc cttcasgctg gactgagctg ctctcccaca gggtttctgt    2520
gcagctggat tttctctgtt gcatacatgc ctggcatctg tctccccttg ttcctgagtg    2580
gccccacatg gggctctgag caggctgtat ctggattctg gcaataaaag tactctggat    2640
gctgtaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaag ggcggcc                  2687
```

<210> 58
<211> 619
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (526)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (619)
<223> n equals a,t,g, or c

<400> 58

```
tcatcagctt tcacctggat tatcgtgaca gcctcctact gcttctctat catgtggcca      60
gagctatctt cctaaaatgc attgcatagt tgatcaagtc actctctggc ctaaaacctt     120
ccttggctcc ctgctgccct caggataaag tctggacccc tcagcatggc ttgtgagact     180
catggtgtcc ttgtccctgc tcacctctct ggtctcatca cttgccttct tgcattctgg     240
gtcccagcct cctgtatcca gagatgcagt ggctctccat tgccactctg attcctcctt     300
tcttttggtc acagagaaag ggtactttct ctgtcaaatc tcaacttaga cttgacttcc     360
tccaaggagc tttggctata ctctctcctc ccgaccccca ccctggcata ctacacagat     420
```

```
cactctgggc tcacttgcct gcctaatggt catctcccca gtagactgta agctccttga      480
gggcaaggat tgtgttggaa tttttgtatt aacagtgcct ggcttngtgc ctggcaccta      540
gaaagcactc aataaatgtt tgtttaatga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      600
aaaaaaaaaa aaaaaaaan                                                   619
```

<210> 59
<211> 1378
<212> DNA
<213> Homo sapiens

<400> 59

```
tcgacttctg ggatgtagat tctcctttat tgaattcttc attttcactc gcagtatgat       60
ttattttttt cacactgtat tttacactgc atatgtttct cttataacga gggtcacttt      120
cttcctgccc aggattggaa tcaattacag ctatgcaatg tttttgtttt agcatcttct      180
taattacagg cttggcagaa gagttttgtg aacaactctc catttcactg gctgaagaag      240
aaatacaact gtcctctaca gttgaacatt tctgtatgac agcatttcca tggtaatgag      300
gattaggttc atactttggt ttttccaaac cggggaaaca aacaacagcc aaaaaccagt      360
gtgcagcttc attaaggggt acaaaaataa aatccttctc aaaaatatct acgtgccggg      420
tccatgtttt tactctccca tgccgttttt gctgtattga cagattagtt gtttcatgat      480
ttctcctctc tctctgatta aggcgtttat agaaaaaaga actgaatata tgaattcggt      540
cagcgtcttc cttcttcagt ttttcaagca ccaagtattt caaataaaag tctataataa      600
catcatttaa aaattctcct tcatttagac agtgcaggtc ctcattggta acagagatgc      660
ctcccttagc tggaggtggt ggatatacta tcaacttttc tactgggcca atgaagatgg      720
tgtggttttc tccagtttct tcttcttcat caaaaaactg aaattcttgt ttgcttctaa      780
gttgtatttt agattcaaat gatacagttt taattttgtt ttccttttgc ccacaacttc      840
ctttgatgct ctcttcatag gttcttgtac aggcaacaag tctgccatta gcttcttcaa      900
agggaatttt cgcaaaaaaa ttggagatgt tattcttcat accaatttca ttaatgatac      960
tttcaaatac catatttgcc ggaggatcaa ggccatttttg aaaaattaaa attatatatt     1020
gttcttctaa atttgttaat ttatttactc ctttacaatc attccaaact ttatcctcct     1080
tattcatttg cagttggatg ctcagctttt gataaactgc tggaattgct tgaagaaaca     1140
ctacaggtaa ttttcggaca ttacaccatt cacatttagt tagatcagag gtatttaata     1200
taatctctac aggatcatgg tctggttcgt ctagctgtat cttgataaaa tctaaacaaa     1260
aaattacagg ctctattaac agccggaaga gtgttcctac tcgtcgacgc ggccgcgaat     1320
tcccgggtcg acgagctcac tagtcggcgg ccgctctaga ggatccctcg aggggccc       1378
```

<210> 60
<211> 1126
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (21)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (35)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (49)
<223> n equals a,t,g, or c

<220>
<221> SITE

<222> (99)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1012)
<223> n equals a,t,g, or c

<400> 60
tccggcttcg taatgtggtg ngaaattgta acggnataac aatttcacnc aggaaccagc 60
tatgcccatg attacgccaa gttcgaaatt aaccctcant aaaggaccaa aagtgaagtt 120
ccaccgcggt gccggcccgc tctagaaact agtggatccc ccgggctgca ggaattcggc 180
acgagccggc ccgtaccgcc aggcgatcgc gctgatggcg gcgctggcag cagcggccaa 240
gaaggtgtgg agcgcgcggc ggctgctggt gctgctgttc acgccgctcg cgctgctgcc 300
ggtggtcttc gccctcccgc ccaaggaagg ccgctgcttg tttgtcatcc tgctcatggc 360
ggtgtactgg tgcacggagg ccctgccgct ctcagtgacg gcgctgctgc ccatcgtcct 420
gttccccttc atgggcatct tgccctccaa caaggtctgc cccagtact tcctcgacac 480
caacttcctc ttcctcagtg ggctgatcat ggccagcgcc attgaggagt ggaacctgca 540
ccggcgaatc gccctcaaga tcctgatgct tgttggagtc cagccggcca ggctcatcct 600
ggggatgatg gtgaccacct cgttcttgtc catgtggctg agcaacaccg cctccactgc 660
catgatgctt cccattgcca atgccatcct gaaaagtctc tttggccaga aggaggttcg 720
aaaggacccc agccaggaga gtgaagagaa cacaggaata gaacccaata ctttcctctc 780
tgaggaaagg ctgaaacttc aagctcccct tgtgataaga cttggtcaga taactgagtc 840
tggtcaatgg aatatgagtg gaaatgatgt gtgcaacttc cgggttctgt ccttcctgcc 900
gggtggaatg tgaatatgat ggcacctggg acccaaagac aggagccaca tcttgagaga 960
tagatggcag atctgcccct gtggctttgg atcatttacc tcagtgaaca cnacaagcat 1020
tatccatgaa accataggtt ttgtgtgcta gttctagttt ttaaaatatg aattaaatta 1080
aatacgtatc tgttaaaact taaaaaaaaa aaaaaaaaaa ctcgag 1126

<210> 61
<211> 2078
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (337)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (492)
<223> n equals a,t,g, or c

<400> 61
gattattttc aatagattgt caataaatta tcaaattatg gaaatatcct ttagattcct 60
gtgataatgc tttgtgcatg ttttctatta tttagaaaat gaaaacagca gtcatttgac 120
cagccatgtt atgacaccag ataatattct gcaaggatct tccaaacagg gagaaactgc 180
aatgggaaca atctttggat atctacattg tgtcaaatgt tatgtgcttt atttcatttt 240
catacttata acagctgtat atcacagttt ttattatcca cattatagag gcaaggcact 300
gatatcagga acttgagtaa ttggcttaca cagcaantgt agttgaaata gaagccagga 360
ctgtctgatt cccaagacag tgttcttgta ctgcaggtaa gcctggtgtt gctgggkttc 420
cctagcactg agtattgcag aaatacggag atttatttac tcaggtgaat gatgaagcag 480
aatctttatt tngcttttta aattatkgat gggkcckgag ttaagctagt tcaccaatga 540
gtctcaaagg gtgaagaact ggcctgtgta gttttaaaac aaagcagcag ttttcttcat 600
ttgtagatat tatatttaat ttaccttgca tttccaatag cattaaatat tagaagcgta 660
taagcttttt ctttttatgc ctaggggata tggcttaaca ctgagaaaca cttgagaaac 720
actgccacat tctaaggaac aaccaataat aagaaaaatt atttcatata aaaggatgca 780

gcttgcatat aaaatgctga attcaactga agttcattat gctgccttta tgtgagctca 840
ggggtgacct tcatgctctg gactcttaaa ggatccagtg tcggatacag ctctgccatt 900
ggagcaatgt gttccataac tagggttgcc taagtatatc cctctcctcg ktatctatag 960
tttttcttta aaggtgtgct tttcaaaaca tgatgttatt tcatatacmt atatatatat 1020
atgcacacat acatatacmt catgcatgka tcatatatgt gtgtgtatgt atgtatctat 1080
cttcaatctt tcaggaaagt ttgtaaaawa tagccctaag tagaattatg gggaaacagt 1140
tgcagaactg ctgaaattgg ctcagatgaa aaggaaagag caaaaatcta ggttattcac 1200
aggaagttag tccagctgtg ttttgcgagg catgaaccag gctgaatcag agcaagaaca 1260
ggttgcaatc ttaggtcaca tggcaattaa attccagcta tagaatattg aagacatgta 1320
agtgcttaat ttaaggatta ttcaatgcag tgaataaatt tatatcattc ccaaaagtat 1380
gcacatcaga taatgagtta actgcatgta acttgaaaac cttaaatatt taactgaaag 1440
gattttgtgc atagaaagat gtcttagtca atgtaaaaat gccagtgatt tgtgtagcat 1500
gtcctttgct aaaagtcatt atataaactg aagtcactta tctttgtttc caatgtgata 1560
atattccaca tttaacaggt gataattatt gaaaatatta gtttgcctca ctaatattgt 1620
gtccgagata ttctagttta aaccaagtaa ctaatactgt aaaagaagta ttccttttat 1680
gaagccagca ttatcctgat actagaactg ggaagagaca cacacaaaaa gaaaacttca 1740
ggccaatatc gctgatgaac atcaatgtga aaatcttcaa taaaatactg gcaaaccgaa 1800
tccagcagca tgaggcgggt ggatcacaag gtcaggagat cgagaccatc ctggctaaca 1860
tggtgaaacc ccatctctac taaaaataca aaaaattagc cgggcatggt gatgggcacc 1920
tgtagtccca gctactgggg aggctgaggc aggagaatgg cgtgaacctg ggaggcggaa 1980
cttacagtga gccgagattg caccactgca ctccagcctg ggtgacagag caagactctg 2040
tctcaaaaaa aaaaaaaaaa aaaaaaaaaa aactcgta 2078

<210> 62
<211> 762
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (10)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (12)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (42)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (219)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (747)
<223> n equals a,t,g, or c

<400> 62
cgagtcagtn ancgagaaag cggaagagcg cccaatcgca anccgcctct ccccgcgcgt 60
tgcccgattc attaatgcag ctggcacgac aggtttcccg actgaaaagc ggccagtgag 120
cgcaacgcaa ttaatgtgag ttagctcact cattaggcac cccaggcttt acactttatg 180
cttccggctc gtatgttgtg tggaattgtg agcggatanc aatttcacac aggaaacagc 240

tatgaccatg attacgccaa gctcgaaatt aacccucact aaagggamca aaagctggag 300
ctccaccgcg gtggcggccg ctctagaact agtggatccc ccgggctgca ggaattcggc 360
acgagcacaa atgcctatac aaaacttttt tccatgtcct caatactttg tatcagatta 420
tttatatttc tcatggtttg gtttcttttt cttgtcttca tttttctgaa ggtaaaaggg 480
gatttttccc cccttttct gatctgtaac ttgttttgta tttggatgat tacagcgtg 540
agccaccgcc tccagccaca aatacttttt agtcgccata agcataatca agaaatcatt 600
ttgcaaatgg taagcttttc atgttgtgta ttctttccca tgattagaga ggtaaaaagt 660
gscctgggat gcataaagat gtcgtagacm tmtgcaatct gccacattat ttctttaaaa 720
aaaaaaaara aaaactcgag ggggggnacg gaacccaggg cg 762

<210> 63
<211> 1094
<212> DNA
<213> Homo sapiens

<400> 63
tcggcacgag gtcaatcaag tgaaatatca tgtaaactgt ccagcagctt tgaaagtaga 60
gaatgaacaa ggccccttcc ccacccaccc tgtggaaagc ccgtctggtt tggtgtcctc 120
ctggacagcg tcttgccggt caccttggc catctcccgg tgcgtggttc agatgtgggt 180
cctgctttcc tgccccctcc ctcctctgtg cctgcctgcc tctgctgtgc cgggccagtg 240
ccttggtggc cagtggagtg gacaccagct gcgactgcgt gggaggggct ggcattgccg 300
ctgccactgc agggcttggg cggctgacat gggacgaggc ttgcacagct gccagctcct 360
gtctcgctga ctttttttat acagttttgt ctgggccacc gccttcagtg ccacgggccc 420
cttgccgttc aggctgctcc tcatagatga acaaggccct gccccgtgtc cttaccctt 480
agagctgttt aaattcaaat gaactgaaac tgaatatgaa aaatccaggc cctcagccgc 540
ccaggccatg tttcaagtgc tccatggcca catgtggctg gtggacagtg cagctctaga 600
acattccatc accacagagg gttctgctgg acagtggcct tgggggctgt tttgagggtc 660
cgcctgtcag tctcctggca tcaaagtcat tctgccattg tcaagttaca gttattttcc 720
ttttacctcc aagccactat gtgcgtatgc tgctatgtgt ctgtatttcc cgctaaactt 780
cctgtcacgg agggaagggt gccacaggcc cagctcctgg agggggtttg gatgtctggg 840
tggggggaag ggtgccacag gcccagctcc cggagggggt ttggatgtct gggtgggggc 900
cagggcgcca cagttccagc tcccggaggg ggtttggatg tctgggcggg gctttcttca 960
tgttccatgt atgataacgg tgactggggg gtttacagag agaggcatac aaatagtgtt 1020
ggagtgttgt tttcgctaat ataaatgttt gaatagctaa aaaaaaaaaa aaaaaactcg 1080
aggggggggcc cggt 1094

<210> 64
<211> 1361
<212> DNA
<213> Homo sapiens

<400> 64
cccgggtcga cccacgcgtc cgaatttctt tagtgtattt tatgtacttt tgtattaatt 60
acattgggta gactgttcca taaatgttga atagatccta tttgttggtt aatgctattg 120
ttgtgtatcc tgctgatttt ctgtgtagtt ggtctatcag ttgttgggag aagagtgttg 180
aagtctacaa ctataattgt gtatttgtct attactcctt tcagttcttt cagttccatt 240
tcacatattt tccagctctt gattggtgca cattaatgat tactatgtct tcttggtgaa 300
tagaccattt tataatttta tgatgtacct ctcttgtcac tttctttgct ctgaagtcta 360
cctgatatta atatagtcac tctagctttc tttggagtaa tgttagtgtg atatatcttt 420
tttcgtcctt ttacttttaa ccctatctat atcattatat tattttaagt gagttttttg 480
tagatagcac ttacttgtgt ctgtcatgtt tttaaatcca ctgtacaagt acaaatctgt 540
ctttattttt catttttatc cttattttga gacagagtct cactttgaca ctcagcctag 600
aatgcagtgg tgtgatctcg gctcactgca acctctgcct ccgagggtca agcaatcctt 660
tcacctcagc ctcccaagta gctgggacta caggcatgaa ccaccatgcc tggctaattt 720
ttttttttt tttttttgta gagatgggga tttaccatgt tgctgaggct ggccctgaac 780
ccctgggctc aaacgacctg cccagctcag cctcccagag aaatatgatt ttaattagca 840
catttagatc atttactttc aatggaatta ttgatgtatt acaattcaag tctgtcattt 900

tatttattgc cttccatttt tccctccgtt tttcatttct gtgctttttt tctttgcatg 960
taaacatgtt ttaggattct gttttgatgt atttagagta ttttttagtg tatcggttta 1020
tgtagctttt ctagtggatc ctttaagtat tacattatat atacataact aagaagtata 1080
tcagtgtcat cattttacca gttcaagtaa agtacagaaa tctttgtccc ttttacctgt 1140
cctgcttata atgtaaatgt cttaaagatt tccttgacac acatttagaa ccatatcaca 1200
gtgttgtttt tgcttcagtt gtgaaatata atttagaaac tcatgagaat aaaaacccat 1260
tatatttatt tataaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1320
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa agggcggccg c 1361

<210> 65
<211> 947
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (67)
<223> n equals a,t,g, or c

<400> 65
ctttctatag ttaaagccgg tacgcctgca ggtaccggtc cggaattccc gggtcgaccc 60
acgcgtncgg tttctgggtt ctaggccctg cttccttgcc cctttgctgc agaagggcag 120
ctgaaggctc accctagaaa ccgggcctgg tgggtcttac ccggctcact ccctcccttg 180
tccttacaca tacaggaaga caagacctga gtggtgctgt ctttgtgtcc gtcgtgtatg 240
gctctccctg tctttcatttc ttctcactct gtctctaaac ctctctctct ctcccttccc 300
cctcagtact tartctacag acctatgtgc gtgtycctat ccttctgtcc ttttctctct 360
tcagctctcc ctgcctctca cacacaattt tacatgcccc gaggagccaa gtttgggaca 420
tttaccctcc aggcatctgt gtcccctctt gaagagaaaa cacacagctt cacacatcca 480
ggcatagggg gcaagctctt ggggcatcag gaccctggag caccaggtcc ttcctggaat 540
attagatcca cctggagcac caggtctctc taagtctcac ctggggaatt cggtcccacc 600
tgggtcacca gttcccacct agagcactgt gtcctgccct agagcacaaa gacctgctcc 660
tcccgagact ctctctgact gcagccaggc atagtaccct tgcctgtgtt tgctccctgg 720
tccacagatt tggtggctgg gcaggtgcct ggacagtgat gaggtcttgc cgccttaact 780
gtccccccca gtcacttctc ccacaggccc agcaggacgc agtcctgagg atcagggatt 840
ctacagctgc attaaaatca atcctatcca aaaaaaaaaa aaaaagggcg gccgctctag 900
aggatccaag cttacgtacg cgtgcatgcg acatcaagct ctgaaga 947

<210> 66
<211> 1376
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (18)
<223> n equals a,t,g, or c

<400> 66
ggcgggcggc gcggaagngg cggckgcgcg gccggggcag ccatgtcgcc attgtctgcg 60
gcgcgggcgg ccctgcgggt ctacgcggta ggcgccgcgg tgatcctggc gcagctgctg 120
cggcgctgcc gcgggggctt cctggagcca gttytccccc cacgacctga ccgtgtcgct 180
atagtgacgg gagggacaga tggcattggc tattctacag cgaagcatct ggcgagactt 240
ggcatgcatg ttatcatagc tggaaataat gacagcaaag ccaaacaagt tgtaagcaaa 300
ataaaagaag aaaccttgaa cgacaaagtg gaatttttat actgtgactt ggcttccatg 360
acttccatcc ggcagtttgt gcagaagttc aagatgaaga agattcctct ccatgtcctg 420
atcaacaatg ctggggtgat gatggtccct cagaggaaaa ccagagatgg attcgaagaa 480
catttcggcc tgaactacct agggcacttc ctgctgacca accttctctt ggatacgctg 540

```
aaagagtctg ggtcccctgg ccacagtgcg agggtggtca ccgtctcctc tgccacccat      600
tacgtcgctg agctgaacat ggatgacctt cagagcagtg cctgctactc accccacgca      660
gcctacgccc agagcaagct ggcccttgtc ctgttcacct accacctcca gcggctgctg      720
gcggctgagg gaagccacgt gaccgccaac gtggtggacc ccggggtggt caacacggac      780
stctacaagc acgtgttctg ggccacccgt ctggcgaaga agcttctcgg ctggttgctt      840
ttcaagaccc ccgatgaagg agcgtggact tccatctacg cagcagtcac cccagagctg      900
gaaggagttg gtggccgtta cctatacaac gagaaagaga ccaagtccct ccacgtcacc      960
tacaaccaga aactgcagca gcagctgtgg tctaagagtt gtgagatgac tggggtcctt     1020
gatgtgaccc tgtgatatcc tgtctcagga tagctgctgc cccaagaaac acattgcacc     1080
tgccaatagc ttgtgggtct gtgaagactg cggtgtttca gtttctcaca cccacctscc     1140
cacagggctc tgtcctctag ttttgagaca gctgcctcaa cctctgcaga acttcaagaa     1200
gccaaataaa cattttggag gataatcacc ccaagtggtc ttcaaccata aactttgtga     1260
ttccaaagtg cccagttgtc acaggtgcca taaataatta cattttccaa cataaaaaaa     1320
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaagggc ggccgc         1376
```

<210> 67
<211> 2434
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (10)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (12)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (27)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (73)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (75)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (103)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (130)
<223> n equals a,t,g, or c

<400> 67

```
ctggggtan tncaagaacc ctctgtngga cttagatgtc aagctctttc ctttgggcag      60
cgtgtttcct ttntncgagt agtgtgctgt gtaaactaaa ttngccggtt cgctttccat     120
```

```
ttcctgacan ttgagatgga atgccttgac cattggtgct ctgacagaga agtcatggag 180
tcattgccat ttcctggttg ccctttggca atgtgatcct gttagtagag gttttctagc 240
ttctactaag atatttcttt ccctaaccat catacacttg gcatgtttca ttcccatctc 300
ctttcccctc accttaaagg agactacccc tttgccccat attgtcaacc taattttctc 360
tcgtactctc tctagtgaat gatgtgctac caagtatatg ccaggctgtg agaggattat 420
actgagtagt agaaagaagc taatttgaaa taaaaattat ttgtataatt aagaaagcag 480
attagatgca catggtcaac aggaagttga ctgtatgtct gctagttaga ttcaaaacat 540
cataaagatg atagcatgtc aatatattag cctagccatt atgttagcct ttgttaggtg 600
ggcagctttt ctgctttttc ccttcctctg tggtgacaac ggaggaaata tccaacagaa 660
atacgtctaa cagggaaatt gggatcatag tttatatgca tctgatttga aaggagtatt 720
gaggaaggtt ttcatatatg atctatcttt ggattaaaaa gaacatttat gaaatcaagc 780
cttctaacac tagttataat tgagaagcaa cagtaactcc gtggacagca atcaagctta 840
aaattgtaaa taaatatggg gataattcag ttgttgcaaa aaaagggcag aattcagtag 900
aataaagtcc ttttctctta caggtattaa atgaggacag agaacctcag gtgttcttat 960
gctagtgctt gctgagtgca tactaagaaa gcaattccaa atagatgtat acatctagag 1020
agagtggtat tagagattca gtgtatgtat ttatttacat gagaggaaac tggaatataa 1080
tcccataaat tattggaata taatcccata aattatcacc ttttatgact ggaaaatatt 1140
tgccaatgaa gaaatggtct gtaggtattt gtcttaagat ttttggctgt ttaataaaaa 1200
tgtaacttta acggtttctt atagttgcct ttataaagtg tattgtctaa aatattttig 1260
tatcatgtgc ctttgaaatt tgacagctga tttgggtgtt ggatttctgc ccagccattt 1320
atcagtatta tcattttatt cagtagctgg caggtgtatt agacaaacga gacttaggta 1380
aggaatggaa cctttcctgt ggtttgactg cacatcacac cagaagactc cagtatccct 1440
cattccagaa tgaggaaaaa gtattctaca aagaacctaa tcacctctgt gaaatctatg 1500
ggatggaaac agtgtggcct taggagtcaa atagtctctg catggtgggg aggatcatga 1560
tggaatatgt gaatttctac ttctagaagt tgtgaaatag gtcctgcact tttgcagaat 1620
gtccttcttt aaacctggct tattccacag ctgtagctga taacatgacc tggggcttag 1680
ctgctctagc cctgggtttt tcgagacctc acactgcctg gcccctggcc atccacctaa 1740
ggactgcctg ctttctggtc acatgtggac cttgatacga ctaagcggtt acatatgtgg 1800
ttgtgcaaaa gctttctgtt taatgcatag tgttaccgat ttacatcttg gttttcagtg 1860
gcactatgtc taggaggcaa tatcctttta aacagtgctt tggctaagat agatacttgt 1920
gaatcaaaga tagcacagaa atgaactaag tatatcccat ttggaattat attttgatac 1980
tatttaaaat ggtttcacct gttaaagggc caacagaact cttggtttta cttttgtaat 2040
tactgtacag aaaatttcaa gagtgtttga gtgcttgtca tcaggtgttt tccttaataa 2100
gtagggatat gatcatttac aggaattata tatgaaaaaa gtttttgaaa tgtatttttg 2160
tgatgtgcta tgttgagggg aaaccaaata tttatgattt taaaacattc gtatgaaaac 2220
attgtacaat gtaatatgct caactttctc aatttttgc taatttttct aagatacatt 2280
aaaaatgttt tatatttttt tttaagtaaa atggacccag taagaaaatt aaaaatacca 2340
gaacataaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2400
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 2434
```

<210> 68
<211> 1086
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (10)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (77)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1056)

<223> n equals a,t,g, or c

<400> 68

```
ttgaaacacn cttttgagca ttaggtccca gctccaccgc ggtggcggcc gctctagaac      60
tagtggatcc cccgggntgc akkaattcgy cacgagcaac ctgtagtgag ttggctgtca     120
ctcagcagct ctggaaaatt acctgtctgc actgaatttc ctcatcagta aaatggaaat     180
gattatagta ctgaccttgt aggattattc taaaaatcag agaagttcat gcagcttaga     240
acagtgccag gcacatggca aatgctatgg catacttaag catcttcctc tgtggtgcct     300
cgtcatcacc atgtgattgt gccttgcttg tccctgtttc acttttcaga gggagaaaag     360
tggccaactt taagaatcaa aattctgatg ttacttcggg aaatgcatag agccagagag     420
acacaatttg acttagtatg atccacatca tcccctcagg ctgaatagtg gtggcatgca     480
catctatacc aaaatgtttt accttttttg tagaaggaaa atatttgtat cttctattcc     540
atatcttaga tctttataag agcacttaag ttcaacctcc taagaaactg ccaattttgt     600
tgatcatgat agtctgcaca gattttcgta ctatttagtg ktgggagtgc cttagggacc     660
atcaacaaca ggsccctcct tttatccatg agactactga ggccttggag gttatttgtc     720
catccatggc gggtgcacrg ctagaggtta tctggttagt agcccaacta agattagaac     780
ccaggaattt tgatttaatc tcaaatgacc tcttttattt ctgcatccgg gaaggagaag     840
aggaaagtaa acgggaaatt catgttatct atggaaaagt tatcagtttg atgtttatta     900
aatgatttgt ttcaggagat tgtttacaac ttttatcttc ctagacaata atttctgta     960
agagtaaagt catggtcatt aaggtagtca tattaatgta ttcagtaasc tgtgaagaaa    1020
aatatatatc aatgttttcc aataaaatac agtgantacc tgaaaaaaaa aaaaaaaaaa    1080
aaaaaa                                                               1086
```

<210> 69
<211> 1262
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (568)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (639)
<223> n equals a,t,g, or c

<400> 69

```
cctyctatag gkmaagctgg tackcctgca ggtaccggtc cggaattccc gggtcgaccc      60
acgcgtccgc ttacaacttc tctyttgttt ctgtgtttct tccacaccat tatggcgtat     120
ttactgatct acaaccggtt ttaagttagt tgcctgctta aaatttctc atgaattctc     180
attacatttt caaacaaaat ccaaagtttt taccatgacc ttgtggyatat ctttctgacc    240
tcatttacta ctgttatctt ccttattcat tccattccac ccacagtggc cttcttgcaa     300
gtcagagaat gcaacaaata tgctcctgcc ttggggcatt tgcacttctg ttcttttggc     360
ctggtcactt cacctccaca ttctccattt tttatgactt tcttcctata tttggatctc     420
tgttcaaatg tcacccctca aaaaggcctt caaaactacc ctatttaaaa tagcacctgc     480
cactgccatc tccataccca ttttcatttt tccatagcac ttatccctac ttggcattat     540
gttatatatt tgtttatttg kttactgnct gtctccccca ctggactgta agctccatga     600
ctgtaagtac atagatgaat tacaaaatga atcaatggng aawtatcctt gmcatatatt     660
atttaatgat tttgmctcca ttttaagtaa aaaaaaaata ccattttttt cactcttcaa     720
agtgatatag tttaatcttc taaactacat ttttctcatt tcccgattta attaaatcag     780
tgatataaaa aaaagagtga tggggatatg tgaaagaaga ctaaaataga tgccaggaaa     840
tactaaaact gctgaagttt agtggtatat tttttcttta cacacagtat tatttgagtt     900
actaattgtg tcactgaatt acagaataag caaaatacta ggtaaacaga atcacgcttg     960
ggggctatat tttgtgtaaa atttgtgtta tgcaaaaata atattaaata tttaattact    1020
acagttttgt tatttctttc ttattttagg aaatgatttg cagctgagtg aatcaggaag    1080
tgacagtgat gactgaagaa atatytagct ataaataaaa atttatacag catgtataat    1140
```

```
ttattttgta ttaacaataa aaattcctaa gactgaggga aatatgtctt aacttttgat    1200
gataaaagaa attaaatttg atttcagaaat ttcaaaaaaa aaaaaaaaaa aagggcggcc   1260
gc                                                                   1262

<210> 70
<211> 1642
<212> DNA
<213> Homo sapiens

<400> 70
ggcgcgctgc ccggarctgc ctgggttgcg ctgccggcca cgtccccgcg ccgggcctca      60
ggctccttcc tactgtccga gggccaccag gccgccgggg gcctgctgcg cccggatgcg     120
tctgttacta gagtggagag tctaccttcg tctcacatgt gccacaaagg atggcatggc     180
ccgggagtgc cccaccacgt ggctttcacc ccctgcaaag ccagacttcg cccagcgaca     240
cagtgtcaag cccacagctc tccaaggagg aagatggtcc aggctgggag catcycctta     300
gcagcagcct ctgatccctt ggccaagcag gagggaacca ttagcagcct gaggagctgg     360
ctggctggga gcctcgggga ccgcccagcc ttgctcccag ctcacccaca agatgtggac     420
agctcttgtg ctcatttgga ttttytcctt gtccttatct gaaagccatg cggcatccaa     480
cgatccacgc aactttgtcc ctaacaaaat gtggaaggga ttagtcaaga ggaatgcatc     540
tgtggaaaca gttgataata aaacgtctga ggatgtaacc atggcagcag cttctcctgt     600
cacattgacc aaagggattc ggcagcccam ctcaactcta tggaagtcac aacagaggac     660
acaagcagga cagatgtgag tgaaccagca acttcaggag gtgcagctga tggtgtgacc     720
tccattgctc ccacggctgt ggcctccagt acgactgcgg cctccattac gactgcggcc     780
tccagtatga ctgtggcctc cagtgctccc acgactgcag cctccagtac aactgtggcc     840
tccattgctc ccacgactac agcctccagt atgactgcgg cctccagcac tcccatgaca     900
cttgcactcc ccgcgcccac gtccacttyc acagggcgga ccccgtccac taccgccact     960
gggcatccat ctctcagcac agccctcgca caagtgccaa agagcagcgc gttgccaaga    1020
acagcaaccc tggccacatt ggccacacgt gctcagactg tagcgaccac agcaaacaca    1080
agcagcccca tgagcactcg tccaagtcct tccaagcaca tgcccagtga caccgcggca    1140
agccctgtac cccctatgck tccccaagca caaggtccca ttagccaggt gtcagtggac    1200
cagcctgtgg ttaacacaac awataaatcc acamccatgc cctcaaacac aaccmcwgag    1260
cccctcaccc aggccgtggt agacaaaact ctccttctgg tggtgctgtt actcggggtg    1320
acccttttca tcacagtctt ggttttgttt gccctgcagg cctatgagag ctacaagaag    1380
aaggactaca cccaggtgga ctacttaatc aacgggatgt atgcggactc agaaatgtga    1440
gggggcgggg ggcctggcgg gaggcctggc cccttcctcg tcctttcctt ttgcctttga    1500
gaccaaacca agtgcttcca aattcttttg gtgcaattga ggagatatgc cagatgctta    1560
aacacattta attgctgtca gattaattcc atgatcacta aagagttgct gcttttttca    1620
taaaaaaaaa aaaaaaaaag gg                                             1642

<210> 71
<211> 921
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (4)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (9)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (11)
```

<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (15)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (20)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (901)
<223> n equals a,t,g, or c

<400> 71
gcgnggggna naggnaagcn ccccactatt gggttcaaaa gctggagctc caccgcggtg 60
gcggccgctc tagaactagt ggatcccccg ggctgcagga attcggcacg aggtctgagc 120
agataagatt aagggctggg tctgtgctca attaactcct gtgggcacgg gggctgggaa 180
gagcaaagtc agcggtgcct acagtcagca ccatgctggg cctgccgtgg aagggaggtc 240
tgtcctgggc gctgctgctg cttctcttag gctcccagat cctgctgatc tatgcctggc 300
atttccacga gcaaagggac tgtgatgaac acaatgtcat ggctcgttac ctccctgcca 360
cagtggagtt tgctgtccac acattcaacc aacagagcaa ggactactat gcctacagac 420
tggggcacat cttgaattcc tggaaggagc aggtggagtc caagactgta ttctcaatgg 480
agctactgct ggggagaact aggtgtggga aatttgaaga cgacattgac aactgccatt 540
tccaagaaag cacagagctg aacaatactt tcacctgctt cttcaccatc agcaccaggc 600
cctggatgac tcagttcagc ctcctgaaca agacctgctt ggagggattc cactgagtga 660
aacccactca caggcttgtc catgtgctgc tcccacattc cgtggacatc agcactactc 720
tyctgaggac tcttcagtgg ctgagcagct ttggacttgt ttgttatcct atttgcatg 780
tgtttgagat ctcagatcag tgttttagaa aatccacaca tcttgagcct aatcatgtag 840
tgtagatcat taaacatcag cattttaaga aaaaaaaaaa aaaaaaarct cgagggggg 900
nccggtaccc agggcggaag a 921

<210> 72
<211> 906
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (34)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (833)
<223> n equals a,t,g, or c

<400> 72
ggaaattctc cctcactaat tggaacaaaa gctngagctc caccgcggtg gcggccgctc 60
tagaactagt ggatcccccg ggctgcagga attcggcacg agggaagaga gaggggaggg 120
tgagcagagg acaggccggg agttttccgg gaacggagga agagcagtgg aggctgccag 180
gatgaggctg ctgtgtggcc tgtggctgtg gctctccttg ctgaaagtcc tgcaggccca 240
gaccccaacc cccctgccac tcccgccccc gatgcagagc ttccaaggaa accagttcca 300
gggggaatgg ttcgtcctgg gcctggcggg caacagcttc aggccggagc acagggcgct 360
gctgaacgct ttcaccgcaa cttttgagct aagtgatgat ggccgctttg aggtgtggaa 420

```
tgcgatgact cgaggccagc actgtgacac atggtcttat gtgctgatac cggcagccca    480
gcctgggcag ttcactgtgg accacggtgt gggcaggagc tggttgctgc ctcccgggac    540
gctggaccag ttcatctgcc tgggcagagc tcargcctc tcggatgaca acattgtctt    600
cccagatgtg actggargtg ccctggacct carcagcctg ccctgggtgg cagccccagc    660
ctgaccactc agacagccgc ggcccccaag gcctgactct tcttgtggga gggcgaggct    720
ggtcacccca ggccagcgtc tgttgaagga tgaagcagct cctgtccggc ccagccctgc    780
ctcacagctg tgcgagctct gccctcctca gctctcaaac ctgaataaat gcnccaagcc    840
cagaaaaaaa aaaaaaaaaa aaaaaaaaaa ctcgaggggg ggcccggtac ccaattcgga    900
agattg                                                               906
```

<210> 73
<211> 680
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (7)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (9)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (15)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (16)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (22)
<223> n equals a,t,g, or c

<400> 73

```
cactcantng aacannagct cnagctccac cgcggtggcg gccgctctag aactagtgga     60
tcccccgggc tgcaggaatt cggcacgaga tatttcgctg gaccctagaa aagccaccac    120
gacctgtggg ccatgatgct accccaatgg ctgctgctgc tgttcctcct cttcttcttt    180
ctcttcctcc tcaccagggg ctcacttttct ccaacaaaat acaacctttt ggagctcaag    240
gagtcttgca tccggaacca ggactgcgag actggctgct gccaacgtgc tccagacaat    300
tgcgagtcgc actgcgcgga gaaggggtcc gagggcagtc tgtgtcaaac gcaggtgttc    360
tttggccagt atagagcgtg tccctgcctg cggaacctga cttgtatata ttcaaagaat    420
gagaaatggc ttagcatcgc ctatggccgt tgtcagaaaa ttggaaggca gaagttggct    480
aagaaaatgt tcttctagtg ctccctcctt cttgctgsct cctcctycty cacctgctct    540
cctccctacc cagagctctg tgktcacccct gttccccaga gcctccacca tgagtggagg    600
gaagtgggga gtgattgaaa taaagagctt tttcaatgaa aaaaaaaaaa aaaaaaaaaa    660
aaactcgagg gggggcccgg                                                680
```

<210> 74
<211> 1633
<212> DNA

<213> Homo sapiens

<400> 74
ggcacgagca tcagtaagta ggagctaggg aagagaaagc atgcaaaagg gcaagaatca 60
ggagaattga tatagtagct ggacagaact ctagatgtgt gtgtgtgaga gaaagagagg 120
cagggagaag gagggaggag ttacccccac gatgacctcc aacttccctt tctgcaccct 180
catcctgggg atagcacagg ctcaggcctg ccctggttgc cctggcgatt ggcctggcct 240
gggctcaggg gtgggggagg ggctgcacca cattaggacc tgccgtactc caatcccatg 300
cagtcctcct gctcctgctg ctgcgtgcct gggctctggt catgccaggc ttccttgtgt 360
cctgcgtctg tggccggttc ctgccaacct gtctagtcct ttcaggcttg aggccctgca 420
ttgctctttc tggtcctctc ccctccttcc cgctccccat ctagcctttt ttgggttccg 480
ggatctgctg acagactttc ttcttgctgc ctgcctgctt acatttcaga agacccctct 540
ggaactgccc atggctgtgg tccacctgct ggtagcaacg ccctgttacc aaatgctaga 600
taatctgcca ctcccctctg cagccgccaa ctggtgctga gctgccacct gttgtctgtt 660
tccacaccct tgtacactgc attctgcctg tcactctgga cagctgccca gcagctgcag 720
ctgaggccgt cctgccagca cctaccgcag ccccatgggt ggtcctgtcc agttcctggc 780
gctcccagcc tgcctcatct gctgtactta cagagccaca tctggttgaa tacagagctg 840
gggtagcctg gatgggccca tggcacactc actcccagag aggcgggcat cctctctctg 900
gacctctagg gaagggcagg gtctggagcc caataataaa acacagtaat gataatcata 960
gctaatgttt actgagaact taggatgtga taggctcaat gatttaccag aattactcta 1020
tactgcataa ctaccctatc aggtaagtac tattaatatc ccctttccca catgaagaaa 1080
ctaaggctaa ccaatagaaa tgaacctgtc taatgtccca tgggcataat tcatggagcc 1140
aggattcaga accaggtgct ttacttcagg gctgaagctc ataaccacta gaccaaagcg 1200
cctcctccgt gacctctggg gaaggcccag caacatcctc tattgcgtcc aatgacttct 1260
ccctggtctg agatccactg actcacaggg gtagggttaa ggttaaggcc agagtctcag 1320
ctaagctttg gatactttct tctggatttg gagaaggctg gaataactga atttctgctc 1380
atcttcagga gcggcctact agagccacac atttcccagc tctccttgtg tgtttcccag 1440
acccttcttc catcgtgtcc tctcccttag gctcctggaa agttttcaga gagaatcacc 1500
cagtggtaac attgttaaac aaaacaggaa aatgggactt gtgtgtatat atgattaaat 1560
tattaattga tggatctacc ttcttagctc gtgccgaatt cgatatcaag cttatcgata 1620
ccgtcgacct cga 1633

<210> 75
<211> 1022
<212> DNA
<213> Homo sapiens

<400> 75
ttcccgggtc gacccacgcg tccgcccacg cgtccggctt ggggccagca ccctgtctca 60
aagatggcaa aatgaggcta gttctggatg agctagctgg tgtgggttcc aaccatagga 120
acacactgat gctcaaatcc taaggtgcca agctctaggc cctggaggct ggtagaacag 180
gatctatgcc tggaatcctg gcagggattc ctgtcaagga cttgtgttta agcctgcttc 240
agggcttcag gctgcttctg ctctgtgtct gcccaggctg gctgagcggg tggatgggtg 300
gacagaaggg ctcaccaagg attgtggaca tagggtaggc cctggtacca cgggtttcag 360
gctgttatca cttcccttgt aggaacatag ccagaagcag atgagccagg gtagagggct 420
ggcccctcct ctcatcttcc cttcagtctt aaattgtctc cagcgatggg aagaggccag 480
ggactgtaac ccttgtgctg tgtattctct gagcctctgc tcactctcag ggccaagcag 540
ctcccaagcc ggggccctct cttggccaaa atctgaggag cagtctaggt tacaggcttt 600
ttggtaggta ggttctggct gcctgttaat gcagttaggc cccctgatta ggtacagtga 660
gaaacaagct agaacaaccc tggcccagaa gactgtgcac tccagcaaga tccagggatg 720
atagccttgc agggccactg ggagtttgtg cccaagcttc tccctcttct ctccccaggg 780
ggcactggga ctggtccctg ccctcatcct tagcctgggc cttccccaga cgtattaaag 840
agaagtatga ttcctctgtc ttcagttctt ttcaggggca tcctgcccat agtacccagt 900
tcccaagggg cccccagtca cgtggtgaag cctagcactc atgcagctct tagggaacca 960
aaaaccagca ctgaaataaa gctgaatgac tgactgaaaa aaaaaaaaaa aaagggcggc 1020
cg 1022

```
<210> 76
<211> 1184
<212> DNA
<213> Homo sapiens

<400> 76
agcaaaaggt gaagagagaa aggaagcttt ttctctaaaa atggtgcagc tatcctctga      60
accaatttcc ttcggtttaa tgtacctgta tcttggggtt tttttccact taatttatcc     120
tggagctctt tccataacaa cacttggaaa gcactctcat cctttttca ctgctgaaca      180
gaattccact gtgtggatgg aacatactct atttcaccag tcccctgtag ccagtcactt     240
ggtttgtttc caatcttttg cttttcaga gtaataacct tgtatgtcta tcattttgta      300
tgcatacagg tttatatgta ggaaaaattc ctagagtagg attgctggac caatggataa     360
aagtatattg tggacagaca atgccaaatt gcctttcaga gactgtggcc ctgtgcaccc     420
catcaggcat gtgtgactac caaagctcct gtcagctgtt ttattttatc tcctttccag     480
tctcaggctc aatgcagaac tttgaggtaa gcttttctaa aatgtaggct cctaaacgcc     540
acagccagct ctgccacatg aaggagagct caaatgagac agaaacagcc tctgggcagg     600
atttctatcc tgcacagata tattttccac attctgggaa accgtgaagc ttccagagcc     660
acaattcccc agaaacacat ccccctgctg gtacagccaa gccccagaac aagctgtgct     720
tgcctggcac ctcaaagcca agcaccatgg atgccacttg ccatgggtgc ctgcaatttc     780
aaataatgag aaataagaaa tttcagcttc tcagtccctc tagccaacat ttcaggtgca     840
tgacagcctc aggtggcaag cagctactct gccggacagg gcagaagatg gaacacccca     900
tccctgggga agatcacgag gtcaggagat caagaccatc ctggctaaca cagtgaaacc     960
ccgtctctac tgaaaataca aaacattagc tgggtgtggt ggcaggcacc tgtagtccca    1020
gctactcagg aggctgaggc aggagaatgg cgtgaacctg ggaggtggag gttgcagtga    1080
gccaagattg cgccactgca ctccagcctg gcaacagagt aagactccat atcaaaaaaa    1140
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa                     1184
```

```
<210> 77
<211> 312
<212> DNA
<213> Homo sapiens

<400> 77
aattcccggg tcgacccacg cgtccgtgat gagtggattt gtactcttac ccaggtcctg      60
agggccagcc cacccagcat ccccacccct gatgacgctg tccctacaac tggctgaact     120
ggtgcatttt gtgtgtgcct tccagagcca gtggactggt gtgtatccaa tgatgccacc     180
tctgaaacct acagaaccac tatgctttgc atgtgtaccc tgcagggtct gagggccagg     240
ctgtctggta gctctgctcc tgggtgacag agcaagactc tgtctcaaaa aaaaaaaaaa     300
agggcggccg ct                                                        312
```

```
<210> 78
<211> 1370
<212> DNA
<213> Homo sapiens

<400> 78
tggttaaaga gtacgacatt ttagtcaggg ctgagcacag cgcctggccg aggagtgctt      60
ttatatgctc ttggaagtat atggggactc catttctgtc actgtggcga ttccacttat     120
gcattcacca tgccaatcca aggcagctga tggcttagga aagtcagaga ctgagatgtt     180
aaaatccttg gggctatcta ccaacatgtc tccattccac ctgttagggt taaaggtttt     240
tctaacctgg gccctgacct tagcacagat ctgcctatat ttttttgaag ttcagccact     300
tggactatta gccctaaact ttttctgtac tgccactgca gggctgaagg agctttgcat     360
gcatccacca agtctggctt tcacacctga atttcacacc tcgctttcac ccttagctat     420
tccatctttc tgtggaacat cagtgtcact tagcaatagc catacaatcc cattatcctt     480
atacctacct ttcccttcaa agtctcggat gcctgataca ttgcacctgc tagtgcattc     540
actcccatta gtacactccc aagtccttcc agtgaaagat gtaacaattg aatggccact     600
ctgccaaagg tgcctgggct ctacctgcca ccagtgatgg ggtcctcaca gccaacccag     660
```

```
tggtgtatca tccatttcca aaaccatctc amtgcctgtt ttcttggacc actcctggca    720
tcaactgttt caggttagag tgactgaaaa tttgggktat aagatattta ttagagatca    780
atatctatta aaaatgtgaa aggaagcagg attktgctga ggaagaagat aacaacaaag    840
ataccacaat gtcagcccat caaagccttt ggccaaccca gcasaaaaat ctggagcagg    900
tgtayctttt tcagagtctc cccagttagg tcaaaatgtg cgcctttaca cccgcacttc    960
cctcaatcac gggcttcagg ctgtcctggg catgacctca gatgaagcgg ctcacacagc   1020
tgaggctaac gttgtcggac ctgacagctg aaagccgttt gctgaccaca ctcccacagc   1080
cgagcagcat gcccttgctt ggaggaggat ttggatgaca cagctctatg tctgccgtat   1140
tttgggggtc acattcctca cacccagctc tgcctcaaat ggcaacattg acaaaaattc   1200
attccagttg caaaccaatt gtagaatact ataaaaccag agtacaagtc taatagcata   1260
aatctcatcc taagtggaaa agaaagggtc atttattcac acatttttgg ggaaaaaaaa   1320
acaacctttg ctatgtcttt attacaacac ggatactcac aaaaaatagt              1370
```

<210> 79
<211> 368
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (5)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (13)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (35)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (351)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (367)
<223> n equals a,t,g, or c

<400> 79

```
aatgnaactc tcnttactaa ttggaaccaa agctngagct ccaccgcggt ggcggccgct     60
ctagaactag tggatccccc gggctgcagg aattcggcac gaggtccagg tgtctttatt    120
tcagatgttc tgtttttcct ctattttctg ctcacatgaa catacacact tgccaggcac    180
attctggctt ttcttatttc tctttctgat tttgcctcct tcctgcccct gttttcttcc    240
cttttctctg gctatagaaa ctgtcaggtg gccttgctgg catcatccta cctcttttga    300
actgtgttac ccaggaactt ccatttatta tgcctcgagg gggggcccgg nacccaattc    360
ggaagant                                                             368
```

<210> 80
<211> 1088
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (4)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (5)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (9)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (11)
<223> n equals a,t,g, or c

<400> 80
```
nttnnaacng naaatctccc cttactattg ggaacaaaag ctggagctcc accgcggtgg     60
cggccgctct agaactagtg gatcccccgg gctgcaggaa ttcggcacga gattccccag    120
aattggttca tcttgggaaa ggaaggccta ggaagctgat gacctacttg ttttgttcat    180
ccatttctct actgcttctt aaagtgcact caagcggtca ccaggacatc agaaaagcca    240
aatccaaggt cccaaggctc ttgatcatcc agtgcccaca acagagggag taagctagac    300
ggagaagctg aagtgaagga ggaaagagag aagggggtgc ctgttccacc cccttcctag    360
cagctgcctc tgtgggctcc ataatcccca tgccctctcc cccaccccac cctccggccg    420
mccacctctc ctccacccac cccattcatc agtaggaggg cactgtatca gcacagcctt    480
tcaaggcctg acagttcctt tctgggtgcc ccccacatgt aaccacttaa cccccagcac    540
aaagggccag cctgaatggg cttggagccg gtggctcgtg cgragggga ggcctcaata    600
ggatttgggg agctgggtgt ataaaccgct ctgctccagc agccctcaat ggaggagctg    660
gagttggggc atgtgccgag gggaggagct cggcagctgc atcccgsccc tgaacaatga    720
tttattcatt ctcctggcac gcacagagaa gacaggctgg ggaaacatgg ccccacaaat    780
cgccctcagc ctcagctgat tcccacggca atcattgcag ttcagagtgc cccctcccac    840
ttgtaatgtt ttgcctcaag cttgcccttc ctcttcctgg taaggaagta gactacatta    900
cgggaggcct taagtagcct taaattcagg caagcatcgt tctttgagtt ggttgcaccc    960
aaactcaatc tcactctctc aaagctttct ggccaggttt tcctcacaca cccatagaaa   1020
cagatgcaga caaaaaaaaa aaaaaaaaaa actcgagggg gggcccggaa cccaattcgg   1080
aagatttg                                                            1088
```

<210> 81
<211> 1862
<212> DNA
<213> Homo sapiens

<400> 81
```
ggcacgagct ctgcaaagct ccctctgctc cagcacgtcc tgtatttttt caactttgga     60
tgtttgcaca agctattatc ttttgcaaga atgtcctgcc ccctcctatc catctgtgga    120
agtcaacctt tctttagggc ccagaggaaa acctatcacc ttctacacct tcccagatgc    180
ccaccatttg ggttaaactc tgcctcctcc aggtttgcca tggtcttttc cctctcttaa    240
agcactggtc ccagccatg ccattgtgtg tcaccttggc tcctgtctcc tactggctgt    300
agatctttgg garggagga actggggaat tttcatcctg gggctatggg atagtgctta    360
```

cccctaagta taaaataagc aagaatcctt gaattgaaaa gctccagtga cttgatagct 420
tccaacagcc cctaaagatg gggtagtcca ctgctcccta tataggaagg aagaggttca 480
cagtctcatg gatttagcag ccttcgtagc ctcaggatct ttcccaatgt ccccagttct 540
cctgctgggc cagctgtggt ctctgagaat gctcagttcc ctgggctagg ctggcttatg 600
gggccctccc tcctggacct gggtccatgt gaccaagtgg ccagccagcg agagagccct 660
gggtgatgag catctggaag tcagcttgct tgtctgccct aatcacagcc ctgggctcta 720
ccctcaagta ccctactcac atggtccaag agggaaccac tcttctgtca ttccctcccc 780
ttctgctcct catcctaccc acccagctgt tctgggcaag atcctgtggg catgatggaa 840
tcctcccttt tctctaccat ccatcccttt gatcacctaa tcctrcarct gccctccaac 900
caaggtgttc tttctatacc aaaaaatctg atcaggccat cactcctctg tttaaaacca 960
ttcaacggct acccactgcc ctcaggataa aaactaaaat tcttaacagg atttacaaat 1020
tcttcacctg gcccttttga gataagagga tttataatct tttcaaagcc aacaagcatc 1080
ctgagacaat cttaattttt gcagctgtcc aagctattta agattgatga ggtctgcamt 1140
aagttgttaa atggtgatta atttatctgg cctgaatggc akgtgaattc caaggggatc 1200
atttttctct accttccttg ctgcacattg ggacacagca aggccaggac acccttytta 1260
ggtgactgsg taaccaggtt cattaaggca gtcagcgcag agaagaagca gaaaatgggg 1320
aggagttgtg taaatgaaat tgccgataat accaaaggaa ccccaagaga ggttcagtct 1380
cccaacaatt gcagctttgc tgcaacatgg cagggtggga caggggtagg tttggatctg 1440
ggctgctttg ccmtggaagt ggggttacag ggcagggaga ggcttaccat cactgagcat 1500
ctttaattga ctttgtcatt ttastgagaa cttacaaatt gagctattct tcattgagtt 1560
atatttggaa gcaggttcaa tacataatac agtcctccct ctagaatttc tgctttatgt 1620
ccacgtgatg cagcttgttc atttctgaat tccttttaat gacaaaaaca tttggaagga 1680
atgtaaagac tcaaaaaggg gatggcatgt aaactatagt tggaacaata tgtggccatt 1740
taaaagaagt gttgtccagg aggtggaggt tgcagtgagc tgagattgca ccactgcact 1800
ctagcctggg ccatagaatg agactccttc tcaaaaaaaa aaaagaaaaa aaaaaactcg 1860
ag 1862

<210> 82
<211> 1618
<212> DNA
<213> Homo sapiens

<400> 82
ccacgcgtcc gcaaggagcc agaggccatg cagtggctca gggtccgtga gtcgcctggg 60
gaggccacag gacacagggt caccatgggg acagccgccc tgggtcccgt ctgggcagcg 120
ctcctgctct ttctcctgat gtgtgagatc cctatggtgg agctcacctt tgacagagct 180
gtggccagcg actgccaacg gtgctgtgac tctgaggacc ccctggatcc tgcccatgta 240
tcctcagcct cttcctccgg ccgcccccac gccctgcctg agatcagacc ctacattaat 300
atcaccatcc tgaagggtga caaaggggac ccaggcccaa tgggcctgcc agggtacatg 360
ggcagggagg gtccccaagg ggagcctggc cctcagggca gcaagggtga caagggggag 420
atgggcagcc ccggcgcccc gtgccagaag cgcttcttcg ccttctcagt gggccgcaag 480
acggccctgc acagcggcga ggacttccag acgctgctct tcgaaagggt ctttgtgaac 540
cttgatgggt gctttgacat ggcgaccggc cagtttgctg ctcccctgcg tggcatctac 600
ttcttcagcc tcaatgtgca cagctggaat tacaaggaga cgtacgtgca cattatgcat 660
aaccagaaag aggctgtcat cctgtacgcg cagcccagcg agcgcagcat catgcagagc 720
cagagtgtga tgctggacct ggcctacggg gaccgcgtct gggtgcggct cttcaagcgc 780
cagcgcgaga acgccatcta cagcaacgac ttcgacacct acatcacctt cagcggccac 840
ctcatcaagg ccgaggacga ctgagggcct ctgggccacc ctcccggctg gagagctcag 900
ctgatacggc atcctgcgag aagacctgcc ctcctcactg ggatcccctt cctgcctcct 960
cccagggctc tgccagggcc ttgctcagtc ccttccacca aagtcatctg aacttccgtt 1020
tcccagggcc tccagctgcc ctcagacact gatgtctgtc cccaggtgct ctctgcccct 1080
catgcccctc tcaccggccc agtgccccga ctctccaggc tttatcaagg tgctaaggcc 1140
cgggtgggca gctcctcgtc tcagagcccc cctccggcct ggtgctgcct ttacaaacac 1200
ctgcaggaga agggccacgg aagccccagg ctttagagcc ctcagcaggt ctggggagct 1260
agagcaaagg agggacctca ggccttccgt ttcttcttcc agggtggggt ggcctggtgt 1320
tcccctagcc ttccaaaccc aggtggcctg cccttctccc cagagggagg cggcctccgc 1380
ccattggtgc tcatgcagac tctggggctg aggtgccccg gggggtgatc tctggtgctc 1440
acagtcgagg gagccgtggc tccatggcca gatgacggaa acagggtctg accaagtgcc 1500

aggaagacct gtgctataaa ccaccctgcc tgatcctgcc cctgcctgac cccgccacgc 1560
cctgccgtcc agcatgatta aagaatgctg tctcctcttg gaaaaaaaaa aaaaaaa 1618

<210> 83
<211> 2034
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (14)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (382)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1999)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2027)
<223> n equals a,t,g, or c

<400> 83
actcactaag gganCaaagc tggagctcca ccgcggtggc ggccgctcta gaactagtgg 60
atcccccggg ctgcaggaat tcggcacgag atctaccggg agakggaytc tgaaagggcc 120
ccggccagcg tccctgagac gccaacggca gtcactgccc cccattccag ctcctgggat 180
acgtactatc agccccgtgc cctggagaaa catgctgaca gcatcctggc actggcttca 240
gtattctggt ccatctctta ttactcctct cccttcgcct tcttctactt gtacaggaaa 300
ggttacttga gtttgtccaa agtggtgccg ttttctcact atgctgggac attgctgcta 360
cttctggcag gtgtggcctg cntccgaggc attcgccgct ggaccaaccc ccagtaccgg 420
cagttcatca ccatcttgga agcaacacat cggaaccagt cttcagaaaa caagaggcag 480
cttgccaact acaactttga cttccggagc tggccagtcg acttccactg ggaagaaccc 540
agcagccgga aggagtctcg agggggccct tcccgccggg gtgtggccct gcttcgccca 600
gagcccctgc accgggggac agcagacacc ctcctcaacc gggttaagaa gctgccctgt 660
cagatcacca gctacctggt ggcgcacacc ctagggcgcc ggatgctgta tccaggctct 720
gtgtacctgc tgcagaaggc cctcatgcct gtgctgctgc agggccaggc ccgactggtg 780
gaagagtgta atgggcgccg ggcaaayctg ctggcctgtg atggcaatga gattgacacc 840
atgtttgtgg accggcgggg gacagctgag ccccagggac agaagctggt gatctgctgt 900
gaggggaatg ctgggtttta tgaggtgggc tgcgtctcca cgcccctgga agctggatat 960
tcagtcctgg gctggaatca tccaggcttt gctggaagca cgggggtgcc attcccgcag 1020
aatgaggcta atgccatgga tgtggtggtc cagtttgcca tccaccgcct rggcttccag 1080
ccccaggaca tcatcatcta cgcctggtcc atcggcggct tcactgccac gtgggcagcc 1140
atgtcctacc cagatgttag tgccatgatc ctggatgcct cctttgatga cctggtgccc 1200
ttggccttga aggtcatgcc agacagctgg aggggcctgg tgaccaggac cgtgaggcag 1260
catctcaatc taaacaacgc ggagcagctg tgcagatacc agggtcctgt actgctgatc 1320
cggagaacca aggatgagat catcaccacc acggttcctg aggacatcat gtccaaccga 1380
ggcaatgacc tcctgctgaa gctcctgcag catcggtatc ccgggtgat ggcagaggag 1440
ggtcttcgag tggtgaggca gtggttggag gcctcctcac agctggagga agcctcaatt 1500
tatagccgat gggaggtcga agaggactgg tgtctgtctg tcctccgctc ctaccacgca 1560
gaacacgggc ccgacttccc ctggagcgtg gggaggaca tgagtgcaga tggacggcgg 1620
cagctggctt tgtttctggc tcggaagcat cctgcacaact ttgaggccac tcactgcacc 1680
ccactcccag cccagaactt ccagatgccc tggcacctct agggaccaac tgggactcat 1740

```
tatggaagaa tggggtgaga ggagacatga ggaaagaccc tcttatttgt gattctctgt     1800
gttcatgttg ctgtttatag tttgtggaaa gtgggggacc atcccccttc tcaccactgt     1860
tcctcttgca cgtttcccct cattcatgtg gctgtactta accttctcca acatacatcc     1920
tgcattacat gaatggatta ttcctaataa ttaataaaaa ggtatttttt ctacaaaaaa     1980
aaaaaaaaaa aaactccana attacttcct aaaaccggcc cgcgggnccc atcc           2034
```

<210> 84
<211> 2240
<212> DNA
<213> Homo sapiens

<400> 84

```
tcgaccacgc gtccgcttcc tcatgctgcc cgctcgccta ccgttcaggc tgctgagcct       60
tttccttcgt ggatccgctc ccacggcagc gcgccatggc ctccgggagc cgctcctgga      120
gaggaggtgc gctgccgcct cctccttcca gcactcatcg agtctgggac gcgagcttcc      180
ttatgacccc gtggacacgg agggctttgg agaaggtggt gacatgcagg agcgttttct      240
gttcccggag tacatcctgg atccggagcc gcaacccacc cgcgaaaagc agctgcagga      300
gctccagcaa cagcaggagg aggaggagcg acagaggcag cagcggcggg aggagcggcg      360
acagcaaaac ctacgggcca ggtcccggga gcacccggtc gtggggcacc cggacccggc      420
attgccgccc agcggcgtga actgctcggg ctgcggggca gagctgcact gccaggacgc      480
cggagtgccc ggctacctgc cccgagagaa gttcctccgc acggcggagg cagacggcgg      540
gctggcacgg accgtgtgcc agcgctgctg gctgctgtcg caccaccggc gcgctctacg      600
cctgcaggtg agccgcgagc agtacctgga gctggtgagc gccgcgttgc ggcggcccgg      660
cccctccctg gtgctctaca tggtggacct gctggacctg cccgacgccc tgctgcccga      720
cttgcccgcg ctggtgggcc ccaagcagct gatcgtgctg ggaaacaaag tggacctcct      780
gccccaggat gctcctggct accggcagag gctgcgggag cgactgtggg aggactgtgc      840
ccgcgccggg ctcctgctgg cccctggcca ccaagggcca cagcgccccg tcaaggacga      900
gccacaggac ggggagaatc cgaatccgcc gaactggtcc cgcacagtgg tcagggacgt      960
gcggctgatc agcgccaaga ccggctatgg agtggaagag ttgatctctg cccttcagcg     1020
ctcctggcgc taccgtgggg acgtctactt agtgggcgcc accaacgccg gcaaatccac     1080
tctctttaac acgctcctgg agtccgatta ctgcactgcc aagggctccg acgccatcga     1140
cagagccacc atctcccctt ggccaggtac tacattaaac cttctgaagt ttcctatttg     1200
caacccaact ccttacagaa tgtttaaaag gcatcaaaga cttaaaaaag attcaactca     1260
agctgaagaa gatcttagtg agcaagaaca aaatcagctt aatgtcctca aaaagcatgg     1320
ttatgtcgta ggaagagttg gaaggacatt cttgtattca gaagaacaga aggataacat     1380
tccctttgag tttgatgctg attcacttgc ctttgacatg gaaaatgacc ctgttatggg     1440
tacacacaaa tccaccaaac aagtagaatt gactgcacaa gatgtgaaag atgcccactg     1500
gttttatgac acccctggaa ttacaaaaga aaattgtatt ttaaatcttc taacagaaaa     1560
agaagtaaat attgttttgc caacacagtc cattgttcca agaacctttg tgcttaaacc     1620
aggaatggtt ctgtttttgg gtgctatagg ccgcatagat ttcctgcagg gaaatcagtc     1680
agcttggttt acagtcgtgg cttccaacat cctccctgtg catatcacct ccttggacag     1740
ggcagacgct ctgtatcaga agcatgcagg tcatacgtta ctccagattc caatgggtgg     1800
aaaagaacga atggcaggat ttcctcctct tgttgctgaa gacattatgt taaaagaagg     1860
actgggggca tctgaagcag tggccgacat caagtttttcc tctgcaggtt gggtttcagt    1920
aacacctaat tttaaggaca gactgcatct ccgaggctat acacctgaag gaacagtttt     1980
gaccgtccgg ccccctctct tgccatatat tgttaacatc aaaggacagc gcatcaagaa     2040
aagtgtggcc tataaaacca agaagcctcc ttcccttatg tacaacgtga ggaagaagaa     2100
aggaaagata aatgtatgag accgaccttg ttcactccag atattaactg tattgaacac     2160
aacaaaatac attgaatttg tattaaacat ataacgcata aataaagctc ccattcttac     2220
ccttaaaaaa aaaaaaaaaa                                                 2240
```

<210> 85
<211> 1488
<212> DNA
<213> Homo sapiens

<400> 85

```
cgccaagttt ccggagggag agggtagaaa ctggaggggg tggacctgtc actcacggga      60
ctgagggtcc ttttctcccg ctcccaggag gaacgagaat gaatatgact caagcccggg     120
ttctggtggc tgcagtggtg gggttggtgg ctgtcctgct ctacgcctcc atccacaaga     180
ttgaggaggg ccatctggct gtgtactaca ggggaggagc tttactaact agccccagtg     240
gaccaggcta tcatatcatg ttgcctttca ttactacgtt cagatctgtg cagacaacac     300
tacaaactga tgaagttaaa aatgtgcctt gtggaacaag tggtggggtc atgatctata     360
ttgaccgaat agaagtggtt aatatgttgg ctccttatgc agtgtttgat atcgtgagga     420
actatactgc agattatgac aagaccttaa tcttcaataa aatccaccat gagctgaacc     480
agttctgcag tgcccacaca cttcaggaag tttacattga attgtttgat caaatagatg     540
aaaacctgaa gcaagctctg cagaaagact taaacctcat ggccccaggt ctcactatac     600
aggctgtgcg tgttacaaaa cccaaaatcc cagaagccat aagaagaaat tttgagttaa     660
tggaggctga gaagacaaaa ctccttatag ctgcacagaa acaaaaggtt gtggaaaaag     720
aagctgagac agagaggaaa aaggcagtta tagaagcaga gaagattgca caagtggcaa     780
aaattcggtt tcagcagaaa gtgatggaaa aagaaactga aaagcgcatt tctgaaatcg     840
aagatgctgc attcctggcc cgagagaaag cgaaagcaga tgctgaatat tatgctgcac     900
acaaatatgc cacctcaaac aagcacaagt tgaccccgga atatctggag ctcaaaaagt     960
accaggccat tgcttctaac agtaagatct atttggcag caacatccct aacatgttcg     1020
tggactcctc atgtgctttg aaatattcag atattaggac tggaagagaa agctcactcc    1080
cctctaagga ggctcttgaa ccctctggag agaacgtcat ccaaaacaaa gagagcacag    1140
gttgatgcaa gaggtggaaa tgttctccat atcaagatgt ggcccaaggg gttaagtggg    1200
aacaatcatt atacggactc ttcagattta cagagaactt acacttcatc tgttccacct    1260
ctcctgcgat agtcctgggt gctccactga ttggaggata gagccagctg tctgacacac    1320
aaatggtctt ttcagccaca gtcttatcaa gtatcctata tgtattcctt tctaaactgc    1380
tactcatgaa tgaggaaagt ctgatgctaa gatactgcct gcactggaat gttaaacact    1440
aaatatataa caagctgtgt ttcctaagc tgaaaaaaaa aaaaaaa                  1488
```

```
<210> 86
<211> 3174
<212> DNA
<213> Homo sapiens

<400> 86
gcggacgctg grcscaaaca ctaaggcctg agcggtgaca atcgaggcga gatgatggtc      60
aacagggaat gcctcgtggg agaaaaaaga caatttattt ctcagcgctg attttgagat     120
gatgggcttg ggaaacgggc gtcgcagcat gaagtcgccg cccctcgtgc tggccgccct     180
ggtggcctgc atcatcgtct tgggcttcaa ctactggatt gcgagctccc ggagcgtgga     240
cctccagaca cggatcatgg agctggaagg cagggtccgc aggcgggctg cagagagagg     300
cgccgtggag ctgaagaaga acgagttcca gggagagctg gagaagcagc gggagcagct     360
tgacaaaatc cagtccagcc acaacttcca gctggagagc gtcaacaagc tgtaccagga     420
cgaaaaggcg gttttggtga ataacatcac cacaggtgag aggctcatcc gagtgctgca     480
agaccagtta aagaccctgc agaggaatta cggcaggctg cagcaggatg tcctccagtt     540
tcagaagaac cagaccaacc tggagaggaa gttctcctac gacctgagcc agtgcatcaa     600
tcagatgaag gaggtgaagg aacagtgtga ggagcgaata gaagaggtca ccaaaaaggg     660
gaatgaagct gtagcttcca gagacctgag tgaaaacaac gaccagagac agcagctcca     720
agccctcagt gagcctcagc ccaggctgca ggcagcaggc ctgccacaca cagaggtgcc     780
acaagggaag ggaaacgtgc ttggtaacag caagtcccag acaccagccc ccagttccga     840
agtggttttg gattcaaaga gacaagttga gaaagaggaa accaatgaga tccaggtggt     900
gaatgaggag cctcagaggg acaggctgcc gcaggagcca ggccgggagc aggtggtgga     960
agacagacct gtaggtggaa gaggcttcgg gggagccgga gaactgggcc agaccccaca    1020
ggtgcaggct gccctgtyag tgagccagga aaatccagag atggagggcc ctgagcgaga    1080
ccagcttgtc atccccgacg gacaggagga ggagcaggaa gctgccgggg aagggagaaa    1140
ccagcagaaa ctgagaggag aagatgacta caacatggat gaaaatgaag cagaatctga    1200
gacagacaag caagcagccc tggcagggaa tgacagaaac atagatgttt ttaatgttga    1260
agatcagaaa agagacacca taaatttact tgatcagcgt gaaaagcgga atcatacact    1320
ctgaattgaa ctggaatcac atatttcaca acagggccga agagatgact ataaaatgtt    1380
catgagggac tgaatactga aaactgtgaa atgtactaaa taaaatgtac atctgaagat    1440
gattattgtg aaatttagt atgcactttg tgtaggaaaa aatggaatgg tcttttaaac    1500
agcttttggg gggtactttg gaagtgtcta ataaggtgtc acaatttttg gtagtaggta    1560
```

tttcgtgaga agttcaacac caaaactgga acatagttct ccttcaagtg ttggcgacag 1620
cggggcttcc tgattctgga atataacttt gtgtaaatta acagccacct atagaagagt 1680
ccatctgctg tgaaggagag acagagaact ctgggttccg tcgtcctgtc cacgtgctgt 1740
accaagtgct ggtgccagcc tgttacctgt tctcactgaa aagtctggct aatgctcttg 1800
tgtagtcact tctgattctg acaatcaatc aatcaatggc ctagagcact gactgttaac 1860
acaaacgtca ctagcaaagt agcaacagct ttaagtctaa atacaaagct gttctgtgtg 1920
agaatttttt aaaaggctac ttgtataata acccttgtca ttttaatgt acaaaacgct 1980
attaagtggc ttagaatttg aacatttgtg gtctttattt actttgcttc gtgtgtgggc 2040
aaagcaacat cttccctaaa tatatattac caagaaaagc aagaagcaga ttaggttttt 2100
gacaaaacaa acaggccaaa agggggctga cctggagcag agcatggtga gaggcaaggc 2160
atgagagggc aagtttgttg tggacagatc tgtgcctact ttattactgg agtaaaagaa 2220
aacaaagttc attgatgtcg aaggatatat acagtgttag aaattaggac tgtttagaaa 2280
aacaggaata caatggttgt ttttatcata gtgtacacat ttagcttgtg gtaaatgact 2340
cacaaaactg attttaaaat caagttaatg tgaattttga aaattactac ttaatcctaa 2400
ttcacaataa caatggcatt aagtttgac ttgagttggt tcttagtatt atttatggta 2460
aataggctct taccacttgc aaataactgg ccacatcatt aatgactgac ttcccagtaa 2520
ggctctctaa ggggtaagta ggaggatcca caggatttga gatgctaagg ccccagagat 2580
cgtttgatcc aaccctctta ttttcagagg ggaaaatggg gcctagaagt tacagagcat 2640
ctagctggtg cgctggcacc cctggcctca cacagactcc cgagtagctg ggactacagg 2700
cacacagtca ctgaagcagg ccctgtttgc aattcacgtt gccacctcca acttaaacat 2760
tcttcatatg tgatgtcctt agtcactaag gttaaacttt cccacccaga aaaggcaact 2820
tagataaaat cttagagtac tttcatactc ttctaagtcc tcttccagcc tcactttgag 2880
tcctccttgg ggttgatagg aattttctct tgctttctca ataaagtctc tattcatctc 2940
atgtttaatt tgtacgcata gaattgctga gaaataaaat gttctgttca acttaaaaaa 3000
cttgtcacag ctctgttttt ttgcttttcc ccttcatcct ctattagatc cttaaagaat 3060
ccaccctcaa actgtggact aaggatggca gtttgcctta aaccttctgt ggaatgagat 3120
gggctgtcag gacgtcttca acccacagta ccccgaaagc tttgtgctca ccac 3174

<210> 87
<211> 2780
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (2760)
<223> n equals a,t,g, or c

<400> 87
ggcgccgcgg gcggggggtc ccggggccac gtggacgccg acggctctgg tctgcggcgt 60
gtggacactg ccagcggctg cagccgactt ggaatgacct gggagacaaa tacaacagca 120
tggaagakgc caaagtctat gtggctaaag tggactgcac ggcccactcc gacgtgtgct 180
ccgcccaggg ggtgcgagga taccccacct taaagctttt caagccaggc caagaagctg 240
tgaagtacca gggtcctcgg gacttccaga cactggaaaa ctggatgctg cagacactga 300
acgaggagcc agtgacacca gagccggaag tggaaccgcc cagtgccccc gagctcaagc 360
aagggctgta tgagctctca gcaagcaact ttgagctgca cgttgcacaa ggcgaccact 420
ttatcaagtt cttcgctccg tggtgtggtc actgcaaagc cctggctcca acctgggagc 480
agctggctct gggccttgaa cattccgaaa ctgtcaagat tggcaaggtt gattgtacac 540
agcactatga actctgctcc ggaaaccagg ttcgtggcta tcccactctt ctctggttcc 600
gagatgggaa aaaggtggat cagtacaagg gaaagcggga tttggagtca ctgagggagt 660
acgtggagtc gcagctgcag cgcacagaga ctggagcgac ggagaccgtc acgccctcag 720
aggccccggt gctggcagct gagcccgagg ctgacaaggg cactgtgttg gcactcactg 780
aaaataactt cgatgacacc attgcagaag gaataacctt catcaagttt tatgctccat 840
ggtgtggtca ttgtaagact ctggctccta cttgggagga actctctaaa aaggaattcc 900
ctggtctggc gggggtcaag atcgccgaag tagactgcac tgctgaacgg aatatctgca 960
gcaagtattc ggtacgaggc taccccacgt tattgctttt ccgaggaggg aagaaagtca 1020
gtgagcacag tggaggcaga gaccttgact cgttacaccg ctttgtcctg agccaagcga 1080
aagacgaact ttaggaacac agttggaggt cacctctcct gcccagctcc cgcaccctgc 1140

gtttaggagt tcagtcccac agaggccact gggttcccag tggtggctgt tcagaaagca 1200
gaacatacta agcgtgaggt atcttctttg tgtgtgtgtt ttccaagcca acacactcta 1260
cagattcttt attaagttaa gtttctctaa gtaaatgtgt aactcatggt cactgtgtaa 1320
acattttcag tggcgatata tcccctttga ccttctcttg atgaatttta catggtttcc 1380
tttgagacta aaatagcgtt gagggaaatg aaattgctgg actatttgtg gctcctgagt 1440
tgagtgattt tggtgaaaga aagcacatcc aaagcatagt ttacctgccc acgagttctg 1500
gaaaggtggc cttgtggcag tattgacgtt cctctgatct taaggtcaca gttgactcaa 1560
tactgtgttg gtccgtagca tggagcagat tgaaatgcaa aaacccacac ctctggaaga 1620
taccttcacg gccgctgctg gagcttctgt tgctgtgaat acttctctca gtgtgagagg 1680
ttagccgtga tgaaagcagc gttacttctg accgtgcctg agtaagagaa tgctgatgcc 1740
ataactttat gtgtcgatac ttgtcaaatc agttactgtt caggggatcc ttctgtttct 1800
cacggggtga aacatgtctt tagttcctca tgttaacacg aagccagagc ccacatgaac 1860
tgttggatgt cttccttaga aagggtaggc atggaaaatt ccacgaggct cattctcagt 1920
atctcattaa ctcattgaaa gattccagtt gtatttgtca cctggggtga caagaccaga 1980
caggctttcc caggcctggg tatccaggga ggctctgcag ccctgctgaa gggccctaac 2040
tagagttcta gagtttctga ttctgtttct cagtagtcct tttagaggct tgctatactt 2100
ggtctgcttc aaggaggtcg accttctaat gtatgaagaa tgggatgcat ttgatctcaa 2160
gaccaaagac agatgtcagt gggctgctct ggccctggtg tgcacggctg tggcagctgt 2220
tgatgccagt gtcctctaac tcatgctgtc cttgtgatta aacacctcta tctcccttgg 2280
gaataagcac atacaggctt aagctctaag ataggtgttt gtcctttac catcgagcta 2340
cttcccataa taaccacttt gcatccaaca ctcttcaccc acctcccata cgcaagggga 2400
tgtggatact tggcccaaag taactggtgg taggaatctt agaaacaaga ccacttatac 2460
tgtctgtctg aggcagaaga taacagcagc atctcgacca gcctctgcct taaaggaaat 2520
ctttattaat cacgtatggt tcacagataa ttcttttttt aaaaaaaccc aacctcctag 2580
agaagcacaa ctgtcaagag tcttgtacac acaacttcag ctttgcatca cgagtcttgt 2640
attccaagaa aatcaaagtg gtacaatttg tttgtttaca ctatgatact ttctaaataa 2700
actctttttt tttaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaggggg gggggggggn 2760
ggggcccccc ccccccaaa 2780

<210> 88
<211> 1061
<212> DNA
<213> Homo sapiens

<400> 88
aattcggcac gagagaagga aatacatcaa aatgcccaca ttggttatct gtagaggata 60
gaatgaaaga tggctttatt ctcttgtttg ctcttattaa agcaatcaga tggtgcttct 120
cctgtactca gagccctggc tgcttcctgc ctggcctctc ctgcgggctg ctgtggaacc 180
agaaaagcct taaacggaaa tgtgggagag aaggttggat tcactttcat gtctttccag 240
ggttgtgacc cctcaagtcc tggttgcctt tgctgttctc tattaccttc aaacagccag 300
ctcgtcttta tttctttttt agttttgtcg gggttggctt gatagatgtt agtccatcat 360
agccagatgt gtctagcctt gtcttttgaa tgcaagattt aggatgtggg tacttagctg 420
ttagtggaca tcagagtcac tagtcaggat gaaagagttc ttggctttaa ctcccagaaa 480
ttctggtaac gtcatgtata gtgacggccg catgtctaac aggtggccag gtaagtcttt 540
tggggtggtc tgtgaatcac agtttgggag acattgactt ttagggagtt tgttctgaat 600
tcactagata atagagatat aatacagagc tttgaaagct ggtgtcttga tgacagagcc 660
gtggcaatgg ggagggttga ggaggtggct gttgggcctg tctcctggtg agagttgaaa 720
gggcctgaac tcaagcagag gcctcagaac cgaaaggtgg tggaaggatg cagcaagagg 780
cgccacacag gagtactctg cgccctggca gggtctcaat acacgtggga gtggtgagag 840
ggagaacttt aagtccaggt tttgtgcctc agtgacttag tgtggccata tcattagaaa 900
tgtgttgagg ccgggcacag tggctcatgt ctgtaatccc agcactttga gaggctgagg 960
caggaggatg gcttgaggcc aggagtttaa aaccagcctg gacaacatag tgagagcctg 1020
tctctacaaa aaaaaaaaaa aaaaactcga ggggggcccc g 1061

<210> 89
<211> 1342
<212> DNA

<213> Homo sapiens

<400> 89
ccacgcgtcc gggcgcgcgg gtgaaaggcg cattgatgca gcctgcggcg gcctcggagc 60
gcggcggagc agacgctgac cacgttcctc tcctcggtct cctccgcctc cagctccgcg 120
ctgcccggca gccgggagcc atgcgacccc agggccccgc cgcctccccg cagcggctcc 180
gcggcctcct gctgctcctg ctgctgcagc tgcccgcgcc gtcgagcgcc tctgagatcc 240
ccaaggggaa gcaaaaggcg cagctccggc agagggaggt ggtggacctg tataatggaa 300
tgtgcttaca agggccagca ggagtgcctg gtcgagacgg gagccctggg gccaatggca 360
ttccgggtac acctgggatc ccaggtcggg atggattcaa aggagaaaag gggaatgtc 420
tgagggaaag ctttgaggag tcctggacac ccaactacaa gcagtgttca tggagttcat 480
tgaattatgg catagatctt gggaaaattg cggagtgtac atttacaaag atgcgttcaa 540
atagtgctct aagagttttg ttcagtggct cacttcggct aaaatgcaga aatgcatgct 600
gtgagcgttg gtatttcaca ttcaatggag ctgaatgttc aggacctctt cccattgaag 660
ctataattta tttggaccaa ggaagccctg aaatgaattc aacaattaat attcatcgca 720
cttcttctgt ggaaggactt tgtgaaggaa ttggtgctgg attagtggat gttgctatct 780
gggttggcac ttgttcagat tacccaaaag gagatgcttc tactggatgg aattcagttt 840
ctcgcatcat tattgaagaa ctaccaaaat aaatgcttta attttcattt gctacctctt 900
tttttattat gccttggaat ggttcactta aatgacattt taaataagtt tatgtataca 960
tctgaatgaa aagcaaagct aaatatgttt acagaccaaa gtgtgatttc acactgtttt 1020
taaatctagc attattcatt ttgcttcaat caaaagtggt ttcaatattt cttttagttg 1080
gttagaatac tttcttcata gtcacattct ctcaacctat aatttggaat attgttgtgg 1140
tcttttgttt tttctcttag tatagcattt ttaaaaaaat ataaaagcta ccaatctttg 1200
tacaatttgt aaatgttaag aatttttttt atatctctta aataaaaatt atttccaaaa 1260
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1320
aaaaaaaaaa aaaaaaaaaa aa 1342

<210> 90
<211> 770
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (690)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (762)
<223> n equals a,t,g, or c

<400> 90
ggtagggtcg ggkcgaccyr cgcgtccggc tcttcctcag gcggcggcca tggcgggaca 60
ggaggatccg gtgcagcggg agattcacca ggactgggct aaccgggagt acattgagat 120
aatcaccagc agcatcaaga aaatcgcaga ctttctcaac tcgttcgata tgtcttgtcg 180
ttcaagactt gcaacactaa acgagaaatt gacagccctt gaacggagaa tagagtacat 240
tgaagctcgg gtgacaaaag gtgagacact cacctagaac agtgccgtgc tgctgctggg 300
aagttgcttt acacaacaca ggccacatgg gaaaggcccc agcagccttc agctccttcc 360
tttctcctta aagagcaaca gggcttattc ttgtttttct tttttcaaaa gtgtggcctt 420
tgggctctgc catctggggt gtggtgtggt atgtgggaag aagttcagag gaaccgttgg 480
aaacgacgtt aggcatttta ccttttcagt aacattttat acatctactt gtcaatgtat 540
ttgagacatt cacagccaaa agcctgggac tctttgtgaa ggtcctcctc amctctatct 600
ttctttctct ctctctcaaa ctttccttaa agttctcatt gcctttgcac tgcttctgtg 660
aacagtcttt gtctcctccc cacctttggn ggaaagtgcg gggcagtcct ggtcaagaca 720
ctcatgccct ggcaatgtgg cctgcagaga atgttgttgt anccaccagt 770

<210> 91
<211> 1570
<212> DNA
<213> Homo sapiens

<400> 91
```
gatggtttta ctgaagttgc taaaagttta cagaaaagga agtgcaggaa catttcacaa      60
atctacaatc tgtgagtatc acatcctgta tagctgtmaa cactggaata aggaagggct     120
gatgactttc agaagatgaa ggtaagtaga aaccgttgat gggactgaga aaccagagtt     180
aaaacctctt tggagcttct gaggactcag ctggaaccaa cgggcacagt tggcaacacc     240
atcatgacat cacaacctgt tcccaatgag accatcatag tgctcccatc aaatgtcatc     300
aacttctccc aagcagagaa acccgaaccc accaaccagg ggcaggatag cctgaagaaa     360
catctacacg cagaaatcaa agttattggg actatccaga tcttgtgtgg catgatggta     420
ttgagcttgg ggatcatttt ggcatctgct tccttctctc caaattttac ccaagtgact     480
tctacactgt tgaactctgc ttacccattc ataggacccct tttttttat catctctggc     540
tctctatcaa tcgccacaga gaaaaggttr accaagcttt tggtgcatag cagcctggtt     600
ggaagcattc tgagtgctct gtctgccctg gtgggtttca ttatcctgtc tgtcaaacag     660
gccaccttaa atcctgcctc actgcagtgt gagttggaca aaaataatat accaacaaga     720
agttatgttt cttactttta tcatgattca ctttatacca cggactgcta tacagccaaa     780
gccagtctgg ctggawctct ctctctgatg ctgatttgca ctctgctgga attctgccta     840
gctgtgctca ctgctgtgct gcggtggaaa caggcttact ctgacttccc tgggagtgta     900
cttttcctgc ctcacagtta cattggtaat tctggcatgt cctcaaaaat gactcatgac     960
tgtggatatg aagaactatt gacttcttaa gaaaaaaggg agaaatatta atcagaaagt    1020
tgattcttat gataatatgg aaaagttaac cattatagaa aagcaaagct tgagtttcct    1080
aaatgtaagc ttttaaagta atgaacatta aaaaaaacca ttatttcact gtcatttaag    1140
atatgtgttc attggggatc tcttgatttg cctgacattg acttcagcaa aagcacgggg    1200
ctgtaaatta ccatttacta gattagccaa atagtctgaa tttccagaaa acaaggcaga    1260
atgatcattc ccagaaacat ttcccagaaa atgtttccca gaaaactaga cagmatgatc    1320
attcaatgga tcacagtgaa gcaaaggaca caactttta ttgtacccct taattgtcaa    1380
caggagttaa ctgatttgtt gtggtgctca gacttttta tacaggtgct agtgttttat    1440
cctatgtatt ttaactcatt agtgcataaa ggcaagcccc atataatgaa gtctcagggt    1500
atatgaaagt agctggcttc aaaataaaat ttttgagtgc aaaaaaaaaa aaaaataaaa    1560
aaaaaaaaaa                                                           1570
```

<210> 92
<211> 2950
<212> DNA
<213> Homo sapiens

<400> 92
```
cccggctccc gcccgctccc agccgggccc cccagcggtc ggcgggacgg ctcccggctg      60
cagtctgccc gcccgccccg cgcgggggcc gagtcgcgaa gcgcgcctgc gacccggcgt     120
ccgggcgcgc tggagaggac gcgaggagcc atgaggcgcc agctgcgaag gtggcggcgc     180
tgctgctcgg gctgctcttg gagtgcacag aagccaaaaa gcattgctgg tatttcgaag     240
gactctatcc aacctattat atatgccgct cctacgagga ctgctgtggc tccaggtgct     300
gtgtgcgggc cctctccata cagaggctgt ggtacttctg gttccttctg atgatgggcg     360
tgcttttctg ctgcggagcc ggcttcttca tccggaggcg catgtacccc ccgccgctga     420
tcgaggagcc agccttcaat gtgtcctaca ccaggcagcc cccaaatccc ggcccaggag     480
cccagcagcc ggggccgccc tattacacyg acccaggagg accggggatg aaccctgtcg     540
ggaattccat ggcaatggct ttccaggtcc cacccaactc accccagggg agtgtggcct     600
gcccgccccc tccagcctac tgcaacacgc ctccgccccc gtacgaacag gtagtgaagg     660
ccaagtagtg gggtgcccac gtgcaagagg agagacagga gagggccttt ccctggcctt     720
tctgtcttcg ttgatgttca cttccaggaa cggtctcgtg ggctgctaag ggcagttcct     780
ctgatatcct cacagcaagc acagctctct ttcaggcttt ccatggagta caatatatga     840
actcacactt tgtctcctct gttgcttctg tttctgacgc atctgtgctc tcacatggta     900
gtgtggtgac agtccccgag ggctgacgtc cttacggtgg cgtgaccaga tctacaggag     960
agagactgag aggaagaagg cagtgctgga ggtgcaggtg gcatgtagag gggccaggcc    1020
gagcatccca ggcaagcatc cttctgcccg ggtattaata ggaagcccca tgccgggcgg    1080
```

ctcagccgat gaagcagcag ccgactgagc tgagcccagc aggtcatctg ctccagcctg 1140
tcctctcgtc agccttcctc ttccagaagc tgttggagag acattcagga gagagcaagc 1200
cccttgtcat gtttctgtct ctgttcatat cctaaagata gacttctcct gcaccgccag 1260
gaaagggtag cacgtgcagc tctcaccgca gatggggcct agaatcaggc ttgcttggag 1320
gcctgacagt gatctgacat ccactaagca aatttattta aattcatggg aaatcacttc 1380
ctgccccaaa ctgagacatt gcattttgtg agctcttggt ctgatttgga gaaaggactg 1440
ttacccattt ttttggtgtg tttatggaag tgcatgtaga gcgtcctgcc ctttgaaatc 1500
agactgggtg tgtgtcttcc ctggacatca ctgcctctcc agggcattct caggcccggg 1560
ggtctccttc cctcaggcag ctccagtggt gggttctgaa gggtgctttc aaaacggggc 1620
acatctggct gggaagtcac atggactctt ccagggagag agaccagctg aggcgtctct 1680
ctctgaggtt gtgttgggtc taagcgggtg tgtgctgggc tccaaggagg aggagcttgc 1740
tgggaaaaga caggagaagt actgactcaa ctgcactgac catgttgtca taattagaat 1800
aaagaagaag tggtcggaaa tgcacattcc tggataggaa tcacagctca ccccaggatc 1860
tcacaggtag tctcctgagt agttgacggc tagcggggag ctagttccgc cgcatagtta 1920
tagtgttgat gtgtgaacgc tgacctgtcc tgtgtgctaa gagctatgca gcttagctga 1980
ggcgcctaga ttactagatg tgctgtatca cggggaatga ggtgggggtg cttatttttt 2040
aatgaactaa tcagagcctc ttgagaaatt gttactcatt gaactggagc atcaagacat 2100
ctcatggaag tggatacgga gtgatttggt gtccatgctt ttcactctga ggacatttaa 2160
tcggagaacc tcctggggaa ttttgtggga gacacttggg aacaaaacag acaccctggg 2220
aatgcagttg caagcacaga tgctgccacc agtgtctctg accaccctgg tgtgactgct 2280
gactgccagc gtggtacctc ccatgctgca ggcctccatc taaatgagac aacaaagcac 2340
aatgttcact gtttacaacc aagacaactg cgtgggtcca aacactcctc ttcctccagg 2400
tcatttgttt tgcattttta atgtctttat tttttgtaat gaaaaagcac actaagctgc 2460
ccctggaatc gggtgcagct gaataggcac ccaaaagtcc gtgactaaat ttcgtttgtc 2520
tttttgatag caaattatgt taagagacag tgatggctag ggctcaacaa ttttgtattc 2580
ccatgtttgt gtgagacaga gtttgttttc ccttgaactt ggttagaatt gtgctactgt 2640
gaacgctgat cctgcatatg gaagtcccrc ttcggtgaca tttcctggcc attcttgttt 2700
ccattgtgtg gatggtgggt tgtgcccact tcctggagtg agacagctcc tggtgtgtag 2760
aattcccgga gcgtccgtgg ttcagagtaa acttgaagca gatctgtgca tgcttttcct 2820
ctgcaacaat tggctcgttt ctcttttttg ttctcttttg ataggatcct gtttcctatg 2880
tgtgcaaaat aaaaataaat ttgggcaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2940
aaaaaaaaag 2950

<210> 93
<211> 1722
<212> DNA
<213> Homo sapiens

<400> 93
ggcacgagcc agagcaggct gctaggcctg gggccaccac tgcccctggg tgctacaccc 60
agtgtgctgg gtcactggga acttcctgaa gtgctgtcac ctgaactggg cccccaagga 120
tggggtgcgg gcagtaccgc aggaagagga gcagcccctg tgaagattga gagctgccag 180
aggctctgtg attggctgcg gcacgatgac ccgcgcacgg attggctgct tcgggccggg 240
gggccgggcc cgggggacag aatccgcccc cgaaccttca aagagggtac cccccggcag 300
gagctggcag accyaggagg tgcgacagac ccgcggggca aacggactgg ggccaagagc 360
cgggagcgcg ggcgcaaagg caccagggcc cgcccagggc gccgcgcagc acggccttgg 420
gggttctgcg ggccttcggg tgcgcgtctc gcctctagcc atggggtccg cagcgttgga 480
gatcctgggc ctggtgctgt gcctggtggg ctgggggggt ctgatcctgg cgtgcgggct 540
gcccatgtgg caggtgaccg ccttcctgga ccacaacatc gtgacggcgc agaccacctg 600
gaaggggctg tggatgtcgt gcgtggtgca gagcacsggg cacatgcagt gcaaagtgta 660
cgactcggtg ctggctctga gcaccgaggt gcaggcggcg cgggcgctca ccgtgagcgc 720
cgtgctgctg gcgttcgttg cgctcttcgt gaccctggcg ggcgcgcagt gcaccacctg 780
cgtggccccg ggcccggcca argcgcgtgt ggccctcacg ggaggcgtgc tctacctgtt 840
ttgcgggctg ctggcgctcg tgccactctg ctggttcgcc aacattgtcg tccgcgagtt 900
ttacgacccg tctgtgcccg tgtcgcagaa gtacgagctg ggcgcagcgc tgtacatcgg 1020
ctgggcggcc accgcgctgc tcatggtagg cggctgcctc ttgtgctgcg gcgcctgggt 1020
ctgcaccggc cgtcccgacc tcagcttccc cgtgaagtac tcagcgccgc ggcggcccac 1080
ggccaccggc gactacgaca agaagaacta cgtctgaggg cgctgggcac ggccgggccc 1140

```
ctcctgccag ccacgcctgc gaggcgttgg ataagcctgc ggagccccgc atggaccgcg     1200
gcttccgccg ggtagcgcgg cgcgcaggct cctcggaacg tccggctctg cgccccgacg     1260
cggctcctgg atccgctcct gcctgcgccc gcagctgacc ttctcctgcc actagcccgg     1320
ccctgccctt aacagacgga atgaagtttc cttttctgtg cgcggcgctg tttccatagg     1380
cagagcgggt gtcagactga ggatttcgct tcccctccaa gacgctgggg gtcttggctg     1440
ctgccttact tcccagaggc tcctgctgac ttccgagggg cggatgcaga gcccagggcc     1500
cccaccggaa gatgtgtaca gctggtcttt actccatcgg cagggcccga gcccagggac     1560
cagtgacttg gcctggacct cccggtctca ctccagcatc tccccaggca aggcttgtgg     1620
gcaccggagc ttgagagagg gcgggagtgg gaaggctaag aatctgctta gtaaatggtt     1680
tgaactctca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa                        1722
```

<210> 94
<211> 635
<212> DNA
<213> Homo sapiens

<400> 94

```
gcctaaagag agctccccca ggaccagccc tggccaaggg attgctgcag ccctcatcca       60
ccttccaagc actggaaaca aacattggag accaagtgag gcgtcactca acagccgtag      120
taatcaggga aatgacaagt tacatactga tatcctttgt tttgctgatt ggagttgggt      180
gcattgaaaa agatcagtcg tgcccagtgt ttgggggaag gaagcgtctt cacctgttgt      240
ttgtggcagg acagttgagg caggtgagga tgctgagagg tgagctcagc tgtgcctgtt      300
accgtccaca tgtgcaagcc cttcagctcg gtggttgtac ttgtttttga gatgcagttt      360
cactcttgtc acccaggctg gagtgcatgg catgatcttg gctcgctgca acatccgcct      420
cccgggttca agcgattctc ctgtctctac taaaaataca aaaattagct gggtgtggtg      480
gtgcgtgcct ttaatcccag ctactcagaa ggctgaggtg caagaattgc ttgaacctgg      540
gaggtggagg ttgccgtggg ccgagatcac gccaccgcac tccagcctag gcaacagagc      600
tagactgtct caaaaaaaaa aaaatgaccc tcgag                                 635
```

<210> 95
<211> 3798
<212> DNA
<213> Homo sapiens

<400> 95

```
ccacgcgtcc ggggcttcat acaggaaatc tattgctgtg tcaagttcca gagaaaagct       60
tctgttcgtc caagttacta accaggctaa accacataga cgtgaaggaa ggggctagaa      120
ggaagggagt gccccactgt tgatggggta agaggatcct gtactgagaa gttgaccaga      180
gagggtctca ccatgcgcac agttccttct gtaccagtgt ggaggaaaag tactgagtga      240
agggcagaaa aagagaaaac agaaatgctc tgcccttgga gaactgctaa cctagggcta      300
ctgttgattt tgactatctt cttagtggcc gaagcggagg gtgctgctca accaaacaac      360
tcattaatgc tgcaaactag caaggagaat catgctttag cttcaagcag tttatgtatg      420
gatgaaaaac agattacaca gaactactcg aaagtactcg cagaagttaa cacttcatgg      480
cctgtaaaga tggctacaaa tgctgtgctt tgttgccctc ctatcgcatt aagaaatttg      540
atcataatаa catgggaaat aatcctgaga ggccagcctt cctgcacaaa agcctacaag      600
aaagaaacaa atgagaccaa ggaaaccaac tgtactgatg agagaataac ctgggtctcc      660
agacctgatc agaattcgga ccttcagatt cgtaccgtgg ccatcactca tgacgggtat      720
tacagatgca taatggtaac acctgatggg aatttccatc gtggatatca cctccaagtg      780
ttagttacac ctgaagtgac cctgtttcaa aacaggaata gaactgcagt atgcaaggca      840
gttgcaggga agccagctgc gcatatctcc tggatcccag agggcgattg tgccactaag      900
caagaatact ggagcaatgg cacagtgact gttaagagta catgccactg ggaggtccac      960
aatgtgtcta ccgtgaactg ccacgtctcc catttgactg gcaacaagag tctgtacata     1020
gagctacttc ctgttccagg tgccaaaaaa tcagcaaaat tatatattcc atatatcatc     1080
cttactatta ttattttgac catcgtggga ttcatttggt tgttgaaagt caatggctgc     1140
agaaaatata aattgaataa aacagaatct actccagttg ttgaggagga tgaaatgcag     1200
ccctatgcca gctacacaga gaagaacaat cctctctatg atactacaaa caagctgaag     1260
gcatctgagg cattacaaag tgaagttgac acagacctcc atactttata agttgttgga     1320
```

```
ctctagtacc aagaaacaac aacaaacgag atacattata attactgtct gattttctta     1380
cagttctaga atgaagactt atattgaaat taggttttcc aaggttctta gaagacattt     1440
taatggattc tcattcatac ccttgtataa ttggaatttt tgattcttag ctgctaccag     1500
ctagttctct gaagaactga tgttattaca aagaaaatac atgcccatga ccaaatattc     1560
aaattgtgca ggacagtaaa taatgaaaac caaatttcct caagaaataa ctgaagaagg     1620
agcaagtgtg aacagtttct tgtgtatcct ttcagaatat tttaatgtac atatgacatg     1680
tgtatatgcc tatggtatat gtgtcaattt atgtgtcccc ttacatatac atgcacatat     1740
ctttgtcaag gcaccagtgg gaacaataca ctgcattact gttctataca tatgaaaacc     1800
taataatata agtcttagag atcattttat atcatgacaa gtagagctac ctcattcttt     1860
ttaatggtta tataaaattc cattgtatag ttatatcatt atttaattaa aaacaaccct     1920
aatgatggat atttagattc ttttaagttt tgtttatttc ttttaagttt tgtttgtggt     1980
ataaacaata ccacatagaa tgtttcttgt gcatatatct ctttgttttt gagtatatct     2040
gtaggataac tttcttgagt ggaattgtca ggtcaaaggg tttgtgcatt ttactattga     2100
tatatatgtt aaattgtgtc aaatatatat gtcaaattcc ctccaacatt gtttaaatgt     2160
gcctttccct aaatttctat tttaataact gtactattcc tgcttctaca gttgccactt     2220
tctcttttta atcaaccaga ttaaatatga tgtgagatta taataagaat tatactattt     2280
aataaaaatg gatttatatt tttggtcatg tttgtaagag agtgaatgca cgtgtgagaa     2340
cattagcttc ttctgaactc attatatctc cacacaggtg ttgatacttg atgcctaaca     2400
gttttgcaga tgtgctacat tggaattgtg tatttttatg gtgtacattc tattgtgata     2460
tatttattga ataattaatg tctattgacc atataagtgg cgaaaaatgc accatagagg     2520
acatggggta tttatttaca aactatgagc tacataataa gcaagtggcc atgggatggc     2580
atgaccctcc cctccatatt tttgtggagc aaaatattgg caatgtttat gtaaatcatt     2640
gttaatatca tgaaattatt tttaattaaa aacataagtc tatttgctcc atagcagaaa     2700
aaacatgaga agttttttca tcatgataga aattgaaaca aaatatattc attcttcaat     2760
cataccatct gagattttta agacagctat tttgtcttat aagtatattt ttctccctct     2820
agacatttca gttactatgg attttgtcct caaagggacc tttagtctat tttggatgta     2880
aagctaatct aatgacactt ggcacatgat attttgatca agccattttg acttgaccaa     2940
aaagcagtgt ccattaggtt tctgcatata aatattacca agcaatgttc acaatagaca     3000
tcattacact gtccttgaaa tttattaatt cttcatccaa ccctggttga gctgaggctc     3060
atagttaggt tcaagactat ctgtttaaat attactgaaa aacaaagtaa gacagtacta     3120
tgcttacctc ttaacttgat aatgtcaaaa caggcatgtt aaatgacatc atagaaaaga     3180
cttcaagata atttatagaa gttaaattat attgtacaga aaataattgt atgaaaatct     3240
ctactatggg gctggaacat ggttgaacat tagaatgata taaaaaatta tatatattct     3300
ccaaatccac gctagacctg tcaaattaga gaatctagag attagacctg gcgtgtcagc     3360
aaggtcatcc aggaagcaga ggctgagacg gagttaggtg tgattactta catagtcgat     3420
tacattttac aaataacatt ttatatgtct catttactgt gctttctccc catcccattt     3480
tgtatctttt cctttgcttt gctagatttg tcaatttctc ctctctttct gtctctctct     3540
ctttcaatat ctctaataat ttgaaagtaa ttcatcataa ctaaatatct attggggtta     3600
tgcttcactt acaaacttct gaaaacggct ttactgagat ataattgata tatttaagtg     3660
tacagtttgt taaattttgc acatatttaa aatgtggact ttggtaaatg ttgacatagt     3720
tttacatctg tgaaaccatc agcataatca agataataaa cttgtccatc accccccaaa     3780
aaaaaaaaaa aaaaaaaa                                                   3798
```

<210> 96
<211> 2683
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (2640)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2676)
<223> n equals a,t,g, or c

```
<400> 96
acaasgtmac gcctgacagg tmaccggatc cgggaattcc cgggtcgacc cacggcgtcc
gcatttgcaa taacagaaaa ggaattgcat gtatgaagtt ttcaatcgtg ggcttttctt      60
tgttgtgggg agggggtcgg gggatagttt gatttccatt ttctgaaaac gacagacttg     120
gattctgttt gtgtgtgcat attttatcca gccttaagtt ataaagctca tctgtcccgc     180
tgcattccct gtgtattttc aggacatggc tcgtgggtgt gtgtgttcat tgtgtgcgtc     240
tgtatgtatt tttctgtcat cactyttccc tctcctcccg agtgtgcatt cagttaatat     300
aatcagttgc ttgcttcttt caaagtgctt tgaaggtctt gaactcatgt gtgagcatct     360
ttatcaacta tcccaattgc atgttctcca tcacatattc tcttatttgc tctgtacccc     420
ctgagaatat gttttagaga tattggaata aagctgtctg ggtaaggagt aggcttagcc     480
gacctatgaa taatacactt tagtctagtt ctttattcta aatctggatt gccagtattg     540
tgtatttaaa ccaagtctgt gaatacctgc tttttttggc cacagagtaa caagttttca     600
tgtaagatct tcataccaaa gtaggaagta aaaatagctt agaaagctct gtcaggtgtt     660
ttgtgcagct gacagargta atgttacatc acctaaaaaa gaaagataca cggtcagtta     720
tcctaaaaat aaattgtttg gaaagtacaa tgcaccacat ttttgtagaa gtctactatt     780
tgataaacag ttgaaattca agatgtgttt gacccttagt catttttact ctttggttct     840
gagtatacct attttcttag cgtatctgcc ttgtttatct ttttcttcac cttttaacaa     900
gtatgacata ggaaagtcat tttttttag aattcatgga tcagtctgat ctactcttat      960
tcataatgga acatgtaaat atactgaaaa ctgtttttca ggagagaaat atgagttgga    1020
gggaaggaaa agtggttcta ctaatgttcc aaaatcctca tcagagaagg tatgatgttc    1080
tcaggtgtgg aaaatatttt ttagttgatt gagaatgcag gtttaacaga agagataagg    1140
ggcataatga ctgctggttt tccagactgg attttcctac cgcaactatt aatgttctca    1200
gagttgatga ggaccacctt tgtgtataca cttgtagttt taaaccttgc attggtaaca    1260
aaatgatcaa ctttaatcca ggtagaattc aagatggctg tacttcagtt gtatgataaa    1320
attaatggtt ctcatgactt gtgtggcatc taaaaataat gtttttatag catctctctg    1380
ccactaaatt gttgacttga atttgggaa aaaaaaaagt tggtgttgat atgtatatgt     1440
gtgtgtgtat atatgtattt ataaacaagt gtgtttgagt aacaagtgag tttcatagtc    1500
ttcccctacg catgtgtatt ccacacacaa atggctgagt tatagtcata aaacaatttg    1560
caataaaaaa aaaaccaaaa cagattgtca gttaaccagg aaacagttaa tgttttttaa    1620
tgaatctggc attatagtga gcaaatgtcg tattaattta ggctaatttc taatactacc    1680
ataatttgtg tctaaatttc tgttggggta gaaattacta aaattgtggg gagtttttc     1740
tgattttac attgctttag gaaacatttt tactaattca gctgtcttag gtaaaatgaa     1800
tagttttctt cctgtttttt tatgtgtcat tgttagtggt ctcagaattc tgatcagtaa    1860
ctttgtgtat gatgctgaat tacaaaccgt ttgaatgatc cagttgaaaa cgtatccctc    1920
tactttcttc agttgtagaa aaggttaatt tccctcagtg tcccacatta taccaaccta    1980
agagaagaac aggtaatagg gayaaataaa catacggtgg tttcagtggt tttggtcatg    2040
tgtccacagg agaaactaac cattcagttg tcttaatttt agttcgttct accctgtgag    2100
gagtttgttt ccatcagttg ttgactttcc aaaatgttgc attaagtaat agttgtcact    2160
ctgttggtct catggtcaat atcaatcaga ctttcatgat ctctactaat tattagtaga    2220
gtcctgtact atgtctgtaa ctactaagtt taaagaaaag cacatagtca cttcatctct    2280
tttttcctta gcctacgctc actccccaac ccatcccaac attgacatgc tatctgtgga    2340
caaatagcag ttctcagaat ctagtcaagt tgccatcatc cccttgcct tggccgttca     2400
tagtaggtat gcatatgttt gtttctgtac agtactgtgt gtgtgtgtgt atatatatat    2460
acatctgtat gcacacatct ttgataaaat agctatttga ctagcagggt taaagtggct    2520
tttaattact tcgtgagtgt tattggatac atcttaaaaa aaaaaaatct ggacccagan    2580
ccatgccata cttggttgga ctatttggg gcattnaaaa ttg                        2640
                                                                     2683

<210> 97
<211> 2181
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (5)
<223> n equals a,t,g, or c

<400> 97
```

gtacnggatt cccgggtcga cccacgcrtc cggcaggcag aggggcagtg ggcgcgggga
agatgattct gggcctcccc catctactgt cattaaccaa aatgaaacat ttgccaacat 60
aatttttaaa cctactgtag tacaacaagc caggattgcc cagaatggaa ttttgggaga 120
ctttatcatt agatatgacg tcaatagaga acagagcatt ggggacatcc aggttctaaa 180
tggctatttt gtgcactact ttgctcctaa agaccttcct cctttaccca agaatgtggt 240
attcgtgctt gacagcagtg cttctatggt gggaaccaaa ctccggcaga ccaaggatgc 300
cctcttcaca attctccatg acctccgacc ccaggaccgt ttcagtatca ttggattttc 360
caaccggatc aaagtatgga aggaccactt gatatcagtc actccagaca gcatcaggga 420
tgggaaagtg tacattcacc atatgtcacc cactggaggc acagacatca acggggtcct 480
gcagagggcc atcaggctcc tcaacaagta cgtggcccac agtggcattg gagaccggag 540
cgtgtccctc atcgtcttcc tgacggatgg gaagcccacg gtcggggaga cgcacaccct 600
caagatcctc aacaacaccc gagaggccgc ccgaggccaa gtctgcatct tcaccattgg 660
catcggcaac gacgtggact tcaggctgct ggagaaactg tcgctggaga actgcggcct 720
cacacggcgc gtgcacgagg aggaggacgc aggctcgcag ctcatcgggt tctacgatga 780
aatcaggacc ccgctcctct ctgacatccg catcgattat cccccccagct cagtggtgca 840
ggccaccaag accctgttcc ccaactactt caacggctcg gagatcatca ttgcggggaa 900
gctggtggac aggaagctgg atcacctgca cgtggaggtc accgccagca acagtaagaa 960
attcatcatc ctgaagacag atctgcctgt gcggcctcag aaggcaggga aagatgtcac 1020
aggaagcccc aggcctggag gcgatggaga gggggacmcc aaccacatcg agcgtctctg 1080
gagctacctc accacaaagg agctgctgag ctcctggctg caaagtgacg atgaaccgga 1140
gaaggagcgg ctgcggcagc gggcccaggc cctggctgtg agctaccgct tcctcactcc 1200
cttcacctcc atgaagctga gggggccggt cccacgcatg gacggcctgg aggaggccca 1260
cggcatgtcg gctgccatgg gacccgaacc ggtggtgcag agcgtgcgag gagctggcac 1320
gcagccagga cctttgctca agaagccata ccagccaaga attaaaatct ctaaaacatc 1380
agtggatggt gatccccact ttgttgtgga tttcccccctg agcagactca ccgtgtgctt 1440
caacattgat gggcagcccg gggacatcct caggctggtc tctgatcaca gggactctgg 1500
tgtcacagtg aacggagagt taattggggc acccgcccct ccaaatggcc acaagaaaca 1560
gcgcacttac ttgcgcacta tcaccatcct catcaacaag ccagagagat cttatctcga 1620
gatcacaccg agcagagtca tcttggatgg tggggacaga ctggtgctcc cctgcaacca 1680
gagtgtggtg gtggggagct ggggkctgga ggtgtccgtg tctgccaacg ccaatgtcac 1740
cgtcaccatc cagggctcca tagcctttgt catcctcatc cacctctaca aaaagccggc 1800
gcccttccag cgacaccacc tgggtttcta cattgccaac agcgagggcc tttccagcaa 1860
ctgccacgga ctgctgggtc agttcctgaa tcaggatgcc agactcacag aagaccctgc 1920
agggcccagc cagaacctca ctcaccctct gctccttcag gtgggagagg ggcctgaggc 1980
cgtcctaaca gtgaaaggcc accaagtccc agtggtctgg aagcaaagga agatttacaa 2040
cggggaagag cagwtagayt gytggtttgc caggaacatg ccgccaaact gattgacggg 2100
gagtacagga ttacctggca t 2160
2181

<210> 98
<211> 1957
<212> DNA
<213> Homo sapiens

<400> 98
acgcgtccgg aggcggcagg ctcatggcgc cggcgtcgcg gttgctcgcg ctctggcgc
tggcggctgt ggctctaccc ggctccgggg cggagggcga cggcgggtgg cgcccgggcg 60
ggccgggggc cgtggcggag gaggagcgct gcacggtyga gcgtcgggcc gacctcacct 120
acgcggagtt cgtgcagcag tacgccttcg tcaggcccgt catcctgcag ggactcacgg 180
acaactcgag gttccgggcc ctgtgctccc gcgacaggtt gctggcttcg tttggggaca 240
gagtggtccg gctgagcacc gccaacacct actcctacca caaagtggac ttgcccttcc 300
aggagtatgt ggagcagctg ctgcaccccc aggaccccac ctccctgggc aatgacaccc 360
tgtacttctt cggggacaac aacttcaccg agtgggcctc tctctttcgg cactactccc 420
cacccccatt tggcctgctg ggaaccgctc cagcttacag ctttggaatc gcaggagctg 480
gctcggggt gcccttccac tggcatggac ccgggtactc agaagtgatc tacggtcgta 540
agcgctggtt cctttaccca cctgagaaga cgccagagtt ccaccccaac aagaccacgc 600
tggcctggct ccgggacaca tacccagcct gcaccgtctg cacggccctg gagtgtacca 660
tccgggctgg tgaggtgctg acttcccgac cgctggtggc atgctacgct caaccttgac 720
accagcgtct tcatctcacc ttcctcggct agccaaaaca gctggcagga ctgccggtca 780
840

```
cacaccagca cgtcccacct cgtgctcacg gattttatta cacagatagt ggcggcaatg      900
gcctcagccc agcccaccct cacctgcttt tccagcccac aaagggggac gatcacggcc      960
cagcaaaagc gatgctgaga ggggaaacag tccagagtcc aacagcagaa cttgggggaa     1020
gcggtcgggg tggccaggaa cataaactat gtatagcggc cgggggcttc tgcccagggc     1080
tcccctggac caggacgcca ggtagggcag ggaacctcag tagtcctcca cccagccatt     1140
ctcagagatg aatgcgtcaa taacctcctt catagccaag ttggggatga gctgttcctg     1200
ggtcaggggg ctccgggtca cggggtcaaa atgacccaca cgctgcagtg acaagaaggg     1260
cagagggcag tcatggggcc caggaccatg ccactggccc tgctccccca gccgcaggcc     1320
tcacctgcag gtgctcctcg atgtccttgc ggtcgtaggt gatgccactg ggcgtgatgc     1380
acggctcccg catcagctca aagctgatct tgccacacag gtagtcgggg atgtctcgct     1440
tctgtggcac aggggcacac ggtcagaggc tgaaaagggg cactgcacga gcacctgcca     1500
gccatcggca gcaagcgaca cacactcacc ttcctcttct catccacctg agaaaaaagc     1560
tcgtccatgt ccgccatgta cttgtcctgt gaagagttga gtgctgtgct tgggggagac     1620
accccacctc cctcctccat ggggcacaga cccaacacaa ggcggggatg ctcccacgcc     1680
acgtgcacac acacagaccc acatgtgggt gggggcacc ctcacgtgct tggcctcaat      1740
gcaggcctgc tgggcccgga cgtggctgtc gtcctcatca ccctcgtggt ttcgctggca     1800
ctcttccagc tccctggggg ttgaccagga gccggtcaga gatggacctg gccagatgtc     1860
tgaccacacc ccaatctcag agctaacatc cacacttccc cacatttcct gcttgccagt     1920
aaagccttcg ataaacaaaa aaaaaaaaaa aaaaaaa                              1957
```

<210> 99
<211> 1112
<212> DNA
<213> Homo sapiens

<400> 99

```
ccacgcgtcc gcccaccaac aaaggcactt gcagttacat tcaccacatt tgtaacggag       60
ccattgaagc atattggaaa aggaactggg gaatttatta aagcactcat gaaggaaatt      120
ccagcgctgc ttcatcttcc agtgctgata attatggcat tagccatcct gagtttctgc      180
tatggtgctg gaaaatcagt tcatgtgctg agacatatag gcggtcctga gagagaacct      240
ccccaggcac ttcggccacg ggatagaaga cggcaggagg aaattgatta tagacctgat      300
ggtggagcag gtgatgccga tttccattat aggggccaaa tgggccccac tgagcaaggc      360
ccttatgcca aaacgtatga gggtagaaga gagattttga gagagagaga tgttgacttg      420
agatttcaga ctggcaacaa gagccctgaa gtgctccggg catttgatgt accagacgca      480
gaggcacgag agcatcccac ggtggtaccc agtcataaat cacctgtttt ggatacaaag      540
cccaaggaga caggtggaat cctgggggaa ggcacaccga aagaaagcag tactgaaagc      600
agccagtcgg ccaagcctgt ctctggccaa gacacatcag ggaatacaga aggttcaccc      660
gcagcggaaa aggcccagct caagtctgaa gccgcaggca gcccagacca aggcagcaca      720
tacagccccg caagaggtgt ggctggacca cgtggacagg atccggtcag cagcccctgt      780
ggctagagga acaccagcac aaacgacagc ctcaagtctc cttcgagctt tgtaaagtaa      840
tctcacaagc tgccaaagaa cacatcccaa gcagtaatca cagatgatga agcaccttac      900
aggacccctc caccctcaaa cgcgcatgtc cagagaagta ttaatgcctt aatagactac      960
tgaaggttaa ctatttacat cattctaaaa atattttaag ctgtattaca gtgctataaa     1020
ttctcctttt aaggaaaaaa gtaatagatt gtttccttac cgtgtttgaa aggaaaaaaa     1080
ataaatccat agtaactaaa aaaaaaaaaa aa                                   1112
```

<210> 100
<211> 887
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (303)
<223> n equals a,t,g, or c

<400> 100

```
ggcacgagag aattataggt gcatgatggg gcttttggag actggcaatg ttctgttttg     60
ggtctgggta gtggttactt gtgtgtattc actttatgct aactcattga actgtacaga    120
tatggactgt gcccctttct atatgtgtgt aatgcttcaa caaaagtgtc aatagtgatg    180
catgcacatg ttaaaatttc aaactatatt aaagagtgtg caattaaaag gaagttatcc    240
tctcactcta aagtcctatt tcctctcttc agtctatcat tactactagt ttctagtata    300
tcntttagaa atgkgctgta aaagaacaat gatgtgtatg tctctacagg tatatattta    360
ttctttttgt aattacaaaa atataaactc actacatatg ttattctacc acatgctttt    420
tttcatgtaa cagtatgtct tagacatctt ttcctattat tgcgtggaag ctatcaacct    480
tattctttgt aatgactcca taaattattc tactgtgaaa acacaccatg tttaaccagt    540
tctctgttag tgaacattta ggattttcc agtttttaaa tattacagtg acatattaaa     600
cattaaacat atcttttgac acatgtcctt gcacacatgt ataggtatga tggactttaa    660
caccctttgg ctagattctt tagcacataa cgtaaatatc ccatagagtc aaaaccaccc    720
ttaaaacttc ctcaggaggc tgggtgtggt ggctcacgcc cgtaatccca gcactttagg    780
aggccgaggt gggcggatca cgaggtcagg agatcgagac catcctggcc aacatggtga    840
aaccctgtct ctactaaaaa tacaaaaaaa aaaaaaaaaa actcgta                  887
```

<210> 101
<211> 1248
<212> DNA
<213> Homo sapiens

<400> 101

```
ccacgcgtcc ggtctattaa ggtgacagaa ctgaagggcc tggccaacca tgtggttgtg     60
ggcagtgtct cctgtgagac caaggacctg tttgccgccc tgccccaggt tgtggctgtg    120
gatatcaatg accttggtac catcaagctc agcctggaag tcacatggag ccccttcgac    180
aaggatgacc agccctcagc tgcttcttct gtcaacaagg cctccacagt caccaagcgc    240
ttctccacct atagccagag cccaccggac acaccctcac ttcgggaaca ggctttctat    300
aacatgctgc gacggcagga ggagctggag aatgggacag catggtccct gtcatctgaa    360
tcttcagacg actcatccag cccacagctc tcaggcactg cccgccactc accagcccct    420
aggcccctgg tgcagcagcc cgagcccctt cccatccaag ttgccttccg caggcctgag    480
acccccagct ctgggccctt ggatgaggag ggggccgtgg ccccagtcct ggcaaatggg    540
catgcaccct acagtcggac tctgagccac atcagtgagg ctagtgtaaa tgctgccttg    600
gctgaggctt cagtggaggc cgttggccca aaaagcctat cctggggacc tagcccacct    660
acacacccag ctcccaccca tggaaagcac cccagtcctg ttcctcctgc cctggaccct    720
ggccactctg ccacaagctc taccctcggt acaacaggct ctgtccccac atctacagac    780
cctgccccat ctgcacacct agactcagtt cataagtcca cagactctgg cccttcagaa    840
ctgccaggcc ccactcacac cactacaggc tctacctata gtgccattac cactacccac    900
agtgctccaa gcccccctcac tcacactact acaggctcca cccacaagcc cataatctct    960
acccttacta ctacaggccc taccctcaat atcataggcc cagtccagac taccacaagc   1020
cccacccaca ctatgccaag cccttcttcc cacagcaata gtccccaata cgtagatttt   1080
tgctcttctg tatgtgacaa catttttgta cattatgtta ttggaatttt ctttcataca   1140
ttatattcct ctaaaactct caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa   1200
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa                1248
```

<210> 102
<211> 1841
<212> DNA
<213> Homo sapiens

<400> 102

```
ggcacgagct ggtgcaggag ctggagcagt accagttgtt gccgaagaga ttggactggg     60
agggcaacga gcacaacagg agctacgagg agttggtctt gtccaataag catgtggctc    120
ctgatcatct tttgcaaatc tgccagcgca tcggtcctat gttggataaa gaaattccac    180
ccagtatttc aagagtcact tctttacttg gtgcaggaag gcagtctttg ctacgtacag    240
caaaaggtac cttaatttga agaagtgttc tgctttgtat taatagccta ataattatta    300
taattgtgaa gtaatgtaag catgtggaag aaaggtgata atgtaactat aaatcatgct    360
gtggactata aaattctctg catttagcat egaacattga attttattac ataagtgttt    420
```

```
aatgggtcct tctgcattaa aaaagttgat aaagatatag atgttaagct aaaaagcttg     480
aatttattct gagatgttgt ttgaggtttt atcaatgtga gttcttaatt ttccattttg     540
tagctcactc ataacttcat tgaatgtaat tgtatgtgtc taataaactc tttaaatgct     600
agaggtattt catttgatat ttagcttctg aaagcccttt gttataaagg gaagtgattt     660
tctaaatttg gtagcagctt gaaaacaagc accacaaatg taaaattgca tggttctttt     720
tttactaatt taattttttt gccaagttat gtgctagcaa aatgtttgaa attgctattc     780
tttttctgtt agcttggtat atatgactta gactaagtat atgtatgtga tataatatat     840
gtgtacatgt ggctaaactg ctaatgggca aagattgttg gttcttctga tgctgagtat     900
acatcaagtt catcccatga ttatttttta ttacgagcta ttgctgatgt gatgctactc     960
ttagctgcac caccagtata aagcttaact gagaaagaac acccctccct cttagttccg    1020
tgccagactg gtttgttagc tttagttgtt tcttagtgct ctagccatgt caccctgtgg    1080
cactaatcag gacactgttt atattcttcc tcttctgtgt ccctattcac tttgtaatta    1140
ttctatttta gctggttata tggtagttaa ttggtagcct gtttcccttt gttttcttta    1200
cttgtgtcaa gctccatgtc gtttgttttgt gatgagcagt gatttagaac tggccagacc    1260
ttagaagagt cttcagcaag ctgccctagg gtaggggcat attctctgtt tgttttgtac    1320
tggtacccca ggaggatgcc ttgtaactgc tctttggtca tgatagtggt aatgaatcca    1380
ttcatgtaaa atgcaatatg tctgttagtt tggggcaccc gaggctcagt agaggtttag    1440
tatgatgcct tccctttctt ctttgagtta tgaagaaact aatttctggc acagtgtgac    1500
tgcttcaaac ctatgttctg ctgctatctc ctatagagga gggcagactt ttttttctta    1560
gtgcatttgc tggtaggtca aggagggatg gactttgaat tagtgttcag agtcacagat    1620
cctacgtatg tgctcttcag tagaggattt tctgtgatcc tacaatgaag ggaaagctat    1680
ataatttatt ggtacttcct aaagatagag actaaagtca tggtagtatt ggccaaatta    1740
attttaaaac tgaacaagtc atgaattttc atataaatca aagaactttt tccttataaa    1800
agcttccatt tttgaaaagt tgaaaaaaaa aaaaaaaaaa a                        1841
```

<210> 103
<211> 685
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (678)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (679)
<223> n equals a,t,g, or c

<400> 103

```
actacggctg cgagaagacg acagaagggg ggcggcgacg gaggaggagg atggaggcgg      60
tggtgttcgt cttctctctc ctcgattgtt gcgcgctcat cttcctctcg gtctacttca     120
taattacatt gtctgattta gaatgtgatt acattaatgc tagatcatgt tgctcaaaat     180
taaacaagtg ggtaattcca gaattgattg gccataccat tgtcactgta ttactgctca     240
tgtcattgca ctggttcatc ttccttctca acttacctgt tgccactlgg aatatatatc     300
gatacattat ggtgccgagt ggtaacatgg gagtgtttga tccaacagaa atacacaatc     360
gagggcagct gaagtcacac atgaaagaag ccatgatcaa gcttggtttc cacttgctct     420
gcttcttcat gtatctttat agtatgatct tagctttgat aaatgactga agctggagaa     480
gccgtggttg aagtcagcct acactacagt gcacagttga ggagccagag acttcttaaa     540
tcatccttag aaccgtgacc atagcagtat atatttttcct cttggaacaa aaaactattt    600
ttgctgtatt tttaccatat aaagtattta aaaaacatga aaaaaaaaaa aaaaaaaaaa     660
aaaaaaaaaa aaaaaaanna aaaaa                                           685
```

<210> 104
<211> 1168
<212> DNA

<213> Homo sapiens

<400> 104
```
ggcacgagcc cccgccccct ccctccctcc cctcccttcc ccggccccgg ctctggcccc      60
ggcccattcg ctgttgggtc ttctgctagg gaggatgtcg ggttcgtcgc tgcccagcgc     120
cctggccctc tcgctgttgc tggtctctgg ctccctcctc ccagggccag gcgccgctca     180
gaacgtgaga gtacaatctg gacaggatca gaagtagaga atgaagttgt aagagaaagg     240
gaaagacaga agaaaggctg cagtagtaca aggagaaaag caggatgcaa gaatgaggaa     300
tgaatctttg tttgaggagc atccggaaaa atataagctg tcagaaagag taaatagacc     360
agggacctct aaagtaaatt cacacatcaa agttaaaata atgttggaga atcacctcct     420
gtgaaaaatt ggcttagctt tcagtatgcc tctttaaaca aaacattatc attttataca     480
aattttaaa atgttgttca taatatggag tttaatttta agcaccttag ataatgcatt      540
tgttagcttg tttctgaaat ttttatggat tttttttttc aaaattccta attttagttg     600
gtaaggatta acttcgggaa gacaggaaac ccctccagta aaattaattg gttataaatg     660
gttacatatt ttaggcttat atacataaca aaacttctaa ctgaatttaa aagtgatctt     720
gtgtaaaaac attattctag tgatattgat gtctaaattt aaaagagtga atacacaagt     780
aaaatatatc tgcttttttaa ggatctattc agtttaggaa ggagagtcaa aatttgtatt    840
taatttcaat ttattatatt gtctgaaact gaaagtaggc ctaacttttg tttgcttttg     900
tgtatgtaca aaggcaaaca tttatcaatc aactcttatt aatttgagat tattttgacc     960
tgattgcctca gaactttttgt ctatctgtat agaaatgggg ttttctaaat atttaaagaa  1020
tttcctacgt atgtaaattt acttgcacac agtaagttag ggagacatt taatattcct     1080
cagatacctg ctgttttctt gttgtgtttc ttgtttttca aataaataaa ctgagtgtta    1140
tctgttcatt aaaatagaat gtagtcag                                       1168
```

<210> 105
<211> 1175
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (24)
<223> n equals a,t,g, or c

<400> 105
```
gcatggaaat atatcctata catnaagtgc tgtcctgagc tgtacatwta gccatattta      60
grattttatt argcaggatt caaggcctcc taaaaatgga tattcagata ttttaaaata     120
cactattaag gaatgcaatg taaaatcaca ctaacatttg catagcactt tatagtttac     180
aaaatgcctt cacatatacg agctcattta tttctccttc tcttctttct attcatctat     240
caaggaatat cttctataag ccaggcatca ggcttgacac tgaagacaca aaatgaaaaa     300
gatatacaag tctctattct taaagagttc gtagtttaat gaagtgaccc aaaaagtaaa     360
cagttgcaat ataacatgca aaggagtgtg atgaaataca cctagagtac tatgaaaatg     420
gcatagaggg accaagcctg taatgaagtc agagaaagta aaagaggtga agcckgagct     480
aagttttaaa ggatgaacaa aaattgacca gacaaaggag ttggagaagt gggatggtac     540
aggataaaag cctttctaat ttggggaagt gtgagtcgtc gatattagat gatattatta     600
atagattgtg cacagagtgc acatggtaga gaggtgagag atgaggtagc actgttaggg     660
cagataggtg aattctcaca gtaaccctgt gwtgtacmtt atcatcctcc tctccattat     720
gtaggggaga acaccaaagc ccaaagagat taagtaactt tccagaattt tgatttcaaa     780
tcctaagcgt ttggtagctg tgtttccctg catatagtct gcctcaaaag aaaatttaaa     840
gttgtatttt gtattaaatt taaacaaata raggccgggt gcagtggctc acgcctgtag     900
tcccagcact ttggtaggcc aaggtgggcg gatcacctga ggtcaggatt tcgagaccag     960
cctggccaat atggtgaaac ccatctcta ctaacataca aaaattagct gggcatggtg    1020
gcacatgcct gtaatcctgg ctacttggga agctgaggca ggagaatctc ttgaacccag    1080
gaggcggagg ttgcagtgag ccgagattgt gccactgcac tacaacctgg acaacagagc    1140
aagattccgt ctcaaaaaaa aaaaaaaaaa ctcga                               1175
```

<210> 106

```
<211> 1021
<212> DNA
<213> Homo sapiens

<400> 106
ggcacgagaa taaaatagat ttagggtatt cgacacattt aatacataat gaatagtgaa      60
tttcttgaat aatataatgc ctaaatgtga ctgatatgca aaatatttaa atcccttaca     120
ggatgtgcat ttaccaatca gaacacatgt tggctttact gcttgtatta gttttctgta     180
ttagtttgct tgtattagtt tgctggggca gccataacaa agtaccacag aaatttatat     240
tctcacaatt ctggggggcta gaagactgag ataaagatgt ctgcagggtt ggtttcttct     300
aaggactctc ttgttggctt gtagatggtt gttgtctccc tgtgtcttca cctgcacttc     360
cctctgtacc tgcccgtatc ttaatctctt cttataagga cagagtcata ttggattagg     420
gcctcaccct aatgacctcc ttttaactta attacctctt tagagactct gtcttcaaat     480
acaggcacat tctgaggtac tttaaggtta gaacttcaac atatgcattt ggaactgggg     540
cataactgag tccatgacac tattggagag ggttctggag ccataacaga tggaatgaat     600
gggccttgtt tggattctaa tttaaataaa ccaactatag aaaaacatgt tttaggcaat     660
cagatttttt gttatgggct aaatatttag aagatgttaa gaaatgttta ttaatttcat     720
taggtaaaat aatgttggtg tggttatgta gagtatgact tacgtgcaca gaacagaatg     780
ataaggtgtc caggatttgc tttaaaatat tctagatttt tttaaaaggt gagaggaaat     840
gacacatgta tatctaaatt ttgatggttg ttgaagctgg ctggtaggta cctagtattt     900
cattatactt tttcctttgt gtgtttggaa atttttataa taagcaggaa aaataaaagt     960
aagaatatat gtattataga taatttgaaa tatgtagaat catgaaaaaa aaaaaaaaaa    1020
a                                                                    1021


<210> 107
<211> 830
<212> DNA
<213> Homo sapiens

<400> 107
ggcacgagta aggactgtgt tctttatgca tttcttgatc caggcatggc agttcctctt      60
ttcctgtaca tattcacact cctgccactt ctaccctttc tcttatccct ctgcttttca     120
cctctgactg taaaaagaag tagcagttcc gaaagcaaga gttccctatg aacacggaag     180
aagacattgg caactttga gtacaacaac tatatttaat agagtaattt aagaacatca     240
gccagtgaat tttatacaag atagtgaaag agaaaaggaa gattaattag ggtagtttta     300
ggatgccatt aaatagccta gaattagggg agtagtcgtt gaatagaaag gaggccacaa     360
atttgaggga tataagctaa gaattggtaa gccaagaaga aggaaaaggt ttgggcagta     420
aggataatga ggaacaaaat agagaactca gaagcaatat ctgactgtta tcattggaag     480
aatttttttg cttgcttgag gctggatatt gaagtggatc aggatacttg agtgactatc     540
tgatgggctt ttggaactag ctctcaagag gtgaaaatta gctttttttt cttttctttt     600
cttttttttt tttttgagg caaggtctca ctgttgttga ggctgaacct cctgggctca     660
agcagttgtc ccattgcagc ctcctcagat actctgtaag ccaaggcagg gggaatattt     720
tgtgctcagt agtttgaggc tgtggtgagc taagatcaca ctgctgtgct cacttcagcc     780
tgggcaacac agtgaaaccc cgtctccatc tgtttaaaaa aaaaaaaaaa               830


<210> 108
<211> 1301
<212> DNA
<213> Homo sapiens

<400> 108
aagagggtgg ctgccgagtt cttgtttgtc ctgtgctctg agagtggtga gttatggaga      60
cccaggtccc agcccacccc acctcagcca ggcttgcaca ctgacctctg ccttgcccct     120
cagtgccccg attcatcaag tacacaggct atgggaatgc tgctggcctt ctggctgcca     180
ggggcctcat ggcaggaggc cggcccgagg gccagtactc agaggatgag gacacagaca     240
cagatgagta caaggaagcc aaagccagca taaaccctgt gaccgggagg gtggaggaga     300
agccgcctaa ccctatggag ggcatgacag aggagcagaa ggagcacgag gccatgaagc     360
```

tggtgaccat gtttgacaag ctctccagga acagagtcat ccagccaatg gggatgagtc 420
cccggggtca tcttacgtcc ctgcaggatg ccatgtgcga gactatggag cagcagctct 480
cctcggaccc tgactcggac cctgactgag gatggcagct cttctgctcc cccatcagga 540
ctggtgctgc ttccagagac ttccttgggg ttgcaacctg gggaagccac atcccactgg 600
atccacaccc gcccccactt ctccatctta gaaacccctt ctcttgactc ccgttctgtt 660
catgatttgc ctctggtcca gtttctcatc tctggactgc aacggtcttc ttgtgctaga 720
actcaggctc agcctcgaat tccacagacg aagtactttc ttttgtctgc gccaagagga 780
atgtgttcag aagctgctgc ctgagggcag ggcctacctg ggcacacaga agagcatatg 840
ggagggcagg ggtttgggtg tgggtgcaca caaagcaagc accatctggg attggcacac 900
tggcagagcc agtgtgttgg ggtatgtgct gcacttccca gggagaaaac ctgtcagaac 960
tttccatacg agtatatcag aacacaccct tccaaggtat gtatgctctg ttgttcctgt 1020
cctgtcttca ctgagcgcag ggctggaggc ctcttagaca ttctccttgg tcctcgttca 1080
gctgcccact gtagtatcca cagtgcccga gttctcgctg gttttggcaa ttaaacctcc 1140
ttcctactgg tttagactac acttacaaca aggaaaatgc ccctcgtgtg accatagatt 1200
gagatttata ccacatacca cacatagcca cagaaacatc atcttgaaat aaagaagagt 1260
tttggacaaa aaaaaaaaaa aaaaaaaaaa aaaaaactcg a 1301

<210> 109
<211> 1932
<212> DNA
<213> Homo sapiens

<400> 109
aatttttttt tttttttttt tttttttgaa aaaaaaaatg ggtagtgtat attttgcagg 60
tttaagacaa ctcaggacaa taaaaacaat ggactttaca tgtgtatata tatagctctc 120
ttaggcacca taatcagtat gagccaacaa tatttaaact tgattcaggc cacattcaga 180
catttgctct tatatacaaa tatttaaatt aaatacaatc tgaaatgtgt tctgttacat 240
acaaaaaagg aaaaactata caacgcagag cagtgtgtgt gttttaaata attacattta 300
catgtaagct aaatggaacc agcaatggtg ctcaagtttt tatcatccct tccagaaaat 360
ctttttctac catctcttct atttttgcc tggctttgct ggaacatggt ttgtggttct 420
ccagtttcat gtccttatta gggaaggcat ttgagtagag gataggactc cctgagtgtc 480
ctccacatcg gcttgtgact ttgctgttga agacttgact gagcacattg aagaacggca 540
ggagctgctc catactgcgc acggtgcaga tggtgagcag caagtgccct ggctcccaac 600
ccaatgttct ccctgagttg tcttcctctg gatttttctg cagaaaacaa aaagtgaact 660
ggtattaata caacagacaa tgtggtatgt tagaaaaatt aaaaatatat aaactttggc 720
aattggtcaa gaaatgaata caaatgacat taagtttcta actcctgacc tgatcaaaac 780
cctttggtgct tctgagacct tttactgcca tttattagtt ttacatggag cagtctaaca 840
ttgtagtaat agttcccaac tagaatgcgc agataagctt agttaacaga aatagctttg 900
aacaggaata gagtcaaaca taaaagtttt atgttgtgct ttgtatttac tcaaaaagct 960
cccaggtttc tgaaccctca ctactgtaac caaggactag gtcacaaaat tactacagaa 1020
aaaaggaaca aagtgcttta tacatttcat aatatatccc cttttattat aattagttaa 1080
ttccctttta tctaaatggc ctaaatttgc catgatggta gcagtgtcca aagtgaataa 1140
ttactgtcag tactgcatca cagagaaagg aagggatccc tcaggagaca ctgctgtctc 1200
cttctgggtt gtgctaaaca acatagggag gaaagctgga cctggagtca aaggaattga 1260
gttagtgtgc tggctctgcc atacttacgg caccccttggg caggatatac aaaggttcct 1320
cacttataaa atgggacagt ctaaaactac cttttagtag agaagtcaaa tgagaaggta 1380
tgtgaaaact ctgtcaacta aatataaaga ctaataattt gggtattaag aggctagttt 1440
gagaagccac ctgaattaca caaacacagc tacagacatc attctgtcta gagaaagata 1500
agagagaaca ggttggttga acttgggcag aatcacagat acaattccac actaaagaat 1560
gaaaataagc aatgaattag acagaaggaa gaaatcatga agacttagga agcagaatta 1620
caatctgtca tattaacaaa tggagtttgc cttctaagat cagatgttgc tcagaaactt 1680
tcattgttta cctaataatt taatatcact agtttcctag tgggtcaagc agatgcaaaa 1740
tccagcttat ttcttctat gtgctctcaa gcttattgct tattttaaag taaaatcctg 1800
aaaaaggaaa atattaggtt ggtgcaaacg taattgcggt ttttgcattg ttgaaatttg 1860
ccgttttata ttggagtaca ttcttaaata aatgtggtta tgttatacaa aaaaaaaaaa 1920
aaaaaactcg ag 1932

<210> 110
<211> 1534
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1212)
<223> n equals a,t,g, or c

<400> 110
```
tcgaagatag gttcgagacg gtggatgttg cagctgatca tgcagttggg ttcggtgctg      60
ctcacacgct gccccttttg gggctgcttc agccagctca tgctgtacgc tgagagggct     120
gaggcacgcc ggaagcccga catcccagtg ccttacctgt atttcgacat gggggcagcc     180
gtgctgtgcg ctagtttcat gtcctttggc gtgaagcggc gctggttcgc gctgggggcc     240
gcactccaat tggccattag cacctacgcc gcctacatcg gggctacgt ccactacggg     300
gactggctga aggtccgtat gtactcgcgc acagttgcca tcatcggcgg ctttcttgtg     360
ttggccagcg gtgctgggga gctgtaccgc cggaaacctc gcagccgctc cctgcagtcc     420
accggccagg tgttcctggg tatctacctc atctgtgtgg cctactcact gcagcacagc     480
aaggaggacc ggctggcgta tctgaaccat ctcccaggag gggagctgat gatccagctg     540
ttcttcgtgc tgtatggcat cctggcccct ggcctttctg tcaggctact acgtgaccct     600
cgctgcccag atcctggctg tactgctgcc ccctgtcatg ctgctcattg atggcaatgt     660
tgcttactgg cacaacacgc ggcgtgttga gttctggaac cagatgaagc tccttggaga     720
gagtgtgggc atcttcggaa ctgctgtcat cctggccact gatggctgag ttttatggca     780
agaggctgag atgggcacag ggagccactg agggtcaccc tgccttcctc cttgctggcc     840
cagctgctgt ttatttatgc tttttggtct gtttgcttga tcttttgctt ttttaaaatt     900
gtttttgca gttaagaggc agctcatttg tccaaatttc tgggcttcag cgcttgggag     960
ggcaggaacc ctggcactaa tgctgtacaa ggtttttttc ctgttaggaa gaacttgagg    1020
ccagctgccc actgagtctt ctgtccctga agaaagggag tattgggcag ggcttgggat    1080
ccggctactg agagtgggag agtgggagac agaggaagga agatggagat tggaagtgag    1140
caaatgtgaa aaattcctct ttgaacctgg cagatgcagc taaactctgc agtagtgttt    1200
ggagactgtg anagggagtg tgtgtgttga cacatgtgga tcaggcccag gaagggcaca    1260
ggggctgagc actacagaag tcacatgggt tctcagggta tgccaggggc agaaacagta    1320
ccggctctct gtcactcacc ttgagagtag agcagaccct gttctgctct gggctgtgaa    1380
ggggtggagc aggcagtggc cagctttgcc cttcctgctg tctctgtttc tagctccatg    1440
gttggcctgg tgggggtgga gttccctccc aaacaccaga ccacacagtc ctccaaaaat    1500
aaacatttta tatagacaaa aaaaaaaaaa aaaa                                1534
```

<210> 111
<211> 2871
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1234)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1259)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1283)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1284)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1297)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1378)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1912)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1913)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1935)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1947)
<223> n equals a,t,g, or c

<400> 111
```
gcggcgaggc ggcggtggtg gctgagtccg tggtggcaga ggcgaaggcg acagctctag      60
gggttggcac cggccccgag aggaggatgc gggtccggat agggctgacg ctgctgctgt     120
gtgcggtgct gctgagcttg gcctcggcgt cctcggatga agaaggcagc caggatgaat     180
ccttaggatt ccaagactac tttgacatca gatgagtcag taaaggacca tactactgca     240
ggcagagtag ttgctggtca aatatttctt gattcagaag aatctgaatt agaatcctct     300
attcaagaag aggaagacag cctcaagagc caagaggggg aaagtgtcac agaagatatc     360
agctttctag agtctccaaa tccagaaaac aaggactatg aagagccaaa gaaagtacgg     420
aaaccaggta gtctggacat tttccttgct tttgatttta tttaggggac aactgaaaat     480
tttaagctaa tgaataaaga agctgaagaa gactggcttc actgattatt acccacaaat     540
aatatatgga gtgtagtttg gagagaattt ctagatttta atataccaaa gttattcact     600
taacagattt gacccaagtt acataagctg aattccatag atgagattgc atttatcttt     660
ttattaatat cctgacgttt ctttttggaa tcaagtatgt aaataccttt ctcactgaga     720
aatttaaaaa aataatatgt cagggtagca tacaaaacag aaactcagga agaactgtct     780
aacatgccac tatggttatt ttcaggattg tggtaggatt attactacaa taaccttgtc     840
gatcatccta ggtaatttga tttaggtgtt tatccctcca gcttgacgct tgtgtgtact     900
tccatcctat tctaactttc acaatcttga aacctctact tttcaattta aaacttgacc     960
tttttcacaa tagtcttcta aatattaatc cttttaaaaa ttattaatgt atgcattcta    1020
ccatgtcttg ttgcccttct gtcatttatt atttcaatga tcactgcctt atctgtttat    1080
tattccatta ctaaccactc tcaggaactg atccaaattg gaacttttta aaaaaataga    1140
attttttttt actacaaata taccattctc atgaatacaa aactattttt aaaaaattaa    1200
aagtacctga atcccatcaa ctagaaataa cagntgctca catcatggag aatattctnt    1260
caggattttt ttaggtgtat cannagnttt aagaaaacta aattgggtca aaatgtgtat    1320
tctatgttgc agcctgcatt ttgcacttaa cagtttacca tgaatgtttt tccatgtnat    1380
```

```
ttagcttatt ttcaatttga tagttaatgg ctataaaaaa ttttatttgt aaatatatgg     1440
taccataaac caaaacgttt atgttttgct gggagatcat tttagatgta tctttgtgcc     1500
tatctgtgaa aatttcctta gaattcttaa agtaaatttg ctgaattgga tgtaaaagtt     1560
taaaagacag tagatacaca ttgttaaatt gttcttcaga aaagtgattc tgtttacttc     1620
ctctgaaaat acctctttcc ctgtacctca cccaagtgtg tattaccatt ttaaaatttt     1680
tactaaatat aatttaattc attcttcatt ttttaattag ggattttttt tttttttttt     1740
tagtttttat attttttagag acatggtctc actctgtcac tcaggctgga gtgcagtggc     1800
acgatcatag ttcactgcag ccttgaactc aggtgatctc cctctttggc ctcccaaagt     1860
gctgggatta caggcatgag acactacatc aagcctggga aattttttaaa cnngcataaa     1920
aagtagaggg taaantgcca cccccttncca accctcactc agcttcaata aacatcaaca     1980
ttctgctggt cttttcatct ttactaccct acacacattt gcccttttttt tctttcctag     2040
aatattttaa ggcaaattcc gcatgtgctt ttacatctct gtgtctctct ctagtaagaa     2100
tgctcttttc agcaaaatca cagaattagc cattactcct ttattaccta atacccagac     2160
tgtttaattt ttctagttgc ttcaagtgtc tgtttacaat ttatttgttt gaattcattt     2220
ctaagctact caggaggctg agtcaggaga attgcttgaa ccctagaggc agaggttgca     2280
gtgagctgag atcgtgccac tgtactccag cctgggtgac aaagtgagac tccatgtcat     2340
aacaaaacaa aacaaaacaa aacatgacga aacaaacaac acaattgaat aatatccctc     2400
agttattatt tagagaagag atgactcaat ataaatgtaa tatgtgatcc atttggtcac     2460
agaatgaatt tcagtcattg cttaggtaag cctggtaaaa aaaaaaaaaa cgggattcca     2520
tgattagtgt gttgaaaaag gggtttgccc aaagtgtaac agacagagcc gggtgcagtg     2580
gctcacgcct gtaatcccag aactttggga ggccaaggca ggcggatcac gaggtcaaga     2640
gattgagaca atcctggcca acatggtgaa gccctgtatc aactaaaaat acaaaaacaa     2700
ttagctgggc gtggtgacat gtgcctgtag tcccagctac tcaggaggct gaggcaggag     2760
aattgcttga acctgggagg cggaggctgc agtgagctga gattgctcca ctgcactcca     2820
gcctggccac agagtgagat tccatctcaa aaaaaaaaaa aaaaaaaaaa a              2871
```

<210> 112
<211> 1037
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (936)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (946)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (951)
<223> n equals a,t,g, or c

<400> 112

```
ccggtccgga attcccgggt cgacccacgc gtccgggcgg gcgcaggacg tgcactatgg       60
ctcggggctc gctgcgccgg ttgctgcggc tcctcgtgct ggggctctgg ctggcgttgc      120
tgcgctccgt ggccggggag caagcgccag gcaccgcccc ctgctcccgc ggcagctcct      180
ggagcgcgga cctggacaag tgcatggact gcagcacctc ctgcccctt ccggctgctt       240
tcgcccatcc ttgggggcgc tctgagcctg accttcgtgc tggggctgct ttctggcttt      300
ttggtctgga gacgatgccg caggagagag aagttcacca cccccataga ggagaccggc      360
ggagagggct gcccagctgt ggcgctgatc cagtgacaat gtgccccctg ccagccgggg      420
ctcgcccact catcattcat tcatccattc tagagccagt ctctgcctcc cagacgcggc      480
gggagccaag ctcctccaac cacaaggggg gtgggggcg gtgaatcacc tctgaggcct       540
gggcccaggg ttcaggggaa ccttccaagg tgtctggttg ccctgcctct ggctccagaa      600
cagaaaggga gcctcacgct ggctcacaca aaacagctga cactgactaa ggaactgcag      660
```

catttgcaca ggggaagggg gtgccctcct tcctagaggc cctgggggcc aggctgactt 720
ggggggcaga cttgacacta ggccccactc actcagatgt cctgaaattc caccacgggg 780
gtcaccctgg ggggttaggg acctattttt aacactaggg ggctggccca ctaggagggc 840
tggccctaag atacagaccc ccccaactcc ccaaagcggg ggggggatat ttattttggg 900
gagagtttgg aggggagggg gatttttttt ttaaangatt ttttantttt naaaaaaaaa 960
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1020
aaaaaaaaaa aaaaaaa 1037

<210> 113
<211> 2214
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (289)
<223> n equals a,t,g, or c

<400> 113
cggacgcgtg ggtcgaccca cgcgtccggg aaaaarggaa aaratgccgt gtaaaatctc 60
gttctgtgtc tgaattgccg taggctcaga tcttcatttg aggttctgtg tctgaattgc 120
cgtaggctca gatcttcatt tgaggttatg ttctataagt taacgttgat cttgtgtgag 180
ctttcggtag ctggagtaac acaggcggcc tcacagcgac ctctccagcg ccttccaagg 240
cacatctgca gccagcgtam tcctcctggg agatgcctcc tcaaggccnt gctccagacc 300
acgtgggrar ggcctgacaa gccaattccc aggctgtccc cacccttgra gagtgaccct 360
aaacgctaga cagatgggga atgggaaaga aaagaaagct gcagacctca agttaaaatt 420
ccctcaaaaa cgtttttatt tatctgcttt ttctgaaagg ataaaggctt tttgaaaatt 480
attttctaac aaataacatg aacacttcta gaaaccctag aaaaacacaa agtattcaaa 540
atagaaagaa aaattaccca ttactcttta agccagcatt atccattgcg gtgcttttgg 600
agttgggtga ggccgtagcc tctgccaagt caaggagccc ggtggtggct gtggcattcc 660
tgcagggttg tttttttttc tttgagatgg agtctcactc ttgtcacccc agctggaatg 720
tggtggtgta aacagctcac tgcagccttg accctgaggc tcaagcgatc cttctgcctt 780
ggcctcctga gtagctggga tcccaggcga gagtcaccac accctgtcca tgttcctgca 840
ggtcttgata tgcgaggacg ctgtgtcttc cctgccacat ttcttcttcc tttcttgaga 900
cagacccttg ctccatcacc caggccagac tgtggtsgtg cgaacacggc tcactgcagc 960
ctcgaccctc aggctcaagc gatcctcacc cctcggaccc ccaaagtgct gggatcacag 1020
gcgagagtca ccatgctggc ctgaatcttc agggtatttr cggttgargt gycacttact 1080
tarccatscc tgtttcaaga gtgtaggtgg tcaccctgtc tctgccgctg acctggcctg 1140
gaccctcggc tgtgagaggg aggggtgggc tgggctggag gaacctraag ccctcgtgat 1200
gtcacaagcc catctggctg ggcatcccct gctgtgtcct gagctgcaca tgccccaggt 1260
ggcccccaca gcagaggcga gccactgrag ggtgragggc ttccacggac ggtcttcagg 1320
ggragaagaa gggcccaggc ccccaggaga ctcaggagac cagagcctgg ggtcaggggc 1380
tmagcagggg ctyarccagg gctggatgtc cggagccagc cccgmagccc tgkgktcttt 1440
gttcttcgca ctcccaccgt ccgtgtgaac agctccagcc ccacctgcgc ctccctgtgc 1500
tgggctccat cagggagccc agaagacgtg tgtgcttctg aaattgggtc cctacatgcc 1560
tttgtcccag tgcaccttgc tccttccatt tactatcgag atttaaatgc ctgttttctc 1620
cccagaggtt gacggatata ttcagacgtt acgacacgga tcaggacggc tggattcagg 1680
tgtcgtacga acagtacctg tccatggtct tcagtatcgt atgaccctgg cctctcgtga 1740
agagcagcac aacatggaaa gagccaaaat gtcacagttc ctatctgtga gggaatggag 1800
cacaggtgca gttagatgct gttcttcctt tagattttgt cacgtgggga cccagctgta 1860
catatgtgga taagctgatt aatggttttg caactgtaat agtagctgta tcgttctaat 1920
gcagacattg gatttggtga ctgtctcatt gtgccatgag gtaaatgtaa tgtttcaggc 1980
attctgcttg caaaaaaatc tatcatgtgc ttttctagat gtctctggtt ctatagtgca 2040
aatgctttta ttagccaata ggaattttaa aataacatgg aacttacaca aaaggctttt 2100
catgtgcctt acttttttaa aaaggagttt attgtattca ttggaatatg tgacgtaagc 2160
aataaaggga atgttagacg tgtaaaaaaa aaaaaaaaaa aaaaaaaaaa aaag 2214

<210> 114
<211> 3300
<212> DNA
<213> Homo sapiens

<400> 114
```
tcgacccacg cgtccggtga gaggcaagga cttttcatct ttagggcatt ctgaccacgt      60
cctgcttcag agagattgtt cccggcgtct cagtgctatg gggagcaggt tcctcctggt     120
cctgctctca ggtctcactg tcttactggc tctgccagga tcagaagcca agaattctgg     180
agcttcctgt cctccatgcc ctaaatatgc cagctgccac aacagcaccc actgtacttg     240
tgaagatggc tttcgggcca ggtctggcag gacatacttt catgattcct ctgagaagtg     300
tgaagatatt aatgaatgtg aaaccgggct ggcaaagtgc aagtataaag catattgtag     360
gaataaagtt ggaggttaca tctgtagctg tttggtaaaa tatactttat tcaactttct     420
ggctggtatt atagattatg atcatccgga ttgttatgag aacaatagtc aagggacgac     480
acagtcaaac gtggatattt gggtgagtgg ggtgaagcct ggatttggga aacagctggt     540
acgtataact atgccatttt cctacccaaa cattaacatg tcttcctgtg atttttaggg     600
tagggtagtt ctatccaggg gtaattttgt cctctgtccc aaggtcatct gtcaatgact     660
ggggacactt ttggttgtca taccttgggg gtgatgtgtg tgactggcat ctggtggatg     720
gagaccaggg atacagctca acatcctaca gtgcccagga cagcctccca caatcaagaa     780
gtgcctagtg ccatatgtcc atagagatag agaaatacaa gtgtaggggg aaagtgcctc     840
agctggcatt caaagaccta catcaagcac ctacattctc aatgccacac gcaccttgta     900
gcaccttaat aaatatcgtt gccttctggg ctccccactc caacacttgt gcatattccc     960
tatttcttac atttcagtaa gagtcaatct aattagctta atttttttgg aaggaaaatc    1020
tgagaagaaa tggaagcaga gaggactttg caagaagggc tactcaacta attcaaagcg    1080
tggagttgag catctggaat gcgagttttg cttctccagg aaagggtcaa atttctgaat    1140
ttgatatagt ctatgaaacc aagaggtgca atgagacaag ggagaatgct tttctggaag    1200
ctggaaataa caccatggat atcaactgtg ctgatgcttt aaaaggaaac ctaagagaga    1260
gcactgcagt tgccctatca cttatcaatc tcttggggat attctgaatg catccttttt    1320
tagtaaacga aaagggatgc aggaagtaaa actgaactct tacgttgtga gcggcaccat    1380
cggtttgaag gaaaaaattt ccctctctga acctgtgttc ctgacttttc gccataatca    1440
gcctggtgac aagagaacaa aacatatctg tgtctactgg gagggatcag agggaggccg    1500
ctggtccacg gagggctgct ctcatgtgca cagcaacggt tcttacacca aatgcaagtg    1560
cttccatctg tccagctttg ccgtcctcgt ggctcttgcc cccaaggagg accctgtgct    1620
gaccgtgatc acccaggtgg ggctgaccat ctctctgctg tgcctcttcc tggccatcct    1680
caccttcctc ctgtgccggc ccatccagaa caccagcacc tccctccatc tagagctctc    1740
cctctgcctc ttcctggccc acctcctgtt cctgacgggc atcaacagaa ctgagcctga    1800
ggtgctgtgc tccatcattg cagggctgct gcacttcctc tacctggctt gcttcacctg    1860
gatgctcctg gaagggctgc acctcttcct caccgtcagg aacctcaagg tggccaacta    1920
caccagcacg ggcagattca agaagaggtt catgtaccct gtaggctacg ggatcccagc    1980
tgtgattatt gctgtgtcag caatagttgg accccagaat tatggaacat ttactcactg    2040
ttggctcaag cttgataaag gattcatctg gagcttcatg ggccagtag cagtcattat    2100
cttgataaac ctggtgttct acttccaagt tctgtggatt ttgagaagca aactttcctc    2160
cctcaataaa gaagtttcca ccattcagga caccagagtc atgacattta aagccatttc    2220
tcagctattt atcctgggct gttcttgggg ccttggtttt tttatggttg aagaagtagg    2280
gaagacgatt ggatcaatca ttgcatactc attcaccatc atcaacaccc ttcagggagt    2340
gttgctcttt gtggtacact gtctccttaa tcgccaggtt cgaatggaat ataaaaagtg    2400
gtttagtggg atgcggaaag ggtagaaac tgaaagcact gagatgtctc gctctactac    2460
ccaaaccaaa acggaagaag tggggaagtc ctcagaaatc tttcataaag gaggcactgc    2520
atcatcatct gcagagtcaa ccaagcaacc gcagccacag gttcatctcg tctctgctgc    2580
ttggctaaag atgaactgac ctggcaagtg ccatggcaat gacccggaag ttacccctcc    2640
tttccgtttg tctacagcgc ccctgtggtc acacatagat tggacaaatg ccactatttc    2700
tagctttcct gtgaaaagtc taggctcatt cacctatttt ggctttttat gttcatagaa    2760
agaacaagac atttgggaga attcttagat ccagagtcca gtagtgtggc acgtgcaatg    2820
aagtgtcgga aggatgcatt ttaaagatgg cgggcgggag aagtggattt tcttcttgca    2880
gctactgcca ccttgccaga aactcactaa ctggcatctg gattcagctc atagttccct    2940
ttctggcctc tctgctgtat tttatgctcc caaagatctt acattaacac tccacattca    3000
cataattcaa caattttcat atggatcagt attaaagagg gtgttgcatt ttgcaataca    3060
aaaatgcatt atcaggtgct ggagaggatg tggagaaata ggaacacttt tacactgttg    3120
gtgggactgt aaactagttc aaccatcgtg gaagtcagtg tggcgattcc tcagggatct    3180
```

agaactagaa ataccatttg acacagctat cccattactg ggtatatacc ccaagggcta 3240
taaatcatgc tgctataaag acacatgcac acgtaaaaaa aaaaaaaaag ggcggccgct 3300

<210> 115
<211> 1286
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1149)
<223> n equals a,t,g, or c.

<400> 115
gactgcttta cggacattgg atgaagccga agcatttaga atggtgcctg gcacacagtt 60
ggtgcgtgat atggttaagc tttgtgtccc cacccacatc tcatcttgaa tgtgacggtt 120
tccccggctc cctcctgccg ccatgtgaag aaggtcgttg cttcccctttc accttccacc 180
accatgattg ccatggatgc tccccactcc aaagcagccc tggacagcat taacgagctg 240
cccgagaaca tcctgctgga gctgttcacg cacgtgcccg cccgccagct gctgctgaac 300
tgccgcctgg tctgcagcct ctggcgggga cctcatcgac ctcatgaccc tctggaaacg 360
caatgcctgc gagagggctt catcaccaag gactgggacc agcccgtggc cgactggaaa 420
atcttctatt tcctacggag cctgcatagg aactcctgcg caacccgtgt gctgaagagg 480
atatgtttgc atggcaaatt gatttcaatg gtggggaccg ctggaaggtg gagagcctcc 540
ctggagccca cgggacagat tttcctgacc cccaaagtcaa gaagtatttt gtcacatcct 600
acgaaatgtg cctcaagtcc cagctggtgg accttgtagc cgagggctac tgggaggagc 660
tactagacac attccggccg gacatcgtgg ttaaggactg gtttgctgcc agagccgact 720
gtggctgcac ctaccaactc aaagtgcagc tggcctcggc tgactacttc gtgttggcct 780
ccttcgagcc cccacctgtg accatccaac agtggaacaa tgccacatgg acagaggtct 840
cctacacctt ctcagactac ccccggggtg tccgctacat cctcttccag catgggggca 900
gggacaccca gtactgggca ggctggtatg ggccccgagt caccaacagc agcattgtcg 960
tcagccccaa gatgaccagg aaccaggcct cctccgaggc tcagcctggg cagaagcatg 1020
gacaggagga ggctgcccaa tcgccctacc gagctgttgt ccagatttcc tgacagctgt 1080
ccatcctgtg tctgggtcag ccagaggttc ctccaggcag gagctgagca tggggtgggc 1140
aagtgaggnc cctgtaccaa gcgacttctg ccccggttca accctaccaa gcttggggga 1200
acttactgca catagctctg acgttttgtt gtaataaatg ttttcaggcc gggcaaaaaa 1260
aaaaaaaaaa aaaaaaaaaa aaaaaa 1286

<210> 116
<211> 2189
<212> DNA
<213> Homo sapiens

<400> 116
ggaattcggc acgaggcgcc cgaggatgtg ctgctggccg ctgctcctgc tgtgggggct 60
gctccccggg acggcggcgg gggcctcggg ccgaacctat ccgcaccgga ccctcctgga 120
ctcggagggc aagtactggc tgggctggag ccagcggggc agccagatcg ccttccgcct 180
ccaggtgcgc actgcaggct acgtgggctt cggcttctcg cccaccgggg ccatggcgtc 240
cgccgacatc gtcgtgggcg gggtggccca cgggcggccc tacctccagg attattttac 300
aaatgcaaat agagagttga aaaaagatgc tcagcaagat taccatctag aatatgccat 360
ggaaaatagc acacacacaa taattgaatt taccagagag ctgcatacat gtgacataaa 420
tgacaagagt ataacggata gcactgtgag agtgatctgg gcctaccacc atgaagatgc 480
aggagaagct ggtcccaagt accatgactc caataggggc accaagagtt tgcggttatt 540
gaatcctgag aaaactagtg tgctatctac agccttacca tactttgatc tggtaaatca 600
cgacgtcccc atcccaaaca aagatacaac atattggtgc caaatgttta agattcctgt 660
gttccaagaa aagcatcatg taataaaggt tgagccagtg atacagagag gccatgagag 720
tctggtgcac cacatcctgc tctatcagtg cagcaacaac tttaacgaca gcgttcctgg 780
aatccgggca cgaattgcta tcaccccaac atgcccgatg cattcctcac ctgtgaaact 840

```
gtgattttg cctgggctat tggtggagag ggcttttctt atccacctca tgttggatta      900
tcccttggca ctccattaga tccgcattat gtgctcctag aagtccatta tgataatccc     960
acttatgagg aaggcttaat agataattct ggactgaggt tattttacac aatggatata    1020
aggaaatatg atgctggggt gattgaggct ggcctctggg tgagcctctt ccataccatc    1080
cctccaggga tgcctgagtt ccagtctgag ggtcactgca ctttggagtg cctggaagag    1140
gctctggaag ccgaaaagcc aagtggaatt catgtgtttg ctgttcttct ccatgctcac    1200
ctggctggca gaggcatcag gctgcgtcat tttcgaaaag ggaaggaaat gaaattactt    1260
gcctatgatg atgattttga cttcaatttc caggagtttc agtatctaaa ggaagaacaa    1320
acaatcttac caggagataa cctaattact gagtgtcgct acaacacgaa agatagagct    1380
gagatgactt ggggaggact aagcaccagg agtgaaatgt gtctctcata ccttctttat    1440
tacccaagaa ttaatcttac tcgatgtgca agtattccag acattatgga acaacttcag    1500
ttcattgggg ttaaggagat ctacagacca gtcacgacct ggcctttcat tatcaaaagt    1560
cccaagcaat ataaaaacct ttctttcatg gatgctatga ataagttaa atggactaaa     1620
aaggaaggtc tctccttcaa caagctggtc ctcagcctgc cagtgaatgt gagatgttcc    1680
aagacagaca atgctgagtg gtcgattcca aggaatgaca gcattacctc cagatataga    1740
aagaccctat aaagcagaac cctttggtgt gtggcacgtc ttcttcctct tccctgcaca    1800
gagatttctc ccatcaactt gcttgtttgc cttctgctac tcagctgcac gctgagcacc    1860
aagagcttgt gatcaaaatt ctgttggact tgacaatgtt ttctatgatc tgaacctgtc    1920
atttgaagta caggttaaag actgtgtcca ctttgggcat gaagagtgtg gagacttttc    1980
ttccccattt tccctccctc cttttttcct tccatgttac atgagagaca tcaatcaggt    2040
tctcttctct ttcttagaaa tatctgatgt tatatataca tggtcaataa aataaaactg    2100
gcctgactta agataaccat tttaaaaaat tgggctgtca tgtgggaata aaagaattct    2160
ttctttccta aaaaaaaaaa aaaaaaaaa                                       2189
```

<210> 117
<211> 1763
<212> DNA
<213> Homo sapiens

<400> 117

```
ggtggcctag agatgctgct gccgcggttg cagttgtcgc gcacgcctct gcccgccagc      60
ccgctccacc gccgtagcgc ccgagtgtcg gggggcgcac ccgagtcggg ccatgaggcc     120
ggggaaccgcg ctacaggccg tgctgctggc cgtgctgctg gtggggctgc gggccgcgac    180
gggtcgcctg ctgagtgggc agccagtctg ccggggaggg acacagaggc cctgttataa     240
agtcatttac ttccatgata cttctcgaag actgaacttt gaggaagcca aagaagcctg     300
caggagggga tggaggccag ctagtcagca tcgagttctg aagatgaaca gaaactgata     360
gaaaakttca ttgaaaacct cttgccatct gatggtgayt tctggawtgg gctcaggagg     420
cgtgaggaga aacaaagcaa tagcacagct gccaggacct ttatgcttgg actgatggca     480
gcatatcaca atttaggaac tggtatgtgg atgagccgtc ctgcggcagc gaggtctgcg     540
tggtcatgta ccatcagcca tcggcacccg ctggcatcgg aggcccctac atgttccagt     600
ggaatgatga ccggtgcaac atgaagaaca atttcatttg caaatattct gatgagaaac     660
cagcagttcc ttctagagaa gctgaaggtg aggaaacaga gctgacaaca cctgtacttc     720
cagaagaaac acaggaagaa gatgccaaaa aaacatttaa agaaagtaga gaagctgcct     780
tgaatctggc ctacatccta atccccagca ttcccctcct cctcctcctt gkggtcacca     840
cagttgtatg ttgggtttgg atctgtagaa aaagaaaacg ggagcagcca gaccctagca     900
caaagaagca acacaccatc tggccctctc ctcaccaggg aaacagcccg gacctagagg     960
tctacaatgt catwagaaaa caaagcgaag ctgacttagc tgagacccgg ccagacctga    1020
agaatatttc attccgagtg tgttcgggag aagccactcc cgatgacatg tcttgtgact    1080
atgacaacat ggctgtgaac ccatcagaaa gtgggtttgt gactctggtg agcgtggaga    1140
gtggatttgt gaccaatgac atttatgagt tctccccaga ccaaatgggg aggagtaagg    1200
agtctggatg ggtggaaaat gaaatatatg gttattagga catataaaaa actgaaactg    1260
acaacaatgg aaaagaaatg ataagcaaaa tcctcttatt ttctataagg aaaatacaca    1320
gaaggtctat gaacaagctt agatcaggtc ctgtggatga gcatgtggtc cccacgacct    1380
cctgttggac ccccacgttt tggctgtatc ctttatccca gccagtcatc cagctcgacc    1440
ttatgagaag gtaccttgcc caggtctggc acatagtaga gtctcaataa atgtcacttg    1500
gttggttgta tctaactttt aagggacaga gctttacctg gcagtgataa agatgggctg    1560
tggagcttgg aaaaccacct ctgttttcct tgctctatac agcagcacat attatcatac    1620
agacagaaaa tccagaatct tttcaaagcc cacatatggt agcacaggtt ggcctgtgca    1680
```

```
tcggcaattc tcatatctgt tttttcaaa gaataaaatc aaataaagag caggaaaaaa      1740
aaaaaaaaaa aaaaaaactc gag                                              1763
```

<210> 118
<211> 1375
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (18)
<223> n equals a,t,g, or c

<400> 118

```
ggcgggcggc gcggaagngg cggckgcgcg gccggggcag ccatgtcgcc attgtctgcg        60
gcgcgggcgg ccctgcgggt ctacgcggta ggcgccgcgg tgatcctggc gcagctgctg       120
cggcgctgcc gsgggggctt cctggagcca gttytccccc cacgacctga ccgtgtcgct       180
atagtgacgg gagggacaga tggcattggc tattctacag cgaacatctg gcgagacttg       240
gcatgcatgt tatcatagct ggaaataatg acagcaaagc caaacaagtt gtaagcaaaa       300
taaaagaaga aaccttgaac gacaaagtgg aatttttata ctgtgacttg gcttccatga       360
cttccatccg gcagtttgtg cagaagttca agatgaagaa gattcctctc catgtcctga       420
tcaacaatgc tggggtgatg atggtccctc agaggaaaac cagagatgga ttcgaagaac       480
atttcggcct gaactaccta gggcacttcc tgctgaccaa ccttctcttg gatacgctga       540
aagagtctgg gtcccctggc cacagtgcga gggtggtcac cgtctcctct gccacccatt       600
acgtcgctga gctgaacatg gatgaccttc agagcagtgc ctgctactca ccccacgcag       660
cctacgccca gagcaagctg gcccttgtcc tgttcaccta ccacctccag cggctgctgg       720
cggctgaggg aagccacgtg accgccaacg tggtggaccc cggggtggtc aacacggacs       780
tctacaagca cgtgttctgg gccacccgtc tggcgaagaa gcttctcggc tggttgcttt       840
tcaagacccc cgatgaagga gcgtggactt ccatctacgc agcagtcacc ccagagctgg       900
aaggagttgg tggccgttac ctatacaacg agaaagagac caagtccctc cacgtcacct       960
acaaccagaa actgcagcag cagctgtggt ctaagagttg tgagatgact ggggtccttg      1020
atgtgaccct gtgatatcct gtctcaggat agctgctgcc ccaagaaaca cattgcacct      1080
gccaatagct tgtgggtctg tgaagactgc ggtgtttgag tttctcacac ccacctgccc      1140
acagggctct gtcctctagt tttgagacag ctgcctcaac ctctgcagaa cttcaagaag      1200
ccaaataaac attttggagg ataatcaccc caagtggtct tcaaccataa actttgtgat      1260
tccaaagtgc ccagttgtca caggtgccat aaataattac attttccaac ataaaaaaaa      1320
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaagggcg gccgc           1375
```

<210> 119
<211> 1022
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (937)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (990)
<223> n equals a,t,g, or c

<400> 119

```
ggcacgagag agccrgcggc ccgagccggg gccatggcga actgctgagc tgcgtcctag        60
gcccccggct ctacaaaatc taccgggaga gggactctga aagggccccg gccagcgtcc       120
ctgagacgcc aacggcagtc actgcccccc attccagctc ctgggatacg tactatcagc       180
```

```
cccgtgccct ggagaaacat gctgacagca tcctggcact ggcttcagta ttctggtcca      240
tctcttatta ctcctctccc ttcgccttct tctacttgta caggaaaggt tacttgagtt      300
tgtccaaagt ggtgccgttt tctcactatg ctgggacatt gctgctactt ctggcaggtg      360
tggcctgctc cgaggcattg gccgctggac caacccccag taccggcagt tcatcaccat      420
cttggaagca acacatcgga accagtcttc agaaaacaag aggcagcttg ccaactacaa      480
ctttgacttc cggagctggc cagtcgactt ccactgggaa gaacccagca gccggaagga      540
gtctcgaggg ggcccttccc gccggggtgt ggccctgctt cgcccagagc ccctgcaccg      600
ggggacagca gacaccctcc tcaaccgggt taagaagctg ccttgtcaga tcaccagcta      660
cctggtggcg cacaccctag ggcgccggat gctgtatcca ggctctgtgt acctgctgca      720
gaaggccctc atgcctgtgc tgctgcaggg ccaggcccga ctggtggaag agtgtaatgg      780
gcgccgggca aagctgctgg cctgtgatgg caatgagatt gacaccatgt ttgtggaccg      840
gcgggggaca gctgagcccc aggacagaag ctggtgatct gctgtgargg gaatgctggg      900
ttttatgarg tgggctgcgt ctccamgccc ctggaanctg gatattcatc ckgggtggaa      960
tcatccagct ttgctggaac acaggggtn ccattcccgc aaaatgaagg ctaatgccat     1020
gg                                                                   1022
```

<210> 120
<211> 2311
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (654)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (2293)
<223> n equals a,t,g, or c

<400> 120

```
tcgacccacg cgtccgcttc ctcatgctgc ccgctcgcct accgttcagg ctgctgagcc       60
ttttcctccg tggatccgct cccacggcag cgcgccatgg cctccgggag ccgctcctgg      120
agaggaggtg cgctgccgcc tcctccttcc agcactcatc gagtctggga cgcgagcttc      180
cttatgaccc cgtggacacg gagggctttg gagaaggtgg tgacatgcag gagcgttttc      240
tgttcccgga gtacatcctg gatccggagc cgcaacccac ccgcgaaaag cagctgcagg      300
agctccagca acagcaggag gaggaggagc gacagaggca gcagcggcgg gaggagcggc      360
gacagcaaaa cctacgggcc aggtcccggg agcacccggt cgtggggcac ccggacccgg      420
cattgccgcc cagcggcgtg aactgctcgg gctgcggggc asasctgcac tgccaggacg      480
ccggagtgcc cggctacctg ccccgagaga agttcctccg cacggcggag gcagacggcg      540
ggctggcacg gaccgtgtgc cagcgctgct ggctgctgtc gcaccaccgg cgcgctctac      600
gcctgcaggt gagccgcgag cagtacctgg agctggtgag cgccgcgttg cggnggcccg      660
gcccctccct ggtgctctac atggtggacc tgctggacct gcccgacgcc ctgctgcccg      720
acttgcccgc gctggtgggc cccaagcagc tgatcgtgct gggaaacaaa gtggacctcc      780
tgccccagga tgctcctggc taccggcaga ggctgcggga gcgactgtgg gaggactgtg      840
cccgcgccgg gctcctgctg gcccctggca ccaaggccca cagcgccccg tcaaggacga      900
gccacaggac ggggagaatc cgaatccgcc gaactggtcc cgcacagtgg tcagggacgt      960
gcggctgatc agcgccaaga ccggctatgg agtggaagag ttgatctctg cccttcagcg     1020
ctcctggcgc taccgtgggg acgtctactt agtgggcgcc accaacgccg gcaaatccac     1080
tctctttaac acgctcctgg agtccgatta ctgcactgcc aagggctccg aggccatcga     1140
cagagccacc atctcccctt ggccaggtac tacattaaac cttctgaagt ttcctatttg     1200
caacccaact ccttacagaa tgtttaaaag gcatcaaaga cttaaaaaag attcaactca     1260
agctgaagaa gatcttagtg agcaagaaca aaatcagctt aatgtcctca aaaagcatgg     1320
ttatgtcgta ggaagagttg gaaggacatt cttgtattca gaagaacaga aggataacat     1380
tccctttgag tttgatgctg attcacttgc ctttgacatg gaaaatgacc ctgttatggg     1440
tacacacaaa tccaccaaac aagtagaatt gactgcacaa gatgtgaaag atgcccactg     1500
gttttatgac acccctggaa ttacaaaaga aaattgtatt ttaaatcttc taacagaaaa     1560
```

agaagtaaat attgttttgc caacacagtc cattgttcca agaacttttg tgcttaaacc 1620
aggaatggtt ctgtttttgg gtgctatagg ccgcatagat ttcctgcagg gaaatcagtc 1680
agcttggttt acagtcgtgg cttccaacat cctccctgtg catatcacct ccttggacag 1740
ggcagacgct ctgtatcaga agcatgcagg tcatacgtta ctccagattc caatgggtgg 1800
aaaagaacga atggctggat ttcctcctct tgttgctgaa gacattatgt taaaagaagg 1860
actgggggca tctgaagcag tggccgacat caagttttcc tctgcaggtt gggtttcagt 1920
aacacctaat tttaaggaca gactgcatct ccgaggctat acacctgaag gaacagtttt 1980
gaccgtccgg ccccctctct tgccatatat tgttaacatc aaaggacagc gcatcaagaa 2040
aagtgtggcc tataaaacca agaagcctcc ttcccttatg tacaacgtga ggaagaagaa 2100
aggaaagata aatgtatgag accgaccttg ttcactccag atattaactg tattgaacac 2160
aacaaaatac attgaatttg tattaaacat ataacgcata aataaagctc ccattcttac 2220
ccttaaaaaa aaaaaaaaag ggcggccgct ctagaggatc caagcttacg tacgcgtgca 2280
tgcgacgtca tanctcgtct ataggaactg g 2311

<210> 121
<211> 1286
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1284)
<223> n equals a,t,g, or c

<400> 121
gggcgcgcgg gtgaaaggcg cattgatgca gcctgcggcg gcctcggagc gcggcggagc 60
agacgctgac cacgttcctc tcctcggtct cctccgcctc cagctccgcg ctgcccggca 120
gccgggagcc atgcgacccc agggccccgc cgcctccccg cagcggctcc gcggcctcct 180
gctgctcctg ctgctgcagc tgcccgcgcc gtcgagcgcc tctgagatcc ccaaggggaa 240
gcaaaaggcg cactccggca gagggaggtg gtggacctgt ataatggaat gtgcttacaa 300
gggccagcag gagtgcctgg tcgagacggg agccctgggg ccaatggcat tccgggtaca 360
cctgggatcc caggtcggga tggattcaaa ggagaaaagg gggaatgtct gacggaaagc 420
tttgaggagt cctggacacc caactacaag cagtgttcat ggagttcatt gaattatggc 480
atagatcttg ggaaaattgc ggagtgtaca tttacaaaga tgcgttcaaa tagtgctcta 540
agagttttgt tcagtggctc acttcggcta aaatgcagaa atgcatgctg tcagcgttgg 600
tatttcacat tcaatggagc tgaatgttca ggacctcttc ccattgaagc tataatttat 660
ttggaccaag gaagccctga aatgaattca acaattaata ttcatcgcac ttcttctgtg 720
gaaggacttt gtgaaggaat tggtgctgga ttagtggatg ttgctatctg ggttggcact 780
tgttcagatt acccaaaagg agatgcttct actggatgga attcagtttc tcgcatcatt 840
attgaagaac taccaaaata aatgctttaa ttttcatttg ctacctcttt ttttattatg 900
ccttggaatg gttcacttaa atgacatttt aaataagttt atgtatacat ctgaatgaaa 960
agcaaagcta aatatgttta cagaccaaag tgtgatttca cactgttttt aaatctagca 1020
ttattcattt tgcttcaatc aaaagtggtt tcaatatttt ttttagttgg ttagaatact 1080
ttcttcatag tcacattctc tcaacctata atttggaata ttgttgtggt cttttgtttt 1140
ttctcttagt atagcatttt taaaaaaata taaaagctac caatctttgt acaatttgta 1200
aatgttaaga attttttta tatctgttaa ataaaattta tttccaacaa aaaaaaaaaa 1260
aaaaaaaaaa aaaaaaaaaa aaanaa 1286

<210> 122
<211> 1380
<212> DNA
<213> Homo sapiens

<400> 122
cagacccgcg gggcaaacgg actggggcca agagccggga gcgcggcgc aaaggcacca 60
gggcccgccc agggcgccgc gcacacggcc ttgggggttc tgcgggcctt cgggtgcgcg 120
tctcgcctct agccatgggg tccgcagcgt tggagatcct gggcctggtg ctgtgcctgg 180

tgggctgggg gggtctgatc ctggcgtgcg ggctgcccat gtggcaggtg accgccttcc 240
tggaccacaa catcgtgacg gcgcagacca cctggaaggg gctgtggatg tcgtgcgtgg 300
tgcagagcac gggcacatgc agtgcaaagt gtacgactcg gtgctggctc tgagcaccga 360
ggtgcaggcg gcgcgggcgc tcaccgtgag cgccgtgctg ctggcgttcg ttgcgctctt 420
cgtgaccctg gcgggcgcgc agtgcaccac ctgcgtggcc ccgggcccgg ccaaggcgcg 480
tgtggccctc acgggaggcg tgctctacct gttttgcggg ctgctggcgc tcgtgccact 540
ctgctggttc gccaacattg tcgtccgcga gttttacgac ccgtctgtgc ccgtgtcgca 600
gaagtacgag ctgggcgcac gctgtacatc ggctgggcgg ccaccgcgct gctcatggta 660
ggcggctgcc tcttgtgctg cggcgcctgg gtctgcaccg gccgtcccga cctcagcttc 720
cccgtgaagt actcagcgcc gcggcggccc acggccaccg gcgactacga caagaagaac 780
tacgtctgag ggcgctgggc acggccgggc ccctcctgcc agccacgcct gcgaggcgtt 840
ggataagcct ggggagcccc gcatggaccg cggcttccgc cgggtagcgc ggcgcgcagg 900
ctcctcggaa cgtccggctc tgcgccccga cgcggctcct ggatccgctc ctgcctgcgc 960
ccgcagctga ccttctcctg ccactagccc ggccctgccc ttaacagacg gaatgaagtt 1020
tccttttctg tgcgcggcgc tgtttccata ggcagagcgg gtgtcagact gaggatttcg 1080
cttcccctcc aagacgctgg gggtcttggc tgctgcctta cttcccagag gctcctgctg 1140
acttcggagg ggcggatgca gagcccaggg cccccaccgg aagatgtgta cacctggtct 1200
ttactccatc ggcagggccc gagcccaggg accagtgact tggcctggac ctcccggtct 1260
cactccagca tctccccagg caaggcttgt gggcaccgga gcttgagaga gggcgggagt 1320
gggaaggcta agaatctgct tagtaaatgg tttgaactct caaaaaaaaa aaaaaaaaaa 1380

<210> 123
<211> 3793
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (1102)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1132)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1199)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1228)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1229)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (1231)
<223> n equals a,t,g, or c

<220>
<221> SITE

<222> (3176)
<223> n equals a,t,g, or c

<400> 123

```
ggggcttcat acaggaaatc tattgctgtg tcaagttcca gagaaaagct tctgttcgtc 60
caagttacta accaggctaa accacataga cgtgaaggaa ggggctagaa ggaagggagt 120
gccccactgt tgatggggta agaggatcct gtactgagaa gttgaccaga gagggtctca 180
ccatgcgcac agttccttct gtaccagtgt ggaggaaaag tactgagtga agggcagaaa 240
aagagaaaac agaaatgctc tgcccttgga gaactgctaa cctagggcta ctgttgattt 300
tgactatctt cttagtggcc gaagcggagg gtgctgctca accaaacaac tcattaatgc 360
tgcaaactag caaggagaat catgctttag cttcaagcag tttatgtatg gatgaaaaac 420
agattacaca gaactactcg aaagtactcg cagaagttaa cacttcatgg cctgtaaaga 480
tggctacaaa tgctgtgctt tgttgccctc ctatcgcatt aagaaatttg atcataataa 540
catgggaaat aatcctgaga ggccagcctt cctgcacaaa agcctacaag aaagaaacaa 600
atgagaccaa ggaaaccaac tgtactgatg agagaataac ctgggtctcc agacctgatc 660
agaattcgga ccttcagatt cgtaccgtgg ccatcactca tgacgggtat tacagatgca 720
taatggtaac acctgatggg aatttccatc gtggatatca cctccaagtg ttagttacac 780
ctgaagtgac cctgtttcaa aacaggaata gaactgcagt atgcaaggca gttgcaggga 840
agccagctgc gcatatctcc tggatcccag agggcgattg tgccactaag caagaatact 900
ggagcaatgg cacagtgact gttaagagta catgccactg ggaggtccac aatgtgtcta 960
ccgtgaactg ccacgtctcc catttgactg gcaacaagag tctgtacata gagctacttc 1020
ctgttccagg tgccaaaaaa tcatcaaaat tatatattcc atatatcatc cttactatta 1080
ttattttgac catcgtggga tncatttggt tgttgaaagt caatggctgc anaaaatata 1140
aattgaataa accagaatct actccagttg ttgaggagga tgaaatgcag ccctatgcnt 1200
tttacacaga gaagaacaat cctctctnng ntactacaaa caaggtgaag gcatctgagg 1260
cattacaaag tgaagttgac acagacctcc atactttata agttgttgga ctctagtacc 1320
aagaaacaac aacaaacgag atacattata attactgtct gattttctta cagttctaga 1380
atgaagactt atattgaaat taggttttcc aaggttctta gaagacattt taatggattc 1440
tcattcatac ccttgtataa ttggaatttt tgattcttag ctgctaccag ctagttctct 1500
gaagaactga tgttattaca aagaaaatac atgcccatga ccaaatattc aaattgtgca 1560
ggacagtaaa taatgaaaac caaatttcct caagaaataa ctgaagaagg agcaagtgtg 1620
aacagtttct tgtgtatcct ttcagaatat tttaatgtac atatgacatg tgtatatgcc 1680
tatggtatat gtgtcaattt atgtgtcccc ttacatatac catgcaccct atctttgtca 1740
aggcaccagt gggaacaata cactgcatta ctgttctata catatgaaaa cctaataata 1800
taagtcttag agatcatttt atatcatgac aagtagagct acctcattct ttttaatggt 1860
tatataaaat tccattgtat agttatatca ttatttaatt aaaaacaacc ctaatgatgg 1920
atatttagat tcttttaagt tttgtttatt tcttttaagt tttgtttgtg gtataaacaa 1980
taccacatag aatgtttctt gtgcatatat ctctttgttt ttgagtatat ctgtaggata 2040
actttcttga gtggaattgt caggtcaaag ggtttgtgca ttttactatt gatatatatg 2100
ttaaattgtg tcaaatatat atgtcaaatt ccctccaaca ttgtttaaat gtgcctttcc 2160
ctaaatttct attttaataa ctgtactatt cctgcttcta cagttgccac tttctctttt 2220
taatcaacca gattaaatat gatgtgagat tataataaga attatactat ttaataaaaa 2280
tggatttata tttttggtca tgtttgtaag agagtgaatg cacgtgtgag aacattagct 2340
tcttctgaac tcattatatc tccacagagg tgttgatact tgatgcctaa cagttttgca 2400
gatgtgctac attggaattg tgtattttta tggtgtacat tctattgtga tatatttatt 2460
gaataattaa tgtctattga ccatataagt ggcgaaaaat gcaccataga ggacatgggg 2520
tatttattta caaactatga gctacataat aagcaagtgc ccatgggatg gcatgaccct 2580
cccctccata tttttgtgga gcaaaatatt ggcaatgttt atgtaaatca ttgttaatat 2640
catgaaatta tttttaatta aaaacataag tctatttgct ccatagcaga aaaaacatga 2700
gaagtttttt catcatgata gaaattgaaa caaaatatat tcattcttca atcataccat 2760
ctgagatttt taagacagct attttgtctt ataagtatat ttttctccct ctagacattt 2820
cagttactat ggattttgtc ctcaaaggga cytttagtct aattttggga tgtaaagcta 2880
atcttaatga cacttggcac atgatatttt gatcaagcca ttttgacttg accaaaaagc 2940
agtgtccatt aggtttctgc atataaatat taccaagcaa tgttcacaat agacatcatt 3000
acactgtcct tgaaatttat taattcttca tccaaccctg gttgagctga ggctcatagt 3060
taggttcaag actatctgtt taaatattac tgaaaaacaa agtangacag tactatgctt 3120
acctcttaac ttgataatgt caaaccaggc atgttaaatg acatcataga aaaganttca 3180
agataattta tagaagttaa attatattgt acagaaaata attgtatgaa aatctctact 3240
atggggctgg aacatggttg aacattagaa tgataтaaaa aattatatat attctccaaa 3300
```

```
tccacgctag acctgtcaaa ttagagaatc tagagattag acctggcgtg tcagcaaggt   3360
catccaggaa gcagaggctg agacggagtt aggtgtgatt acttacatag tcgattacat   3420
tttacaaata acattttata tgtctcattt actgtgcttt ctccccatcc catttgtat    3480
cttttccttt gctttgctag atttgtcaat tttctctctc tttctgtctc tctctctttc   3540
aatatctcta ataatttgaa agtaattcat cataactaaa tatctattgg ggttatgctt   3600
cacttacaaa cttctgaaaa cggctttact gagatataat tgatatattt aagtgtacag   3660
tttgttaaat tttgcacata tttaaaatgt ggactttggt aaatgttgac atagttttac   3720
atctgtgaaa ccatcagcat aatcaagata ataaacttgt ccatcacccc ccaaaaaaaa   3780
aaaaaaaaaa aaa                                                       3793
```

<210> 124
<211> 370
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (370)
<223> Xaa equals stop translation

<400> 124

```
Met Leu Gly Ala Phe Val Trp Pro Ser Leu Leu Leu Leu Ala Ala Ala
1               5                   10                  15

Cys Ile Cys Leu Leu Thr Phe Ile Asn Cys Ala Tyr Val Lys Trp Gly
            20                  25                  30

Thr Leu Val Gln Asp Ile Phe Thr Tyr Ala Lys Val Leu Ala Leu Ile
        35                  40                  45

Ala Val Ile Val Ala Gly Ile Val Arg Leu Gly Gln Gly Ala Ser Thr
    50                  55                  60

His Phe Glu Asn Ser Phe Glu Gly Ser Ser Phe Ala Val Gly Asp Ile
65                  70                  75                  80

Ala Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr Ser Gly Trp Asp Thr
                85                  90                  95

Leu Asn Tyr Val Thr Glu Glu Ile Lys Asn Pro Glu Arg Asn Leu Pro
            100                 105                 110

Leu Ser Ile Gly Ile Ser Met Pro Ile Val Thr Ile Ile Tyr Ile Leu
        115                 120                 125

Thr Asn Val Ala Tyr Tyr Thr Val Leu Asp Met Arg Asp Ile Leu Ala
    130                 135                 140

Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln Ile Phe Gly Ile Phe
145                 150                 155                 160

Asn Trp Ile Ile Pro Leu Ser Val Ala Leu Ser Cys Phe Gly Gly Leu
                165                 170                 175

Asn Ala Ser Ile Val Ala Ala Ser Arg Leu Phe Phe Val Gly Ser Arg
            180                 185                 190

Glu Gly His Leu Pro Asp Ala Ile Cys Met Ile His Val Glu Arg Phe
```

```
            195                           200                           205

Thr Pro Val Pro Ser Leu Leu Phe Asn Gly Ile Met Ala Leu Ile Tyr
    210                     215                     220

Leu Cys Val Glu Asp Ile Phe Gln Leu Ile Asn Tyr Tyr Ser Phe Ser
225                     230                     235                 240

Tyr Trp Phe Phe Val Gly Leu Ser Ile Val Gly Gln Leu Tyr Leu Arg
                245                     250                     255

Trp Lys Glu Pro Asp Arg Pro Arg Pro Leu Lys Leu Ser Val Phe Phe
            260                     265                     270

Pro Ile Val Phe Cys Leu Cys Thr Ile Phe Leu Val Ala Val Pro Leu
        275                     280                     285

Tyr Ser Asp Thr Ile Asn Ser Leu Ile Gly Ile Ala Ile Ala Leu Ser
    290                     295                     300

Gly Leu Pro Phe Tyr Phe Leu Ile Ile Arg Val Pro Glu His Lys Arg
305                     310                     315                 320

Pro Leu Tyr Leu Arg Arg Ser Trp Gly Leu Pro Gln Gly Thr Ser Arg
                325                     330                     335

Ser Cys Val Cys Gln Leu Leu Gln Lys Trp Ile Trp Lys Met Glu Glu
            340                     345                     350

Arg Cys Pro Ser Asn Gly Ile Pro Ser Leu Thr Lys His His Leu Glu
        355                     360                     365

Ser Xaa
    370
```

<210> 125
<211> 86
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (86)
<223> Xaa equals stop translation

<400> 125

```
Met Gly Phe Trp Cys Gly Cys Pro Phe Cys Leu Leu Val Val Leu Leu
 1               5                  10                  15

Thr Asp Arg Thr Leu Ser Cys Arg Ser Val Gly Val Pro Cys Asn Val
            20                  25                  30

Arg Cys Gln Cys Ala Pro Ala Gly Gly Cys Leu Pro Val Arg Leu Leu
        35                  40                  45

Ala Gly Gln Gly Ser Gly Thr His Leu Arg Arg Gln Ser Ala Arg Ser
    50                  55                  60
```

Gln Ile Ser Ser Cys Met Leu Gly Glu Pro Leu Leu Ser Ser Lys Leu
65 70 75 80

Ser Asp Arg Asp Ile Xaa
85

<210> 126
<211> 44
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (44)
<223> Xaa equals stop translation

<400> 126
Met Tyr Thr Lys Thr His Lys Phe Lys Phe Tyr Asn Phe Leu Ser Leu
1 5 10 15

Trp Ile Trp Lys Ile Phe Phe Leu Leu Phe Phe Ile Leu Ile Val Ala
20 25 30

Leu Ala Phe Pro Ile Pro Cys Leu Ser Ile Phe Xaa
35 40

<210> 127
<211> 319
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (264)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (303)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 127
Met Asn Thr Asp His Leu Arg Leu Thr Val Pro Asn Gly Ile Gly Ala
1 5 10 15

Leu Lys Leu Arg Glu Met Glu His Tyr Phe Ser Gln Gly Leu Ser Val
20 25 30

Gln Leu Phe Asn Asp Gly Ser Lys Gly Lys Leu Asn His Leu Cys Gly
35 40 45

Ala Asp Phe Val Lys Ser His Gln Lys Pro Pro Gln Gly Met Glu Ile
50 55 60

Lys Ser Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile
65 70 75 80

```
Val Tyr Tyr Tyr His Asp Ala Asp Gly His Phe His Leu Ile Asp Gly
                85                  90                  95

Asp Lys Ile Ala Thr Leu Ile Ser Ser Phe Leu Lys Glu Leu Leu Val
            100                 105                 110

Glu Ile Gly Glu Ser Leu Asn Ile Gly Val Val Gln Thr Ala Tyr Ala
        115                 120                 125

Asn Gly Ser Ser Thr Arg Tyr Leu Glu Glu Val Met Lys Val Pro Val
    130                 135                 140

Tyr Cys Thr Lys Thr Gly Val Lys His Leu His His Lys Ala Gln Glu
145                 150                 155                 160

Phe Asp Ile Gly Val Tyr Phe Glu Ala Asn Gly His Gly Thr Ala Leu
                165                 170                 175

Phe Ser Thr Ala Val Glu Met Lys Ile Lys Gln Ser Ala Glu Gln Leu
            180                 185                 190

Glu Asp Lys Lys Arg Lys Ala Ala Lys Met Leu Glu Asn Ile Ile Asp
        195                 200                 205

Leu Phe Asn Gln Ala Ala Gly Asp Ala Ile Ser Asp Met Leu Val Ile
    210                 215                 220

Glu Ala Ile Leu Ala Leu Lys Gly Leu Thr Val Gln Gln Trp Asp Ala
225                 230                 235                 240

Leu Tyr Thr Asp Leu Pro Asn Arg Gln Leu Lys Val Gln Val Ala Asp
                245                 250                 255

Arg Arg Val Ile Ser Thr Thr Xaa Ala Glu Arg Gln Ala Val Thr Pro
            260                 265                 270

Pro Gly Leu Gln Glu Ala Ile Asn Asp Leu Val Lys Lys Tyr Lys Leu
        275                 280                 285

Ser Arg Ala Phe Val Arg Pro Ser Gly Thr Glu Asp Val Val Xaa Ser
    290                 295                 300

Ile Cys Arg Ser Arg Leu Thr Arg Lys Cys Arg Ser Pro Cys Thr
305                 310                 315


<210> 128
<211> 46
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (46)
<223> Xaa equals stop translation

<400> 128
Met Asp Met Val Cys Phe Cys Ile Tyr Leu Gly Leu Leu Lys Phe Ile
1               5                   10                  15
```

```
Ser Ala Ile Phe Cys Ser Phe Ser Glu Glu Val Leu Tyr Ile Ser Phe
            20                  25                  30

Val Lys Cys Ile Pro Lys Tyr Phe Val Glu Met Leu Leu Xaa
        35                  40                  45


<210> 129
<211> 709
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (189)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (275)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (414)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (438)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (641)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (643)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (696)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (697)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 129
Met Ala Gly Leu Asn Cys Gly Val Ser Ile Ala Leu Leu Gly Val Leu
  1               5                  10                  15

Leu Leu Gly Ala Ala Arg Leu Pro Arg Gly Ala Glu Ala Phe Glu Ile
            20                  25                  30
```

```
Ala Leu Pro Arg Glu Ser Asn Ile Thr Val Leu Ile Lys Leu Gly Thr
        35                  40                  45

Pro Thr Leu Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser Lys Arg His
    50                  55                  60

Ile Thr Met Leu Ser Ile Lys Ser Gly Glu Arg Ile Val Phe Thr Phe
65                  70                  75                  80

Ser Cys Gln Ser Pro Glu Asn His Phe Val Ile Glu Ile Gln Lys Asn
                85                  90                  95

Ile Asp Cys Met Ser Gly Pro Cys Pro Phe Gly Glu Val Gln Leu Gln
            100                 105                 110

Pro Ser Thr Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe Ile Trp Asp
        115                 120                 125

Val Lys Ala His Lys Ser Ile Gly Leu Glu Leu Gln Phe Ser Ile Pro
    130                 135                 140

Arg Leu Arg Gln Ile Gly Pro Gly Glu Ser Cys Pro Asp Gly Val Thr
145                 150                 155                 160

His Ser Ile Ser Gly Arg Ile Asp Ala Thr Val Val Arg Ile Gly Thr
                165                 170                 175

Phe Cys Ser Asn Gly Thr Val Ser Arg Ile Lys Met Xaa Glu Gly Val
            180                 185                 190

Lys Met Ala Leu His Leu Pro Trp Phe His Pro Arg Asn Val Ser Gly
        195                 200                 205

Phe Ser Ile Ala Asn Arg Ser Ser Ile Lys Arg Leu Cys Ile Ile Glu
    210                 215                 220

Ser Val Phe Glu Gly Glu Gly Ser Ala Thr Leu Met Ser Ala Asn Tyr
225                 230                 235                 240

Pro Glu Gly Phe Pro Glu Asp Glu Leu Met Thr Trp Gln Phe Val Val
                245                 250                 255

Pro Ala His Leu Arg Ala Ser Val Ser Phe Leu Asn Phe Asn Leu Ser
            260                 265                 270

Asn Cys Xaa Arg Lys Glu Glu Arg Val Glu Tyr Tyr Ile Pro Gly Ser
        275                 280                 285

Thr Thr Asn Pro Glu Val Phe Lys Leu Glu Asp Lys Gln Pro Gly Asn
    290                 295                 300

Met Ala Gly Asn Phe Asn Leu Ser Leu Gln Gly Cys Asp Gln Asp Ala
305                 310                 315                 320

Gln Ser Pro Gly Ile Leu Arg Leu Gln Phe Gln Val Leu Val Gln His
                325                 330                 335

Pro Gln Asn Glu Ser Asn Lys Ile Tyr Val Val Asp Leu Ser Asn Glu
```

340 345 350

Arg Ala Met Ser Leu Thr Ile Glu Pro Arg Pro Val Lys Gln Ser Arg
355 360 365

Lys Phe Val Pro Gly Cys Phe Val Cys Leu Glu Ser Arg Thr Cys Ser
370 375 380

Ser Asn Leu Thr Leu Thr Ser Gly Ser Lys His Lys Ile Ser Phe Leu
385 390 395 400

Cys Asp Asp Leu Thr Arg Leu Trp Met Asn Val Glu Lys Xaa Ile Ser
405 410 415

Cys Thr Asp His Arg Tyr Cys Gln Arg Lys Ser Tyr Ser Leu Gln Val
420 425 430

Pro Ser Asp Ile Leu Xaa Leu Pro Val Glu Leu His Asp Phe Ser Trp
435 440 445

Lys Leu Leu Val Pro Lys Asp Arg Leu Ser Leu Val Leu Val Pro Ala
450 455 460

Gln Lys Leu Gln Gln His Thr His Glu Lys Pro Cys Asn Thr Ser Phe
465 470 475 480

Ser Tyr Leu Val Ala Ser Ala Ile Pro Ser Gln Asp Leu Tyr Phe Gly
485 490 495

Ser Phe Cys Pro Gly Gly Ser Ile Lys Gln Ile Gln Val Lys Gln Asn
500 505 510

Ile Ser Val Thr Leu Arg Thr Phe Ala Pro Ser Phe Arg Gln Glu Ala
515 520 525

Ser Arg Gln Gly Leu Thr Val Ser Phe Ile Pro Tyr Phe Lys Glu Glu
530 535 540

Gly Val Phe Thr Val Thr Pro Asp Thr Lys Ser Lys Val Tyr Leu Arg
545 550 555 560

Thr Pro Asn Trp Asp Arg Gly Leu Pro Ser Leu Thr Ser Val Ser Trp
565 570 575

Asn Ile Ser Val Pro Arg Asp Gln Val Ala Cys Leu Thr Phe Phe Lys
580 585 590

Glu Arg Ser Gly Val Val Cys Gln Thr Gly Arg Ala Phe Met Ile Ile
595 600 605

Gln Glu Gln Arg Thr Arg Ala Glu Glu Ile Phe Ser Leu Asp Glu Asp
610 615 620

Val Leu Pro Lys Pro Ser Phe His His His Ser Phe Trp Val Asn Ile
625 630 635 640

Xaa Asn Xaa Ser Pro Thr Ser Gly Lys Gln Leu Asp Leu Leu Phe Ser
645 650 655

```
Val Thr Leu Thr Pro Arg Thr Val Asp Leu Thr Val Ile Leu Ile Ala
            660                 665                 670

Ala Val Gly Gly Gly Val Leu Leu Leu Ser Ala Leu Gly Leu Ile Ile
        675                 680                 685

Cys Cys Val Lys Lys Lys Lys Xaa Xaa Thr Arg Gly Pro Ala Val Gly
    690                 695                 700

Ile Tyr Asn Gly Asn
705


<210> 130
<211> 415
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (415)
<223> Xaa equals stop translation

<400> 130
Met Thr Lys Ala Arg Leu Phe Arg Leu Trp Leu Val Leu Gly Ser Val
  1               5                  10                  15

Phe Met Ile Leu Leu Ile Ile Val Tyr Trp Asp Ser Ala Gly Ala Ala
             20                  25                  30

His Phe Tyr Leu His Thr Ser Phe Ser Arg Pro His Thr Gly Pro Pro
         35                  40                  45

Leu Pro Thr Pro Gly Pro Asp Arg Asp Arg Glu Leu Thr Ala Asp Ser
     50                  55                  60

Asp Val Asp Glu Phe Leu Asp Lys Phe Leu Ser Ala Gly Val Lys Gln
 65                  70                  75                  80

Ser Asp Leu Pro Arg Lys Glu Thr Glu Gln Pro Pro Ala Pro Gly Ser
                 85                  90                  95

Met Glu Glu Asn Val Arg Gly Tyr Asp Trp Ser Pro Arg Asp Ala Arg
            100                 105                 110

Arg Ser Pro Asp Gln Gly Arg Gln Gln Ala Glu Arg Arg Ser Val Leu
        115                 120                 125

Arg Gly Phe Cys Ala Asn Ser Ser Leu Ala Phe Pro Thr Lys Glu Arg
    130                 135                 140

Ala Phe Asp Asp Ile Pro Asn Ser Glu Leu Ser His Leu Ile Val Asp
145                 150                 155                 160

Asp Arg His Gly Ala Ile Tyr Cys Tyr Val Pro Lys Val Ala Cys Thr
                165                 170                 175

Asn Trp Lys Arg Val Met Ile Val Leu Ser Gly Ser Leu Leu His Arg
            180                 185                 190
```

Gly Ala Pro Tyr Arg Asp Pro Leu Arg Ile Pro Arg Glu His Val His
195 200 205

Asn Ala Ser Ala His Leu Thr Phe Asn Lys Phe Trp Arg Arg Tyr Gly
210 215 220

Lys Leu Ser Arg His Leu Met Lys Val Lys Leu Lys Lys Tyr Thr Lys
225 230 235 240

Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe Arg
245 250 255

Ser Lys Phe Glu Leu Glu Asn Glu Glu Phe Tyr Arg Lys Phe Ala Val
260 265 270

Pro Met Leu Arg Leu Tyr Ala Asn His Thr Ser Leu Pro Ala Ser Ala
275 280 285

Arg Glu Ala Phe Arg Ala Gly Leu Lys Val Ser Phe Ala Asn Phe Ile
290 295 300

Gln Tyr Leu Leu Asp Pro His Thr Glu Lys Leu Ala Pro Phe Asn Glu
305 310 315 320

His Trp Arg Gln Val Tyr Arg Leu Cys His Pro Cys Gln Ile Asp Tyr
325 330 335

Asp Phe Val Gly Lys Leu Glu Thr Leu Asp Glu Asp Ala Ala Gln Leu
340 345 350

Leu Gln Leu Leu Gln Val Asp Arg Gln Leu Arg Phe Pro Pro Ser Tyr
355 360 365

Arg Asn Arg Thr Ala Ser Ser Trp Glu Glu Asp Trp Phe Ala Lys Ile
370 375 380

Pro Leu Ala Trp Arg Gln Gln Leu Tyr Lys Leu Tyr Glu Ala Asp Phe
385 390 395 400

Val Leu Phe Gly Tyr Pro Lys Pro Glu Asn Leu Leu Arg Asp Xaa
405 410 415

<210> 131
<211> 242
<212> PRT
<213> Homo sapiens

<400> 131
Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
1 5 10 15

Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
20 25 30

Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
35 40 45

Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
50 55 60

Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
65 70 75 80

Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
85 90 95

Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
100 105 110

Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr
115 120 125

Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
130 135 140

Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
145 150 155 160

Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
165 170 175

Leu Ala Phe Leu Ser Gly Tyr Tyr Val Thr Leu Ala Ala Gln Ile Leu
180 185 190

Ala Val Leu Leu Pro Pro Val Met Leu Leu Ile Asp Gly Asn Val Ala
195 200 205

Tyr Trp His Asn Thr Arg Arg Val Glu Phe Trp Asn Gln Met Lys Leu
210 215 220

Leu Gly Glu Ser Val Gly Ile Phe Gly Thr Ala Val Ile Leu Ala Thr
225 230 235 240

Asp Gly

<210> 132
<211> 313
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (313)
<223> Xaa equals stop translation

<400> 132
Met Glu Ser Leu Tyr Asp Leu Trp Glu Phe Tyr Leu Pro Tyr Leu Tyr
1 5 10 15

Ser Cys Ile Ser Leu Met Gly Cys Leu Leu Leu Leu Leu Cys Thr Pro
20 25 30

Val Gly Leu Ser Arg Met Phe Thr Val Met Gly His Leu Leu Val Lys
35 40 45

Pro Thr Ile Leu Glu Asp Leu Asp Glu Gln Ile Tyr Ile Ile Thr Leu
50 55 60

Glu Glu Glu Ala Leu Gln Arg Arg Leu Asn Gly Leu Ser Ser Ser Val
65 70 75 80

Glu Tyr Asn Ile Met Glu Leu Glu Gln Glu Leu Glu Asn Val Lys Thr
85 90 95

Leu Lys Thr Lys Leu Glu Arg Arg Lys Lys Ala Ser Ala Trp Glu Arg
100 105 110

Asn Leu Val Tyr Pro Ala Val Met Val Leu Leu Leu Ile Glu Thr Ser
115 120 125

Ile Ser Val Leu Leu Val Ala Cys Asn Ile Leu Cys Leu Leu Val Asp
130 135 140

Glu Thr Ala Met Pro Lys Gly Thr Arg Gly Pro Gly Ile Gly Asn Ala
145 150 155 160

Ser Leu Ser Thr Phe Gly Phe Val Gly Ala Ala Leu Glu Ile Ile Leu
165 170 175

Ile Phe Tyr Leu Met Val Ser Ser Val Val Gly Phe Tyr Ser Leu Arg
180 185 190

Phe Phe Gly Asn Phe Thr Pro Lys Lys Asp Asp Thr Thr Met Thr Lys
195 200 205

Ile Ile Gly Asn Cys Val Ser Ile Leu Val Leu Ser Ser Ala Leu Pro
210 215 220

Val Met Ser Arg Thr Leu Gly Ile Thr Arg Phe Asp Leu Leu Gly Asp
225 230 235 240

Phe Gly Arg Phe Asn Trp Leu Gly Asn Phe Tyr Ile Val Leu Ser Tyr
245 250 255

Asn Leu Leu Phe Ala Ile Val Thr Thr Leu Cys Leu Val Arg Lys Phe
260 265 270

Thr Ser Ala Val Arg Glu Glu Leu Phe Lys Ala Leu Gly Leu His Lys
275 280 285

Leu His Leu Pro Asn Thr Ser Arg Asp Ser Glu Thr Ala Lys Pro Ser
290 295 300

Val Asn Gly His Gln Lys Ala Leu Xaa
305 310

<210> 133
<211> 183
<212> PRT
<213> Homo sapiens

<220>

<221> SITE
<222> (183)
<223> Xaa equals stop translation

<400> 133

```
Met Met Val Cys Ser Ile Met Met Tyr Phe Leu Leu Gly Ile Thr Leu
1               5                   10                  15

Leu Arg Ser Tyr Met Gln Ser Val Trp Thr Glu Glu Ser Gln Cys Thr
            20                  25                  30

Leu Leu Asn Ala Ser Ile Thr Glu Thr Phe Asn Cys Ser Phe Ser Cys
        35                  40                  45

Gly Pro Asp Cys Trp Lys Leu Ser Gln Tyr Pro Cys Leu Gln Val Tyr
    50                  55                  60

Val Asn Leu Thr Ser Ser Gly Glu Lys Leu Leu Leu Tyr His Thr Glu
65                  70                  75                  80

Glu Thr Ile Lys Ile Asn Gln Lys Cys Ser Tyr Ile Pro Lys Cys Gly
                85                  90                  95

Lys Asn Phe Glu Glu Ser Met Ser Leu Val Asn Val Val Met Glu Asn
            100                 105                 110

Phe Arg Lys Tyr Gln His Phe Ser Cys Tyr Ser Asp Pro Glu Gly Asn
        115                 120                 125

Gln Lys Ser Val Ile Leu Thr Lys Leu Tyr Ser Ser Asn Val Leu Phe
    130                 135                 140

His Ser Leu Phe Trp Pro Thr Cys Met Met Ala Gly Gly Val Ala Ile
145                 150                 155                 160

Val Ala Met Val Lys Leu Thr Gln Tyr Leu Ser Leu Leu Cys Glu Arg
                165                 170                 175

Ile Gln Arg Ile Asn Arg Xaa
            180
```

<210> 134
<211> 147
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (147)
<223> Xaa equals stop translation

<400> 134

```
Met Trp Lys Leu Trp Arg Ala Glu Glu Gly Ala Ala Ala Leu Gly Gly
1               5                   10                  15

Ala Leu Phe Leu Leu Leu Phe Ala Leu Gly Val Arg Gln Leu Leu Lys
            20                  25                  30
```

Gln Arg Arg Pro Met Gly Phe Pro Pro Gly Pro Pro Gly Leu Pro Phe
35 40 45

Ile Gly Asn Ile Tyr Ser Leu Ala Ala Ser Ser Glu Leu Pro His Val
50 55 60

Tyr Met Arg Lys Gln Ser Gln Val Tyr Gly Glu Val Gln Pro Arg Arg
65 70 75 80

Ala Pro Gly Arg Glu Gly Arg Gln Ala Gly Pro Gly Trp Pro Gly Pro
85 90 95

Ser Trp Leu Asp Leu Trp Pro Pro Leu Gly Arg Leu Val Gly Thr Ser
100 105 110

Pro Cys Ala Gly Cys Pro Leu Arg Asp Thr Arg Phe Pro Gly Leu Glu
115 120 125

Gly Arg Ser Pro Arg Arg Arg Ala Pro Leu Gln Gly Glu Pro Arg Pro
130 135 140

Cys Arg Xaa
145

<210> 135
<211> 122
<212> PRT
<213> Homo sapiens

<400> 135
Met Arg Val Arg Ile Gly Leu Thr Leu Leu Leu Cys Ala Val Leu Leu
1 5 10 15

Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser
20 25 30

Leu Asp Ser Lys Thr Thr Leu Thr Ser Asp Glu Ser Val Lys Asp His
35 40 45

Thr Thr Ala Gly Arg Val Val Ala Gly Gln Ile Phe Leu Asp Ser Glu
50 55 60

Glu Ser Glu Leu Glu Ser Ser Ile Gln Glu Glu Glu Asp Ser Leu Lys
65 70 75 80

Ser Gln Glu Gly Glu Ser Val Thr Glu Asp Ile Ser Phe Leu Glu Ser
85 90 95

Pro Asn Pro Glu Asn Lys Asp Tyr Glu Glu Pro Lys Lys Val Arg Lys
100 105 110

Pro Gly Ser Leu Asp Ile Phe Leu Ala Phe
115 120

<210> 136
<211> 112
<212> PRT

<213> Homo sapiens

<400> 136
Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly
1 5 10 15

Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly
20 25 30

Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys
35 40 45

Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Ala Leu Ala His
50 55 60

Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp
65 70 75 80

Leu Phe Gly Leu Glu Thr Met Pro Gln Arg Glu Lys Phe Thr Thr Pro
85 90 95

Ile Glu Glu Thr Gly Gly Glu Gly Cys Pro Ala Val Ala Leu Ile Gln
100 105 110

<210> 137
<211> 140
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (140)
<223> Xaa equals stop translation

<400> 137
Met Leu Leu Gly Pro Val Pro Ile Leu His Ile Lys Ser Gln Leu Trp
1 5 10 15

Leu Leu Val Leu Ile Leu Val Val Ser Gly Leu Ser Ala Gly Met Ser
20 25 30

Ile Ile Pro Thr Phe Pro Glu Ile Leu Ser Cys Ala His Glu Asn Gly
35 40 45

Phe Glu Glu Gly Leu Ser Thr Leu Gly Leu Val Ser Gly Leu Phe Ser
50 55 60

Ala Met Trp Ser Ile Gly Ala Phe Met Gly Pro Thr Leu Gly Gly Phe
65 70 75 80

Leu Tyr Glu Lys Ile Gly Phe Glu Trp Ala Ala Ala Ile Gln Gly Leu
85 90 95

Trp Ala Leu Ile Ser Gly Leu Ala Met Gly Leu Phe Tyr Leu Leu Glu
100 105 110

```
Tyr Ser Arg Arg Lys Arg Ser Lys Ser Gln Asn Ile Leu Ser Thr Glu
        115                 120                 125

Glu Glu Arg Thr Thr Leu Leu Pro Asn Glu Thr Xaa
    130                 135                 140


<210> 138
<211> 404
<212> PRT
<213> Homo sapiens

<400> 138
Met Arg Leu Gln Asp Val Tyr Met Leu Asn Val Lys Gly Leu Ala Arg
  1               5                  10                  15

Gly Val Phe Gln Arg Val Thr Gly Ser Ala Ile Thr Asp Leu Tyr Ser
             20                  25                  30

Pro Lys Arg Leu Phe Ser Leu Thr Gly Asp Asp Cys Phe Gln Val Gly
         35                  40                  45

Lys Val Ala Tyr Asp Met Gly Asp Tyr Tyr His Ala Ile Pro Trp Leu
     50                  55                  60

Glu Glu Ala Val Ser Leu Phe Arg Gly Ser Tyr Gly Glu Trp Lys Thr
 65                  70                  75                  80

Glu Asp Glu Ala Ser Leu Glu Asp Ala Leu Asp His Leu Ala Phe Ala
                 85                  90                  95

Tyr Phe Arg Ala Gly Asn Val Ser Cys Ala Leu Ser Leu Ser Arg Glu
            100                 105                 110

Phe Leu Leu Tyr Ser Pro Asp Asn Lys Arg Met Ala Arg Asn Val Leu
        115                 120                 125

Lys Tyr Glu Arg Leu Leu Ala Glu Ser Pro Asn His Val Val Ala Glu
    130                 135                 140

Ala Val Ile Gln Arg Pro Asn Ile Pro His Leu Gln Thr Arg Asp Thr
145                 150                 155                 160

Tyr Glu Gly Leu Cys Gln Thr Leu Gly Ser Gln Pro Thr Leu Tyr Gln
                165                 170                 175

Ile Pro Ser Leu Tyr Cys Ser Tyr Glu Thr Asn Ser Asn Ala Tyr Leu
            180                 185                 190

Leu Leu Gln Pro Ile Arg Lys Glu Val Ile His Leu Glu Pro Tyr Ile
        195                 200                 205

Ala Leu Tyr His Asp Phe Val Ser Asp Ser Glu Ala Gln Lys Ile Arg
    210                 215                 220

Glu Leu Ala Glu Pro Trp Leu Gln Arg Ser Val Val Ala Ser Gly Glu
225                 230                 235                 240
```

Lys Gln Leu Gln Val Glu Tyr Arg Ile Ser Lys Ser Ala Trp Leu Lys
245 250 255

Asp Thr Val Asp Leu Lys Leu Val Thr Leu Asn His Arg Ile Ala Ala
260 265 270

Leu Thr Gly Leu Asp Val Arg Pro Pro Tyr Ala Glu Tyr Leu Gln Val
275 280 285

Val Asn Tyr Gly Ile Gly Gly His Tyr Glu Pro His Phe Asp His Ala
290 295 300

Thr Ser Pro Ser Ser Pro Leu Tyr Arg Met Lys Ser Gly Asn Arg Val
305 310 315 320

Ala Thr Phe Met Ile Tyr Leu Ser Ser Val Glu Ala Gly Gly Ala Thr
325 330 335

Ala Phe Ile Tyr Ala Asn Leu Ser Val Pro Val Val Arg Asn Ala Ala
340 345 350

Leu Phe Trp Trp Asn Leu His Arg Ser Gly Glu Gly Asp Ser Asp Thr
355 360 365

Leu His Ala Gly Cys Pro Val Leu Val Gly Asp Lys Trp Val Ala Asn
370 375 380

Lys Trp Ile His Glu Tyr Gly Gln Glu Phe Arg Arg Pro Cys Ser Ser
385 390 395 400

Ser Pro Glu Asp

<210> 139
<211> 96
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (96)
<223> Xaa equals stop translation

<400> 139
Met Lys Ala Pro His Thr Gly Val Leu His Leu Gly Ser Val Trp Val
1 5 10 15

Phe Leu Gly Pro Phe Leu Leu Gly Val Gly Tyr Thr Leu Thr Phe Asn
20 25 30

Pro Leu Ser Gly Cys Met Ser Thr Val Arg Trp Leu Asn Ser Asn Ile
35 40 45

Thr Ala Asn Arg Thr Leu Ser Arg Ser Val Cys His Val Thr Pro Leu
50 55 60

His Arg Ser Leu Ser Pro His Asp Gly Glu Tyr Leu Arg Gln Met Leu
65 70 75 80

Leu Asn Ser Ser Ser Arg Ala Gly Glu Ala Gly Ser Trp Gly Tyr Xaa
85 90 95

<210> 140
<211> 240
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (240)
<223> Xaa equals stop translation.

<400> 140
Met Gly Ser Cys Ala Arg Leu Leu Leu Leu Trp Gly Cys Thr Val Val
1 5 10 15

Ala Ala Gly Leu Ser Gly Val Ala Gly Val Ser Ser Arg Cys Glu Lys
20 25 30

Ala Cys Asn Pro Arg Met Gly Asn Leu Ala Leu Gly Arg Lys Leu Trp
35 40 45

Ala Asp Thr Thr Cys Gly Gln Asn Ala Thr Glu Leu Tyr Cys Phe Tyr
50 55 60

Ser Glu Asn Thr Asp Leu Thr Cys Arg Gln Pro Lys Cys Asp Lys Cys
65 70 75 80

Asn Ala Ala Tyr Pro His Leu Ala His Leu Pro Ser Ala Met Ala Asp
85 90 95

Ser Ser Phe Arg Phe Pro Arg Thr Trp Trp Gln Ser Ala Glu Asp Val
100 105 110

His Arg Glu Lys Ile Gln Leu Asp Leu Glu Ala Glu Phe Tyr Phe Thr
115 120 125

His Leu Ile Val Met Phe Lys Ser Pro Arg Pro Ala Ala Met Val Leu
130 135 140

Asp Arg Ser Gln Asp Phe Gly Lys Thr Trp Lys Pro Tyr Lys Tyr Phe
145 150 155 160

Ala Thr Asn Cys Ser Ala Thr Phe Gly Leu Glu Asp Asp Val Val Lys
165 170 175

Lys Gly Ala Ile Cys Thr Ser Lys Tyr Ser Ser Pro Phe Pro Cys Thr
180 185 190

Gly Arg Lys Val Ile Phe Lys Ala Leu Ser Pro Pro Tyr Asp Thr Glu
195 200 205

Asn Pro Tyr Ser Ala Lys Val Gln Glu Gln Leu Lys Ile Thr Asn Leu

210 215 220

Pro Arg Ala Ala Ala Glu Thr Thr Val Leu Ser Leu Ser Glu Lys Xaa
225 230 235 240

<210> 141
<211> 54
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (54)
<223> Xaa equals stop translation

<400> 141
Met Met Ile Ser Gly Leu Lys Leu Leu Val Leu Phe Leu Lys Phe Ala
1 5 10 15

Pro Glu Asn Tyr Cys Leu Ser Thr Glu Thr Leu Gln Met Pro Asn Arg
20 25 30

His Leu Arg Leu Ser Lys Ala Thr Cys Tyr Leu Met Lys Cys Leu Leu
35 40 45

Pro Ser Tyr Phe Glu Xaa
50

<210> 142
<211> 67
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (67)
<223> Xaa equals stop translation

<400> 142
Met Arg Ser Leu Ile Ser Ser His Pro Cys Gln His Leu Leu Leu Leu
1 5 10 15

Leu Leu Leu Leu Phe Leu Ile Leu Ala Ile Leu Val Asp Val Lys Trp
20 25 30

Tyr Leu Val Leu Phe Ile Cys Ile Ser Leu Met Thr Ser Asp Val Glu
35 40 45

His Leu Phe Met Cys Leu Leu Ala Ile Arg Ile Ser Ser Trp Arg Asn
50 55 60

Val Tyr Xaa
65

<210> 143
<211> 108
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (58)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (67)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 143

```
Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly
1               5                   10                  15

Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His
            20                  25                  30

Ile Cys Ser Gln Arg Asn Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa
        35                  40                  45

Leu Gln Thr Thr Trp Gly Xaa Pro Asp Xaa Gln Phe Pro Gly Cys Pro
    50                  55                  60

His Pro Xaa Arg Val Thr Leu Asn Ala Arg Gln Met Gly Asn Gly Lys
65                  70                  75                  80

Glu Lys Lys Ala Ala Asp Leu Lys Leu Lys Phe Pro Gln Lys Arg Phe
                85                  90                  95

Tyr Leu Ser Ala Phe Ser Glu Arg Ile Lys Ala Phe
            100                 105
```

<210> 144
<211> 84
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (84)
<223> Xaa equals stop translation

<400> 144

```
Met Ala Ser Val Gly Thr Thr Leu Val Ser Pro Leu Leu Cys Leu Leu
1               5                   10                  15

Ile Pro Thr Arg Val Ser Asp Pro Trp Leu Gln Asn Thr Pro Leu His
            20                  25                  30

Pro Trp Lys Thr Ile Thr Ile Ile Asp Tyr Tyr Leu Ser Leu Gly Phe
        35                  40                  45

Leu Gly Trp Thr Gly Leu Ser Trp Val Val His Phe Gly Ala Ser Ala
    50                  55                  60

Val Met Gly Arg Gln Trp Leu Gly Ser Leu Gln Arg Leu Pro Cys Ile
65                  70                  75                  80

Ser Gly Ser Xaa
```

<210> 145
<211> 166
<212> PRT
<213> Homo sapiens

<400> 145

```
Met Gly Ser Arg Phe Leu Leu Val Leu Leu Ser Gly Leu Thr Val Leu
1               5                   10                  15

Leu Ala Leu Pro Gly Ser Glu Ala Lys Asn Ser Gly Ala Ser Cys Pro
            20                  25                  30

Pro Cys Pro Lys Tyr Ala Ser Cys His Asn Ser Thr His Cys Thr Cys
        35                  40                  45

Glu Asp Gly Phe Arg Ala Arg Ser Gly Arg Thr Tyr Phe His Asp Ser
    50                  55                  60

Ser Glu Lys Cys Glu Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys
65                  70                  75                  80

Cys Lys Tyr Lys Ala Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys
                85                  90                  95

Ser Cys Leu Val Lys Tyr Thr Leu Phe Asn Phe Leu Ala Gly Ile Ile
            100                 105                 110

Asp Tyr Asp His Pro Asp Cys Tyr Glu Asn Asn Ser Gln Gly Thr Thr
        115                 120                 125

Gln Ser Asn Val Asp Ile Trp Val Ser Gly Val Lys Pro Gly Phe Gly
    130                 135                 140

Lys Gln Leu Val Arg Ile Thr Met Pro Phe Ser Tyr Pro Asn Ile Asn
145                 150                 155                 160

Met Ser Ser Cys Asp Phe
                165
```

<210> 146
<211> 70
<212> PRT
<213> Homo sapiens

<400> 146
Met Lys Pro Lys His Leu Glu Trp Cys Leu Ala His Ser Trp Cys Val
1   5   10   15

Ile Trp Leu Ser Phe Val Ser Pro Pro Thr Ser His Leu Glu Cys Asp
            20   25   30

Gly Phe Pro Gly Ser Leu Leu Pro Pro Cys Glu Glu Gly Arg Cys Phe
        35   40   45

Pro Phe Thr Phe His His His Asp Cys His Gly Cys Ser Pro Leu Gln
    50   55   60

Ser Ser Pro Gly Gln His
65   70

<210> 147
<211> 412
<212> PRT
<213> Homo sapiens

<400> 147
Met Cys Cys Trp Pro Leu Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr
1   5   10   15

Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp
            20   25   30

Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile
        35   40   45

Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe
    50   55   60

Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val
65   70   75   80

Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg
                85   90   95

Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met
            100   105   110

Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr
        115   120   125

Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile
    130   135   140

Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His
145   150   155   160

```
Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys
                165                 170                 175

Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln
            180                 185                 190

Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe
        195                 200                 205

Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro
    210                 215                 220

Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr
225                 230                 235                 240

Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Leu Glu Ser Gly His Glu
                245                 250                 255

Cys Tyr His Pro Asn Met Pro Asp Ala Phe Leu Thr Cys Glu Thr Val
            260                 265                 270

Ile Phe Ala Trp Ala Ile Gly Gly Glu Gly Phe Ser Tyr Pro Pro His
        275                 280                 285

Val Gly Leu Ser Leu Gly Thr Pro Leu Asp Pro His Tyr Val Leu Leu
    290                 295                 300

Glu Val His Tyr Asp Asn Pro Thr Tyr Glu Glu Gly Leu Ile Asp Asn
305                 310                 315                 320

Ser Gly Leu Arg Leu Phe Tyr Thr Met Asp Ile Arg Lys Tyr Asp Ala
                325                 330                 335

Gly Val Ile Glu Ala Gly Leu Trp Val Ser Leu Phe His Thr Ile Pro
            340                 345                 350

Pro Gly Met Pro Glu Phe Gln Ser Glu Gly His Cys Thr Leu Glu Cys
        355                 360                 365

Leu Glu Glu Leu Trp Lys Pro Lys Ser Gln Val Glu Phe Met Cys Leu
    370                 375                 380

Leu Phe Phe Ser Met Leu Thr Trp Leu Ala Glu His Gln Ala Ala Ser
385                 390                 395                 400

Phe Ser Lys Arg Glu Gly Asn Glu Ile Thr Cys Leu
                405                 410
```

<210> 148
<211> 85
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (85)
<223> Xaa equals stop translation

<400> 148
Met Asn Val Phe Leu Pro Pro Ala Leu Gly Thr Trp Gly Val Ala Arg
1 5 10 15

Phe Phe Pro His Leu Val Pro Glu Arg Trp Cys Leu Val Phe Cys Cys
20 25 30

Trp Ile Phe Phe Phe Phe Phe Phe Phe Cys Thr Lys Val Ala Thr Arg
35 40 45

Ser Val Leu Gly Asp Gln Ala Gly Leu Gly Val Gly Gly Pro His Leu
50 55 60

Pro Leu Pro Gly Ser His Ser Val Ser Val Pro Glu Lys Thr Ile Phe
65 70 75 80

Ser Leu Lys Gln Xaa
85

<210> 149
<211> 154
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (154)
<223> Xaa equals stop translation

<400> 149
Met Gly Arg Leu Pro Leu Leu Arg Arg Val Leu Lys Gly Leu Gln Leu
1 5 10 15

Leu Leu Ser Leu Leu Ala Phe Ile Cys Glu Glu Val Val Ser Gln Cys
20 25 30

Thr Leu Cys Gly Gly Leu Tyr Phe Phe Glu Phe Val Ser Cys Ser Ala
35 40 45

Phe Leu Leu Ser Leu Leu Ile Leu Ile Val Tyr Cys Thr Pro Phe Tyr
50 55 60

Glu Arg Val Asp Thr Thr Lys Val Lys Ser Ser Asp Phe Tyr Ile Thr
65 70 75 80

Leu Gly Thr Gly Cys Val Phe Leu Leu Ala Ser Ile Ile Phe Val Ser
85 90 95

Thr His Asp Arg Thr Ser Ala Glu Ile Ala Ala Ile Val Phe Gly Phe
100 105 110

Ile Ala Ser Phe Met Phe Leu Leu Asp Phe Ile Thr Met Leu Tyr Glu
115 120 125

Lys Arg Gln Glu Ser Gln Leu Arg Lys Pro Glu Asn Thr Thr Arg Ala
130 135 140

Glu Ala Leu Thr Glu Pro Leu Asn Ala Xaa

145 150

<210> 150
<211> 130
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (130)
<223> Xaa equals stop translation

<400> 150
Met Arg Gly His Leu Ala Gly Phe Pro Ala Leu Ser Gly Leu Ala Ser
1 5 10 15

Val Cys Leu Trp Ala Thr Phe Ser Ala Gln Leu Pro Gly Pro Val Ala
20 25 30

Ala Thr Ser Trp Thr Pro Ala Pro Leu Gly Cys Ser Ala Ala Arg Ser
35 40 45

Gly Pro Glu Lys Arg Leu Gly Thr Ala Ala Pro Gly Ser Ala Ala Ser
50 55 60

Leu Ala Gln Ala Gly Pro Gly Ala Pro Cys Arg Val Leu Pro Val Asp
65 70 75 80

Pro Ala Pro Ala Ala Leu Asn Val Arg Glu Pro Gly Trp Leu Gly Gly
85 90 95

Leu Phe Asp Gly Ala Leu Leu Gln Val Leu Leu Asn Phe Leu Arg Lys
100 105 110

Ser Thr Asp Val Leu Met Asp Thr Arg Glu Ala Glu Ser Leu Glu Val
115 120 125

Glu Xaa
130

<210> 151
<211> 62
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (62)
<223> Xaa equals stop translation

<400> 151
Met Leu Phe Trp Ala Tyr Pro Ile Cys Val Phe Ile Asp Ser Leu Ser
1 5 10 15

Cys Gln Pro Cys Leu Trp Ser Thr Gly Ala Thr Ser His Phe Asn Ser
20 25 30

```
Pro Thr Thr Ser Pro Leu Phe Thr Leu Phe Met Pro Cys Ala Leu Ala
            35                  40                  45

Pro Asn Pro Phe Thr Gln Leu Gly Lys Leu Asp Asp Arg Xaa
    50                  55                  60


<210> 152
<211> 225
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (225)
<223> Xaa equals stop translation

<400> 152
Met Gly Ile Phe Pro Gly Ile Ile Leu Ile Phe Leu Arg Val Lys Phe
  1               5                  10                  15

Ala Thr Ala Ala Val Ile Val Ser Gly His Gln Lys Ser Thr Thr Val
             20                  25                  30

Ser His Glu Met Ser Gly Leu Asn Trp Lys Pro Phe Val Tyr Gly Gly
         35                  40                  45

Leu Ala Ser Ile Val Ala Glu Phe Gly Thr Phe Pro Val Asp Leu Thr
    50                  55                  60

Lys Thr Arg Leu Gln Val Gln Gly Gln Ser Ile Asp Ala Arg Phe Lys
 65                  70                  75                  80

Glu Ile Lys Tyr Arg Gly Met Phe His Ala Leu Phe Arg Ile Cys Lys
                 85                  90                  95

Glu Glu Gly Val Leu Ala Leu Tyr Ser Gly Ile Ala Pro Ala Leu Leu
            100                 105                 110

Arg Gln Ala Ser Tyr Gly Thr Ile Lys Ile Gly Ile Tyr Gln Ser Leu
        115                 120                 125

Lys Arg Leu Phe Val Glu Arg Leu Glu Asp Glu Thr Leu Leu Ile Asn
    130                 135                 140

Met Ile Cys Gly Val Val Ser Gly Val Ile Ser Ser Thr Ile Ala Asn
145                 150                 155                 160

Pro Thr Asp Val Leu Lys Ile Arg Met Gln Ala Gln Gly Ser Leu Phe
                165                 170                 175

Gln Gly Ser Met Ile Gly Ser Phe Ile Asp Ile Tyr Gln Gln Glu Gly
            180                 185                 190

Thr Arg Gly Leu Trp Arg Val Ser Thr Leu Phe Leu Leu Leu Ser Tyr
        195                 200                 205

Thr Leu Ser Ser Tyr Asn Leu Gln Arg Ile Phe Phe Tyr Ile Lys Thr
    210                 215                 220
```

Xaa
225

<210> 153
<211> 69
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (69)
<223> Xaa equals stop translation

<400> 153
Met Leu Met Leu Leu Thr Leu Leu Val Leu Gly Met Val Trp Val Ala
1 5 10 15

Ser Ala Ile Val Asp Lys Asn Lys Ala Asn Arg Glu Ser Leu Tyr Asp
20 25 30

Phe Trp Glu Tyr Tyr Leu Pro Tyr Leu Tyr Ser Cys Ile Ser Phe Leu
35 40 45

Gly Val Leu Leu Leu Leu Ala Ala Gly Arg Pro Gly Gly Ala Ala Val
50 55 60

Leu Leu Ser Leu Xaa
65

<210> 154
<211> 84
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (84)
<223> Xaa equals stop translation

<400> 154
Met Tyr Gly Val Cys Leu Cys Val Ile Val Cys Val Ser Gly Val Ser
1 5 10 15

Leu Cys Leu Tyr Val Trp Gly Val Ser Val Cys Asp Cys Val Ser Val
20 25 30

Phe Met Cys Val Cys Leu Cys Val Ile Phe Cys Val Tyr Gly Lys Pro
35 40 45

Arg Thr Glu His Tyr His Ser Pro His Leu Ala Lys Gln Lys Ala Phe
50 55 60

Arg Glu Met Cys Gly Arg His Asp Val Ser Ala Ala Gly Ile Phe Gln
65 70 75 80

Ser Tyr Val Xaa

<210> 155
<211> 61
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (61)
<223> Xaa equals stop translation

<400> 155
Met His Val Leu Leu Phe Ser Phe Leu Ile Pro Phe Leu Leu Leu Ser
1   5   10   15

Pro Val Gly Val Thr Cys Asn Ser His Met Leu Glu Arg Gln Val Ser
            20   25   30

Trp Leu Lys Lys Arg Ser Thr Gln Ala Ser Gln Gln Phe Asn Lys Phe
        35   40   45

Leu Arg Gly Ile Ser Asn Val Gly Arg Ile Val Ile Xaa
    50   55   60

<210> 156
<211> 84
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (84)
<223> Xaa equals stop translation

<400> 156
Met Cys Leu Leu Val Glu Tyr Ser Leu Met Ile Leu Thr Ile Ile Pro
1   5   10   15

Ser Leu Leu Ser Phe Val Leu Cys Leu Lys Gly Ile Lys His Gly Asn
            20   25   30

Tyr Ile Phe Gln Thr Pro Leu Pro Glu Gly Tyr Gly Trp Ile Ser Ala
        35   40   45

Met Ser Gly Leu Cys Ile Lys Phe Gly Arg Arg Lys Arg Arg Lys Thr
    50   55   60

Trp Leu Leu Gln Val Gly Thr Leu Ala Thr Ile Asp Thr Glu Phe Ala
65   70   75   80

Arg Ser Cys Xaa

<210> 157
<211> 162

<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (162)
<223> Xaa equals stop translation

<400> 157

```
Met Ala Leu Ser Leu Thr Leu Cys Phe Val Met Phe Trp Thr Pro Asn
 1               5                  10                  15

Val Ser Glu Lys Ile Leu Ile Asp Ile Ile Gly Val Asp Phe Ala Phe
            20                  25                  30

Ala Glu Leu Cys Val Val Pro Leu Arg Ile Phe Ser Phe Phe Pro Val
        35                  40                  45

Pro Val Thr Val Arg Ala His Leu Thr Gly Trp Leu Met Thr Leu Lys
    50                  55                  60

Lys Thr Phe Val Leu Ala Pro Ser Ser Val Leu Arg Ile Ile Val Leu
65                  70                  75                  80

Ile Ala Ser Leu Val Val Leu Pro Tyr Leu Gly Val His Gly Ala Thr
                85                  90                  95

Leu Gly Val Gly Ser Leu Leu Ala Gly Phe Val Gly Glu Ser Thr Met
            100                 105                 110

Val Ala Ile Ala Ala Cys Tyr Val Tyr Arg Lys Gln Lys Lys Lys Met
        115                 120                 125

Glu Asn Glu Ser Ala Thr Glu Gly Glu Asp Ser Ala Met Thr Asp Met
    130                 135                 140

Pro Pro Thr Glu Glu Val Thr Asp Ile Val Glu Met Arg Glu Glu Asn
145                 150                 155                 160

Glu Xaa
```

<210> 158
<211> 146
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (96)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (107)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE
<222> (111)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (115)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (122)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (132)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 158
Met Glu Pro Gln Leu Gly Pro Glu Ala Ala Ala Leu Arg Pro Gly Trp
1 5 10 15

Leu Ala Leu Leu Leu Trp Val Ser Ala Leu Ser Cys Ser Phe Ser Leu
20 25 30

Pro Ala Ser Ser Leu Ser Ser Leu Val Pro Gln Val Arg Thr Ser Tyr
35 40 45

Asn Phe Gly Arg Thr Phe Leu Gly Leu Asp Lys Cys Asn Ala Cys Ile
50 55 60

Gly Thr Ser Ile Cys Lys Lys Phe Phe Lys Glu Glu Ile Arg Ser Asp
65 70 75 80

Asn Trp Leu Ala Ser His Leu Gly Thr Ala Ser Arg Phe Pro Leu Xaa
85 90 95

Ser Tyr Pro Cys Lys Leu Leu Gln Met Ile Xaa Lys Ile Trp Xaa Pro
100 105 110

Cys Gly Xaa Leu Leu Thr Gly Gln Gln Xaa Ser Asn Glu Ile Ser Lys
115 120 125

Gln Glu Ile Xaa Cys Leu Leu His Pro Pro Pro Lys Asn Leu His Ile
130 135 140

Asp Val
145

<210> 159
<211> 143
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (143)

<223> Xaa equals stop translation

<400> 159
Met Trp Trp Ala Val Met Gly Gly Val Ile Gly Ser Trp Leu Ser Pro
1 5 10 15

Leu Ser Ile Ala Glu Cys Cys His Asp Leu Trp Thr Ser Gln Ser Cys
20 25 30

Glu His Ala Gly Ala Leu Cys Gly Asp Leu Leu Cys Ala Cys Arg Lys
35 40 45

Val Gly Val Trp Cys Ala Leu Gln Gln His Trp Trp Asn Arg Cys Val
50 55 60

Cys Pro His Ala Val Ile Arg Val His Cys Thr Gly Ala Ser Tyr Thr
65 70 75 80

Leu Gln Lys Ile Cys Ser Cys Asn Pro Lys Phe Met Gly Arg His Pro
85 90 95

His Arg Trp Gln Gln Ile Arg Lys Cys Ser Gln Pro Val Leu Arg Gly
100 105 110

Ser Arg Ala Ala Phe Ile Trp Val Arg Leu Ala Ala Leu Asn Phe Ile
115 120 125

Ser Ser Phe Arg Cys Ile Ser Leu Ile Ser Tyr Ser Ala Phe Xaa
130 135 140

<210> 160
<211> 51
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (51)
<223> Xaa equals stop translation

<400> 160
Met Lys Val Ser Asp Phe Asn Phe Leu Ile Phe Leu Ile Phe Ala Leu
1 5 10 15

Phe Leu Thr Leu Glu Ala Phe Leu Lys Phe Thr Lys Arg Val Leu Ala
20 25 30

Val Val Gly Asn Leu Pro Glu Pro Pro Ile Ile Lys Thr Ile Gly Phe
35 40 45

Leu Tyr Xaa
50

<210> 161
<211> 65
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (65)
<223> Xaa equals stop translation

<400> 161
Met Val Trp Ser Ala Ala Pro Ala Pro Cys Cys Leu Leu Gly Val Leu
1 5 10 15

Gly Leu Val Gln Val Leu Gly Ala Gln Ala Val Gly Pro Trp Thr Ala
20 25 30

Ser Ala Cys Leu Gly Ala Ala Gln Ala Gln Pro Cys Arg Pro Cys Lys
35 40 45

Glu Ser Ser Leu Arg Leu Phe Ser Ala Ser Ala Pro Ser Met Thr His
50 55 60

Xaa
65

<210> 162
<211> 59
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (59)
<223> Xaa equals stop translation

<400> 162
Met Glu Lys Tyr Cys Leu Gly Asn Asn Met Leu Ser Arg Phe Cys Leu
1 5 10 15

Phe Leu Ile Met Leu Leu His Ile Leu Leu Phe Leu Val Ile Phe Ile
20 25 30

Gln Arg His Thr Val Val Ser Leu Ser Lys His His Pro Phe Val Pro
35 40 45

Thr Asn Gly Ser Lys Ser Tyr Ser Ser Phe Xaa
50 55

<210> 163
<211> 374
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (84)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE

<222> (112)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 163
```
Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu
1               5                   10                  15

Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val
            20                  25                  30

Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His
        35                  40                  45

Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg
    50                  55                  60

Arg Asp Gly Gly Gln Leu Val Ser Ile Glu Ser Glu Asp Glu Gln Lys
65                  70                  75                  80

Leu Ile Glu Xaa Phe Ile Glu Asn Leu Leu Pro Ser Asp Gly Asp Phe
                85                  90                  95

Trp Ile Gly Leu Arg Arg Arg Glu Glu Lys Gln Ser Asn Ser Thr Xaa
            100                 105                 110

Cys Gln Asp Leu Tyr Ala Trp Thr Asp Gly Ser Ile Ser Gln Phe Arg
        115                 120                 125

Asn Trp Tyr Val Asp Glu Pro Ser Cys Gly Ser Glu Val Cys Val Val
    130                 135                 140

Met Tyr His Gln Pro Ser Ala Pro Ala Gly Ile Gly Gly Pro Tyr Met
145                 150                 155                 160

Phe Gln Trp Asn Asp Asp Arg Cys Asn Met Lys Asn Asn Phe Ile Cys
                165                 170                 175

Lys Tyr Ser Asp Glu Lys Pro Ala Val Pro Ser Arg Glu Ala Glu Gly
            180                 185                 190

Glu Glu Thr Glu Leu Thr Thr Pro Val Leu Pro Glu Glu Thr Gln Glu
        195                 200                 205

Glu Asp Ala Lys Lys Thr Phe Lys Glu Ser Arg Glu Ala Ala Leu Asn
    210                 215                 220

Leu Ala Tyr Ile Leu Ile Pro Ser Ile Pro Leu Leu Leu Leu Leu Val
225                 230                 235                 240

Val Thr Thr Val Val Cys Trp Val Trp Ile Cys Arg Lys Arg Lys Arg
                245                 250                 255

Glu Gln Pro Asp Pro Ser Thr Lys Lys Gln His Thr Ile Trp Pro Ser
            260                 265                 270

Pro His Gln Gly Asn Ser Pro Asp Leu Glu Val Tyr Asn Val Ile Arg
        275                 280                 285

Lys Gln Ser Glu Ala Asp Leu Ala Glu Thr Arg Pro Asp Leu Lys Asn
```

```
    290                 295                 300

Ile Ser Phe Arg Val Cys Ser Gly Glu Ala Thr Pro Asp Asp Met Ser
305                 310                 315                 320

Cys Asp Tyr Asp Asn Met Ala Val Asn Pro Ser Glu Ser Gly Phe Val
                325                 330                 335

Thr Leu Val Ser Val Glu Ser Gly Phe Val Thr Asn Asp Ile Tyr Glu
            340                 345                 350

Phe Ser Pro Asp Gln Met Gly Arg Ser Lys Glu Ser Gly Trp Val Glu
        355                 360                 365

Asn Glu Ile Tyr Gly Tyr
    370
```

```
<210> 164
<211> 64
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (64)
<223> Xaa equals stop translation

<400> 164
Met His Pro Gln Leu Ile Pro Ser Val Ile Ala Val Val Phe Ile Leu
  1               5                  10                  15

Leu Leu Gly Val Cys Phe Ile Ala Ser Cys Leu Val Thr His His Asn
            20                  25                  30

Phe Ser Arg Cys Lys Arg Gly Thr Gly Val His Lys Leu Glu His His
        35                  40                  45

Ala Lys Leu Lys Cys Ile Lys Glu Lys Ser Glu Leu Lys Ser Cys Xaa
    50                  55                  60
```

```
<210> 165
<211> 743
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (743)
<223> Xaa equals stop translation

<400> 165
Met Ala Val Arg Glu Leu Cys Phe Pro Arg Gln Arg Gln Val Leu Phe
  1               5                  10                  15
```

Leu Phe Leu Phe Trp Gly Val Ser Leu Ala Gly Ser Gly Phe Gly Arg
20 25 30

Tyr Ser Val Thr Glu Glu Thr Glu Lys Gly Ser Phe Val Val Asn Leu
35 40 45

Ala Lys Asp Leu Gly Leu Ala Glu Gly Glu Leu Ala Ala Arg Gly Thr
50 55 60

Arg Val Val Ser Asp Asp Asn Lys Gln Tyr Leu Leu Leu Asp Ser His
65 70 75 80

Thr Gly Asn Leu Leu Thr Asn Glu Lys Leu Asp Arg Glu Lys Leu Cys
85 90 95

Gly Pro Lys Glu Pro Cys Met Leu Tyr Phe Gln Ile Leu Met Asp Asp
100 105 110

Pro Phe Gln Ile Tyr Arg Ala Glu Leu Arg Val Arg Asp Ile Asn Asp
115 120 125

His Ala Pro Val Phe Gln Asp Lys Glu Thr Val Leu Lys Ile Ser Glu
130 135 140

Asn Thr Ala Glu Gly Thr Ala Phe Arg Leu Glu Arg Ala Gln Asp Pro
145 150 155 160

Asp Gly Gly Leu Asn Gly Ile Gln Asn Tyr Thr Ile Ser Pro Asn Ser
165 170 175

Phe Phe His Ile Asn Ile Ser Gly Gly Asp Glu Gly Met Ile Tyr Pro
180 185 190

Glu Leu Val Leu Asp Lys Ala Leu Asp Arg Glu Glu Gln Gly Glu Leu
195 200 205

Ser Leu Thr Leu Thr Ala Leu Asp Gly Gly Ser Pro Ser Arg Ser Gly
210 215 220

Thr Ser Thr Val Arg Ile Val Val Leu Asp Val Asn Asp Asn Ala Pro
225 230 235 240

Gln Phe Ala Gln Ala Leu Tyr Glu Thr Gln Ala Pro Glu Asn Ser Pro
245 250 255

Ile Gly Phe Leu Ile Val Lys Val Trp Ala Glu Asp Val Asp Ser Gly
260 265 270

Val Asn Ala Glu Val Ser Tyr Ser Phe Phe Asp Ala Ser Glu Asn Ile
275 280 285

Arg Thr Thr Phe Gln Ile Asn Pro Phe Ser Gly Glu Ile Phe Leu Arg
290 295 300

Glu Leu Leu Asp Tyr Glu Leu Val Asn Ser Tyr Lys Ile Asn Ile Gln
305 310 315 320

Ala Met Asp Gly Gly Gly Leu Ser Ala Arg Cys Arg Val Leu Val Glu
325 330 335

```
Val Leu Asp Thr Asn Asp Asn Pro Pro Glu Leu Ile Val Ser Ser Phe
            340                 345                 350

Ser Asn Ser Val Ala Glu Asn Ser Pro Glu Thr Pro Leu Ala Val Phe
        355                 360                 365

Lys Ile Asn Asp Arg Asp Ser Gly Glu Asn Gly Lys Met Val Cys Tyr
    370                 375                 380

Ile Gln Glu Asn Leu Pro Phe Leu Leu Lys Pro Ser Val Glu Asn Phe
385                 390                 395                 400

Tyr Ile Leu Ile Thr Glu Gly Ala Leu Asp Arg Glu Ile Arg Ala Glu
                405                 410                 415

Tyr Asn Ile Thr Ile Thr Val Thr Asp Leu Gly Thr Pro Arg Leu Lys
            420                 425                 430

Thr Glu His Asn Ile Thr Val Leu Val Ser Asp Val Asn Asn Asn Ala
        435                 440                 445

Pro Ala Phe Thr Gln Thr Ser Tyr Thr Leu Phe Val Arg Glu Asn Asn
    450                 455                 460

Ser Pro Ala Leu His Ile Gly Ser Val Ser Ala Thr Asp Arg Asp Ser
465                 470                 475                 480

Gly Thr Asn Ala Gln Val Thr Tyr Ser Leu Leu Pro Pro Gln Asp Pro
                485                 490                 495

His Leu Pro Leu Ala Ser Leu Val Ser Ile Asn Ala Asp Asn Gly His
            500                 505                 510

Leu Phe Ala Leu Arg Ser Leu Asp Tyr Glu Ala Leu Gln Ala Phe Glu
        515                 520                 525

Phe Arg Val Gly Ala Thr Asp Arg Gly Ser Pro Ala Leu Asn Ser Glu
    530                 535                 540

Ala Leu Gly Ala Arg Ala Gly Ala Gly Arg Gln Arg Gln Leu Ala Leu
545                 550                 555                 560

Arg Ala Val Pro Ala Ala Glu Arg Leu Arg Ala Leu His Arg Ala Gly
                565                 570                 575

Ala Pro Gly Gly Arg Ala Gly Leu Pro Gly Asp Gln Gly Gly Gly Gly
            580                 585                 590

Gly Arg Arg Leu Gly Pro Glu Arg Leu Ala Val Val Pro Ala Ala Gln
        595                 600                 605

Gly His Gly Ala Arg Ala Val Arg Cys Val Gly Ala Gln Trp Gly Gly
    610                 615                 620

Ala His Arg Gln Ala Ala Glu Arg Ala Arg Arg Ser Gln Ala Gln Ala
625                 630                 635                 640

Gly Gly Ala Cys Gln Gly Gln Trp Arg Ala Ser Ser Leu Gly His Arg
```

645 650 655

His Ala Ala Arg Ala Pro Gly Gly Arg Leu Leu Pro Ala Leu Pro Ala
660 665 670

Ser Pro Gly Gly Gly Pro Gly Pro Gly Pro Gly Arg Leu Ala His Arg
675 680 685

Leu Pro Gly Gly Gly Val Gly Leu Gly Val Phe Ala Leu Pro Pro Leu
690 695 700

Gly Ala Pro Val Arg Gly Gly Ala Ala Val Gln Glu Glu Gln Gly Gly
705 710 715 720

Leu Gly Gly Ser Leu Leu Gly Ala Arg Gly Ser Phe Ser Arg Ala Ser
725 730 735

Gly Gly Arg Glu Gly Arg Xaa
740

<210> 166
<211> 214
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (214)
<223> Xaa equals stop translation

<400> 166
Met Asn Arg Met Glu Leu Leu Lys Leu Leu Leu Thr Cys Phe Ser Glu
1 5 10 15

Ala Met Tyr Leu Pro Pro Ala Pro Glu Ser Gly Ser Thr Asn Pro Trp
20 25 30

Val Gln Phe Phe Cys Ser Thr Glu Asn Arg His Ala Leu Pro Leu Phe
35 40 45

Thr Ser Leu Leu Asn Thr Val Cys Ala Tyr Asp Pro Val Gly Tyr Gly
50 55 60

Ile Pro Tyr Asn His Leu Leu Phe Ser Asp Tyr Arg Glu Pro Leu Val
65 70 75 80

Glu Glu Ala Ala Gln Val Leu Ile Val Thr Leu Asp His Asp Ser Ala
85 90 95

Ser Ser Ala Ser Pro Thr Val Asp Gly Thr Thr Thr Gly Thr Ala Met
100 105 110

Asp Asp Ala Asp Pro Pro Gly Pro Glu Asn Leu Phe Val Asn Tyr Leu
115 120 125

Ser Arg Ile His Arg Glu Glu Asp Phe Gln Phe Ile Leu Lys Gly Ile
130 135 140

Ala Arg Leu Leu Ser Asn Pro Leu Leu Gln Thr Tyr Leu Pro Asn Ser
145 150 155 160

Thr Lys Lys Asp Pro Val Pro Pro Gly Ala Ala Ser Ser Leu Leu Glu
165 170 175

Ala Leu Arg Leu Gln Gln Glu Ile Pro Leu Leu Arg Ala Glu Glu Gln
180 185 190

Arg Arg Pro Arg His Pro Cys Pro His Pro Leu Leu Pro Gln Arg Cys
195 200 205

Pro Gly Arg Ser Val Xaa
210

<210> 167
<211> 213
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (213)
<223> Xaa equals stop translation

<400> 167
Met Pro Ser Leu Arg Phe Leu Ala Leu Ala Leu Leu Leu Ala Ile Leu
1 5 10 15

Pro Ala Leu Pro Asn Ala His Ala Ala Pro Gly Ile Gly Gly Leu Ile
20 25 30

Gly Gly Gly Ser Gln Ala Ser Ala Lys Glu Glu Pro Gln Ser Asn Ala
35 40 45

Gln Pro Ser Ala Asp Glu Arg Lys Gln Arg Leu Leu Ser Gln Ala Glu
50 55 60

Glu Thr Arg Gln Arg Leu Thr Asp Leu Lys Ala Glu Leu Ala Gly Ala
65 70 75 80

Pro Lys Glu Ile Ser Glu Ala Gln Arg Thr Leu Ser Lys Leu Val Ser
85 90 95

Glu Asp Asn Ser Asp Leu Pro Glu Arg Leu Ser Lys Leu Ser Val Pro
100 105 110

Val Leu Glu Gln Arg Leu Ala Ala Arg Val Asp Glu Leu Ala Leu Trp
115 120 125

Gln Gln Ala Leu Ser Ala Ala Asn Ser Met Leu Ile Ser Ala Gln Thr
130 135 140

Arg Pro Glu Arg Ala Gln Ala Asp Ile Ser Lys Asn Gln Leu Arg Ile
145 150 155 160

Asp Glu Ile Asn Gly Leu Leu Lys Ser Gly Arg Glu Asn Asn Lys Pro
165 170 175

Leu Thr Asp Glu Arg Arg Ala Leu Leu Glu Ser Thr Ser Arg Ala Ala
180 185 190

Ala Gly Pro Ser Ile Phe His Pro Gly Gly Val Pro Gly Lys Cys Thr
195 200 205

Gln Phe Ala Leu Xaa
210

<210> 168
<211> 75
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (75)
<223> Xaa equals stop translation

<400> 168
Met Phe Thr Ser Phe Gly Leu Ala Ser Pro Arg Ile Leu Phe Cys Phe
1 5 10 15

Cys Phe Phe Asp Leu Gly Phe Ile Phe Phe Cys Val Leu Tyr Tyr Ile
20 25 30

Val Lys Gly Ile Leu Ala Glu Thr Leu Val Phe Gly Ala Arg Gly Glu
35 40 45

Gln Glu Cys Trp Ala Val Tyr Phe Arg Trp Arg Thr His Leu Gln Thr
50 55 60

Phe Gly Leu Phe Ser Phe Asn Cys Ser Val Xaa
65 70 75

<210> 169
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 169
Met Phe Leu Cys Leu Phe Phe Phe Phe Phe Asn Ala Thr Gln Gly Asn
1 5 10 15

Ile Phe Ile Ser Phe Leu Ser Gly Leu Pro Gln Cys Ile Phe Ile Ser
20 25 30

Phe Glu Thr Lys Arg Phe Trp Lys Leu Phe Phe Cys Ser Phe Lys Xaa
35 40 45

<210> 170
<211> 88
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (88)
<223> Xaa equals stop translation

<400> 170
Met Gly Leu His Leu Arg Pro Tyr Arg Val Gly Leu Leu Pro Asp Gly
1 5 10 15

Leu Leu Phe Leu Leu Leu Leu Leu Met Leu Leu Ala Asp Pro Ala Leu
20 25 30

Pro Ala Gly Arg His Pro Pro Val Val Leu Val Pro Gly Asp Leu Gly
35 40 45

Asn Gln Leu Glu Ala Lys Leu Asp Lys Pro Thr Val Val His Tyr Leu
50 55 60

Cys Ser Lys Lys Thr Glu Ser Tyr Phe Thr Ile Trp Leu Asn Leu Glu
65 70 75 80

Leu Leu Leu Pro Val His His Xaa
85

<210> 171
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 171
Met Ala Cys Glu Thr His Gly Val Leu Val Pro Ala His Leu Ser Gly
1 5 10 15

Leu Ile Thr Cys Leu Leu Ala Phe Trp Val Pro Ala Ser Cys Ile Gln
20 25 30

Arg Cys Ser Gly Ser Pro Leu Pro Leu Xaa
35 40

<210> 172
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 172
Met Gln Cys Phe Leu Phe Ser Ile Phe Leu Ile Thr Gly Leu Ala Glu
1 5 10 15

Glu Phe Cys Glu Gln Leu Ser Ile Ser Leu Ala Glu Glu Glu Ile Gln
20 25 30

Leu Ser Ser Thr Val Glu His Phe Cys Met Thr Ala Phe Ser Trp Xaa
35 40 45

<210> 173
<211> 233
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (233)
<223> Xaa equals stop translation

<400> 173
Met Ala Ala Leu Ala Ala Ala Ala Lys Lys Val Trp Ser Ala Arg Arg
1 5 10 15

Leu Leu Val Leu Leu Phe Thr Pro Leu Ala Leu Leu Pro Val Val Phe
20 25 30

Ala Leu Pro Pro Lys Glu Gly Arg Cys Leu Phe Val Ile Leu Leu Met
35 40 45

Ala Val Tyr Trp Cys Thr Glu Ala Leu Pro Leu Ser Val Thr Ala Leu
50 55 60

Leu Pro Ile Val Leu Phe Pro Phe Met Gly Ile Leu Pro Ser Asn Lys
65 70 75 80

Val Cys Pro Gln Tyr Phe Leu Asp Thr Asn Phe Leu Phe Leu Ser Gly
85 90 95

Leu Ile Met Ala Ser Ala Ile Glu Glu Trp Asn Leu His Arg Arg Ile
100 105 110

Ala Leu Lys Ile Leu Met Leu Val Gly Val Gln Pro Ala Arg Leu Ile
115 120 125

Leu Gly Met Met Val Thr Thr Ser Phe Leu Ser Met Trp Leu Ser Asn
130 135 140

Thr Ala Ser Thr Ala Met Met Leu Pro Ile Ala Asn Ala Ile Leu Lys
145 150 155 160

Ser Leu Phe Gly Gln Lys Glu Val Arg Lys Asp Pro Ser Gln Glu Ser
165 170 175

Glu Glu Asn Thr Gly Ile Glu Pro Asn Thr Phe Leu Ser Glu Glu Arg
180 185 190

Leu Lys Leu Gln Ala Pro Leu Val Ile Arg Leu Gly Gln Ile Thr Glu
195 200 205

Ser Gly Gln Trp Asn Met Ser Gly Asn Asp Val Cys Asn Phe Arg Val
210 215 220

Leu Ser Phe Leu Pro Gly Gly Met Xaa
225 230

<210> 174
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 174
Met Gly Thr Ile Phe Gly Tyr Leu His Cys Val Lys Cys Tyr Val Leu
1 5 10 15

Tyr Phe Ile Phe Ile Leu Ile Thr Ala Val Tyr His Ser Phe Tyr Tyr
20 25 30

Pro His Tyr Arg Gly Lys Ala Leu Ile Ser Gly Thr Xaa
35 40 45

<210> 175
<211> 85
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (77)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (85)
<223> Xaa equals stop translation

<400> 175
Met Val Trp Phe Leu Phe Leu Val Phe Ile Phe Leu Lys Val Lys Gly
1 5 10 15

Asp Phe Phe Pro Pro Phe Leu Ile Cys Asn Leu Phe Cys Ile Trp Met
20 25 30

Ile Thr Gly Val Ser His Arg Leu Gln Pro Gln Ile Leu Phe Ser Arg
35 40 45

His Lys His Asn Gln Glu Ile Ile Leu Gln Met Val Ser Phe Ser Cys
50 55 60

Cys Val Phe Phe Pro Met Ile Arg Glu Val Lys Ser Xaa Leu Gly Cys
65 70 75 80

Ile Lys Met Ser Xaa
85

<210> 176
<211> 66
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (66)
<223> Xaa equals stop translation

<400> 176
Met Trp Val Leu Leu Ser Cys Pro Leu Pro Pro Leu Cys Leu Pro Ala
1 5 10 15

Ser Ala Val Pro Gly Gln Cys Leu Gly Gly Gln Trp Ser Gly His Gln
20 25 30

Leu Arg Leu Arg Gly Arg Gly Trp His Cys Arg Cys His Cys Arg Ala
35 40 45

Trp Ala Ala Asp Met Gly Arg Gly Leu His Ser Cys Gln Leu Leu Ser
50 55 60

Arg Xaa
65

<210> 177
<211> 55
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (55)
<223> Xaa equals stop translation

<400> 177
Met Leu Leu Leu Cys Ile Leu Leu Ile Phe Cys Val Val Gly Leu Ser
1 5 10 15

Val Val Gly Arg Arg Val Leu Lys Ser Thr Thr Ile Ile Val Tyr Leu
20 25 30

Ser Ile Thr Pro Phe Ser Ser Phe Ser Ser Ile Ser His Ile Phe Gln

35 40 45

Leu Leu Ile Gly Ala His Xaa
50 55

<210> 178
<211> 83
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (4)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (83)
<223> Xaa equals stop translation

<400> 178
Met Cys Val Xaa Leu Ser Phe Cys Pro Phe Leu Ser Ser Ala Leu Pro
1 5 10 15

Ala Ser His Thr Gln Phe Tyr Met Pro Arg Gly Ala Lys Phe Gly Thr
20 25 30

Phe Thr Leu Gln Ala Ser Val Ser Pro Leu Glu Glu Lys Thr His Ser
35 40 45

Phe Thr His Pro Gly Ile Gly Gly Lys Leu Leu Gly His Gln Asp Pro
50 55 60

Gly Ala Pro Gly Pro Ser Trp Asn Ile Arg Ser Thr Trp Ser Thr Arg
65 70 75 80

Ser Leu Xaa

<210> 179
<211> 330
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (247)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 179
Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
1 5 10 15

Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
20 25 30

Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
35 40 45

Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Lys His Leu Ala
50 55 60

Arg Leu Gly Met His Val Ile Ile Ala Gly Asn Asn Asp Ser Lys Ala
65 70 75 80

Lys Gln Val Val Ser Lys Ile Lys Glu Glu Thr Leu Asn Asp Lys Val
85 90 95

Glu Phe Leu Tyr Cys Asp Leu Ala Ser Met Thr Ser Ile Arg Gln Phe
100 105 110

Val Gln Lys Phe Lys Met Lys Lys Ile Pro Leu His Val Leu Ile Asn
115 120 125

Asn Ala Gly Val Met Met Val Pro Gln Arg Lys Thr Arg Asp Gly Phe
130 135 140

Glu Glu His Phe Gly Leu Asn Tyr Leu Gly His Phe Leu Leu Thr Asn
145 150 155 160

Leu Leu Leu Asp Thr Leu Lys Glu Ser Gly Ser Pro Gly His Ser Ala
165 170 175

Arg Val Val Thr Val Ser Ser Ala Thr His Tyr Val Ala Glu Leu Asn
180 185 190

Met Asp Asp Leu Gln Ser Ser Ala Cys Tyr Ser Pro His Ala Ala Tyr
195 200 205

Ala Gln Ser Lys Leu Ala Leu Val Leu Phe Thr Tyr His Leu Gln Arg
210 215 220

Leu Leu Ala Ala Glu Gly Ser His Val Thr Ala Asn Val Val Asp Pro
225 230 235 240

Gly Val Val Asn Thr Asp Xaa Tyr Lys His Val Phe Trp Ala Thr Arg
245 250 255

Leu Ala Lys Lys Leu Leu Gly Trp Leu Leu Phe Lys Thr Pro Asp Glu
260 265 270

Gly Ala Trp Thr Ser Ile Tyr Ala Ala Val Thr Pro Glu Leu Glu Gly
275 280 285

Val Gly Gly Arg Tyr Leu Tyr Asn Glu Lys Glu Thr Lys Ser Leu His
290 295 300

Val Thr Tyr Asn Gln Lys Leu Gln Gln Gln Leu Trp Ser Lys Ser Cys
305 310 315 320

Glu Met Thr Gly Val Leu Asp Val Thr Leu

325 330

<210> 180
<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 180
Met Ile Ala Cys Gln Tyr Ile Ser Leu Ala Ile Met Leu Ala Phe Val
1 5 10 15

Arg Trp Ala Ala Phe Leu Leu Phe Pro Phe Leu Cys Gly Asp Asn Gly
20 25 30

Gly Asn Ile Gln Gln Lys Tyr Val Xaa
35 40

<210> 181
<211> 52
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (52)
<223> Xaa equals stop translation

<400> 181
Met Ala Asn Ala Met Ala Tyr Leu Ser Ile Phe Leu Cys Gly Ala Ser
1 5 10 15

Ser Ser Pro Cys Asp Cys Ala Leu Leu Val Pro Val Ser Leu Phe Arg
20 25 30

Gly Arg Lys Val Ala Asn Phe Lys Asn Gln Asn Ser Asp Val Thr Ser
35 40 45

Gly Asn Ala Xaa
50

<210> 182
<211> 55
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (55)
<223> Xaa equals stop translation

<400> 182

Met Gln Gln Ile Cys Ser Cys Leu Gly Ala Phe Ala Leu Leu Phe Phe
1   5   10   15

Trp Pro Gly His Phe Thr Ser Thr Phe Ser Ile Phe Tyr Asp Phe Leu
            20   25   30

Pro Ile Phe Gly Ser Leu Phe Lys Cys His Pro Ser Lys Arg Pro Ser
        35   40   45

Lys Leu Pro Tyr Leu Lys Xaa
    50   55

<210> 183
<211> 62
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (62)
<223> Xaa equals stop translation

<400> 183
Met Arg Leu Leu Leu Glu Trp Arg Val Tyr Leu Arg Leu Thr Cys Ala
1   5   10   15

Thr Lys Asp Gly Met Ala Arg Glu Cys Pro Thr Thr Trp Leu Ser Pro
            20   25   30

Pro Ala Lys Pro Asp Phe Ala Gln Arg His Ser Val Lys Pro Thr Ala
        35   40   45

Leu Gln Gly Gly Arg Trp Ser Arg Leu Gly Ala Ser Pro Xaa
    50   55   60

<210> 184
<211> 148
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (148)
<223> Xaa equals stop translation

<400> 184
Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala Leu Leu Leu
1   5   10   15

Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp His Phe His
            20   25   30

Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg Tyr Leu Pro
        35   40   45

Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser Lys Asp
    50   55   60

```
Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys Glu Gln
 65                  70                  75                  80

Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu Gly Arg Thr
                 85                  90                  95

Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe Gln Glu
            100                 105                 110

Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr Ile Ser Thr
        115                 120                 125

Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr Cys Leu Glu
    130                 135                 140

Gly Phe His Xaa
145


<210> 185
<211> 161
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (146)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (151)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (161)
<223> Xaa equals stop translation

<400> 185
Met Arg Leu Leu Cys Gly Leu Trp Leu Trp Leu Ser Leu Leu Lys Val
  1               5                  10                  15

Leu Gln Ala Gln Thr Pro Thr Pro Leu Pro Leu Pro Pro Pro Met Gln
             20                  25                  30

Ser Phe Gln Gly Asn Gln Phe Gln Gly Glu Trp Phe Val Leu Gly Leu
         35                  40                  45

Ala Gly Asn Ser Phe Arg Pro Glu His Arg Ala Leu Leu Asn Ala Phe
     50                  55                  60

Thr Ala Thr Phe Glu Leu Ser Asp Asp Gly Arg Phe Glu Val Trp Asn
 65                  70                  75                  80

Ala Met Thr Arg Gly Gln His Cys Asp Thr Trp Ser Tyr Val Leu Ile
                 85                  90                  95
```

```
Pro Ala Ala Gln Pro Gly Gln Phe Thr Val Asp His Gly Val Gly Arg
            100                 105                 110

Ser Trp Leu Leu Pro Pro Gly Thr Leu Asp Glu Phe Ile Cys Leu Gly
        115                 120                 125

Arg Ala Gln Gly Leu Ser Asp Asp Asn Ile Val Phe Pro Asp Val Thr
    130                 135                 140

Gly Xaa Ala Leu Asp Leu Xaa Ser Leu Pro Trp Val Ala Ala Pro Ala
145                 150                 155                 160

Xaa


<210> 186
<211> 122
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (122)
<223> Xaa equals stop translation

<400> 186
Met Met Leu Pro Gln Trp Leu Leu Leu Leu Phe Leu Leu Phe Phe Phe
  1               5                  10                  15

Leu Phe Leu Leu Thr Arg Gly Ser Leu Ser Pro Thr Lys Tyr Asn Leu
             20                  25                  30

Leu Glu Leu Lys Glu Ser Cys Ile Arg Asn Gln Asp Cys Glu Thr Gly
         35                  40                  45

Cys Cys Gln Arg Ala Pro Asp Asn Cys Glu Ser His Cys Ala Glu Lys
     50                  55                  60

Gly Ser Glu Gly Ser Leu Cys Gln Thr Gln Val Phe Phe Gly Gln Tyr
 65                  70                  75                  80

Arg Ala Cys Pro Cys Leu Arg Asn Leu Thr Cys Ile Tyr Ser Lys Asn
                 85                  90                  95

Glu Lys Trp Leu Ser Ile Ala Tyr Gly Arg Cys Gln Lys Ile Gly Arg
            100                 105                 110

Gln Lys Leu Ala Lys Lys Met Phe Phe Xaa
        115                 120


<210> 187
<211> 163
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
```

<222> (163)
<223> Xaa equals stop translation

<400> 187
```
Met Thr Ser Asn Phe Pro Phe Cys Thr Leu Ile Leu Gly Ile Ala Gln
  1               5                  10                  15

Ala Gln Ala Cys Pro Gly Cys Pro Gly Asp Trp Pro Gly Leu Gly Ser
             20                  25                  30

Gly Val Gly Glu Gly Leu His His Ile Arg Thr Cys Arg Thr Pro Ile
         35                  40                  45

Pro Cys Ser Pro Pro Ala Pro Ala Ala Ala Cys Leu Gly Ser Gly His
     50                  55                  60

Ala Arg Leu Pro Cys Val Leu Arg Leu Trp Pro Val Pro Ala Asn Leu
 65                  70                  75                  80

Ser Ser Pro Phe Arg Leu Glu Ala Leu His Cys Ser Phe Trp Ser Ser
                 85                  90                  95

Pro Leu Leu Pro Ala Pro His Leu Ala Phe Phe Gly Phe Arg Asp Leu
            100                 105                 110

Leu Thr Asp Phe Leu Leu Ala Ala Cys Leu Leu Thr Phe Gln Lys Thr
        115                 120                 125

Pro Leu Glu Leu Pro Met Ala Val Val His Leu Leu Val Ala Thr Pro
    130                 135                 140

Cys Tyr Gln Met Leu Asp Asn Leu Pro Leu Pro Ser Ala Ala Ala Asn
145                 150                 155                 160

Trp Cys Xaa
```

<210> 188
<211> 51
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (51)
<223> Xaa equals stop translation

<400> 188
```
Met Pro Gly Ile Leu Ala Gly Ile Pro Val Lys Asp Leu Cys Leu Ser
  1               5                  10                  15

Leu Leu Gln Gly Phe Arg Leu Leu Leu Leu Cys Val Cys Pro Gly Trp
             20                  25                  30

Leu Ser Gly Trp Met Gly Gly Gln Lys Gly Ser Pro Arg Ile Val Asp
         35                  40                  45

Ile Gly Xaa
```

50

<210> 189
<211> 65
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (65)
<223> Xaa equals stop translation

<400> 189
Met Tyr Leu Tyr Leu Gly Val Phe Phe His Leu Ile Tyr Pro Gly Ala
1 5 10 15

Leu Ser Ile Thr Thr Leu Gly Lys His Ser His Pro Phe Phe Thr Ala
20 25 30

Glu Gln Asn Ser Thr Val Trp Met Glu His Thr Leu Phe His Gln Ser
35 40 45

Pro Val Ala Ser His Leu Val Cys Phe Gln Ser Phe Ala Phe Ser Glu
50 55 60

Xaa
65

<210> 190
<211> 47
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (47)
<223> Xaa equals stop translation

<400> 190
Met Thr Leu Ser Leu Gln Leu Ala Glu Leu Val His Phe Val Cys Ala
1 5 10 15

Phe Gln Ser Gln Trp Thr Gly Val Tyr Pro Met Met Pro Pro Leu Lys
20 25 30

Pro Thr Glu Pro Leu Cys Phe Ala Cys Val Pro Cys Arg Val Xaa
35 40 45

<210> 191
<211> 144
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (144)

<223> Xaa equals stop translation

<400> 191
Met Ser Pro Phe His Leu Leu Gly Leu Lys Val Phe Leu Thr Trp Ala
1 5 10 15

Leu Thr Leu Ala Gln Ile Cys Leu Tyr Phe Phe Glu Val Gln Pro Leu
20 25 30

Gly Leu Leu Ala Leu Asn Phe Phe Cys Thr Ala Thr Ala Gly Leu Lys
35 40 45

Glu Leu Cys Met His Pro Pro Ser Leu Ala Phe Thr Pro Glu Phe His
50 55 60

Thr Ser Leu Ser Pro Leu Ala Ile Pro Ser Phe Cys Gly Thr Ser Val
65 70 75 80

Ser Leu Ser Asn Ser His Thr Ile Pro Leu Ser Leu Tyr Leu Pro Phe
85 90 95

Pro Ser Lys Ser Arg Met Pro Asp Thr Leu His Leu Leu Val His Ser
100 105 110

Leu Pro Leu Val His Ser Gln Val Leu Pro Val Lys Asp Val Thr Ile
115 120 125

Glu Trp Pro Leu Cys Gln Arg Cys Leu Gly Ser Thr Cys His Gln Xaa
130 135 140

<210> 192
<211> 81
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (76)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (81)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 192
Met Phe Cys Phe Ser Ser Ile Phe Cys Ser His Glu His Thr His Leu
1 5 10 15

Pro Gly Thr Phe Trp Leu Phe Leu Phe Leu Phe Leu Ile Leu Pro Pro
20 25 30

Ser Cys Pro Cys Phe Leu Pro Phe Ser Leu Ala Ile Glu Thr Val Arg
35 40 45

```
Trp Pro Cys Trp His His Pro Thr Ser Phe Glu Leu Cys Tyr Pro Gly
     50                  55                  60

Thr Ser Ile Tyr Tyr Ala Ser Arg Gly Gly Pro Xaa Pro Asn Ser Glu
65                  70                  75                  80

Xaa



<210> 193
<211> 45
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (45)
<223> Xaa equals stop translation

<400> 193
Met Thr Tyr Leu Phe Cys Ser Ser Ile Ser Leu Leu Leu Leu Lys Val
 1               5                  10                  15

His Ser Ser Gly His Gln Asp Ile Arg Lys Ala Lys Ser Lys Val Pro
            20                  25                  30

Arg Leu Leu Ile Ile Gln Cys Pro Gln Gln Arg Glu Xaa
        35                  40                  45


<210> 194
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 194
Met Pro Thr Ile Trp Val Lys Leu Cys Leu Leu Gln Val Cys His Gly
 1               5                  10                  15

Leu Phe Pro Leu Leu Lys His Trp Ser Gln Pro Met Pro Leu Cys Val
            20                  25                  30

Thr Leu Ala Pro Val Ser Tyr Trp Leu Xaa
        35                  40


<210> 195
<211> 260
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
```

<222> (260)
<223> Xaa equals stop translation

<400> 195
Met Gly Thr Ala Ala Leu Gly Pro Val Trp Ala Ala Leu Leu Leu Phe
1   5   10   15

Leu Leu Met Cys Glu Ile Pro Met Val Glu Leu Thr Phe Asp Arg Ala
            20   25   30

Val Ala Ser Asp Cys Gln Arg Cys Cys Asp Ser Glu Asp Pro Leu Asp
        35   40   45

Pro Ala His Val Ser Ser Ala Ser Ser Ser Gly Arg Pro His Ala Leu
    50   55   60

Pro Glu Ile Arg Pro Tyr Ile Asn Ile Thr Ile Leu Lys Gly Asp Lys
65   70   75   80

Gly Asp Pro Gly Pro Met Gly Leu Pro Gly Tyr Met Gly Arg Glu Gly
                85   90   95

Pro Gln Gly Glu Pro Gly Pro Gln Gly Ser Lys Gly Asp Lys Gly Glu
            100   105   110

Met Gly Ser Pro Gly Ala Pro Cys Gln Lys Arg Phe Phe Ala Phe Ser
        115   120   125

Val Gly Arg Lys Thr Ala Leu His Ser Gly Glu Asp Phe Gln Thr Leu
    130   135   140

Leu Phe Glu Arg Val Phe Val Asn Leu Asp Gly Cys Phe Asp Met Ala
145   150   155   160

Thr Gly Gln Phe Ala Ala Pro Leu Arg Gly Ile Tyr Phe Phe Ser Leu
                165   170   175

Asn Val His Ser Trp Asn Tyr Lys Glu Thr Tyr Val His Ile Met His
            180   185   190

Asn Gln Lys Glu Ala Val Ile Leu Tyr Ala Gln Pro Ser Glu Arg Ser
        195   200   205

Ile Met Gln Ser Gln Ser Val Met Leu Asp Leu Ala Tyr Gly Asp Arg
    210   215   220

Val Trp Val Arg Leu Phe Lys Arg Gln Arg Glu Asn Ala Ile Tyr Ser
225   230   235   240

Asn Asp Phe Asp Thr Tyr Ile Thr Phe Ser Gly His Leu Ile Lys Ala
                245   250   255

Glu Asp Asp Xaa
            260

<210> 196
<211> 117
<212> PRT

```
<213> Homo sapiens

<400> 196
Met Leu Gly His Cys Cys Tyr Phe Trp Gln Val Trp Pro Ala Ser Glu
1               5                   10                  15

Ala Leu Ala Ala Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser
            20                  25                  30

Trp Lys Gln His Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu
        35                  40                  45

Pro Thr Thr Thr Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly
    50                  55                  60

Lys Asn Pro Ala Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly
65                  70                  75                  80

Val Trp Pro Cys Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr
                85                  90                  95

Pro Ser Ser Thr Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr
            100                 105                 110

Trp Trp Arg Thr Pro
        115


<210> 197
<211> 698
<212> PRT
<213> Homo sapiens

<400> 197
Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg
1               5                   10                  15

Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu
            20                  25                  30

Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu
        35                  40                  45

Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu
    50                  55                  60

Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp
65                  70                  75                  80

Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln
                85                  90                  95

Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg
            100                 105                 110

Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly
        115                 120                 125

His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys
```

130 135 140

Gly Ala Glu Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro
145 150 155 160

Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg
165 170 175

Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu
180 185 190

Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala
195 200 205

Leu Arg Arg Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu
210 215 220

Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro
225 230 235 240

Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp
245 250 255

Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys
260 265 270

Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly His Gln Gly Pro Gln Arg
275 280 285

Pro Val Lys Asp Glu Pro Gln Asp Gly Glu Asn Pro Asn Pro Pro Asn
290 295 300

Trp Ser Arg Thr Val Val Arg Asp Val Arg Leu Ile Ser Ala Lys Thr
305 310 315 320

Gly Tyr Gly Val Glu Glu Leu Ile Ser Ala Leu Gln Arg Ser Trp Arg
325 330 335

Tyr Arg Gly Asp Val Tyr Leu Val Gly Ala Thr Asn Ala Gly Lys Ser
340 345 350

Thr Leu Phe Asn Thr Leu Leu Glu Ser Asp Tyr Cys Thr Ala Lys Gly
355 360 365

Ser Asp Ala Ile Asp Arg Ala Thr Ile Ser Pro Trp Pro Gly Thr Thr
370 375 380

Leu Asn Leu Leu Lys Phe Pro Ile Cys Asn Pro Thr Pro Tyr Arg Met
385 390 395 400

Phe Lys Arg His Gln Arg Leu Lys Lys Asp Ser Thr Gln Ala Glu Glu
405 410 415

Asp Leu Ser Glu Gln Glu Gln Asn Gln Leu Asn Val Leu Lys Lys His
420 425 430

Gly Tyr Val Val Gly Arg Val Gly Arg Thr Phe Leu Tyr Ser Glu Glu
435 440 445

Gln Lys Asp Asn Ile Pro Phe Glu Phe Asp Ala Asp Ser Leu Ala Phe
450 455 460

Asp Met Glu Asn Asp Pro Val Met Gly Thr His Lys Ser Thr Lys Gln
465 470 475 480

Val Glu Leu Thr Ala Gln Asp Val Lys Asp Ala His Trp Phe Tyr Asp
485 490 495

Thr Pro Gly Ile Thr Lys Glu Asn Cys Ile Leu Asn Leu Leu Thr Glu
500 505 510

Lys Glu Val Asn Ile Val Leu Pro Thr Gln Ser Ile Val Pro Arg Thr
515 520 525

Phe Val Leu Lys Pro Gly Met Val Leu Phe Leu Gly Ala Ile Gly Arg
530 535 540

Ile Asp Phe Leu Gln Gly Asn Gln Ser Ala Trp Phe Thr Val Val Ala
545 550 555 560

Ser Asn Ile Leu Pro Val His Ile Thr Ser Leu Asp Arg Ala Asp Ala
565 570 575

Leu Tyr Gln Lys His Ala Gly His Thr Leu Leu Gln Ile Pro Met Gly
580 585 590

Gly Lys Glu Arg Met Ala Gly Phe Pro Pro Leu Val Ala Glu Asp Ile
595 600 605

Met Leu Lys Glu Gly Leu Gly Ala Ser Glu Ala Val Ala Asp Ile Lys
610 615 620

Phe Ser Ser Ala Gly Trp Val Ser Val Thr Pro Asn Phe Lys Asp Arg
625 630 635 640

Leu His Leu Arg Gly Tyr Thr Pro Glu Gly Thr Val Leu Thr Val Arg
645 650 655

Pro Pro Leu Leu Pro Tyr Ile Val Asn Ile Lys Gly Gln Arg Ile Lys
660 665 670

Lys Ser Val Ala Tyr Lys Thr Lys Lys Pro Pro Ser Leu Met Tyr Asn
675 680 685

Val Arg Lys Lys Lys Gly Lys Ile Asn Val
690 695

<210> 198
<211> 348
<212> PRT
<213> Homo sapiens

<400> 198
Met Asn Met Thr Gln Ala Arg Val Leu Val Ala Ala Val Val Gly Leu
1 5 10 15

Val Ala Val Leu Leu Tyr Ala Ser Ile His Lys Ile Glu Glu Gly His

20 25 30

Leu Ala Val Tyr Tyr Arg Gly Gly Ala Leu Leu Thr Ser Pro Ser Gly
35 40 45

Pro Gly Tyr His Ile Met Leu Pro Phe Ile Thr Thr Phe Arg Ser Val
50 55 60

Gln Thr Thr Leu Gln Thr Asp Glu Val Lys Asn Val Pro Cys Gly Thr
65 70 75 80

Ser Gly Gly Val Met Ile Tyr Ile Asp Arg Ile Glu Val Val Asn Met
85 90 95

Leu Ala Pro Tyr Ala Val Phe Asp Ile Val Arg Asn Tyr Thr Ala Asp
100 105 110

Tyr Asp Lys Thr Leu Ile Phe Asn Lys Ile His His Glu Leu Asn Gln
115 120 125

Phe Cys Ser Ala His Thr Leu Gln Glu Val Tyr Ile Glu Leu Phe Asp
130 135 140

Gln Ile Asp Glu Asn Leu Lys Gln Ala Leu Gln Lys Asp Leu Asn Leu
145 150 155 160

Met Ala Pro Gly Leu Thr Ile Gln Ala Val Arg Val Thr Lys Pro Lys
165 170 175

Ile Pro Glu Ala Ile Arg Arg Asn Phe Glu Leu Met Glu Ala Glu Lys
180 185 190

Thr Lys Leu Leu Ile Ala Ala Gln Lys Gln Lys Val Val Glu Lys Glu
195 200 205

Ala Glu Thr Glu Arg Lys Lys Ala Val Ile Glu Ala Glu Lys Ile Ala
210 215 220

Gln Val Ala Lys Ile Arg Phe Gln Gln Lys Val Met Glu Lys Glu Thr
225 230 235 240

Glu Lys Arg Ile Ser Glu Ile Glu Asp Ala Ala Phe Leu Ala Arg Glu
245 250 255

Lys Ala Lys Ala Asp Ala Glu Tyr Tyr Ala Ala His Lys Tyr Ala Thr
260 265 270

Ser Asn Lys His Lys Leu Thr Pro Glu Tyr Leu Glu Leu Lys Lys Tyr
275 280 285

Gln Ala Ile Ala Ser Asn Ser Lys Ile Tyr Phe Gly Ser Asn Ile Pro
290 295 300

Asn Met Phe Val Asp Ser Ser Cys Ala Leu Lys Tyr Ser Asp Ile Arg
305 310 315 320

Thr Gly Arg Glu Ser Ser Leu Pro Ser Lys Glu Ala Leu Glu Pro Ser
325 330 335

Gly Glu Asn Val Ile Gln Asn Lys Glu Ser Thr Gly
340 345

<210> 199
<211> 401
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (307)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 199
Met Met Gly Leu Gly Asn Gly Arg Arg Ser Met Lys Ser Pro Pro Leu
1 5 10 15

Val Leu Ala Ala Leu Val Ala Cys Ile Ile Val Leu Gly Phe Asn Tyr
20 25 30

Trp Ile Ala Ser Ser Arg Ser Val Asp Leu Gln Thr Arg Ile Met Glu
35 40 45

Leu Glu Gly Arg Val Arg Arg Arg Ala Ala Glu Arg Gly Ala Val Glu
50 55 60

Leu Lys Lys Asn Glu Phe Gln Gly Glu Leu Glu Lys Gln Arg Glu Gln
65 70 75 80

Leu Asp Lys Ile Gln Ser Ser His Asn Phe Gln Leu Glu Ser Val Asn
85 90 95

Lys Leu Tyr Gln Asp Glu Lys Ala Val Leu Val Asn Asn Ile Thr Thr
100 105 110

Gly Glu Arg Leu Ile Arg Val Leu Gln Asp Gln Leu Lys Thr Leu Gln
115 120 125

Arg Asn Tyr Gly Arg Leu Gln Gln Asp Val Leu Gln Phe Gln Lys Asn
130 135 140

Gln Thr Asn Leu Glu Arg Lys Phe Ser Tyr Asp Leu Ser Gln Cys Ile
145 150 155 160

Asn Gln Met Lys Glu Val Lys Glu Gln Cys Glu Glu Arg Ile Glu Glu
165 170 175

Val Thr Lys Lys Gly Asn Glu Ala Val Ala Ser Arg Asp Leu Ser Glu
180 185 190

Asn Asn Asp Gln Arg Gln Gln Leu Gln Ala Leu Ser Glu Pro Gln Pro
195 200 205

Arg Leu Gln Ala Ala Gly Leu Pro His Thr Glu Val Pro Gln Gly Lys
210 215 220

Gly Asn Val Leu Gly Asn Ser Lys Ser Gln Thr Pro Ala Pro Ser Ser
225 230 235 240

Glu Val Val Leu Asp Ser Lys Arg Gln Val Glu Lys Glu Glu Thr Asn
245 250 255

Glu Ile Gln Val Val Asn Glu Glu Pro Gln Arg Asp Arg Leu Pro Gln
260 265 270

Glu Pro Gly Arg Glu Gln Val Val Glu Asp Arg Pro Val Gly Gly Arg
275 280 285

Gly Phe Gly Gly Ala Gly Glu Leu Gly Gln Thr Pro Gln Val Gln Ala
290 295 300

Ala Leu Xaa Val Ser Gln Glu Asn Pro Glu Met Glu Gly Pro Glu Arg
305 310 315 320

Asp Gln Leu Val Ile Pro Asp Gly Gln Glu Glu Glu Gln Glu Ala Ala
325 330 335

Gly Glu Gly Arg Asn Gln Gln Lys Leu Arg Gly Glu Asp Asp Tyr Asn
340 345 350

Met Asp Glu Asn Glu Ala Glu Ser Glu Thr Asp Lys Gln Ala Ala Leu
355 360 365

Ala Gly Asn Asp Arg Asn Ile Asp Val Phe Asn Val Glu Asp Gln Lys
370 375 380

Arg Asp Thr Ile Asn Leu Leu Asp Gln Arg Glu Lys Arg Asn His Thr
385 390 395 400

Leu

<210> 200
<211> 324
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 200
Met Glu Xaa Ala Lys Val Tyr Val Ala Lys Val Asp Cys Thr Ala His
1 5 10 15

Ser Asp Val Cys Ser Ala Gln Gly Val Arg Gly Tyr Pro Thr Leu Lys
20 25 30

Leu Phe Lys Pro Gly Gln Glu Ala Val Lys Tyr Gln Gly Pro Arg Asp
35 40 45

Phe Gln Thr Leu Glu Asn Trp Met Leu Gln Thr Leu Asn Glu Glu Pro
50 55 60

Val Thr Pro Glu Pro Glu Val Glu Pro Pro Ser Ala Pro Glu Leu Lys

```
65                  70                  75                  80

Gln Gly Leu Tyr Glu Leu Ser Ala Ser Asn Phe Glu Leu His Val Ala
                85                  90                  95

Gln Gly Asp His Phe Ile Lys Phe Phe Ala Pro Trp Cys Gly His Cys
            100                 105                 110

Lys Ala Leu Ala Pro Thr Trp Glu Gln Leu Ala Leu Gly Leu Glu His
        115                 120                 125

Ser Glu Thr Val Lys Ile Gly Lys Val Asp Cys Thr Gln His Tyr Glu
    130                 135                 140

Leu Cys Ser Gly Asn Gln Val Arg Gly Tyr Pro Thr Leu Leu Trp Phe
145                 150                 155                 160

Arg Asp Gly Lys Lys Val Asp Gln Tyr Lys Gly Lys Arg Asp Leu Glu
                165                 170                 175

Ser Leu Arg Glu Tyr Val Glu Ser Gln Leu Gln Arg Thr Glu Thr Gly
            180                 185                 190

Ala Thr Glu Thr Val Thr Pro Ser Glu Ala Pro Val Leu Ala Ala Glu
        195                 200                 205

Pro Glu Ala Asp Lys Gly Thr Val Leu Ala Leu Thr Glu Asn Asn Phe
    210                 215                 220

Asp Asp Thr Ile Ala Glu Gly Ile Thr Phe Ile Lys Phe Tyr Ala Pro
225                 230                 235                 240

Trp Cys Gly His Cys Lys Thr Leu Ala Pro Thr Trp Glu Glu Leu Ser
                245                 250                 255

Lys Lys Glu Phe Pro Gly Leu Ala Gly Val Lys Ile Ala Glu Val Asp
            260                 265                 270

Cys Thr Ala Glu Arg Asn Ile Cys Ser Lys Tyr Ser Val Arg Gly Tyr
        275                 280                 285

Pro Thr Leu Leu Leu Phe Arg Gly Gly Lys Lys Val Ser Glu His Ser
    290                 295                 300

Gly Gly Arg Asp Leu Asp Ser Leu His Arg Phe Val Leu Ser Gln Ala
305                 310                 315                 320

Lys Asp Glu Leu


<210> 201
<211> 90
<212> PRT
<213> Homo sapiens

<400> 201
Met Ala Leu Phe Ser Cys Leu Leu Leu Leu Lys Gln Ser Asp Gly Ala
1               5                   10                  15
```

```
Ser Pro Val Leu Arg Ala Leu Ala Ala Ser Cys Leu Ala Ser Pro Ala
        20                  25                  30

Gly Cys Cys Gly Thr Arg Lys Ala Leu Asn Gly Asn Val Gly Glu Lys
        35                  40                  45

Val Gly Phe Thr Phe Met Ser Phe Gln Gly Cys Asp Pro Ser Ser Pro
    50                  55                  60

Gly Cys Leu Cys Cys Ser Leu Leu Pro Ser Asn Ser Gln Leu Val Phe
65                  70                  75                  80

Ile Ser Phe Leu Val Leu Ser Gly Leu Ala
                85                  90


<210> 202
<211> 243
<212> PRT
<213> Homo sapiens

<400> 202
Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
 1               5                  10                  15

Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
            20                  25                  30

Ile Pro Lys Gly Lys Gln Lys Ala Gln Leu Arg Gln Arg Glu Val Val
        35                  40                  45

Asp Leu Tyr Asn Gly Met Cys Leu Gln Gly Pro Ala Gly Val Pro Gly
    50                  55                  60

Arg Asp Gly Ser Pro Gly Ala Asn Gly Ile Pro Gly Thr Pro Gly Ile
65                  70                  75                  80

Pro Gly Arg Asp Gly Phe Lys Gly Glu Lys Gly Glu Cys Leu Arg Glu
                85                  90                  95

Ser Phe Glu Glu Ser Trp Thr Pro Asn Tyr Lys Gln Cys Ser Trp Ser
            100                 105                 110

Ser Leu Asn Tyr Gly Ile Asp Leu Gly Lys Ile Ala Glu Cys Thr Phe
        115                 120                 125

Thr Lys Met Arg Ser Asn Ser Ala Leu Arg Val Leu Phe Ser Gly Ser
    130                 135                 140

Leu Arg Leu Lys Cys Arg Asn Ala Cys Cys Glu Arg Trp Tyr Phe Thr
145                 150                 155                 160

Phe Asn Gly Ala Glu Cys Ser Gly Pro Leu Pro Ile Glu Ala Ile Ile
                165                 170                 175

Tyr Leu Asp Gln Gly Ser Pro Glu Met Asn Ser Thr Ile Asn Ile His
            180                 185                 190
```

Arg Thr Ser Ser Val Glu Gly Leu Cys Glu Gly Ile Gly Ala Gly Leu
195 200 205

Val Asp Val Ala Ile Trp Val Gly Thr Cys Ser Asp Tyr Pro Lys Gly
210 215 220

Asp Ala Ser Thr Gly Trp Asn Ser Val Ser Arg Ile Ile Ile Glu Glu
225 230 235 240

Leu Pro Lys

<210> 203
<211> 75
<212> PRT
<213> Homo sapiens

<400> 203
Met Ala Gly Gln Glu Asp Pro Val Gln Arg Glu Ile His Gln Asp Trp
1 5 10 15

Ala Asn Arg Glu Tyr Ile Glu Ile Ile Thr Ser Ser Ile Lys Lys Ile
20 25 30

Ala Asp Phe Leu Asn Ser Phe Asp Met Ser Cys Arg Ser Arg Leu Ala
35 40 45

Thr Leu Asn Glu Lys Leu Thr Ala Leu Glu Arg Arg Ile Glu Tyr Ile
50 55 60

Glu Ala Arg Val Thr Lys Gly Glu Thr Leu Thr
65 70 75

<210> 204
<211> 248
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (185)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 204
Met Thr Ser Gln Pro Val Pro Asn Glu Thr Ile Ile Val Leu Pro Ser
1 5 10 15

Asn Val Ile Asn Phe Ser Gln Ala Glu Lys Pro Glu Pro Thr Asn Gln
20 25 30

Gly Gln Asp Ser Leu Lys Lys His Leu His Ala Glu Ile Lys Val Ile
35 40 45

Gly Thr Ile Gln Ile Leu Cys Gly Met Met Val Leu Ser Leu Gly Ile
50 55 60

Ile Leu Ala Ser Ala Ser Phe Ser Pro Asn Phe Thr Gln Val Thr Ser

```
65                  70                  75                  80

Thr Leu Leu Asn Ser Ala Tyr Pro Phe Ile Gly Pro Phe Phe Phe Ile
                85                  90                  95

Ile Ser Gly Ser Leu Ser Ile Ala Thr Glu Lys Arg Leu Thr Lys Leu
            100                 105                 110

Leu Val His Ser Ser Leu Val Gly Ser Ile Leu Ser Ala Leu Ser Ala
        115                 120                 125

Leu Val Gly Phe Ile Ile Leu Ser Val Lys Gln Ala Thr Leu Asn Pro
    130                 135                 140

Ala Ser Leu Gln Cys Glu Leu Asp Lys Asn Asn Ile Pro Thr Arg Ser
145                 150                 155                 160

Tyr Val Ser Tyr Phe Tyr His Asp Ser Leu Tyr Thr Thr Asp Cys Tyr
                165                 170                 175

Thr Ala Lys Ala Ser Leu Ala Gly Xaa Leu Ser Leu Met Leu Ile Cys
            180                 185                 190

Thr Leu Leu Glu Phe Cys Leu Ala Val Leu Thr Ala Val Leu Arg Trp
        195                 200                 205

Lys Gln Ala Tyr Ser Asp Phe Pro Gly Ser Val Leu Phe Leu Pro His
    210                 215                 220

Ser Tyr Ile Gly Asn Ser Gly Met Ser Ser Lys Met Thr His Asp Cys
225                 230                 235                 240

Gly Tyr Glu Glu Leu Leu Thr Ser
                245
```

<210> 205
<211> 168
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (83)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 205

```
Met Pro Leu Leu Arg Gly Leu Leu Trp Leu Gln Val Leu Cys Ala Gly
1               5                   10                  15

Pro Leu His Thr Glu Ala Val Val Leu Leu Val Pro Ser Asp Asp Gly
            20                  25                  30

Arg Ala Phe Leu Leu Arg Ser Arg Leu Leu His Pro Glu Ala His Val
        35                  40                  45

Pro Pro Ala Ala Asp Arg Gly Ala Ser Leu Gln Cys Val Leu His Gln
    50                  55                  60
```

Ala Ala Pro Lys Ser Arg Pro Arg Ser Pro Ala Ala Gly Ala Ala Leu
65 70 75 80

Leu His Xaa Pro Arg Arg Thr Gly Asp Glu Pro Cys Arg Glu Phe His
85 90 95

Gly Asn Gly Phe Pro Gly Pro Thr Gln Leu Thr Pro Gly Glu Cys Gly
100 105 110

Leu Pro Ala Pro Ser Ser Leu Leu Gln His Ala Ser Ala Pro Val Arg
115 120 125

Thr Gly Ser Glu Gly Gln Val Val Gly Cys Pro Arg Ala Arg Gly Glu
130 135 140

Thr Gly Glu Gly Leu Ser Leu Ala Phe Leu Ser Ser Leu Met Phe Thr
145 150 155 160

Ser Arg Asn Gly Leu Val Gly Cys
165

<210> 206
<211> 218
<212> PRT
<213> Homo sapiens

<400> 206
Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val
1 5 10 15

Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val
20 25 30

Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Thr Trp Lys
35 40 45

Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly His Met Gln Cys
50 55 60

Lys Val Tyr Asp Ser Val Leu Ala Leu Ser Thr Glu Val Gln Ala Ala
65 70 75 80

Arg Ala Leu Thr Val Ser Ala Val Leu Leu Ala Phe Val Ala Leu Phe
85 90 95

Val Thr Leu Ala Gly Ala Gln Cys Thr Thr Cys Val Ala Pro Gly Pro
100 105 110

Ala Lys Ala Arg Val Ala Leu Thr Gly Gly Val Leu Tyr Leu Phe Cys
115 120 125

Gly Leu Leu Ala Leu Val Pro Leu Cys Trp Phe Ala Asn Ile Val Val
130 135 140

Arg Glu Phe Tyr Asp Pro Ser Val Pro Val Ser Gln Lys Tyr Glu Leu
145 150 155 160

Gly Ala Ala Leu Tyr Ile Gly Trp Ala Ala Thr Ala Leu Leu Met Val

```
                165                 170                 175

Gly Gly Cys Leu Leu Cys Cys Gly Ala Trp Val Cys Thr Gly Arg Pro
            180                 185                 190

Asp Leu Ser Phe Pro Val Lys Tyr Ser Ala Pro Arg Arg Pro Thr Ala
        195                 200                 205

Thr Gly Asp Tyr Asp Lys Lys Asn Tyr Val
    210                 215


<210> 207
<211> 73
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (73)
<223> Xaa equals stop translation

<400> 207
Met Thr Ser Tyr Ile Leu Ile Ser Phe Val Leu Leu Ile Gly Val Gly
  1               5                  10                  15

Cys Ile Glu Lys Asp Gln Ser Cys Pro Val Phe Gly Gly Arg Lys Arg
             20                  25                  30

Leu His Leu Leu Phe Val Gly Gly Gln Leu Arg Gln Val Arg Met Leu
         35                  40                  45

Arg Gly Glu Leu Ser Cys Ala Cys Tyr Arg Pro His Val Gln Ala Leu
     50                  55                  60

Gln Leu Gly Gly Cys Thr Cys Phe Xaa
 65                  70


<210> 208
<211> 348
<212> PRT
<213> Homo sapiens

<400> 208
Met Leu Cys Pro Trp Arg Thr Ala Asn Leu Gly Leu Leu Leu Ile Leu
  1               5                  10                  15

Thr Ile Phe Leu Val Ala Glu Ala Glu Gly Ala Ala Gln Pro Asn Asn
             20                  25                  30

Ser Leu Met Leu Gln Thr Ser Lys Glu Asn His Ala Leu Ala Ser Ser
         35                  40                  45

Ser Leu Cys Met Asp Glu Lys Gln Ile Thr Gln Asn Tyr Ser Lys Val
     50                  55                  60

Leu Ala Glu Val Asn Thr Ser Trp Pro Val Lys Met Ala Thr Asn Ala
 65                  70                  75                  80
```

Val Leu Cys Cys Pro Pro Ile Ala Leu Arg Asn Leu Ile Ile Ile Thr
85 90 95

Trp Glu Ile Ile Leu Arg Gly Gln Pro Ser Cys Thr Lys Ala Tyr Lys
100 105 110

Lys Glu Thr Asn Glu Thr Lys Glu Thr Asn Cys Thr Asp Glu Arg Ile
115 120 125

Thr Trp Val Ser Arg Pro Asp Gln Asn Ser Asp Leu Gln Ile Arg Thr
130 135 140

Val Ala Ile Thr His Asp Gly Tyr Tyr Arg Cys Ile Met Val Thr Pro
145 150 155 160

Asp Gly Asn Phe His Arg Gly Tyr His Leu Gln Val Leu Val Thr Pro
165 170 175

Glu Val Thr Leu Phe Gln Asn Arg Asn Arg Thr Ala Val Cys Lys Ala
180 185 190

Val Ala Gly Lys Pro Ala Ala His Ile Ser Trp Ile Pro Glu Gly Asp
195 200 205

Cys Ala Thr Lys Gln Glu Tyr Trp Ser Asn Gly Thr Val Thr Val Lys
210 215 220

Ser Thr Cys His Trp Glu Val His Asn Val Ser Thr Val Asn Cys His
225 230 235 240

Val Ser His Leu Thr Gly Asn Lys Ser Leu Tyr Ile Glu Leu Leu Pro
245 250 255

Val Pro Gly Ala Lys Lys Ser Ala Lys Leu Tyr Ile Pro Tyr Ile Ile
260 265 270

Leu Thr Ile Ile Ile Leu Thr Ile Val Gly Phe Ile Trp Leu Leu Lys
275 280 285

Val Asn Gly Cys Arg Lys Tyr Lys Leu Asn Lys Thr Glu Ser Thr Pro
290 295 300

Val Val Glu Glu Asp Glu Met Gln Pro Tyr Ala Ser Tyr Thr Glu Lys
305 310 315 320

Asn Asn Pro Leu Tyr Asp Thr Thr Asn Lys Val Lys Ala Ser Glu Ala
325 330 335

Leu Gln Ser Glu Val Asp Thr Asp Leu His Thr Leu
340 345

<210> 209
<211> 73
<212> PRT
<213> Homo sapiens

<220>

<221> SITE
<222> (73)
<223> Xaa equals stop translation

<400> 209
Met Ala Arg Gly Cys Val Cys Ser Leu Cys Ala Ser Val Cys Ile Phe
1 5 10 15

Leu Ser Ser Leu Phe Pro Leu Leu Pro Ser Val His Ser Val Asn Ile
20 25 30

Ile Ser Cys Leu Leu Leu Ser Lys Cys Phe Glu Gly Leu Glu Leu Met
35 40 45

Cys Glu His Leu Tyr Gln Leu Ser Gln Leu His Val Leu His His Ile
50 55 60

Phe Ser Tyr Leu Leu Cys Thr Pro Xaa
65 70

<210> 210
<211> 608
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (265)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (597)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 210
Met Val Gly Thr Lys Leu Arg Gln Thr Lys Asp Ala Leu Phe Thr Ile
1 5 10 15

Leu His Asp Leu Arg Pro Gln Asp Arg Phe Ser Ile Ile Gly Phe Ser
20 25 30

Asn Arg Ile Lys Val Trp Lys Asp His Leu Ile Ser Val Thr Pro Asp
35 40 45

Ser Ile Arg Asp Gly Lys Val Tyr Ile His His Met Ser Pro Thr Gly
50 55 60

Gly Thr Asp Ile Asn Gly Val Leu Gln Arg Ala Ile Arg Leu Leu Asn
65 70 75 80

Lys Tyr Val Ala His Ser Gly Ile Gly Asp Arg Ser Val Ser Leu Ile
85 90 95

Val Phe Leu Thr Asp Gly Lys Pro Thr Val Gly Glu Thr His Thr Leu
100 105 110

Lys Ile Leu Asn Asn Thr Arg Glu Ala Ala Arg Gly Gln Val Cys Ile

115 120 125

Phe Thr Ile Gly Ile Gly Asn Asp Val Asp Phe Arg Leu Leu Glu Lys
130 135 140

Leu Ser Leu Glu Asn Cys Gly Leu Thr Arg Arg Val His Glu Glu Glu
145 150 155 160

Asp Ala Gly Ser Gln Leu Ile Gly Phe Tyr Asp Glu Ile Arg Thr Pro
165 170 175

Leu Leu Ser Asp Ile Arg Ile Asp Tyr Pro Pro Ser Ser Val Val Gln
180 185 190

Ala Thr Lys Thr Leu Phe Pro Asn Tyr Phe Asn Gly Ser Glu Ile Ile
195 200 205

Ile Ala Gly Lys Leu Val Asp Arg Lys Leu Asp His Leu His Val Glu
210 215 220

Val Thr Ala Ser Asn Ser Lys Lys Phe Ile Ile Leu Lys Thr Asp Val
225 230 235 240

Pro Val Arg Pro Gln Lys Ala Gly Lys Asp Val Thr Gly Ser Pro Arg
245 250 255

Pro Gly Gly Asp Gly Glu Gly Asp Xaa Asn His Ile Glu Arg Leu Trp
260 265 270

Ser Tyr Leu Thr Thr Lys Glu Leu Leu Ser Ser Trp Leu Gln Ser Asp
275 280 285

Asp Glu Pro Glu Lys Glu Arg Leu Arg Gln Arg Ala Gln Ala Leu Ala
290 295 300

Val Ser Tyr Arg Phe Leu Thr Pro Phe Thr Ser Met Lys Leu Arg Gly
305 310 315 320

Pro Val Pro Arg Met Asp Gly Leu Glu Glu Ala His Gly Met Ser Ala
325 330 335

Ala Met Gly Pro Glu Pro Val Val Gln Ser Val Arg Gly Ala Gly Thr
340 345 350

Gln Pro Gly Pro Leu Leu Lys Lys Pro Tyr Gln Pro Arg Ile Lys Ile
355 360 365

Ser Lys Thr Ser Val Asp Gly Asp Pro His Phe Val Val Asp Phe Pro
370 375 380

Leu Ser Arg Leu Thr Val Cys Phe Asn Ile Asp Gly Gln Pro Gly Asp
385 390 395 400

Ile Leu Arg Leu Val Ser Asp His Arg Asp Ser Gly Val Thr Val Asn
405 410 415

Gly Glu Leu Ile Gly Ala Pro Ala Pro Pro Asn Gly His Lys Lys Gln
420 425 430

Arg Thr Tyr Leu Arg Thr Ile Thr Ile Leu Ile Asn Lys Pro Glu Arg
435 440 445

Ser Tyr Leu Glu Ile Thr Pro Ser Arg Val Ile Leu Asp Gly Gly Asp
450 455 460

Arg Leu Val Leu Pro Cys Asn Gln Ser Val Val Val Gly Ser Trp Gly
465 470 475 480

Leu Glu Val Ser Val Ser Ala Asn Ala Asn Val Thr Val Thr Ile Gln
485 490 495

Gly Ser Ile Ala Phe Val Ile Leu Ile His Leu Tyr Lys Lys Pro Ala
500 505 510

Pro Phe Gln Arg His His Leu Gly Phe Tyr Ile Ala Asn Ser Glu Gly
515 520 525

Leu Ser Ser Asn Cys His Gly Leu Leu Gly Gln Phe Leu Asn Gln Asp
530 535 540

Ala Arg Leu Thr Glu Asp Pro Ala Gly Pro Ser Gln Asn Leu Thr His
545 550 555 560

Pro Leu Leu Leu Gln Val Gly Glu Gly Pro Glu Ala Val Leu Thr Val
565 570 575

Lys Gly His Gln Val Pro Val Val Trp Lys Gln Arg Lys Ile Tyr Asn
580 585 590

Gly Glu Glu Gln Xaa Asp Cys Trp Phe Ala Arg Asn Met Pro Pro Asn
595 600 605

<210> 211
<211> 252
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (252)
<223> Xaa equals stop translation.

<400> 211
Met Ala Pro Ala Ser Arg Leu Leu Ala Leu Trp Ala Leu Ala Ala Val
1 5 10 15

Ala Leu Pro Gly Ser Gly Ala Glu Gly Asp Gly Gly Trp Arg Pro Gly
20 25 30

Gly Pro Gly Ala Val Ala Glu Glu Glu Arg Cys Thr Val Glu Arg Arg
35 40 45

Ala Asp Leu Thr Tyr Ala Glu Phe Val Gln Gln Tyr Ala Phe Val Arg
50 55 60

Pro Val Ile Leu Gln Gly Leu Thr Asp Asn Ser Arg Phe Arg Ala Leu
65 70 75 80

Cys Ser Arg Asp Arg Leu Leu Ala Ser Phe Gly Asp Arg Val Val Arg
85 90 95

Leu Ser Thr Ala Asn Thr Tyr Ser Tyr His Lys Val Asp Leu Pro Phe
100 105 110

Gln Glu Tyr Val Glu Gln Leu Leu His Pro Gln Asp Pro Thr Ser Leu
115 120 125

Gly Asn Asp Thr Leu Tyr Phe Phe Gly Asp Asn Asn Phe Thr Glu Trp
130 135 140

Ala Ser Leu Phe Arg His Tyr Ser Pro Pro Pro Phe Gly Leu Leu Gly
145 150 155 160

Thr Ala Pro Ala Tyr Ser Phe Gly Ile Ala Gly Ala Gly Ser Gly Val
165 170 175

Pro Phe His Trp His Gly Pro Gly Tyr Ser Glu Val Ile Tyr Gly Arg
180 185 190

Lys Arg Trp Phe Leu Tyr Pro Pro Glu Lys Thr Pro Glu Phe His Pro
195 200 205

Asn Lys Thr Thr Leu Ala Trp Leu Arg Asp Thr Tyr Pro Ala Cys Thr
210 215 220

Val Cys Thr Ala Leu Glu Cys Thr Ile Arg Ala Gly Glu Val Leu Thr
225 230 235 240

Ser Arg Pro Leu Val Ala Cys Tyr Ala Gln Pro Xaa
245 250

<210> 212
<211> 226
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (226)
<223> Xaa equals stop translation

<400> 212
Met Lys Glu Ile Pro Ala Leu Leu His Leu Pro Val Leu Ile Ile Met
1 5 10 15

Ala Leu Ala Ile Leu Ser Phe Cys Tyr Gly Ala Gly Lys Ser Val His
20 25 30

Val Leu Arg His Ile Gly Gly Pro Glu Arg Glu Pro Pro Gln Ala Leu
35 40 45

Arg Pro Arg Asp Arg Arg Arg Gln Glu Glu Ile Asp Tyr Arg Pro Asp

50 55 60

Gly Gly Ala Gly Asp Ala Asp Phe His Tyr Arg Gly Gln Met Gly Pro
65 70 75 80

Thr Glu Gln Gly Pro Tyr Ala Lys Thr Tyr Glu Gly Arg Arg Glu Ile
85 90 95

Leu Arg Glu Arg Asp Val Asp Leu Arg Phe Gln Thr Gly Asn Lys Ser
100 105 110

Pro Glu Val Leu Arg Ala Phe Asp Val Pro Asp Ala Glu Ala Arg Glu
115 120 125

His Pro Thr Val Val Pro Ser His Lys Ser Pro Val Leu Asp Thr Lys
130 135 140

Pro Lys Glu Thr Gly Gly Ile Leu Gly Glu Gly Thr Pro Lys Glu Ser
145 150 155 160

Ser Thr Glu Ser Ser Gln Ser Ala Lys Pro Val Ser Gly Gln Asp Thr
165 170 175

Ser Gly Asn Thr Glu Gly Ser Pro Ala Ala Glu Lys Ala Gln Leu Lys
180 185 190

Ser Glu Ala Ala Gly Ser Pro Asp Gln Gly Ser Thr Tyr Ser Pro Ala
195 200 205

Arg Gly Val Ala Gly Pro Arg Gly Gln Asp Pro Val Ser Ser Pro Cys
210 215 220

Gly Xaa
225

<210> 213
<211> 51
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (51)
<223> Xaa equals stop translation

<400> 213
Met Met Gly Leu Leu Glu Thr Gly Asn Val Leu Phe Trp Val Trp Val
1 5 10 15

Val Val Thr Cys Val Tyr Ser Leu Tyr Ala Asn Ser Leu Asn Cys Thr
20 25 30

Asp Met Asp Cys Ala Pro Phe Tyr Met Cys Val Met Leu Gln Gln Lys
35 40 45

Cys Gln Xaa
50

<210> 214
<211> 172
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (172)
<223> Xaa equals stop translation

<400> 214
```
Met Trp Leu Trp Ala Val Ser Pro Val Arg Pro Arg Thr Cys Leu Pro
 1               5                  10                  15

Pro Cys Pro Arg Leu Trp Leu Trp Ile Ser Met Thr Leu Val Pro Ser
            20                  25                  30

Ser Ser Ala Trp Lys Ser His Gly Ala Pro Ser Thr Arg Met Thr Ser
        35                  40                  45

Pro Gln Leu Leu Leu Leu Ser Thr Arg Pro Pro Gln Ser Pro Ser Ala
    50                  55                  60

Ser Pro Pro Ile Ala Arg Ala His Arg Thr His Pro His Phe Gly Asn
65                  70                  75                  80

Arg Leu Ser Ile Thr Cys Cys Asp Gly Arg Arg Ser Trp Arg Met Gly
                85                  90                  95

Gln His Gly Pro Cys His Leu Asn Leu Gln Thr Thr His Pro Ala His
            100                 105                 110

Ser Ser Gln Ala Leu Pro Ala Thr His Gln Pro Leu Gly Pro Trp Cys
        115                 120                 125

Ser Ser Pro Ser Pro Phe Pro Ser Lys Leu Pro Ser Ala Gly Leu Arg
    130                 135                 140

Pro Pro Ala Leu Gly Pro Trp Met Arg Arg Gly Pro Trp Pro Gln Ser
145                 150                 155                 160

Trp Gln Met Gly Met His Pro Thr Val Gly Leu Xaa
                165                 170
```

<210> 215
<211> 48
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (48)
<223> Xaa equals stop translation

<400> 215
```
Met Trp Leu Leu Ile Ile Phe Cys Lys Ser Ala Ser Ala Ser Val Leu
 1               5                  10                  15
```

```
Cys Trp Ile Lys Lys Phe His Pro Val Phe Gln Glu Ser Leu Leu Tyr
            20                  25                  30

Leu Val Gln Glu Gly Ser Leu Cys Tyr Val Gln Gln Lys Val Pro Xaa
        35                  40                  45



<210> 216
<211> 139
<212> PRT
<213> Homo sapiens

<400> 216
Met Glu Ala Val Val Phe Val Phe Ser Leu Leu Asp Cys Cys Ala Leu
  1               5                  10                  15

Ile Phe Leu Ser Val Tyr Phe Ile Ile Thr Leu Ser Asp Leu Glu Cys
            20                  25                  30

Asp Tyr Ile Asn Ala Arg Ser Cys Cys Ser Lys Leu Asn Lys Trp Val
        35                  40                  45

Ile Pro Glu Leu Ile Gly His Thr Ile Val Thr Val Leu Leu Leu Met
    50                  55                  60

Ser Leu His Trp Phe Ile Phe Leu Leu Asn Leu Pro Val Ala Thr Trp
 65                  70                  75                  80

Asn Ile Tyr Arg Tyr Ile Met Val Pro Ser Gly Asn Met Gly Val Phe
                 85                  90                  95

Asp Pro Thr Glu Ile His Asn Arg Gly Gln Leu Lys Ser His Met Lys
            100                 105                 110

Glu Ala Met Ile Lys Leu Gly Phe His Leu Leu Cys Phe Phe Met Tyr
        115                 120                 125

Leu Tyr Ser Met Ile Leu Ala Leu Ile Asn Asp
    130                 135


<210> 217
<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 217
Met Ser Gly Ser Ser Leu Pro Ser Ala Leu Ala Leu Ser Leu Leu Leu
  1               5                  10                  15
```

Val Ser Gly Ser Leu Leu Pro Gly Pro Gly Ala Ala Gln Asn Val Arg
20 25 30

Val Gln Ser Gly Gln Asp Gln Lys Xaa
35 40

<210> 218
<211> 52
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (52)
<223> Xaa equals stop translation

<400> 218
Met Pro Ser His Ile Arg Ala His Leu Phe Leu Leu Leu Phe Phe Leu
1 5 10 15

Phe Ile Tyr Gln Gly Ile Ser Ser Ile Ser Gln Ala Ser Gly Leu Thr
20 25 30

Leu Lys Thr Gln Asn Glu Lys Asp Ile Gln Val Ser Ile Leu Lys Glu
35 40 45

Phe Val Val Xaa
50

<210> 219
<211> 49
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (49)
<223> Xaa equals stop translation

<400> 219
Met Cys Ile Tyr Gln Ser Glu Gln Met Leu Ala Leu Leu Leu Val Leu
1 5 10 15

Val Phe Cys Ile Ser Leu Leu Val Leu Val Cys Trp Gly Ser His Asn
20 25 30

Lys Val Pro Gln Lys Phe Ile Phe Ser Gln Phe Trp Gly Leu Glu Asp
35 40 45

Xaa

<210> 220
<211> 42
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals stop translation

<400> 220
Met Ala Val Pro Leu Phe Leu Tyr Ile Phe Thr Leu Leu Pro Leu Leu
1   5   10   15

Pro Phe Leu Leu Ser Leu Cys Phe Ser Pro Leu Thr Val Lys Arg Ser
            20   25   30

Ser Ser Ser Glu Ser Lys Ser Ser Leu Xaa
        35   40

<210> 221
<211> 41
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (41)
<223> Xaa equals stop translation

<400> 221
Met Gly Met Leu Leu Ala Phe Trp Leu Pro Gly Ala Ser Trp Gln Glu
1   5   10   15

Ala Gly Pro Arg Ala Ser Thr Gln Arg Met Arg Thr Gln Thr Gln Met
            20   25   30

Ser Thr Arg Lys Pro Lys Pro Ala Xaa
        35   40

<210> 222
<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals stop translation

<400> 222
Met Glu Pro Ala Met Val Leu Lys Phe Leu Ser Ser Leu Pro Glu Asn
1   5   10   15

Leu Phe Leu Pro Ser Leu Leu Phe Phe Ala Trp Leu Cys Trp Asn Met
            20   25   30

Val Cys Gly Ser Pro Val Ser Cys Pro Tyr Xaa
        35   40

<210> 223
<211> 204
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (204)
<223> Xaa equals stop translation

<400> 223
Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
1 5 10 15

Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
20 25 30

Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
35 40 45

Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
50 55 60

Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
65 70 75 80

Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
85 90 95

Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
100 105 110

Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr
115 120 125

Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
130 135 140

Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
145 150 155 160

Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
165 170 175

Pro Gly Leu Ser Val Arg Leu Leu Arg Asp Pro Arg Cys Pro Asp Pro
180 185 190

Gly Cys Thr Ala Ala Pro Cys His Ala Ala His Xaa
195 200

<210> 224
<211> 43
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)

<223> Xaa equals stop translation

<400> 224
Met Arg Val Arg Ile Gly Leu Thr Leu Leu Leu Cys Ala Val Leu Leu
1   5   10   15

Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser
            20   25   30

Leu Gly Phe Gln Asp Tyr Phe Asp Ile Arg Xaa
        35   40

<210> 225
<211> 156
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (156)
<223> Xaa equals stop translation

<400> 225
Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly
1   5   10   15

Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly
            20   25   30

Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys
        35   40   45

Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Ala Leu Ala His
    50   55   60

Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp
65   70   75   80

Leu Phe Gly Leu Glu Thr Met Pro Gln Glu Arg Glu Val His His Pro
                85   90   95

His Arg Gly Asp Arg Arg Arg Gly Leu Pro Ser Cys Gly Ala Asp Pro
            100   105   110

Val Thr Met Cys Pro Leu Pro Ala Gly Ala Arg Pro Leu Ile Ile His
        115   120   125

Ser Ser Ile Leu Glu Pro Val Ser Ala Ser Gln Thr Arg Arg Glu Pro
    130   135   140

Ser Ser Ser Asn His Lys Gly Gly Gly Gly Arg Xaa
145   150   155

<210> 226
<211> 74
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (74)
<223> Xaa equals stop translation

<400> 226

```
Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly
 1               5                  10                  15

Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His
            20                  25                  30

Ile Cys Ser Gln Arg Xaa Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa
        35                  40                  45

Leu Gln Thr Thr Trp Xaa Xaa Pro Asp Lys Pro Ile Pro Arg Leu Ser
    50                  55                  60

Pro Pro Leu Xaa Ser Asp Pro Lys Arg Xaa
65                  70
```

<210> 227
<211> 167
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (167)
<223> Xaa equals stop translation

<400> 227

Met Gly Ser Arg Phe Leu Leu Val Leu Leu Ser Gly Leu Thr Val Leu
1 5 10 15

Leu Ala Leu Pro Gly Ser Glu Ala Lys Asn Ser Gly Ala Ser Cys Pro
20 25 30

Pro Cys Pro Lys Tyr Ala Ser Cys His Asn Ser Thr His Cys Thr Cys
35 40 45

Glu Asp Gly Phe Arg Ala Arg Ser Gly Arg Thr Tyr Phe His Asp Ser
50 55 60

Ser Glu Lys Cys Glu Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys
65 70 75 80

Cys Lys Tyr Lys Ala Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys
85 90 95

Ser Cys Leu Val Lys Tyr Thr Leu Phe Asn Phe Leu Ala Gly Ile Ile
100 105 110

Asp Tyr Asp His Pro Asp Cys Tyr Glu Asn Asn Ser Gln Gly Thr Thr
115 120 125

Gln Ser Asn Val Asp Ile Trp Val Ser Gly Val Lys Pro Gly Phe Gly
130 135 140

Lys Gln Leu Val Arg Ile Thr Met Pro Phe Ser Tyr Pro Asn Ile Asn
145 150 155 160

Met Ser Ser Cys Asp Phe Xaa
165

<210> 228
<211> 71
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (71)
<223> Xaa equals stop translation

<400> 228
Met Lys Pro Lys His Leu Glu Trp Cys Leu Ala His Ser Trp Cys Val
1 5 10 15

Ile Trp Leu Ser Phe Val Ser Pro Pro Thr Ser His Leu Glu Cys Asp
20 25 30

Gly Phe Pro Gly Ser Leu Leu Pro Pro Cys Glu Glu Gly Arg Cys Phe
35 40 45

Pro Phe Thr Phe His His His Asp Cys His Gly Cys Ser Pro Leu Gln
50 55 60

Ser Ser Pro Gly Gln His Xaa
65 70

<210> 229
<211> 273
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (273)
<223> Xaa equals stop translation

<400> 229
Met Cys Cys Trp Pro Leu Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr
1 5 10 15

Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp
20 25 30

Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile
35 40 45

Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe
50 55 60

Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val
65 70 75 80

Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg
85 90 95

Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met
100 105 110

Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr
115 120 125

Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile
130 135 140

Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His
145 150 155 160

Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys
165 170 175

Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln
180 185 190

Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe
195 200 205

Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro
210 215 220

Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr
225 230 235 240

Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Pro Gly Ile Arg Ala Arg

245 250 255

Ile Ala Ile Thr Pro Thr Cys Pro Met His Ser Ser Pro Val Lys Leu
260 265 270

Xaa

<210> 230
<211> 82
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (82)
<223> Xaa equals stop translation

<400> 230
Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu
1 5 10 15

Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val
20 25 30

Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His
35 40 45

Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg
50 55 60

Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met Asn Arg
65 70 75 80

Asn Xaa

<210> 231
<211> 71
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 231
Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
1 5 10 15

Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
20 25 30

Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
35 40 45

Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Asn Ile Trp Arg
50 55 60

Asp Leu Ala Cys Met Leu Ser
65 70

<210> 232
<211> 225
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 232
His Glu Arg Ala Xaa Gly Pro Ser Arg Gly His Gly Glu Leu Leu Ser
1 5 10 15

Cys Val Leu Gly Pro Arg Leu Tyr Lys Ile Tyr Arg Glu Arg Asp Ser
20 25 30

Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val Thr Ala
35 40 45

Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala Leu Glu
50 55 60

Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp Ser Ile
65 70 75 80

Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg Lys Gly
85 90 95

Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala Gly Thr
100 105 110

Leu Leu Leu Leu Leu Ala Gly Val Ala Cys Ser Glu Ala Leu Ala Ala
115 120 125

Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His
130 135 140

Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr
145 150 155 160

Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala
165 170 175

Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys
180 185 190

Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr
195 200 205

Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr
210 215 220

Pro
225

<210> 233
<211> 314
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (147)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (211)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 233
Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg
1 5 10 15

Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu
20 25 30

Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu
35 40 45

Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu
50 55 60

Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp
65 70 75 80

Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln
85 90 95

Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg
100 105 110

Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly
115 120 125

His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys
130 135 140

Gly Ala Xaa Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro
145 150 155 160

Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg
165 170 175

Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu
180 185 190

Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala
195 200 205

Leu Arg Xaa Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu
210 215 220

Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro
225 230 235 240

Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp
245 250 255

Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys
260 265 270

Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly Thr Lys Gly His Ser Ala
275 280 285

Pro Ser Arg Thr Ser His Arg Thr Gly Arg Ile Arg Ile Arg Arg Thr
290 295 300

Gly Pro Ala Gln Trp Ser Gly Thr Cys Gly
305 310

<210> 234
<211> 93
<212> PRT
<213> Homo sapiens

<400> 234
Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
1 5 10 15

Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
20 25 30

Ile Pro Lys Gly Lys Gln Lys Ala His Ser Gly Arg Gly Arg Trp Trp
35 40 45

Thr Cys Ile Met Glu Cys Ala Tyr Lys Gly Gln Gln Glu Cys Leu Val
50 55 60

Glu Thr Gly Ala Leu Gly Pro Met Ala Phe Arg Val His Leu Gly Ser
65 70 75 80

Gln Val Gly Met Asp Ser Lys Glu Lys Arg Gly Asn Val
85 90

<210> 235
<211> 73
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (73)
<223> Xaa equals stop translation

<400> 235

Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val
1 5 10 15

Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val
20 25 30

Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Thr Trp Lys
35 40 45

Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Thr Cys Ser Ala
50 55 60

Lys Cys Thr Thr Arg Cys Trp Leu Xaa
65 70

<210> 236
<211> 349
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (283)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (293)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (325)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (326)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (349)
<223> Xaa equals stop translation

<400> 236
Met Leu Cys Pro Trp Arg Thr Ala Asn Leu Gly Leu Leu Leu Ile Leu
1 5 10 15

Thr Ile Phe Leu Val Ala Glu Ala Glu Gly Ala Ala Gln Pro Asn Asn
20 25 30

Ser Leu Met Leu Gln Thr Ser Lys Glu Asn His Ala Leu Ala Ser Ser
35 40 45

Ser Leu Cys Met Asp Glu Lys Gln Ile Thr Gln Asn Tyr Ser Lys Val
50 55 60

```
Leu Ala Glu Val Asn Thr Ser Trp Pro Val Lys Met Ala Thr Asn Ala
65                  70                  75                  80

Val Leu Cys Cys Pro Pro Ile Ala Leu Arg Asn Leu Ile Ile Ile Thr
                85                  90                  95

Trp Glu Ile Ile Leu Arg Gly Gln Pro Ser Cys Thr Lys Ala Tyr Lys
            100                 105                 110

Lys Glu Thr Asn Glu Thr Lys Glu Thr Asn Cys Thr Asp Glu Arg Ile
        115                 120                 125

Thr Trp Val Ser Arg Pro Asp Gln Asn Ser Asp Leu Gln Ile Arg Thr
    130                 135                 140

Val Ala Ile Thr His Asp Gly Tyr Tyr Arg Cys Ile Met Val Thr Pro
145                 150                 155                 160

Asp Gly Asn Phe His Arg Gly Tyr His Leu Gln Val Leu Val Thr Pro
                165                 170                 175

Glu Val Thr Leu Phe Gln Asn Arg Asn Arg Thr Ala Val Cys Lys Ala
            180                 185                 190

Val Ala Gly Lys Pro Ala Ala His Ile Ser Trp Ile Pro Glu Gly Asp
        195                 200                 205

Cys Ala Thr Lys Gln Glu Tyr Trp Ser Asn Gly Thr Val Thr Val Lys
    210                 215                 220

Ser Thr Cys His Trp Glu Val His Asn Val Ser Thr Val Asn Cys His
225                 230                 235                 240

Val Ser His Leu Thr Gly Asn Lys Ser Leu Tyr Ile Glu Leu Leu Pro
                245                 250                 255

Val Pro Gly Ala Lys Lys Ser Ser Lys Leu Tyr Ile Pro Tyr Ile Ile
            260                 265                 270

Leu Thr Ile Ile Ile Leu Thr Ile Val Gly Xaa Ile Trp Leu Leu Lys
        275                 280                 285

Val Asn Gly Cys Xaa Lys Tyr Lys Leu Asn Lys Pro Glu Ser Thr Pro
    290                 295                 300

Val Val Glu Glu Asp Glu Met Gln Pro Tyr Ala Phe Tyr Thr Glu Lys
305                 310                 315                 320

Asn Asn Pro Leu Xaa Xaa Thr Thr Asn Lys Val Lys Ala Ser Glu Ala
                325                 330                 335

Leu Gln Ser Glu Val Asp Thr Asp Leu His Thr Leu Xaa
            340                 345
```

<210> 237
<211> 17
<212> PRT
<213> Homo sapiens

<400> 237
Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr Ser Gly Trp Asp Thr Leu
1 5 10 15

Asn

<210> 238
<211> 14
<212> PRT
<213> Homo sapiens

<400> 238
Val Thr Glu Glu Ile Lys Asn Pro Glu Arg Asn Leu Pro Leu
1 5 10

<210> 239
<211> 9
<212> PRT
<213> Homo sapiens

<400> 239
Ile Gly Ile Ser Met Pro Ile Val Thr
1 5

<210> 240
<211> 13
<212> PRT
<213> Homo sapiens

<400> 240
Ile Tyr Ile Leu Thr Asn Val Ala Tyr Tyr Thr Val Leu
1 5 10

<210> 241
<211> 11
<212> PRT
<213> Homo sapiens

<400> 241
Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln
1 5 10

<210> 242
<211> 13
<212> PRT
<213> Homo sapiens

<400> 242
Val Ala Leu Ser Cys Phe Gly Gly Leu Asn Ala Ser Ile
1 5 10

<210> 243
<211> 15
<212> PRT
<213> Homo sapiens

<400> 243
Ser Arg Leu Phe Phe Val Gly Ser Arg Glu Gly His Leu Pro Asp
1 5 10 15

<210> 244
<211> 11
<212> PRT
<213> Homo sapiens

<400> 244
Ser Phe Ser Tyr Trp Phe Phe Val Gly Leu Ser
1 5 10

<210> 245
<211> 11
<212> PRT
<213> Homo sapiens

<400> 245
Val Gly Gln Leu Tyr Leu Arg Trp Lys Glu Pro
1 5 10

<210> 246
<211> 16
<212> PRT
<213> Homo sapiens

<400> 246
Arg Pro Arg Pro Leu Lys Leu Ser Val Phe Phe Pro Ile Val Phe Cys
1 5 10 15

<210> 247
<211> 9
<212> PRT
<213> Homo sapiens

<400> 247
Asp Thr Ile Asn Ser Leu Ile Gly Ile
1 5

<210> 248
<211> 44
<212> PRT
<213> Homo sapiens

<400> 248

Ala Thr Ala Leu Pro Pro Lys Ile Val Gly Ser Ala Thr Arg Tyr Leu
1 5 10 15

Gln Val Leu Cys Met Ser Val Ala Ala Glu Met Asp Leu Glu Asp Gly
20 25 30

Gly Glu Met Pro Lys Gln Arg Asp Pro Lys Ser Asn
35 40

<210> 249
<211> 352
<212> PRT
<213> Homo sapiens

<400> 249
Leu Leu Ala Ala Ala Cys Ile Cys Leu Leu Thr Phe Ile Asn Cys Ala
1 5 10 15

Tyr Val Lys Trp Gly Thr Leu Val Gln Asp Ile Phe Thr Tyr Ala Lys
20 25 30

Val Leu Ala Leu Ile Ala Val Ile Val Ala Gly Ile Val Arg Leu Gly
35 40 45

Gln Gly Ala Ser Thr His Phe Glu Asn Ser Phe Glu Gly Ser Ser Phe
50 55 60

Ala Val Gly Asp Ile Ala Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr
65 70 75 80

Ser Gly Trp Asp Thr Leu Asn Tyr Val Thr Glu Glu Ile Lys Asn Pro
85 90 95

Glu Arg Asn Leu Pro Leu Ser Ile Gly Ile Ser Met Pro Ile Val Thr
100 105 110

Ile Ile Tyr Ile Leu Thr Asn Val Ala Tyr Tyr Thr Val Leu Asp Met
115 120 125

Arg Asp Ile Leu Ala Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln
130 135 140

Ile Phe Gly Ile Phe Asn Trp Ile Ile Pro Leu Ser Val Ala Leu Ser
145 150 155 160

Cys Phe Gly Gly Leu Asn Ala Ser Ile Val Ala Ala Ser Arg Leu Phe
165 170 175

Phe Val Gly Ser Arg Glu Gly His Leu Pro Asp Ala Ile Cys Met Ile
180 185 190

His Val Glu Arg Phe Thr Pro Val Pro Ser Leu Leu Phe Asn Gly Ile
195 200 205

Met Ala Leu Ile Tyr Leu Cys Val Glu Asp Ile Phe Gln Leu Ile Asn
210 215 220

Tyr Tyr Ser Phe Ser Tyr Trp Phe Phe Val Gly Leu Ser Ile Val Gly

225 230 235 240

Gln Leu Tyr Leu Arg Trp Lys Glu Pro Asp Arg Pro Arg Pro Leu Lys
245 250 255

Leu Ser Val Phe Phe Pro Ile Val Phe Cys Leu Cys Thr Ile Phe Leu
260 265 270

Val Ala Val Pro Leu Tyr Ser Asp Thr Ile Asn Ser Leu Ile Gly Ile
275 280 285

Ala Ile Ala Leu Ser Gly Leu Pro Phe Tyr Phe Leu Ile Ile Arg Val
290 295 300

Pro Glu His Lys Arg Pro Leu Tyr Leu Arg Arg Ile Val Gly Ser Ala
305 310 315 320

Thr Arg Tyr Leu Gln Val Leu Cys Met Ser Val Ala Ala Glu Met Asp
325 330 335

Leu Glu Asp Gly Gly Glu Met Pro Lys Gln Arg Asp Pro Lys Ser Asn
340 345 350

<210> 250
<211> 119
<212> PRT
<213> Homo sapiens

<400> 250
Ala Ala Arg Gly Ser Gly Val Arg Asp Pro Leu Glu Glu Ala Val Cys
1 5 10 15

Pro Phe Ser Asp Leu Gln Leu His Ala Gly Arg Thr Thr Ala Leu Phe
20 25 30

Lys Ala Val Arg Gln Gly His Leu Ser Leu Gln Arg Leu Leu Leu Ser
35 40 45

Phe Val Cys Leu Cys Pro Ala Pro Arg Gly Gly Ala Tyr Arg Gly Arg
50 55 60

Gln Ala Ser Leu Ser Cys Gly Gly Leu His Pro Val Arg Ala Ser Arg
65 70 75 80

Leu Leu Cys Leu Pro Lys Gln Ala Trp Ala Met Ala Gly Ala Pro Pro
85 90 95

Pro Val Ser Leu Pro Pro Cys Ser Leu Ile Ser Asp Cys Cys Ala Ser
100 105 110

Asn Gln Arg Asp Ser Val Gly
115

<210> 251

<211> 356
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (37)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (280)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 251
Leu Ser Lys Ala Phe Leu Asp Ser Pro Asn Arg Leu Leu Ala Val Glu
1 5 10 15

Met Asn Thr Asp His Leu Arg Leu Thr Val Pro Asn Gly Ile Gly Ala
20 25 30

Leu Lys Leu Arg Xaa Met Glu His Tyr Phe Ser Gln Gly Leu Ser Val
35 40 45

Gln Leu Phe Asn Asp Gly Ser Lys Gly Lys Leu Asn His Leu Cys Gly
50 55 60

Ala Asp Phe Val Lys Ser His Gln Lys Pro Pro Gln Gly Met Glu Ile
65 70 75 80

Lys Ser Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile
85 90 95

Val Tyr Tyr Tyr His Asp Ala Asp Gly His Phe His Leu Ile Asp Gly
100 105 110

Asp Lys Ile Ala Thr Leu Ile Ser Ser Phe Leu Lys Glu Leu Leu Val
115 120 125

Glu Ile Gly Glu Ser Leu Asn Ile Gly Val Val Gln Thr Ala Tyr Ala
130 135 140

Asn Gly Ser Ser Thr Arg Tyr Leu Glu Glu Val Met Lys Val Pro Val
145 150 155 160

Tyr Cys Thr Lys Thr Gly Val Lys His Leu His His Lys Ala Gln Glu
165 170 175

Phe Asp Ile Gly Val Tyr Phe Glu Ala Asn Gly His Gly Thr Ala Leu
180 185 190

Phe Ser Thr Ala Val Glu Met Lys Ile Lys Gln Ser Ala Glu Gln Leu
195 200 205

Glu Asp Lys Lys Arg Lys Ala Ala Lys Met Leu Glu Asn Ile Ile Asp
210 215 220

Leu Phe Asn Gln Ala Ala Gly Asp Ala Ile Ser Asp Met Leu Val Ile
225 230 235 240

```
Glu Ala Ile Leu Ala Leu Lys Gly Leu Thr Val Gln Gln Trp Asp Ala
            245                 250                 255

Leu Tyr Thr Asp Leu Pro Asn Arg Gln Leu Lys Val Gln Val Ala Asp
        260                 265                 270

Arg Arg Val Ile Ser Thr Thr Xaa Ala Glu Arg Gln Ala Val Thr Pro
    275                 280                 285

Pro Gly Leu Gln Glu Ala Ile Asn Asp Leu Val Lys Lys Tyr Lys Leu
    290                 295                 300

Ser Arg Ala Phe Val Arg Pro Ser Gly Thr Glu Asp Val Val Arg Val
305                 310                 315                 320

Tyr Ala Glu Ala Asp Ser Gln Glu Ser Ala Asp His Leu Ala His Glu
            325                 330                 335

Val Ser Leu Ala Val Phe Gln Leu Ala Gly Gly Ile Gly Glu Arg Pro
        340                 345                 350

Gln Pro Gly Phe
    355


<210> 252
<211> 26
<212> PRT
<213> Homo sapiens

<400> 252
Leu Ser Lys Ala Phe Leu Asp Ser Pro Asn Arg Leu Leu Ala Val Glu
 1               5                  10                  15

Met Asn Thr Asp His Leu Arg Leu Thr Val
            20                  25


<210> 253
<211> 28
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (11)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 253
Pro Asn Gly Ile Gly Ala Leu Lys Leu Arg Xaa Met Glu His Tyr Phe
 1               5                  10                  15

Ser Gln Gly Leu Ser Val Gln Leu Phe Asn Asp Gly
            20                  25


<210> 254
<211> 28
```

<212> PRT
<213> Homo sapiens

<400> 254
Ser Lys Gly Lys Leu Asn His Leu Cys Gly Ala Asp Phe Val Lys Ser
1 5 10 15

His Gln Lys Pro Pro Gln Gly Met Glu Ile Lys Ser
20 25

<210> 255
<211> 28
<212> PRT
<213> Homo sapiens

<400> 255
Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile Val Tyr
1 5 10 15

Tyr Tyr His Asp Ala Asp Gly His Phe His Leu Ile
20 25

<210> 256
<211> 28
<212> PRT
<213> Homo sapiens

<400> 256
Asp Gly Asp Lys Ile Ala Thr Leu Ile Ser Ser Phe Leu Lys Glu Leu
1 5 10 15

Leu Val Glu Ile Gly Glu Ser Leu Asn Ile Gly Val
20 25

<210> 257
<211> 28
<212> PRT
<213> Homo sapiens

<400> 257
Val Gln Thr Ala Tyr Ala Asn Gly Ser Ser Thr Arg Tyr Leu Glu Glu
1 5 10 15

Val Met Lys Val Pro Val Tyr Cys Thr Lys Thr Gly
20 25

<210> 258
<211> 28
<212> PRT
<213> Homo sapiens

<400> 258
Val Lys His Leu His His Lys Ala Gln Glu Phe Asp Ile Gly Val Tyr
1 5 10 15

Phe Glu Ala Asn Gly His Gly Thr Ala Leu Phe Ser
20 25

<210> 259
<211> 28
<212> PRT
<213> Homo sapiens

<400> 259
Thr Ala Val Glu Met Lys Ile Lys Gln Ser Ala Glu Gln Leu Glu Asp
1 5 10 15

Lys Lys Arg Lys Ala Ala Lys Met Leu Glu Asn Ile
20 25

<210> 260
<211> 28
<212> PRT
<213> Homo sapiens

<400> 260
Ile Asp Leu Phe Asn Gln Ala Ala Gly Asp Ala Ile Ser Asp Met Leu
1 5 10 15

Val Ile Glu Ala Ile Leu Ala Leu Lys Gly Leu Thr
20 25

<210> 261
<211> 28
<212> PRT
<213> Homo sapiens

<400> 261
Val Gln Gln Trp Asp Ala Leu Tyr Thr Asp Leu Pro Asn Arg Gln Leu
1 5 10 15

Lys Val Gln Val Ala Asp Arg Arg Val Ile Ser Thr
20 25

<210> 262
<211> 28
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 262
Thr Xaa Ala Glu Arg Gln Ala Val Thr Pro Pro Gly Leu Gln Glu Ala
1 5 10 15

Ile Asn Asp Leu Val Lys Lys Tyr Lys Leu Ser Arg
20 25

<210> 263
<211> 24
<212> PRT
<213> Homo sapiens

<400> 263
Ala Phe Val Arg Pro Ser Gly Thr Glu Asp Val Val Arg Val Tyr Ala
1 5 10 15

Glu Ala Asp Ser Gln Glu Ser Ala
20

<210> 264
<211> 26
<212> PRT
<213> Homo sapiens

<400> 264
Asp His Leu Ala His Glu Val Ser Leu Ala Val Phe Gln Leu Ala Gly
1 5 10 15

Gly Ile Gly Glu Arg Pro Gln Pro Gly Phe
20 25

<210> 265
<211> 443
<212> PRT
<213> Homo sapiens

<400> 265
Gly Thr Arg Ala Ala Pro Gly Leu Gly Ala Trp Gly Arg Arg Ser Pro
1 5 10 15

Pro Ser Phe Ser Pro Pro Arg Pro Arg Arg Pro Gly Val Met Ala Gly
20 25 30

Leu Asn Cys Gly Val Ser Ile Ala Leu Leu Gly Val Leu Leu Leu Gly
35 40 45

Ala Ala Arg Leu Pro Arg Gly Ala Glu Ala Phe Glu Ile Ala Leu Pro
50 55 60

Arg Glu Ser Asn Ile Thr Val Leu Ile Lys Leu Gly Thr Pro Thr Leu
65 70 75 80

Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser Lys Arg His Ile Thr Met
85 90 95

Leu Ser Ile Lys Ser Gly Glu Arg Ile Val Phe Thr Phe Ser Cys Gln
100 105 110

Ser Pro Glu Asn His Phe Val Ile Glu Ile Gln Lys Asn Ile Asp Cys
115 120 125

Met Ser Gly Pro Cys Pro Phe Gly Glu Val Gln Leu Gln Pro Ser Thr

130 135 140

Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe Ile Trp Asp Val Lys Ala
145 150 155 160

His Lys Ser Ile Gly Leu Glu Leu Gln Phe Ser Ile Pro Arg Leu Arg
165 170 175

Gln Ile Gly Pro Gly Glu Ser Cys Pro Asp Gly Val Thr His Ser Ile
180 185 190

Ser Gly Arg Ile Asp Ala Thr Val Val Arg Ile Gly Thr Phe Cys Ser
195 200 205

Asn Gly Thr Val Ser Arg Ile Lys Met Gln Glu Gly Val Lys Met Ala
210 215 220

Leu His Leu Pro Trp Phe His Pro Arg Asn Val Ser Gly Phe Ser Ile
225 230 235 240

Ala Asn Arg Ser Ser Ile Lys Arg Leu Cys Ile Ile Glu Ser Val Phe
245 250 255

Glu Gly Glu Gly Ser Ala Thr Leu Met Ser Ala Asn Tyr Pro Glu Gly
260 265 270

Phe Pro Glu Asp Glu Leu Met Thr Trp Gln Phe Val Val Pro Ala His
275 280 285

Leu Arg Ala Ser Val Ser Phe Leu Asn Phe Asn Leu Ser Asn Cys Glu
290 295 300

Arg Lys Glu Glu Arg Val Glu Tyr Tyr Ile Pro Gly Ser Thr Thr Asn
305 310 315 320

Pro Glu Val Phe Lys Leu Glu Asp Lys Gln Pro Gly Asn Met Ala Gly
325 330 335

Asn Phe Asn Leu Ser Leu Gln Gly Cys Asp Gln Asp Ala Gln Ser Pro
340 345 350

Gly Ile Leu Arg Leu Gln Phe Gln Val Leu Val Gln His Pro Gln Asn
355 360 365

Glu Ser Asn Lys Ile Tyr Val Val Asp Leu Ser Asn Glu Arg Ala Met
370 375 380

Ser Leu Thr Ile Glu Pro Arg Pro Val Lys Gln Ser Arg Lys Phe Val
385 390 395 400

Pro Gly Cys Phe Val Cys Leu Glu Ser Arg Thr Cys Ser Ser Asn Leu
405 410 415

Thr Leu Thr Ser Gly Ser Lys His Lys Ile Ser Phe Leu Cys Asp Asp
420 425 430

Leu Thr Arg Leu Trp Met Asn Val Glu Lys Pro
435 440

<210> 266
<211> 159
<212> PRT
<213> Homo sapiens

<400> 266
Phe Glu Ile Ala Leu Pro Arg Glu Ser Asn Ile Thr Val Leu Ile Lys
1 5 10 15

Leu Gly Thr Pro Thr Leu Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser
20 25 30

Lys Arg His Ile Thr Met Leu Ser Ile Lys Ser Gly Glu Arg Ile Val
35 40 45

Phe Thr Phe Ser Cys Gln Ser Pro Glu Asn His Phe Val Ile Glu Ile
50 55 60

Gln Lys Asn Ile Asp Cys Met Ser Gly Pro Cys Pro Phe Gly Glu Val
65 70 75 80

Gln Leu Gln Pro Ser Thr Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe
85 90 95

Ile Trp Asp Val Lys Ala His Lys Ser Ile Gly Leu Glu Leu Gln Phe
100 105 110

Ser Ile Pro Arg Leu Arg Gln Ile Gly Pro Gly Glu Ser Cys Pro Asp
115 120 125

Gly Val Thr His Ser Ile Ser Gly Arg Ile Asp Ala Thr Val Val Arg
130 135 140

Ile Gly Thr Phe Cys Ser Asn Gly Thr Val Ser Arg Ile Lys Met
145 150 155

<210> 267
<211> 9
<212> PRT
<213> Homo sapiens

<400> 267
Phe Val Arg Asp Pro Phe Val Arg Leu
1 5

<210> 268
<211> 13
<212> PRT
<213> Homo sapiens

<400> 268
Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser
1 5 10

<210> 269

<211> 15
<212> PRT
<213> Homo sapiens

<400> 269
Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe
1   5   10   15

<210> 270
<211> 380
<212> PRT
<213> Homo sapiens

<400> 270
Tyr Leu His Thr Ser Phe Ser Arg Pro His Thr Gly Pro Pro Leu Pro
1   5   10   15

Thr Pro Gly Pro Asp Arg Asp Arg Glu Leu Thr Ala Asp Ser Asp Val
            20   25   30

Asp Glu Phe Leu Asp Lys Phe Leu Ser Ala Gly Val Lys Gln Ser Asp
        35   40   45

Leu Pro Arg Lys Glu Thr Glu Gln Pro Pro Ala Pro Gly Ser Met Glu
    50   55   60

Glu Asn Val Arg Gly Tyr Asp Trp Ser Pro Arg Asp Ala Arg Arg Ser
65   70   75   80

Pro Asp Gln Gly Arg Gln Gln Ala Glu Arg Arg Ser Val Leu Arg Gly
                85   90   95

Phe Cys Ala Asn Ser Ser Leu Ala Phe Pro Thr Lys Glu Arg Ala Phe
            100   105   110

Asp Asp Ile Pro Asn Ser Glu Leu Ser His Leu Ile Val Asp Asp Arg
        115   120   125

His Gly Ala Ile Tyr Cys Tyr Val Pro Lys Val Ala Cys Thr Asn Trp
    130   135   140

Lys Arg Val Met Ile Val Leu Ser Gly Ser Leu Leu His Arg Gly Ala
145   150   155   160

Pro Tyr Arg Asp Pro Leu Arg Ile Pro Arg Glu His Val His Asn Ala
                165   170   175

Ser Ala His Leu Thr Phe Asn Lys Phe Trp Arg Arg Tyr Gly Lys Leu
            180   185   190

Ser Arg His Leu Met Lys Val Lys Leu Lys Lys Tyr Thr Lys Phe Leu
        195   200   205

Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe Arg Ser Lys
    210   215   220

Phe Glu Leu Glu Asn Glu Glu Phe Tyr Arg Lys Phe Ala Val Pro Met
225   230   235   240

Leu Arg Leu Tyr Ala Asn His Thr Ser Leu Pro Ala Ser Ala Arg Glu
245 250 255

Ala Phe Arg Ala Gly Leu Lys Val Ser Phe Ala Asn Phe Ile Gln Tyr
260 265 270

Leu Leu Asp Pro His Thr Glu Lys Leu Ala Pro Phe Asn Glu His Trp
275 280 285

Arg Gln Val Tyr Arg Leu Cys His Pro Cys Gln Ile Asp Tyr Asp Phe
290 295 300

Val Gly Lys Leu Glu Thr Leu Asp Glu Asp Ala Ala Gln Leu Leu Gln
305 310 315 320

Leu Leu Gln Val Asp Arg Gln Leu Arg Phe Pro Pro Ser Tyr Arg Asn
325 330 335

Arg Thr Ala Ser Ser Trp Glu Glu Asp Trp Phe Ala Lys Ile Pro Leu
340 345 350

Ala Trp Arg Gln Gln Leu Tyr Lys Leu Tyr Glu Ala Asp Phe Val Leu
355 360 365

Phe Gly Tyr Pro Lys Pro Glu Asn Leu Leu Arg Asp
370 375 380

<210> 271
<211> 274
<212> PRT
<213> Homo sapiens

<400> 271
Lys Leu Val Arg Leu Gln Val Pro Val Arg Asn Ser Arg Val Asp Pro
1 5 10 15

Arg Val Arg Ser Lys Ile Gly Ser Arg Arg Trp Met Leu Gln Leu Ile
20 25 30

Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
35 40 45

Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
50 55 60

Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
65 70 75 80

Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
85 90 95

Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
100 105 110

Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
115 120 125

Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
130 135 140

Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr
145 150 155 160

Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
165 170 175

Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
180 185 190

Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
195 200 205

Leu Ala Phe Leu Ser Gly Tyr Tyr Val Thr Leu Ala Ala Gln Ile Leu
210 215 220

Ala Val Leu Leu Pro Pro Val Met Leu Leu Ile Asp Gly Asn Val Ala
225 230 235 240

Tyr Trp His Asn Thr Arg Arg Val Glu Phe Trp Asn Gln Met Lys Leu
245 250 255

Leu Gly Glu Ser Val Gly Ile Phe Gly Thr Ala Val Ile Leu Ala Thr
260 265 270

Asp Gly

<210> 272
<211> 203
<212> PRT
<213> Homo sapiens

<400> 272
Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys
1 5 10 15

Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys
20 25 30

Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val
35 40 45

Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala
50 55 60

Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile
65 70 75 80

Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser
85 90 95

Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala
100 105 110

Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr

115 120 125

Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu
130 135 140

Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly
145 150 155 160

Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala
165 170 175

Pro Gly Leu Ser Val Arg Leu Leu Arg Asp Pro Arg Cys Pro Asp Pro
180 185 190

Gly Cys Thr Ala Ala Pro Cys His Ala Ala His
195 200

<210> 273
<211> 407
<212> PRT
<213> Homo sapiens

<400> 273
Ser Asn Glu Ile Leu Leu Ser Phe Pro Gln Asn Tyr Tyr Ile Gln Trp
1 5 10 15

Leu Asn Gly Ser Leu Ile His Gly Leu Trp Asn Leu Ala Ser Leu Phe
20 25 30

Ser Asn Leu Cys Leu Phe Val Leu Met Pro Phe Ala Phe Phe Phe Leu
35 40 45

Glu Ser Glu Gly Phe Ala Gly Leu Lys Lys Gly Ile Arg Ala Arg Ile
50 55 60

Leu Glu Thr Leu Val Met Leu Leu Leu Leu Ala Leu Leu Ile Leu Gly
65 70 75 80

Ile Val Trp Val Ala Ser Ala Leu Ile Asp Asn Asp Ala Ala Ser Met
85 90 95

Glu Ser Leu Tyr Asp Leu Trp Glu Phe Tyr Leu Pro Tyr Leu Tyr Ser
100 105 110

Cys Ile Ser Leu Met Gly Cys Leu Leu Leu Leu Leu Cys Thr Pro Val
115 120 125

Gly Leu Ser Arg Met Phe Thr Val Met Gly His Leu Leu Val Lys Pro
130 135 140

Thr Ile Leu Glu Asp Leu Asp Glu Gln Ile Tyr Ile Ile Thr Leu Glu
145 150 155 160

Glu Glu Ala Leu Gln Arg Arg Leu Asn Gly Leu Ser Ser Ser Val Glu
165 170 175

Tyr Asn Ile Met Glu Leu Glu Gln Glu Leu Glu Asn Val Lys Thr Leu
180 185 190

Lys Thr Lys Leu Glu Arg Arg Lys Lys Ala Ser Ala Trp Glu Arg Asn
195 200 205

Leu Val Tyr Pro Ala Val Met Val Leu Leu Leu Ile Glu Thr Ser Ile
210 215 220

Ser Val Leu Leu Val Ala Cys Asn Ile Leu Cys Leu Leu Val Asp Glu
225 230 235 240

Thr Ala Met Pro Lys Gly Thr Arg Gly Pro Gly Ile Gly Asn Ala Ser
245 250 255

Leu Ser Thr Phe Gly Phe Val Gly Ala Ala Leu Glu Ile Ile Leu Ile
260 265 270

Phe Tyr Leu Met Val Ser Ser Val Val Gly Phe Tyr Ser Leu Arg Phe
275 280 285

Phe Gly Asn Phe Thr Pro Lys Lys Asp Asp Thr Thr Met Thr Lys Ile
290 295 300

Ile Gly Asn Cys Val Ser Ile Leu Val Leu Ser Ser Ala Leu Pro Val
305 310 315 320

Met Ser Arg Thr Leu Gly Ile Thr Arg Phe Asp Leu Leu Gly Asp Phe
325 330 335

Gly Arg Phe Asn Trp Leu Gly Asn Phe Tyr Ile Val Leu Ser Tyr Asn
340 345 350

Leu Leu Phe Ala Ile Val Thr Thr Leu Cys Leu Val Arg Lys Phe Thr
355 360 365

Ser Ala Val Arg Glu Glu Leu Phe Lys Ala Leu Gly Leu His Lys Leu
370 375 380

His Leu Pro Asn Thr Ser Arg Asp Ser Glu Thr Ala Lys Pro Ser Val
385 390 395 400

Asn Gly His Gln Lys Ala Leu
405

<210> 274
<211> 165
<212> PRT
<213> Homo sapiens

<400> 274
Arg Ser Tyr Met Gln Ser Val Trp Thr Glu Glu Ser Gln Cys Thr Leu
1 5 10 15

Leu Asn Ala Ser Ile Thr Glu Thr Phe Asn Cys Ser Phe Ser Cys Gly
20 25 30

Pro Asp Cys Trp Lys Leu Ser Gln Tyr Pro Cys Leu Gln Val Tyr Val
35 40 45

Asn Leu Thr Ser Ser Gly Glu Lys Leu Leu Leu Tyr His Thr Glu Glu
50 55 60

Thr Ile Lys Ile Asn Gln Lys Cys Ser Tyr Ile Pro Lys Cys Gly Lys
65 70 75 80

Asn Phe Glu Glu Ser Met Ser Leu Val Asn Val Val Met Glu Asn Phe
85 90 95

Arg Lys Tyr Gln His Phe Ser Cys Tyr Ser Asp Pro Glu Gly Asn Gln
100 105 110

Lys Ser Val Ile Leu Thr Lys Leu Tyr Ser Ser Asn Val Leu Phe His
115 120 125

Ser Leu Phe Trp Pro Thr Cys Met Met Ala Gly Gly Val Ala Ile Val
130 135 140

Ala Met Val Lys Leu Thr Gln Tyr Leu Ser Leu Leu Cys Glu Arg Ile
145 150 155 160

Gln Arg Ile Asn Arg
165

<210> 275
<211> 155
<212> PRT
<213> Homo sapiens

<400> 275
Ala Phe Ala His Leu Gln Leu Gly Pro Met Trp Lys Leu Trp Arg Ala
1 5 10 15

Glu Glu Gly Ala Ala Ala Leu Gly Gly Ala Leu Phe Leu Leu Leu Phe
20 25 30

Ala Leu Gly Val Arg Gln Leu Leu Lys Gln Arg Arg Pro Met Gly Phe
35 40 45

Pro Pro Gly Pro Pro Gly Leu Pro Phe Ile Gly Asn Ile Tyr Ser Leu
50 55 60

Ala Ala Ser Ser Glu Leu Pro His Val Tyr Met Arg Lys Gln Ser Gln
65 70 75 80

Val Tyr Gly Glu Val Gln Pro Arg Arg Ala Pro Gly Arg Glu Gly Arg
85 90 95

Gln Ala Gly Pro Gly Trp Pro Gly Pro Ser Trp Leu Asp Leu Trp Pro
100 105 110

Pro Leu Gly Arg Leu Val Gly Thr Ser Pro Cys Ala Gly Cys Pro Leu
115 120 125

Arg Asp Thr Arg Phe Pro Gly Leu Glu Gly Arg Ser Pro Arg Arg Arg
130 135 140

Ala Pro Leu Gln Gly Glu Pro Arg Pro Cys Arg

145 150 155

<210> 276
<211> 42
<212> PRT
<213> Homo sapiens

<400> 276
Met Arg Val Arg Ile Gly Leu Thr Leu Leu Leu Cys Ala Val Leu Leu
1 5 10 15

Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser
20 25 30

Leu Gly Phe Gln Asp Tyr Phe Asp Ile Arg
35 40

<210> 277
<211> 155
<212> PRT
<213> Homo sapiens

<400> 277
Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly
1 5 10 15

Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly
20 25 30

Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys
35 40 45

Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Ala Leu Ala His
50 55 60

Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp
65 70 75 80

Leu Phe Gly Leu Glu Thr Met Pro Gln Glu Arg Glu Val His His Pro
85 90 95

His Arg Gly Asp Arg Arg Arg Gly Leu Pro Ser Cys Gly Ala Asp Pro
100 105 110

Val Thr Met Cys Pro Leu Pro Ala Gly Ala Arg Pro Leu Ile Ile His
115 120 125

Ser Ser Ile Leu Glu Pro Val Ser Ala Ser Gln Thr Arg Arg Glu Pro
130 135 140

Ser Ser Ser Asn His Lys Gly Gly Gly Gly Arg
145 150 155

<210> 278
<211> 207
<212> PRT

<213> Homo sapiens

<400> 278

Gly Thr Ser Phe Leu Asp Pro Thr Leu Ser Leu Phe Val Leu Glu Lys
1 5 10 15

Phe Asn Leu Pro Ala Gly Tyr Val Gly Leu Val Phe Leu Gly Met Ala
20 25 30

Leu Ser Tyr Ala Ile Ser Ser Pro Leu Phe Gly Leu Leu Ser Asp Lys
35 40 45

Arg Pro Pro Leu Arg Lys Trp Leu Leu Val Phe Gly Asn Leu Ile Thr
50 55 60

Ala Gly Cys Tyr Met Leu Leu Gly Pro Val Pro Ile Leu His Ile Lys
65 70 75 80

Ser Gln Leu Trp Leu Leu Val Leu Ile Leu Val Val Ser Gly Leu Ser
85 90 95

Ala Gly Met Ser Ile Ile Pro Thr Phe Pro Glu Ile Leu Ser Cys Ala
100 105 110

His Glu Asn Gly Phe Glu Glu Gly Leu Ser Thr Leu Gly Leu Val Ser
115 120 125

Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala Phe Met Gly Pro Thr
130 135 140

Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe Glu Trp Ala Ala Ala
145 150 155 160

Ile Gln Gly Leu Trp Ala Leu Ile Ser Gly Leu Ala Met Gly Leu Phe
165 170 175

Tyr Leu Leu Glu Tyr Ser Arg Arg Lys Arg Ser Lys Ser Gln Asn Ile
180 185 190

Leu Ser Thr Glu Glu Glu Arg Thr Thr Leu Leu Pro Asn Glu Thr
195 200 205

<210> 279
<211> 85
<212> PRT
<213> Homo sapiens

<400> 279

Gly Thr Arg Glu Ala Arg Leu Arg Asp Leu Thr Arg Phe Tyr Asp Lys
1 5 10 15

Val Leu Ser Leu His Glu Asp Ser Thr Thr Pro Val Ala Asn Pro Leu
20 25 30

Leu Ala Phe Thr Leu Ile Lys Arg Leu Gln Ser Asp Trp Arg Asn Val
35 40 45

Val His Ser Leu Glu Ala Ser Glu Asn Ile Arg Ala Leu Lys Asp Gly

```
 50                  55                  60

Tyr Glu Lys Val Glu Gln Asp Leu Pro Ala Phe Glu Asp Leu Glu Gly
 65                  70                  75                  80

Ala Ala Arg Ala Leu
                85


<210> 280
<211> 7
<212> PRT
<213> Homo sapiens

<400> 280
Ala Leu Met Arg Leu Gln Asp
  1               5


<210> 281
<211> 7
<212> PRT
<213> Homo sapiens

<400> 281
Val Glu Ala Gly Gly Ala Thr
  1               5


<210> 282
<211> 489
<212> PRT
<213> Homo sapiens

<400> 282
Gly Thr Arg Glu Ala Arg Leu Arg Asp Leu Thr Arg Phe Tyr Asp Lys
  1               5                  10                  15

Val Leu Ser Leu His Glu Asp Ser Thr Thr Pro Val Ala Asn Pro Leu
             20                  25                  30

Leu Ala Phe Thr Leu Ile Lys Arg Leu Gln Ser Asp Trp Arg Asn Val
         35                  40                  45

Val His Ser Leu Glu Ala Ser Glu Asn Ile Arg Ala Leu Lys Asp Gly
     50                  55                  60

Tyr Glu Lys Val Glu Gln Asp Leu Pro Ala Phe Glu Asp Leu Glu Gly
 65                  70                  75                  80

Ala Ala Arg Ala Leu Met Arg Leu Gln Asp Val Tyr Met Leu Asn Val
                 85                  90                  95

Lys Gly Leu Ala Arg Gly Val Phe Gln Arg Val Thr Gly Ser Ala Ile
            100                 105                 110

Thr Asp Leu Tyr Ser Pro Lys Arg Leu Phe Ser Leu Thr Gly Asp Asp
        115                 120                 125
```

Cys Phe Gln Val Gly Lys Val Ala Tyr Asp Met Gly Asp Tyr Tyr His
130 135 140

Ala Ile Pro Trp Leu Glu Glu Ala Val Ser Leu Phe Arg Gly Ser Tyr
145 150 155 160

Gly Glu Trp Lys Thr Glu Asp Glu Ala Ser Leu Glu Asp Ala Leu Asp
165 170 175

His Leu Ala Phe Ala Tyr Phe Arg Ala Gly Asn Val Ser Cys Ala Leu
180 185 190

Ser Leu Ser Arg Glu Phe Leu Leu Tyr Ser Pro Asp Asn Lys Arg Met
195 200 205

Ala Arg Asn Val Leu Lys Tyr Glu Arg Leu Leu Ala Glu Ser Pro Asn
210 215 220

His Val Val Ala Glu Ala Val Ile Gln Arg Pro Asn Ile Pro His Leu
225 230 235 240

Gln Thr Arg Asp Thr Tyr Glu Gly Leu Cys Gln Thr Leu Gly Ser Gln
245 250 255

Pro Thr Leu Tyr Gln Ile Pro Ser Leu Tyr Cys Ser Tyr Glu Thr Asn
260 265 270

Ser Asn Ala Tyr Leu Leu Leu Gln Pro Ile Arg Lys Glu Val Ile His
275 280 285

Leu Gln Pro Tyr Ile Ala Leu Tyr His Asp Phe Val Ser Asp Ser Glu
290 295 300

Ala Gln Lys Ile Arg Glu Leu Ala Glu Pro Trp Leu Gln Arg Ser Val
305 310 315 320

Val Ala Ser Gly Glu Lys Gln Leu Gln Val Glu Tyr Arg Ile Ser Lys
325 330 335

Ser Ala Trp Leu Lys Asp Thr Val Asp Leu Lys Leu Val Thr Leu Asn
340 345 350

His Arg Ile Ala Ala Leu Thr Gly Leu Asp Val Arg Pro Pro Tyr Ala
355 360 365

Glu Tyr Leu Gln Val Val Asn Tyr Gly Ile Gly Gly His Tyr Glu Pro
370 375 380

His Phe Asp His Ala Thr Ser Pro Ser Ser Pro Leu Tyr Arg Met Lys
385 390 395 400

Ser Gly Asn Arg Val Ala Thr Phe Met Ile Tyr Leu Ser Ser Val Glu
405 410 415

Ala Gly Gly Ala Thr Ala Phe Ile Tyr Ala Asn Leu Ser Val Pro Val
420 425 430

Val Arg Asn Ala Ala Leu Phe Trp Trp Asn Leu His Arg Ser Gly Glu
435 440 445

Gly Asp Ser Asp Thr Leu His Ala Gly Cys Pro Val Leu Val Gly Asp
450 455 460

Lys Trp Val Ala Asn Lys Trp Ile His Glu Tyr Gly Gln Glu Phe Arg
465 470 475 480

Arg Pro Cys Ser Ser Ser Pro Glu Asp
485

<210> 283
<211> 136
<212> PRT
<213> Homo sapiens

<400> 283
Ile Gln Pro Ser His Ala Ala Leu Leu His Cys Arg Ser Thr Phe Arg
1 5 10 15

Lys Thr Glu Cys Leu Asp Pro Trp Trp Val Arg Arg Gln Leu Leu Gly
20 25 30

Met Ala Gly Ile Gly Gly Leu Gln Lys Met Lys Ala Pro His Thr Gly
35 40 45

Val Leu His Leu Gly Ser Val Trp Val Phe Leu Gly Pro Phe Leu Leu
50 55 60

Gly Val Gly Tyr Thr Leu Thr Phe Asn Pro Leu Ser Gly Cys Met Ser
65 70 75 80

Thr Val Arg Trp Leu Asn Ser Asn Ile Thr Ala Asn Arg Thr Leu Ser
85 90 95

Arg Ser Val Cys His Val Thr Pro Leu His Arg Ser Leu Ser Pro His
100 105 110

Asp Gly Glu Tyr Leu Arg Gln Met Leu Leu Asn Ser Ser Ser Arg Ala
115 120 125

Gly Glu Ala Gly Ser Trp Gly Tyr
130 135

<210> 284
<211> 86
<212> PRT
<213> Homo sapiens

<400> 284
Cys Ser Ser Pro Pro Gly Arg Leu Pro Trp Cys Trp Thr Ala Pro Arg
1 5 10 15

Thr Leu Gly Lys His Gly Ser Leu Ile Ser Thr Leu Arg Leu Thr Ala
20 25 30

Pro Leu His Leu Ala Trp Lys Met Met Leu Ser Arg Lys Ala Leu Phe
35 40 45

Val Leu Leu Asn Thr Pro Val Leu Phe His Ala Leu Glu Gly Arg Leu
50 55 60

Phe Ser Lys Leu Cys His His His Thr Ile Gln Arg Thr Leu Thr Val
65 70 75 80

Pro Lys Phe Arg Ser Ser
85

<210> 285
<211> 75
<212> PRT
<213> Homo sapiens

<400> 285
Arg Ser Pro Thr Ser Arg Val Gln Leu Leu Lys Arg Gln Ser Cys Pro
1 5 10 15

Cys Gln Arg Asn Asp Leu Asn Glu Glu Pro Gln His Phe Thr His Tyr
20 25 30

Ala Ile Tyr Asp Phe Ile Val Lys Gly Ser Cys Phe Cys Asn Gly His
35 40 45

Ala Asp Gln Cys Ile Pro Val His Gly Phe Arg Pro Val Lys Ala Pro
50 55 60

Gly Thr Phe His Met Val His Gly Lys Cys Met
65 70 75

<210> 286
<211> 296
<212> PRT
<213> Homo sapiens

<400> 286
His Asn Thr Ala Gly Ser His Cys Gln His Cys Ala Pro Leu Tyr Asn
1 5 10 15

Asp Arg Pro Trp Glu Ala Ala Asp Gly Lys Thr Gly Ala Pro Asn Glu
20 25 30

Cys Arg Thr Cys Lys Cys Asn Gly His Ala Asp Thr Cys His Phe Asp
35 40 45

Val Asn Val Trp Glu Ala Ser Gly Asn Arg Ser Gly Gly Val Cys Asp
50 55 60

Asp Cys Gln His Asn Thr Glu Gly Gln Tyr Cys Gln Arg Cys Lys Pro
65 70 75 80

Gly Phe Tyr Arg Asp Leu Arg Arg Pro Phe Ser Ala Pro Asp Ala Cys
85 90 95

Lys Pro Cys Ser Cys His Pro Val Gly Ser Ala Val Leu Pro Ala Asn
100 105 110

```
Ser Val Thr Phe Cys Asp Pro Ser Asn Gly Asp Cys Pro Cys Lys Pro
        115                 120                 125

Gly Val Ala Gly Arg Arg Cys Asp Arg Cys Met Val Gly Tyr Trp Gly
    130                 135                 140

Phe Gly Asp Tyr Gly Cys Arg Pro Cys Asp Cys Ala Gly Ser Cys Asp
145                 150                 155                 160

Pro Ile Thr Gly Asp Cys Ile Ser Ser His Thr Asp Ile Asp Trp Tyr
                165                 170                 175

His Glu Val Pro Asp Phe Arg Pro Val His Asn Lys Ser Glu Pro Ala
            180                 185                 190

Trp Glu Trp Glu Asp Ala Gln Gly Phe Ser Ala Leu Leu His Ser Gly
        195                 200                 205

Lys Cys Glu Cys Lys Glu Gln Thr Leu Gly Asn Ala Lys Ala Phe Cys
    210                 215                 220

Gly Met Lys Tyr Ser Tyr Val Leu Lys Ile Lys Ile Leu Ser Ala His
225                 230                 235                 240

Asp Lys Gly Thr His Val Glu Val Asn Val Lys Ile Lys Lys Val Leu
                245                 250                 255

Lys Ser Thr Lys Leu Lys Ile Phe Arg Gly Lys Ala Asn Ile Ile Ser
            260                 265                 270

Arg Ile Met Asp Gly Gln Arg Met His Leu Ser Asn Pro Gln Ser Trp
        275                 280                 285

Phe Gly Ile Pro Cys Ser Arg Thr
    290                 295


<210> 287
<211> 37
<212> PRT
<213> Homo sapiens

<400> 287
Cys Asp Asp Cys Gln His Asn Thr Glu Gly Gln Tyr Cys Gln Arg Cys
 1               5                  10                  15

Lys Pro Gly Phe Tyr Arg Asp Leu Arg Arg Pro Phe Ser Ala Pro Asp
            20                  25                  30

Ala Cys Lys Pro Cys
        35


<210> 288
<211> 36
<212> PRT
<213> Homo sapiens
```

<400> 288
Cys Pro Cys Lys Pro Gly Val Ala Gly Arg Arg Cys Asp Arg Cys Met
1 5 10 15

Val Gly Tyr Trp Gly Phe Gly Asp Tyr Gly Cys Arg Pro Cys Asp Cys
20 25 30

Ala Gly Ser Cys
35

<210> 289
<211> 66
<212> PRT
<213> Homo sapiens

<400> 289
Asn Ile Ser Ser Gln Tyr Cys Ile Leu Lys Ser Leu Glu Met Met Ile
1 5 10 15

Ser Gly Leu Lys Leu Leu Val Leu Phe Leu Lys Phe Ala Pro Glu Asn
20 25 30

Tyr Cys Leu Ser Thr Glu Thr Leu Gln Met Pro Asn Arg His Leu Arg
35 40 45

Leu Ser Lys Ala Thr Cys Tyr Leu Met Lys Cys Leu Leu Pro Ser Tyr
50 55 60

Phe Glu
65

<210> 290
<211> 88
<212> PRT
<213> Homo sapiens

<400> 290
Pro Ile Glu Gly Thr Pro Ala Gly Thr Gly Pro Glu Phe Pro Gly Arg
1 5 10 15

Pro Thr Arg Pro Gln Arg Met Arg Ser Leu Ile Ser Ser His Pro Cys
20 25 30

Gln His Leu Leu Leu Leu Leu Leu Leu Leu Phe Leu Ile Leu Ala Ile
35 40 45

Leu Val Asp Val Lys Trp Tyr Leu Val Leu Phe Ile Cys Ile Ser Leu
50 55 60

Met Thr Ser Asp Val Glu His Leu Phe Met Cys Leu Leu Ala Ile Arg
65 70 75 80

Ile Ser Ser Trp Arg Asn Val Tyr
85

<210> 291

<211> 60
<212> PRT
<213> Homo sapiens

<400> 291
Asn Trp Val Pro Thr Cys Leu Cys Pro Ser Ala Pro Cys Ser Phe His
1   5   10   15

Leu Leu Ser Arg Phe Lys Cys Leu Phe Ser Pro Gln Arg Leu Thr Asp
            20   25   30

Ile Phe Arg Arg Tyr Asp Thr Asp Gln Asp Gly Trp Ile Gln Val Ser
        35   40   45

Tyr Glu Gln Tyr Leu Ser Met Val Phe Ser Ile Val
    50   55   60

<210> 292
<211> 33
<212> PRT
<213> Homo sapiens

<400> 292
Gln Arg Leu Thr Asp Ile Phe Arg Arg Tyr Asp Thr Asp Gln Asp Gly
1   5   10   15

Trp Ile Gln Val Ser Tyr Glu Gln Tyr Leu Ser Met Val Phe Ser Ile
            20   25   30

Val

<210> 293
<211> 73
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (54)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (55)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (68)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 293
Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly
1 5 10 15

Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His
20 25 30

Ile Cys Ser Gln Arg Xaa Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa
35 40 45

Leu Gln Thr Thr Trp Xaa Xaa Pro Asp Lys Pro Ile Pro Arg Leu Ser
50 55 60

Pro Pro Leu Xaa Ser Asp Pro Lys Arg
65 70

<210> 294
<211> 95
<212> PRT
<213> Homo sapiens

<400> 294
Thr Ser Ser Pro Val Phe Ser Phe Cys Ser Met Ala Val Arg Glu Pro
1 5 10 15

Asp His Leu Gln Arg Val Ser Leu Pro Arg Tyr Asn Val Ser Ala Ser
20 25 30

Leu Gln Trp Leu Pro Cys His Arg Ile Val Leu Gln Pro Trp His Met
35 40 45

Cys Ala Met Trp Glu Leu Gly Gln Val Leu Phe His Pro Val Ala Pro
50 55 60

Arg Glu Gly Ala Ala Pro Ser Pro Val Ser Thr Leu Thr Trp Pro Ser
65 70 75 80

Ser Cys Ser His Ser Glu Ser Thr Met Glu Leu Glu Leu Gln Phe
85 90 95

<210> 295
<211> 16
<212> PRT
<213> Homo sapiens

<400> 295
Met Ala Val Arg Glu Pro Asp His Leu Gln Arg Val Ser Leu Pro Arg
1 5 10 15

<210> 296
<211> 7
<212> PRT
<213> Homo sapiens

<400> 296
Leu Pro Cys His Arg Ile Val
1 5

<210> 297
<211> 15
<212> PRT
<213> Homo sapiens

<400> 297
Ser Leu Gln Trp Leu Pro Cys His Arg Ile Val Leu Gln Pro Trp
1 5 10 15

<210> 298
<211> 454
<212> PRT
<213> Homo sapiens

<400> 298
Cys Phe Lys Arg Lys Pro Lys Arg Glu His Cys Ser Cys Pro Ile Thr
1 5 10 15

Tyr Gln Ser Leu Gly Asp Ile Leu Asn Ala Ser Phe Phe Ser Lys Arg
20 25 30

Lys Gly Met Gln Glu Val Lys Leu Asn Ser Tyr Val Val Ser Gly Thr
35 40 45

Ile Gly Leu Lys Glu Lys Ile Ser Leu Ser Glu Pro Val Phe Leu Thr
50 55 60

Phe Arg His Asn Gln Pro Gly Asp Lys Arg Thr Lys His Ile Cys Val
65 70 75 80

Tyr Trp Glu Gly Ser Glu Gly Gly Arg Trp Ser Thr Glu Gly Cys Ser
85 90 95

His Val His Ser Asn Gly Ser Tyr Thr Lys Cys Lys Cys Phe His Leu
100 105 110

Ser Ser Phe Ala Val Leu Val Ala Leu Ala Pro Lys Glu Asp Pro Val
115 120 125

Leu Thr Val Ile Thr Gln Val Gly Leu Thr Ile Ser Leu Leu Cys Leu
130 135 140

Phe Leu Ala Ile Leu Thr Phe Leu Leu Cys Arg Pro Ile Gln Asn Thr
145 150 155 160

Ser Thr Ser Leu His Leu Glu Leu Ser Leu Cys Leu Phe Leu Ala His
165 170 175

Leu Leu Phe Leu Thr Gly Ile Asn Arg Thr Glu Pro Glu Val Leu Cys
180 185 190

Ser Ile Ile Ala Gly Leu Leu His Phe Leu Tyr Leu Ala Cys Phe Thr
195 200 205

Trp Met Leu Leu Glu Gly Leu His Leu Phe Leu Thr Val Arg Asn Leu
210 215 220

Lys Val Ala Asn Tyr Thr Ser Thr Gly Arg Phe Lys Lys Arg Phe Met
225 230 235 240

Tyr Pro Val Gly Tyr Gly Ile Pro Ala Val Ile Ile Ala Val Ser Ala
245 250 255

Ile Val Gly Pro Gln Asn Tyr Gly Thr Phe Thr His Cys Trp Leu Lys
260 265 270

Leu Asp Lys Gly Phe Ile Trp Ser Phe Met Gly Pro Val Ala Val Ile
275 280 285

Ile Leu Ile Asn Leu Val Phe Tyr Phe Gln Val Leu Trp Ile Leu Arg
290 295 300

Ser Lys Leu Ser Ser Leu Asn Lys Glu Val Ser Thr Ile Gln Asp Thr
305 310 315 320

Arg Val Met Thr Phe Lys Ala Ile Ser Gln Leu Phe Ile Leu Gly Cys
325 330 335

Ser Trp Gly Leu Gly Phe Phe Met Val Glu Glu Val Gly Lys Thr Ile
340 345 350

Gly Ser Ile Ile Ala Tyr Ser Phe Thr Ile Ile Asn Thr Leu Gln Gly
355 360 365

Val Leu Leu Phe Val Val His Cys Leu Leu Asn Arg Gln Val Arg Met
370 375 380

Glu Tyr Lys Lys Trp Phe Ser Gly Met Arg Lys Gly Val Glu Thr Glu
385 390 395 400

Ser Thr Glu Met Ser Arg Ser Thr Thr Gln Thr Lys Thr Glu Glu Val
405 410 415

Gly Lys Ser Ser Glu Ile Phe His Lys Gly Gly Thr Ala Ser Ser Ser
420 425 430

Ala Glu Ser Thr Lys Gln Pro Gln Pro Gln Val His Leu Val Ser Ala
435 440 445

Ala Trp Leu Lys Met Asn
450

<210> 299
<211> 101
<212> PRT

<213> Homo sapiens

<400> 299
Phe Phe Trp Lys Glu Asn Leu Arg Arg Asn Gly Ser Arg Glu Asp Phe
1 5 10 15

Ala Arg Arg Ala Thr Gln Leu Ile Gln Ser Val Glu Leu Ser Ile Trp
20 25 30

Asn Ala Ser Phe Ala Ser Pro Gly Lys Gly Gln Ile Ser Glu Phe Asp
35 40 45

Ile Val Tyr Glu Thr Lys Arg Cys Asn Glu Thr Arg Glu Asn Ala Phe
50 55 60

Leu Glu Ala Gly Asn Asn Thr Met Asp Ile Asn Cys Ala Asp Ala Leu
65 70 75 80

Lys Gly Asn Leu Arg Glu Ser Thr Ala Val Ala Leu Ser Leu Ile Asn
85 90 95

Leu Leu Gly Ile Phe
100

<210> 300
<211> 27
<212> PRT
<213> Homo sapiens

<400> 300
Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys Cys Lys Tyr Lys Ala
1 5 10 15

Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys
20 25

<210> 301
<211> 12
<212> PRT
<213> Homo sapiens

<400> 301
Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys Ser Cys
1 5 10

<210> 302
<211> 331
<212> PRT
<213> Homo sapiens

<400> 302
Ala Leu Cys Pro His Pro His Leu Ile Leu Asn Val Thr Val Ser Pro
1 5 10 15

Ala Pro Ser Cys Arg His Val Lys Lys Val Val Ala Ser Pro Ser Pro
20 25 30

```
Ser Thr Thr Met Ile Ala Met Asp Ala Pro His Ser Lys Ala Ala Leu
        35                  40                  45

Asp Ser Ile Asn Glu Leu Pro Glu Asn Ile Leu Leu Glu Leu Phe Thr
    50                  55                  60

His Val Pro Ala Arg Gln Leu Leu Leu Asn Cys Arg Leu Val Cys Ser
65                  70                  75                  80

Leu Trp Arg Asp Leu Ile Asp Leu Met Thr Leu Trp Lys Arg Lys Cys
                85                  90                  95

Leu Arg Glu Gly Phe Ile Thr Lys Asp Trp Asp Gln Pro Val Ala Asp
            100                 105                 110

Trp Lys Ile Phe Tyr Phe Leu Arg Ser Leu His Arg Asn Leu Leu Arg
        115                 120                 125

Asn Pro Cys Ala Glu Glu Asp Met Phe Ala Trp Gln Ile Asp Phe Asn
    130                 135                 140

Gly Gly Asp Arg Trp Lys Val Glu Ser Leu Pro Gly Ala His Gly Thr
145                 150                 155                 160

Asp Phe Pro Asp Pro Lys Val Lys Lys Tyr Phe Val Thr Ser Tyr Glu
                165                 170                 175

Met Cys Leu Lys Ser Gln Leu Val Asp Leu Val Ala Glu Gly Tyr Trp
            180                 185                 190

Glu Glu Leu Leu Asp Thr Phe Arg Pro Asp Ile Val Val Lys Asp Trp
        195                 200                 205

Phe Ala Ala Arg Ala Asp Cys Gly Cys Thr Tyr Gln Leu Lys Val Gln
    210                 215                 220

Leu Ala Ser Ala Asp Tyr Phe Val Leu Ala Ser Phe Glu Pro Pro Pro
225                 230                 235                 240

Val Thr Ile Gln Gln Trp Asn Asn Ala Thr Trp Thr Glu Val Ser Tyr
                245                 250                 255

Thr Phe Ser Asp Tyr Pro Arg Gly Val Arg Tyr Ile Leu Phe Gln His
            260                 265                 270

Gly Gly Arg Asp Thr Gln Tyr Trp Ala Gly Trp Tyr Gly Pro Arg Val
        275                 280                 285

Thr Asn Ser Ser Ile Val Val Ser Pro Lys Met Thr Arg Asn Gln Ala
    290                 295                 300

Ser Ser Glu Ala Gln Pro Gly Gln Lys His Gly Gln Glu Glu Ala Ala
305                 310                 315                 320

Gln Ser Pro Tyr Arg Ala Val Val Gln Ile Phe
                325                 330
```

<210> 303
<211> 328
<212> PRT
<213> Homo sapiens

<400> 303
Arg Gln Arg Ser Trp Asn Pro Gly Thr Asn Cys Tyr His Pro Asn Met
1 5 10 15

Pro Asp Ala Phe Leu Thr Cys Glu Thr Val Ile Phe Ala Trp Ala Ile
20 25 30

Gly Gly Glu Gly Phe Ser Tyr Pro Pro His Val Gly Leu Ser Leu Gly
35 40 45

Thr Pro Leu Asp Pro His Tyr Val Leu Leu Glu Val His Tyr Asp Asn
50 55 60

Pro Thr Tyr Glu Glu Gly Leu Ile Asp Asn Ser Gly Leu Arg Leu Phe
65 70 75 80

Tyr Thr Met Asp Ile Arg Lys Tyr Asp Ala Gly Val Ile Glu Ala Gly
85 90 95

Leu Trp Val Ser Leu Phe His Thr Ile Pro Pro Gly Met Pro Glu Phe
100 105 110

Gln Ser Glu Gly His Cys Thr Leu Glu Cys Leu Glu Glu Ala Leu Glu
115 120 125

Ala Glu Lys Pro Ser Gly Ile His Val Phe Ala Val Leu Leu His Ala
130 135 140

His Leu Ala Gly Arg Gly Ile Arg Leu Arg His Phe Arg Lys Gly Lys
145 150 155 160

Glu Met Lys Leu Leu Ala Tyr Asp Asp Asp Phe Asp Phe Asn Phe Gln
165 170 175

Glu Phe Gln Tyr Leu Lys Glu Glu Gln Thr Ile Leu Pro Gly Asp Asn
180 185 190

Leu Ile Thr Glu Cys Arg Tyr Asn Thr Lys Asp Arg Ala Glu Met Thr
195 200 205

Trp Gly Gly Leu Ser Thr Arg Ser Glu Met Cys Leu Ser Tyr Leu Leu
210 215 220

Tyr Tyr Pro Arg Ile Asn Leu Thr Arg Cys Ala Ser Ile Pro Asp Ile
225 230 235 240

Met Glu Gln Leu Gln Phe Ile Gly Val Lys Glu Ile Tyr Arg Pro Val
245 250 255

Thr Thr Trp Pro Phe Ile Ile Lys Ser Pro Lys Gln Tyr Lys Asn Leu
260 265 270

Ser Phe Met Asp Ala Met Asn Lys Phe Lys Trp Thr Lys Lys Glu Gly
275 280 285

```
Leu Ser Phe Asn Lys Leu Val Leu Ser Leu Pro Val Asn Val Arg Cys
    290                 295                 300

Ser Lys Thr Asp Asn Ala Glu Trp Ser Ile Pro Arg Asn Asp Ser Ile
305                 310                 315                 320

Thr Ser Arg Tyr Arg Lys Thr Leu
                325


<210> 304
<211> 272
<212> PRT
<213> Homo sapiens

<400> 304
Met Cys Cys Trp Pro Leu Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr
  1               5                  10                  15

Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp
             20                  25                  30

Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile
         35                  40                  45

Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe
     50                  55                  60

Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val
 65                  70                  75                  80

Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg
                 85                  90                  95

Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met
            100                 105                 110

Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr
        115                 120                 125

Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile
    130                 135                 140

Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His
145                 150                 155                 160

Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys
                165                 170                 175

Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln
            180                 185                 190

Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe
        195                 200                 205

Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro
    210                 215                 220
```

Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr
225 230 235 240

Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Pro Gly Ile Arg Ala Arg
245 250 255

Ile Ala Ile Thr Pro Thr Cys Pro Met His Ser Ser Pro Val Lys Leu
260 265 270

<210> 305
<211> 207
<212> PRT
<213> Homo sapiens

<400> 305
Thr Gly Thr Phe Trp Ser Pro Arg Ser Gln Arg Arg Gly Cys Cys Gly
1 5 10 15

Arg Arg Ala Pro Arg Pro Glu Ala Met Glu Asn Gly Ala Val Tyr Ser
20 25 30

Pro Thr Thr Glu Glu Asp Pro Gly Pro Ala Arg Gly Pro Arg Ser Gly
35 40 45

Leu Ala Ala Tyr Phe Phe Met Gly Arg Leu Pro Leu Leu Arg Arg Val
50 55 60

Leu Lys Gly Leu Gln Leu Leu Leu Ser Leu Leu Ala Phe Ile Cys Glu
65 70 75 80

Glu Val Val Ser Gln Cys Thr Leu Cys Gly Gly Leu Tyr Phe Phe Glu
85 90 95

Phe Val Ser Cys Ser Ala Phe Leu Leu Ser Leu Leu Ile Leu Ile Val
100 105 110

Tyr Cys Thr Pro Phe Tyr Glu Arg Val Asp Thr Thr Lys Val Lys Ser
115 120 125

Ser Asp Phe Tyr Ile Thr Leu Gly Thr Gly Cys Val Phe Leu Leu Ala
130 135 140

Ser Ile Ile Phe Val Ser Thr His Asp Arg Thr Ser Ala Glu Ile Ala
145 150 155 160

Ala Ile Val Phe Gly Phe Ile Ala Ser Phe Met Phe Leu Leu Asp Phe
165 170 175

Ile Thr Met Leu Tyr Glu Lys Arg Gln Glu Ser Gln Leu Arg Lys Pro
180 185 190

Glu Asn Thr Thr Arg Ala Glu Ala Leu Thr Glu Pro Leu Asn Ala
195 200 205

<210> 306
<211> 135
<212> PRT
<213> Homo sapiens

<400> 306
Ala Ser Ala Pro Arg Val Met Arg Gly His Leu Ala Gly Phe Pro Ala
1 5 10 15

Leu Ser Gly Leu Ala Ser Val Cys Leu Trp Ala Thr Phe Ser Ala Gln
20 25 30

Leu Pro Gly Pro Val Ala Ala Thr Ser Trp Thr Pro Ala Pro Leu Gly
35 40 45

Cys Ser Ala Ala Arg Ser Gly Pro Glu Lys Arg Leu Gly Thr Ala Ala
50 55 60

Pro Gly Ser Ala Ala Ser Leu Ala Gln Ala Gly Pro Gly Ala Pro Cys
65 70 75 80

Arg Val Leu Pro Val Asp Pro Ala Pro Ala Ala Leu Asn Val Arg Glu
85 90 95

Pro Gly Trp Leu Gly Gly Leu Phe Asp Gly Ala Leu Leu Gln Val Leu
100 105 110

Leu Asn Phe Leu Arg Lys Ser Thr Asp Val Leu Met Asp Thr Arg Glu
115 120 125

Ala Glu Ser Leu Glu Val Glu
130 135

<210> 307
<211> 188
<212> PRT
<213> Homo sapiens

<400> 307
Asn Lys Leu His Ser Phe Pro Val Phe Leu Ser Gln Leu Leu Leu Asp
1 5 10 15

Arg Gln Leu Leu His Ala Pro Gln Thr Leu Pro Thr Pro His Cys Gly
20 25 30

Gly Ser Ser Arg Pro Gly Pro Ser His Pro Pro Trp Leu Leu Ile Gln
35 40 45

Leu Pro Cys Val His Val Ala Leu Trp Gln Met Leu Arg Asp Phe Ser
50 55 60

Asp Ser Arg Ile Thr Pro Ser Thr Leu Thr Thr Gln Pro Ala Ala Gln
65 70 75 80

Thr Ala Ala Pro Ala Lys Asp Gln Glu Ser Asp Ile Val Gly Gly Glu
85 90 95

Gly Ile Leu Cys Asp Ile Ala Phe Leu Gln Glu Asp His Pro Leu Gly

```
                100                         105                         110

Val Gly Gly Ala Ser Ala Pro Ser Ser Arg Arg Glu Leu Ser Arg Arg
        115                     120                     125

Gly Val His Thr Gln Thr Leu Pro Glu Asp Gly Thr Leu His Gly Thr
    130                     135                     140

Pro Ser Ser Ser Phe Asp Cys Gly Ile Lys Tyr Ile Ile Ser Trp Pro
145                     150                     155                     160

Leu Ala Pro Gly Cys Asp Leu Pro Ser Leu Glu Leu Ser Leu Val Cys
                165                     170                     175

Lys Gly Val Ser Ser Cys Met Gly Phe Ala Ala Gly
            180                     185


<210> 308
<211> 78
<212> PRT
<213> Homo sapiens

<400> 308
Pro Gly Arg Pro Thr Arg Pro Thr Lys Asn Lys Val Cys Val Cys Leu
 1               5                  10                  15

Gly Met Leu Phe Trp Ala Tyr Pro Ile Cys Val Phe Ile Asp Ser Leu
            20                  25                  30

Ser Cys Gln Pro Cys Leu Trp Ser Thr Gly Ala Thr Ser His Phe Asn
        35                  40                  45

Ser Pro Thr Thr Ser Pro Leu Phe Thr Leu Phe Met Pro Cys Ala Leu
    50                  55                  60

Ala Pro Asn Pro Phe Thr Gln Leu Gly Lys Leu Asp Asp Arg
65                  70                  75


<210> 309
<211> 10
<212> PRT
<213> Homo sapiens

<400> 309
Pro Val Asp Leu Thr Lys Thr Arg Leu Gln
 1               5                  10


<210> 310
<211> 10
<212> PRT
<213> Homo sapiens

<400> 310
Pro Thr Asp Val Leu Lys Ile Arg Met Gln
 1               5                  10
```

<210> 311
<211> 313
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (117)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 311
Met Thr Phe Gly Ser Thr Ile Ser Pro Thr Ser Thr His Ala Ser Pro
1 5 10 15

Ser Leu Gly Phe Cys Cys Ser Trp Leu Leu Glu Asp Leu Glu Glu Gln
20 25 30

Leu Tyr Cys Ser Ala Phe Glu Glu Ala Ala Leu Thr Arg Arg Ile Cys
35 40 45

Asn Pro Thr Ser Cys Trp Leu Pro Leu Asp Met Glu Leu Leu His Arg
50 55 60

Gln Val Leu Ala Leu Gln Thr Gln Arg Val Leu Leu Gly Met Trp Leu
65 70 75 80

Arg Arg Ala Trp Asp Thr Trp Val Ser Pro Arg Arg Val Ala Pro Gly
85 90 95

Ser Arg Cys Leu Leu Thr Ala Ser His Pro Cys Thr Glu Lys Arg Arg
100 105 110

Lys Ala Ser Ala Xaa Gln Arg Asn Leu Gly Tyr Pro Leu Ala Met Leu
115 120 125

Cys Leu Leu Val Leu Thr Gly Leu Ser Val Leu Ile Val Ala Ile His
130 135 140

Ile Leu Glu Leu Leu Ile Asp Glu Ala Ala Met Pro Arg Gly Met Gln
145 150 155 160

Gly Thr Ser Leu Gly Gln Val Ser Phe Ser Lys Leu Gly Ser Phe Gly
165 170 175

Ala Val Ile Gln Val Val Leu Ile Phe Tyr Leu Met Val Ser Ser Val
180 185 190

Val Gly Phe Tyr Ser Ser Pro Leu Phe Arg Ser Leu Arg Pro Arg Trp
195 200 205

His Asp Thr Ala Met Thr Gln Ile Ile Gly Asn Cys Val Cys Leu Leu
210 215 220

Val Leu Ser Ser Ala Leu Pro Val Phe Ser Arg Thr Leu Gly Leu Thr
225 230 235 240

Arg Phe Asp Leu Leu Gly Asp Phe Gly Arg Phe Asn Trp Leu Gly Asn
245 250 255

Phe Tyr Ile Val Phe Leu Tyr Asn Ala Ala Phe Ala Gly Leu Thr Thr
260 265 270

Leu Cys Leu Val Lys Thr Phe Thr Ala Ala Val Arg Ala Glu Leu Ile
275 280 285

Arg Ala Phe Gly Leu Asp Arg Leu Pro Leu Pro Val Ser Gly Phe Pro
290 295 300

Gln Ala Ser Arg Lys Thr Gln His Gln
305 310

<210> 312
<211> 92
<212> PRT
<213> Homo sapiens

<400> 312
Leu Cys Val Cys Leu Val Tyr Leu Cys Met Tyr Gly Val Cys Leu Cys
1 5 10 15

Val Ile Val Cys Val Ser Gly Val Ser Leu Cys Leu Tyr Val Trp Gly
20 25 30

Val Ser Val Cys Asp Cys Val Ser Val Phe Met Cys Val Cys Leu Cys
35 40 45

Val Ile Phe Cys Val Tyr Gly Lys Pro Arg Thr Glu His Tyr His Ser
50 55 60

Pro His Leu Ala Lys Gln Lys Ala Phe Arg Glu Met Cys Gly Arg His
65 70 75 80

Asp Val Ser Ala Ala Gly Ile Phe Gln Ser Tyr Val
85 90

<210> 313
<211> 207
<212> PRT
<213> Homo sapiens

<400> 313
Gly His Met Pro Tyr Gly Trp Leu Thr Glu Ile Arg Ala Val Tyr Pro
1 5 10 15

Ala Phe Asp Lys Asn Asn Pro Ser Asn Lys Leu Val Ser Thr Ser Asn
20 25 30

Thr Val Thr Ala Ala His Ile Lys Lys Phe Thr Phe Val Cys Met Ala
35 40 45

Leu Ser Leu Thr Leu Cys Phe Val Met Phe Trp Thr Pro Asn Val Ser
50 55 60

Glu Lys Ile Leu Ile Asp Ile Ile Gly Val Asp Phe Ala Phe Ala Glu
65 70 75 80

Leu Cys Val Val Pro Leu Arg Ile Phe Ser Phe Phe Pro Val Pro Val
85 90 95

Thr Val Arg Ala His Leu Thr Gly Trp Leu Met Thr Leu Lys Lys Thr
100 105 110

Phe Val Leu Ala Pro Ser Ser Val Leu Arg Ile Ile Val Leu Ile Ala
115 120 125

Ser Leu Val Val Leu Pro Tyr Leu Gly Val His Gly Ala Thr Leu Gly
130 135 140

Val Gly Ser Leu Leu Ala Gly Phe Val Gly Glu Ser Thr Met Val Ala
145 150 155 160

Ile Ala Ala Cys Tyr Val Tyr Arg Lys Gln Lys Lys Lys Met Glu Asn
165 170 175

Glu Ser Ala Thr Glu Gly Glu Asp Ser Ala Met Thr Asp Met Pro Pro
180 185 190

Thr Glu Glu Val Thr Asp Ile Val Glu Met Arg Glu Glu Asn Glu
195 200 205

<210> 314
<211> 114
<212> PRT
<213> Homo sapiens

<400> 314
Gln Val Val Phe Val Ala Ile Leu Leu His Ser His Leu Glu Cys Arg
1 5 10 15

Glu Pro Leu Leu Ile Pro Ile Leu Ser Leu Tyr Met Gly Ala Leu Val
20 25 30

Arg Cys Thr Thr Leu Cys Leu Gly Tyr Tyr Lys Asn Ile His Asp Ile
35 40 45

Ile Pro Asp Arg Ser Gly Pro Glu Leu Gly Gly Asp Ala Thr Ile Arg
50 55 60

Lys Met Leu Ser Phe Trp Trp Pro Leu Ala Leu Ile Leu Ala Thr Gln
65 70 75 80

Arg Ile Ser Arg Pro Ile Val Asn Leu Phe Val Ser Arg Asp Leu Gly
85 90 95

Gly Ser Ser Ala Ala Thr Glu Ala Val Ala Ile Leu Thr Ala Thr Tyr
100 105 110

Pro Val

<210> 315
<211> 115

<212> PRT
<213> Homo sapiens

<400> 315
Arg Cys Cys Cys Arg Gly Cys Ser Cys Arg Ala Arg Leu Cys Pro Pro
1 5 10 15

Ala Arg Ser Thr Ala Val Ala Pro Glu Cys Arg Gly Ala His Pro Ser
20 25 30

Arg Ala Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val
35 40 45

Leu Leu Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln
50 55 60

Pro Val Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr
65 70 75 80

Phe His Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala
85 90 95

Cys Arg Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met
100 105 110

Asn Arg Asn
115

<210> 316
<211> 81
<212> PRT
<213> Homo sapiens

<400> 316
Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu
1 5 10 15

Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val
20 25 30

Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His
35 40 45

Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg
50 55 60

Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met Asn Arg
65 70 75 80

Asn

<210> 317
<211> 290
<212> PRT
<213> Homo sapiens

<400> 317

```
Ile Arg His Glu Gln Gln Gly Glu Glu Asp Asp Glu His Ala Arg Pro
  1               5                  10                  15

Leu Ala Glu Ser Leu Leu Leu Ala Ile Ala Asp Leu Leu Phe Cys Pro
             20                  25                  30

Asp Phe Thr Val Gln Ser His Arg Arg Ser Thr Val Asp Ser Ala Glu
         35                  40                  45

Asp Val His Ser Leu Asp Ser Cys Glu Tyr Ile Trp Glu Ala Gly Val
     50                  55                  60

Gly Phe Ala His Ser Pro Gln Pro Asn Tyr Ile His Asp Met Asn Arg
 65                  70                  75                  80

Met Glu Leu Leu Lys Leu Leu Leu Thr Cys Phe Ser Glu Ala Met Tyr
                 85                  90                  95

Leu Pro Pro Ala Pro Glu Ser Gly Ser Thr Asn Pro Trp Val Gln Phe
            100                 105                 110

Phe Cys Ser Thr Glu Asn Arg His Ala Leu Pro Leu Phe Thr Ser Leu
        115                 120                 125

Leu Asn Thr Val Cys Ala Tyr Asp Pro Val Gly Tyr Gly Ile Pro Tyr
    130                 135                 140

Asn His Leu Leu Phe Ser Asp Tyr Arg Glu Pro Leu Val Glu Glu Ala
145                 150                 155                 160

Ala Gln Val Leu Ile Val Thr Leu Asp His Asp Ser Ala Ser Ser Ala
                165                 170                 175

Ser Pro Thr Val Asp Gly Thr Thr Thr Gly Thr Ala Met Asp Asp Ala
            180                 185                 190

Asp Pro Pro Gly Pro Glu Asn Leu Phe Val Asn Tyr Leu Ser Arg Ile
        195                 200                 205

His Arg Glu Glu Asp Phe Gln Phe Ile Leu Lys Gly Ile Ala Arg Leu
    210                 215                 220

Leu Ser Asn Pro Leu Leu Gln Thr Tyr Leu Pro Asn Ser Thr Lys Lys
225                 230                 235                 240

Asp Pro Val Pro Pro Gly Ala Ala Ser Ser Leu Leu Glu Ala Leu Arg
                245                 250                 255

Leu Gln Gln Glu Ile Pro Leu Leu Arg Ala Glu Glu Gln Arg Arg Pro
            260                 265                 270

Arg His Pro Cys Pro His Pro Leu Leu Pro Gln Arg Cys Pro Gly Arg
        275                 280                 285

Ser Val
    290
```

<210> 318
<211> 318
<212> PRT
<213> Homo sapiens

<400> 318
Arg Leu Val Tyr Asn Lys Thr Ser Arg Ala Thr Gln Phe Pro Asp Gly
1   5   10   15

Val Asp Val Arg Val Pro Gly Phe Gly Lys Thr Phe Ser Leu Glu Phe
            20   25   30

Leu Asp Pro Ser Lys Ser Ser Val Gly Ser Tyr Phe His Thr Met Val
        35   40   45

Glu Ser Leu Val Gly Trp Gly Tyr Thr Arg Gly Glu Asp Val Arg Gly
    50   55   60

Ala Pro Tyr Asp Trp Arg Arg Ala Pro Asn Glu Asn Gly Pro Tyr Phe
65   70   75   80

Leu Ala Leu Arg Glu Met Ile Glu Glu Met Tyr Gln Leu Tyr Gly Gly
                85   90   95

Pro Val Val Leu Val Ala His Ser Met Gly Asn Met Tyr Thr Leu Tyr
            100   105   110

Phe Leu Gln Arg Gln Pro Gln Ala Trp Lys Asp Lys Tyr Ile Arg Ala
        115   120   125

Phe Val Ser Leu Gly Ala Pro Trp Gly Gly Val Ala Lys Thr Leu Arg
    130   135   140

Val Leu Ala Ser Gly Asp Asn Asn Arg Ile Pro Val Ile Gly Pro Leu
145   150   155   160

Lys Ile Arg Glu Gln Gln Arg Ser Ala Val Ser Thr Ser Trp Leu Leu
                165   170   175

Pro Tyr Asn Tyr Thr Trp Ser Pro Glu Lys Val Phe Val Gln Thr Pro
            180   185   190

Thr Ile Asn Tyr Thr Leu Arg Asp Tyr Arg Lys Phe Phe Gln Asp Ile
        195   200   205

Gly Phe Glu Asp Gly Trp Leu Met Arg Gln Asp Thr Glu Gly Leu Val
    210   215   220

Glu Ala Thr Met Pro Pro Gly Val Gln Leu His Cys Leu Tyr Gly Thr
225   230   235   240

Gly Val Pro Thr Pro Asp Ser Phe Tyr Tyr Glu Ser Phe Pro Asp Arg
                245   250   255

Asp Pro Lys Ile Cys Phe Gly Asp Gly Asp Gly Thr Val Asn Leu Lys
            260   265   270

Ser Ala Leu Gln Cys Gln Ala Trp Gln Ser Arg Gln Glu His Gln Val
        275   280   285

Leu Leu Gln Glu Leu Pro Gly Ser Glu His Ile Glu Met Leu Ala Asn
290 295 300

Ala Thr Thr Leu Ala Tyr Leu Lys Arg Val Leu Leu Gly Pro
305 310 315

<210> 319
<211> 362
<212> PRT
<213> Homo sapiens

<400> 319
Met Asn Lys Glu Asp Lys Val Trp Asn Asp Cys Lys Gly Val Asn Lys
1 5 10 15

Leu Thr Asn Leu Glu Glu Gln Tyr Ile Ile Leu Ile Phe Gln Asn Gly
20 25 30

Leu Asp Pro Pro Ala Asn Met Val Phe Glu Ser Ile Ile Asn Glu Ile
35 40 45

Gly Ile Lys Asn Asn Ile Ser Asn Phe Phe Ala Lys Ile Pro Phe Glu
50 55 60

Glu Ala Asn Gly Arg Leu Val Ala Cys Thr Arg Thr Tyr Glu Glu Ser
65 70 75 80

Ile Lys Gly Ser Cys Gly Gln Lys Glu Asn Lys Ile Lys Thr Val Ser
85 90 95

Phe Glu Ser Lys Ile Gln Leu Arg Ser Lys Gln Glu Phe Gln Phe Phe
100 105 110

Asp Glu Glu Glu Glu Thr Gly Glu Asn His Thr Ile Phe Ile Gly Pro
115 120 125

Val Glu Lys Leu Ile Val Tyr Pro Pro Pro Pro Ala Lys Gly Gly Ile
130 135 140

Ser Val Thr Asn Glu Asp Leu His Cys Leu Asn Glu Gly Glu Phe Leu
145 150 155 160

Asn Asp Val Ile Ile Asp Phe Tyr Leu Lys Tyr Leu Val Leu Glu Lys
165 170 175

Leu Lys Lys Glu Asp Ala Asp Arg Ile His Ile Phe Ser Ser Phe Phe
180 185 190

Tyr Lys Arg Leu Asn Gln Arg Glu Arg Arg Asn His Glu Thr Thr Asn
195 200 205

Leu Ser Ile Gln Gln Lys Arg His Gly Arg Val Lys Thr Trp Thr Arg
210 215 220

His Val Asp Ile Phe Glu Lys Asp Phe Ile Phe Val Pro Leu Asn Glu
225 230 235 240

Ala Ala His Trp Phe Leu Ala Val Val Cys Phe Pro Gly Leu Glu Lys
245 250 255

Pro Lys Tyr Glu Pro Asn Pro His Tyr His Glu Asn Ala Val Ile Gln
260 265 270

Lys Cys Ser Thr Val Glu Asp Ser Cys Ile Ser Ser Ser Ala Ser Glu
275 280 285

Met Glu Ser Cys Ser Gln Asn Ser Ser Ala Lys Pro Val Ile Lys Lys
290 295 300

Met Leu Asn Lys Lys His Cys Ile Ala Val Ile Asp Ser Asn Pro Gly
305 310 315 320

Gln Glu Glu Ser Asp Pro Arg Tyr Lys Arg Asn Ile Cys Ser Val Lys
325 330 335

Tyr Ser Val Lys Lys Ile Asn His Thr Ala Ser Glu Asn Glu Glu Phe
340 345 350

Asn Lys Gly Glu Ser Thr Ser Gln Lys Ser
355 360

<210> 320
<211> 330
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (247)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 320
Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
1 5 10 15

Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
20 25 30

Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
35 40 45

Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Asn Ile Trp Arg
50 55 60

Asp Leu Gly Met His Val Ile Ile Ala Gly Asn Asn Asp Ser Lys Ala
65 70 75 80

Lys Gln Val Val Ser Lys Ile Lys Glu Glu Thr Leu Asn Asp Lys Val
85 90 95

```
Glu Phe Leu Tyr Cys Asp Leu Ala Ser Met Thr Ser Ile Arg Gln Phe
            100                 105                 110

Val Gln Lys Phe Lys Met Lys Lys Ile Pro Leu His Val Leu Ile Asn
        115                 120                 125

Asn Ala Gly Val Met Met Val Pro Gln Arg Lys Thr Arg Asp Gly Phe
    130                 135                 140

Glu Glu His Phe Gly Leu Asn Tyr Leu Gly His Phe Leu Leu Thr Asn
145                 150                 155                 160

Leu Leu Leu Asp Thr Leu Lys Glu Ser Gly Ser Pro Gly His Ser Ala
                165                 170                 175

Arg Val Val Thr Val Ser Ser Ala Thr His Tyr Val Ala Glu Leu Asn
            180                 185                 190

Met Asp Asp Leu Gln Ser Ser Ala Cys Tyr Ser Pro His Ala Ala Tyr
        195                 200                 205

Ala Gln Ser Lys Leu Ala Leu Val Leu Phe Thr Tyr His Leu Gln Arg
    210                 215                 220

Leu Leu Ala Ala Glu Gly Ser His Val Thr Ala Asn Val Val Asp Pro
225                 230                 235                 240

Gly Val Val Asn Thr Asp Xaa Tyr Lys His Val Phe Trp Ala Thr Arg
                245                 250                 255

Leu Ala Lys Lys Leu Leu Gly Trp Leu Leu Phe Lys Thr Pro Asp Glu
            260                 265                 270

Gly Ala Trp Thr Ser Ile Tyr Ala Ala Val Thr Pro Glu Leu Glu Gly
        275                 280                 285

Val Gly Gly Arg Tyr Leu Tyr Asn Glu Lys Glu Thr Lys Ser Leu His
    290                 295                 300

Val Thr Tyr Asn Gln Lys Leu Gln Gln Gln Leu Trp Ser Lys Ser Cys
305                 310                 315                 320

Glu Met Thr Gly Val Leu Asp Val Thr Leu
                325                 330
```

<210> 321
<211> 71
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (38)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 321

```
Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val
1               5                   10                  15
```

```
Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly
            20                  25                  30

Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val
        35                  40                  45

Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Asn Ile Trp Arg
    50                  55                  60

Asp Leu Ala Cys Met Leu Ser
65                  70


<210> 322
<211> 266
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (97)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (174)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (195)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (199)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (206)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 322
Met Glu Val Thr Thr Glu Asp Thr Ser Arg Thr Asp Val Ser Glu Pro
1               5                   10                  15

Ala Thr Ser Gly Gly Ala Ala Asp Gly Val Thr Ser Ile Ala Pro Thr
            20                  25                  30

Ala Val Ala Ser Ser Thr Thr Ala Ala Ser Ile Thr Thr Ala Ala Ser
        35                  40                  45

Ser Met Thr Val Ala Ser Ser Ala Pro Thr Thr Ala Ala Ser Ser Thr
    50                  55                  60

Thr Val Ala Ser Ile Ala Pro Thr Thr Thr Ala Ser Ser Met Thr Ala
65                  70                  75                  80
```

Ala Ser Ser Thr Pro Met Thr Leu Ala Leu Pro Ala Pro Thr Ser Thr
85 90 95

Xaa Thr Gly Arg Thr Pro Ser Thr Thr Ala Thr Gly His Pro Ser Leu
100 105 110

Ser Thr Ala Leu Ala Gln Val Pro Lys Ser Ser Ala Leu Pro Arg Thr
115 120 125

Ala Thr Leu Ala Thr Leu Ala Thr Arg Ala Gln Thr Val Ala Thr Thr
130 135 140

Ala Asn Thr Ser Ser Pro Met Ser Thr Arg Pro Ser Pro Ser Lys His
145 150 155 160

Met Pro Ser Asp Thr Ala Ala Ser Pro Val Pro Pro Met Xaa Pro Gln
165 170 175

Ala Gln Gly Pro Ile Ser Gln Val Ser Val Asp Gln Pro Val Val Asn
180 185 190

Thr Thr Xaa Lys Ser Thr Xaa Met Pro Ser Asn Thr Thr Xaa Glu Pro
195 200 205

Leu Thr Gln Ala Val Val Asp Lys Thr Leu Leu Leu Val Val Leu Leu
210 215 220

Leu Gly Val Thr Leu Phe Ile Thr Val Leu Val Leu Phe Ala Leu Gln
225 230 235 240

Ala Tyr Glu Ser Tyr Lys Lys Lys Asp Tyr Thr Gln Val Asp Tyr Leu
245 250 255

Ile Asn Gly Met Tyr Ala Asp Ser Glu Met
260 265

<210> 323
<211> 99
<212> PRT
<213> Homo sapiens

<400> 323
Ala Arg Cys Pro Glu Leu Pro Gly Leu Arg Cys Arg Pro Arg Pro Arg
1 5 10 15

Ala Gly Pro Gln Ala Pro Ser Tyr Cys Pro Arg Ala Thr Arg Pro Pro
20 25 30

Gly Ala Cys Cys Ala Arg Met Arg Leu Leu Leu Glu Trp Arg Val Tyr
35 40 45

Leu Arg Leu Thr Cys Ala Thr Lys Asp Gly Met Ala Arg Glu Cys Pro
50 55 60

Thr Thr Trp Leu Ser Pro Pro Ala Lys Pro Asp Phe Ala Gln Arg His
65 70 75 80

Ser Val Lys Pro Thr Ala Leu Gln Gly Gly Arg Trp Ser Arg Leu Gly
85 90 95

Ala Ser Pro

<210> 324
<211> 96
<212> PRT
<213> Homo sapiens

<400> 324
Leu Pro Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser
1 5 10 15

Lys Asp Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys
20 25 30

Glu Gln Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu Gly
35 40 45

Arg Thr Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe
50 55 60

Gln Glu Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr Ile
65 70 75 80

Ser Thr Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr Cys
85 90 95

<210> 325
<211> 166
<212> PRT
<213> Homo sapiens

<400> 325
Leu Leu Trp Ala Arg Gly Leu Gly Arg Ala Lys Ser Ala Val Pro Thr
1 5 10 15

Val Ser Thr Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala
20 25 30

Leu Leu Leu Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp
35 40 45

His Phe His Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg
50 55 60

Tyr Leu Pro Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln
65 70 75 80

Ser Lys Asp Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp
85 90 95

Lys Glu Gln Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu
100 105 110

Gly Arg Thr Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His
115 120 125

Phe Gln Glu Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr
130 135 140

Ile Ser Thr Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr
145 150 155 160

Cys Leu Glu Gly Phe His
165

<210> 326
<211> 214
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (200)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (205)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 326
Leu Glu Gln Lys Leu Glu Leu His Arg Gly Gly Gly Arg Ser Arg Thr
1 5 10 15

Ser Gly Ser Pro Gly Leu Gln Glu Phe Gly Thr Arg Glu Glu Arg Gly
20 25 30

Glu Gly Glu Gln Arg Thr Gly Arg Glu Phe Ser Gly Asn Gly Gly Arg
35 40 45

Ala Val Glu Ala Ala Arg Met Arg Leu Leu Cys Gly Leu Trp Leu Trp
50 55 60

Leu Ser Leu Leu Lys Val Leu Gln Ala Gln Thr Pro Thr Pro Leu Pro
65 70 75 80

Leu Pro Pro Pro Met Gln Ser Phe Gln Gly Asn Gln Phe Gln Gly Glu
85 90 95

Trp Phe Val Leu Gly Leu Ala Gly Asn Ser Phe Arg Pro Glu His Arg
100 105 110

Ala Leu Leu Asn Ala Phe Thr Ala Thr Phe Glu Leu Ser Asp Asp Gly
115 120 125

Arg Phe Glu Val Trp Asn Ala Met Thr Arg Gly Gln His Cys Asp Thr
130 135 140

```
Trp Ser Tyr Val Leu Ile Pro Ala Ala Gln Pro Gly Gln Phe Thr Val
145                 150                 155                 160

Asp His Gly Val Gly Arg Ser Trp Leu Leu Pro Pro Gly Thr Leu Asp
                165                 170                 175

Gln Phe Ile Cys Leu Gly Arg Ala Gln Gly Leu Ser Asp Asp Asn Ile
            180                 185                 190

Val Phe Pro Asp Val Thr Gly Xaa Ala Leu Asp Leu Xaa Ser Leu Pro
        195                 200                 205

Trp Val Ala Ala Pro Ala
    210


<210> 327
<211> 181
<212> PRT
<213> Homo sapiens

<400> 327
Met Cys Val Cys Glu Arg Lys Arg Gly Arg Glu Lys Glu Gly Gly Val
  1               5                  10                  15

Thr Pro Thr Met Thr Ser Asn Phe Pro Phe Cys Thr Leu Ile Leu Gly
             20                  25                  30

Ile Ala Gln Ala Gln Ala Cys Pro Gly Cys Pro Gly Asp Trp Pro Gly
         35                  40                  45

Leu Gly Ser Gly Val Gly Glu Gly Leu His His Ile Arg Thr Cys Arg
     50                  55                  60

Thr Pro Ile Pro Cys Ser Pro Pro Ala Pro Ala Ala Ala Cys Leu Gly
 65                  70                  75                  80

Ser Gly His Ala Arg Leu Pro Cys Val Leu Arg Leu Trp Pro Val Pro
                 85                  90                  95

Ala Asn Leu Ser Ser Pro Phe Arg Leu Glu Ala Leu His Cys Ser Phe
            100                 105                 110

Trp Ser Ser Pro Leu Leu Pro Ala Pro His Leu Ala Phe Phe Gly Phe
        115                 120                 125

Arg Asp Leu Leu Thr Asp Phe Leu Leu Ala Ala Cys Leu Leu Thr Phe
    130                 135                 140

Gln Lys Thr Pro Leu Glu Leu Pro Met Ala Val Val His Leu Leu Val
145                 150                 155                 160

Ala Thr Pro Cys Tyr Gln Met Leu Asp Asn Leu Pro Leu Pro Ser Ala
                165                 170                 175

Ala Ala Asn Trp Cys
            180
```

<210> 328
<211> 195
<212> PRT
<213> Homo sapiens

<400> 328
Tyr Leu Trp Gly Arg Pro Arg Leu Arg Met Arg Ala Gly Thr Ser Pro
1 5 10 15

Ser Ala Pro Trp Gly Glu Lys Arg Glu Lys Leu Gly His Lys Leu Pro
20 25 30

Val Ala Leu Gln Gly Tyr His Pro Trp Ile Leu Leu Glu Cys Thr Val
35 40 45

Phe Trp Ala Arg Val Val Leu Ala Cys Phe Ser Leu Tyr Leu Ile Arg
50 55 60

Gly Pro Asn Cys Ile Asn Arg Gln Pro Glu Pro Thr Tyr Gln Lys Ala
65 70 75 80

Cys Asn Leu Asp Cys Ser Ser Asp Phe Gly Gln Glu Arg Ala Pro Ala
85 90 95

Trp Glu Leu Leu Gly Pro Glu Ser Glu Gln Arg Leu Arg Glu Tyr Thr
100 105 110

Ala Gln Gly Leu Gln Ser Leu Ala Ser Ser His Arg Trp Arg Gln Phe
115 120 125

Lys Thr Glu Gly Lys Met Arg Gly Gly Ala Ser Pro Leu Pro Trp Leu
130 135 140

Ile Cys Phe Trp Leu Cys Ser Tyr Lys Gly Ser Asp Asn Ser Leu Lys
145 150 155 160

Pro Val Val Pro Gly Pro Thr Leu Cys Pro Gln Ser Leu Val Ser Pro
165 170 175

Ser Val His Pro Ser Thr Arg Ser Ala Ser Leu Gly Arg His Arg Ala
180 185 190

Glu Ala Ala
195

<210> 329
<211> 50
<212> PRT
<213> Homo sapiens

<400> 329
Met Pro Gly Ile Leu Ala Gly Ile Pro Val Lys Asp Leu Cys Leu Ser
1 5 10 15

Leu Leu Gln Gly Phe Arg Leu Leu Leu Leu Cys Val Cys Pro Gly Trp
20 25 30

Leu Ser Gly Trp Met Gly Gly Gln Lys Gly Ser Pro Arg Ile Val Asp

35 40 45

Ile Gly
50

<210> 330
<211> 90
<212> PRT
<213> Homo sapiens

<400> 330
Ala Lys Gly Glu Glu Arg Lys Glu Ala Phe Ser Leu Lys Met Val Gln
1 5 10 15

Leu Ser Ser Glu Pro Ile Ser Phe Gly Leu Met Tyr Leu Tyr Leu Gly
20 25 30

Val Phe Phe His Leu Ile Tyr Pro Gly Ala Leu Ser Ile Thr Thr Leu
35 40 45

Gly Lys His Ser His Pro Phe Phe Thr Ala Glu Gln Asn Ser Thr Val
50 55 60

Trp Met Glu His Thr Leu Phe His Gln Ser Pro Val Ala Ser His Leu
65 70 75 80

Val Cys Phe Gln Ser Phe Ala Phe Ser Glu
85 90

<210> 331
<211> 56
<212> PRT
<213> Homo sapiens

<400> 331
Gly Pro Ala His Pro Ala Ser Pro Pro Leu Met Thr Leu Ser Leu Gln
1 5 10 15

Leu Ala Glu Leu Val His Phe Val Cys Ala Phe Gln Ser Gln Trp Thr
20 25 30

Gly Val Tyr Pro Met Met Pro Pro Leu Lys Pro Thr Glu Pro Leu Cys
35 40 45

Phe Ala Cys Val Pro Cys Arg Val
50 55

<210> 332
<211> 18
<212> PRT
<213> Homo sapiens

<400> 332
Met Leu Leu Glu Val Tyr Gly Asp Ser Ile Ser Val Thr Val Ala Ile
1 5 10 15

Pro Leu

<210> 333
<211> 19
<212> PRT
<213> Homo sapiens

<400> 333
Met His Ser Pro Cys Gln Ser Lys Ala Ala Asp Gly Leu Gly Lys Ser
1 5 10 15

Glu Thr Glu

<210> 334
<211> 10
<212> PRT
<213> Homo sapiens

<400> 334
Met Leu Lys Ser Leu Gly Leu Ser Thr Asn
1 5 10

<210> 335
<211> 200
<212> PRT
<213> Homo sapiens

<400> 335
Ala Gln Arg Leu Ala Glu Glu Cys Phe Tyr Met Leu Leu Glu Val Tyr
1 5 10 15

Gly Asp Ser Ile Ser Val Thr Val Ala Ile Pro Leu Met His Ser Pro
20 25 30

Cys Gln Ser Lys Ala Ala Asp Gly Leu Gly Lys Ser Glu Thr Glu Met
35 40 45

Leu Lys Ser Leu Gly Leu Ser Thr Asn Met Ser Pro Phe His Leu Leu
50 55 60

Gly Leu Lys Val Phe Leu Thr Trp Ala Leu Thr Leu Ala Gln Ile Cys
65 70 75 80

Leu Tyr Phe Phe Glu Val Gln Pro Leu Gly Leu Leu Ala Leu Asn Phe
85 90 95

Phe Cys Thr Ala Thr Ala Gly Leu Lys Glu Leu Cys Met His Pro Pro
100 105 110

Ser Leu Ala Phe Thr Pro Glu Phe His Thr Ser Leu Ser Pro Leu Ala
115 120 125

Ile Pro Ser Phe Cys Gly Thr Ser Val Ser Leu Ser Asn Ser His Thr
130 135 140

```
Ile Pro Leu Ser Leu Tyr Leu Pro Phe Pro Ser Lys Ser Arg Met Pro
145                 150                 155                 160

Asp Thr Leu His Leu Leu Val His Ser Leu Pro Leu Val His Ser Gln
                165                 170                 175

Val Leu Pro Val Lys Asp Val Thr Ile Glu Trp Pro Leu Cys Gln Arg
            180                 185                 190

Cys Leu Gly Ser Thr Cys His Gln
        195                 200


<210> 336
<211> 99
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (94)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (99)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 336
Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Val Gln Val Ser Leu
  1               5                  10                  15

Phe Gln Met Phe Cys Phe Ser Ser Ile Phe Cys Ser His Glu His Thr
             20                  25                  30

His Leu Pro Gly Thr Phe Trp Leu Phe Leu Phe Leu Phe Leu Ile Leu
         35                  40                  45

Pro Pro Ser Cys Pro Cys Phe Leu Pro Phe Ser Leu Ala Ile Glu Thr
     50                  55                  60

Val Arg Trp Pro Cys Trp His His Pro Thr Ser Phe Glu Leu Cys Tyr
 65                  70                  75                  80

Pro Gly Thr Ser Ile Tyr Tyr Ala Ser Arg Gly Gly Pro Xaa Pro Asn
                 85                  90                  95

Ser Glu Xaa


<210> 337
<211> 96
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
```

<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (3)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 337
Xaa Asn Xaa Lys Ser Pro Leu Thr Ile Gly Asn Lys Ser Trp Ser Ser
1 5 10 15

Thr Ala Val Ala Ala Ala Leu Glu Leu Val Asp Pro Pro Gly Cys Arg
20 25 30

Asn Ser Ala Arg Asp Ser Pro Glu Leu Val His Leu Gly Lys Gly Arg
35 40 45

Pro Arg Lys Leu Met Thr Tyr Leu Phe Cys Ser Ser Ile Ser Leu Leu
50 55 60

Leu Leu Lys Val His Ser Ser Gly His Gln Asp Ile Arg Lys Ala Lys
65 70 75 80

Ser Lys Val Pro Arg Leu Leu Ile Ile Gln Cys Pro Gln Gln Arg Glu
85 90 95

<210> 338
<211> 54
<212> PRT
<213> Homo sapiens

<400> 338
Gly Pro Glu Glu Asn Leu Ser Pro Ser Thr Pro Ser Gln Met Pro Thr
1 5 10 15

Ile Trp Val Lys Leu Cys Leu Leu Gln Val Cys His Gly Leu Phe Pro
20 25 30

Leu Leu Lys His Trp Ser Gln Pro Met Pro Leu Cys Val Thr Leu Ala
35 40 45

Pro Val Ser Tyr Trp Leu
50

<210> 339
<211> 287
<212> PRT
<213> Homo sapiens

<400> 339
Pro Arg Val Arg Lys Glu Pro Glu Ala Met Gln Trp Leu Arg Val Arg
1 5 10 15

Glu Ser Pro Gly Glu Ala Thr Gly His Arg Val Thr Met Gly Thr Ala
20 25 30

Ala Leu Gly Pro Val Trp Ala Ala Leu Leu Leu Phe Leu Leu Met Cys
35 40 45

Glu Ile Pro Met Val Glu Leu Thr Phe Asp Arg Ala Val Ala Ser Asp
50 55 60

Cys Gln Arg Cys Cys Asp Ser Glu Asp Pro Leu Asp Pro Ala His Val
65 70 75 80

Ser Ser Ala Ser Ser Ser Gly Arg Pro His Ala Leu Pro Glu Ile Arg
85 90 95

Pro Tyr Ile Asn Ile Thr Ile Leu Lys Gly Asp Lys Gly Asp Pro Gly
100 105 110

Pro Met Gly Leu Pro Gly Tyr Met Gly Arg Glu Gly Pro Gln Gly Glu
115 120 125

Pro Gly Pro Gln Gly Ser Lys Gly Asp Lys Gly Glu Met Gly Ser Pro
130 135 140

Gly Ala Pro Cys Gln Lys Arg Phe Phe Ala Phe Ser Val Gly Arg Lys
145 150 155 160

Thr Ala Leu His Ser Gly Glu Asp Phe Gln Thr Leu Leu Phe Glu Arg
165 170 175

Val Phe Val Asn Leu Asp Gly Cys Phe Asp Met Ala Thr Gly Gln Phe
180 185 190

Ala Ala Pro Leu Arg Gly Ile Tyr Phe Phe Ser Leu Asn Val His Ser
195 200 205

Trp Asn Tyr Lys Glu Thr Tyr Val His Ile Met His Asn Gln Lys Glu
210 215 220

Ala Val Ile Leu Tyr Ala Gln Pro Ser Glu Arg Ser Ile Met Gln Ser
225 230 235 240

Gln Ser Val Met Leu Asp Leu Ala Tyr Gly Asp Arg Val Trp Val Arg
245 250 255

Leu Phe Lys Arg Gln Arg Glu Asn Ala Ile Tyr Ser Asn Asp Phe Asp
260 265 270

Thr Tyr Ile Thr Phe Ser Gly His Leu Ile Lys Ala Glu Asp Asp
275 280 285

<210> 340
<211> 339
<212> PRT
<213> Homo sapiens

<400> 340
Met Leu Tyr Pro Gly Ser Val Tyr Leu Leu Gln Lys Ala Leu Met Pro

1 5 10 15

Val Leu Leu Gln Gly Gln Ala Arg Leu Val Glu Glu Cys Asn Gly Arg
20 25 30

Arg Ala Lys Leu Leu Ala Cys Asp Gly Asn Glu Ile Asp Thr Met Phe
35 40 45

Val Asp Arg Arg Gly Thr Ala Glu Pro Gln Gly Gln Lys Leu Val Ile
50 55 60

Cys Cys Glu Gly Asn Ala Gly Phe Tyr Glu Val Gly Cys Val Ser Thr
65 70 75 80

Pro Leu Glu Ala Gly Tyr Ser Val Leu Gly Trp Asn His Pro Gly Phe
85 90 95

Ala Gly Ser Thr Gly Val Pro Phe Pro Gln Asn Glu Ala Asn Ala Met
100 105 110

Asp Val Val Val Gln Phe Ala Ile His Arg Leu Gly Phe Gln Pro Gln
115 120 125

Asp Ile Ile Ile Tyr Ala Trp Ser Ile Gly Gly Phe Thr Ala Thr Trp
130 135 140

Ala Ala Met Ser Tyr Pro Asp Val Ser Ala Met Ile Leu Asp Ala Ser
145 150 155 160

Phe Asp Asp Leu Val Pro Leu Ala Leu Lys Val Met Pro Asp Ser Trp
165 170 175

Arg Gly Leu Val Thr Arg Thr Val Arg Gln His Leu Asn Leu Asn Asn
180 185 190

Ala Glu Gln Leu Cys Arg Tyr Gln Gly Pro Val Leu Leu Ile Arg Arg
195 200 205

Thr Lys Asp Glu Ile Ile Thr Thr Thr Val Pro Glu Asp Ile Met Ser
210 215 220

Asn Arg Gly Asn Asp Leu Leu Leu Lys Leu Leu Gln His Arg Tyr Pro
225 230 235 240

Arg Val Met Ala Glu Glu Gly Leu Arg Val Val Arg Gln Trp Leu Glu
245 250 255

Ala Ser Ser Gln Leu Glu Glu Ala Ser Ile Tyr Ser Arg Trp Glu Val
260 265 270

Glu Glu Asp Trp Cys Leu Ser Val Leu Arg Ser Tyr Gln Ala Glu His
275 280 285

Gly Pro Asp Phe Pro Trp Ser Val Gly Glu Asp Met Ser Ala Asp Gly
290 295 300

Arg Arg Gln Leu Ala Leu Phe Leu Ala Arg Lys His Leu His Asn Phe
305 310 315 320

Glu Ala Thr His Cys Thr Pro Leu Pro Ala Gln Asn Phe Gln Met Pro
325 330 335

Trp His Leu

<210> 341
<211> 127
<212> PRT
<213> Homo sapiens

<400> 341
Val Cys Pro Lys Trp Cys Arg Phe Leu Thr Met Leu Gly His Cys Cys
1 5 10 15

Tyr Phe Trp Gln Val Trp Pro Ala Ser Glu Ala Leu Ala Ala Gly Pro
20 25 30

Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His Ile Gly
35 40 45

Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr Leu Thr
50 55 60

Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala Ala Gly
65 70 75 80

Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys Phe Ala
85 90 95

Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr Gly Leu
100 105 110

Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr Pro
115 120 125

<210> 342
<211> 554
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (16)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (109)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 342
Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Ile Tyr Arg Glu Xaa
1 5 10 15

Asp Ser Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val
20 25 30

Thr Ala Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala
35 40 45

Leu Glu Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp
50 55 60

Ser Ile Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg
65 70 75 80

Lys Gly Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala
85 90 95

Gly Thr Leu Leu Leu Leu Leu Ala Gly Val Ala Cys Xaa Arg Gly Ile
100 105 110

Gly Arg Trp Thr Asn Pro Gln Tyr Arg Gln Phe Ile Thr Ile Leu Glu
115 120 125

Ala Thr His Arg Asn Gln Ser Ser Glu Asn Lys Arg Gln Leu Ala Asn
130 135 140

Tyr Asn Phe Asp Phe Arg Ser Trp Pro Val Asp Phe His Trp Glu Glu
145 150 155 160

Pro Ser Ser Arg Lys Glu Ser Arg Gly Gly Pro Ser Arg Arg Gly Val
165 170 175

Ala Leu Leu Arg Pro Glu Pro Leu His Arg Gly Thr Ala Asp Thr Leu
180 185 190

Leu Asn Arg Val Lys Lys Leu Pro Cys Gln Ile Thr Ser Tyr Leu Val
195 200 205

Ala His Thr Leu Gly Arg Arg Met Leu Tyr Pro Gly Ser Val Tyr Leu
210 215 220

Leu Gln Lys Ala Leu Met Pro Val Leu Leu Gln Gly Gln Ala Arg Leu
225 230 235 240

Val Glu Glu Cys Asn Gly Arg Arg Ala Lys Leu Leu Ala Cys Asp Gly
245 250 255

Asn Glu Ile Asp Thr Met Phe Val Asp Arg Arg Gly Thr Ala Glu Pro
260 265 270

Gln Gly Gln Lys Leu Val Ile Cys Cys Glu Gly Asn Ala Gly Phe Tyr
275 280 285

Glu Val Gly Cys Val Ser Thr Pro Leu Glu Ala Gly Tyr Ser Val Leu
290 295 300

Gly Trp Asn His Pro Gly Phe Ala Gly Ser Thr Gly Val Pro Phe Pro
305 310 315 320

Gln Asn Glu Ala Asn Ala Met Asp Val Val Val Gln Phe Ala Ile His
325 330 335

Arg Leu Gly Phe Gln Pro Gln Asp Ile Ile Ile Tyr Ala Trp Ser Ile

340 345 350

Gly Gly Phe Thr Ala Thr Trp Ala Ala Met Ser Tyr Pro Asp Val Ser
355 360 365

Ala Met Ile Leu Asp Ala Ser Phe Asp Asp Leu Val Pro Leu Ala Leu
370 375 380

Lys Val Met Pro Asp Ser Trp Arg Gly Leu Val Thr Arg Thr Val Arg
385 390 395 400

Gln His Leu Asn Leu Asn Asn Ala Glu Gln Leu Cys Arg Tyr Gln Gly
405 410 415

Pro Val Leu Leu Ile Arg Arg Thr Lys Asp Glu Ile Ile Thr Thr Thr
420 425 430

Val Pro Glu Asp Ile Met Ser Asn Arg Gly Asn Asp Leu Leu Leu Lys
435 440 445

Leu Leu Gln His Arg Tyr Pro Arg Val Met Ala Glu Glu Gly Leu Arg
450 455 460

Val Val Arg Gln Trp Leu Glu Ala Ser Ser Gln Leu Glu Glu Ala Ser
465 470 475 480

Ile Tyr Ser Arg Trp Glu Val Glu Glu Asp Trp Cys Leu Ser Val Leu
485 490 495

Arg Ser Tyr Gln Ala Glu His Gly Pro Asp Phe Pro Trp Ser Val Gly
500 505 510

Glu Asp Met Ser Ala Asp Gly Arg Arg Gln Leu Ala Leu Phe Leu Ala
515 520 525

Arg Lys His Leu His Asn Phe Glu Ala Thr His Cys Thr Pro Leu Pro
530 535 540

Ala Gln Asn Phe Gln Met Pro Trp His Leu
545 550

<210> 343
<211> 225
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 343
His Glu Arg Ala Xaa Gly Pro Ser Arg Gly His Gly Glu Leu Leu Ser
1 5 10 15

Cys Val Leu Gly Pro Arg Leu Tyr Lys Ile Tyr Arg Glu Arg Asp Ser
20 25 30

Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val Thr Ala
35 40 45

Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala Leu Glu
50 55 60

Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp Ser Ile
65 70 75 80

Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg Lys Gly
85 90 95

Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala Gly Thr
100 105 110

Leu Leu Leu Leu Leu Ala Gly Val Ala Cys Ser Glu Ala Leu Ala Ala
115 120 125

Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His
130 135 140

Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr
145 150 155 160

Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala
165 170 175

Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys
180 185 190

Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr
195 200 205

Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr
210 215 220

Pro
225

<210> 344
<211> 299
<212> PRT
<213> Homo sapiens

<400> 344
Met Phe Lys Arg His Gln Arg Leu Lys Lys Asp Ser Thr Gln Ala Glu
1 5 10 15

Glu Asp Leu Ser Glu Gln Glu Gln Asn Gln Leu Asn Val Leu Lys Lys
20 25 30

His Gly Tyr Val Val Gly Arg Val Gly Arg Thr Phe Leu Tyr Ser Glu
35 40 45

Glu Gln Lys Asp Asn Ile Pro Phe Glu Phe Asp Ala Asp Ser Leu Ala
50 55 60

Phe Asp Met Glu Asn Asp Pro Val Met Gly Thr His Lys Ser Thr Lys

```
65                  70                  75                  80

Gln Val Glu Leu Thr Ala Gln Asp Val Lys Asp Ala His Trp Phe Tyr
                85                  90                  95

Asp Thr Pro Gly Ile Thr Lys Glu Asn Cys Ile Leu Asn Leu Leu Thr
            100                 105                 110

Glu Lys Glu Val Asn Ile Val Leu Pro Thr Gln Ser Ile Val Pro Arg
        115                 120                 125

Thr Phe Val Leu Lys Pro Gly Met Val Leu Phe Leu Gly Ala Ile Gly
    130                 135                 140

Arg Ile Asp Phe Leu Gln Gly Asn Gln Ser Ala Trp Phe Thr Val Val
145                 150                 155                 160

Ala Ser Asn Ile Leu Pro Val His Ile Thr Ser Leu Asp Arg Ala Asp
                165                 170                 175

Ala Leu Tyr Gln Lys His Ala Gly His Thr Leu Leu Gln Ile Pro Met
            180                 185                 190

Gly Gly Lys Glu Arg Met Ala Gly Phe Pro Pro Leu Val Ala Glu Asp
        195                 200                 205

Ile Met Leu Lys Glu Gly Leu Gly Ala Ser Glu Ala Val Ala Asp Ile
    210                 215                 220

Lys Phe Ser Ser Ala Gly Trp Val Ser Val Thr Pro Asn Phe Lys Asp
225                 230                 235                 240

Arg Leu His Leu Arg Gly Tyr Thr Pro Glu Gly Thr Val Leu Thr Val
                245                 250                 255

Arg Pro Pro Leu Leu Pro Tyr Ile Val Asn Ile Lys Gly Gln Arg Ile
            260                 265                 270

Lys Lys Ser Val Ala Tyr Lys Thr Lys Lys Pro Pro Ser Leu Met Tyr
        275                 280                 285

Asn Val Arg Lys Lys Lys Gly Lys Ile Asn Val
    290                 295


<210> 345
<211> 314
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (147)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (211)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<400> 345

```
Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg
  1               5                  10                  15

Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu
             20                  25                  30

Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu
         35                  40                  45

Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu
     50                  55                  60

Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp
 65                  70                  75                  80

Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln
                 85                  90                  95

Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg
            100                 105                 110

Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly
        115                 120                 125

His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys
    130                 135                 140

Gly Ala Xaa Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro
145                 150                 155                 160

Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg
                165                 170                 175

Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu
            180                 185                 190

Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala
        195                 200                 205

Leu Arg Xaa Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu
    210                 215                 220

Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro
225                 230                 235                 240

Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp
                245                 250                 255

Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys
            260                 265                 270

Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly Thr Lys Gly His Ser Ala
        275                 280                 285

Pro Ser Arg Thr Ser His Arg Thr Gly Arg Ile Arg Ile Arg Arg Thr
    290                 295                 300
```

Gly Pro Ala Gln Trp Ser Gly Thr Cys Gly
305 310

<210> 346
<211> 380
<212> PRT
<213> Homo sapiens

<400> 346
Pro Ser Phe Arg Arg Glu Arg Val Glu Thr Gly Gly Gly Gly Pro Val
1 5 10 15

Thr His Gly Thr Glu Gly Pro Phe Leu Pro Leu Pro Gly Gly Thr Arg
20 25 30

Met Asn Met Thr Gln Ala Arg Val Leu Val Ala Ala Val Val Gly Leu
35 40 45

Val Ala Val Leu Leu Tyr Ala Ser Ile His Lys Ile Glu Glu Gly His
50 55 60

Leu Ala Val Tyr Tyr Arg Gly Gly Ala Leu Leu Thr Ser Pro Ser Gly
65 70 75 80

Pro Gly Tyr His Ile Met Leu Pro Phe Ile Thr Thr Phe Arg Ser Val
85 90 95

Gln Thr Thr Leu Gln Thr Asp Glu Val Lys Asn Val Pro Cys Gly Thr
100 105 110

Ser Gly Gly Val Met Ile Tyr Ile Asp Arg Ile Glu Val Val Asn Met
115 120 125

Leu Ala Pro Tyr Ala Val Phe Asp Ile Val Arg Asn Tyr Thr Ala Asp
130 135 140

Tyr Asp Lys Thr Leu Ile Phe Asn Lys Ile His His Glu Leu Asn Gln
145 150 155 160

Phe Cys Ser Ala His Thr Leu Gln Glu Val Tyr Ile Glu Leu Phe Asp
165 170 175

Gln Ile Asp Glu Asn Leu Lys Gln Ala Leu Gln Lys Asp Leu Asn Leu
180 185 190

Met Ala Pro Gly Leu Thr Ile Gln Ala Val Arg Val Thr Lys Pro Lys
195 200 205

Ile Pro Glu Ala Ile Arg Arg Asn Phe Glu Leu Met Glu Ala Glu Lys
210 215 220

Thr Lys Leu Leu Ile Ala Ala Gln Lys Gln Lys Val Val Glu Lys Glu
225 230 235 240

Ala Glu Thr Glu Arg Lys Lys Ala Val Ile Glu Ala Glu Lys Ile Ala
245 250 255

Gln Val Ala Lys Ile Arg Phe Gln Gln Lys Val Met Glu Lys Glu Thr

```
            260                           265                      270

Glu Lys Arg Ile Ser Glu Ile Glu Asp Ala Ala Phe Leu Ala Arg Glu
        275                     280                     285

Lys Ala Lys Ala Asp Ala Glu Tyr Tyr Ala Ala His Lys Tyr Ala Thr
    290                     295                     300

Ser Asn Lys His Lys Leu Thr Pro Glu Tyr Leu Glu Leu Lys Lys Tyr
305                     310                     315                 320

Gln Ala Ile Ala Ser Asn Ser Lys Ile Tyr Phe Gly Ser Asn Ile Pro
                325                     330                     335

Asn Met Phe Val Asp Ser Ser Cys Ala Leu Lys Tyr Ser Asp Ile Arg
            340                     345                     350

Thr Gly Arg Glu Ser Ser Leu Pro Ser Lys Glu Ala Leu Glu Pro Ser
        355                     360                     365

Gly Glu Asn Val Ile Gln Asn Lys Glu Ser Thr Gly
    370                     375                     380


<210> 347
<211> 422
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (328)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 347
Trp Ser Thr Gly Asn Ala Ser Trp Glu Lys Lys Asp Asn Phe Ile Leu
 1               5                  10                  15

Ser Ala Asp Phe Glu Met Met Gly Leu Gly Asn Gly Arg Arg Ser Met
            20                  25                  30

Lys Ser Pro Pro Leu Val Leu Ala Ala Leu Val Ala Cys Ile Ile Val
        35                  40                  45

Leu Gly Phe Asn Tyr Trp Ile Ala Ser Ser Arg Ser Val Asp Leu Gln
    50                  55                  60

Thr Arg Ile Met Glu Leu Glu Gly Arg Val Arg Arg Arg Ala Ala Glu
65                  70                  75                  80

Arg Gly Ala Val Glu Leu Lys Lys Asn Glu Phe Gln Gly Glu Leu Glu
                85                  90                  95

Lys Gln Arg Glu Gln Leu Asp Lys Ile Gln Ser Ser His Asn Phe Gln
            100                 105                 110

Leu Glu Ser Val Asn Lys Leu Tyr Gln Asp Glu Lys Ala Val Leu Val
        115                 120                 125
```

Asn Asn Ile Thr Thr Gly Glu Arg Leu Ile Arg Val Leu Gln Asp Gln
130 135 140

Leu Lys Thr Leu Gln Arg Asn Tyr Gly Arg Leu Gln Gln Asp Val Leu
145 150 155 160

Gln Phe Gln Lys Asn Gln Thr Asn Leu Glu Arg Lys Phe Ser Tyr Asp
165 170 175

Leu Ser Gln Cys Ile Asn Gln Met Lys Glu Val Lys Glu Gln Cys Glu
180 185 190

Glu Arg Ile Glu Glu Val Thr Lys Lys Gly Asn Glu Ala Val Ala Ser
195 200 205

Arg Asp Leu Ser Glu Asn Asn Asp Gln Arg Gln Gln Leu Gln Ala Leu
210 215 220

Ser Glu Pro Gln Pro Arg Leu Gln Ala Ala Gly Leu Pro His Thr Glu
225 230 235 240

Val Pro Gln Gly Lys Gly Asn Val Leu Gly Asn Ser Lys Ser Gln Thr
245 250 255

Pro Ala Pro Ser Ser Glu Val Val Leu Asp Ser Lys Arg Gln Val Glu
260 265 270

Lys Glu Glu Thr Asn Glu Ile Gln Val Val Asn Glu Glu Pro Gln Arg
275 280 285

Asp Arg Leu Pro Gln Glu Pro Gly Arg Glu Gln Val Val Glu Asp Arg
290 295 300

Pro Val Gly Gly Arg Gly Phe Gly Gly Ala Gly Glu Leu Gly Gln Thr
305 310 315 320

Pro Gln Val Gln Ala Ala Leu Xaa Val Ser Gln Glu Asn Pro Glu Met
325 330 335

Glu Gly Pro Glu Arg Asp Gln Leu Val Ile Pro Asp Gly Gln Glu Glu
340 345 350

Glu Gln Glu Ala Ala Gly Glu Gly Arg Asn Gln Gln Lys Leu Arg Gly
355 360 365

Glu Asp Asp Tyr Asn Met Asp Glu Asn Glu Ala Glu Ser Glu Thr Asp
370 375 380

Lys Gln Ala Ala Leu Ala Gly Asn Asp Arg Asn Ile Asp Val Phe Asn
385 390 395 400

Val Glu Asp Gln Lys Arg Asp Thr Ile Asn Leu Leu Asp Gln Arg Glu
405 410 415

Lys Arg Asn His Thr Leu
420

<210> 348

<211> 14
<212> PRT
<213> Homo sapiens

<400> 348
Ser Leu His Arg Phe Val Leu Ser Gln Ala Lys Asp Glu Leu
1 5 10

<210> 349
<211> 19
<212> PRT
<213> Homo sapiens

<400> 349
Phe Ile Lys Phe Phe Ala Pro Trp Cys Gly His Cys Lys Ala Leu Ala
1 5 10 15

Pro Thr Trp

<210> 350
<211> 19
<212> PRT
<213> Homo sapiens

<400> 350
Phe Ile Lys Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Thr Leu Ala
1 5 10 15

Pro Thr Trp

<210> 351
<211> 363
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (42)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 351
Arg Arg Gly Arg Gly Val Pro Gly Pro Arg Gly Arg Arg Arg Leu Trp
1 5 10 15

Ser Ala Ala Cys Gly His Cys Gln Arg Leu Gln Pro Thr Trp Asn Asp
20 25 30

Leu Gly Asp Lys Tyr Asn Ser Met Glu Xaa Ala Lys Val Tyr Val Ala
35 40 45

Lys Val Asp Cys Thr Ala His Ser Asp Val Cys Ser Ala Gln Gly Val
50 55 60

Arg Gly Tyr Pro Thr Leu Lys Leu Phe Lys Pro Gly Gln Glu Ala Val

65 70 75 80

Lys Tyr Gln Gly Pro Arg Asp Phe Gln Thr Leu Glu Asn Trp Met Leu
85 90 95

Gln Thr Leu Asn Glu Glu Pro Val Thr Pro Glu Pro Glu Val Glu Pro
100 105 110

Pro Ser Ala Pro Glu Leu Lys Gln Gly Leu Tyr Glu Leu Ser Ala Ser
115 120 125

Asn Phe Glu Leu His Val Ala Gln Gly Asp His Phe Ile Lys Phe Phe
130 135 140

Ala Pro Trp Cys Gly His Cys Lys Ala Leu Ala Pro Thr Trp Glu Gln
145 150 155 160

Leu Ala Leu Gly Leu Glu His Ser Glu Thr Val Lys Ile Gly Lys Val
165 170 175

Asp Cys Thr Gln His Tyr Glu Leu Cys Ser Gly Asn Gln Val Arg Gly
180 185 190

Tyr Pro Thr Leu Leu Trp Phe Arg Asp Gly Lys Lys Val Asp Gln Tyr
195 200 205

Lys Gly Lys Arg Asp Leu Glu Ser Leu Arg Glu Tyr Val Glu Ser Gln
210 215 220

Leu Gln Arg Thr Glu Thr Gly Ala Thr Glu Thr Val Thr Pro Ser Glu
225 230 235 240

Ala Pro Val Leu Ala Ala Glu Pro Glu Ala Asp Lys Gly Thr Val Leu
245 250 255

Ala Leu Thr Glu Asn Asn Phe Asp Asp Thr Ile Ala Glu Gly Ile Thr
260 265 270

Phe Ile Lys Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Thr Leu Ala
275 280 285

Pro Thr Trp Glu Glu Leu Ser Lys Lys Glu Phe Pro Gly Leu Ala Gly
290 295 300

Val Lys Ile Ala Glu Val Asp Cys Thr Ala Glu Arg Asn Ile Cys Ser
305 310 315 320

Lys Tyr Ser Val Arg Gly Tyr Pro Thr Leu Leu Leu Phe Arg Gly Gly
325 330 335

Lys Lys Val Ser Glu His Ser Gly Gly Arg Asp Leu Asp Ser Leu His
340 345 350

Arg Phe Val Leu Ser Gln Ala Lys Asp Glu Leu
355 360

<210> 352
<211> 93

<212> PRT
<213> Homo sapiens

<400> 352
Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
1 5 10 15

Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
20 25 30

Ile Pro Lys Gly Lys Gln Lys Ala His Ser Gly Arg Gly Arg Trp Trp
35 40 45

Thr Cys Ile Met Glu Cys Ala Tyr Lys Gly Gln Gln Glu Cys Leu Val
50 55 60

Glu Thr Gly Ala Leu Gly Pro Met Ala Phe Arg Val His Leu Gly Ser
65 70 75 80

Gln Val Gly Met Asp Ser Lys Glu Lys Arg Gly Asn Val
85 90

<210> 353
<211> 273
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (210)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 353
Glu Thr Arg Val Lys Thr Ser Leu Glu Leu Leu Arg Thr Gln Leu Glu
1 5 10 15

Pro Thr Gly Thr Val Gly Asn Thr Ile Met Thr Ser Gln Pro Val Pro
20 25 30

Asn Glu Thr Ile Ile Val Leu Pro Ser Asn Val Ile Asn Phe Ser Gln
35 40 45

Ala Glu Lys Pro Glu Pro Thr Asn Gln Gly Gln Asp Ser Leu Lys Lys
50 55 60

His Leu His Ala Glu Ile Lys Val Ile Gly Thr Ile Gln Ile Leu Cys
65 70 75 80

Gly Met Met Val Leu Ser Leu Gly Ile Ile Leu Ala Ser Ala Ser Phe
85 90 95

Ser Pro Asn Phe Thr Gln Val Thr Ser Thr Leu Leu Asn Ser Ala Tyr
100 105 110

Pro Phe Ile Gly Pro Phe Phe Phe Ile Ile Ser Gly Ser Leu Ser Ile
115 120 125

Ala Thr Glu Lys Arg Leu Thr Lys Leu Leu Val His Ser Ser Leu Val

```
    130                 135                 140

Gly Ser Ile Leu Ser Ala Leu Ser Ala Leu Val Gly Phe Ile Ile Leu
145                 150                 155                 160

Ser Val Lys Gln Ala Thr Leu Asn Pro Ala Ser Leu Gln Cys Glu Leu
                165                 170                 175

Asp Lys Asn Asn Ile Pro Thr Arg Ser Tyr Val Ser Tyr Phe Tyr His
            180                 185                 190

Asp Ser Leu Tyr Thr Thr Asp Cys Tyr Thr Ala Lys Ala Ser Leu Ala
        195                 200                 205

Gly Xaa Leu Ser Leu Met Leu Ile Cys Thr Leu Leu Glu Phe Cys Leu
    210                 215                 220

Ala Val Leu Thr Ala Val Leu Arg Trp Lys Gln Ala Tyr Ser Asp Phe
225                 230                 235                 240

Pro Gly Ser Val Leu Phe Leu Pro His Ser Tyr Ile Gly Asn Ser Gly
                245                 250                 255

Met Ser Ser Lys Met Thr His Asp Cys Gly Tyr Glu Glu Leu Leu Thr
            260                 265                 270

Ser


<210> 354
<211> 192
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (129)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 354
Met Met Val Leu Ser Leu Gly Ile Ile Leu Ala Ser Ala Ser Phe Ser
  1               5                  10                  15

Pro Asn Phe Thr Gln Val Thr Ser Thr Leu Leu Asn Ser Ala Tyr Pro
             20                  25                  30

Phe Ile Gly Pro Phe Phe Phe Ile Ile Ser Gly Ser Leu Ser Ile Ala
         35                  40                  45

Thr Glu Lys Arg Leu Thr Lys Leu Leu Val His Ser Ser Leu Val Gly
     50                  55                  60

Ser Ile Leu Ser Ala Leu Ser Ala Leu Val Gly Phe Ile Ile Leu Ser
 65                  70                  75                  80

Val Lys Gln Ala Thr Leu Asn Pro Ala Ser Leu Gln Cys Glu Leu Asp
                 85                  90                  95
```

```
Lys Asn Asn Ile Pro Thr Arg Ser Tyr Val Ser Tyr Phe Tyr His Asp
            100                 105                 110

Ser Leu Tyr Thr Thr Asp Cys Tyr Thr Ala Lys Ala Ser Leu Ala Gly
        115                 120                 125

Xaa Leu Ser Leu Met Leu Ile Cys Thr Leu Leu Glu Phe Cys Leu Ala
    130                 135                 140

Val Leu Thr Ala Val Leu Arg Trp Lys Gln Ala Tyr Ser Asp Phe Pro
145                 150                 155                 160

Gly Ser Val Leu Phe Leu Pro His Ser Tyr Ile Gly Asn Ser Gly Met
                165                 170                 175

Ser Ser Lys Met Thr His Asp Cys Gly Tyr Glu Glu Leu Leu Thr Ser
            180                 185                 190
```

```
<210> 355
<211> 204
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (119)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 355
Gly Ala Ser Cys Glu Gly Gly Gly Ala Ala Ala Arg Ala Ala Leu Gly
 1               5                  10                  15

Val His Arg Ser Gln Lys Ala Leu Leu Val Phe Arg Arg Thr Leu Ser
            20                  25                  30

Asn Leu Leu Tyr Met Pro Leu Leu Arg Gly Leu Leu Trp Leu Gln Val
        35                  40                  45

Leu Cys Ala Gly Pro Leu His Thr Glu Ala Val Val Leu Leu Val Pro
    50                  55                  60

Ser Asp Asp Gly Arg Ala Phe Leu Leu Arg Ser Arg Leu Leu His Pro
65                  70                  75                  80

Glu Ala His Val Pro Pro Ala Ala Asp Arg Gly Ala Ser Leu Gln Cys
                85                  90                  95

Val Leu His Gln Ala Ala Pro Lys Ser Arg Pro Arg Ser Pro Ala Ala
            100                 105                 110

Gly Ala Ala Leu Leu His Xaa Pro Arg Arg Thr Gly Asp Glu Pro Cys
        115                 120                 125

Arg Glu Phe His Gly Asn Gly Phe Pro Gly Pro Thr Gln Leu Thr Pro
    130                 135                 140
```

```
Gly Glu Cys Gly Leu Pro Ala Pro Ser Ser Leu Leu Gln His Ala Ser
145                 150                 155                 160

Ala Pro Val Arg Thr Gly Ser Glu Gly Gln Val Val Gly Cys Pro Arg
                165                 170                 175

Ala Arg Gly Glu Thr Gly Glu Gly Leu Ser Leu Ala Phe Leu Ser Ser
            180                 185                 190

Leu Met Phe Thr Ser Arg Asn Gly Leu Val Gly Cys
        195                 200


<210> 356
<211> 72
<212> PRT
<213> Homo sapiens

<400> 356
Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val
 1               5                  10                  15

Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val
            20                  25                  30

Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Thr Trp Lys
        35                  40                  45

Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Thr Cys Ser Ala
    50                  55                  60

Lys Cys Thr Thr Arg Cys Trp Leu
65                  70


<210> 357
<211> 115
<212> PRT
<213> Homo sapiens

<400> 357
Leu Lys Arg Ala Pro Pro Gly Pro Ala Leu Ala Lys Gly Leu Leu Gln
 1               5                  10                  15

Pro Ser Ser Thr Phe Gln Ala Leu Glu Thr Asn Ile Gly Asp Gln Val
            20                  25                  30

Arg Arg His Ser Thr Ala Val Val Ile Arg Glu Met Thr Ser Tyr Ile
        35                  40                  45

Leu Ile Ser Phe Val Leu Leu Ile Gly Val Gly Cys Ile Glu Lys Asp
    50                  55                  60

Gln Ser Cys Pro Val Phe Gly Gly Arg Lys Arg Leu His Leu Leu Phe
65                  70                  75                  80

Val Gly Gly Gln Leu Arg Gln Val Arg Met Leu Arg Gly Glu Leu Ser
                85                  90                  95
```

```
Cys Ala Cys Tyr Arg Pro His Val Gln Ala Leu Gln Leu Gly Gly Cys
            100                 105                 110

Thr Cys Phe
        115


<210> 358
<211> 88
<212> PRT
<213> Homo sapiens

<400> 358
Val Ile Lys Leu Ile Cys Pro Ala Ala Phe Pro Val Tyr Phe Gln Asp
  1               5                  10                  15

Met Ala Arg Gly Cys Val Cys Ser Leu Cys Ala Ser Val Cys Ile Phe
             20                  25                  30

Leu Ser Ser Leu Phe Pro Leu Leu Pro Ser Val His Ser Val Asn Ile
         35                  40                  45

Ile Ser Cys Leu Leu Leu Ser Lys Cys Phe Glu Gly Leu Glu Leu Met
     50                  55                  60

Cys Glu His Leu Tyr Gln Leu Ser Gln Leu His Val Leu His His Ile
 65                  70                  75                  80

Phe Ser Tyr Leu Leu Cys Thr Pro
                 85


<210> 359
<211> 716
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (2)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (373)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (705)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 359
Tyr Xaa Ile Pro Gly Ser Thr His Ala Ser Gly Arg Gln Arg Gly Ser
  1               5                  10                  15

Gly Arg Gly Glu Asp Asp Ser Gly Pro Pro Pro Ser Thr Val Ile Asn
             20                  25                  30
```

```
Gln Asn Glu Thr Phe Ala Asn Ile Ile Phe Lys Pro Thr Val Val Gln
        35                  40                  45

Gln Ala Arg Ile Ala Gln Asn Gly Ile Leu Gly Asp Phe Ile Ile Arg
    50                  55                  60

Tyr Asp Val Asn Arg Glu Gln Ser Ile Gly Asp Ile Gln Val Leu Asn
65                  70                  75                  80

Gly Tyr Phe Val His Tyr Phe Ala Pro Lys Asp Leu Pro Pro Leu Pro
                85                  90                  95

Lys Asn Val Val Phe Val Leu Asp Ser Ser Ala Ser Met Val Gly Thr
            100                 105                 110

Lys Leu Arg Gln Thr Lys Asp Ala Leu Phe Thr Ile Leu His Asp Leu
        115                 120                 125

Arg Pro Gln Asp Arg Phe Ser Ile Ile Gly Phe Ser Asn Arg Ile Lys
    130                 135                 140

Val Trp Lys Asp His Leu Ile Ser Val Thr Pro Asp Ser Ile Arg Asp
145                 150                 155                 160

Gly Lys Val Tyr Ile His His Met Ser Pro Thr Gly Gly Thr Asp Ile
                165                 170                 175

Asn Gly Val Leu Gln Arg Ala Ile Arg Leu Leu Asn Lys Tyr Val Ala
            180                 185                 190

His Ser Gly Ile Gly Asp Arg Ser Val Ser Leu Ile Val Phe Leu Thr
        195                 200                 205

Asp Gly Lys Pro Thr Val Gly Glu Thr His Thr Leu Lys Ile Leu Asn
    210                 215                 220

Asn Thr Arg Glu Ala Ala Arg Gly Gln Val Cys Ile Phe Thr Ile Gly
225                 230                 235                 240

Ile Gly Asn Asp Val Asp Phe Arg Leu Leu Glu Lys Leu Ser Leu Glu
                245                 250                 255

Asn Cys Gly Leu Thr Arg Arg Val His Glu Glu Glu Asp Ala Gly Ser
            260                 265                 270

Gln Leu Ile Gly Phe Tyr Asp Glu Ile Arg Thr Pro Leu Leu Ser Asp
        275                 280                 285

Ile Arg Ile Asp Tyr Pro Pro Ser Ser Val Val Gln Ala Thr Lys Thr
    290                 295                 300

Leu Phe Pro Asn Tyr Phe Asn Gly Ser Glu Ile Ile Ile Ala Gly Lys
305                 310                 315                 320

Leu Val Asp Arg Lys Leu Asp His Leu His Val Glu Val Thr Ala Ser
                325                 330                 335

Asn Ser Lys Lys Phe Ile Ile Leu Lys Thr Asp Val Pro Val Arg Pro
```

```
            340                     345                     350

Gln Lys Ala Gly Lys Asp Val Thr Gly Ser Pro Arg Pro Gly Gly Asp
        355                     360                     365

Gly Glu Gly Asp Xaa Asn His Ile Glu Arg Leu Trp Ser Tyr Leu Thr
    370                     375                     380

Thr Lys Glu Leu Leu Ser Ser Trp Leu Gln Ser Asp Asp Glu Pro Glu
385                     390                     395                     400

Lys Glu Arg Leu Arg Gln Arg Ala Gln Ala Leu Ala Val Ser Tyr Arg
                405                     410                     415

Phe Leu Thr Pro Phe Thr Ser Met Lys Leu Arg Gly Pro Val Pro Arg
            420                     425                     430

Met Asp Gly Leu Glu Glu Ala His Gly Met Ser Ala Ala Met Gly Pro
        435                     440                     445

Glu Pro Val Val Gln Ser Val Arg Gly Ala Gly Thr Gln Pro Gly Pro
    450                     455                     460

Leu Leu Lys Lys Pro Tyr Gln Pro Arg Ile Lys Ile Ser Lys Thr Ser
465                     470                     475                     480

Val Asp Gly Asp Pro His Phe Val Val Asp Phe Pro Leu Ser Arg Leu
                485                     490                     495

Thr Val Cys Phe Asn Ile Asp Gly Gln Pro Gly Asp Ile Leu Arg Leu
            500                     505                     510

Val Ser Asp His Arg Asp Ser Gly Val Thr Val Asn Gly Glu Leu Ile
        515                     520                     525

Gly Ala Pro Ala Pro Pro Asn Gly His Lys Lys Gln Arg Thr Tyr Leu
    530                     535                     540

Arg Thr Ile Thr Ile Leu Ile Asn Lys Pro Glu Arg Ser Tyr Leu Glu
545                     550                     555                     560

Ile Thr Pro Ser Arg Val Ile Leu Asp Gly Gly Asp Arg Leu Val Leu
                565                     570                     575

Pro Cys Asn Gln Ser Val Val Val Gly Ser Trp Gly Leu Glu Val Ser
            580                     585                     590

Val Ser Ala Asn Ala Asn Val Thr Val Thr Ile Gln Gly Ser Ile Ala
        595                     600                     605

Phe Val Ile Leu Ile His Leu Tyr Lys Lys Pro Ala Pro Phe Gln Arg
    610                     615                     620

His His Leu Gly Phe Tyr Ile Ala Asn Ser Glu Gly Leu Ser Ser Asn
625                     630                     635                     640

Cys His Gly Leu Leu Gly Gln Phe Leu Asn Gln Asp Ala Arg Leu Thr
                645                     650                     655
```

Glu Asp Pro Ala Gly Pro Ser Gln Asn Leu Thr His Pro Leu Leu Leu
660 665 670

Gln Val Gly Glu Gly Pro Glu Ala Val Leu Thr Val Lys Gly His Gln
675 680 685

Val Pro Val Val Trp Lys Gln Arg Lys Ile Tyr Asn Gly Glu Glu Gln
690 695 700

Xaa Asp Cys Trp Phe Ala Arg Asn Met Pro Pro Asn
705 710 715

<210> 360
<211> 387
<212> PRT
<213> Homo sapiens

<400> 360
Pro Arg Val Arg Ser Ile Lys Val Thr Glu Leu Lys Gly Leu Ala Asn
1 5 10 15

His Val Val Val Gly Ser Val Ser Cys Glu Thr Lys Asp Leu Phe Ala
20 25 30

Ala Leu Pro Gln Val Val Ala Val Asp Ile Asn Asp Leu Gly Thr Ile
35 40 45

Lys Leu Ser Leu Glu Val Thr Trp Ser Pro Phe Asp Lys Asp Asp Gln
50 55 60

Pro Ser Ala Ala Ser Ser Val Asn Lys Ala Ser Thr Val Thr Lys Arg
65 70 75 80

Phe Ser Thr Tyr Ser Gln Ser Pro Pro Asp Thr Pro Ser Leu Arg Glu
85 90 95

Gln Ala Phe Tyr Asn Met Leu Arg Arg Gln Glu Glu Leu Glu Asn Gly
100 105 110

Thr Ala Trp Ser Leu Ser Ser Glu Ser Ser Asp Asp Ser Ser Ser Pro
115 120 125

Gln Leu Ser Gly Thr Ala Arg His Ser Pro Ala Pro Arg Pro Leu Val
130 135 140

Gln Gln Pro Glu Pro Leu Pro Ile Gln Val Ala Phe Arg Arg Pro Glu
145 150 155 160

Thr Pro Ser Ser Gly Pro Leu Asp Glu Glu Gly Ala Val Ala Pro Val
165 170 175

Leu Ala Asn Gly His Ala Pro Tyr Ser Arg Thr Leu Ser His Ile Ser
180 185 190

Glu Ala Ser Val Asn Ala Ala Leu Ala Glu Ala Ser Val Glu Ala Val
195 200 205

Gly Pro Lys Ser Leu Ser Trp Gly Pro Ser Pro Pro Thr His Pro Ala

210 215 220

Pro Thr His Gly Lys His Pro Ser Pro Val Pro Pro Ala Leu Asp Pro
225 230 235 240

Gly His Ser Ala Thr Ser Ser Thr Leu Gly Thr Thr Gly Ser Val Pro
245 250 255

Thr Ser Thr Asp Pro Ala Pro Ser Ala His Leu Asp Ser Val His Lys
260 265 270

Ser Thr Asp Ser Gly Pro Ser Glu Leu Pro Gly Pro Thr His Thr Thr
275 280 285

Thr Gly Ser Thr Tyr Ser Ala Ile Thr Thr Thr His Ser Ala Pro Ser
290 295 300

Pro Leu Thr His Thr Thr Thr Gly Ser Thr His Lys Pro Ile Ile Ser
305 310 315 320

Thr Leu Thr Thr Thr Gly Pro Thr Leu Asn Ile Ile Gly Pro Val Gln
325 330 335

Thr Thr Thr Ser Pro Thr His Thr Met Pro Ser Pro Ser Ser His Ser
340 345 350

Asn Ser Pro Gln Tyr Val Asp Phe Cys Ser Ser Val Cys Asp Asn Ile
355 360 365

Phe Val His Tyr Val Ile Gly Ile Phe Phe His Thr Leu Tyr Ser Ser
370 375 380

Lys Thr Leu
385

<210> 361
<211> 260
<212> PRT
<213> Homo sapiens

<400> 361
Pro Arg Val Arg Ser Ile Lys Val Thr Glu Leu Lys Gly Leu Ala Asn
1 5 10 15

His Val Val Val Gly Ser Val Ser Cys Glu Thr Lys Asp Leu Phe Ala
20 25 30

Ala Leu Pro Gln Val Val Ala Val Asp Ile Asn Asp Leu Gly Thr Ile
35 40 45

Lys Leu Ser Leu Glu Val Thr Trp Ser Pro Phe Asp Lys Asp Asp Gln
50 55 60

Pro Ser Ala Ala Ser Ser Val Asn Lys Ala Ser Thr Val Thr Lys Arg
65 70 75 80

Phe Ser Thr Tyr Ser Gln Ser Pro Pro Asp Thr Pro Ser Leu Arg Glu
85 90 95

```
Gln Ala Phe Tyr Asn Met Leu Arg Arg Gln Glu Glu Leu Glu Asn Gly
            100                 105                 110

Thr Ala Trp Ser Leu Ser Ser Glu Ser Ser Asp Asp Ser Ser Ser Pro
        115                 120                 125

Gln Leu Ser Gly Thr Ala Arg His Ser Pro Ala Pro Arg Pro Leu Val
    130                 135                 140

Gln Gln Pro Glu Pro Leu Pro Ile Gln Val Ala Phe Arg Arg Pro Glu
145                 150                 155                 160

Thr Pro Ser Ser Gly Pro Leu Asp Glu Glu Gly Ala Val Ala Pro Val
                165                 170                 175

Leu Ala Asn Gly His Ala Pro Tyr Ser Arg Thr Leu Ser His Ile Ser
            180                 185                 190

Glu Ala Ser Val Asn Ala Ala Leu Ala Glu Ala Ser Val Glu Ala Val
        195                 200                 205

Gly Pro Lys Ser Leu Ser Trp Gly Pro Ser Pro Pro Thr His Pro Ala
    210                 215                 220

Pro Thr His Gly Lys His Pro Ser Pro Val Pro Pro Ala Leu Asp Pro
225                 230                 235                 240

Gly His Ser Ala Thr Ser Ser Thr Leu Gly Thr Thr Gly Ser Val Pro
                245                 250                 255

Thr Ser Thr Asp
            260


<210> 362
<211> 155
<212> PRT
<213> Homo sapiens

<400> 362
Tyr Gly Cys Glu Lys Thr Thr Glu Gly Gly Arg Arg Arg Arg Arg Arg
 1               5                  10                  15

Met Glu Ala Val Val Phe Val Phe Ser Leu Leu Asp Cys Cys Ala Leu
            20                  25                  30

Ile Phe Leu Ser Val Tyr Phe Ile Ile Thr Leu Ser Asp Leu Glu Cys
        35                  40                  45

Asp Tyr Ile Asn Ala Arg Ser Cys Cys Ser Lys Leu Asn Lys Trp Val
    50                  55                  60

Ile Pro Glu Leu Ile Gly His Thr Ile Val Thr Val Leu Leu Leu Met
65                  70                  75                  80

Ser Leu His Trp Phe Ile Phe Leu Leu Asn Leu Pro Val Ala Thr Trp
                85                  90                  95
```

```
Asn Ile Tyr Arg Tyr Ile Met Val Pro Ser Gly Asn Met Gly Val Phe
            100                 105                 110

Asp Pro Thr Glu Ile His Asn Arg Gly Gln Leu Lys Ser His Met Lys
        115                 120                 125

Glu Ala Met Ile Lys Leu Gly Phe His Leu Leu Cys Phe Phe Met Tyr
    130                 135                 140

Leu Tyr Ser Met Ile Leu Ala Leu Ile Asn Asp
145                 150                 155


<210> 363
<211> 70
<212> PRT
<213> Homo sapiens

<400> 363
Ala Arg Ala Pro Ala Pro Ser Leu Pro Pro Leu Pro Ser Pro Ala Pro
  1               5                  10                  15

Ala Leu Ala Pro Ala His Ser Leu Leu Gly Leu Leu Leu Gly Arg Met
            20                  25                  30

Ser Gly Ser Ser Leu Pro Ser Ala Leu Ala Leu Ser Leu Leu Leu Val
        35                  40                  45

Ser Gly Ser Leu Leu Pro Gly Pro Gly Ala Ala Gln Asn Val Arg Val
    50                  55                  60

Gln Ser Gly Gln Asp Gln
 65                  70


<210> 364
<211> 56
<212> PRT
<213> Homo sapiens

<400> 364
Gly Thr Ser Lys Asp Cys Val Leu Tyr Ala Phe Leu Asp Pro Gly Met
  1               5                  10                  15

Ala Val Pro Leu Phe Leu Tyr Ile Phe Thr Leu Leu Pro Leu Leu Pro
            20                  25                  30

Phe Leu Leu Ser Leu Cys Phe Ser Pro Leu Thr Val Lys Arg Ser Ser
        35                  40                  45

Ser Ser Glu Ser Lys Ser Ser Leu
    50                  55
```

PCT/US99/17130

Applicant's or agent's file reference number	PZ031PCT	International application	Unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

REC'D 18 AUG 1999
WIPO PCT

A. The indications made below relate to the microorganism referred to in the description on page 280, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
July 27, 1998	203069

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

Europe
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☒ This sheet was received by the International Bureau on: 18 AUGUST 1999
Authorized officer Yvette Simms, PCT International Division	Authorized officer

Form PCT/RO/134 (July 1992)

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International application	Unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 243, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
June 11, 1998	209965

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

Europe
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer Yvette Z. Simms PCT International Division	Authorized officer

Form PCT/RO/134 (July 1992)

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International application	Unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 249, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
June 26, 1998	203027

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

Europe
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer Yvonne E. Simms, PCT International Division	Authorized officer

Form PCT/RO/134 (July 1992)

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International application	Unassigned

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 253, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution: American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
July 27, 1998	203071

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

Europe
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer Yvette E. Simms, PCT International Division	Authorized officer

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International application

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13*bis*)

A. The indications made below relate to the microorganism referred to in the description on page 259, line N/A

B. IDENTIFICATION OF DEPOSIT — Further deposits are identified on an additional sheet ☐

Name of depositary institution American Type Culture Collection

Address of depositary institution *(including postal code and country)*

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
July 27, 1998	203070

C. ADDITIONAL INDICATIONS *(leave blank if not applicable)* — This information is continued on an additional sheet ☐

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *(if the indications are not for all designated States)*

Europe
In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

E. SEPARATE FURNISHING OF INDICATIONS *(leave blank if not applicable)*

The indications listed below will be submitted to the International Bureau later *(specify the general nature of the indications e.g., "Accession Number of Deposit")*

For receiving Office use only	For International Bureau use only
☒ This sheet was received with the international application	☐ This sheet was received by the International Bureau on:
Authorized officer Yvette E. Simms PCT International Division	Authorized officer

Form PCT/RO/134 (July 1992)

CANADA

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later that at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17130

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.
US CL :Please See Extra Sheet.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5; 435/69.1, 320.1, 252.3, 325, 6, 7.1; 530/350, 300, 387.1; 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG - Biotech Files

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JACOBS, K. A. et al. A Genetic Selection For Isolating cDNAs Encoding Secreted Proteins. Gene. 1997, Vol. 198, pages 289-296, see entire document.	1-23

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
05 OCTOBER 1999	21 OCT 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer ELIZABETH C. KEMMERER
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/17130

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1-23
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

Please See Extra Sheet.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.